<SEC-DOCUMENT>0001628280-23-016486.txt : 20230508
<SEC-HEADER>0001628280-23-016486.hdr.sgml : 20230508
<ACCEPTANCE-DATETIME>20230508171108
ACCESSION NUMBER:		0001628280-23-016486
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230508
DATE AS OF CHANGE:		20230508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		23898851

	BUSINESS ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sgmo-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:1e97b392-2501-45be-8bcc-91b1f8c19bb8,g:c3a18027-401c-4098-a3df-6fe057e7c69a,d:056ce7da447f48a894f20e0202bfb367--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:sgmo="http://www.sangamo.com/20230331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180L2ZyYWc6NTY1YTZmYTQ1NTZhNDhlN2FmMWUwNGU5MjFkMmQ4OTkvdGFibGU6MWUxZTdlMWExNDQxNDUyMDk2YmFlY2E4YWJlYmQ3MWYvdGFibGVyYW5nZToxZTFlN2UxYTE0NDE0NTIwOTZiYWVjYThhYmViZDcxZl8yLTEtMS0xLTcwMjc1_be3a74f1-22a5-402e-98dd-aa0fc2555b35">false</ix:nonNumeric><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180L2ZyYWc6NTY1YTZmYTQ1NTZhNDhlN2FmMWUwNGU5MjFkMmQ4OTkvdGFibGU6MWUxZTdlMWExNDQxNDUyMDk2YmFlY2E4YWJlYmQ3MWYvdGFibGVyYW5nZToxZTFlN2UxYTE0NDE0NTIwOTZiYWVjYThhYmViZDcxZl8zLTEtMS0xLTcwMjc1_709db881-dbb0-4732-90e8-c397d1a38cdf">2023</ix:nonNumeric><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180L2ZyYWc6NTY1YTZmYTQ1NTZhNDhlN2FmMWUwNGU5MjFkMmQ4OTkvdGFibGU6MWUxZTdlMWExNDQxNDUyMDk2YmFlY2E4YWJlYmQ3MWYvdGFibGVyYW5nZToxZTFlN2UxYTE0NDE0NTIwOTZiYWVjYThhYmViZDcxZl80LTEtMS0xLTcwMjc1_df97d1ac-b084-440c-bc57-e96bc2d61ea6">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180L2ZyYWc6NTY1YTZmYTQ1NTZhNDhlN2FmMWUwNGU5MjFkMmQ4OTkvdGFibGU6MWUxZTdlMWExNDQxNDUyMDk2YmFlY2E4YWJlYmQ3MWYvdGFibGVyYW5nZToxZTFlN2UxYTE0NDE0NTIwOTZiYWVjYThhYmViZDcxZl81LTEtMS0xLTcwMjc1_d626476c-c837-4b3d-ac19-5ab53fc2e7de">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180L2ZyYWc6NTY1YTZmYTQ1NTZhNDhlN2FmMWUwNGU5MjFkMmQ4OTkvdGFibGU6MWUxZTdlMWExNDQxNDUyMDk2YmFlY2E4YWJlYmQ3MWYvdGFibGVyYW5nZToxZTFlN2UxYTE0NDE0NTIwOTZiYWVjYThhYmViZDcxZl82LTEtMS0xLTcwMjc1_61f8ed31-13a1-40eb-a7a9-85c928481dba">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a52ec1aaba84b2281ad30d4bd939c0c_I20230504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i9a68418627e64a97967175e21376a7f3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic4324bd7b11f411d9e7d667c237daef0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia30a9e39409b461c99159daa010f6c5c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedb9034932fc40c08ea5573339590e7f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac4ded14953b49d1addd06f731f72c7b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f7c9d06ff1b4ead8670defb0e972860_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0c77020818e4b5580a54602bc3733dc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc69df1bb8ee4558ae36144749414ed9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60c69134c4f4a03998a810770abe5f2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a6b4846ff7445a7bd06205ce088da41_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccea421e2a0c4b47b469cdf5d493c0e0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba3dfb89f8ba47408fd34040b407e005_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5abbb2c7d7944601bf890210157c2b4d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91ca40960ab74c8fbafd0d9349205312_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c7722be40df413c8e437a49f401590f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff108f8c09274a6cbb44e10d8867b38a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6d1271621d4cac8be74b9a037e4707_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53a89059a55449d3bc69e3f6de7098b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i579b5f75540647cd977142ae38f4b321_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ccefc4a682e42bda1dd7730db19dcc0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e912a9a7bc746bd96bb5d87a08b8206_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a85436c7c142278657c85e7ea9997b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeae407467224307ae4941c1984b4b7f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68b3111e2494397846164214ce99690_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3bdcc1051374821b3877c109bd673ae_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34bf2d104a444cc9834054ced8faa7f7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie262d508238d48dc8b762871a33221db_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id596b784d404435db73b47602bb3f897_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02b85f2e8972441db23e17a30d5bff74_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76070b5a1a6143119c52bcf7c53c9b73_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c3ceda2ae9f4af0871fc85dd870550f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iaca29c7b3b79472aaf0ee13bc56470ac_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5248b3610244c38b223f129709425f6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90890f44b0704bb8ac590e628ae519de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1342bd78484460185b8895a3f6308ea_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i228888ff63774a0da4d18154fc729ad5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie462eedb4107492bbce0acc5ff5754d8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc8ea2db07274d118686e8a982ad7e70_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1352fdf2ec644672809d7dd3d3bed33d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76977228f122459ba5f628b5569cae61_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f7da342c5ac4a7ea636981a736322b9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d6fe81f256c4cc8b6f7fc522fdd2281_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f61e5cec7984b35ac4292098852fc91_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9898b19bcd74221a4ff8f06d9cb7cf7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92619e333cc24f9e975a7de1bb2abeea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a1749f9f00c4883957a94b42aedc00f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eacf9813ba44226a063dc9009a4a15f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dceda8408ab4f4fbd7740cca575d5b0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea9e2a9aacec47b5a0dad2b07a352357_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869c2ae932a24254b8289f3374d6a37b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie603a77a75c24e5bb6587690295c6f3d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee59432e21b44a0e8975d6f3b16c5c4a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26ea0b74cc8544e1a3c671264db84d1e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d56b50a62c74d6185fdc6510e7cc1eb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6032041d43be43a9bb2dc9299dffabad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i483c837a581a4a55b5c3d56642557778_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43cfc63e1c6c4f118396790ecc913456_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2b09c75601c44e5b6a50a7decb6edde_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13fb183572b948d48d0e0dde8e690e47_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1429086824143138e26fa0505ab0fed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iead8dc5bda5146e0849851aa8f041938_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37baec065284201ae771b20cce5ff25_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae8f85ae07f54b72871595f4e0b87538_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i862b92b01544466ba544053538532461_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i749604d15996441483daf9b51492bbbb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07e496ca5ed849de88c1758f1bfec843_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i030f27a6938f4ae3b1d61555d37da11b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia99bbd5a24a34bdb914d71eed48233f3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78fdaa779102440c8193f79514249c1b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ef8c6fa4624c93842e0f3638e26f25_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75fa9da1a76b437cb308a2069d2b6eab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceb0eb1a3d40494d975a79e8bcfe27f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5c39a22139a4538b0384f237621d593_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f4b7dc92a60450187eb7cba78d4c993_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab229808f3044fba8b9d5250cb15ae30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b36ed08a50e40e19b52b258e576bdcb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i202c7c1338114a3bb3508dd0e372fd84_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7057bf4fdd9c4e7eaa545683b37732c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if73e2cb32fab46ffbe55e9f5a5da0de2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02fe7f2d5f244d2b94f1aaaaefcea866_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9260c94253f4086af0b69700e462ff9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd16acd018e74a0eb2ef2d18b3ee3a05_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i023a682c38c1450e86a5514fd42920ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if75b8fa59ce34fb895f1352a74043e96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7724b0150a1d4054a320c6e4ef27fccd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ed6d25a758441dbb31e2700f31431a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6febdf9b3c3b4c168661eb22fdc0ed1e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce4a249017b49d09aabf529ed967fae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb946291e031440cbc217d13ca32b3be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d5cfc64a3af4b758962c25f72175778_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dfcb895014c45b9afa399178f988a8f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb05bb816d48471695d20ca909641996_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e171ab888a84b13bd2208636c991ac8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i710edc7861594a64934aa92ebca6d053_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic22c629aefe14ad9a522a27354756d3e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c5f113b72b84c4b83630824ece95871_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e703c64cdfb44f3ba9f51bd3b3515d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2beb4271e37a4f91875382a0f384b26b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9bac443782f4620ba81a5a825bcf681_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if22b2e9750244dc98e0c8b4d07365f2c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b64c2dbe567488896866da512af7840_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72394fea9c574b08a7bf8ac3b21f6a13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46d82c5052ab497b84f515cc2d04ad09_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:USGovernmentSponsoredAgencyBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ecf1a446814705933fbfd6cb111914_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:USGovernmentSponsoredAgencyBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0be6f0fd28e547138aedec8a3f9ad6c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:USGovernmentSponsoredAgencyBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b32d58beb5e49b0addbd7559d9a7775_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:USGovernmentSponsoredAgencyBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93fcf6ad011a47d8bd403279bf5444bd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19697738bf094279973b7cad292bc53f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i054c316aa399405fb28e17d9ac5f6b7b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e3248fa7b3248df8737d1c52d665c5b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f9b4275c69b4a3da6c127b76ab498d0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4f486712abb466bb4fed83def8c8c69_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e554d5745be4b61b64b3b228f9ea2b6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1113f5d2f3014aeab32e8e98f8161f84_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i739dc723663c47d7b30394d8567919dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i382c5b6d179045cab6406d5372cc5441_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib74d65ada2ff4867ab5f3259d7d950ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if54118fa133440819c9192da179240e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9f8bb01a8d149d993b5ba9c67d52a69_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0441be5e852742ed898a9eb78b769265_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i775d20c1dc4c46e68398640e2b73e1dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if04730ad90e0401eb7693f8828b8bc5d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if03492c5aa4e4c55a0716a7facf39b4e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:USGovernmentSponsoredAgencyBondMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddef1edbf4fe4f019d6237e6e633beb1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie99095be5cac40ca995b3b8a0de25abf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4f07d68b8514889b8593d1beef8cb7e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be2098986b14f5aba5262c6164a6fbf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cdb317881c34a669c3a4df636cafb89_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e26658540754e0ba357cda42d689a27_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e5f30daa4cb48669190ba5dc2800f62_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i588781fc38e24f71a49cbdd5825112e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b05399697d7401c8737c92e33455724_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i172244f350cb475a8efec0046cc9297b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0092f362bc744248b2ee6e610a3b5e63_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id24f43f5449b47339b9d23c5322eea68_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5044101e1ffb43ab96fa6fd4cd659e29_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8aae65c355c4bd7aef72344aa0fafbf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f7ce4041a0342d09c2e6c57209b7339_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i977ddd133dc44b5c99432be67e32bb97_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad08cddce894baca70373a9ee5375ff_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product_target"><xbrli:measure>sgmo:product_target</xbrli:measure></xbrli:unit><xbrli:context id="if9678c76539b432b81f74d4fb3103970_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8df8676b78c46d5b518f1f954613aa3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="material_right"><xbrli:measure>sgmo:material_right</xbrli:measure></xbrli:unit><xbrli:context id="idf5d83fd29e747b2a85c289b3b68ab01_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe0c5537708d428dbd32614f200d7d29_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie59f379330a44413acc5ad3572d12de6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3bd4a20f8df4d748a7351f9176c8c95_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife0d48cc54154af988cfabb60294c669_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97d4c70ae0c0480394a8206308620896_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b3bd979dbaf42b2bf7fdb23a295bcbd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff80b48ae31a4224bcf6ebf172a029de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a46a4d74d0f40ca9fe4e5cc2553ae18_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb85aa7ee95148ddb651de001786d085_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82bf0e01b49943c59780d56860d0ef71_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb9738ab009e47ebac491659d9db20da_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1079febd1d943e5ace3d337ff8b9934_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdb866cb8cc240e6abb838057088d3c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia36d19d9949d425a80f1c8e75d714302_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d2d40bca9274579a944d3bfb4f13ab1_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf64bd796644ec09771a94c61a501b4_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>sgmo:milestone</xbrli:measure></xbrli:unit><xbrli:unit id="option"><xbrli:measure>sgmo:option</xbrli:measure></xbrli:unit><xbrli:context id="if7e6bd6cba7449d5b279f7359132b372_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cab29510fb3439faf882035775ddfa8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="performance_obligation"><xbrli:measure>sgmo:performance_obligation</xbrli:measure></xbrli:unit><xbrli:context id="if963029c76a14422a76e678b607647db_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee75a68ffae4d08aad2ebe053849936_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc29cb92c1914e68bb97632d9995dd99_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba08bfacba1f4aae9ffd92a1c8ee0b02_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd84ec8a1904360957c6aa234b8c110_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i012246fb152f4311b9ef64728a20ab16_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf91751f6b9c4cd9aa62ef768250ea52_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06bd9d0df2534688ae2923ab3b06ae9a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i044b8bca774a41859553cfa2ca705546_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16fce833379e4e6f95302de92112cbfe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0996de9b8bdd4847801e39a50b5843fe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb3c135c2da14ac9b065d23532ddd743_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>sgmo:program</xbrli:measure></xbrli:unit><xbrli:context id="ie1283de320cb4464a5b41896a5803c3e_D20140101-20220628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2022-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i040ae2a932da4ee5aba8f53c0572ebbc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>sgmo:product</xbrli:measure></xbrli:unit><xbrli:context id="i8f019967b98f4beba43811efc7cd5926_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db635d14915401bb7ab7d501b675ba5_D20220906-20220906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-06</xbrli:startDate><xbrli:endDate>2022-09-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc0f7863a60402b9f2453ef3b887ecb_D20140101-20220628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2022-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65542dbae8514435bdf257a1ff5bcbdf_I20220628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46c2c921be69493ab19f0a486451504a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddc8eb02f5594eb4bb70b4f4e16dfa8a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i739fc14c91ed4a9398145c3822bdc624_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64cb91ba588b40d3823c99c78f047007_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d62212323d64616b08b97898e6dca41_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b80b373e4f543d3b9c64cd42f6123e0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29862757a85b4766a731ee17cf896271_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f62cc7bdbf4e2ca26b9868e600b6d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ae7e8c20abb44979f894b0080a9de5b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i667f4bba088b4392976bb60dcc384764_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i804a404f96394a898c058d278efa5149_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebe23428fae3453f85cfddd95fced287_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib47491017133498e9f1034163ad56858_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe6c9c6208944000ac68a96e46025955_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id44c480d79c746f99af60191b7721577_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bbeee49f7d24edbb0671d6d2fd4fe37_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82259a8cc3b54b86845b0a1e5c8c8688_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37f8e9f8ba844603a13fb45940884450_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8b7dbf6a794472a89a395389c47d284_D20170501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8723ec4942574f6abacf98a666e76565_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf3bbfd75e0a43a385745a5d6b39cac5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ed8ae1e943412696f1b850bcd91902_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc4df0af832c47e19018df300e7262e2_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f057163ceda4cb2866e24c3fb357cfe_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a4ef27fa9844922a3e39563222cc964_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2c186114dc94e028f5fe60291fb4cc4_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i560f370cf92a49b99828eb1352749470_D20171201-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e962757cf94476a83ff1404fcbf850b_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a15336c720b4849b73c702ec05c48ae_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b6cafe71ed842fe933713b923d60a51_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec01e4d31367438cb373cd06b7a6321f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc67d44a220419d862851946595abe3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e652ef597fe49c8b7cf086423e5272b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="asset_group"><xbrli:measure>sgmo:asset_group</xbrli:measure></xbrli:unit><xbrli:context id="i4de9bbe9fefc453f850b2fe7edb090a7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b032998eb547589205c3c16fdb0326_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25d41c01311744a48c5daac7d4e3944b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idca29878377148449e09cef54c91263d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28c3caeac8e54328899e8c3cb465e877_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f991f47f9a74b6b9b29e3bac240a7eb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i817e2132beca4a9a89cee830995c6d63_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b85c71c37b542f2882458b5be990823_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ced4258fc4d4d42a76a05c7d77967a2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d74086bfd334bcea39a99837791ca5d_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c3f507349cf479bbcbd3ad2bdc85b31_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d843ac73dfb466ab2ba144b1a49bdb5_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>sgmo:employee</xbrli:measure></xbrli:unit><xbrli:context id="i4127fb82d88648f383b7c0ae50821b64_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifae7a07494d54449804932a865f643bc_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i056ce7da447f48a894f20e0202bfb367_1"></div><div style="min-height:36pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.527%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjcx_1719e036-8c5b-4599-b184-7728ab8c5fe4">10-Q</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6YmE3MjVlOWMzYjIzNDA1Yzk5MjM0NjhlYjk1ODFlMWYvdGFibGVyYW5nZTpiYTcyNWU5YzNiMjM0MDVjOTkyMzQ2OGViOTU4MWUxZl8wLTAtMS0xLTcwMjc1_eb09a0df-c2e0-4574-9427-2ee6f7e1be34">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMzE_049edcab-1712-4296-b8ba-15e2acd7b3bb">March 31, 2023</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6Y2E3YTlhNjQxMTYyNGU5OTlmMmRkZGJiYWUwODJjOTkvdGFibGVyYW5nZTpjYTdhOWE2NDExNjI0ZTk5OWYyZGRkYmJhZTA4MmM5OV8wLTAtMS0xLTcwMjc1_465cb1f5-55e6-45bb-a4b3-3bdf4e2b8c3c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY2_219f0ebb-f362-48ad-b0c5-65496e5bac53">000-30171</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY3_0f730648-661b-4d9b-a762-f75fd8d0a3cf">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:30.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18wLTAtMS0xLTcwMjc1_dbfd2f38-7dad-4165-acd9-91b310fb58c8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18wLTQtMS0xLTcwMjc1_fc85f3a5-4030-4dd8-8b87-80c6862915e7">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18zLTAtMS0xLTcwMjc1L3RleHRyZWdpb246ZTE2ODY4MTM2OTY4NDdkMWFiMTMzODk2NTI2YzYzZTZfNA_d4ff39db-f0e5-422b-9868-2f4e79b6e26f">7000 Marina Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18zLTAtMS0xLTcwMjc1L3RleHRyZWdpb246ZTE2ODY4MTM2OTY4NDdkMWFiMTMzODk2NTI2YzYzZTZfOA_1e382c23-8a49-4dee-8859-259bdb2d24e1">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18zLTAtMS0xLTcwMjc1L3RleHRyZWdpb246ZTE2ODY4MTM2OTY4NDdkMWFiMTMzODk2NTI2YzYzZTZfMTI_04756797-1abb-4ef2-8396-d22707e58806">California</ix:nonNumeric>, <ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18zLTAtMS0xLTcwMjc1L3RleHRyZWdpb246ZTE2ODY4MTM2OTY4NDdkMWFiMTMzODk2NTI2YzYzZTZfMTY_a9141a2c-e85e-4ed0-b4c3-0adb4ee2362a">94005</ix:nonNumeric></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY4_17f07b45-2c41-4ad9-b3de-60128a324a6b">510</ix:nonNumeric>) <ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY5_1b03777d-eea9-446b-b62d-98c7c06351f9">970-6000</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:38.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NzViOWUwMmRmMGQyNDMwMTk3Zjg1OWYzYjg5ZGJjMzIvdGFibGVyYW5nZTo3NWI5ZTAyZGYwZDI0MzAxOTdmODU5ZjNiODlkYmMzMl8xLTAtMS0xLTcwMjc1_1c76ea86-b09f-40ee-919d-1a6ce448ebf0">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NzViOWUwMmRmMGQyNDMwMTk3Zjg1OWYzYjg5ZGJjMzIvdGFibGVyYW5nZTo3NWI5ZTAyZGYwZDI0MzAxOTdmODU5ZjNiODlkYmMzMl8xLTItMS0xLTcwMjc1_aed16af0-0380-48f6-a5a1-180088fb6185">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NzViOWUwMmRmMGQyNDMwMTk3Zjg1OWYzYjg5ZGJjMzIvdGFibGVyYW5nZTo3NWI5ZTAyZGYwZDI0MzAxOTdmODU5ZjNiODlkYmMzMl8xLTQtMS0xLTcwMjc1_7afc3384-6eb2-4dcd-97b4-cda83e775659">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY0_0f7b6239-425c-4ad3-970a-d8aa5980eec3">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY1_c592fa81-5e3c-490b-a152-2b282a08dee0">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:2pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:21.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6YWJlYzQ2NWU5MWQ5NDA2NjhlZWIwZmUxZTBmZDM2MTIvdGFibGVyYW5nZTphYmVjNDY1ZTkxZDk0MDY2OGVlYjBmZTFlMGZkMzYxMl8wLTAtMS0xLTcwMjc1_d47da5d3-29a1-495e-ad31-e9689873a249">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6YWJlYzQ2NWU5MWQ5NDA2NjhlZWIwZmUxZTBmZDM2MTIvdGFibGVyYW5nZTphYmVjNDY1ZTkxZDk0MDY2OGVlYjBmZTFlMGZkMzYxMl8xLTQtMS0xLTcwMjc1_99bc2e5c-0fc6-479f-a9f3-7ba87554dd43">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6YWJlYzQ2NWU5MWQ5NDA2NjhlZWIwZmUxZTBmZDM2MTIvdGFibGVyYW5nZTphYmVjNDY1ZTkxZDk0MDY2OGVlYjBmZTFlMGZkMzYxMl8yLTQtMS0xLTcwMjc1_c39b5df5-ea1d-4c16-bac0-f55a807b1772">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;No&#160;&#160; <ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjcw_4ab77afb-c0a7-4d50-9d58-10b7a71f866b">&#9746;</ix:nonNumeric></span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of May&#160;4, 2023, <ix:nonFraction unitRef="shares" contextRef="i7a52ec1aaba84b2281ad30d4bd939c0c_I20230504" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMTc4_99186126-c4b8-4f06-8ab2-1409115b798a">171,825,530</ix:nonFraction> shares of the issuer&#8217;s common stock, par value $0.01 per share, were outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.527%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i056ce7da447f48a894f20e0202bfb367_16">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_19">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_19">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_22">Condensed Consolidated Balance Sheets at March 31, 2023 and December 31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_25">Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_28">Condensed Consolidated Statements of Comprehensive</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_28"> Income (</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_28">Loss</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_28">)</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_28"> for the Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_31">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_34">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_34">10</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_37">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_79">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_79">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_100">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_100">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_100">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_103">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_103">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_103">38</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i056ce7da447f48a894f20e0202bfb367_106">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_109">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_109">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_112">Item&#160;1A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_112">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_112">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_115">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_115">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_115">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_118">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_118">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_118">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_121">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_121">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_121">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_124">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_124">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_124">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_127">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_127">46</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i056ce7da447f48a894f20e0202bfb367_130">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_130">47</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated or the context suggests otherwise, references in this Quarterly Report on Form 10-Q, or Quarterly Report, to &#8220;Sangamo,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Sangamo Therapeutics, Inc. and our subsidiaries, including Sangamo Therapeutics France S.A.S. and Sangamo Therapeutics UK Ltd.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third-party trade names, trademarks and service marks appearing in this Quarterly Report are the property of their respective holders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some statements contained in this report are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to our future events, including our anticipated operations, research, development, manufacturing and commercialization activities, clinical trials, operating results and financial condition. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated research and development of product candidates and potential commercialization of any resulting approved products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, rate of progress, enrollment, dosing, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of our product candidates, including the durability of therapeutic effects;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of technologies used by us in our product candidates, including our gene therapy and cell therapy technologies, zinc finger, or ZF, technology platform, zinc finger nucleases, or ZF&#160;nucleases, and zinc finger transcriptional regulators, or ZF-TRs, which include zinc finger repressors, or ZF-Rs, and zinc finger activators, or ZF-As;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements, including our ability to find a potential new collaboration partner for the BIVV003 program;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated revenues from existing and new collaborations and the timing thereof;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the impact of the macroeconomic environment, including the impacts of the COVID-19 pandemic, on our business and operations and the business and operations of our collaborators, including clinical trials and manufacturing, and our ability to manage such impacts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development and other expenses;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers or from our own in-house manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of Sangamo and our collaborators and strategic partners to obtain and maintain regulatory approvals for product candidates and the timing and costs associated with obtaining regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business and operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain and maintain rights to the technologies required to develop and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments, including the impact on our competitive position of rival products and product candidates and our ability to meet such competition;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategic pipeline prioritization, including plans for advancing our preclinical programs, and related restructuring, including our plans to reduce our manufacturing and allogenic research footprints, and the expected charges and cost savings associated with such restructurings and any future cost reduction measures;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions and events that raise substantial doubt about our ability to continue as a going concern;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the growth of our business;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected operating and financial performance;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our operational and legal risks; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans, objectives, expectations and intentions and any other statements that are not historical facts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by use of future dates or by terms such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, without limitation:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biotechnology company with no approved products or product revenues. Our success depends substantially on clinical trial results demonstrating safety and efficacy of our product candidates to the satisfaction of regulatory authorities. Obtaining positive clinical trial results and regulatory approvals is expensive, lengthy, challenging and unpredictable and may never occur for any product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Success in research and preclinical studies or early clinical trial results may not be indicative of results obtained in later trials. Likewise, preliminary, initial or interim data from clinical trials may be materially different from final data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our product candidates are based on novel ZF technologies that have yet to yield any approved commercially viable therapeutic products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have historically incurred significant operating losses since inception and anticipate continued losses for the foreseeable future. We may never become profitable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding to execute our operating plan and continue to operate as a going concern. We may be unable to raise additional capital on favorable terms, if at all, which would harm or preclude our ability to develop our technology and product candidates and could delay or terminate some or all of our programs. Future sales and issuances of equity securities could also result in substantial dilution to our stockholders.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely heavily on collaborations with larger biopharmaceutical companies to generate revenues and develop, obtain regulatory approvals for and commercialize many of our product candidates. If conflicts arise with our collaborators or if the collaborations terminate for any reason, our revenues and product development efforts would be negatively impacted.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotechnology and genomic medicine are highly competitive businesses. Our competitors may develop rival technologies and products that are superior to or are commercialized more quickly than our technologies and product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing genomic medicines is complex, expensive, highly regulated and risky. We currently rely heavily on third</span><span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">party manufacturers and have limited experience manufacturing products ourselves. Manufacturing challenges may result in unexpected costs, supply interruptions and harm and delay to our product development efforts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain regulatory approvals for our product candidates, our approved products may not gain market acceptance among physicians and patients and adequate coverage and reimbursement from third-party payors and may not demonstrate commercial viability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain, maintain and enforce necessary and desirable intellectual property protections for our technologies and product candidates in all desired jurisdictions, which could adversely affect the value of our technologies and our product development efforts and could increase the risks of costly, lengthy and distracting litigation with unpredictable results.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties, who may or may not be competitors, may allege that we are infringing, misappropriating, or otherwise practicing in an unauthorized manner their patents or other proprietary rights. Such allegations may result in infringement actions, other misappropriation actions or threats of such actions, all of which could increase the risks of costly, lengthy and distracting litigation with unpredictable results.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on hiring, integrating and retaining additional highly qualified skilled employees and retaining current key executives and employees, which may be challenging given that the competition for these individuals is intense.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic could continue to adversely impact our business and operations and the business and operations of our collaborators, manufacturers and other business partners. If such impacts become material, our revenues and product development efforts could be negatively impacted.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock has been and will likely continue to be volatile, and you could lose all or part of any investment in our common stock.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have recorded, and may be required to record in the future, significant charges if our intangible assets or long-lived assets become impaired.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to meet continued listing standards of the Nasdaq Stock Market LLC, our common stock may be delisted. Delisting could adversely affect the liquidity of our common stock and the market price of our common stock could decrease, and our ability to obtain sufficient additional capital to fund our operations and to continue as a going concern would be substantially impaired.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our recent restructuring may not result in anticipated savings or operational efficiencies, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional discussion of the risks, uncertainties and other factors described above, as well as other risks and uncertainties material to our business, can be found under &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on February&#160;23, 2023, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q, and we encourage you to refer to that additional discussion. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as of the date of this filing. You should read this report completely and with the understanding that our actual future results and the timing of events may be materially different from what we expect, and we cannot otherwise guarantee that any forward-looking statement will be realized. We hereby qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You are advised, however, to consult any further disclosures we make on related subjects. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes discussion of certain clinical studies and trials relating to various product candidates. These studies typically are part of a larger body of clinical data relating to such product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical data are subject to differing interpretations, and even if we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i056ce7da447f48a894f20e0202bfb367_19"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div id="i056ce7da447f48a894f20e0202bfb367_22"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:74.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMy0xLTEtMS03MDI3NQ_7469e025-55b9-4354-a724-a6991daadccd">78,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMy0zLTEtMS03MDI3NQ_85678995-2326-4564-b666-e171cd179b7a">100,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNC0xLTEtMS03MDI3NQ_84f46bbc-796f-4d74-af49-ae020903dbe2">127,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNC0zLTEtMS03MDI3NQ_e279733b-d059-49b6-97da-cd15ad18bb9a">177,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:InterestReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNS0xLTEtMS03MDI3NQ_22fd7406-1dda-460b-8204-1dfbf807a182">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNS0zLTEtMS03MDI3NQ_fa8d26cf-1e2a-45ab-b82a-6546cb7fea9b">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNi0xLTEtMS03MDI3NQ_20d1a411-350f-4027-9d1d-4ca2ad58b09d">7,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNi0zLTEtMS03MDI3NQ_eb0ca283-6a31-479c-a0cc-38a2f12b342d">3,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNy0xLTEtMS03MDI3NQ_5af0e3ac-1675-4be3-9f9f-83282bf5f9b1">13,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNy0zLTEtMS03MDI3NQ_e7e1790f-7d4a-4f04-87dd-5e8f17da8eb3">18,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfOC0xLTEtMS03MDI3NQ_c70efcfe-9244-441d-aa6c-3cfb92ec60e6">227,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfOC0zLTEtMS03MDI3NQ_c3c75aa9-3528-47fc-8c33-f00339f9dfd0">300,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfOS0xLTEtMS03MDI3NQ_0498924c-071a-4a00-8592-a8e3551c92d5">35,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfOS0zLTEtMS03MDI3NQ_25c407ac-3f6f-4c00-b886-3bdfd12fbc59">29,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTAtMS0xLTEtNzAyNzU_c5b5623a-b259-46b9-8163-7bf6de3e8b29">59,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTAtMy0xLTEtNzAyNzU_35a3180e-80dd-43d4-b07e-38f3287c4100">63,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTEtMS0xLTEtNzAyNzU_d79b3a90-4eaa-4f24-8bb3-894968e96519">51,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTEtMy0xLTEtNzAyNzU_fa1cc973-00ae-4ca9-a33a-c0452e041273">50,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTItMS0xLTEtNzAyNzU_697d5986-3d2e-4f5b-96e3-51dadd17ba96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTItMy0xLTEtNzAyNzU_2c7255b1-f7a1-4e47-8787-373d5112af68">37,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTMtMS0xLTEtNzAyNzU_3b48ae51-9d7f-447a-b45f-a16c73439c05">48,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTMtMy0xLTEtNzAyNzU_0b82494c-34fc-4a4d-ba4d-5a9c1229ae7b">62,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTQtMS0xLTEtNzAyNzU_e2fe6d2c-0e34-440d-ac07-fdc42208ab18">16,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTQtMy0xLTEtNzAyNzU_69a7a4f0-7ea9-4651-8f91-b5be16ea4ef2">17,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTUtMS0xLTEtNzAyNzU_fd548bd9-1baa-4d77-b2c2-f15acb6fd435">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTUtMy0xLTEtNzAyNzU_e81ba7ad-ad2d-47a1-930d-5caeadea6905">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTYtMS0xLTEtNzAyNzU_9b55bb03-151d-496b-a29d-d70cdeae823b">440,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTYtMy0xLTEtNzAyNzU_88afce86-da8e-4529-9a3e-d30c00d422b8">562,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTktMS0xLTEtNzAyNzU_1a5238a6-d349-4266-be7f-d68f88a9de26">19,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTktMy0xLTEtNzAyNzU_8d555722-b196-4aae-b053-78bdbe906f90">22,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjAtMS0xLTEtNzAyNzU_c83136cb-fdab-4939-9b2c-4dfd81a81007">12,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjAtMy0xLTEtNzAyNzU_09768e40-3b86-4f1e-a037-76c7dade8918">21,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjEtMS0xLTEtNzAyNzU_c157a5c5-2296-4076-9ce2-06ebb407a594">15,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjEtMy0xLTEtNzAyNzU_95c6a648-544b-4110-b32b-31a8d8186e8f">16,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjItMS0xLTEtNzAyNzU_5753d39f-6707-4a18-93b3-ba3c9cb66a41">9,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjItMy0xLTEtNzAyNzU_2da710bd-3d70-4e48-b90c-c98a3e6f1552">51,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjMtMS0xLTEtNzAyNzU_c3587880-a858-468e-bc64-730114979c37">57,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjMtMy0xLTEtNzAyNzU_e7e71433-b409-4c87-94c2-52388aa1d1cf">111,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjQtMS0xLTEtNzAyNzU_490a71b1-cadc-410d-a3c9-18bbed6806e6">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjQtMy0xLTEtNzAyNzU_b36c9052-b436-4c8d-8e31-5481a5e42b1a">109,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjUtMS0xLTEtNzAyNzU_70e10f62-3db8-43eb-8e24-f05ee1f1696c">37,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjUtMy0xLTEtNzAyNzU_bdf6d896-6d85-4e09-abcb-369924560918">38,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjYtMS0xLTEtNzAyNzU_62a57228-3936-473f-a9c9-06a3ade5f17d">6,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjYtMy0xLTEtNzAyNzU_c73f041b-c9a8-4fbf-80d0-1379f67fef60">6,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjctMS0xLTEtNzAyNzU_9203b65d-9d8f-4d42-b047-631d77f14516">1,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjctMy0xLTEtNzAyNzU_6798e880-4666-4525-a480-235d61643fc1">1,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjgtMS0xLTEtNzAyNzU_573f90d0-a69d-4007-b1d3-9fe284b8201a">104,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjgtMy0xLTEtNzAyNzU_ea8b3927-1858-4da6-b31b-cba7dee97273">267,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjktMS0xLTEtNzAyNzU_12ddff0e-4d29-44fb-af3b-27030ff40433"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjktMy0xLTEtNzAyNzU_3ae8f8e4-0299-4b5a-8b3f-dbd2935effbc"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzEtMS0xLTEtNzAyNzU_285b8caa-7449-4e0d-a6be-576493c295e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzEtMy0xLTEtNzAyNzU_40523772-b3e3-4af5-80a9-165168d5ac4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzItMS0xLTEtNzAyNzU_f02ebc54-69f5-49e4-9ca0-ebfdf0a715e4">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzItMy0xLTEtNzAyNzU_284a2be0-9c17-4575-8501-6ded7821054f">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzMtMS0xLTEtNzAyNzU_87ed1c12-f1f5-4e7e-b0bd-40ebe421ae1d">1,467,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzMtMy0xLTEtNzAyNzU_b856a4a9-f8af-4628-b971-2abeed60ce8e">1,450,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzQtMS0xLTEtNzAyNzU_21fc2271-c7b3-465e-9fd3-3ae3bbcd178e">1,127,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzQtMy0xLTEtNzAyNzU_e4c668d4-73ed-4754-9687-feabae1657b2">1,148,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzUtMS0xLTEtNzAyNzU_98a02b18-fc3a-4777-a356-991e27340508">5,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzUtMy0xLTEtNzAyNzU_a4f236f8-5afc-4bab-a41c-dc2a1513e8f2">8,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzYtMS0xLTEtNzAyNzU_27a617c6-f61f-47db-b27e-cc272c338142">335,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzYtMy0xLTEtNzAyNzU_82bb8f4b-2bdd-498e-ae8a-24b37c387a7c">294,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzktMS0xLTEtNzAyNzU_b89e2d4f-ea20-4b03-9a0a-40f9cb345c73">440,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzktMy0xLTEtNzAyNzU_3d4b1d27-1b56-42a1-be38-29f413e2b152">562,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except per share amounts)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:74.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMi0xLTEtMS03MDI3NQ_2a8dedc7-bfd6-4903-8f64-33ad694f3a48">157,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMi0zLTEtMS03MDI3NQ_3aa9ddfc-ebb3-46a3-9939-69c7f9b2516b">28,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNC0xLTEtMS03MDI3NQ_62ba8749-8439-4418-a447-9a6955a9ba1c">63,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNC0zLTEtMS03MDI3NQ_c343b606-bba8-4105-9cb9-7564c936b852">58,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNS0xLTEtMS03MDI3NQ_90a2b23b-482a-4252-b16b-8d3f10b1acb6">18,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNS0zLTEtMS03MDI3NQ_e7e3b816-7c00-4725-8567-c111760234d3">14,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNi0xLTEtMS03NTc4NQ_a990f9c8-4679-48c5-abbd-034f891b5365">38,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNi0zLTEtMS03NTc5Mw_a38e4d57-6036-44ba-aefb-5105073a8d65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNy0xLTEtMS03NzkxMQ_cdc86a7d-c53b-4902-bc0b-0f469a08cc2e">20,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNy0zLTEtMS03NzkxMQ_8523e0be-3a5d-4959-b552-9e64709951c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNi0xLTEtMS03MDI3NQ_aad7af59-f91a-4df9-b002-266ce3fb057b">139,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNi0zLTEtMS03MDI3NQ_1a89a6cd-c2b9-4461-95fc-14a3d08a2c0b">73,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNy0xLTEtMS03MDI3NQ_3e9043e5-a9b0-4a14-af09-8a1d1d618921">18,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNy0zLTEtMS03MDI3NQ_86a13e89-29c3-4fcd-af35-217f79a85aab">45,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfOC0xLTEtMS03MDI3NQ_8c214bf1-edea-411a-b11d-e0aa3ba16e4c">3,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:InterestAndOtherIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfOC0zLTEtMS03MDI3NQ_c960be12-ff62-4af9-a00d-674c9c761e85">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfOS0xLTEtMS03MDI3NQ_a663b45b-c02b-4ae5-bfa1-225f89b4d150">21,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfOS0zLTEtMS03MDI3NQ_bc7f278c-df61-4675-942b-a83bbe0e8ec0">43,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTAtMS0xLTEtNzAyNzU_5a85f55b-7541-4d20-831c-3443791d4df2">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTAtMy0xLTEtNzAyNzU_dfc17d6d-6dff-4d48-bfd4-f4acf30e509b">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTMtMS0xLTEtNzAyNzU_ddc94f8e-06dd-413f-951d-aa8c94b003bd">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTMtMy0xLTEtNzAyNzU_efeef886-3aa3-409c-b695-adcb6d75d08a">43,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTQtMS0xLTEtNzAyNzU_74a64542-4dfe-4890-9207-505cad9900d9">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTQtMy0xLTEtNzAyNzU_051261bc-55cb-4842-85e7-e7d874ab62c6">0.30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTYtMS0xLTEtNzM5ODA_64404d27-45b3-440d-bed6-f0bae357999a">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTYtMy0xLTEtNzM5ODg_0e6391ba-4b96-4a84-8111-5ada282f768f">0.30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTUtMS0xLTEtNzAyNzU_c5b07f5c-9b61-4908-a8af-fe25cb150565">168,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTUtMy0xLTEtNzAyNzU_421b2e0d-de08-49c1-9a08-cf356c81d75e">146,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTktMS0xLTEtNzM5OTY_0fd6f2d7-cc52-45d0-812a-7c1d7690c152">169,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTktMy0xLTEtNzQwMDQ_203d4f4b-1ac4-4416-a222-c8abb4ddbfe1">146,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:74.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfMi0xLTEtMS03MDI3NQ_22ec58bd-6a8f-487d-a93d-fae6d2c41498">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfMi0zLTEtMS03MDI3NQ_fa4a806a-448e-47f1-9099-baafbd870147">43,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfMy0xLTEtMS03MDI3NQ_24a99a0b-881f-43f3-83d7-24f415e9e9bf">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfMy0zLTEtMS03MDI3NQ_210fe362-3910-418f-9714-8c1cb26cce07">1,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net pension (loss) gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfNC0xLTEtMS03MDI3NQ_7bde5a56-3cba-4066-a0e0-d1076dd8e34b">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfNC0zLTEtMS03MDI3NQ_28be355b-bdb4-48e6-8bf8-fa65d0bbd649">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfNS0xLTEtMS03MDI3NQ_a335e0b9-826f-4681-9543-81153d937202">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfNS0zLTEtMS03MDI3NQ_a9462161-b03f-4287-a8a6-b1c5a85ad55b">1,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfOS0xLTEtMS03MDI3NQ_2de31bcf-39b3-4648-afff-a401f6c55311">23,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfOS0zLTEtMS03MDI3NQ_0b50049a-d899-480d-963e-6800c5021fba">46,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.563%"><tr><td style="width:1.0%"></td><td style="width:30.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.421%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia30a9e39409b461c99159daa010f6c5c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy0xLTEtMS03MDI3NQ_b6cd1439-2f78-4c15-a392-adf029f3963e">166,793,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia30a9e39409b461c99159daa010f6c5c_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy0zLTEtMS03MDI3NQ_c4345085-703e-49d0-9c72-026773fb6b4f">1,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb9034932fc40c08ea5573339590e7f_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy01LTEtMS03MDI3NQ_10fdc0e1-713e-4f2e-a8cd-51a42732d78b">1,450,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac4ded14953b49d1addd06f731f72c7b_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy03LTEtMS03MDI3NQ_0b8a6e22-5e55-4d8e-8679-e9538aed0096">1,148,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f7c9d06ff1b4ead8670defb0e972860_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy05LTEtMS03MDI3NQ_295150da-22e4-423d-b141-83ac1752d9cb">8,404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy0xMS0xLTEtNzAyNzU_01222d17-a7b8-4f9c-992b-b95f0ec8f5fb">294,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock in connection with at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0c77020818e4b5580a54602bc3733dc_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNC0xLTEtMS03MDI3NQ_3e28b91c-d572-4cc6-97b0-5c146eb8ee68">3,962,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c77020818e4b5580a54602bc3733dc_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNC0zLTEtMS03MDI3NQ_663da430-530f-4b09-bd2e-199807f1111c">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc69df1bb8ee4558ae36144749414ed9_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNC01LTEtMS03MDI3NQ_99e47949-07b0-48c2-a068-ff202c8f6d6e">9,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNC0xMS0xLTEtNzAyNzU_f9fb9b14-fbb4-439a-a4f4-5ae63686b6ea">9,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0c77020818e4b5580a54602bc3733dc_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNS0xLTEtMS03MDI3NQ_7e74049f-3448-45b9-a402-dde63034798a">1,015,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c77020818e4b5580a54602bc3733dc_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNS0zLTEtMS03MDI3NQ_f91a37da-8378-4c8b-940d-d96920574b6b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc69df1bb8ee4558ae36144749414ed9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNS01LTEtMS03MDI3NQ_2be61be1-9f4e-4c47-90c3-0379e01dbfb6">1,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNS0xMS0xLTEtNzAyNzU_eba774ca-4b09-4c78-a8da-4b317afbeead">1,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc69df1bb8ee4558ae36144749414ed9_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNy01LTEtMS03MDI3NQ_13459ab8-e6fe-4aa3-a611-688781360f9c">8,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNy0xMS0xLTEtNzAyNzU_68a6cc46-4bbf-4aa0-8931-a1ca2c41fba1">8,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60c69134c4f4a03998a810770abe5f2_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfOS05LTEtMS03MDI3NQ_3735bee6-2a87-4f28-8def-a5b5148dcf69">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfOS0xMS0xLTEtNzAyNzU_3729da10-a694-414a-a340-31c2c7b8fce9">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net pension loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id60c69134c4f4a03998a810770abe5f2_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTAtOS0xLTEtNzAyNzU_c2bb0d0e-0ddc-4d3b-aed4-58e841912c0e">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTAtMTEtMS0xLTcwMjc1_5de03ee3-fe94-450e-9807-625fe40692df">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized gain on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60c69134c4f4a03998a810770abe5f2_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTEtOS0xLTEtNzAyNzU_361f89e4-78b0-4a63-9528-bce0263bf8af">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTEtMTEtMS0xLTcwMjc1_7306061a-38b0-43c7-9592-dfbc7ea44210">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6b4846ff7445a7bd06205ce088da41_D20230101-20230331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTMtNy0xLTEtNzAyNzU_e2a271d9-1140-4c6b-9b59-80cc6d0b20dd">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTMtMTEtMS0xLTcwMjc1_4c89f76e-518e-46dc-a6f1-0cabbc70f215">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iccea421e2a0c4b47b469cdf5d493c0e0_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtMS0xLTEtNzAyNzU_441aabf9-cf6e-4ba9-8f6e-999112dfb436">171,771,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccea421e2a0c4b47b469cdf5d493c0e0_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtMy0xLTEtNzAyNzU_8e5354d3-eab4-4dda-9af4-43e2abf03802">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3dfb89f8ba47408fd34040b407e005_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtNS0xLTEtNzAyNzU_22f1af98-bbba-4d60-99ca-5695dfc70d2d">1,467,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5abbb2c7d7944601bf890210157c2b4d_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtNy0xLTEtNzAyNzU_50148880-32d5-47cf-a988-4172830a1e3d">1,127,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91ca40960ab74c8fbafd0d9349205312_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtOS0xLTEtNzAyNzU_d377bf77-a0ea-42fc-a5fc-12f85457f314">5,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtMTEtMS0xLTcwMjc1_10445f2d-f813-4beb-916d-8a6ad8a32a46">335,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.706%"><tr><td style="width:1.0%"></td><td style="width:30.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.399%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.399%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.399%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.399%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.405%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>(Loss) Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c7722be40df413c8e437a49f401590f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy0xLTEtMS03MDI3NQ_87ee4383-befe-4742-a98f-34db444e1dad">145,921,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c7722be40df413c8e437a49f401590f_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy0zLTEtMS03MDI3NQ_66c7a998-dea0-4471-92d8-6401fcc57c6f">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff108f8c09274a6cbb44e10d8867b38a_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy01LTEtMS03MDI3NQ_dc812f1d-a1e2-445f-b192-b5841eeeed99">1,334,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac6d1271621d4cac8be74b9a037e4707_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy03LTEtMS03MDI3NQ_8f0b5e06-77f5-42ff-b4ca-d382ea852c41">956,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a89059a55449d3bc69e3f6de7098b1_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy05LTEtMS03MDI3NQ_9e2d829b-2306-49da-b254-e69056123270">3,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy0xMy0xLTEtNzAyNzU_2e3b0874-d0c7-4000-8d11-b606fae3695d">375,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i579b5f75540647cd977142ae38f4b321_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNS0xLTEtMS03MDI3NQ_7b4748b7-dfdd-4c6d-b267-90e6ba1f3b7b">743,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579b5f75540647cd977142ae38f4b321_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNS0zLTEtMS03MDI3NQ_e268999f-917e-41da-898b-70215d846818">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ccefc4a682e42bda1dd7730db19dcc0_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNS01LTEtMS03MDI3NQ_3e5ac3cb-e381-4a06-876e-8d07752f6820">1,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNS0xMy0xLTEtNzAyNzU_bbbccc95-fd06-4ca6-b2a0-de6e20015ecd">1,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ccefc4a682e42bda1dd7730db19dcc0_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNy01LTEtMS03MDI3NQ_91d511bb-05e4-4ee4-9c99-4d7b68f3d1b9">7,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNy0xMy0xLTEtNzAyNzU_774b5439-dd18-4d1a-92b6-da6cae868916">7,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e912a9a7bc746bd96bb5d87a08b8206_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfOS05LTEtMS03MDI3NQ_018e968b-8f37-4232-a37d-ff9f8d0337fb">1,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfOS0xMy0xLTEtNzAyNzU_9497cfc5-b4e4-4299-8065-4e2e52503bd8">1,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net pension gains</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e912a9a7bc746bd96bb5d87a08b8206_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTAtOS0xLTEtNzA3Njg_e49ec20f-afd7-47a0-9335-aaa9f776d4e4">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTAtMTMtMS0xLTcwOTAy_503f8d70-15ee-4339-824d-c3d9491ac596">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e912a9a7bc746bd96bb5d87a08b8206_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTAtOS0xLTEtNzAyNzU_ea6211ca-e578-4791-b89e-95fbc3d3f9a2">1,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTAtMTMtMS0xLTcwMjc1_7de7ce4c-c1a3-42d5-9d6a-78558c27b7fd">1,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1a85436c7c142278657c85e7ea9997b_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTItNy0xLTEtNzAyNzU_5d1cd66f-a62d-4801-b32c-5ed8fe7065b3">43,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTItMTMtMS0xLTcwMjc1_47af44dd-4b50-4a2d-adfd-aa47d9e67c1c">43,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibeae407467224307ae4941c1984b4b7f_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtMS0xLTEtNzAyNzU_352d0d0a-81f3-4aef-ab3b-b9f8711e8ad0">146,664,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeae407467224307ae4941c1984b4b7f_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtMy0xLTEtNzAyNzU_36fc3d72-a1c5-4565-937f-b07f9ee8d93c">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68b3111e2494397846164214ce99690_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtNS0xLTEtNzAyNzU_24044a60-c812-4475-87b2-c9da0868cc47">1,340,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3bdcc1051374821b3877c109bd673ae_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtNy0xLTEtNzAyNzU_9af5cfe5-4892-49ca-825c-7e07400ab517">1,000,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34bf2d104a444cc9834054ced8faa7f7_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtOS0xLTEtNzAyNzU_c716f458-8111-4e21-a7f0-ff682c60ba32">6,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtMTMtMS0xLTcwMjc1_cb6cef30-9fb2-46f7-8bcc-14f6465ce860">334,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:74.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMy0xLTEtMS03MDI3NQ_407f39cf-5176-4d19-8178-48f8da7846c5">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMy0zLTEtMS03MDI3NQ_1ca14b67-71c4-43d2-959d-296d34a54dd1">43,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNS0xLTEtMS03NTk1Nw_b5775063-59d3-4e61-8a26-97c53df7e0ba">38,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNS0zLTEtMS03NTk2Ng_873705f6-5d60-4b9b-b1f4-dc871af6d458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNy0xLTEtMS03NzkzNg_d2879dd8-4bfb-47c4-8c8f-5329047ff152">20,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNy0zLTEtMS03NzkzNg_19902290-4368-4bbc-b2a3-368f25965c3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNS0xLTEtMS03MDI3NQ_6b1f5790-730f-429b-b761-6560cf56eadc">3,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNS0zLTEtMS03MDI3NQ_0b7b0a97-71ce-434c-bbe8-6ae13ab20a9b">2,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Accretion of discounts) amortization of premium on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNi0xLTEtMS03MDI3NQ_adecc40e-97d1-4ddd-8324-58e5287e328b">1,048</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNi0zLTEtMS03MDI3NQ_b0a77e31-1b97-4428-ae5c-3a79304a93ab">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and other changes in operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" sign="-" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNy0xLTEtMS03MDI3NQ_6e91642d-18b2-4586-8c86-11e5b8b2bbe2">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNy0zLTEtMS03MDI3NQ_e72c3bea-0d3c-4031-a617-e1a115435520">2,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfOS0xLTEtMS03MDI3NQ_89ff0663-37e5-406b-8960-837cb5ff165a">8,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfOS0zLTEtMS03MDI3NQ_b6775239-7f50-4586-81c3-dac1b7906083">7,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTItMS0xLTEtNzAyNzU_fc4709fd-4726-4ed0-9b91-0a131aa2c14d">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTItMy0xLTEtNzAyNzU_c0c4ad74-8c27-402c-a267-fc8fa9814584">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTMtMS0xLTEtNzAyNzU_255e60ab-58b0-401d-b24a-a66ad2d65634">3,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTMtMy0xLTEtNzAyNzU_c20554c3-4229-421a-a81a-3e98f4c19ba0">925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTQtMS0xLTEtNzAyNzU_b98937f3-8b02-4632-b577-67d40be57d97">6,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTQtMy0xLTEtNzAyNzU_a3aefada-9c36-4830-b06b-8e7cbce49f8f">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTUtMS0xLTEtNzAyNzU_28727f34-cf5f-4522-9b0c-4eb3d4374da6">1,905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTUtMy0xLTEtNzAyNzU_d730b596-b538-42b1-afc3-31c4e00ce5dd">3,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTctMS0xLTEtNzAyNzU_f55b5c97-4e83-47f7-b28b-606c167e4d03">8,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTctMy0xLTEtNzAyNzU_e1ccdfd2-6da9-4c49-a0b7-57fe0bab122f">8,270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTktMS0xLTEtNzAyNzU_c59285a9-f1d0-401d-ab15-7d4a34137bc2">149,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTktMy0xLTEtNzAyNzU_cacc3cbf-8f35-4d28-989f-7ad57d6f0acd">21,004</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjAtMS0xLTEtNzAyNzU_10301ea6-9237-43ef-aef4-1a83c32f395b">1,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjAtMy0xLTEtNzAyNzU_ba115c5f-c386-40c1-be49-0493fd5f59d5">972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjEtMS0xLTEtNzAyNzU_28ac59eb-db6d-4a6a-a781-f563f3a2c515">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjEtMy0xLTEtNzAyNzU_4ebe2f2b-1ca2-41ad-9138-2136e8ecdcf3">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjItMS0xLTEtNzAyNzU_3110aa94-be3c-4a88-80c0-f3326c7b55fe">66,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjItMy0xLTEtNzAyNzU_38d2fef8-8540-46a9-8f51-8cb45c2ceba9">58,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjQtMS0xLTEtNzAyNzU_3e7e57e9-633f-485e-ae05-57ecb3138030">36,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjQtMy0xLTEtNzAyNzU_d43177e6-192c-4239-93b5-405182745624">65,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjUtMS0xLTEtNzAyNzU_ad1ba6f9-b636-4fe3-b470-da83a51d8662">82,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjUtMy0xLTEtNzAyNzU_ce059791-6e7c-435e-99f8-d379e25ee78c">70,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjctMS0xLTEtNzAyNzU_9682e9af-3de3-422b-a599-6d2c35e0b340">10,200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjctMy0xLTEtNzAyNzU_90b429b9-22ef-4c78-95c4-7cf7b15e1347">2,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzAtMS0xLTEtNzAyNzU_3148e555-87bf-4eb4-95d1-96f1f9b8e1f0">35,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzAtMy0xLTEtNzAyNzU_83cc2793-c9dd-48b4-bac5-c8617d843257">1,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie262d508238d48dc8b762871a33221db_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzItMS0xLTEtNzAyNzU_15c2eae3-c68e-4a7d-9c90-f8e80b4b3dbd">9,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id596b784d404435db73b47602bb3f897_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzItMy0xLTEtNzAyNzU_5a3280fa-821c-4c23-aa92-8ea054b25518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzQtMS0xLTEtNzAyNzU_18c4b5d0-cd50-43a5-aef4-9425386f1214">1,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzQtMy0xLTEtNzAyNzU_1b1bb0e9-9527-467f-8ec3-b016accc39d7">1,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzUtMS0xLTEtNzAyNzU_d9f1a151-4ead-4d6c-af5e-a898fefb457e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzUtMy0xLTEtNzAyNzU_7213884b-eb53-4e93-9bc3-ef6570d64d80">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzctMS0xLTEtNzAyNzU_2ce0226f-205c-4d73-bb81-2aa6eaa86472">8,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzctMy0xLTEtNzAyNzU_2a69a884-a5d4-4f01-858a-db7148fe6d54">1,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzgtMS0xLTEtNzAyNzU_c377f424-0743-40f0-be6d-e06f264632be">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzgtMy0xLTEtNzAyNzU_07f31527-f793-423b-9747-a6df44e9552c">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzktMS0xLTEtNzAyNzU_b2a8fec2-b834-4150-893c-faa9e7b9b6d0">22,203</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzktMy0xLTEtNzAyNzU_31eedfab-5546-47de-a41b-b4e1760386cc">58,615</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDAtMS0xLTEtNzAyNzU_f15f8945-55fd-4ac8-8d01-a21322ebab3a">101,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDAtMy0xLTEtNzAyNzU_4d65d93a-07d6-4322-8ab7-15a91f3bdd3f">180,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDEtMS0xLTEtNzAyNzU_d72292c5-ddc5-4beb-bccc-53dc398841f3">79,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDEtMy0xLTEtNzAyNzU_2b149776-8528-4929-b033-f19221232cfb">121,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment included in unpaid liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDMtMS0xLTEtNzAyNzU_50b26076-46d4-4606-a77d-002b44183f09">5,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDMtMy0xLTEtNzAyNzU_95c0ae72-5753-4635-b736-fb21dc2d9dd9">2,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance included in contra-lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="sgmo:TenantImprovementAllowanceWithinContraLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDUtMS0xLTEtNzAyNzU_f253792e-c745-40eb-82e2-11cead6d6374">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="sgmo:TenantImprovementAllowanceWithinContraLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDUtMy0xLTEtNzAyNzU_6e7ad268-8118-403d-9dd3-3495ab6330ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i056ce7da447f48a894f20e0202bfb367_40"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1&#8212;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwNDA_3c8f2f50-3147-4331-9559-f847db4fd65b" continuedAt="ia3fbec4e12c94dcbb259f51dd71a3960" escape="true">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ia3fbec4e12c94dcbb259f51dd71a3960" continuedAt="i9d7b846749164d9fa3efcbbced6c1170"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.</span></div><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzU_a41d88cf-634c-4f1c-adbf-ae66c23a2693" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The Condensed Consolidated Balance Sheet data at December&#160;31, 2022 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;2022 Annual Report&#8221;) as filed with the SEC on February&#160;23,&#160;2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2022, included in the 2022 Annual Report.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity, Capital Resources and Management&#8217;s Plans</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. In recent years, the Company&#8217;s operations have been funded primarily through collaborations and strategic partnerships, research grants and from the issuance of equity securities. As of March&#160;31, 2023, the Company had capital resources of $<ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNDM5ODA0NjU1ODYzMA_16ab28cf-57ed-4dc7-846a-739f0949f639">241.0</ix:nonFraction>&#160;million consisting of cash, cash equivalents, and marketable securities. Management believes that the Company&#8217;s existing cash, cash equivalents, and marketable securities in combination with other planned cost reduction initiatives will be sufficient to fund its operations for at least the next 12 months from the date these Condensed Consolidated Financial Statements are issued.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standard Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements&#8212;Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 205-40&#8221;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the Condensed Consolidated Financial Statements are issued. As required under ASC Topic 205-40, management&#8217;s evaluation should initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the Condensed Consolidated Financial Statements are issued. </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Substantial Doubt Raised</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the first step of the evaluation, the Company concluded that the following conditions raised substantial doubt about its ability to continue as a going concern:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although the Company reported net income of $<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MTk0_fee0dd20-16b2-4d98-bd1e-7b7663c0ce4e">21.1</ix:nonFraction>&#160;million for the three months ended March 31, 2023 primarily due to the termination of a collaboration agreement, the Company has a history of recurring net losses, including $<ix:nonFraction unitRef="usd" contextRef="i02b85f2e8972441db23e17a30d5bff74_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODI3ODM3_af7c7b9d-0506-4f65-ab84-78df4f75b8b6">192.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i76070b5a1a6143119c52bcf7c53c9b73_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODI3ODQ1_7ed6b3c3-eeab-4c19-affb-aef0251b0c0e">178.3</ix:nonFraction>&#160;million for the years ended December 31, 2022 and 2021, respectively; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MTU5_62bfd9cd-8c28-4a5b-a529-7ba36aca933b">1,127.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MTY4_a294ece8-3b1c-4bcf-b32b-5a15c6d79582">1,148.5</ix:nonFraction>&#160;million as of March&#160;31, 2023 and December 31, 2022, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="i9d7b846749164d9fa3efcbbced6c1170" continuedAt="ifd351e1fb48f43e29f5c5bc4b8c0219b"><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration of Management&#8217;s Plans</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the second step of this assessment, the Company is required to evaluate whether it is probable that its plans will be effectively implemented within one year after the Condensed Consolidated Financial Statements are issued and whether it is probable those plans will alleviate the substantial doubt about its ability to continue as a going concern.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified several actions, including cost reduction measures that already have been initiated or that would be initiated in a timely manner, to address the Company&#8217;s liquidity needs over the twelve-month period from the date the Condensed Consolidated Financial Statements are issued, as follows:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deferral and reprioritization of certain research and development programs that would involve reduced program and headcount spend;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduction in force that would be intended to extend the cash runway necessary to fund operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pause on any new hiring and reduction in ancillary expenses such as travel and recruitment expenses; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduction in non-critical capital and operating expenditures including additional equipment, lab improvements, efficiency projects, and business support spend.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Assessment of Ability to Continue as a Going Concern</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes management&#8217;s plans, as described more fully above, will provide sufficient liquidity to meet its financial obligations and maintain levels of liquidity over the twelve-month period from the date the Condensed Consolidated Financial Statements are issued. Therefore, management has concluded these plans alleviate the substantial doubt that was raised about the Company&#8217;s ability to continue as a going concern for at least twelve months from the date that the Condensed Consolidated Financial Statements are issued. Determining the extent to which conditions or events raise substantial doubt about the Company&#8217;s ability to continue as a going concern and the extent to which mitigating plans sufficiently alleviate any such substantial doubt requires significant judgment and estimation by the Company. The Company makes assumptions that management&#8217;s plans will be effectively implemented and alleviate substantial doubt and its ability to continue as a going concern. The Company believes that the estimated values used in its going concern analysis are based on reasonable assumptions. However, such assumptions are inherently uncertain and actual results could differ materially from those estimates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Plans and Considerations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be required to raise substantial additional capital to fund its operations and support its research and development endeavors. In this regard, the Company is actively seeking substantial additional capital, including through public or private equity or debt financings, royalty financings or other sources, such as strategic collaborations. However, additional capital may not be available to the Company, on terms that are acceptable or at all. If adequate funds are not available to the Company on a timely basis, or at all, the Company will be required to take additional actions to address its liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering its research and development activities, which could have a material adverse effect on the Company&#8217;s business. If the Company raises additional capital through public or private equity offerings, including sales pursuant to the Company&#8217;s at-the-market offering program with Jefferies LLC, the ownership interest of its existing stockholders will be diluted, and such dilution may be substantial, and the terms of any new equity securities may have a preference over, and include rights superior to, the Company&#8217;s common stock. If the Company raises additional capital through royalty financings or other collaborations, strategic alliances or licensing arrangements with third parties, it may need to relinquish certain valuable rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable. If the Company raises additional capital through debt financing, the Company may be subject to specified financial covenants or covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or pursuing certain transactions, any of which could restrict the Company&#8217;s ability to commercialize its product candidates or operate as a business. In addition, management&#8217;s cost reduction plans are intended to reduce the Company&#8217;s operating expenses and optimize its cash resources. Based on the timing of these cost reduction plans, the Company expects to start realizing the benefit of its efforts beginning in the second quarter of 2023; however, there can be no assurance that the Company will realize the benefits of the cost reduction plans on the anticipated timeline, or at all.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="ifd351e1fb48f43e29f5c5bc4b8c0219b" continuedAt="i50b9a5b6b8154bb297666f12a56d3588"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwNDU_2339d9ac-bd55-43ff-86b3-56c125c2652f" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Kite Pharma, Inc. This adjustment was driven by a reduction in the estimated future level of the Company&#8217;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of $<ix:nonFraction unitRef="usd" contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MDAx_cbe4eba4-de0f-4f3e-b123-2b383829a2d9">8.9</ix:nonFraction>&#160;million, an increase in net income of $<ix:nonFraction unitRef="usd" contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331" decimals="-5" name="sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MDIw_519392f1-389b-451a-926a-5f35d889e1d6">8.9</ix:nonFraction>&#160;million, and an increase in the Company&#8217;s basic and diluted earnings per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331" decimals="2" name="sgmo:IncreaseDecreaseInEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MDg1_2922173e-dc6b-416a-b0b2-6e2e5e72928f">0.06</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331" decimals="2" name="sgmo:IncreaseDecreaseInEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MDkz_00973f9f-3438-4096-acf8-d4a2a07c323b">0.05</ix:nonFraction>, respectively, for the three months ended March 31, 2023.</span></div><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzY_0eb33e11-1c2c-4552-b220-f87384b54422" continuedAt="i68ea918a9f2f4e74839bb64b3fbece74" escape="true"><div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and licensing agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#8217; product sales. All funds received from the Company&#8217;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. One of the Company&#8217;s contracts also contains a provision where the Company reimburses its customer for certain costs they incur which is accounted for as a reduction to the contract transaction price as the Company does not acquire any distinct goods or services in exchange for such payments. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the Company&#8217;s performance obligations in its collaboration agreements represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct. Options to license the Company&#8217;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g., a right to a discount the customer would not have received if they did not purchase the Company&#8217;s services under the existing contract. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from bundles of licenses of intellectual property and research and development services are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#8217;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#8217;s performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="i50b9a5b6b8154bb297666f12a56d3588" continuedAt="i43f651b738874e00b20cbce995461031"><ix:continuation id="i68ea918a9f2f4e74839bb64b3fbece74"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period of performance and level of effort, including the value of Company researchers&#8217; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current expectations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.</span></div><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMjk_2166e608-1351-4242-95fe-88e47178e733" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:74.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0c3ceda2ae9f4af0871fc85dd870550f_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMi0xLTEtMS03NDIyNg_a135f0b7-c35a-4472-ad3f-bfa91f2718a4">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaca29c7b3b79472aaf0ee13bc56470ac_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMi0zLTEtMS03NDIyNg_ca794735-ff69-4d20-b7a4-6725742d54df">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib5248b3610244c38b223f129709425f6_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMy0xLTEtMS03NDIzNg_cc1f0fa3-df31-4c08-993a-ba930d4ac020">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i90890f44b0704bb8ac590e628ae519de_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMy0zLTEtMS03NDIzNg_4ab68dbe-872c-4d61-a746-f578ed60d6e3">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1342bd78484460185b8895a3f6308ea_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMi0xLTEtMS03MDI3NQ_70901e2a-44d3-4094-91b7-8d2228aad6cb">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i228888ff63774a0da4d18154fc729ad5_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMi0zLTEtMS03MDI3NQ_16afddc7-1b24-4892-977f-3fdc2539950a">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi S.A.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie462eedb4107492bbce0acc5ff5754d8_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfNS0xLTEtMS03MDI3NQ_0f549ad0-42ad-4fa4-a73e-0f5579dd1b17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc8ea2db07274d118686e8a982ad7e70_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfNS0zLTEtMS03MDI3NQ_b870efa9-ca0b-42c0-b767-1fd7bdd64ca5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMjE5OTAyMzMxMzU0NQ_46c95f99-98ff-4f5f-9259-b93ac22a5722" continuedAt="ie0ba556227c54621a121ee3d48cc8690" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill, Intangible Assets and Long-lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased in-process research and development (&#8220;IPR&amp;D&#8221;) projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events and circumstances indicate that these assets may be impaired. The Company evaluates the fair value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In testing for goodwill impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the Company elects to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, the Company performs a quantitative goodwill impairment test to compare the fair value of its reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit&#8217;s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value (but not in excess of the carrying value of goodwill). </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to testing goodwill for impairment, the Company also tests impairment for its other indefinite-lived and long-lived assets. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="i43f651b738874e00b20cbce995461031" continuedAt="i02502460508c4aceb2e719e1440bbba3"><ix:continuation id="ie0ba556227c54621a121ee3d48cc8690"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates that the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div></ix:continuation><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzE_79f48ed6-54bd-47ef-98ee-cfd562639a32" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consists of a letter of credit for $<ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTE2Mzc_7ff4562b-a923-457a-a7bf-1168b2c3088e">1.5</ix:nonFraction>&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzg_201c9b5e-5186-46fa-9253-f8c3c8b1b5d0" escape="true"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzg_7d3c596e-2fbb-4110-ba44-ce1d9b33e4b9" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMS0xLTEtMS03MDI3NQ_9f6b9c46-b5d9-48cd-a363-54a1f148243b">78,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMS0zLTEtMS03MDI3NQ_8a39f882-69b4-4a67-8ac7-0db5ed763a60">100,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMS01LTEtMS03MDI3NQ_d8f648e1-dfcd-41e6-9f6d-d93836aa7f52">120,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMS03LTEtMS03MDI3NQ_29065a33-3548-45cd-83e1-85bd8727a201">178,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMi0xLTEtMS03MDI3NQ_249edf83-a8b1-4a32-aecb-6baeaa4cd1ec">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMi0zLTEtMS03MDI3NQ_2287ce51-8420-49b4-a370-a811d1ca1984">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMi01LTEtMS03MDI3NQ_d9fddf5e-8249-4c14-93c9-6a19f5ad75ac">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMi03LTEtMS03MDI3NQ_a6631e20-caa3-45fd-a629-919cac49abf4">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMy0xLTEtMS03MDI3NQ_14a136eb-89c3-49d9-ac27-b65ed26680e8">79,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMy0zLTEtMS03MDI3NQ_db77c51e-1e6d-4b94-b12e-58cd0b5bd39b">101,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMy01LTEtMS03MDI3NQ_c9685869-5720-4e5d-b735-42cdc728dad1">121,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMy03LTEtMS03MDI3NQ_f5a019e4-2e15-477e-93e3-272246dce7ba">180,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMjE5OTAyMzMyNTc5NQ_ee94b5f5-00b9-4667-bc33-387180a4bf3c" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company will evaluate the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is recognized, the Company will recognize lease impairment and subsequently amortize the remaining lease asset on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#8217;s useful life or the end of the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="i02502460508c4aceb2e719e1440bbba3"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzk_dbdc3624-364e-4682-9eb6-aafbe55058ae" escape="true"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div></ix:nonNumeric></ix:continuation><div id="i056ce7da447f48a894f20e0202bfb367_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2&#8212;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RleHRyZWdpb246YWI2Zjk3ZjMwNTcyNDlmMjkyYWNkNTY4ODFjMGM1NGFfMjI1Ng_9141f492-e279-4395-9930-15517dbf3a8f" continuedAt="if18c1053b680455184d346a317d0b386" escape="true"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RleHRyZWdpb246YWI2Zjk3ZjMwNTcyNDlmMjkyYWNkNTY4ODFjMGM1NGFfMjI2MA_5ae03b7f-38e3-4cbb-9a7e-41e08cc9b03c" continuedAt="iac092f0851e940fab7a2fdfa56250a3a" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="iac092f0851e940fab7a2fdfa56250a3a" continuedAt="i19e87b7cfc994cb395ff3bf140e5c5a2"><ix:continuation id="if18c1053b680455184d346a317d0b386"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div></ix:continuation><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RleHRyZWdpb246YWI2Zjk3ZjMwNTcyNDlmMjkyYWNkNTY4ODFjMGM1NGFfMjI1OA_2ca330c5-ce5d-43c0-b1cc-942f6044bab5" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1352fdf2ec644672809d7dd3d3bed33d_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfNS0xLTEtMS03MDI3NQ_a158e9de-ea42-4b12-8efc-852c9f0c0a64">34,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76977228f122459ba5f628b5569cae61_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfNS0zLTEtMS03MDI3NQ_940f2ef3-0e70-4538-a537-dadc1db67edc">34,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f7da342c5ac4a7ea636981a736322b9_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfNS01LTEtMS03MDI3NQ_6eadc4af-89cc-4d6f-a403-e164855b188f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d6fe81f256c4cc8b6f7fc522fdd2281_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfNS03LTEtMS03MDI3NQ_d41c60c2-69a2-4c66-bea9-b386c45b888f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f61e5cec7984b35ac4292098852fc91_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfOC0xLTEtMS03MDI3NQ_a20d709a-7081-46fb-805d-cbb8b130d056">34,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9898b19bcd74221a4ff8f06d9cb7cf7_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfOC0zLTEtMS03MDI3NQ_aec56d1d-fdb1-421f-b7e3-22f83350c325">34,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92619e333cc24f9e975a7de1bb2abeea_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfOC01LTEtMS03MDI3NQ_809ad2fc-c046-4fad-a80b-790f0d025431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a1749f9f00c4883957a94b42aedc00f_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfOC03LTEtMS03MDI3NQ_d0c64087-e9e1-44cd-aad0-4547b0b37f04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eacf9813ba44226a063dc9009a4a15f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTAtMS0xLTEtNzAyNzU_8814c1e1-0041-419a-a1a2-b2fba58842b3">33,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dceda8408ab4f4fbd7740cca575d5b0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTAtMy0xLTEtNzAyNzU_29a6fd11-fd7c-41bb-af72-d7eba3fc7f30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea9e2a9aacec47b5a0dad2b07a352357_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTAtNS0xLTEtNzAyNzU_09353fd8-1fb8-400f-ab3c-a93c911d0948">33,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i869c2ae932a24254b8289f3374d6a37b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTAtNy0xLTEtNzAyNzU_efc55d78-ed74-4440-bd36-afa2d2a3500f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie603a77a75c24e5bb6587690295c6f3d_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTEtMS0xLTEtNzAyNzU_b8ef62f1-83b9-4a37-8f70-8d4fef640259">70,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee59432e21b44a0e8975d6f3b16c5c4a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTEtMy0xLTEtNzAyNzU_75f0d900-42c7-4f25-b0a7-d7454ce79e7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ea0b74cc8544e1a3c671264db84d1e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTEtNS0xLTEtNzAyNzU_e7372fcc-ca61-47c4-a203-41d7f179e7c2">70,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d56b50a62c74d6185fdc6510e7cc1eb_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTEtNy0xLTEtNzAyNzU_0d73f841-5586-4847-9216-29bf4de675d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6032041d43be43a9bb2dc9299dffabad_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTItMS0xLTEtNzAyNzU_00ff1fb9-e9d9-46df-8842-e2437351f68b">8,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483c837a581a4a55b5c3d56642557778_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTItMy0xLTEtNzAyNzU_13e1c0c9-69dc-476d-9d8a-2d3bb4ff2a2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43cfc63e1c6c4f118396790ecc913456_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTItNS0xLTEtNzAyNzU_3d714758-624f-473a-bab1-b63894a505ab">8,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2b09c75601c44e5b6a50a7decb6edde_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTItNy0xLTEtNzAyNzU_9ce9a52b-889e-4d89-9e32-6eb981115d96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13fb183572b948d48d0e0dde8e690e47_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTMtMS0xLTEtNzAyNzU_e6be0d93-730d-4710-8e80-f80e608211a1">14,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1429086824143138e26fa0505ab0fed_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTMtMy0xLTEtNzAyNzU_40f28f55-3558-4d1f-bbfa-b13120d35b9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead8dc5bda5146e0849851aa8f041938_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTMtNS0xLTEtNzAyNzU_f5477062-6fdf-4c50-b11c-01a3ebba80c8">14,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37baec065284201ae771b20cce5ff25_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTMtNy0xLTEtNzAyNzU_2198f79d-d620-4e78-aadc-94fc69b82d1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8f85ae07f54b72871595f4e0b87538_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTQtMS0xLTEtNzAyNzU_3788455d-0620-418e-a275-0c27d0125130">5,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862b92b01544466ba544053538532461_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTQtMy0xLTEtNzAyNzU_56379ba2-49cb-4c63-9328-f64a82088fb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i749604d15996441483daf9b51492bbbb_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTQtNS0xLTEtNzAyNzU_0912dde1-bec5-42e5-8ffb-22b4e75ec21c">5,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e496ca5ed849de88c1758f1bfec843_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTQtNy0xLTEtNzAyNzU_948fcd5c-2e8a-48bf-93da-1649c36b88b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i030f27a6938f4ae3b1d61555d37da11b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTUtMS0xLTEtNzAyNzU_79822569-8307-40f1-95d2-f34dccc8614c">29,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia99bbd5a24a34bdb914d71eed48233f3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTUtMy0xLTEtNzAyNzU_3f940f65-faba-46d5-9da6-0f9bbf1a1db7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fdaa779102440c8193f79514249c1b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTUtNS0xLTEtNzAyNzU_4adc011c-e609-4c98-af2e-dbc8300b5f80">29,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ef8c6fa4624c93842e0f3638e26f25_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTUtNy0xLTEtNzAyNzU_e5aa9c5a-d15f-4f10-a7d0-a506b2f9d08a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f61e5cec7984b35ac4292098852fc91_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTYtMS0xLTEtNzAyNzU_6e3a5aa5-3109-4d94-9232-c16ce7af6b71">162,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9898b19bcd74221a4ff8f06d9cb7cf7_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTYtMy0xLTEtNzAyNzU_69197231-bd50-4436-8f90-dcd48a9335f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92619e333cc24f9e975a7de1bb2abeea_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTYtNS0xLTEtNzAyNzU_781a4435-395c-40e9-ab26-4b71984a7f7f">162,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a1749f9f00c4883957a94b42aedc00f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTYtNy0xLTEtNzAyNzU_e739a03f-bc74-49b1-af57-9c5b36e89097">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f61e5cec7984b35ac4292098852fc91_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTctMS0xLTEtNzAyNzU_bafa6ddf-1d03-4702-b368-36db4e7f0ed2">197,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9898b19bcd74221a4ff8f06d9cb7cf7_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTctMy0xLTEtNzAyNzU_44f365a2-abb4-4240-8114-199c833595d7">34,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92619e333cc24f9e975a7de1bb2abeea_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTctNS0xLTEtNzAyNzU_d93c05a1-f8e6-4ac8-aaf5-1d9cea7db1f0">162,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a1749f9f00c4883957a94b42aedc00f_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTctNy0xLTEtNzAyNzU_8ecd562e-c1d4-451a-9bb6-6771f36a3449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75fa9da1a76b437cb308a2069d2b6eab_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNS0xLTEtMS03MDI3NQ_6a3040bd-ddea-421e-bc42-dc27af142c65">50,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb0eb1a3d40494d975a79e8bcfe27f9_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNS0zLTEtMS03MDI3NQ_d368c85a-d382-435b-b4c3-17c18096139b">50,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5c39a22139a4538b0384f237621d593_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNS01LTEtMS03MDI3NQ_867892ba-2beb-418b-bb22-68506295017d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f4b7dc92a60450187eb7cba78d4c993_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNS03LTEtMS03MDI3NQ_028a9e6a-b1a6-4dd5-a985-edf473da6c2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab229808f3044fba8b9d5250cb15ae30_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNi0xLTEtMS03MDI3NQ_b426d2cf-84b8-4918-b348-fecdd6471bff">50,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b36ed08a50e40e19b52b258e576bdcb_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNi0zLTEtMS03MDI3NQ_2203a7ec-ff5c-44d7-9a10-a413a913c886">50,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202c7c1338114a3bb3508dd0e372fd84_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNi01LTEtMS03MDI3NQ_e0bdee6e-ccf6-47d1-9b0b-94372340e57f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7057bf4fdd9c4e7eaa545683b37732c2_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNi03LTEtMS03MDI3NQ_fc971556-1f51-49c4-916a-218975171515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if73e2cb32fab46ffbe55e9f5a5da0de2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOC0xLTEtMS03MDI3NQ_4cfda76d-8b29-4685-aa5d-29fc8874e94d">18,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02fe7f2d5f244d2b94f1aaaaefcea866_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOC0zLTEtMS03MDI3NQ_deba7efe-e95a-4540-b7ef-0f001400f539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9260c94253f4086af0b69700e462ff9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOC01LTEtMS03MDI3NQ_754951ca-e691-43f0-a221-30218076e8d9">18,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd16acd018e74a0eb2ef2d18b3ee3a05_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOC03LTEtMS03MDI3NQ_cc72587c-bb6f-470d-b303-efbcbd1c0f28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023a682c38c1450e86a5514fd42920ab_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOS0xLTEtMS03MDI3NQ_3232cae3-95a5-4f78-94e1-f5341f4bc2ae">101,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75b8fa59ce34fb895f1352a74043e96_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOS0zLTEtMS03MDI3NQ_79642652-20fc-4e0c-9c9e-9ceac53b809a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7724b0150a1d4054a320c6e4ef27fccd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOS01LTEtMS03MDI3NQ_67a6638c-c0b6-4578-810a-09168716f1f8">101,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed6d25a758441dbb31e2700f31431a6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOS03LTEtMS03MDI3NQ_1b72631d-7eee-4dc1-bb8b-703b9994aa5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6febdf9b3c3b4c168661eb22fdc0ed1e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTAtMS0xLTEtNzAyNzU_df5dc39d-9a01-4d08-9a56-9ab3844d5960">11,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce4a249017b49d09aabf529ed967fae_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTAtMy0xLTEtNzAyNzU_25c3094c-421f-4583-b78c-7f44af6cd960">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb946291e031440cbc217d13ca32b3be_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTAtNS0xLTEtNzAyNzU_bd7ae44c-907e-4b3e-a397-96789adb5998">11,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d5cfc64a3af4b758962c25f72175778_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTAtNy0xLTEtNzAyNzU_d020f7ad-35fd-4f71-9432-2d664d7ca7a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dfcb895014c45b9afa399178f988a8f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtMS0xLTEtNzEyMjM_5f8195f1-5bb5-442f-8816-8d3971e0936f">24,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb05bb816d48471695d20ca909641996_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtMy0xLTEtNzEyMjM_3041a834-37e9-4b30-b92d-9d70c53f90b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e171ab888a84b13bd2208636c991ac8_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtNS0xLTEtNzEyMjM_5a47ae08-567c-4dc0-920a-ac3d6e070d02">24,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i710edc7861594a64934aa92ebca6d053_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtNy0xLTEtNzEyMjM_939f547f-1355-4251-a5a9-2c8c9c4f8e25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22c629aefe14ad9a522a27354756d3e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtMS0xLTEtNzExNzQ_b4db5bc9-d770-44a2-b2ce-1df04384309e">7,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5f113b72b84c4b83630824ece95871_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtMy0xLTEtNzExOTA_7df65f8c-cc20-448c-bf61-346b0f764bbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e703c64cdfb44f3ba9f51bd3b3515d0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtNS0xLTEtNzExNzQ_1ce668dc-24c9-4fd7-b191-9ff136af5573">7,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2beb4271e37a4f91875382a0f384b26b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtNy0xLTEtNzExOTA_4f331d59-875d-48e3-9acb-daf5bc4e242e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bac443782f4620ba81a5a825bcf681_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTItMS0xLTEtNzAyNzU_6eb11fb4-7371-4f19-8b11-7488200d3513">37,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if22b2e9750244dc98e0c8b4d07365f2c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTItMy0xLTEtNzAyNzU_01b52cdb-7d3f-4a25-92e8-ffb675638e10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b64c2dbe567488896866da512af7840_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTItNS0xLTEtNzAyNzU_3873146a-2a56-4374-a206-f020537b9635">37,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72394fea9c574b08a7bf8ac3b21f6a13_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTItNy0xLTEtNzAyNzU_6dbb1fc4-f790-4bdb-a159-b6133d70e414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46d82c5052ab497b84f515cc2d04ad09_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtMS0xLTEtNzEyMTU_96235082-efd4-4126-87f3-320529aaaecf">5,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33ecf1a446814705933fbfd6cb111914_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtMy0xLTEtNzEyMTU_4ce84d59-9272-4683-ba6d-abfe6aa37c87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0be6f0fd28e547138aedec8a3f9ad6c4_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtNS0xLTEtNzEyMTU_ef905001-fe4b-4303-b27f-ad92dfb7e649">5,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b32d58beb5e49b0addbd7559d9a7775_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtNy0xLTEtNzEyMTU_e88c12e2-a8b5-438d-942e-5679c58266f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab229808f3044fba8b9d5250cb15ae30_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTMtMS0xLTEtNzAyNzU_399bead3-4b2d-4302-b146-3e3f589dad1c">207,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b36ed08a50e40e19b52b258e576bdcb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTMtMy0xLTEtNzAyNzU_2bc071c5-671a-4f86-b6f2-68d3d26032b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202c7c1338114a3bb3508dd0e372fd84_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTMtNS0xLTEtNzAyNzU_9c09cf33-3e48-4501-ad33-b36eec575987">207,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7057bf4fdd9c4e7eaa545683b37732c2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTMtNy0xLTEtNzAyNzU_98623a7c-e30e-48ea-b200-236416c51eee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab229808f3044fba8b9d5250cb15ae30_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtMS0xLTEtNzAyNzU_365e44c5-9251-412d-85ad-3b692b84cd52">257,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b36ed08a50e40e19b52b258e576bdcb_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtMy0xLTEtNzAyNzU_9f200a26-1054-48db-aedf-b3eedc19b1df">50,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202c7c1338114a3bb3508dd0e372fd84_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtNS0xLTEtNzAyNzU_a5fda2ca-9574-4016-a57a-6f5fc66882fa">207,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7057bf4fdd9c4e7eaa545683b37732c2_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtNy0xLTEtNzAyNzU_67b98157-1b57-4242-b9eb-f765d6c7b11d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="i19e87b7cfc994cb395ff3bf140e5c5a2"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3&#8212;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjczOQ_32976dbb-ca70-4c59-8952-c97e7e125951" continuedAt="i08928187fc4c4a2995afb1f256e8a452" escape="true">CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i08928187fc4c4a2995afb1f256e8a452" continuedAt="ifb0a5af4bbdb47daa9b0d4ebfdbd560a"><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjc0NA_e3806a2e-45e1-4586-9ce8-8b23192afe04" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93fcf6ad011a47d8bd403279bf5444bd_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNC0xLTEtMS03MDI3NQ_b768ec37-abeb-43e9-929c-eef4be5af6e2">34,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93fcf6ad011a47d8bd403279bf5444bd_I20230331" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNC0zLTEtMS03MDI3NQ_ec382301-fb73-42a1-9dbb-61f40f2957d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93fcf6ad011a47d8bd403279bf5444bd_I20230331" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNC01LTEtMS03MDI3NQ_02804faf-f64e-465c-8404-bf49527b2c40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93fcf6ad011a47d8bd403279bf5444bd_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNC03LTEtMS03MDI3NQ_5fdf7514-a395-4167-a1af-ef78a8a9a5e8">34,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19697738bf094279973b7cad292bc53f_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNy0xLTEtMS03MDI3NQ_88df9861-cf5c-495b-849b-9ef88f229c48">34,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19697738bf094279973b7cad292bc53f_I20230331" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNy0zLTEtMS03MDI3NQ_20ea6ed6-1d8a-4b23-87ab-6793293c4210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19697738bf094279973b7cad292bc53f_I20230331" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNy01LTEtMS03MDI3NQ_04a919d8-6dfa-4597-988c-d8ccddf7a0d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19697738bf094279973b7cad292bc53f_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNy03LTEtMS03MDI3NQ_1e519318-84ea-45cf-8380-33e4ca800fa2">34,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054c316aa399405fb28e17d9ac5f6b7b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfOS0xLTEtMS03MDI3NQ_e7b3adf2-5b99-41a3-9e74-34f41dfb3e12">33,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054c316aa399405fb28e17d9ac5f6b7b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfOS0zLTEtMS03MDI3NQ_c0f573d5-39d4-47bb-8e06-f6cd0d011373">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i054c316aa399405fb28e17d9ac5f6b7b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfOS01LTEtMS03MDI3NQ_f081cb1f-e684-4ed2-8acf-9655e3e6e4a8">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i054c316aa399405fb28e17d9ac5f6b7b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfOS03LTEtMS03MDI3NQ_a85fdfcb-cbab-40b9-9a4f-f6add8bc80a4">33,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3248fa7b3248df8737d1c52d665c5b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTAtMS0xLTEtNzAyNzU_8d15f56e-267b-4067-b732-65c28be1ef23">70,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3248fa7b3248df8737d1c52d665c5b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTAtMy0xLTEtNzAyNzU_8dfb4e9c-4915-457c-970e-c94c7e564424">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e3248fa7b3248df8737d1c52d665c5b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTAtNS0xLTEtNzAyNzU_b9fc7c5f-63c2-4568-b7bb-e929dac86320">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3248fa7b3248df8737d1c52d665c5b_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTAtNy0xLTEtNzAyNzU_b52ce681-79c3-4495-8e77-5c99673fde24">70,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9b4275c69b4a3da6c127b76ab498d0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTEtMS0xLTEtNzAyNzU_5cf5f8e5-78d2-4232-93bb-21640fe93d96">8,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9b4275c69b4a3da6c127b76ab498d0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTEtMy0xLTEtNzAyNzU_402f1fb1-a193-4fd6-98ff-b27b0283f445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f9b4275c69b4a3da6c127b76ab498d0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTEtNS0xLTEtNzAyNzU_5a9984f1-0702-4f31-8e1f-8e4aec8dae75">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f9b4275c69b4a3da6c127b76ab498d0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTEtNy0xLTEtNzAyNzU_e68f7fc5-f148-464e-9e14-0c545e70db2a">8,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4f486712abb466bb4fed83def8c8c69_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTItMS0xLTEtNzAyNzU_611fb858-8a97-4e07-a1fe-e47fef0afa87">14,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4f486712abb466bb4fed83def8c8c69_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTItMy0xLTEtNzAyNzU_12e14bf3-3ffc-4645-80a0-153c7e50ba7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4f486712abb466bb4fed83def8c8c69_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTItNS0xLTEtNzAyNzU_7e810fe5-afe2-41af-8e19-046da88bffd3">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4f486712abb466bb4fed83def8c8c69_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTItNy0xLTEtNzAyNzU_adaaaa84-e6b9-455c-9907-a12b9073df5c">14,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e554d5745be4b61b64b3b228f9ea2b6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTMtMS0xLTEtNzAyNzU_2c302156-30d6-4cd5-af65-618c0680910f">5,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e554d5745be4b61b64b3b228f9ea2b6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTMtMy0xLTEtNzAyNzU_7389d964-9f19-4e0e-8193-5a861f6adb3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e554d5745be4b61b64b3b228f9ea2b6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTMtNS0xLTEtNzAyNzU_9416aba0-c0ce-4132-9c8d-99dc12a80fab">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e554d5745be4b61b64b3b228f9ea2b6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTMtNy0xLTEtNzAyNzU_099ede52-ad62-4ab6-aeb5-ca16a9cd9937">5,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1113f5d2f3014aeab32e8e98f8161f84_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTQtMS0xLTEtNzAyNzU_edfef7c7-36a1-42fe-911f-388e6807f8e4">29,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1113f5d2f3014aeab32e8e98f8161f84_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTQtMy0xLTEtNzAyNzU_c99f5d97-53a1-44ae-b506-077d3790f172">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1113f5d2f3014aeab32e8e98f8161f84_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTQtNS0xLTEtNzAyNzU_042d902c-2fb2-4457-ad05-b25fe1dcbb72">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1113f5d2f3014aeab32e8e98f8161f84_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTQtNy0xLTEtNzAyNzU_3ae807dc-c3f5-4f78-b1a0-995e8d473a85">29,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTUtMS0xLTEtNzAyNzU_d4d80305-62e8-4c5e-8f41-34e39d6e65c1">163,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTUtMy0xLTEtNzAyNzU_55eb4caf-886c-4e6f-9a5f-1b9e183f26e1">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTUtNS0xLTEtNzAyNzU_2f80aa73-942a-4b32-8f3d-aae0eb1c9d6f">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTUtNy0xLTEtNzAyNzU_2e60f305-829f-4840-b531-3ca4cfb4cfc8">162,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTYtMS0xLTEtNzAyNzU_5a854553-3da1-4393-8eb3-31a1f5123678">197,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTYtMy0xLTEtNzAyNzU_abefd35f-d579-4acd-aa36-9ea58030791b">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTYtNS0xLTEtNzAyNzU_3f357f11-f21c-42e7-9e68-ceede16b39c9">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTYtNy0xLTEtNzAyNzU_819e0174-0681-4d6a-a182-fac3e8d7954f">197,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739dc723663c47d7b30394d8567919dc_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjEtMS0xLTEtNzAyNzU_81b157db-2913-4cb1-bba0-50bb35685f3a">50,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739dc723663c47d7b30394d8567919dc_I20221231" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjEtMy0xLTEtNzAyNzU_7474553a-1966-44da-82c1-70f957caa1f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739dc723663c47d7b30394d8567919dc_I20221231" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjEtNS0xLTEtNzAyNzU_f638dc5d-9986-4617-9e86-d054dda7eff1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739dc723663c47d7b30394d8567919dc_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjEtNy0xLTEtNzAyNzU_490cdb3d-e33f-43b9-a3a1-ea75fc8c7661">50,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c5b6d179045cab6406d5372cc5441_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjItMS0xLTEtNzAyNzU_6b0f0c4c-a408-44f8-830e-cb783982eb22">50,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c5b6d179045cab6406d5372cc5441_I20221231" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjItMy0xLTEtNzAyNzU_3c2757ae-d039-47c9-9ded-0b53fd598e9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c5b6d179045cab6406d5372cc5441_I20221231" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjItNS0xLTEtNzAyNzU_0311a696-ae23-471b-bcca-7fce4cb9b0ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i382c5b6d179045cab6406d5372cc5441_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjItNy0xLTEtNzAyNzU_a26e3e97-78ce-4a4e-b89a-7f3b1cf0b0ae">50,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib74d65ada2ff4867ab5f3259d7d950ed_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjQtMS0xLTEtNzAyNzU_d2bf7477-f483-4121-ad13-f98ba8534b84">18,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib74d65ada2ff4867ab5f3259d7d950ed_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjQtMy0xLTEtNzAyNzU_c217abcf-c178-4909-aeab-9a7e0105f807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib74d65ada2ff4867ab5f3259d7d950ed_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjQtNS0xLTEtNzAyNzU_a2cae439-a7a5-47cf-8364-7acda6a4a304">293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib74d65ada2ff4867ab5f3259d7d950ed_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjQtNy0xLTEtNzAyNzU_8d1bbe57-39cf-439c-bef8-53e7180a1a36">18,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54118fa133440819c9192da179240e9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjUtMS0xLTEtNzAyNzU_99c191d7-1825-408e-a2d0-eec14073e6d1">101,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54118fa133440819c9192da179240e9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjUtMy0xLTEtNzAyNzU_8bc3f25b-c6c2-45d1-8545-5296626870de">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if54118fa133440819c9192da179240e9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjUtNS0xLTEtNzAyNzU_83d61b5b-c58a-4d13-afe0-1ee2015b1d2b">193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54118fa133440819c9192da179240e9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjUtNy0xLTEtNzAyNzU_f7faf1e6-bc59-4fb0-ad17-ce3814f309fe">101,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9f8bb01a8d149d993b5ba9c67d52a69_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjYtMS0xLTEtNzAyNzU_48799567-6e1b-4ca4-9aea-98684c83002b">11,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9f8bb01a8d149d993b5ba9c67d52a69_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjYtMy0xLTEtNzAyNzU_3110bfc7-e68c-4de0-9d00-66ed2c58ba56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9f8bb01a8d149d993b5ba9c67d52a69_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjYtNS0xLTEtNzAyNzU_a850dfcc-287c-4044-839b-47b6a647003b">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9f8bb01a8d149d993b5ba9c67d52a69_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjYtNy0xLTEtNzAyNzU_9f6c9f3e-7968-4adf-b042-1b955dbe2e74">11,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0441be5e852742ed898a9eb78b769265_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjctMS0xLTEtNzAyNzU_abf977ae-eee1-4a53-b806-8aed67ea5211">24,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0441be5e852742ed898a9eb78b769265_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjctMy0xLTEtNzAyNzU_d7d092e4-b95d-4bef-bd50-d3c1278500c9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0441be5e852742ed898a9eb78b769265_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjctNS0xLTEtNzAyNzU_5641d96a-950a-4f0d-9e29-9a6d459948db">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0441be5e852742ed898a9eb78b769265_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjctNy0xLTEtNzAyNzU_33ab22d6-2274-4b28-9c0a-9ccf5e9ce258">24,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775d20c1dc4c46e68398640e2b73e1dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtMS0xLTEtNzEzNDM_ab93939f-e478-4cca-ba72-18703b4fa210">7,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775d20c1dc4c46e68398640e2b73e1dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtMy0xLTEtNzEzNDM_37669743-6282-4b6f-b3a6-8e46b42f6bf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i775d20c1dc4c46e68398640e2b73e1dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtNS0xLTEtNzEzNDM_3ba476e0-b9cc-4f7c-abfa-6dd89806307b">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775d20c1dc4c46e68398640e2b73e1dd_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtNy0xLTEtNzEzNDM_3b1ad094-3351-47f6-b671-19a4856d86de">7,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04730ad90e0401eb7693f8828b8bc5d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtMS0xLTEtNzAyNzU_0c4e66fe-9e85-4ac5-8ace-1084db5c2c9f">37,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04730ad90e0401eb7693f8828b8bc5d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtMy0xLTEtNzAyNzU_d0c51a77-f9d9-462a-ac70-4eb8dab92b38">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if04730ad90e0401eb7693f8828b8bc5d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtNS0xLTEtNzAyNzU_c4f9da5a-2839-44f3-8a79-6ee300294ceb">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04730ad90e0401eb7693f8828b8bc5d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtNy0xLTEtNzAyNzU_873b30f6-59ae-4048-a8ee-0113c49feddc">37,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03492c5aa4e4c55a0716a7facf39b4e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtMS0xLTEtNzEzNTE_8a0df2fd-a390-4cfd-b4cf-e14df05fdca7">5,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03492c5aa4e4c55a0716a7facf39b4e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtMy0xLTEtNzEzNTE_121b0bc3-94bd-4b68-a733-1799a4ae5c6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if03492c5aa4e4c55a0716a7facf39b4e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtNS0xLTEtNzEzNTE_93776e05-c842-4aa7-a852-746a39725729">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03492c5aa4e4c55a0716a7facf39b4e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtNy0xLTEtNzEzNTE_f8953ba3-9c12-40ca-b551-5d29a535533d">5,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjktMS0xLTEtNzAyNzU_e685ecc4-1323-497f-b257-99f9d891225e">207,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjktMy0xLTEtNzAyNzU_55ea4ad1-42bc-427f-9430-caba84ed3e2e">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjktNS0xLTEtNzAyNzU_101a5bc8-94fd-4d08-ba2c-5bb047addd1f">918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjktNy0xLTEtNzAyNzU_cd7014f4-a652-406f-9713-acb3d8470d3d">207,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtMS0xLTEtNzAyNzU_a72ce3c8-0dea-4cbd-b426-fdff9277f866">258,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtMy0xLTEtNzAyNzU_11f4cb4f-1e0a-49e6-9b61-36f67ea88069">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtNS0xLTEtNzAyNzU_5928018a-6a15-4904-9112-74224fc235de">918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtNy0xLTEtNzAyNzU_fde3f23b-da08-48b2-88ec-d111b40d142d">257,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:36pt"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjc0Ng_1348f896-cfcd-4743-8d2d-3126bc668bb7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:74.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMS0xLTEtMS03MDI3NQ_9abf6fdc-9485-457c-87d1-862fffe05728">127,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMS0zLTEtMS03MDI3NQ_b64b4b68-a9ee-45ef-a90a-9f43733239f8">177,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMi0xLTEtMS03MDI3NQ_f22999fc-4b64-4132-8896-d3652213cb15">35,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMi0zLTEtMS03MDI3NQ_2a0a251b-72fe-42f3-b682-b7d490770b83">29,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMy0xLTEtMS03MDI3NQ_f96a4c75-bc70-45c2-9879-fbf841c0a671">162,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMy0zLTEtMS03MDI3NQ_84acfcf3-c58a-4208-94a0-4597d0cc3968">207,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="0" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjY0_897bad46-7d6d-4894-927e-7c8eae9e2845">no</ix:nonFraction> realized gains and losses on the sales of investments during the three months ended March&#160;31, 2023. Realized gains and losses on the sales of investments were <ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="0" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjc0ODc3OTA3MjY5NQ_3ccdd538-c24a-4396-b467-813edcfcd811">not</ix:nonFraction> material during the three months ended March&#160;31, 2022. Total unrealized gains for securities with net gains in accumulated other comprehensive income were not material for the three months ended March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="ifb0a5af4bbdb47daa9b0d4ebfdbd560a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">did <ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfNzA4_8a1ca219-1e07-4b1d-8ba0-82ae9578ee0b"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfNzA4_9c37a077-fa3f-42ca-a64f-e3ee3680343e"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="INF" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfNzA4_cd659d12-069d-4433-ac9e-ebcd5c9b26c7"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfNzA4_d9bc8f1a-ff1f-4ff3-9e8c-010968b39d1f">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t record an allowance for credit losses or other impairment charges related to its marketable securities for the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2023 and 2022. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that are in a continuous unrealized loss position for greater than 12 months as of March&#160;31, 2023 and December&#160;31, 2022. Based on the scheduled maturities of its investments, the Company determined that it was more likely than not that it will hold these investments for a period of time sufficient for a recovery of its amortized cost basis. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#8217;s ability and intent to hold the investments until maturity, the Company determined that <ix:nonFraction unitRef="usd" contextRef="i9a68418627e64a97967175e21376a7f3_I20230331" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjY0MA_507ef156-1d7c-4573-9b1e-768e5d19755d"><ix:nonFraction unitRef="usd" contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjY0MA_62701416-a86a-48b8-9b19-b1a036eef59c">no</ix:nonFraction></ix:nonFraction> allowance for credit losses related to its marketable securities was required at either March&#160;31, 2023 or December&#160;31, 2022.</span></div></ix:continuation><div id="i056ce7da447f48a894f20e0202bfb367_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4&#8212;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RleHRyZWdpb246MGRkYmZhYzcwYjMwNDJlNTlkZmFmMzhhNGFjYzU3MWZfMTE0MA_0e52cb28-99bd-4f34-a993-4b3c1f888a16" continuedAt="i6ee702e08c78436bae92d07f76737bfa" escape="true">BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i6ee702e08c78436bae92d07f76737bfa" continuedAt="if5f348da684c4fdbaa2b6f6cba3264a3"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share has been computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. </span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RleHRyZWdpb246MGRkYmZhYzcwYjMwNDJlNTlkZmFmMzhhNGFjYzU3MWZfMjE5OTAyMzI1ODE5MA_c640e208-07bc-4e56-9932-8bc8c2373d9a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMy0xLTEtMS03NTY2MA_26e8561d-435d-40b0-a8af-1dec90aeee32">21,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMy0zLTEtMS03NTY2MA_de43b60a-ec66-4bcd-9a50-e57a966ec8f3">43,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNi0xLTEtMS03NTY2MA_a57a5882-6143-44e9-bd3e-f245896ecc4e">168,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNi0zLTEtMS03NTY2MA_4f301c8d-206f-4a9a-96d5-20c8215a63b7">146,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfOS0xLTEtMS03NTY2MA_7ac8102b-a940-464c-aaf7-ab587f3310c0">168,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfOS0zLTEtMS03NTY2MA_10ae6677-b7e6-43d5-9ebb-ecf0d65de719">146,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iddef1edbf4fe4f019d6237e6e633beb1_D20230101-20230331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTEtMS0xLTEtNzU2NjA_11957cb3-231f-430c-8976-1c2d727fd2b3">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie99095be5cac40ca995b3b8a0de25abf_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTEtMy0xLTEtNzU2NjA_9f71aece-e2a2-40a0-b503-f963042d31e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4f07d68b8514889b8593d1beef8cb7e_D20230101-20230331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTItMS0xLTEtNzU2NjA_e03ce4ca-bd50-4d32-afea-087ec4cb1656">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1be2098986b14f5aba5262c6164a6fbf_D20220101-20220331" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTItMy0xLTEtNzU2NjA_5d610f06-a4a1-407f-8383-354b9a814037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTMtMS0xLTEtNzU2NjA_f8b6839e-4191-47bc-b56d-181fda0fa8c6">169,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTMtMy0xLTEtNzU2NjA_fa105b89-b7f7-46b5-ad5c-bf21a5ac00be">146,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNC0xLTEtMS03NTYyMw_cad198ca-e679-4559-9fe4-762c54778b50">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNC0zLTEtMS03NTYyMw_d0de4e11-94aa-405a-9809-061b11a2bec0">0.30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNS0xLTEtMS03NTYyMw_83fa9603-b614-447f-bfe5-d49c85737a2c">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNS0zLTEtMS03NTYyMw_0eaffae4-9a12-4a31-9071-9ca118add8bb">0.30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if5f348da684c4fdbaa2b6f6cba3264a3">The computation of diluted net income per share for the three months ended March&#160;31, 2023 excluded <ix:nonFraction unitRef="shares" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RleHRyZWdpb246MGRkYmZhYzcwYjMwNDJlNTlkZmFmMzhhNGFjYzU3MWZfNTQ5NzU1ODE4Mjg3_5a463656-0b34-41b7-a751-a3fbd57ed69d">14.7</ix:nonFraction>&#160;million shares subject to stock options because their inclusion would have had an anti-dilutive effect on diluted net income per share. The computation of diluted net loss per share for the three months ended March 31, 2022 excluded <ix:nonFraction unitRef="shares" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RleHRyZWdpb246MGRkYmZhYzcwYjMwNDJlNTlkZmFmMzhhNGFjYzU3MWZfNTQ5NzU1ODE4NTE2_861f851e-7d08-4e3c-bcb9-cc1a303f487d">19.1</ix:nonFraction>&#160;million shares subject to stock options, restricted stock units outstanding, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share.</ix:continuation> </span></div><div id="i056ce7da447f48a894f20e0202bfb367_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5&#8212;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5NzY_2f4e8cab-b27f-4b21-a20c-330932c6aa76" continuedAt="i595ce3511959414ba51a8d0bcc69c723" escape="true">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ix:nonNumeric></span></div><ix:continuation id="i595ce3511959414ba51a8d0bcc69c723" continuedAt="i03b425679f364ec39b5493640d9abad3"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Institutes for BioMedical Research, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="i03b425679f364ec39b5493640d9abad3" continuedAt="i0db0d4bd1d294d499f246befa633a0a9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize certain of its zinc finger (&#8220;ZF&#8221;) transcriptional regulators (&#8220;ZF-TRs&#8221;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company was performing early research activities over the collaboration period for each gene target and manufacture the ZF-TRs required for such research, costs of which are funded by Novartis. Novartis was responsible for additional research activities, studies enabling INDs, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company was prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also had the option to license certain of the Company&#8217;s proprietary adeno-associated viruses (&#8220;AAVs&#8221;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Novartis notified the Company of its termination for convenience, effective June 11, 2023 (the &#8220;Novartis Termination Date&#8221;), of the collaboration agreement. Novartis has indicated to the Company that the termination relates to a recent strategic review. As of the Novartis Termination Date, the collaboration agreement will be terminated in its entirety and following the Novartis Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Novartis. As of the Novartis Termination Date, the parties will have no further obligations to develop or to fund the development of any collaboration research programs under the collaboration agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering the agreement, Novartis paid the Company a $<ix:nonFraction unitRef="usd" contextRef="i0cdb317881c34a669c3a4df636cafb89_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTgyNw_a5919ad5-db43-4322-a1ea-6ef484c5a1d2">75.0</ix:nonFraction>&#160;million upfront license fee. Novartis was also obligated to pay the Company for the use of its resources and reimburse third-party costs incurred in the Company&#8217;s conduct of early research activities. The Company was also eligible to earn from Novartis development and commercial milestones and royalties on potential commercial sales of licensed products arising from the collaboration, none of which have been triggered or earned. The agreement was going to continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments received under the agreement are non-refundable and non-creditable. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i9e26658540754e0ba357cda42d689a27_D20200727-20200727" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjk4NA_62b888c9-2e33-481b-8b6a-f32d0e91f9a7">95.1</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i9e26658540754e0ba357cda42d689a27_D20200727-20200727" decimals="-5" name="sgmo:CollaborativeArrangementLicenseFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzAyMw_fb906c62-364b-4344-972a-9890a5b12491">75.0</ix:nonFraction>&#160;million and research costs of $<ix:nonFraction unitRef="usd" contextRef="i9e26658540754e0ba357cda42d689a27_D20200727-20200727" decimals="-5" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzA1OA_7e789a82-b90b-4cca-bc31-eb2d4e8282a5">20.1</ix:nonFraction>&#160;million. All clinical or regulatory milestone amounts were considered fully constrained throughout the term of the agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Novartis in accordance with ASC Topic 606 and concluded that Novartis was a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license was not discrete as it did not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notice of termination was accounted for as a modification of the contract, as it changed both the scope of the Company&#8217;s remaining services and the consideration to which the Company was entitled. The effect of the modification was not material, as the Company was nearing the completion of its assigned early research activities, and consequently, of its sole performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had a receivable of $<ix:nonFraction unitRef="usd" contextRef="i2e5f30daa4cb48669190ba5dc2800f62_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDY3NA_894f65b6-7f19-4344-ace1-c4fad94fbcb8">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i588781fc38e24f71a49cbdd5825112e5_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDY4MQ_3557c041-cbf4-43ed-a99e-d9412176aa56">2.2</ix:nonFraction>&#160;million, respectively, and deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i2e5f30daa4cb48669190ba5dc2800f62_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDcyMw_61c41730-a330-4057-b876-9625706e0fa3">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i588781fc38e24f71a49cbdd5825112e5_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDczMA_3a6e6046-20c0-4aba-8c01-a5b6720215e4">9.6</ix:nonFraction>&#160;million, respectively, related to this agreement. The deferred revenue is expected to be recognized during the quarter ended June 30, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5Nzc_9a15ef74-a7a3-4046-87dc-c9adeb3e94d8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b05399697d7401c8737c92e33455724_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfMy0xLTEtMS03MDI3NQ_72dca1ea-4892-4ce9-bf6a-af75363fc91c">7,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i172244f350cb475a8efec0046cc9297b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfMy0zLTEtMS03MDI3NQ_3c1e5e95-7404-40fb-b21d-a38ccb0d0ff8">7,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0092f362bc744248b2ee6e610a3b5e63_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfNC0xLTEtMS03MDI3NQ_5d99a933-6a8c-4dc5-805d-239342a3b084">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24f43f5449b47339b9d23c5322eea68_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfNC0zLTEtMS03MDI3NQ_aeb68c63-cf26-4297-98cb-a86c2c9d4d2d">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfNS0xLTEtMS03MDI3NQ_6721cc6b-e26c-48e5-945d-ef57129d0d06">9,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5044101e1ffb43ab96fa6fd4cd659e29_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfNS0zLTEtMS03MDI3NQ_7f96b4a2-4d26-451a-af76-37c4c0861279">8,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="ic8aae65c355c4bd7aef72344aa0fafbf_I20201231" decimals="-5" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDg2NQ_1c92e1b0-abb9-4283-a81b-0a59e7a7f436">1.5</ix:nonFraction>&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to <ix:nonFraction unitRef="number" contextRef="i6f7ce4041a0342d09c2e6c57209b7339_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0Ng_e09f2f43-104e-46d2-a25a-5c8c7db39f72">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="i0cdb317881c34a669c3a4df636cafb89_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk1Mg_52581ebf-0c56-49c7-9569-2ce11848aed4">75.0</ix:nonFraction>&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ic8aae65c355c4bd7aef72344aa0fafbf_I20201231" decimals="-5" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTA4MQ_d13f61df-599f-4a85-8a3a-262e81d59d72">1.5</ix:nonFraction>&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance is released into general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic&#160;340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC Topic&#160;340&#8221;). The Company recognized as expense $<ix:nonFraction unitRef="usd" contextRef="ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQyOQ_cedbbb7f-ab15-47ab-98c4-eba2404b5825">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5044101e1ffb43ab96fa6fd4cd659e29_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY0OTI2NzUwMzM1NA_4debb9a6-584b-4306-b7bf-8743b5ddbc41">0.1</ix:nonFraction>&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="i0db0d4bd1d294d499f246befa633a0a9" continuedAt="i76e4d09c7cd44167b8f46d78e0766e3b"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies planned to leverage the Company&#8217;s proprietary ZF technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase <ix:nonFraction unitRef="shares" contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjE4Ng_029eb40a-4bb9-4c18-ae82-b3af4a59a3b5">24,420,157</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i977ddd133dc44b5c99432be67e32bb97_I20200430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjI3Mw_13e82db2-533c-4456-8154-0f5405133716">9.2137</ix:nonFraction>, for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjMyNg_dbb8e626-0595-4018-b6f8-9cb10ddac64d">225.0</ix:nonFraction>&#160;million. The collaboration agreement became effective in April 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Biogen notified the Company of its termination for convenience, effective June 15, 2023 (the &#8220;Biogen Termination Date&#8221;), of the collaboration agreement. Biogen has indicated to the Company that the termination relates to a recent strategic review. As of the Biogen Termination Date, the collaboration agreement will be terminated in its entirety and following the Biogen Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Biogen. As of the Biogen Termination Date, the parties will have no further obligations to develop or to fund the development of any collaboration research programs under the collaboration agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i1ad08cddce894baca70373a9ee5375ff_D20200501-20200531" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjcyMQ_7b33baaf-d736-422b-a9db-d7930b4088c4">125.0</ix:nonFraction>&#160;million in May 2020. The Company was also eligible to receive target selection, research, development, regulatory and commercial milestone payments and royalties on potential net commercial sales of licensed products arising from the collaboration, none of which have been triggered or earned. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize ZF and/or AAV-based products directed to certain neurological disease gene targets selected by Biogen. Biogen had selected <ix:nonFraction unitRef="product_target" contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430" decimals="0" name="sgmo:CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ4NQ_112d1d33-5dad-4df7-8c61-dd3c68eba49a">four</ix:nonFraction> targets over the course of the collaboration and had exclusive rights to nominate up to <ix:nonFraction unitRef="product_target" contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430" decimals="INF" name="sgmo:CollaborationAgreementNumberOfAdditionalProductTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ3NQ_2488557e-0b06-4b29-99d9-1444ce7cd4fd">seven</ix:nonFraction> additional targets. These rights will expire upon the Biogen Termination Date. For each gene target selected by Biogen, the Company performed early research activities, costs of which were shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZF-TRs (or potential other ZF products) targeting therapeutically relevant genes. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price included the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODY0MTc2_ee662491-83cf-4c92-a5f5-ebaac19d9126">125.0</ix:nonFraction>&#160;million and the excess consideration from the stock purchase of $<ix:nonFraction unitRef="usd" contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430" decimals="-5" name="sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODY0MjQ1_0fc7c39e-0082-400e-8f9d-585681568b95">79.6</ix:nonFraction>&#160;million, which represented the difference between the $<ix:nonFraction unitRef="usd" contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODY0Mjkz_9e804dc9-be25-4398-9a93-9da76e5cf330">225.0</ix:nonFraction>&#160;million received for the purchase of the Biogen Shares and the $<ix:nonFraction unitRef="usd" contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430" decimals="-5" name="sgmo:CollaborationAgreementEquityIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODY0MzUy_57d0e55c-3c2a-4f90-887d-dd1f711b65cf">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the clinical or regulatory milestones were included in the transaction price, as all such amounts were fully constrained throughout the term of the collaboration agreement. The transaction price also included actual and estimated cost-sharing payments by Biogen for the work by Company researchers and reimbursement of the Company&#8217;s costs incurred with third parties. The amounts paid and expected to be paid to Biogen for the use of Biogen&#8217;s resources and its expenses were consideration paid to a customer. Since the Company did not acquire distinct goods or services in exchange for these payments, they reduced the transaction price and were recorded as reduction in revenue. The Company used the expected value method to estimate cost sharing payments, taking into account the impact of the constraint. Variable consideration was included in the transaction price only to the extent it was probable a significant reversal of cumulative revenues recognized would not occur. The Company re-evaluated the transaction price as uncertain events were resolved or other changes in circumstances occurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the licenses to its intellectual property for each target were not distinct from the related research and development activities, as the licensed technology was not shared with and could not be utilized by Biogen without the research services to be performed by the Company pursuant to the agreement. On the other hand, each combination of a license to the Company's intellectual property as applied to a specific target and the related research and development activities are a discrete research project that is distinct from any other target&#8217;s project. The targets Biogen could select were options that provided Biogen with material rights, as the exercise of the options did not require payment of a fee commensurate with the value of the incremental license rights. As a result, such options also represented performance obligations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company allocated fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="if9678c76539b432b81f74d4fb3103970_I20200430" decimals="-5" name="sgmo:RevenueRemainingPerformanceObligationFixedConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTEwMDY_c6c9f986-6801-4084-9db3-2d5cfe645ff6">204.6</ix:nonFraction>&#160;million included in the initial transaction price to the existing targets&#8217; license and research services performance obligations and those performance obligations for options that include material rights, based on their relative standalone selling prices. Through March 31, 2023, <ix:nonFraction unitRef="material_right" contextRef="if8df8676b78c46d5b518f1f954613aa3_I20221231" decimals="0" name="sgmo:RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODc3NA_e6adfc05-f849-4374-9ed4-3f6d0dd30cd4">one</ix:nonFraction> material right had expired, and <ix:nonFraction unitRef="material_right" contextRef="if8df8676b78c46d5b518f1f954613aa3_I20221231" decimals="0" name="sgmo:RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODc2NA_369ea9d4-0588-458a-95c8-d4e4457c0acc">seven</ix:nonFraction> material rights remained outstanding and are expected to expire during the quarter ending June 30, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notice of termination was accounted for as a modification of the contract, as it changed both the scope of the Company&#8217;s remaining services and the consideration to which the Company was entitled. The remaining research and development activities to be undertaken by the Company after the notice of termination were not distinct from the related </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="i76e4d09c7cd44167b8f46d78e0766e3b" continuedAt="i93cc8ad3b44346ba871a7ef2f0b9656f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities performed prior to the modification on the same targets but were distinct from the activities on other targets. The remaining material rights were also distinct from the prior research and development activities. To account for the effects of the modification, the Company updated its estimate of the transaction price and allocated the remaining transaction consideration based on the relative standalone selling prices of the remaining distinct goods and services. Progress for each ongoing performance obligation was then remeasured using an updated estimate of the total level of effort required for each performance obligation and the total revised transaction price and a cumulative catch-up in revenue was recorded. The modification resulted in an increase in revenue of $<ix:nonFraction unitRef="usd" contextRef="idf5d83fd29e747b2a85c289b3b68ab01_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1OTQ3MTg2_a606bbc7-7518-4676-a182-a3b0fa5160b7">127.1</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had a receivable of $<ix:nonFraction unitRef="usd" contextRef="ibe0c5537708d428dbd32614f200d7d29_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTMyMjY_1537f25d-b652-4a0a-88a7-0360a1f944cc">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie59f379330a44413acc5ad3572d12de6_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTMyMzM_ed30bd22-9e8b-4dd8-a173-253eb7157c8e">0.5</ix:nonFraction>&#160;million, respectively, and deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="ibe0c5537708d428dbd32614f200d7d29_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTMyNzU_33d079b7-7d37-44a0-bbd9-9249777cdb36">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie59f379330a44413acc5ad3572d12de6_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTMyODI_dabd5a67-52ea-4486-88e8-48aec6d2b532">132.2</ix:nonFraction>&#160;million, respectively, related to this agreement. Changes in deferred revenue balances during the three months ended March 31, 2023 relate primarily to the impact of the contract modification. The amounts of transaction price remaining to be recognized were $<ix:nonFraction unitRef="usd" contextRef="if3bd4a20f8df4d748a7351f9176c8c95_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY0OTI2NzUwMzEyNg_e797e756-4557-48f0-b940-954802b16447">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if8df8676b78c46d5b518f1f954613aa3_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY0OTI2NzUwMzEwNA_ce0a0111-c1aa-4cb5-86f3-804bfe494198">151.3</ix:nonFraction>&#160;million as of March&#160;31, 2023 and December&#160;31, 2022, respectively. The amounts remaining at March 31, 2023 are expected to be recognized during the quarter ending June 30, 2023. </span></div><ix:nonNumeric contextRef="idf5d83fd29e747b2a85c289b3b68ab01_D20230101-20230331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5ODY_e3d8dee5-c85f-4c05-af88-be008b6c031f" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and other fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife0d48cc54154af988cfabb60294c669_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfMy0xLTEtMS03MDI3NQ_1a119f81-304b-4298-aafe-fa6a6d4ece8b">130,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d4c70ae0c0480394a8206308620896_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfMy0zLTEtMS03MDI3NQ_acf96721-813a-474e-8e0d-2851371008af">7,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost-sharing payments for research services, net variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b3bd979dbaf42b2bf7fdb23a295bcbd_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfNC0xLTEtMS03MDI3NQ_a51be67b-003e-442b-88fa-e97e76c7f567">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff80b48ae31a4224bcf6ebf172a029de_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfNC0zLTEtMS03MDI3NQ_7c6a248a-1f2d-4d71-9f08-865e590981f3">3,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf5d83fd29e747b2a85c289b3b68ab01_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfNS0xLTEtMS03MDI3NQ_3f32597d-2a55-44e1-a142-e80431face85">132,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a46a4d74d0f40ca9fe4e5cc2553ae18_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfNS0zLTEtMS03MDI3NQ_4a10a5be-c643-4b23-a09f-c9019e6c71b2">11,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="icb85aa7ee95148ddb651de001786d085_I20201231" decimals="-5" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM0MTk_b75f91eb-6b2f-4128-9aa9-47f67eb112cc">7.0</ix:nonFraction>&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to <ix:nonFraction unitRef="number" contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM1MDA_6d27c6c1-50e2-4871-8d4a-0a1a81497d12">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM1MDY_9e804dc9-be25-4398-9a93-9da76e5cf330">225.0</ix:nonFraction>&#160;million received for the sale of shares and <ix:nonFraction unitRef="number" contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM1NDU_c4fc6563-b884-420e-902e-3da20a6053a8">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM1NTE_ee662491-83cf-4c92-a5f5-ebaac19d9126">125.0</ix:nonFraction>&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i82bf0e01b49943c59780d56860d0ef71_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM4NjA_69cbd9d2-eaa9-4f4e-a2b1-103336bc35a5">4.1</ix:nonFraction>&#160;million, which represents <ix:nonFraction unitRef="number" contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM4ODE_65689fd5-e17d-41d2-9a14-b61fdd93fe96">2</ix:nonFraction>% of the initial transaction price of $<ix:nonFraction unitRef="usd" contextRef="if9678c76539b432b81f74d4fb3103970_I20200430" decimals="-5" name="sgmo:RevenueRemainingPerformanceObligationFixedConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM5MTI_0e0f3d56-7c42-4d3b-8d87-8b1fbcabaaa0">204.6</ix:nonFraction>&#160;million, as a contract cost asset. This balance is released into general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340. The Company recognized as expense $<ix:nonFraction unitRef="usd" contextRef="idb9738ab009e47ebac491659d9db20da_D20230101-20230331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTQxNDg_679f8cac-0b05-4b36-8615-d7c6f48df37f">2.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie1079febd1d943e5ace3d337ff8b9934_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY0OTI2NzUwMzI4Mw_452f3274-bb86-45ea-b6a4-0c209dad02eb">0.1</ix:nonFraction>&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ifdb866cb8cc240e6abb838057088d3c1_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTQyODU_b5972332-583c-403a-bbf5-07f4692afcad">2.9</ix:nonFraction>&#160;million, which represented <ix:nonFraction unitRef="number" contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTQzMDc_eb1cb4f5-d40e-471a-bb70-42e6977ab151">2</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430" decimals="-5" name="sgmo:CollaborationAgreementEquityIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTQzMTc_57d0e55c-3c2a-4f90-887d-dd1f711b65cf">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in net proceeds during the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kite Pharma, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), a Gilead Sciences, Inc. subsidiary, which became effective on April 5, 2018 (&#8220;Effective Date&#8221;), and was amended and restated in September 2019, for the research, development, and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered ex&#160;vivo using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research program term and subject to certain exceptions, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of ex vivo genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of ex vivo genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="i93cc8ad3b44346ba871a7ef2f0b9656f" continuedAt="ic1d79128258046a2bad4a8eeaeb61d65"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Effective Date, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY2NzY_b4d1ce4c-6356-4692-a2f7-f8fd90cb5293">150.0</ix:nonFraction>&#160;million upfront payment from Kite. In addition, Kite reimburses the Company&#8217;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $<ix:nonFraction unitRef="usd" contextRef="ia36d19d9949d425a80f1c8e75d714302_D20180401-20180430" decimals="-8" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY5MTk_bd889af2-8bb9-49d5-94eb-d5dfdb8868c6">3.0</ix:nonFraction>&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $<ix:nonFraction unitRef="usd" contextRef="i3d2d40bca9274579a944d3bfb4f13ab1_D20180401-20180430" decimals="-8" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTcwMjk_12c1763c-1688-41a0-a105-f020e61d0c72">1.3</ix:nonFraction>&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $<ix:nonFraction unitRef="usd" contextRef="ieaf64bd796644ec09771a94c61a501b4_D20180401-20180430" decimals="-8" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTcxNzE_19966b2a-0942-4355-b1ee-3e311282e8e6">1.8</ix:nonFraction>&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first <ix:nonFraction unitRef="milestone" contextRef="ieaf64bd796644ec09771a94c61a501b4_D20180401-20180430" decimals="INF" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTc1NTI_c6e61cc8-5ca4-4817-b882-82be5680e1f6">10</ix:nonFraction> times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial research term in the agreement is <ix:nonNumeric contextRef="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430" name="sgmo:InitialResearchTermOfAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTgxMjU_4c885c58-7ecc-482c-b207-5934a8d7664b">six years</ix:nonNumeric> from the Effective Date. Kite has an option to extend the research term for up to <ix:nonFraction unitRef="option" contextRef="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430" decimals="INF" name="sgmo:NumberOfOptionsToExtendInitialResearchTerm" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTgyMTA_4c250785-cb09-4d95-a4b1-51ebecf60f53">two</ix:nonFraction> additional <ix:nonNumeric contextRef="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430" name="sgmo:ExtendedResearchTermOfAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5ODE_af29be26-2256-422a-92a3-2191b5a12943">one-year</ix:nonNumeric> periods for a separate upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430" decimals="-5" name="sgmo:SeparateUpfrontFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTgyNzA_34e5b598-8226-4212-b0a3-d02e8454a0fa">10.0</ix:nonFraction>&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. Through the amendment and restatement of the agreement in September 2019, the Company and Kite agreed to expand the scope of the collaboration program to incorporate the use of lentiviral or retroviral vectors provided by Kite. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. The transaction price includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="if7e6bd6cba7449d5b279f7359132b372_I20180430" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODg0OTUz_4be4b78a-5d61-439c-bb73-e84b676a8b8c">150.0</ix:nonFraction>&#160;million and estimated reimbursable service costs for the research projects over the estimated performance period. None of the clinical or regulatory milestones have been included in the transaction price, as none of the milestones have yet been achieved, and all amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price also includes actual and estimated payments by Kite for the work by Company researchers and reimbursement of the Company&#8217;s costs incurred with third-parties. The Company uses the expected value method to estimate payments related to the Company&#8217;s researchers&#8217; work, taking into account the impact of constraint. Variable consideration is included in the transaction price only to the extent it is probable a significant reversal of cumulative revenues recognized would not occur. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified <ix:nonFraction unitRef="performance_obligation" contextRef="i1cab29510fb3439faf882035775ddfa8_I20190930" decimals="0" name="sgmo:RevenueNumberOfRemainingPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODc4Mw_387e8bbe-c021-4a7c-8250-598862af6845">four</ix:nonFraction> performance obligations within the Kite agreement as follows: (1) a license to the technology combined with the obligation to perform research and development services to apply the Company&#8217;s technology to Kite-selected targets; (2) production of research materials; and (3-4) <ix:nonFraction unitRef="material_right" contextRef="i1cab29510fb3439faf882035775ddfa8_I20190930" decimals="0" name="sgmo:RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODc5Mw_6edd6d68-4711-4491-b8a2-58ec45d4ac53">two</ix:nonFraction> material rights, each for an extension of the research period for an additional <ix:nonNumeric contextRef="if963029c76a14422a76e678b607647db_D20190901-20190930" name="sgmo:RevenueRemainingPerformanceObligationRenewalPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODgxMQ_7840aee8-21e0-4adf-bd56-e8434e1da985">one-year</ix:nonNumeric> term. Such extensions contain material rights because their exercise does not require payment of a fee that is commensurate with the value of the incremental research term. The license to the Company&#8217;s intellectual property is not distinct from the related research and development activities as the licensed technology is not shared with and cannot be utilized by Kite without the research services performed by the Company. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated variable consideration (payments by Kite for the work performed by the Company&#8217;s researchers and third-party costs, as well as any future milestones and royalties) to the specific performance obligations to which they relate, as such allocation would meet the allocation objective in ASC Topic 606. The Company allocated the fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="i1cab29510fb3439faf882035775ddfa8_I20190930" decimals="-5" name="sgmo:RevenueRemainingPerformanceObligationFixedConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTA5OTUxMTcxMjk0NQ_1ca31fab-b356-48e0-a4b2-4d52bffb3ffc">150.0</ix:nonFraction>&#160;million to the performance obligations based on their relative standalone selling prices. Standalone selling prices of optional research years are similar to those of the initial year, but additionally take into account the intrinsic value of the discount upon exercise and the likelihood of exercise. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fees allocated to options with material rights are deferred until the options are exercised or expire. The exercise of options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#8217;s performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the combined license and research services performance obligations is recognized over time, as Kite consumes the benefit of such services as they are being performed by the Company. For the license combined with research and development services performance obligation, the Company recognizes revenue based on proportional performance of the ongoing research services over the period during which the Company performs the services. The estimation of progress towards the satisfaction of this performance obligation and project costs are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s assumptions regarding the estimated volume of required activities. The production of research materials performance </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="ic1d79128258046a2bad4a8eeaeb61d65" continuedAt="i523461e33a9743f1837a9f06cbcd0999"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligation is accounted for under the right to invoice practical expedient, as the Company has the right to invoice Kite for these services in an amount that corresponds directly with the value of the services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had a receivable of $<ix:nonFraction unitRef="usd" contextRef="idee75a68ffae4d08aad2ebe053849936_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjEyNTQ_e609a943-60fd-4398-9fed-25f258dc7be7">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifc29cb92c1914e68bb97632d9995dd99_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjEyNjE_b40e81fb-78fd-4875-91f1-ca380e3f04b5">0.7</ix:nonFraction>&#160;million, respectively, and deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="idee75a68ffae4d08aad2ebe053849936_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjEzMDM_59461cdc-c14a-4239-b7f3-befa03603921">8.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifc29cb92c1914e68bb97632d9995dd99_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjEzMTA_e01b6248-f31e-4336-bdea-ba60bf1b489f">19.4</ix:nonFraction>&#160;million, respectively, related to this agreement. Changes in deferred revenue balances during the three months ended March 31, 2023 relate to a reduction in the estimated future level of the Company's research and development services, as well as ongoing normal progress in the delivery of the performance obligations. The amounts of transaction price (excluding the amounts recognized as invoiced for the production of research materials performance obligation) remaining to be recognized were $<ix:nonFraction unitRef="usd" contextRef="iba08bfacba1f4aae9ffd92a1c8ee0b02_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODkxNTQ5_96effd01-29a6-42c1-b731-55c0846de208">8.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iecd84ec8a1904360957c6aa234b8c110_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODkxNTI4_eb2d06e8-6f40-41b7-8ee2-3a736c16e1f1">21.2</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="iecd84ec8a1904360957c6aa234b8c110_I20221231" decimals="-5" name="sgmo:RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1OTE3ODQ1_3cee4096-cf79-4c14-91d0-f42b62936f81"><ix:nonFraction unitRef="usd" contextRef="iba08bfacba1f4aae9ffd92a1c8ee0b02_I20230331" decimals="-5" name="sgmo:RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1OTE3ODQ1_80c72b18-732f-4b60-a57a-10aa6d89bf67">1.5</ix:nonFraction></ix:nonFraction>&#160;million relates to fees allocated to options with material rights, as of March&#160;31, 2023 and December&#160;31, 2022, respectively. These amounts are expected to be recognized over the period through 2024. The timing of recognition will be affected by the volume of annual activity under the agreement and by whether and when Kite exercises options for additional years of services and could be subject to significant changes.</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i012246fb152f4311b9ef64728a20ab16_D20230101-20230331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5ODI_f6218f29-75c9-4c2c-b5fc-8e6ca85db3da" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license fee fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf91751f6b9c4cd9aa62ef768250ea52_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfMy0xLTEtMS03MDI3NQ_8f507814-d605-4169-9f28-402ce25a0544">11,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06bd9d0df2534688ae2923ab3b06ae9a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfMy0zLTEtMS03MDI3NQ_0456cd09-c2a7-4b92-977d-8d38b2e2d199">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044b8bca774a41859553cfa2ca705546_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfNC0xLTEtMS03MDI3NQ_c66fb3f0-fe6b-4fef-98e5-b0ab10b8ee92">868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16fce833379e4e6f95302de92112cbfe_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfNC0zLTEtMS03MDI3NQ_14ff7411-28a0-4a7d-905f-bd1fb99c7450">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i012246fb152f4311b9ef64728a20ab16_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfNS0xLTEtMS03MDI3NQ_0a0e90eb-87e6-4d9c-bd79-bb601eaf951e">12,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0996de9b8bdd4847801e39a50b5843fe_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfNS0zLTEtMS03MDI3NQ_ecd2af80-c9d3-4ccc-99ba-493717ee2093">6,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Kite. This adjustment was driven by a reduction in the estimated future level of the Company&#8217;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of $<ix:nonFraction unitRef="usd" contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjU5NzA2OTkwMjI5Mg_cbe4eba4-de0f-4f3e-b123-2b383829a2d9">8.9</ix:nonFraction>&#160;million, an increase in net income of $<ix:nonFraction unitRef="usd" contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331" decimals="-5" name="sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjU5NzA2OTkwMjMyNg_519392f1-389b-451a-926a-5f35d889e1d6">8.9</ix:nonFraction>&#160;million, and an increase in the Company&#8217;s basic and diluted earnings per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331" decimals="2" name="sgmo:IncreaseDecreaseInEarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjU5NzA2OTkwMjQwNA_2922173e-dc6b-416a-b0b2-6e2e5e72928f">0.06</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331" decimals="2" name="sgmo:IncreaseDecreaseInEarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjU5NzA2OTkwMjQxMg_00973f9f-3438-4096-acf8-d4a2a07c323b">0.05</ix:nonFraction>, respectively, for the three months ended March 31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi S.A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement (&#8220;2014 Collaboration Agreement&#8221;) to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The 2014 Collaboration Agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi S.A (&#8220;Sanofi&#8221;). Under the 2014 Collaboration Agreement, the Company was originally jointly conducting <ix:nonFraction unitRef="program" contextRef="ifb3c135c2da14ac9b065d23532ddd743_D20140101-20140131" decimals="INF" name="sgmo:NumberOfResearchProgram" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5MjA_934279dc-6d62-4761-ac67-926d64928da7">two</ix:nonFraction> research programs: a beta thalassemia program, which was discontinued in the third quarter of 2021, and the SCD program, which resulted in the development of SAR445136 (now known as BIVV003), a ZFN, gene-edited cell therapy product candidate for the treatment of SCD. In December 2021, Sanofi notified the Company of its termination for convenience, effective June 28, 2022 (the &#8220;Termination Date&#8221;), of the 2014 Collaboration Agreement. A termination and transition agreement (the &#8220;Termination and Transition Agreement&#8221;) was executed by the parties on September 6, 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the SCD program, the Company and Sanofi were jointly responsible for research and development activities prior to filing of an IND, but Sanofi was responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. Subject to the terms of the agreement, the Company had granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZF and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company had also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company was not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2014 Collaboration Agreement, the Company received an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ifb3c135c2da14ac9b065d23532ddd743_D20140101-20140131" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjM2ODI_5d1d18d5-d87f-4073-95b3-981248187f1d">20.0</ix:nonFraction>&#160;million and was eligible to receive additional payments upon the achievement of specified clinical development, regulatory milestones, and sales milestones, as well as royalty payments for each licensed product based on net sales of such product. Sanofi was also to reimburse Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. Through the Termination Date, a total of $<ix:nonFraction unitRef="usd" contextRef="ie1283de320cb4464a5b41896a5803c3e_D20140101-20220628" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjQwOTg_c1ad8ac1-3375-437b-92ec-73f44dd3e168">13.5</ix:nonFraction>&#160;million was received based on achievement of clinical development milestones. <ix:nonFraction unitRef="product" contextRef="i040ae2a932da4ee5aba8f53c0572ebbc_D20230101-20230331" decimals="INF" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjQxNzg_c51300b1-36f3-47fe-bb0a-4a3c2dae510b">No</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="i8f019967b98f4beba43811efc7cd5926_D20230101-20230331" decimals="INF" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjQyMjM_f904e282-362a-4cdf-8813-95333b462a7a">no</ix:nonFraction> royalty fees have been or will be earned under the 2014 Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In its termination notice to the Company, Sanofi indicated that its termination relates to Sanofi&#8217;s change in strategic direction to focus on allogeneic universal genomic medicine approaches rather than autologous personalized cell therapies. As of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="i523461e33a9743f1837a9f06cbcd0999" continuedAt="if78318b0a2574f3c831d7c5017cbbc96"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Termination Date, the 2014 Collaboration Agreement was terminated in its entirety and following the Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Sanofi. As of the Termination Date, Sanofi has no further obligations under the 2014 Collaboration Agreement to develop or to fund the development of any collaboration research programs under the 2014 Collaboration Agreement. The licenses granted to Sanofi under the 2014 Collaboration Agreement have been terminated, and the license rights have reverted to the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Termination and Transition Agreement, Sanofi granted to the Company exclusive, worldwide, fully paid, royalty-free, perpetual, irrevocable licenses, with the right to grant sublicenses through multiple tiers, to certain of its intellectual property, to develop, manufacture, have manufactured, use, sell, offer to sell, import and otherwise commercialize BIVV003, the product candidate in development under the SCD program. The Company agreed to take on responsibilities for all clinical trials related to BIVV003, including completion of the ongoing clinical trial and the related long-term follow-up study. The Company also assumed all regulatory responsibilities related to BIVV003. Sanofi transferred and assigned to the Company all documentation, materials and contracts with third parties related to BIVV003, and the right to use certain Sanofi-owned or leased equipment related to BIVV003.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi has also agreed to reimburse the Company for the costs of conducting the ongoing clinical trial of BIVV003 and the costs of the long-term follow-up study through December 31, 2023, up to $<ix:nonFraction unitRef="usd" contextRef="i6db635d14915401bb7ab7d501b675ba5_D20220906-20220906" decimals="-5" name="sgmo:ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjYyOTE_632baf89-946c-47d3-807b-c409b87070ec">7.0</ix:nonFraction>&#160;million. In addition, should the Company elect not to continue the development of BIVV003 past December 31, 2023, Sanofi will become obligated to reimburse the Company for the costs of the long-term follow-up study incurred after 2023, up to $<ix:nonFraction unitRef="usd" contextRef="i6db635d14915401bb7ab7d501b675ba5_D20220906-20220906" decimals="-5" name="sgmo:ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjY1Mjg_fa01f00b-1603-48af-8dd6-fe5515009a38">5.3</ix:nonFraction>&#160;million. Sanofi&#8217;s reimbursement obligations will terminate upon certain triggering events, including the Company&#8217;s entering into a contract with a third party for collaboration, partnership, sale, licensing, or divestiture of BIVV003, or if the FDA permits early closure of the clinical trial and/or the long-term follow-up study.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the 2014 Collaboration Agreement in accordance with ASC&#160;Topic&#160;606 and concluded that Sanofi was a customer under that arrangement. The Company identified the performance obligation within this arrangement as a license to the technology combined with ongoing research services activities. The Company concluded that the license was not distinct as it did not have stand-alone value to Sanofi without the research services. As a result, the Company recognized revenue from the upfront payment and the milestones based on progress of performance of the ongoing research services. The estimation of progress towards the satisfaction of the performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s then current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. Sanofi&#8217;s December 2021 notice of termination of the 2014 Collaboration Agreement represented a modification that reduced the expected scope of the Company&#8217;s services and the estimated transaction price and shortened the remaining performance timeline. Consistent with this change, all services provided by the Company under the 2014 Collaboration Agreement were completed by June 28, 2022, and all amounts ultimately included in the transaction price were recognized by such date. The final transaction price of $<ix:nonFraction unitRef="usd" contextRef="i7fc0f7863a60402b9f2453ef3b887ecb_D20140101-20220628" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjgyODg_37e1be0d-ee16-472a-a607-bd77cd887aad">96.3</ix:nonFraction>&#160;million included the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i7fc0f7863a60402b9f2453ef3b887ecb_D20140101-20220628" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjgzMjc_96eb39ae-c44d-48ae-b516-f871e2f40869">20.0</ix:nonFraction>&#160;million, two milestone payments in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i65542dbae8514435bdf257a1ff5bcbdf_I20220628" decimals="-5" name="sgmo:MilestoneRevenueReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjgzODE_42c02e49-593a-44f3-b15e-aa030d9ecdbd">13.5</ix:nonFraction>&#160;million and reimbursement of research costs of $<ix:nonFraction unitRef="usd" contextRef="i7fc0f7863a60402b9f2453ef3b887ecb_D20140101-20220628" decimals="-5" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjg0MjM_755dcfc9-62b3-45e9-88e8-78c3f0776c76">62.8</ix:nonFraction>&#160;million. As of March&#160;31, 2023 and December&#160;31, 2022, the Company had <ix:nonFraction unitRef="usd" contextRef="i46c2c921be69493ab19f0a486451504a_I20221231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ2Nw_281046b7-151f-43b3-8b51-38ddb9436b90"><ix:nonFraction unitRef="usd" contextRef="i46c2c921be69493ab19f0a486451504a_I20221231" decimals="0" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ2Nw_28da7bdc-b276-4af7-8d05-21efc625b332"><ix:nonFraction unitRef="usd" contextRef="iddc8eb02f5594eb4bb70b4f4e16dfa8a_I20230331" decimals="0" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ2Nw_53e0c41a-8526-4bc2-b7fb-efee84fae18b"><ix:nonFraction unitRef="usd" contextRef="iddc8eb02f5594eb4bb70b4f4e16dfa8a_I20230331" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ2Nw_9bdd8bb0-0c5e-49f4-b896-a2206a85c823">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> receivable or deferred revenue related to the 2014 Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that Sanofi is not a customer under the Termination and Transition Agreement as Sanofi is not entitled to receive and cannot use the results of the ongoing clinical trial or the long-term follow-up study. This relationship is also not a collaboration in the scope of ASC Topic&#160;808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company concluded that the assets acquired from Sanofi do not represent a business, as substantially all of their value is concentrated in the acquired or re-acquired licenses to intellectual property. The Company has no obligation to repay Sanofi for its ongoing funding of the clinical trial or long-term follow-up study costs. Therefore, the Company will recognize Sanofi reimbursements as reductions to its research and development expense. During the three months ended March&#160;31, 2023, the Company decreased its research and development expense by $<ix:nonFraction unitRef="usd" contextRef="i739fc14c91ed4a9398145c3822bdc624_D20230101-20230331" decimals="-5" sign="-" name="sgmo:TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjk1MjY_8b54f67f-5988-4e75-bfd2-47538dd1030c">0.5</ix:nonFraction>&#160;million for these reimbursements, which is included within prepaid expenses and other current assets on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2023. </span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i040ae2a932da4ee5aba8f53c0572ebbc_D20230101-20230331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5Nzk_4b0ca81e-04e1-4ebc-bcaf-12698771246c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the 2014 Collaboration Agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64cb91ba588b40d3823c99c78f047007_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfMy0xLTEtMS03MDI3NQ_db157aed-9bb8-4520-9aa5-6786c4d44761">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d62212323d64616b08b97898e6dca41_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfMy0zLTEtMS03MDI3NQ_563c3361-0479-40f1-ac5c-30989cee4ed3">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b80b373e4f543d3b9c64cd42f6123e0_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNC0xLTEtMS03MDI3NQ_80438e43-d247-4962-81c0-74b095f4ca16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29862757a85b4766a731ee17cf896271_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNC0zLTEtMS03MDI3NQ_b252a1ae-cf90-48a3-899e-777018f75dbb">978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f62cc7bdbf4e2ca26b9868e600b6d1_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNS0xLTEtMS03MDI3NQ_9542c210-453e-4982-bd44-973c124c6be5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ae7e8c20abb44979f894b0080a9de5b_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNS0zLTEtMS03MDI3NQ_d1aafb57-7f5d-41ed-a31f-50e7a3122ac4">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040ae2a932da4ee5aba8f53c0572ebbc_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNi0xLTEtMS03MDI3NQ_68103bd0-1788-423c-bad7-4b895863ab6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i667f4bba088b4392976bb60dcc384764_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNi0zLTEtMS03MDI3NQ_d5de29bf-7d69-4b89-a55b-962a6e3487f8">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="if78318b0a2574f3c831d7c5017cbbc96" continuedAt="if702ee5b00c94b93b9fab303fb01f2ab"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Giroctocogene Fitelparvovec Global Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer Inc. (&#8220;Pfizer&#8221;), pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) <ix:nonNumeric contextRef="i804a404f96394a898c058d278efa5149_D20170501-20170531" name="sgmo:AgreementTerminationTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzIzMzI_5583bcd8-a7bc-44f9-b9b5-9903097d40f9">fifteen years</ix:nonNumeric> after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="iebe23428fae3453f85cfddd95fced287_D20170501-20170531" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzMyNTM_9044c275-45df-49f6-9c8f-053fad34ddf0">70.0</ix:nonFraction>&#160;million and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ib47491017133498e9f1034163ad56858_D20170501-20170531" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzMyODk_29fc763f-c32a-4756-9a74-aa34767e368d">208.5</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="iebe23428fae3453f85cfddd95fced287_D20170501-20170531" decimals="-5" name="sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzM0MTg_a51c8b6c-f275-4075-a0dd-027c8d957b9b">266.5</ix:nonFraction>&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="ibe6c9c6208944000ac68a96e46025955_D20170501-20170531" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzM3NDc_0dc745c6-3092-4d98-9e72-58680d50786d">475.0</ix:nonFraction>&#160;million, which includes up to $<ix:nonFraction unitRef="usd" contextRef="id44c480d79c746f99af60191b7721577_I20170531" decimals="-5" name="sgmo:MilestoneRevenueReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzM3NzI_1ee4bce4-c3e6-410e-b234-e3952154b9ea">300.0</ix:nonFraction>&#160;million for giroctocogene fitelparvovec and up to $<ix:nonFraction unitRef="usd" contextRef="i7bbeee49f7d24edbb0671d6d2fd4fe37_I20170531" decimals="-5" name="sgmo:MilestoneRevenueReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzM4MTc_f1c913bc-ade8-413b-b027-060e73d91531">175.0</ix:nonFraction>&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are <ix:nonFraction unitRef="number" contextRef="i82259a8cc3b54b86845b0a1e5c8c8688_I20170531" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODgxMw_24f6ad0f-c5d1-427b-b478-4f4058d1b5aa">14</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i37f8e9f8ba844603a13fb45940884450_I20170531" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODgxOA_5cc908d3-95f3-49e9-89d2-b95271187d34">20</ix:nonFraction>% of the annual worldwide net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, <ix:nonFraction unitRef="milestone" contextRef="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331" decimals="INF" name="sgmo:CollaborativeArrangementNumberOfMilestonesAchieved" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQzOTY_38108c71-a753-4d8e-94e0-ef3b640926c0">two</ix:nonFraction> milestones of $<ix:nonFraction unitRef="usd" contextRef="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ0MTM_b9d7da84-d5b0-4aa9-ab44-00a284f1d2aa">55.0</ix:nonFraction>&#160;million in aggregate have been achieved and paid, however <ix:nonFraction unitRef="product" contextRef="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331" decimals="INF" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ0NjY_bb10032f-6cee-49e4-ba8c-822498a4fb8b">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331" decimals="INF" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ1MTE_a3b8547f-ef1c-414f-8b40-987bb8cb7d14">no</ix:nonFraction> royalty fees have been earned under the agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The total transaction price under this agreement was $<ix:nonFraction unitRef="usd" contextRef="id8b7dbf6a794472a89a395389c47d284_D20170501-20230331" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ3Mzk_f97d29fe-a0a2-46c2-b48a-7f75de45e17b">134.0</ix:nonFraction>&#160;million, which represented the upfront fee and research services fees of $<ix:nonFraction unitRef="usd" contextRef="id8b7dbf6a794472a89a395389c47d284_D20170501-20230331" decimals="-5" name="sgmo:CollaborativeArrangementResearchServiceFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ4MDc_fca4910b-b840-49e6-87b3-b44c68a0a83c">79.0</ix:nonFraction>&#160;million and fees related to <ix:nonFraction unitRef="milestone" contextRef="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331" decimals="0" name="sgmo:CollaborativeArrangementNumberOfMilestonesAchieved" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ4MzA_159876b3-88cc-4ce5-bb37-bd5ea1bed55a">two</ix:nonFraction> achieved milestones in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="id8b7dbf6a794472a89a395389c47d284_D20170501-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ4Nzk_4488465d-7912-41e4-9d52-e783dc2e575f">55.0</ix:nonFraction>&#160;million. Sangamo was responsible for internal and external research costs as part of the upfront fee and had the ability to request additional reimbursement from Pfizer if certain conditions were met. None of the constrained clinical or regulatory milestones were included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at the time was uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license was not discrete as it did not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period during which the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s assumptions regarding the timing of its deliverables.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><ix:continuation id="if702ee5b00c94b93b9fab303fb01f2ab" continuedAt="i5cc765a1a63440c39202dd3e7b80457d"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and <ix:nonFraction unitRef="usd" contextRef="i8723ec4942574f6abacf98a666e76565_D20230101-20230331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzY3MTc_56435719-3ef9-4519-8167-8b9c2023efba"><ix:nonFraction unitRef="usd" contextRef="iaf3bbfd75e0a43a385745a5d6b39cac5_D20220101-20220331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzY3MTc_624a5b2f-10d4-4004-abd4-89b8649fc761">no</ix:nonFraction></ix:nonFraction> revenues have been recognized during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C9ORF72 Research Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZF-TRs to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZF-TRs that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZF-TRs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory exclusivity for a licensed product in a country, and (iii) <ix:nonNumeric contextRef="i36ed8ae1e943412696f1b850bcd91902_D20171201-20171231" name="sgmo:AgreementTerminationTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzgyMTk_9c51fa05-e948-499e-accf-954190d1926b">15</ix:nonNumeric> years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $<ix:nonFraction unitRef="usd" contextRef="i36ed8ae1e943412696f1b850bcd91902_D20171201-20171231" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzk5MTM_db695c23-d0fe-4a04-85c6-92763b6cf925">12.0</ix:nonFraction>&#160;million upfront payment from Pfizer and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ifc4df0af832c47e19018df300e7262e2_D20171201-20171231" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzk5Nzc_fe487e85-be42-497a-8f53-7b7e3f74adfc">60.0</ix:nonFraction>&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i8f057163ceda4cb2866e24c3fb357cfe_D20171201-20171231" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDAxNjM_b4b333c7-a684-40b2-976a-db6445ff8071">90.0</ix:nonFraction>&#160;million in commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties of <ix:nonFraction unitRef="number" contextRef="i8a4ef27fa9844922a3e39563222cc964_I20171231" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODgyMw_120a37a9-a1c8-4ff5-b1e1-bc9af44df3b9">14</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic2c186114dc94e028f5fe60291fb4cc4_I20171231" decimals="2" name="sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODgyOA_ac16b5ea-4760-4b06-ac07-b6a9b277eeec">20</ix:nonFraction>% of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $<ix:nonFraction unitRef="usd" contextRef="i560f370cf92a49b99828eb1352749470_D20171201-20230331" decimals="-5" name="sgmo:MilestonePaymentsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDA5MTM_d3e41fea-0f7a-46c5-a961-a208fd866e15">5.0</ix:nonFraction>&#160;million has been achieved and paid, however <ix:nonFraction unitRef="product" contextRef="i560f370cf92a49b99828eb1352749470_D20171201-20230331" decimals="INF" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDA5NTI_1fed12c5-4d85-4a79-bce6-fb1100a5f0fe">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="i560f370cf92a49b99828eb1352749470_D20171201-20230331" decimals="INF" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDA5OTc_b103f84d-7587-4344-867a-26c17bbb71dc">no</ix:nonFraction> royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pfizer agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The Company concluded the total transaction price under this agreement was $<ix:nonFraction unitRef="usd" contextRef="i1e962757cf94476a83ff1404fcbf850b_D20171201-20171231" decimals="-5" name="sgmo:CollaborativeArrangementTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDEyNjM_eed0f5aa-231a-43a6-9136-caf9ed266aa1">17.0</ix:nonFraction>&#160;million, which represented the upfront fees of $<ix:nonFraction unitRef="usd" contextRef="i9a15336c720b4849b73c702ec05c48ae_D20171201-20171231" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDEzMDU_954fc08e-11e2-49db-875c-c94bc77f9d6f">12.0</ix:nonFraction>&#160;million and fees related to achievement of one milestone in the amount of $<ix:nonFraction unitRef="usd" contextRef="i1e962757cf94476a83ff1404fcbf850b_D20171201-20171231" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDEzNzQ_9300b90d-dfc7-4d7a-9696-812b354ae2e2">5.0</ix:nonFraction>&#160;million. None of the constrained clinical or regulatory milestones were included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at the time was uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $<ix:nonFraction unitRef="usd" contextRef="i9b6cafe71ed842fe933713b923d60a51_D20200901-20200930" decimals="-5" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI2ODM_289f2da9-b785-4e43-8a33-92a0ee9e2d75"><ix:nonFraction unitRef="usd" contextRef="iec01e4d31367438cb373cd06b7a6321f_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI2ODM_744ca230-f257-43b2-a4ed-6f51b542b73d">5.0</ix:nonFraction></ix:nonFraction>&#160;million milestone, which the Company recognized on a cumulative basis during the year ended </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5cc765a1a63440c39202dd3e7b80457d">December 31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and <ix:nonFraction unitRef="usd" contextRef="i7fc67d44a220419d862851946595abe3_D20220101-20220331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5MDM_2faec358-d68f-48ae-9ca0-cbcdad993598"><ix:nonFraction unitRef="usd" contextRef="i3e652ef597fe49c8b7cf086423e5272b_D20230101-20230331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5MDM_4de2f0e9-d813-43df-a787-14604b1fcdbc">no</ix:nonFraction></ix:nonFraction> revenues have been recognized during the three months ended March&#160;31, 2023 and 2022.</ix:continuation> </span></div><div id="i056ce7da447f48a894f20e0202bfb367_1337"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6&#8212;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:AssetImpairmentChargesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF8yMTk5MDIzMjYyNjgz_8124a6cc-0b3e-450a-9491-7a097cc708f1" continuedAt="if31f4a8ad88b4ac2b2643516d65184ba" escape="true">IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</ix:nonNumeric></span></div><ix:continuation id="if31f4a8ad88b4ac2b2643516d65184ba"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, as a result of the sustained decline in the Company&#8217;s stock price and related market capitalization, termination of the collaboration agreements with Biogen and Novartis, and a general decline in equity values in the biotechnology industry, the Company performed an impairment assessment of goodwill, indefinite-lived intangible assets, and long-lived assets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#8217;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#8217;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represents a level&#160;2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a non-cash, pre-tax goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF81NDk3NTU4MjEwMjM_aadd65d1-785e-42e9-b2c7-3be270aa6c98">38.1</ix:nonFraction>&#160;million during the three months ended March 31, 2023. As a result, the goodwill was fully impaired as of March 31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before completing the goodwill impairment assessment, the Company first tested its indefinite-lived intangible assets and then its long-lived assets for impairment. The Company determined its indefinite-lived intangible assets were not impaired, as their carrying values were not in excess of their individual fair values. The Company determined all of its long-lived assets represent <ix:nonFraction unitRef="asset_group" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="0" name="sgmo:LongLivedAssetsNumberOfAssetsGroups" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF8yMTk5MDIzMjY4ODA1_d1c52ff2-3631-419f-9aba-034782c0bfb0">one</ix:nonFraction> asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the single asset group is not recoverable as it exceeded the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. To allocate and recognize the impairment loss, the Company determined individual fair value of long-lived assets. The Company, with the assistance of a third-party valuation firm, applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction. This represents a level&#160;3 nonrecurring fair value measurement. Based on this analysis, the Company recognized non-cash, pre-tax long-lived asset impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF81NDk3NTU4MjY3Mzc_d091654b-9c2f-4f6c-83a4-51d94b58e27c">11.2</ix:nonFraction>&#160;million on the right-of-use assets, $<ix:nonFraction unitRef="usd" contextRef="i4de9bbe9fefc453f850b2fe7edb090a7_D20230101-20230331" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF81NDk3NTU4MjY3NTc_46a41fbd-2ca9-4166-8558-8223e0a69a18">5.0</ix:nonFraction>&#160;million on the related leasehold improvements, and $<ix:nonFraction unitRef="usd" contextRef="if8b032998eb547589205c3c16fdb0326_D20230101-20230331" decimals="-5" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF81NDk3NTU4MjY3Nzc_f38234f0-5f59-4516-ba0e-df863fd734e5">4.2</ix:nonFraction>&#160;million on construction-in-progress, during the three months ended March&#160;31, 2023. No impairment was recognized on the remaining long-lived assets as their carrying values were not in excess of their fair values.</span></div></ix:continuation><div id="i056ce7da447f48a894f20e0202bfb367_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7&#8212;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RleHRyZWdpb246NDZjODExNTBmOGU3NGIxYWFlMTc4NDc5MTIyYzFlNGJfMTgy_3835f8e7-77c5-417d-a68b-cc38bbfd4f14" continuedAt="id0e1bacc62244260b8609a1ef0212ca9" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="id0e1bacc62244260b8609a1ef0212ca9"><ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RleHRyZWdpb246NDZjODExNTBmOGU3NGIxYWFlMTc4NDc5MTIyYzFlNGJfMTgx_bf4aa1dc-8914-4a68-a3c1-774639fa7e1f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:74.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d41c01311744a48c5daac7d4e3944b_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfMi0xLTEtMS03MDI3NQ_a59496e9-a56b-4216-ad18-b9e3b576984d">4,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca29878377148449e09cef54c91263d_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfMi0zLTEtMS03MDI3NQ_dcaa9992-a118-44b4-b8f5-654193463068">4,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28c3caeac8e54328899e8c3cb465e877_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfMy0xLTEtMS03MDI3NQ_ed19accc-b938-4d14-b785-7971e824a775">3,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f991f47f9a74b6b9b29e3bac240a7eb_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfMy0zLTEtMS03MDI3NQ_7d6ce181-a4d9-4876-acbb-1c38e4902fa1">3,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfNC0xLTEtMS03MDI3NQ_79ff789a-7213-4d8d-9b87-54aa978f8183">8,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfNC0zLTEtMS03MDI3NQ_c1f8d74a-30b2-4c9b-bec7-f0e9914bc883">7,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div id="i056ce7da447f48a894f20e0202bfb367_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8&#8212;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfOTk1_48bbfaf8-e886-4ece-aee3-c6fafe318d9f" continuedAt="ida1425235db241c6a496393c2ccdbe4e" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="ida1425235db241c6a496393c2ccdbe4e"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i817e2132beca4a9a89cee830995c6d63_D20200801-20200831" decimals="-5" name="sgmo:StockOfferingProgramMaximumValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfMzg4_470b09e3-e25d-4b6b-b891-5202188ff4f0">150.0</ix:nonFraction>&#160;million through Jefferies as the Company&#8217;s sales agent or principal. In December 2022, the Company entered into Amendment No. 2 to the Open Market Sale Agreement&#8480; which increased the aggregate offering price under the at-the-market offering program by an additional $<ix:nonFraction unitRef="usd" contextRef="i4b85c71c37b542f2882458b5be990823_D20221201-20221231" decimals="-5" name="sgmo:SaleOfStockIncreaseToAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfNTQ5NzU1ODE1MDg5_ee79f0c4-8de3-4f1a-b1c6-d76e70cd0398">175.0</ix:nonFraction> million. The Company is not obligated to sell any shares under the sales agreement. During the three months ended March&#160;31, 2023, the Company sold <ix:nonFraction unitRef="shares" contextRef="i7ced4258fc4d4d42a76a05c7d77967a2_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfNTc1_deba2263-5c65-43a7-b0a5-2a472f60f06a">3,962,430</ix:nonFraction> shares of its common stock for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i7ced4258fc4d4d42a76a05c7d77967a2_D20230101-20230331" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfNjQ2_21a2b804-3471-4b66-9fff-9952cad1ad76">9.7</ix:nonFraction>&#160;million, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i9d74086bfd334bcea39a99837791ca5d_D20230401-20230430" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfNjk0_5c77d941-632d-428f-8ed2-1d99d2ec1154">0.6</ix:nonFraction>&#160;million was received in April 2023 and recorded within prepaid expenses and other current assets on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2023. <ix:nonFraction unitRef="shares" contextRef="i7c3f507349cf479bbcbd3ad2bdc85b31_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfNDk0NzgwMjMyNjQxNQ_d794c4e2-3752-44c3-93a8-2dd342d6733a">No</ix:nonFraction> shares were sold under the sales agreement during the three months ended March&#160;31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9&#8212;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182Ny9mcmFnOjZkMmVkMjYzNTk0YTQ1MDg4ZWU3NzFkMDQ2NzE3NTM0L3RleHRyZWdpb246NmQyZWQyNjM1OTRhNDUwODhlZTc3MWQwNDY3MTc1MzRfMjY3Ng_bf640429-e68c-40f6-8589-cc6ae43477ee" continuedAt="i31eefcec3e10462f97f585fde87cd986" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i31eefcec3e10462f97f585fde87cd986"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s provision for income taxes for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. During the three months ended March&#160;31, 2023 and 2022, the Company recorded income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182Ny9mcmFnOjZkMmVkMjYzNTk0YTQ1MDg4ZWU3NzFkMDQ2NzE3NTM0L3RleHRyZWdpb246NmQyZWQyNjM1OTRhNDUwODhlZTc3MWQwNDY3MTc1MzRfNDM5ODA0NjUyNTM4MA_993cc031-f847-4158-96f3-aa0bbb579d87">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182Ny9mcmFnOjZkMmVkMjYzNTk0YTQ1MDg4ZWU3NzFkMDQ2NzE3NTM0L3RleHRyZWdpb246NmQyZWQyNjM1OTRhNDUwODhlZTc3MWQwNDY3MTc1MzRfNjU5NzA2OTc4NzAyNQ_a5796325-2699-417a-931d-a18a6d53da9f">0.1</ix:nonFraction>&#160;million, respectively. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company continues to maintain a full valuation allowance on its U.S. federal and state net deferred tax assets and on the Sangamo France net deferred tax assets, as the Company believes it is not more likely than not that these benefits will be realized. The tax expense for the three months ended March&#160;31, 2023 was primarily due to foreign income tax expense.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act of 2022 was signed into law, and became effective in 2023, with tax provisions primarily focused on implementing a 15% minimum tax on global adjusted financial statement income and a 1% excise tax on share repurchases. The Company has evaluated the provisions of the tax law and noted that the law change would not have a material impact on the Condensed Consolidated Financial Statements.</span></div></ix:continuation><div id="i056ce7da447f48a894f20e0202bfb367_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10&#8212;<ix:nonNumeric contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N183Ni9mcmFnOmIzNzY0Mzg1YTgyNTRiMzliYmFhYjU4YmM2ZmE1OTJkL3RleHRyZWdpb246YjM3NjQzODVhODI1NGIzOWJiYWFiNThiYzZmYTU5MmRfNDg3_a2847ec4-fe1f-49b1-ba0f-dd44b22359ef" continuedAt="i3589492abdc748b39a745a06d3fbcaa1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3589492abdc748b39a745a06d3fbcaa1">In April 2023, the Company announced a restructuring of operations and corresponding reduction in workforce (the &#8220;Restructuring&#8221;), designed to reduce costs and increase focus on its key strategic priorities. Sangamo expects the Restructuring to result in the elimination of approximately <ix:nonFraction unitRef="employee" contextRef="i0d843ac73dfb466ab2ba144b1a49bdb5_D20230401-20230430" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N183Ni9mcmFnOmIzNzY0Mzg1YTgyNTRiMzliYmFhYjU4YmM2ZmE1OTJkL3RleHRyZWdpb246YjM3NjQzODVhODI1NGIzOWJiYWFiNThiYzZmYTU5MmRfOTkzOQ_81bc5060-6c26-4182-a26a-619911c1d087">120</ix:nonFraction> roles in the United States, or approximately <ix:nonFraction unitRef="number" contextRef="i0d843ac73dfb466ab2ba144b1a49bdb5_D20230401-20230430" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N183Ni9mcmFnOmIzNzY0Mzg1YTgyNTRiMzliYmFhYjU4YmM2ZmE1OTJkL3RleHRyZWdpb246YjM3NjQzODVhODI1NGIzOWJiYWFiNThiYzZmYTU5MmRfMjE5OTAyMzI2NDkwNA_506f160b-c709-48b2-a53a-619233ae7605">27</ix:nonFraction>% of its total United States workforce. The Company currently estimates that it will incur approximately $<ix:nonFraction unitRef="usd" contextRef="i4127fb82d88648f383b7c0ae50821b64_I20230430" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N183Ni9mcmFnOmIzNzY0Mzg1YTgyNTRiMzliYmFhYjU4YmM2ZmE1OTJkL3RleHRyZWdpb246YjM3NjQzODVhODI1NGIzOWJiYWFiNThiYzZmYTU5MmRfMjE5OTAyMzI2NDkxNA_989267a6-72a6-499e-833e-bf9603b8c811">5</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ifae7a07494d54449804932a865f643bc_I20230430" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N183Ni9mcmFnOmIzNzY0Mzg1YTgyNTRiMzliYmFhYjU4YmM2ZmE1OTJkL3RleHRyZWdpb246YjM3NjQzODVhODI1NGIzOWJiYWFiNThiYzZmYTU5MmRfMjE5OTAyMzI2NDkyNg_bb35cf1d-0b22-4cb9-99c7-b52c9230960f">7</ix:nonFraction>&#160;million in cash-based expenses related to employee severance and notice period payments, benefits and related costs in connection with the Restructuring. The Company expects that the majority of the Restructuring charges will be incurred in the second quarter of 2023 and that the execution of the Restructuring will be substantially complete by the end of the third quarter of 2024. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the Restructuring.</ix:continuation></span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section&#160;27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include, without limitation, statements containing the words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and other words of similar import or the negative of those terms or expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially from those set forth in such forward-looking statements as a result of, but not limited to, the &#8220;Risk Factors&#8221; described in Part I, Item 1A our Annual Report on Form 10-K for the year ended December&#160;31,&#160;2022 as filed with the Securities and Exchange Commission on February&#160;23,&#160;2023, or the 2022 Annual Report, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. You should also read the following discussion and analysis in conjunction with our Condensed Consolidated Financial Statements and accompanying notes included in this Quarterly Report and the Consolidated Financial Statements and accompanying notes thereto included in our 2022 Annual Report.</span></div><div id="i056ce7da447f48a894f20e0202bfb367_82"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious diseases. We plan to deliver on this mission through development of our clinical and preclinical product candidates leveraging our novel science and our in-house manufacturing capabilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Updates</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2023, each of Biogen MA, Inc. and Biogen International GmbH, which we refer to together as Biogen, and Novartis Institutes for BioMedical Research, Inc., or Novartis, notified us of their termination for convenience of our respective collaboration agreements with them, with such terminations effective in June 2023. The notice of terminations were accounted for as a modification of the respective agreements, which, in the case of Biogen, resulted in a one-time increase in revenue of $127.1 million. In April 2023, we made the strategic decision to pause further development of the programs that were the subject of these collaborations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2023, we announced a restructuring of operations and a corresponding reduction in workforce, or the Restructuring, designed to reduce costs and increase focus on our three key strategic priorities of (a) our pre-clinical neurology disease epigenetic regulation portfolio, including our Nav 1.7 and prion disease programs, (b) preparations for a potential Phase 3 trial of isaralgagene civaparvovec, our gene therapy to treat Fabry disease, and (c) the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy to treat patients receiving an HLA-A2 mismatched kidney from a living donor. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As part of the Restructuring, we expect to significantly reduce our internal manufacturing and allogeneic research footprints in California. We expect the Restructuring to result in the elimination of approximately 120 roles in the United States, or approximately 27% of our US workforce. We estimate that we will incur approximately $5 million to $7 million in cash-based expenses related to employee severance and notice period payments, benefits and related Restructuring costs. We expect that the majority of the Restructuring charges will be incurred in the second quarter of 2023 and that the execution of the Restructuring will be substantially complete by the end of the third quarter of 2024. We may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the Restructuring.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Programs Updates</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fabry Disease</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Since our last update on February 22, 2023, an additional three patients have been dosed in the Phase 1/2 STAAR study, resulting in a total of 20 patients dosed to date. A total of 20 sites are now active and recruiting. Progress in the study continues with additional male and female patients currently in screening.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Phase 1/2 STAAR study expansion phase is ongoing and preparations for a potential Phase 3 clinical trial actively progress. We plan to meet with the FDA on proposed Phase 3 study design in the summer and a Phase 3 trial start is anticipated in the second half of 2023, depending on regulatory interactions, with dosing of the first patient as early as the first part of 2024. The completion of dosing in the Phase 1/2 expansion phase is expected by the end of 2023 and is not expected to be a gating factor for the commencement of the Phase 3 trial.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2023, a patient in the Phase 1/2 STAAR study experienced a Grade 3 serious adverse event, or SAE, of stroke, requiring hospitalization. The patient has since been discharged, and the Principal Investigator has since determined that the SAE was not related to the ST-920 treatment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renal Transplant Rejection</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2022, we dosed the first patient in our Phase 1/2 STEADFAST study evaluating TX200. The second and third patients were dosed with their personalized TX200 cell therapies in September 2022 and April 2023, respectively. The product candidate continues to be generally well tolerated in all three patients dosed to date. Manufacturing and clinical activities for the second cohort are progressing and additional patients are in pre-screening for potential enrollment in the study. We received positive regulatory feedback for accelerated dose escalation protocol from two European agencies to date. We plan to share initial data from cohort 1 by the end of 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hemophilia A</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dosing to support the primary analysis of the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer Inc., or Pfizer, for patients with moderately severe to severe hemophilia A, is now complete. A pivotal readout is expected in the first half of 2024, with Pfizer anticipating submitting a biologics license application and a marketing authorization application, in the second half of 2024 if the pivotal readout is supportive.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preclinical Programs</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preclinical development is focused in two innovative priority areas: (i) epigenetic regulation for neurological diseases and (ii) CAR-Treg cell therapies for autoimmune disorders. Other indications for our preclinical programs include inflammatory bowel disease, multiple sclerosis, cancer, ALS, and Huntington&#8217;s Disease, some of which we are developing with our collaborators Pfizer, Takeda Pharmaceutical Company Limited, or Takeda, and Kite Pharma, Inc., or Kite.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Restructuring, we made a strategic decision to increase focus on certain of our preclinical programs as one of the key areas of our business, including Nav 1.7 and prion disease as the cornerstones to the neurology epigenetic regulation portfolio. The Nav 1.7 pathway to potentially treat chronic neuropathic pain has been identified as our flagship program in our newly prioritized wholly owned neurology pipeline, with an investigational new drug application, or IND, submission expected in 2024. We plan to present the first data from this program in a platform presentation at the American Society for Cell and Gene Therapy 26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Annual Meeting taking place May 16-20, 2023 in Los Angeles, California. We also continue to advance our wholly owned prion disease program, with an IND submission anticipated in 2025. Identification and selection of engineered adeno-associated virus, or AAV, capsids enhanced for central nervous system delivery continues to progress. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple collaborations with biopharmaceutical companies bring us important financial and strategic benefits and reinforce the potential of our research and development efforts and our ZF technology platform. They leverage our collaborators&#8217; therapeutic and clinical expertise and commercial resources with the goal to bring our medicines more rapidly to patients. We believe these collaborations reflect the value of our ZF technology platform and will potentially expand the addressable markets of our product candidates. To date, we have received approximately $815.0 million in upfront licensing fees, milestone payments and proceeds from sale of our common stock to collaborators and have the opportunity to earn up to $3.6 billion in potential future milestone payments from our collaborations, in addition to potential product royalties.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-House Manufacturing</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate an AAV manufacturing facility in our Brisbane, California headquarters. In connection with the Restructuring, we made the decision to cease cell therapy manufacturing in our facility in Brisbane, California and move our allogeneic cell therapy research to Valbonne, France, alongside cell therapy manufacturing already located in Valbonne, France. Our manufacturing strategy is to provide greater flexibility, quality and control by building a balanced and necessary capacity achieved through our in-house manufacturing and contract manufacturing organization, or CMO, partnerships, investing in manufacturing processes and analytics and developing a strong supply chain.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our business, see &#8220;Business&#8221; in Part I, Item 1 of the 2022 Annual Report.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Macroeconomic Conditions and the COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and operations and those of our collaborators may continue to be affected by financial instability and a general decline in economic conditions in the United States and other countries caused by political instability and conflict, including the ongoing conflict between Russia and Ukraine, and economic or financial challenges caused by current and potential future bank failures or by general health crises such as the COVID-19 pandemic, which have led to market disruptions, including </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant volatility in commodity prices, credit and capital markets instability, including disruptions in access to bank deposits and lending commitments, supply chain interruptions, rising interest rates and global inflationary pressures. These macroeconomic factors could materially and adversely affect our ability to continue to operate as a going concern and other could otherwise have a material adverse effect on our business, operations, operating results and financial condition as well as the price of our common stock. For example, our ability to raise additional capital may be adversely impacted by these macroeconomic factors and we cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will adversely affect our ability to continue as a going concern and our ability to develop our technology and products candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as the global COVID-19 pandemic and its effects continue to evolve, the extent of the impact of the COVID-19 pandemic on our business, operations and development timelines and plans remains uncertain. We have experienced and may in the future experience impacts from the COVID-19 pandemic on our business and operations. For example, our Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec and our STEADFAST study evaluating TX200 experienced delays in their respective timelines due to clinical trial patients and/or donors, as applicable, testing positive for COVID-19, delays in sourcing raw materials, and manufacturing and other technology transfer challenges with our CMOs. If our programs encounter longer-term disruptions as a result of impacts of the COVID-19 pandemic, it could impact our ability to support our biopharmaceutical partners as contemplated in our collaboration agreements and could result in adjustments to our clinical trial timelines. We will continue to monitor the impact of COVID-19 on our operations, research commitments and clinical trials and those of our collaborators, clinical trial sites and CMOs. Disruptions to these operations, and possibly more severe disruptions in the future that could arise due to restrictions applicable in the places we operate or our industry generally or to us and our facilities specifically, could impede our ability to conduct research in a timely manner, comply with our research obligations to our collaborators and advance the development of our therapeutic programs. These delays and disruptions could result in adverse material impacts to our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the section titled &#8220;Risk Factors&#8221; included in Part I, Item 1A of the 2022 Annual Report for additional information on risks and uncertainties related to the COVID-19 pandemic.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Components of Results of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues have consisted primarily of revenues from upfront licensing fees, reimbursements for research services, milestone achievements and research grant funding. We expect revenues to continue to fluctuate from period to period and there can be no assurance that new collaborations or partner reimbursements will continue beyond their initial terms or that we are able to meet the milestones specified in these agreements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income for the three months ended March 31, 2023, we have incurred net losses since inception and expect to incur losses for at least the next several years as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities and revenues from collaborations and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our product candidates from research stage through clinical trials. Pursuant to the terms of our collaboration agreements with Biogen (which agreement will terminate effective June 15, 2023), Novartis (which agreement will terminate effective June 11, 2023), and Kite, and our termination and transition agreement with Sanofi S.A., or Sanofi, certain expenses related to research and development activities will be reimbursed to us. The reimbursement funds to be received from Biogen, Kite, and Novartis through the end of the collaboration agreements will be recognized as revenue as the related costs are incurred and collection is reasonably assured. In this regard, following the effectiveness of the terminations of the Biogen and Novartis agreements, we will not be entitled to any further cost reimbursements. The reimbursement funds to be received from Sanofi will decrease our research and development expense.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative personnel, stock-based compensation expense, professional fees, allocated facilities expenses, patent prosecution expenses and other general corporate expenses. As we continue to advance our product candidates into and through the clinic, we expect the growth of our business to require increased general and administrative expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Condensed Consolidated Financial Statements and the related disclosures have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these Condensed Consolidated Financial Statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our Condensed Consolidated Financial Statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these estimates under different assumptions or conditions. We believe the following policies to be the most critical to an understanding of our financial condition and results of operations because they require us to make estimates, assumptions and judgments about matters that are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies and estimates relating to revenue recognition and valuation of long-lived assets including goodwill and intangible assets are the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements. See Note 1 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization, Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2023, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Part II, Item 7 of the 2022 Annual Report.</span></div><div id="i056ce7da447f48a894f20e0202bfb367_85"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three Months Ended March&#160;31, 2023 and 2022</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"></td><td style="width:62.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.707%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues primarily consisted of amounts earned from our collaboration agreements. We anticipate revenues in future years will be derived primarily from our collaboration agreements with Kite and Pfizer. In this regard, the terminations of our collaboration agreements with Biogen and Novartis will be effective in June 2023 following which we will not be entitled to any further milestone payments or royalties from either Biogen or Novartis, nor will either Biogen or Novartis have any further obligations to develop or to reimburse the costs of any of the programs subject to the Biogen and Novartis collaborations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $129.7&#160;million in revenues for the three months ended March&#160;31, 2023, compared to the same period in 2022, was primarily attributed to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $121.1&#160;million in revenue relating to our collaboration agreement with Biogen, primarily due to the impact of a contract modification resulting from a notification of termination of the collaboration agreement, which resulted in an increase in the measure of proportional cumulative performance; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $6.0&#160;million in revenue relating to our collaboration agreement with Kite, primarily due to a reduction in the estimated future level of the research and development services and as a result, future project costs, which resulted in an adjustment to the measure of proportional cumulative performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $2.5&#160;million in revenue relating to our license agreement with Sigma-Aldrich Corporation; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.9&#160;million in revenue relating to our collaboration agreement with Novartis; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.8&#160;million in revenue relating to our license agreement with Open Monoclonal Technology, Inc. (now Ligand Pharmaceuticals Inc.). </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by a decrease of $1.5&#160;million in revenue relating to our collaboration agreement with Sanofi, due to the termination of collaboration agreement in June 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"></td><td style="width:62.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.707%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,908&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,431&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted primarily of compensation related expenses, including stock-based compensation, laboratory supplies, preclinical and clinical studies, manufacturing clinical supply, contracted research, and allocated facilities and information technology expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $4.6 million in research and development expenses for the three months ended March&#160;31, 2023, compared to the same period in 2022, was primarily attributable to higher headcount and infrastructure related costs, coupled with higher external services to progress our clinical trials. Stock-based compensation expense included in research and development expenses was $4.9 million and $4.7 million for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote substantial resources to research and development in the future. While we anticipate that our research and development expenses will decrease in the near-term in connection with the Restructuring, we ultimately expect research and development expenses to increase in the next several years if we are successful in advancing our clinical programs and if we are able to progress our earlier stage product candidates into clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required to complete our development programs and our development costs for those programs may be impacted by the scope and timing of enrollment in clinical trials for our product candidates, our decisions to pursue development programs in other therapeutic areas, and whether we pursue development of our product candidates with a partner or collaborator or independently. For example, our product candidates are being developed in multiple therapeutic areas, and we do not yet know how many of those therapeutic areas we will continue to pursue. In this regard, in connection with the Restructuring, we have paused further development of certain pre-clinical programs following conclusion of collaborations with Biogen and Novartis. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued therapeutic area is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential therapeutic areas that we may elect to pursue, and even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with our development programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of any necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected. In addition, clinical trials of our product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of the 2022 Annual Report, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation related expenses including stock-based compensation for executive, legal, finance and administrative personnel, professional fees, facilities and information technology expenses, and other general corporate expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $3.2&#160;million in general and administrative expenses for the three months ended March&#160;31, 2023, compared to the same period in 2022, was primarily driven by an increase of $2.5 million in Biogen contract cost asset amortization primarily due to a change in estimate driven by a notification of termination of the collaboration agreement which resulted in increase in the measure of proportional cumulative performance, and an increase of $1.0 million in compensation and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other personnel costs. Stock-based compensation expense included in general and administrative expenses was $3.4&#160;million and $3.0&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we anticipate that our general and administrative expenses will decrease modestly in the near-term in connection with the Restructuring, as we continue to build out our product portfolio and advance our product candidates into the clinic, we expect higher general and administrative expenses to support the growth of the business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Goodwill and Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we concluded our goodwill and certain long-lived assets were impaired due to a sustained decline in our stock price and related market capitalization, termination of the collaboration agreements with Biogen and Novartis, and a general decline in equity values in the biotechnology industry. Based on this analysis, we recognized a non-cash, pre-tax goodwill impairment charge of $38.1&#160;million and long-lived asset impairment charge of $20.4&#160;million during the three months ended March 31, 2023. For more information see Note 6 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Long-Lived Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the accompanying notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net was $3.3 million and $1.3 million for the three months ended March&#160;31, 2023 and 2022, respectively. The increase of $2.0&#160;million for the three months ended March&#160;31, 2023, compared to the same period in 2022, was primarily driven by an increase of $2.1 million in interest income reflecting increases in market interest rates and $0.7 million related to fluctuations in foreign currency exchange rates. These increases were partially offset by a $0.7 million decrease in research tax credits and employee retention credit.</span></div><div id="i056ce7da447f48a894f20e0202bfb367_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses, and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents, and marketable securities totaling $241.0&#160;million, compared to $307.5&#160;million as of December&#160;31, 2022. Our most significant use of capital during the quarter was for employee compensation and external research and development expenses, such as manufacturing, clinical trials and preclinical activity related to our therapeutic programs. Our cash and investment balances are held in a variety of interest-bearing instruments, including U.S. government-sponsored entity debt securities, commercial paper securities, money market funds, corporate debt securities, asset-backed securities and certificates of deposit. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an Open Market Sale Agreement&#8480;, or the sales agreement, with Jefferies LLC, providing for the sale of up to $150.0&#160;million of our common stock from time to time in &#8216;at-the-market&#8217; offerings under an existing shelf registration statement. In December 2022, we entered into Amendment No. 2 to the Open Market Sale Agreement&#8480; which increased the aggregate offering price under the sales agreement by an additional $175.0 million. Approximately $200.0&#160;million remained available under the sales agreement as of March&#160;31, 2023. During the three months ended March&#160;31, 2023, we sold 3,962,430 shares of our common stock for net proceeds of approximately $9.7&#160;million, of which approximately $0.6&#160;million was received in April 2023 and recorded within prepaid expenses and other current assets on our Condensed Consolidated Balance Sheet as of March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standards Codification, or ASC, Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements&#8212;Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have the responsibility to evaluate whether conditions and/or events could raise substantial doubt about our ability to meet our future financial obligations as they become due within twelve months after the date that the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q are issued. We have identified several actions, including cost reduction measures that already have been initiated or that would be initiated in a timely manner, to address our liquidity needs, as follows:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deferral and reprioritization of certain research and development programs that would involve reduced program and headcount spend;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduction in force that would be intended to extend the cash runway necessary to fund operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pause on any new hiring and reduction in ancillary expenses such as travel and recruitment expenses; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduction in non-critical capital and operating expenditures including additional equipment, lab improvements, efficiency projects, and business support spend.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this regard, in April 2023, we announced the Restructuring, including a reduction in force that we expect to result in the elimination of approximately 120 roles in the United States. In addition, as part of the Restructuring, we expect to significantly reduce our internal manufacturing and allogeneic research footprints in California. See &#8220;&#8212;Corporate Update&#8221; above for additional information.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe management&#8217;s plans, as described above, sufficiently alleviate the risk of substantial doubt about our ability to continue as a going concern for at least twelve months from the date that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued. We make assumptions about the probability that management's plans will be effectively implemented and alleviate substantial doubt and our ability to continue as a going concern. However, such assumptions are inherently uncertain and actual results could differ materially from those estimates. In this regard, we could use our available capital resources sooner than we currently expect and changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to raise substantial additional capital to fund our operations and support our research and development endeavors. In this regard, we are actively seeking substantial additional capital, including through public or private equity or debt financings, royalty financings or other sources, such as strategic collaborations. However, additional capital may not be available to us, on terms that are acceptable or at all. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which could have a material adverse effect on our business. While we expect that the majority of the Restructuring charges will be incurred in the second quarter of 2023 and that the execution of the Restructuring will be substantially complete by the end of the third quarter of 2024, we may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the Restructuring. However, we may not achieve the expected benefits of these cost reduction measures and other cost reduction plans on the anticipated timeline, or at all, which could otherwise accelerate our liquidity needs and could force us to further curtail or suspend our operations. Moreover, we rely in part on our collaboration partners to provide funding for and otherwise advance our pre-clinical and clinical programs. However, in June 2022, our collaboration agreement with Sanofi terminated, and in March 2023, Biogen and Novartis notified us of their respective terminations for convenience of our collaboration agreements with them effective in June 2023. While we may identify new collaboration partners who can progress some of the programs that were the subject of these collaborations, we may not be successful in doing so in a timely manner, on acceptable terms or at all, and we may otherwise fail to raise sufficient additional capital in order to progress these programs ourselves or we may determine that for internal resource allocation purposes or for other reasons to abandon development of these programs. In any event, we would require substantial additional funding in order to progress the programs that were the subject of these collaborations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional capital through public or private equity offerings, including sales pursuant to our at-the-market offering program with Jefferies LLC, the ownership interest of our existing stockholders will be diluted, and such dilution may be substantial, and the terms of any new equity securities may have a preference over, and include rights superior to, our common stock. If we raise additional capital through royalty financings or other collaborations, strategic alliances or licensing arrangements with third parties, we may need to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable. If we raise additional capital through debt financing, we may be subject to specified financial covenants or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or pursuing certain transactions, any of which could restrict our ability to commercialize our product candidates or operate as a business.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $66.3&#160;million for the three months ended March&#160;31, 2023, primarily reflecting our net income of $21.1&#160;million, adjusted for a non-cash goodwill and long-lived asset impairment charges of $38.1&#160;million and $20.4&#160;million, respectively, a decrease in prepaid expenses and other assets by $6.2&#160;million, and $12.8&#160;million of non-cash expenses related to stock-based compensation, depreciation and amortization, amortization of premium on marketable securities, and amortization of operating lease right-of-use assets. These increases were offset by a decrease in deferred revenues of $149.8&#160;million mainly attributed to the impact of termination related contract modification for our collaboration agreement with Biogen and change in estimate for our collaboration agreement with Kite, a decrease in accrued compensation and employee benefits by $8.6&#160;million mainly attributed to bonus pay-outs, an increase in accounts receivable by $3.3&#160;million, a decrease in accounts payable and other accrued liabilities by $1.9&#160;million, and a decrease in lease liabilities by $1.2&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $59.0&#160;million for the three months ended March&#160;31, 2022, primarily reflecting our net loss of $44.0&#160;million, a decrease in deferred revenues of $21.0&#160;million, a decrease in accrued compensation and employee </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits by $8.3&#160;million mainly attributed to bonus pay-outs, a decrease in lease liabilities by $1.0&#160;million, and an increase in accounts receivable by $0.9&#160;million. These decreases were partially offset by $12.8&#160;million of non-cash expenses related to stock-based compensation, depreciation and amortization, amortization of premium on marketable securities, and amortization of operating lease right-of-use assets and a $3.6&#160;million increase in accounts payable and other accrued liabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $35.7&#160;million for the three months ended March&#160;31, 2023, related to maturities of marketable securities of $82.2&#160;million, partially offset by purchases of marketable securities of $36.2&#160;million, and purchases of property and equipment of $10.2&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $1.7&#160;million for the three months ended March&#160;31, 2022, mostly related to net maturities and purchases of marketable securities, partially offset by $2.8&#160;million from purchases of property and equipment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $8.0&#160;million for the three months ended March&#160;31, 2023, mostly related to $9.4&#160;million of proceeds from the at-the-market offering, net of offering expenses of $0.3&#160;million, partially offset by taxes paid related to net share settlement of equity awards of $1.1&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $1.6&#160;million for the three months ended March&#160;31, 2022, mostly related to taxes paid related to net share settlement of equity awards of $1.6&#160;million.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital and Capital Expenditure Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate continuing to incur operating losses for at least the next several years and need to raise substantial additional capital. The effects of the current macroeconomic environment, including the COVID-19 pandemic, the effects of war in Ukraine, financial and liquidity challenges associated with current and potential future bank failures, inflation, climate change, rising interest rates and other economic uncertainty and volatility, has resulted and may continue to result in significant disruption of global financial markets, which could impair our ability to access capital on terms that are acceptable or at all, and in turn could negatively affect our liquidity and our ability to continue to operate as a going concern. Future capital requirements beyond the next 12 months will be substantial, and we need to raise substantial additional capital to fund the development, manufacturing and potential commercialization of our product candidates. In this regard, we are actively seeking substantial additional capital, including through public or private equity or debt financings, royalty financings or other sources, such as strategic collaborations. However, additional capital may not be available to us, on terms that are acceptable or at all. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which could have a material adverse effect on our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we focus our efforts on proprietary human therapeutics, we will need to seek FDA approvals of our product candidates, a process that could cost in excess of hundreds of millions of dollars per product. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to advance our product candidate pipeline would be harmed. Our future capital requirements will depend on many forward-looking factors, including the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays that may be caused by changing regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of product candidates that we pursue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and terms of future in-licensing and out-licensing transactions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of procuring clinical and commercial supplies of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products or technologies, including the costs associated with such acquisitions and investments; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of potential disputes and litigation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future minimum contractual obligations as of December&#160;31, 2022 were reported in the 2022 Annual Report. During the three months ended March&#160;31, 2023, there have been no other material changes outside the ordinary course of our business from the contractual obligations previously disclosed in our 2022 Annual Report.</span></div><div id="i056ce7da447f48a894f20e0202bfb367_100"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk relates to our cash, cash equivalents, and marketable securities. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and capturing a market rate of return based on our investment policy parameters and market conditions. We select investments that maximize interest income to the extent possible within these guidelines. To achieve our goals, we maintain a portfolio of cash equivalents and investments in securities of high credit quality and with varying maturities to match projected cash needs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities in our investment portfolio are not leveraged and are classified as available-for-sale. The majority of these available-for-sale securities are short-term in nature and subject to minimal interest rate risk. Our investments currently consist of U.S. government-sponsored entity debt securities, commercial paper securities, corporate debt securities, asset-backed securities and certificates of deposit. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. All investments are carried at market value, which approximates cost. We do not use derivative financial instruments in our investment portfolio. Our market risks at March&#160;31, 2023 have not changed materially from those discussed in Item&#160;7A of our 2022 Annual Report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in the United States as well as in Europe. The functional currency of each foreign subsidiary is the local currency. We are exposed to foreign currency risk, primarily through operations of our subsidiaries in Europe which conduct business primarily in Euros. We record gains and losses within our stockholders&#8217; equity due to the translation of our subsidiaries&#8217; financial statements into U.S. dollars. Our foreign currency exchange risk at March&#160;31, 2023 has not changed materially from that discussed in Item&#160;7A of our 2022 Annual Report.</span></div><div id="i056ce7da447f48a894f20e0202bfb367_103"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision of our principal executive officer and principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of March&#160;31, 2023. Based on that evaluation, as of March&#160;31, 2023, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, for our company have been or will be detected. As these inherent limitations are known features of the disclosure and financial reporting processes, it is possible to design into the processes safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i056ce7da447f48a894f20e0202bfb367_109"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</span></div><div id="i056ce7da447f48a894f20e0202bfb367_112"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below we are providing, in supplemental form, changes to our risk factors from those previously disclosed in Part I, Item 1A of the 2022 Annual Report. Our risk factors disclosed in Part I, Item 1A of the 2022 Annual Report provide additional discussion about these supplemental risks and we encourage you to read and carefully consider the risk factors disclosed in Part I, Item 1A of the 2022 Annual Report for a more complete understanding of the risks and uncertainties material to our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on other programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited resources and may forego or delay pursuit of certain research programs or product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities or pursue collaborations rather than retain sole responsibility for development. Our current and future research and development programs for product candidates may not yield any commercially viable products. The evaluation of the commercial potential or target market for a particular product candidate is forward-looking and based upon assumptions involving, for example and not limited to, market evolution, advances in disease standard of care, competition and reimbursement. This reliance on assumptions means that, if our assumptions prove to be inaccurate or incomplete, we may pursue opportunities that end up having a number of competitors that are more advanced than our product candidates, or we may relinquish valuable rights to a product candidate through strategic collaboration, licensing or other royalty arrangements in cases where it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. For example, we recently made the strategic decision to halt further material investments in the BIVV003 program beyond completion of the Phase 1/2 PRECIZN-1 study in order to prioritize deployment of resources to our Fabry and TX200 programs. While we have launched a search for a collaboration partner who can progress this program to a potential Phase 3 trial, we may not be successful in doing so in a timely manner, on acceptable terms or at all, and as a result, we could miss valuable opportunities to capitalize on the potential of the BIVV003 program. Likewise, in March 2023, Biogen and Novartis notified us of their respective terminations for convenience of our collaboration agreements with them, and in April 2023, we made the strategic decision to pause further development of the programs that were the subject of these collaborations. While we may identify new collaboration partners who can progress some of the programs that were the subject of these collaborations, we may not be successful in doing so in a timely manner, on acceptable terms or at all, and we may otherwise fail to raise sufficient additional capital in order to progress these programs ourselves or we may determine that for internal resource allocation purposes or for other reasons to abandon development of these programs. As a result, we could miss valuable opportunities to capitalize on the potential of the programs. We may also allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration or that does not prove to have viable commercial opportunities. Any failure to use our financial and human resources efficiently could harm our business and operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could have a negative impact on our operations, which could materially and adversely affect our ability to continue to operate as a going concern and otherwise have a material adverse effect on our business, financial condition, results of operations, prospects and market price of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instability and a general decline in economic conditions in the United States and other countries caused by political instability and conflict, including the ongoing conflict between Russia and Ukraine, and economic or financial challenges caused by current and potential future bank failures or by general health crises such as the COVID-19 pandemic, have led to market disruptions, including significant volatility in commodity prices, credit and capital markets instability, including disruptions in access to bank deposits and lending commitments, supply chain interruptions, rising interest rates and global inflationary pressures. These macroeconomic factors could materially and adversely affect our ability to continue to operate as a going concern and other could otherwise have a material adverse effect on our business, operations, operating results and financial condition as well as the price of our common stock. For example, the recent closures of Silicon Valley Bank, or SVB, Signature Bank and First Republic Bank have resulted in broader financial institution liquidity risk and concerns. Although we were able to access all of the funds we had in deposit with SVB and intend to migrate all banking services previously provided by SVB to alternative global banking providers, future adverse developments with respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages. The failure of any bank in which we deposit our funds could reduce the amount of cash we have available for our operations or delay our ability to access such funds. Any such failure </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may increase the possibility of a sustained deterioration of financial market liquidity, or illiquidity at clearing, cash management and/or custodial financial institutions. In the event we have a commercial relationship with a bank that has failed or is otherwise distressed, we may experience delays or other issues in meeting our financial obligations. If other banks and financial institutions fail or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our cash and cash equivalents and investments may be threatened and our ability to raise additional capital when needed could be substantially impaired, which could have a material adverse effect on our business, operations, operating results and financial condition as well as the price of our common stock. In particular, failure to secure any necessary financing in a timely manner and on favorable terms could require us to delay or abandon clinical development plans or we may be forced to further curtail or suspend our operations. In addition, any or all of these factors could disrupt our and our collaborators&#8217; supply chains and adversely affect our and our collaborators&#8217; ability to conduct ongoing and future clinical trials of our product candidates. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have historically incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income of $21.1&#160;million for the three months ended March 31, 2023, primarily due to the termination of the Biogen collaboration agreement, we have a history of recurring net losses, including $192.3&#160;million and $178.3&#160;million for the years ended December 31, 2022 and 2021, respectively, and we have otherwise generated operating losses since we began operations in 1995. The extent of our future losses and the timing of profitability are uncertain, and we expect to incur losses for the foreseeable future. We have been engaged in developing our ZF technology since inception, which has and will continue to require significant research and development expenditures. To date, we have generated our funding from issuance of equity securities, revenues derived from collaboration agreements, other strategic partnerships in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. We expect to continue to incur additional operating losses for the next several years as we continue to develop our product candidates. If the time required to generate significant product revenues and achieve profitability is longer than we currently anticipate or if we are unable to generate liquidity through equity financing or other sources of funding, we may be forced to further curtail or suspend our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding to execute our operating plan and continue to operate as a going concern. We may be unable to raise additional capital on favorable terms, if at all, which would harm or preclude our ability to develop our technology and product candidates and could delay or terminate some or all of our programs. Future sales and issuances of equity securities could also result in substantial dilution to our stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. We expect capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure and research and product development activities. Moreover, we have concluded that there exists substantial doubt about our ability to continue to operate as a going concern. While we currently believe that management&#8217;s plans sufficiently alleviate the risk of substantial doubt about our ability to continue as a going concern for at least twelve months from the date that the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q are issued, we make assumptions about the probability that management's plans will be effectively implemented and alleviate substantial doubt and our ability to continue as a going concern. However, such assumptions are inherently uncertain and actual results could differ materially from those estimates. In this regard, we could use our available capital resources sooner than we currently expect and changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless, in order to remove substantial doubt about our ability to continue as a going concern, we will be required to raise substantial additional capital to fund our operations and support our research and development endeavors. In this regard, we are actively seeking substantial additional capital, including through public or private equity or debt financings, royalty financings or other sources, such as strategic collaborations. However, additional capital may not be available to us, on terms that are acceptable or at all. If adequate funds are not available to us on a timely basis, or at all, we will be required to take additional actions to address our liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering our research and development activities, which could have a material adverse effect on our business, or we may be required to cease operations. In this regard, in April 2023, we announced a restructuring, including a reduction in force that we expect to result in the elimination of approximately 120 roles in the United States, and a significant reduction in our internal manufacturing and allogeneic research footprints in California. While we expect that the majority of the charges associated with the restructuring will be incurred in the second quarter of 2023 and that the execution of the restructuring will be substantially complete by the end of the third quarter of 2024, we may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the restructuring. However, we may not achieve the expected benefits of these cost reduction measures and other cost reduction plans on the anticipated timeline, or at all, which could otherwise accelerate our liquidity needs and could force us to further curtail or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suspend our operations. Moreover, we rely in part on our collaboration partners to provide funding for and otherwise advance our pre-clinical and clinical programs. However, in June 2022, our collaboration agreement with Sanofi terminated, and in March 2023, Biogen and Novartis notified us of their respective terminations for convenience of our collaboration agreements with them effective in June 2023. While we may identify new collaboration partners who can progress some of the programs that were the subject of these collaborations, we may not be successful in doing so in a timely manner, on acceptable terms or at all, and we may otherwise fail to raise sufficient additional capital in order to progress these programs ourselves or we may determine that for internal resource allocation purposes or for other reasons to abandon development of these programs. In any event, we would require substantial additional funding in order to progress the programs that were the subject of these collaborations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional capital through public or private equity offerings, including sales pursuant to our at-the-market offering program with Jefferies LLC, the ownership interest of our existing stockholders will be diluted, and such dilution may be substantial, and the terms of any new equity securities may have a preference over, and include rights superior to, our common stock. If we raise additional capital through royalty financings or other collaborations, strategic alliances or licensing arrangements with third parties, we may need to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable. If we raise additional capital through debt financing, we may be subject to specified financial covenants or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or pursuing certain transactions, any of which could restrict our ability to commercialize our product candidates or operate as a business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek regulatory approvals of our product candidates from the FDA or other comparable foreign regulatory authorities, a process that could cost in excess of hundreds of millions of dollars per product. We may experience difficulties in accessing the capital markets due to external factors beyond our control, such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. For example, our ability to raise additional capital may be adversely impacted by global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, such as has been experienced recently due in part to, among other things, the impacts of the COVID-19 pandemic, the ongoing conflict between Russia and Ukraine, and disruptions in access to bank deposits and lending commitments due to bank failure. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will adversely affect our ability to continue as a going concern and our ability to develop our technology and products candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaborators control certain aspects of our product development efforts, including certain of our clinical trials, which could result in unanticipated delays and other obstacles in the commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on collaborators to design and conduct certain of our clinical trials for some of our product candidates. As a result, these clinical trials may not be conducted in the manner or on the timeline we desire, which may negatively impact our product development efforts. For example, Pfizer is the trial sponsor of the Phase 3 AFFINE trial of giroctocogene fitelparvovec and we depended on the efforts of Pfizer to diligently seek to lift the clinical hold on the Phase 3 AFFINE trial and resume the trial. Although dosing in the AFFINE trial has now resumed, we cannot guarantee that we will not experience future delays in this trial or that the trial will be completed on the anticipated timeframe or at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lack of control over aspects of product development in our collaborations with Kite, Takeda and Pfizer could cause delays or other difficulties in the development and commercialization of our product candidates, which may prevent us from completing the intended IND filings in a timely fashion and receiving any milestone, royalty payments and other benefits under the agreement. In addition, under their respective agreements, our third-party collaborators have certain rights to terminate the agreements by providing us with advance notices, therefore, the actual milestone payments that we may receive under these agreements may be substantially lower than the full amounts provided for under these agreements. For example, in June 2022, our collaboration agreement with Sanofi terminated, and in March 2023, Biogen and Novartis notified us of their respective terminations for convenience of our collaboration agreements with them. As a result, we will not be entitled to any further milestone payments or royalties from any of Sanofi, Biogen or Novartis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaborators licensing our ZF technologies may decide to adopt alternative technologies or products or may be unable or unwilling to develop commercially viable products with our ZF technologies, which would negatively impact our revenues and our strategy to develop product candidates using ZF technologies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our ongoing collaborations leverage our ZF technology platform. These collaborators may elect to adopt alternative technologies in the future, which could decrease the value of our ZF technology platform and impede the development of product candidates using the platform. Additionally, because many of our collaborators are likely to be working on more than one development project, they could choose to shift their resources to projects other than those they are working on with us. If they do so, this would delay our ability to test and develop our ZF technology platform and would delay or terminate the development of our product candidates using the platform. Further, our collaborators may elect not to develop product candidates </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arising out of our collaborations or not to devote sufficient resources to the development, manufacturing, marketing or sale of these product candidates. If they terminate the collaborations with us, such as the recent terminations for convenience of our collaboration agreements with Biogen and Novartis, and we wish to continue developing the product candidates, we will be required to seek the support of other collaborators or develop the products ourselves. We may not be able to identify a suitable partner or negotiate a favorable collaboration agreement, and we may not have sufficient resources and expertise internally, to allow us to continue the development of these product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization of our technologies will depend, in part, on collaborations with other companies. If we are not able to find collaborators in the future or if our collaborators do not diligently pursue product development efforts, we may not be able to develop our technologies or product candidates, which could slow our growth and decrease the market value of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have financial resources ourselves to fully develop, obtain regulatory approval for and commercialize our product candidates. We rely significantly on our collaborations with other biopharmaceutical companies to provide funding for our research and development efforts, including preclinical studies and clinical tests, and expect to rely significantly on such collaborations to provide funding for the lengthy regulatory approval processes required to commercialize our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we have collaborations with Kite to develop product candidates to treat cancer and with Pfizer to develop product candidates to treat hemophilia A and amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the C9ORF72 gene. Any delays to or discontinuances of these collaborations could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also party to collaboration agreements with Novartis to develop product candidates to treat certain neurodevelopment disorders, including autism and intellectual disability and with Biogen to develop product candidates to treat tauopathies including Alzheimer&#8217;s disease, alpha-synuclein related diseases including Parkinson&#8217;s disease and other neurological diseases. In March 2023, Novartis and Biogen notified us of their respective terminations for convenience, each effective in June 2023, of their respective collaboration agreements with us. As a result of these terminations, as of the respective termination dates of the collaboration agreements, we will not be entitled to any milestone payments or royalties from Novartis or Biogen, and Novartis and Biogen will have no further obligations to develop or to reimburse the costs of any of the programs under the applicable agreement. We cannot guarantee that we will be able to come to agreement with Novartis and Biogen on appropriate transition arrangements or otherwise execute an orderly transition under the respective collaboration agreement. In April 2023, we made the strategic decision to pause further development of the programs that were the subject of these collaborations. In the future, we may identify alternative options to advance some of the programs that were subject to such agreements, including potential development internally or with a collaboration partner. However, we cannot guarantee that we will be able to successfully secure any such options, including identifying an alternative suitable collaboration partner or negotiate a favorable alternative collaboration agreement. In such case, we may be unable or unwilling to continue developing the programs subject to these collaboration agreements due to the lack of adequate capital resources or otherwise.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we completed the transition of the rights and obligations of Sanofi, under our prior collaboration agreement back to us. Although we expect to complete the Phase 1/2 PRECIZIN-1 study of BIVV003, our product candidate to treat SCD, we cannot guarantee that we will be able to complete this study in a timely manner or at all. Also, we do not expect to make additional material investments in our SCD program and, accordingly, do not plan to continue developing BIVV003 beyond completion of this study. Although we are currently seeking a potential collaboration partner to advance the development of BIVV003 beyond this study, we cannot guarantee that we will be able to successfully secure any such collaboration in a timely manner, on acceptable terms or at all. In such case, the continued development of BIVV003 could be further delayed or precluded altogether, in which case may choose to discontinue the BIVV003 program. Any further delays to or discontinuance of this program could have an adverse impact on our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to secure additional collaborations or if our collaborators are unable or unwilling to diligently advance the development, regulatory approval and commercialization of our product candidates, our growth may slow and adversely affect our ability to generate funding for development of our technologies and product candidates as well as our ability to continue to operate as a going concern. In addition, our ongoing collaborators may sublicense or abandon development programs with little advance notice, or we may have disagreements or disputes with our collaborators, which would cause associated product development to slow or cease. In addition, the business or operations of our collaborators may change significantly through restructurings, acquisitions, other strategic transactions that may negatively impact their ability to advance our programs. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under typical collaborations, we expect to receive revenue for the research and development of our product candidates based on achievement of specific milestones, as well as royalties based on a percentage of sales of any commercialized products. Achieving these milestones will depend, in part, on the efforts of our collaborators, which we have no control over, as well as our own efforts. In addition, business combinations, changes in a collaborator&#8217;s business strategy and financial difficulties or other factors could result in that collaborator abandoning or delaying development of any product candidates covered by our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration agreement with that collaborator. For example, the transition back to us of the rights and obligations of Sanofi related to BIVV003 and the related termination for convenience by Sanofi of our prior collaboration agreement followed a change in Sanofi&#8217;s strategic direction to focus on allogeneic universal genomic medicine approaches rather than autologous personalized cell therapies. In addition, Novartis&#8217;s and Biogen&#8217;s decisions to terminate their respective collaboration agreements with us each related to a recent strategic review. Further, if we fail or any collaboration partner fails to meet specific milestones, then the collaboration agreement may be terminated, which would preclude our ability to earn any additional milestone payments under that collaboration agreement and would reduce our revenues. In addition, even if a collaboration product candidate is successfully developed and approved for marketing by relevant regulatory authorities, if sales of the commercialized product fails to meet expectations, we could receive lower royalties than expected. In any event, the milestone and royalty payment opportunities associated with our collaborations involve a substantial degree of risk to achieve and may never be received. Accordingly, investors should not assume that we will receive all of the potential milestone payments provided for under our ongoing collaborations, and it is possible that we may never receive any further significant milestone payments or any royalty payments under our collaborations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our recent restructuring may not result in anticipated savings or operational efficiencies, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we announced a restructuring of operations and corresponding reduction in workforce, designed to reduce costs and increase focus on our key strategic priorities. We expect the Restructuring to result in the elimination of approximately 120 roles in the United States, or approximately 27% of our total United States workforce. We may incur additional expenses not currently contemplated due to events associated with the reduction in force, and our restructuring activities may subject us to reputational risks and litigation risks and expenses. We may not realize, in full or in part, the anticipated benefits and savings from this restructuring due to unforeseen difficulties, delays or unexpected costs, which could adversely affect our financial condition. In addition, we may need to undertake additional workforce reductions or restructuring activities in the future.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our restructuring may be disruptive to our operations. For example, in connection with the restructuring, we expect to transition all remaining allogeneic research activities from Sangamo US to Sangamo France. We may experience delays or other difficulties in effectuating the transition of certain research and manufacturing activities in California overseas, which could result in significant disruptions to our business and delays in our development efforts and clinical trial timelines. In addition, our workforce reduction could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and loss of institutional knowledge and expertise. Our workforce reduction could also harm our ability to attract and retain qualified personnel who are critical to our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to meet continued listing standards of the Nasdaq Stock Market LLC, our common stock may be delisted. Delisting could adversely affect the liquidity of our common stock and the market price of our common stock could decrease, and our ability to obtain sufficient additional capital to fund our operations and to continue as a going concern would be substantially impaired.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is currently listed on the Nasdaq Global Select Market. The Nasdaq Stock Market LLC, or Nasdaq, has minimum requirements that a company must meet in order to remain listed on the Nasdaq Global Select Market. These requirements include maintaining a minimum closing bid price of $1.00 per share, or the Bid Price Requirement. While the closing price of our common stock has remained above the minimum closing bid price of $1.00 per share from January 1, 2023 through the date of filing of this report, on April 28, 2023, our common stock traded as low as $1.31 per share and in the future, the closing bid price of our common stock may fall below $1.00 per share. If the closing bid price of our common stock were to remain below $1.00 per share for 30 consecutive trading days, or we do not meet other Nasdaq listing requirements, we would fail to be in compliance with Nasdaq&#8217;s listing standards. There can be no assurance that we will continue to meet the Bid Price Requirement, or any other Nasdaq continued listing requirement, in the future. If we fail to meet these requirements, including the Bid Price Requirement and requirements to maintain minimum levels of stockholders' equity or market values of our common stock, Nasdaq may notify us that we have failed to meet the minimum listing requirements and initiate the delisting process. If our common stock is delisted, the liquidity of our common stock would be adversely affected and the market price of our common stock could decrease, and our ability to obtain sufficient additional capital to fund our operations and to continue as a going concern would be substantially impaired.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have recorded, and may be required to record in the future, significant charges if our intangible assets or long-lived assets become impaired.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test goodwill, indefinite-lived intangible assets and long-lived assets for impairment annually or more frequently if changes in circumstances or the occurrence of events suggest impairment exists. Any significant change in market conditions, including a sustained decline in our stock price, that indicate a reduction in carrying value may give rise to impairment in the period that the change becomes known. For example, during the three months ended March 31, 2023, as a result of the sustained decline in our stock price and related market capitalization, termination of the collaboration agreements with Biogen and Novartis, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and a general decline in equity values in the biotechnology industry, we performed an impairment assessment of goodwill, indefinite-lived intangible assets, and long-lived assets. Based on this assessment, we recognized a non-cash, pre-tax goodwill impairment charge of $38.1&#160;million and long-lived asset impairment charge of $20.4&#160;million during the three months ended March 31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that changes in circumstances, many of which are outside of our control, or in the numerous variables associated with the assumptions and estimates used in assessing the appropriate valuation of our indefinite-lived intangible assets and long-lived assets, could in the future result in an impairment to our intangible assets and long-lived assets, requiring us to record impairment charges, which would adversely affect our results of operations. </span></div><div id="i056ce7da447f48a894f20e0202bfb367_115"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i056ce7da447f48a894f20e0202bfb367_118"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i056ce7da447f48a894f20e0202bfb367_121"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i056ce7da447f48a894f20e0202bfb367_124"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">Seventh Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 9, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm">Fourth Certificate of Amendment of the Seventh Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed May 22, 2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828022032209/sgmo-20221219xxex31fifth.htm">Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed December 19, 2022).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828023006626/exhibit11-amendmentno3toop.htm">Amendment No. 3 to Open Market Sale Agreement between the Company and Jefferies LLC, dated March 7, 2023 (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed March 7, 2023).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20230331xex311.htm">Rule 13a &#8212; 14(a) Certification of Principal Executive Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20230331xex312.htm">Rule 13a &#8212; 14(a) Certification of Principal Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20230331xex321.htm">Certifications Pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from Sangamo&#8217;s Quarterly Report on Form 10-Q for the three months ended March&#160;31, 2023 is formatted in Inline XBRL and it is contained in Exhibit 101</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;The certifications attached as Exhibit&#160;32.1 accompany this Quarterly Report on Form&#160;10-Q pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">#&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Indicates management contract or compensatory plan or arrangement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">+&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i056ce7da447f48a894f20e0202bfb367_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i056ce7da447f48a894f20e0202bfb367_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: May&#160;8, 2023 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ALEXANDER D. MACRAE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Alexander D. Macrae</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ PRATHYUSHA DURAIBABU</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prathyusha Duraibabu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>sgmo-20230331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i36e5604e8e824e49b15a6fc1ff62f87f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Alexander D. Macrae, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:144pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;8, 2023</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>sgmo-20230331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i93d147df097d423fb12e3739dd5cf060_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Prathyusha Duraibabu, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:144pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;8, 2023</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>sgmo-20230331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if8b6d7ca68d742909b061f087370db71_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certifications Pursuant to 18 U.S.C. &#167;1350, as Adopted</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), each of the undersigned hereby certifies in his or her capacity as an officer of Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March&#160;31, 2023, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.116%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;8, 2023</font></div></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;8, 2023</font></div></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 has been provided to Sangamo Therapeutics, Inc. and will be retained by Sangamo Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sgmo-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1e97b392-2501-45be-8bcc-91b1f8c19bb8,g:c3a18027-401c-4098-a3df-6fe057e7c69a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sangamo.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000007 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000008 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIES" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES">
        <link:definition>0000009 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETINCOMELOSSPERSHARE" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE">
        <link:definition>0000010 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES">
        <link:definition>0000011 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS" roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS">
        <link:definition>0000012 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000013 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000014 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.sangamo.com/role/INCOMETAXES">
        <link:definition>0000015 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000016 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000017 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>0000018 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>0000019 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESTables" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables">
        <link:definition>0000020 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETINCOMELOSSPERSHARETables" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables">
        <link:definition>0000021 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
        <link:definition>0000022 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>0000023 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
        <link:definition>0000024 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails">
        <link:definition>0000025 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails">
        <link:definition>0000026 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDetails" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails">
        <link:definition>0000027 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails">
        <link:definition>0000028 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails">
        <link:definition>0000029 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetails">
        <link:definition>0000030 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails">
        <link:definition>0000031 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETINCOMELOSSPERSHARENarrativeDetails" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARENarrativeDetails">
        <link:definition>0000032 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails">
        <link:definition>0000033 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails">
        <link:definition>0000034 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails">
        <link:definition>0000035 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails">
        <link:definition>0000036 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails">
        <link:definition>0000037 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails">
        <link:definition>0000038 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails" roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails">
        <link:definition>0000039 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails">
        <link:definition>0000040 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDetails" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails">
        <link:definition>0000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://www.sangamo.com/role/INCOMETAXESDetails">
        <link:definition>0000042 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>0000043 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" abstract="false" name="CollaborationAgreementNumberOfAdditionalProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementPercentOfInitialRecognition" abstract="false" name="CollaborativeAgreementPercentOfInitialRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sgmo_AchievementOfCommercialMilestonesMember" abstract="true" name="AchievementOfCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_MilestoneRevenueReceivable" abstract="false" name="MilestoneRevenueReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NovartisInstitutesForBioMedicalResearchIncMember" abstract="true" name="NovartisInstitutesForBioMedicalResearchIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_NumberOfResearchProgram" abstract="false" name="NumberOfResearchProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AmortizationAndOtherChangesInRightOfUseAssets" abstract="false" name="AmortizationAndOtherChangesInRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" abstract="false" name="CollaborativeArrangementNumberOfMilestonesAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementLicenseFee" abstract="false" name="CollaborativeArrangementLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_PfizerSB525Member" abstract="true" name="PfizerSB525Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_RevenueRemainingPerformanceObligationRenewalPeriod" abstract="false" name="RevenueRemainingPerformanceObligationRenewalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding" abstract="false" name="RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_SeparateUpfrontFee" abstract="false" name="SeparateUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAgreementEquityIssued" abstract="false" name="CollaborationAgreementEquityIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" abstract="true" name="WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_BiogenMAIncMember" abstract="true" name="BiogenMAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementResearchServiceFees" abstract="false" name="CollaborativeArrangementResearchServiceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" abstract="false" name="SaleOfStockIncreaseToAggregateOfferingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationFixedConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_TenantImprovementAllowanceWithinContraLeaseLiability" abstract="false" name="TenantImprovementAllowanceWithinContraLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" abstract="false" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_USGovernmentSponsoredAgencyBondMember" abstract="true" name="USGovernmentSponsoredAgencyBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod" abstract="false" name="RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_NumberOfOptionsToExtendInitialResearchTerm" abstract="false" name="NumberOfOptionsToExtendInitialResearchTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CNineORFSevenTwoMember" abstract="true" name="CNineORFSevenTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate" abstract="false" name="ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AgreementTerminationTerm" abstract="false" name="AgreementTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_MilestonePaymentsReceived" abstract="false" name="MilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ResearchServicesMember" abstract="true" name="ResearchServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_PfizerC9ORF72Member" abstract="true" name="PfizerC9ORF72Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" abstract="false" name="IncreaseDecreaseInNetIncomeLossAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate" abstract="false" name="ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_StockOfferingProgramMaximumValue" abstract="false" name="StockOfferingProgramMaximumValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" abstract="false" name="ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" abstract="false" name="ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInEarningsPerShareDiluted" abstract="false" name="IncreaseDecreaseInEarningsPerShareDiluted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense" abstract="false" name="TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" abstract="true" name="NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveAndOtherProductsMember" abstract="true" name="SBFiveTwoFiveAndOtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneAxis" abstract="true" name="CollaborativeAgreementMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_InitialResearchTermOfAgreement" abstract="false" name="InitialResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInEarningsPerShareBasic" abstract="false" name="IncreaseDecreaseInEarningsPerShareBasic" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount" abstract="false" name="RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_LongLivedAssetsNumberOfAssetsGroups" abstract="false" name="LongLivedAssetsNumberOfAssetsGroups" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" abstract="false" name="CustomerContractLiabilityMilestonePaymentEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_KitePharmaIncMember" abstract="true" name="KitePharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" abstract="false" name="SaleOfStockExcessConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_RevenueNumberOfRemainingPerformanceObligations" abstract="false" name="RevenueNumberOfRemainingPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" abstract="true" name="RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" abstract="false" name="CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneDomain" abstract="true" name="CollaborativeAgreementMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty" abstract="false" name="CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" abstract="true" name="AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" abstract="false" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired" abstract="false" name="RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementTransactionPrice" abstract="false" name="CollaborativeArrangementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ExtendedResearchTermOfAgreement" abstract="false" name="ExtendedResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" abstract="false" name="NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>sgmo-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1e97b392-2501-45be-8bcc-91b1f8c19bb8,g:c3a18027-401c-4098-a3df-6fe057e7c69a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9145c24b-64be-4c28-a629-e241e7a86bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_423723dc-6be5-43b2-b1ec-3ffeb1058617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9145c24b-64be-4c28-a629-e241e7a86bc0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_423723dc-6be5-43b2-b1ec-3ffeb1058617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_17d3cdcd-2247-4237-bdf4-ee4da7179d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9145c24b-64be-4c28-a629-e241e7a86bc0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_17d3cdcd-2247-4237-bdf4-ee4da7179d1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_dbc64970-817b-4d4d-93a6-d106913b2931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9145c24b-64be-4c28-a629-e241e7a86bc0" xlink:to="loc_us-gaap_InterestReceivableCurrent_dbc64970-817b-4d4d-93a6-d106913b2931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d3649b51-0d3f-4562-8758-ff3f9ba572d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9145c24b-64be-4c28-a629-e241e7a86bc0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d3649b51-0d3f-4562-8758-ff3f9ba572d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8485dded-6308-44a9-bf1e-fa60c51ecdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9145c24b-64be-4c28-a629-e241e7a86bc0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8485dded-6308-44a9-bf1e-fa60c51ecdec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b09d6e09-832f-4650-b944-5710674ac78c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_71be353e-8521-4dbd-8cd3-ca571630d7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b09d6e09-832f-4650-b944-5710674ac78c" xlink:to="loc_us-gaap_Liabilities_71be353e-8521-4dbd-8cd3-ca571630d7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5bdf6e33-3720-498e-aed6-9a305818155f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b09d6e09-832f-4650-b944-5710674ac78c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5bdf6e33-3720-498e-aed6-9a305818155f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_22450011-ce18-43ec-8990-999e077341f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b09d6e09-832f-4650-b944-5710674ac78c" xlink:to="loc_us-gaap_StockholdersEquity_22450011-ce18-43ec-8990-999e077341f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_71d10720-9600-466b-bce7-ea7997f8449f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_46391a3d-4896-4884-911a-a146c822b3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_71d10720-9600-466b-bce7-ea7997f8449f" xlink:to="loc_us-gaap_AssetsCurrent_46391a3d-4896-4884-911a-a146c822b3ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_b925bf5c-646f-4b80-836a-4a5e5baf92df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_71d10720-9600-466b-bce7-ea7997f8449f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_b925bf5c-646f-4b80-836a-4a5e5baf92df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e5da95bd-3a0b-441d-81f9-78a3d532e91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_71d10720-9600-466b-bce7-ea7997f8449f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e5da95bd-3a0b-441d-81f9-78a3d532e91a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b73d92bd-ae29-4f20-a2bb-0e5bc9b0b167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_71d10720-9600-466b-bce7-ea7997f8449f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b73d92bd-ae29-4f20-a2bb-0e5bc9b0b167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ad1c60d1-3d15-455e-8671-6d44bb3e1a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_71d10720-9600-466b-bce7-ea7997f8449f" xlink:to="loc_us-gaap_Goodwill_ad1c60d1-3d15-455e-8671-6d44bb3e1a47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f20634b6-1a68-4542-bada-8fce140b4b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_71d10720-9600-466b-bce7-ea7997f8449f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f20634b6-1a68-4542-bada-8fce140b4b97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d49abfab-d957-45fe-b91f-8b8d4b226551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_71d10720-9600-466b-bce7-ea7997f8449f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d49abfab-d957-45fe-b91f-8b8d4b226551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3dd405b8-d4d2-4bf2-be00-dda74695309e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_71d10720-9600-466b-bce7-ea7997f8449f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3dd405b8-d4d2-4bf2-be00-dda74695309e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8ec40e4e-cccd-4094-ac8b-25d089017176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_06ddd698-2455-4e6e-911a-2498b403e872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ec40e4e-cccd-4094-ac8b-25d089017176" xlink:to="loc_us-gaap_LiabilitiesCurrent_06ddd698-2455-4e6e-911a-2498b403e872" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_54a34913-406b-45fb-89aa-0e6f633ad820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ec40e4e-cccd-4094-ac8b-25d089017176" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_54a34913-406b-45fb-89aa-0e6f633ad820" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b253f223-2101-46f8-9ea0-c3badbd643ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ec40e4e-cccd-4094-ac8b-25d089017176" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b253f223-2101-46f8-9ea0-c3badbd643ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7037ebea-c539-4fd2-9753-17d816bf05d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ec40e4e-cccd-4094-ac8b-25d089017176" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7037ebea-c539-4fd2-9753-17d816bf05d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e79c9671-0dbf-4c92-a36c-7ec139a018ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ec40e4e-cccd-4094-ac8b-25d089017176" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e79c9671-0dbf-4c92-a36c-7ec139a018ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ba9b670-a2a2-4829-bbf4-071f8dae31c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e0cf0e9e-c300-4c53-a2e2-fdea85e4134b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5ba9b670-a2a2-4829-bbf4-071f8dae31c2" xlink:to="loc_us-gaap_PreferredStockValue_e0cf0e9e-c300-4c53-a2e2-fdea85e4134b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ddad59a0-89ce-4830-9f24-9d324af24e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5ba9b670-a2a2-4829-bbf4-071f8dae31c2" xlink:to="loc_us-gaap_CommonStockValue_ddad59a0-89ce-4830-9f24-9d324af24e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_203a903e-b859-4d94-b6f2-b121fc11cdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5ba9b670-a2a2-4829-bbf4-071f8dae31c2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_203a903e-b859-4d94-b6f2-b121fc11cdc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3d8420d2-ff24-44a0-b52a-9681871a3f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5ba9b670-a2a2-4829-bbf4-071f8dae31c2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3d8420d2-ff24-44a0-b52a-9681871a3f66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_241384ea-554d-4931-9475-63dd7b40e5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5ba9b670-a2a2-4829-bbf4-071f8dae31c2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_241384ea-554d-4931-9475-63dd7b40e5f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dc7345d2-b131-4d59-974f-d9ccb23f6cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_321c5919-a90d-4381-8d0d-9780fd63c600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc7345d2-b131-4d59-974f-d9ccb23f6cba" xlink:to="loc_us-gaap_AccountsPayableCurrent_321c5919-a90d-4381-8d0d-9780fd63c600" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f73f769d-a425-4476-906b-0217babc3f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc7345d2-b131-4d59-974f-d9ccb23f6cba" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f73f769d-a425-4476-906b-0217babc3f50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bea71d47-fc6e-45fd-a407-7a0853903ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc7345d2-b131-4d59-974f-d9ccb23f6cba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bea71d47-fc6e-45fd-a407-7a0853903ba1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8b3477d4-9ad0-470e-81d0-0135cf2de0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dc7345d2-b131-4d59-974f-d9ccb23f6cba" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8b3477d4-9ad0-470e-81d0-0135cf2de0ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3522b7d4-633b-48ed-99e3-fd609f31c019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4a4e7a6c-2d13-4701-acf6-3df446986619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3522b7d4-633b-48ed-99e3-fd609f31c019" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4a4e7a6c-2d13-4701-acf6-3df446986619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ce4d3f2-17db-46d8-8953-4f9c23829cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3522b7d4-633b-48ed-99e3-fd609f31c019" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ce4d3f2-17db-46d8-8953-4f9c23829cc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_029b4bf4-7f38-4923-8694-24635ad25179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4d5791f4-461f-492e-a2d8-bd59069b5ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_029b4bf4-7f38-4923-8694-24635ad25179" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4d5791f4-461f-492e-a2d8-bd59069b5ba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e574ced9-6c99-4098-9bfb-729826a6989b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_029b4bf4-7f38-4923-8694-24635ad25179" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e574ced9-6c99-4098-9bfb-729826a6989b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_46889069-f30f-4524-9adc-6d821c13e3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_029b4bf4-7f38-4923-8694-24635ad25179" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_46889069-f30f-4524-9adc-6d821c13e3b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b6f840d2-cfb6-42dd-86a0-c35e5273a6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_029b4bf4-7f38-4923-8694-24635ad25179" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b6f840d2-cfb6-42dd-86a0-c35e5273a6b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f3bac75e-1c12-413d-ba9e-fe3e6f9d2b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5058663-314e-4c91-b61a-a3873652363e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3bac75e-1c12-413d-ba9e-fe3e6f9d2b23" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5058663-314e-4c91-b61a-a3873652363e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9ecd8d5c-cae2-4844-a175-2113501c2427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_f3bac75e-1c12-413d-ba9e-fe3e6f9d2b23" xlink:to="loc_us-gaap_OperatingExpenses_9ecd8d5c-cae2-4844-a175-2113501c2427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6de84120-17e4-4455-84e3-ef1a7d06c1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_72187db6-42e8-4b49-a1fa-41cce256babe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6de84120-17e4-4455-84e3-ef1a7d06c1e9" xlink:to="loc_us-gaap_OperatingIncomeLoss_72187db6-42e8-4b49-a1fa-41cce256babe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_7d914d36-458f-41b2-a252-7c3f881b53f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6de84120-17e4-4455-84e3-ef1a7d06c1e9" xlink:to="loc_us-gaap_InterestAndOtherIncome_7d914d36-458f-41b2-a252-7c3f881b53f5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d3bae2f6-1b7c-43bc-a600-42af530e8e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_74121169-6657-481a-9175-aa60a33b0dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d3bae2f6-1b7c-43bc-a600-42af530e8e3b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_74121169-6657-481a-9175-aa60a33b0dfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_753bcc27-ccce-459f-8c1e-a5c0abd485b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d3bae2f6-1b7c-43bc-a600-42af530e8e3b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_753bcc27-ccce-459f-8c1e-a5c0abd485b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7b617aa8-6386-4dc7-b796-e391e0bfff13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d3bae2f6-1b7c-43bc-a600-42af530e8e3b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_7b617aa8-6386-4dc7-b796-e391e0bfff13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8593a0f9-8be3-4da2-8945-31d8f7bdaaec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d3bae2f6-1b7c-43bc-a600-42af530e8e3b" xlink:to="loc_us-gaap_ProfitLoss_8593a0f9-8be3-4da2-8945-31d8f7bdaaec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c1b2259-b0db-43d7-81de-025d93ee8984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_f0419ad5-e2b1-4191-81fe-62a9f313a91a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c1b2259-b0db-43d7-81de-025d93ee8984" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_f0419ad5-e2b1-4191-81fe-62a9f313a91a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_033a17c1-ab70-4e05-8956-aa42ba5941ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c1b2259-b0db-43d7-81de-025d93ee8984" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_033a17c1-ab70-4e05-8956-aa42ba5941ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e22db828-be32-4de5-b405-2cb03fa2edb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5c1b2259-b0db-43d7-81de-025d93ee8984" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e22db828-be32-4de5-b405-2cb03fa2edb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b0fa35d0-fe59-4e6c-a0b8-e288e10bd7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b841c633-54a2-4917-ad2c-0140c0d3995e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b0fa35d0-fe59-4e6c-a0b8-e288e10bd7ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b841c633-54a2-4917-ad2c-0140c0d3995e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_adf1dd55-64d3-4bf3-9084-6c40197e9425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b0fa35d0-fe59-4e6c-a0b8-e288e10bd7ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_adf1dd55-64d3-4bf3-9084-6c40197e9425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb786e47-bcf9-4ac5-b4cb-5edddd1229b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b0fa35d0-fe59-4e6c-a0b8-e288e10bd7ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb786e47-bcf9-4ac5-b4cb-5edddd1229b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99730f96-5a65-441a-82b0-f4cd2fb72617" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b0fa35d0-fe59-4e6c-a0b8-e288e10bd7ca" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99730f96-5a65-441a-82b0-f4cd2fb72617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520d384e-8c71-409b-bb0f-4bebb65ceeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_520d384e-8c71-409b-bb0f-4bebb65ceeb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3b996818-f3e8-4a79-b27b-01842f20249d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3b996818-f3e8-4a79-b27b-01842f20249d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_de4a2374-1ab4-42db-8e29-0aea11cf5725" xlink:href="sgmo-20230331.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_de4a2374-1ab4-42db-8e29-0aea11cf5725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_37fc3018-6c8c-4720-a92f-f63427b991d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_37fc3018-6c8c-4720-a92f-f63427b991d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_55d5e420-75ce-4e24-9c89-3fc4a31cb069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_55d5e420-75ce-4e24-9c89-3fc4a31cb069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2465aaea-706c-4d16-90e1-e7611c6c1bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2465aaea-706c-4d16-90e1-e7611c6c1bb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_52c44f55-da1b-4235-a2fe-c275bc76d30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_52c44f55-da1b-4235-a2fe-c275bc76d30a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ab3ea81d-4787-4180-99d2-65b6d38e6d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ab3ea81d-4787-4180-99d2-65b6d38e6d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9e5920dd-f5d3-437e-a77b-4336303b56da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_ProfitLoss_9e5920dd-f5d3-437e-a77b-4336303b56da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_827bde42-b61a-4c92-b845-2ecccfdc2e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_ShareBasedCompensation_827bde42-b61a-4c92-b845-2ecccfdc2e77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1eee8472-da10-41db-b1a7-85078d4d8429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1eee8472-da10-41db-b1a7-85078d4d8429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_21783a00-703e-4ac0-ad4e-5ed2d72a5bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_21783a00-703e-4ac0-ad4e-5ed2d72a5bcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d464d9f5-9b3b-4fea-881d-3a6150b9e669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d464d9f5-9b3b-4fea-881d-3a6150b9e669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_a37a74b3-e31f-4bd9-afd8-dde3646bf4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_a37a74b3-e31f-4bd9-afd8-dde3646bf4b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_199a4aae-83fb-49ef-b3c0-5c1fedba0a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2bea3ce9-3c55-466e-bec6-3b27e3305bf9" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_199a4aae-83fb-49ef-b3c0-5c1fedba0a93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e7fb7aa4-88a0-4f06-89a2-b314e5f07670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e016fd6d-5b8c-455c-b106-06e4d12b1b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e7fb7aa4-88a0-4f06-89a2-b314e5f07670" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e016fd6d-5b8c-455c-b106-06e4d12b1b0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c037cb4a-dd4a-4faf-be5a-16234f85c8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e7fb7aa4-88a0-4f06-89a2-b314e5f07670" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c037cb4a-dd4a-4faf-be5a-16234f85c8c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b9f3505c-9e8a-4928-a6ff-edaf75d449df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e7fb7aa4-88a0-4f06-89a2-b314e5f07670" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b9f3505c-9e8a-4928-a6ff-edaf75d449df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6cc8fc3-6bb4-406a-bff5-a790574bb010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bc961ae-8b94-47fd-a3f6-08b535d1b1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6cc8fc3-6bb4-406a-bff5-a790574bb010" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6bc961ae-8b94-47fd-a3f6-08b535d1b1c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a1f03bf6-286e-45d6-96bd-6c8c54b26af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6cc8fc3-6bb4-406a-bff5-a790574bb010" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a1f03bf6-286e-45d6-96bd-6c8c54b26af9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8ca9cc98-aa76-43ea-9c40-36be55eec865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a6fc795d-c508-45e2-b20a-0e8c33a42708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8ca9cc98-aa76-43ea-9c40-36be55eec865" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a6fc795d-c508-45e2-b20a-0e8c33a42708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10c0ca9a-23d1-4e00-8f6d-7d8186ff7aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8ca9cc98-aa76-43ea-9c40-36be55eec865" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10c0ca9a-23d1-4e00-8f6d-7d8186ff7aa7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_ac5ca48d-1e44-42a1-b805-06c04c545dbd" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_8ad00ae4-c941-4eb7-b5d9-c4706e85bb3e" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_ac5ca48d-1e44-42a1-b805-06c04c545dbd" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_8ad00ae4-c941-4eb7-b5d9-c4706e85bb3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_01661ee3-4d7a-4bc6-a90b-0da8b454e973" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_ac5ca48d-1e44-42a1-b805-06c04c545dbd" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_01661ee3-4d7a-4bc6-a90b-0da8b454e973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_1c563dbf-0bc8-4640-a5cd-3b9a02df8d76" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_ac5ca48d-1e44-42a1-b805-06c04c545dbd" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_1c563dbf-0bc8-4640-a5cd-3b9a02df8d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ffff6c46-d189-41a2-b2c3-f74dfc817cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_bef18140-b99a-4db0-9e2f-46f7ab423112" xlink:href="sgmo-20230331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ffff6c46-d189-41a2-b2c3-f74dfc817cab" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_bef18140-b99a-4db0-9e2f-46f7ab423112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_01e11f7a-2061-48e6-982f-3906a8cb0bfc" xlink:href="sgmo-20230331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ffff6c46-d189-41a2-b2c3-f74dfc817cab" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_01e11f7a-2061-48e6-982f-3906a8cb0bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_558543ab-6a9a-452d-adbf-815a43ac66a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ffff6c46-d189-41a2-b2c3-f74dfc817cab" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_558543ab-6a9a-452d-adbf-815a43ac66a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab1e9843-7b96-4b11-8755-f919c24afc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_289d899c-a995-44da-840f-ec5ecee5c545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab1e9843-7b96-4b11-8755-f919c24afc4a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_289d899c-a995-44da-840f-ec5ecee5c545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_df3540f3-ea0d-46a0-9a3b-a0a7f2b68415" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab1e9843-7b96-4b11-8755-f919c24afc4a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_df3540f3-ea0d-46a0-9a3b-a0a7f2b68415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_665c6a00-692f-4bab-9030-f3c74a1aa4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab1e9843-7b96-4b11-8755-f919c24afc4a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_665c6a00-692f-4bab-9030-f3c74a1aa4dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c01ca033-ec57-4306-a4da-07c44444490c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8c3ae478-7856-4ea9-8724-4f6c97055e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c01ca033-ec57-4306-a4da-07c44444490c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8c3ae478-7856-4ea9-8724-4f6c97055e0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_22153287-7634-4fff-a008-e7a56214cab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c01ca033-ec57-4306-a4da-07c44444490c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_22153287-7634-4fff-a008-e7a56214cab1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e551724-aceb-415b-872d-dcbaa1dc385e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4e1ed951-43da-40a7-ae4a-67fc77774403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e551724-aceb-415b-872d-dcbaa1dc385e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4e1ed951-43da-40a7-ae4a-67fc77774403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a6c843d3-a513-4a00-be1c-a75157c061ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9e551724-aceb-415b-872d-dcbaa1dc385e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a6c843d3-a513-4a00-be1c-a75157c061ee" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>sgmo-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1e97b392-2501-45be-8bcc-91b1f8c19bb8,g:c3a18027-401c-4098-a3df-6fe057e7c69a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="if56ac7d8aa8a4a82bdfc60cb468b34e1_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f98f68ae-cfb8-42e2-8eb0-79eb069086eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f98f68ae-cfb8-42e2-8eb0-79eb069086eb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_534f3925-d0a9-461c-bee6-4d262a165d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_CommonStockSharesIssued_534f3925-d0a9-461c-bee6-4d262a165d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64fc6d31-bb0a-4c88-8ed9-a45afbeaa96c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64fc6d31-bb0a-4c88-8ed9-a45afbeaa96c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5e3e12c4-f56d-4ff1-94ae-590cb1955064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5e3e12c4-f56d-4ff1-94ae-590cb1955064" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bb61d55b-56ac-42a2-8a5e-9a8548454ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bb61d55b-56ac-42a2-8a5e-9a8548454ebe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f3aa71ca-f4e1-4531-a490-ce1152c4a7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f3aa71ca-f4e1-4531-a490-ce1152c4a7ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ee650ea8-87ac-4f05-9b46-75716dd3714a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ee650ea8-87ac-4f05-9b46-75716dd3714a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47377f49-581a-46db-a75a-aea5559510f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47377f49-581a-46db-a75a-aea5559510f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_3e1e2f8c-47a4-47a5-865e-9b3b1fd4e2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_3e1e2f8c-47a4-47a5-865e-9b3b1fd4e2e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_84c6b45e-b4bc-499a-a354-4fd0fa85c61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_84c6b45e-b4bc-499a-a354-4fd0fa85c61b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e538f058-de0c-45d7-975b-f1454aea70b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e538f058-de0c-45d7-975b-f1454aea70b8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c52923cd-638f-4586-87b8-e8a559cc1038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_ProfitLoss_c52923cd-638f-4586-87b8-e8a559cc1038" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4c5d3817-0cec-471d-a960-dd06f343ba22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4fdf6521-ceeb-4484-80bd-c5eb8cea3a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bd7e69ee-6f79-4df3-ada2-d587f2f9cf54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f98f68ae-cfb8-42e2-8eb0-79eb069086eb" xlink:to="loc_us-gaap_StatementTable_bd7e69ee-6f79-4df3-ada2-d587f2f9cf54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4843cd16-a50b-48ec-a727-8fb8a3414cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bd7e69ee-6f79-4df3-ada2-d587f2f9cf54" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4843cd16-a50b-48ec-a727-8fb8a3414cec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4843cd16-a50b-48ec-a727-8fb8a3414cec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4843cd16-a50b-48ec-a727-8fb8a3414cec" xlink:to="loc_us-gaap_EquityComponentDomain_4843cd16-a50b-48ec-a727-8fb8a3414cec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4843cd16-a50b-48ec-a727-8fb8a3414cec" xlink:to="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d6624049-63af-43c9-923f-105a30d7cbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:to="loc_us-gaap_CommonStockMember_d6624049-63af-43c9-923f-105a30d7cbf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_301f1dec-ff02-46ec-a5c3-b7f849d1095e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_301f1dec-ff02-46ec-a5c3-b7f849d1095e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d522bd22-50fe-40bc-8b1b-5bb5b48bef9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:to="loc_us-gaap_RetainedEarningsMember_d522bd22-50fe-40bc-8b1b-5bb5b48bef9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e1aa66e-4689-4893-9044-aa3f88c6e27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e1aa66e-4689-4893-9044-aa3f88c6e27c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i63cd8d4b499b4267a5a2df2366fa0191_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_40535f06-f287-4177-8a40-5f47d76ffb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:to="loc_us-gaap_ProfitLoss_40535f06-f287-4177-8a40-5f47d76ffb92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_26b93588-6f91-4f6e-be51-fc3ee64031c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_26b93588-6f91-4f6e-be51-fc3ee64031c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_204e1fef-f77a-483f-af56-84734e57e91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_204e1fef-f77a-483f-af56-84734e57e91f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dfc4ba97-cdb5-4456-b5dc-282d152ec71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dfc4ba97-cdb5-4456-b5dc-282d152ec71c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3336f28f-8306-4284-839a-3f1a212e8380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3336f28f-8306-4284-839a-3f1a212e8380" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_b67d89d9-e765-4b83-8a6b-b10acf5bee0d" xlink:href="sgmo-20230331.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_b67d89d9-e765-4b83-8a6b-b10acf5bee0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_10243d74-0a72-4f2e-93c4-3f62cbe3b74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_us-gaap_ShareBasedCompensation_10243d74-0a72-4f2e-93c4-3f62cbe3b74b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_7f47e40e-dca2-4015-9abb-f51c6ac0dfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_7f47e40e-dca2-4015-9abb-f51c6ac0dfdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ff168dd1-1522-4971-9c4a-e01bfa36f35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ff168dd1-1522-4971-9c4a-e01bfa36f35d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d65434f-6697-4752-935a-6603c7912c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d65434f-6697-4752-935a-6603c7912c11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_eb09eb68-e553-4f8f-8e4d-74de56c43cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_eb09eb68-e553-4f8f-8e4d-74de56c43cf0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ce9ad8be-32d8-4e9c-9450-7ed376c698ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ce9ad8be-32d8-4e9c-9450-7ed376c698ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cd4b0327-c6e4-40b9-9034-ab350cabc991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cd4b0327-c6e4-40b9-9034-ab350cabc991" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b02392f1-4cc9-44a0-a2ad-cfcc6cf93e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b02392f1-4cc9-44a0-a2ad-cfcc6cf93e3a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_85b5eb96-795a-410c-9ba3-efd95d4723b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_85b5eb96-795a-410c-9ba3-efd95d4723b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb742177-cd68-4a34-aa93-d8a7cd269d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb742177-cd68-4a34-aa93-d8a7cd269d28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_97bafa0c-cb9d-4b3e-b6db-3b11034b455a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_97bafa0c-cb9d-4b3e-b6db-3b11034b455a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_1cbd3023-e4c8-4de8-a387-15c67ab53840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_1cbd3023-e4c8-4de8-a387-15c67ab53840" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a1f46f2-b920-4cb6-9b08-d5ff2f5ddc13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a1f46f2-b920-4cb6-9b08-d5ff2f5ddc13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d13b59a4-d86f-4682-a0af-485ec9e5d181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d13b59a4-d86f-4682-a0af-485ec9e5d181" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_120992f6-b271-4e5d-89a6-0a20a89e7021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_120992f6-b271-4e5d-89a6-0a20a89e7021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_62d25ab3-f97a-4d73-aefd-54f7ba3aaf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_62d25ab3-f97a-4d73-aefd-54f7ba3aaf71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_84db641a-3505-4d0c-bbf0-1c4147b20901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_84db641a-3505-4d0c-bbf0-1c4147b20901" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4d0eaad7-3f39-4ec8-afe6-a82d0e27033a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4d0eaad7-3f39-4ec8-afe6-a82d0e27033a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68a47b56-8b30-4eec-bfce-03ce7ba14768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68a47b56-8b30-4eec-bfce-03ce7ba14768" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff835cd3-1301-466c-b9bd-831057ca1108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff835cd3-1301-466c-b9bd-831057ca1108" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30bd6ad0-f9ca-469f-8bcf-ee9d30df785d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30bd6ad0-f9ca-469f-8bcf-ee9d30df785d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d980c61e-6e43-43fd-bf55-2215b53a86e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b80f006c-5797-4edf-bdd8-934cd184246c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b80f006c-5797-4edf-bdd8-934cd184246c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_65fef2da-3f50-4b21-88e0-a9f59f742944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b80f006c-5797-4edf-bdd8-934cd184246c" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_65fef2da-3f50-4b21-88e0-a9f59f742944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability_9fead884-d152-4f18-8c6b-977e08d2913b" xlink:href="sgmo-20230331.xsd#sgmo_TenantImprovementAllowanceWithinContraLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b80f006c-5797-4edf-bdd8-934cd184246c" xlink:to="loc_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability_9fead884-d152-4f18-8c6b-977e08d2913b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_741375bc-7662-47ef-bdc8-b9a93b202140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_StatementTable_741375bc-7662-47ef-bdc8-b9a93b202140" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_65c1c006-fcc3-4478-9966-c60946231d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_741375bc-7662-47ef-bdc8-b9a93b202140" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_65c1c006-fcc3-4478-9966-c60946231d69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65c1c006-fcc3-4478-9966-c60946231d69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_65c1c006-fcc3-4478-9966-c60946231d69" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_65c1c006-fcc3-4478-9966-c60946231d69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f47e07fb-bbf6-492e-9402-11de38c8f5be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_65c1c006-fcc3-4478-9966-c60946231d69" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f47e07fb-bbf6-492e-9402-11de38c8f5be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingMember_11a44319-96ba-420d-9bcb-6d1f39b3ee97" xlink:href="sgmo-20230331.xsd#sgmo_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f47e07fb-bbf6-492e-9402-11de38c8f5be" xlink:to="loc_sgmo_AtTheMarketOfferingMember_11a44319-96ba-420d-9bcb-6d1f39b3ee97" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended" id="ib8b233da6534465fa2ee5d9b0fa6ef36_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_89012b31-c1c5-40ae-8725-6645ccb44240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_2523126a-4cac-4903-ac0d-1f3e26d481dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_89012b31-c1c5-40ae-8725-6645ccb44240" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_2523126a-4cac-4903-ac0d-1f3e26d481dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0aeffc62-36f9-4c6a-93e5-b630c774293e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_89012b31-c1c5-40ae-8725-6645ccb44240" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0aeffc62-36f9-4c6a-93e5-b630c774293e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_08ee6f66-6522-4ef5-b449-622fddda592d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0aeffc62-36f9-4c6a-93e5-b630c774293e" xlink:to="loc_srt_CounterpartyNameAxis_08ee6f66-6522-4ef5-b449-622fddda592d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08ee6f66-6522-4ef5-b449-622fddda592d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_08ee6f66-6522-4ef5-b449-622fddda592d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_08ee6f66-6522-4ef5-b449-622fddda592d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_08ee6f66-6522-4ef5-b449-622fddda592d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6e51acff-b707-4bc5-bcbb-b6de39665ac8" xlink:href="sgmo-20230331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6e51acff-b707-4bc5-bcbb-b6de39665ac8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_a349058e-e63f-4db0-a0ee-29503f037e15" xlink:href="sgmo-20230331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:to="loc_sgmo_BiogenMAIncMember_a349058e-e63f-4db0-a0ee-29503f037e15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_d3c25679-e1a7-441a-b384-d94c378a270c" xlink:href="sgmo-20230331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:to="loc_sgmo_KitePharmaIncMember_d3c25679-e1a7-441a-b384-d94c378a270c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_8e67e50d-ce51-4402-a82c-ad9e70c9db76" xlink:href="sgmo-20230331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:to="loc_sgmo_SanofiMember_8e67e50d-ce51-4402-a82c-ad9e70c9db76" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended" id="ie848abcac4b8410490edb84500e41146_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_ba330a94-40f8-49c8-989d-44540e751919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_ba330a94-40f8-49c8-989d-44540e751919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_366e6d5d-3e6e-4a1d-a82f-ad40f1cd43b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_us-gaap_NetIncomeLoss_366e6d5d-3e6e-4a1d-a82f-ad40f1cd43b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92ca8528-4ba6-42c9-876d-7bbac0984e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92ca8528-4ba6-42c9-876d-7bbac0984e19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_346d5adf-5968-4dae-8ebe-36cf771af0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_346d5adf-5968-4dae-8ebe-36cf771af0a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_985c0a75-b60b-4536-99a5-443fc412a5c3" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_985c0a75-b60b-4536-99a5-443fc412a5c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_57ed2e10-df3b-4f61-b326-6020a7550e63" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_57ed2e10-df3b-4f61-b326-6020a7550e63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_ae0ad56c-8437-401b-9a08-fd3f3a4f2281" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_ae0ad56c-8437-401b-9a08-fd3f3a4f2281" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_431a397b-9a20-4c2b-a802-5946ee5e96de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_431a397b-9a20-4c2b-a802-5946ee5e96de" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49fc7b6e-a099-46a7-bb9b-2794aa82d995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49fc7b6e-a099-46a7-bb9b-2794aa82d995" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_824ee172-94ff-43eb-9358-25db7156de62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49fc7b6e-a099-46a7-bb9b-2794aa82d995" xlink:to="loc_srt_CounterpartyNameAxis_824ee172-94ff-43eb-9358-25db7156de62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_824ee172-94ff-43eb-9358-25db7156de62_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_824ee172-94ff-43eb-9358-25db7156de62" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_824ee172-94ff-43eb-9358-25db7156de62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4aa9aebc-b9d9-4963-abe8-740e66137576" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_824ee172-94ff-43eb-9358-25db7156de62" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4aa9aebc-b9d9-4963-abe8-740e66137576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_b8d099cf-0d50-4d3b-8b74-5d5b34fcbbe4" xlink:href="sgmo-20230331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4aa9aebc-b9d9-4963-abe8-740e66137576" xlink:to="loc_sgmo_KitePharmaIncMember_b8d099cf-0d50-4d3b-8b74-5d5b34fcbbe4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails" xlink:type="extended" id="i6d191681909a43b1a0268ecbd4ab453c_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7e451dd1-6295-4910-b52b-f0a78b125121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6490b0b4-e0fe-4946-911e-41e509421cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7e451dd1-6295-4910-b52b-f0a78b125121" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6490b0b4-e0fe-4946-911e-41e509421cd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_864b3c11-0490-4f8d-89fe-1c39a80384c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7e451dd1-6295-4910-b52b-f0a78b125121" xlink:to="loc_us-gaap_ConcentrationRiskTable_864b3c11-0490-4f8d-89fe-1c39a80384c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f9d36efa-3927-4700-bf59-df88b4f23b8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_864b3c11-0490-4f8d-89fe-1c39a80384c7" xlink:to="loc_srt_CounterpartyNameAxis_f9d36efa-3927-4700-bf59-df88b4f23b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9d36efa-3927-4700-bf59-df88b4f23b8f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f9d36efa-3927-4700-bf59-df88b4f23b8f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f9d36efa-3927-4700-bf59-df88b4f23b8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f9d36efa-3927-4700-bf59-df88b4f23b8f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_3e214769-6f38-4b22-9156-f855daf5681f" xlink:href="sgmo-20230331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:to="loc_sgmo_BiogenMAIncMember_3e214769-6f38-4b22-9156-f855daf5681f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_46a063e8-c267-447e-b28e-215468f25eb1" xlink:href="sgmo-20230331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:to="loc_sgmo_KitePharmaIncMember_46a063e8-c267-447e-b28e-215468f25eb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_893ccb7a-816d-4850-8e47-945f36abd85c" xlink:href="sgmo-20230331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_893ccb7a-816d-4850-8e47-945f36abd85c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_3711534c-6cd6-453b-b6f4-18c14ad12070" xlink:href="sgmo-20230331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:to="loc_sgmo_SanofiMember_3711534c-6cd6-453b-b6f4-18c14ad12070" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bcb50340-b8c5-4c94-81e7-dbe2446cbafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_864b3c11-0490-4f8d-89fe-1c39a80384c7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bcb50340-b8c5-4c94-81e7-dbe2446cbafb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcb50340-b8c5-4c94-81e7-dbe2446cbafb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bcb50340-b8c5-4c94-81e7-dbe2446cbafb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bcb50340-b8c5-4c94-81e7-dbe2446cbafb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_38e4fd0f-ead4-444c-8cf9-5d573b74e179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bcb50340-b8c5-4c94-81e7-dbe2446cbafb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_38e4fd0f-ead4-444c-8cf9-5d573b74e179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_05b8e687-1909-439e-89f1-d904a4e78e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_38e4fd0f-ead4-444c-8cf9-5d573b74e179" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_05b8e687-1909-439e-89f1-d904a4e78e96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_03013f17-d38a-4644-8b26-894495927dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_864b3c11-0490-4f8d-89fe-1c39a80384c7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_03013f17-d38a-4644-8b26-894495927dc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_03013f17-d38a-4644-8b26-894495927dc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_03013f17-d38a-4644-8b26-894495927dc1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_03013f17-d38a-4644-8b26-894495927dc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2d3e35fa-d1e0-45ce-9e52-7ceb770beb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_03013f17-d38a-4644-8b26-894495927dc1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2d3e35fa-d1e0-45ce-9e52-7ceb770beb49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_a745601b-a69e-421a-92ec-839a512db3c4" xlink:href="sgmo-20230331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2d3e35fa-d1e0-45ce-9e52-7ceb770beb49" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_a745601b-a69e-421a-92ec-839a512db3c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended" id="i9c10ee743f9d44aaa76a91e0b2e97d9a_FAIRVALUEMEASUREMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2d0ba26-9612-449a-b834-11f9bf5adc21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ccf4ed22-b2c0-4e08-b35e-40b6b9767c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2d0ba26-9612-449a-b834-11f9bf5adc21" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ccf4ed22-b2c0-4e08-b35e-40b6b9767c8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_572e81ee-cc20-4ed3-8635-f086842e07a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2d0ba26-9612-449a-b834-11f9bf5adc21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_572e81ee-cc20-4ed3-8635-f086842e07a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a31a1571-1734-4069-8648-c093a02904f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2d0ba26-9612-449a-b834-11f9bf5adc21" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a31a1571-1734-4069-8648-c093a02904f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_de8f89cd-b597-44d5-a786-cbaef23e46e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2d0ba26-9612-449a-b834-11f9bf5adc21" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_de8f89cd-b597-44d5-a786-cbaef23e46e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_432d23b6-58b7-497f-977c-4f7287660360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_de8f89cd-b597-44d5-a786-cbaef23e46e6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_432d23b6-58b7-497f-977c-4f7287660360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_432d23b6-58b7-497f-977c-4f7287660360_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_432d23b6-58b7-497f-977c-4f7287660360" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_432d23b6-58b7-497f-977c-4f7287660360_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_77414b1a-6c05-4036-8906-ad74843b8ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_432d23b6-58b7-497f-977c-4f7287660360" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_77414b1a-6c05-4036-8906-ad74843b8ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2f141525-8cee-46ce-a4ce-cb13a2692240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_77414b1a-6c05-4036-8906-ad74843b8ea3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2f141525-8cee-46ce-a4ce-cb13a2692240" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97988ab7-f87b-432c-aebf-91b788e44107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_de8f89cd-b597-44d5-a786-cbaef23e46e6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97988ab7-f87b-432c-aebf-91b788e44107" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97988ab7-f87b-432c-aebf-91b788e44107_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97988ab7-f87b-432c-aebf-91b788e44107" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97988ab7-f87b-432c-aebf-91b788e44107_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_538a010b-5057-487c-abfb-0e73a9a00736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97988ab7-f87b-432c-aebf-91b788e44107" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_538a010b-5057-487c-abfb-0e73a9a00736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_31e4ea4a-9c31-425f-9071-5085b5e68261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_538a010b-5057-487c-abfb-0e73a9a00736" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_31e4ea4a-9c31-425f-9071-5085b5e68261" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_21167297-f1a2-4643-adf1-262b714b2383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_538a010b-5057-487c-abfb-0e73a9a00736" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_21167297-f1a2-4643-adf1-262b714b2383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7b41cf88-9a1e-4d9f-a986-842441d990a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_538a010b-5057-487c-abfb-0e73a9a00736" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7b41cf88-9a1e-4d9f-a986-842441d990a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_64ba947a-ebf9-4027-b958-c9a30a7f98ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_de8f89cd-b597-44d5-a786-cbaef23e46e6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_64ba947a-ebf9-4027-b958-c9a30a7f98ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64ba947a-ebf9-4027-b958-c9a30a7f98ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_64ba947a-ebf9-4027-b958-c9a30a7f98ae" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64ba947a-ebf9-4027-b958-c9a30a7f98ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_64ba947a-ebf9-4027-b958-c9a30a7f98ae" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0558650a-a213-4ec7-b593-c2a4243190bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0558650a-a213-4ec7-b593-c2a4243190bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_9a730bc0-4dfc-4015-9fce-fe0f40ddf553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_9a730bc0-4dfc-4015-9fce-fe0f40ddf553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4c8050cd-d5d4-41a2-a3d1-93b56fec0ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_CommercialPaperMember_4c8050cd-d5d4-41a2-a3d1-93b56fec0ae4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0ed3226f-3b58-46fe-9d0c-8108b2009fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0ed3226f-3b58-46fe-9d0c-8108b2009fd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_34ed380b-7eac-4877-a14b-e2ef0fc17fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_34ed380b-7eac-4877-a14b-e2ef0fc17fd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8ea3ff31-2e7a-4f7e-94f9-9281512d765f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8ea3ff31-2e7a-4f7e-94f9-9281512d765f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_91c4a64b-2751-48b5-ba18-3c650067695a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_91c4a64b-2751-48b5-ba18-3c650067695a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_USGovernmentSponsoredAgencyBondMember_e957c2be-45f2-4004-85e5-c4652f6ac44f" xlink:href="sgmo-20230331.xsd#sgmo_USGovernmentSponsoredAgencyBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_sgmo_USGovernmentSponsoredAgencyBondMember_e957c2be-45f2-4004-85e5-c4652f6ac44f" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i77d04bc7daa145eda30f11f86dbbb403_CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:to="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a590d96-bae3-4cb5-be88-e17b315ef64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a590d96-bae3-4cb5-be88-e17b315ef64b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_7e963152-6761-4347-a1ea-0c3a42feb4db" xlink:href="sgmo-20230331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_7e963152-6761-4347-a1ea-0c3a42feb4db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_30ffde48-ba5f-4af5-b228-814efcc4708a" xlink:href="sgmo-20230331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_30ffde48-ba5f-4af5-b228-814efcc4708a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8a1bd6a-b7e2-467d-bbad-995713e3e15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8a1bd6a-b7e2-467d-bbad-995713e3e15a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b38537ab-171c-464e-8bd1-f857b2988146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b38537ab-171c-464e-8bd1-f857b2988146" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e7f79c92-926b-4fc6-a764-bc024e006075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e7f79c92-926b-4fc6-a764-bc024e006075" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2bf56a7d-1e00-4fd8-8140-bced57446425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2bf56a7d-1e00-4fd8-8140-bced57446425" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87a95160-1fd3-4662-b29f-1e4e7301e4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87a95160-1fd3-4662-b29f-1e4e7301e4d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_ab433d7f-ad13-42d9-a3a7-f50917c80800" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_ab433d7f-ad13-42d9-a3a7-f50917c80800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_a084bd92-213a-40ec-b98b-01828798bc56" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_a084bd92-213a-40ec-b98b-01828798bc56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_d0f7d9db-bb44-4b15-bc69-c7147cefceaa" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_d0f7d9db-bb44-4b15-bc69-c7147cefceaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_be960458-7865-4d3b-b5f9-c72f707ef8de" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_be960458-7865-4d3b-b5f9-c72f707ef8de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a1e1c9a-9e7c-490a-9a06-3b54103a7c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a1e1c9a-9e7c-490a-9a06-3b54103a7c70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6bbd83cb-4a0c-4027-8a77-8f3a6bcb4729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a1e1c9a-9e7c-490a-9a06-3b54103a7c70" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6bbd83cb-4a0c-4027-8a77-8f3a6bcb4729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6bbd83cb-4a0c-4027-8a77-8f3a6bcb4729_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6bbd83cb-4a0c-4027-8a77-8f3a6bcb4729" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6bbd83cb-4a0c-4027-8a77-8f3a6bcb4729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6bbd83cb-4a0c-4027-8a77-8f3a6bcb4729" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0d6679b1-4542-4ed0-a038-695d35d4ed06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0d6679b1-4542-4ed0-a038-695d35d4ed06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_2be8ed71-9863-4199-9a4c-b31f12519877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_CashEquivalentsMember_2be8ed71-9863-4199-9a4c-b31f12519877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32508de2-839f-4081-a0c8-61d6d5d24b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32508de2-839f-4081-a0c8-61d6d5d24b74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_567a4129-ffdf-458b-92e5-2b177c77a20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_CommercialPaperMember_567a4129-ffdf-458b-92e5-2b177c77a20c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fcecdff0-5e8c-4f7e-9c23-aa214844c097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fcecdff0-5e8c-4f7e-9c23-aa214844c097" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4fceae92-d92f-4047-af81-6518d469ffc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4fceae92-d92f-4047-af81-6518d469ffc9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_392899b0-100d-453d-9344-0059dd48498f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_392899b0-100d-453d-9344-0059dd48498f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_27c3fbf8-764b-4ba4-be6f-d47a8a050497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_27c3fbf8-764b-4ba4-be6f-d47a8a050497" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_USGovernmentSponsoredAgencyBondMember_e98b7261-9d29-49c4-a219-dcc2e87a4366" xlink:href="sgmo-20230331.xsd#sgmo_USGovernmentSponsoredAgencyBondMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_sgmo_USGovernmentSponsoredAgencyBondMember_e98b7261-9d29-49c4-a219-dcc2e87a4366" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="extended" id="i4de0c2457a0845818a19f6418b68f072_BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_8a52f66e-e269-417a-a10b-e2e393b473d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_ce8d70d6-04ab-4eed-a6ea-51d872a1692f" xlink:href="sgmo-20230331.xsd#sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8a52f66e-e269-417a-a10b-e2e393b473d6" xlink:to="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_ce8d70d6-04ab-4eed-a6ea-51d872a1692f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4f523e7b-2fc9-4179-8c68-d698dde4191a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_ce8d70d6-04ab-4eed-a6ea-51d872a1692f" xlink:to="loc_us-gaap_NetIncomeLoss_4f523e7b-2fc9-4179-8c68-d698dde4191a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_07317c2b-8185-42cd-b84d-d8df2d38e2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8a52f66e-e269-417a-a10b-e2e393b473d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_07317c2b-8185-42cd-b84d-d8df2d38e2b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_09cd8558-f1bf-4f22-8020-89e05facaad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_07317c2b-8185-42cd-b84d-d8df2d38e2b4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_09cd8558-f1bf-4f22-8020-89e05facaad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_747383ec-3a56-4367-9226-2e2c24b949c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_09cd8558-f1bf-4f22-8020-89e05facaad5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_747383ec-3a56-4367-9226-2e2c24b949c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9352fdd-1bcd-4ebe-86e4-e5893f6b3b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_07317c2b-8185-42cd-b84d-d8df2d38e2b4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9352fdd-1bcd-4ebe-86e4-e5893f6b3b27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_edc680a5-7f49-4656-a3da-8736fe965792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6dc9ebe1-1df8-4c62-a23d-db66b64646e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9352fdd-1bcd-4ebe-86e4-e5893f6b3b27" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6dc9ebe1-1df8-4c62-a23d-db66b64646e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8f298782-fb27-4322-b1fd-a586200463b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9352fdd-1bcd-4ebe-86e4-e5893f6b3b27" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8f298782-fb27-4322-b1fd-a586200463b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_4017026e-2a51-45d1-9f18-89426928978c" xlink:href="sgmo-20230331.xsd#sgmo_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_07317c2b-8185-42cd-b84d-d8df2d38e2b4" xlink:to="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_4017026e-2a51-45d1-9f18-89426928978c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_86d4972e-ecda-4f87-8d2a-7f61aaf023a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_4017026e-2a51-45d1-9f18-89426928978c" xlink:to="loc_us-gaap_EarningsPerShareBasic_86d4972e-ecda-4f87-8d2a-7f61aaf023a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_53d184fd-5191-4cdc-86ff-39573ad665da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_4017026e-2a51-45d1-9f18-89426928978c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_53d184fd-5191-4cdc-86ff-39573ad665da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_32aa6221-e4b6-42cc-b41e-209b6b4fda8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8a52f66e-e269-417a-a10b-e2e393b473d6" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_32aa6221-e4b6-42cc-b41e-209b6b4fda8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3a2571b6-3cf7-41c0-afbc-5f355ac7cc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_32aa6221-e4b6-42cc-b41e-209b6b4fda8c" xlink:to="loc_us-gaap_AwardTypeAxis_3a2571b6-3cf7-41c0-afbc-5f355ac7cc6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a2571b6-3cf7-41c0-afbc-5f355ac7cc6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3a2571b6-3cf7-41c0-afbc-5f355ac7cc6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a2571b6-3cf7-41c0-afbc-5f355ac7cc6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_936a6e94-1cbe-4141-93f4-45f26e45447d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3a2571b6-3cf7-41c0-afbc-5f355ac7cc6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_936a6e94-1cbe-4141-93f4-45f26e45447d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5dd7482b-c92c-4d56-998e-f71f53682bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_936a6e94-1cbe-4141-93f4-45f26e45447d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5dd7482b-c92c-4d56-998e-f71f53682bb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_f667f79f-0c06-44dc-b978-da6cebc5d265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_936a6e94-1cbe-4141-93f4-45f26e45447d" xlink:to="loc_us-gaap_StockCompensationPlanMember_f667f79f-0c06-44dc-b978-da6cebc5d265" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails" xlink:type="extended" id="i54a2d9aefb8d4ebf913c114bb47e7e7e_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_f5fea9b1-438d-4d27-b217-fab7912e0f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_us-gaap_ProceedsFromCollaborators_f5fea9b1-438d-4d27-b217-fab7912e0f68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_81464e36-2f57-4ad3-8493-c15b7bf99ca1" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_81464e36-2f57-4ad3-8493-c15b7bf99ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee_65c49ba4-ab68-4d46-aa96-82c51027fd93" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_sgmo_CollaborativeArrangementLicenseFee_65c49ba4-ab68-4d46-aa96-82c51027fd93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_ab2e98a8-8760-4f35-a172-b95b6cf59d5a" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_ab2e98a8-8760-4f35-a172-b95b6cf59d5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8cc8af38-07ac-4ed7-a541-83ca45b10b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8cc8af38-07ac-4ed7-a541-83ca45b10b74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cb2a5310-16c3-49c2-bd54-efd1a2b51e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cb2a5310-16c3-49c2-bd54-efd1a2b51e73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_194f81f9-e893-4bd2-b617-b1d1af2a1720" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_194f81f9-e893-4bd2-b617-b1d1af2a1720" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_0034139b-05e0-484e-bb6c-abab98125d75" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_0034139b-05e0-484e-bb6c-abab98125d75" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_2984ee0d-71a5-4ad2-83d8-dc112c89a4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_2984ee0d-71a5-4ad2-83d8-dc112c89a4f6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_09430a3c-5cd5-4380-9dfb-d4f4a0180449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_09430a3c-5cd5-4380-9dfb-d4f4a0180449" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f49d8480-869e-42de-bb17-37bb892e9cc2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_09430a3c-5cd5-4380-9dfb-d4f4a0180449" xlink:to="loc_srt_CounterpartyNameAxis_f49d8480-869e-42de-bb17-37bb892e9cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f49d8480-869e-42de-bb17-37bb892e9cc2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f49d8480-869e-42de-bb17-37bb892e9cc2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f49d8480-869e-42de-bb17-37bb892e9cc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f92978a2-620a-4dd8-90a5-746a90679344" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f49d8480-869e-42de-bb17-37bb892e9cc2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f92978a2-620a-4dd8-90a5-746a90679344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_b53352f1-1075-4aa2-a567-1c8b7888f25a" xlink:href="sgmo-20230331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f92978a2-620a-4dd8-90a5-746a90679344" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_b53352f1-1075-4aa2-a567-1c8b7888f25a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6cc44bd8-b4d9-49c3-9105-babefa4a8190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_09430a3c-5cd5-4380-9dfb-d4f4a0180449" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6cc44bd8-b4d9-49c3-9105-babefa4a8190" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6cc44bd8-b4d9-49c3-9105-babefa4a8190_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6cc44bd8-b4d9-49c3-9105-babefa4a8190" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6cc44bd8-b4d9-49c3-9105-babefa4a8190_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0292438-605c-4a65-a938-d6c1077d840b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6cc44bd8-b4d9-49c3-9105-babefa4a8190" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0292438-605c-4a65-a938-d6c1077d840b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_5ceca189-d5b4-48f2-a166-5458a6633223" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0292438-605c-4a65-a938-d6c1077d840b" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_5ceca189-d5b4-48f2-a166-5458a6633223" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="extended" id="i1f8dc6f8114a4078b95901e0f158c51e_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25c5ecff-1b72-45a4-8907-6af7a387a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_4187bb0c-b0be-4f8f-8b43-e715987d7f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25c5ecff-1b72-45a4-8907-6af7a387a81f" xlink:to="loc_us-gaap_RevenuesAbstract_4187bb0c-b0be-4f8f-8b43-e715987d7f6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e237179-df68-4dd7-9985-9503f053e10f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_4187bb0c-b0be-4f8f-8b43-e715987d7f6c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e237179-df68-4dd7-9985-9503f053e10f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f9501cae-59d8-46cd-9647-1a78c7d71aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25c5ecff-1b72-45a4-8907-6af7a387a81f" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f9501cae-59d8-46cd-9647-1a78c7d71aa4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8f4ba978-c103-4635-ad7b-1bcf62472a89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f9501cae-59d8-46cd-9647-1a78c7d71aa4" xlink:to="loc_srt_CounterpartyNameAxis_8f4ba978-c103-4635-ad7b-1bcf62472a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f4ba978-c103-4635-ad7b-1bcf62472a89_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8f4ba978-c103-4635-ad7b-1bcf62472a89" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8f4ba978-c103-4635-ad7b-1bcf62472a89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8f4ba978-c103-4635-ad7b-1bcf62472a89" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_0d306079-c5c4-4546-8e89-783d7905d269" xlink:href="sgmo-20230331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_0d306079-c5c4-4546-8e89-783d7905d269" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_603d633c-2cf6-4e9b-89ea-71f38d13dbf4" xlink:href="sgmo-20230331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:to="loc_sgmo_BiogenMAIncMember_603d633c-2cf6-4e9b-89ea-71f38d13dbf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_1f1495c7-3d98-4c3d-a314-5b6b433857cb" xlink:href="sgmo-20230331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:to="loc_sgmo_KitePharmaIncMember_1f1495c7-3d98-4c3d-a314-5b6b433857cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_c20e4806-549f-42ed-b080-098f7a0e1225" xlink:href="sgmo-20230331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:to="loc_sgmo_SanofiMember_c20e4806-549f-42ed-b080-098f7a0e1225" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_49e496ec-523b-4958-8053-679804045e53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f9501cae-59d8-46cd-9647-1a78c7d71aa4" xlink:to="loc_srt_ProductOrServiceAxis_49e496ec-523b-4958-8053-679804045e53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_49e496ec-523b-4958-8053-679804045e53_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_49e496ec-523b-4958-8053-679804045e53" xlink:to="loc_srt_ProductsAndServicesDomain_49e496ec-523b-4958-8053-679804045e53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c819c86b-d82c-4923-a1d8-347428922af5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_49e496ec-523b-4958-8053-679804045e53" xlink:to="loc_srt_ProductsAndServicesDomain_c819c86b-d82c-4923-a1d8-347428922af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_15c86162-fdf2-4570-a376-be9b42e239a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c819c86b-d82c-4923-a1d8-347428922af5" xlink:to="loc_us-gaap_LicenseAndServiceMember_15c86162-fdf2-4570-a376-be9b42e239a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3bffb737-d422-475a-8d95-484a72560dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LicenseAndServiceMember_15c86162-fdf2-4570-a376-be9b42e239a3" xlink:to="loc_us-gaap_LicenseMember_3bffb737-d422-475a-8d95-484a72560dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_076492ba-cc06-4a33-86bc-c9927caf3e2f" xlink:href="sgmo-20230331.xsd#sgmo_ResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LicenseAndServiceMember_15c86162-fdf2-4570-a376-be9b42e239a3" xlink:to="loc_sgmo_ResearchServicesMember_076492ba-cc06-4a33-86bc-c9927caf3e2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_785e149a-2095-411e-aaa9-d80bad353bf4" xlink:href="sgmo-20230331.xsd#sgmo_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c819c86b-d82c-4923-a1d8-347428922af5" xlink:to="loc_sgmo_MilestoneAchievementMember_785e149a-2095-411e-aaa9-d80bad353bf4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails" xlink:type="extended" id="i22feb3469ed74196bf487da234a2e566_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_740de082-44d7-491d-9d0a-0cd7b2d2fe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_740de082-44d7-491d-9d0a-0cd7b2d2fe5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c96095fa-fa6c-4099-a921-01270e921e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c96095fa-fa6c-4099-a921-01270e921e62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0f7bb6bf-a184-458f-a5a6-1bb5561666b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0f7bb6bf-a184-458f-a5a6-1bb5561666b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_ea3d133f-a4b8-4bc8-bfd7-dadf26c26964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_ProceedsFromCollaborators_ea3d133f-a4b8-4bc8-bfd7-dadf26c26964" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty_e49fa0b2-b39e-4474-bc61-cc62d9fcfec3" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty_e49fa0b2-b39e-4474-bc61-cc62d9fcfec3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_d8a46f70-b1a9-4178-9279-a7704b2e126a" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_d8a46f70-b1a9-4178-9279-a7704b2e126a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_5cb6a778-2cb9-4bfa-9ed1-8b8267e8bac5" xlink:href="sgmo-20230331.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_5cb6a778-2cb9-4bfa-9ed1-8b8267e8bac5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_3fbd07d0-9397-4a42-9451-752d131f3bac" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_3fbd07d0-9397-4a42-9451-752d131f3bac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount_1afc1cc1-ae21-4faa-b5d2-ce5b965084fd" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount_1afc1cc1-ae21-4faa-b5d2-ce5b965084fd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired_94e13afe-3943-4ce2-ac4b-59d401a7679c" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired_94e13afe-3943-4ce2-ac4b-59d401a7679c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding_ecd26ee6-5e71-453b-981f-a4b127611cd4" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding_ecd26ee6-5e71-453b-981f-a4b127611cd4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_eb85ee5c-3c58-4655-b83e-d787691b9a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_eb85ee5c-3c58-4655-b83e-d787691b9a25" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e5b3eb6a-a4d7-4ff6-af76-ef74720a8051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e5b3eb6a-a4d7-4ff6-af76-ef74720a8051" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_841ff4f2-c3c8-4ff7-b9eb-4abb7cc9107c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_841ff4f2-c3c8-4ff7-b9eb-4abb7cc9107c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_067a4044-5cb3-4ed3-8dd9-9beb877d060e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_067a4044-5cb3-4ed3-8dd9-9beb877d060e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_3588a1b1-d328-4db9-8bd7-dffabf688301" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_3588a1b1-d328-4db9-8bd7-dffabf688301" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_0928a758-8bff-4493-a0bf-c5cbeac362fc" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_0928a758-8bff-4493-a0bf-c5cbeac362fc" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_5db1e25d-e1c0-410e-b400-0273e1fc2b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_5db1e25d-e1c0-410e-b400-0273e1fc2b0b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3d78f7d2-0774-4c78-afa4-4e2ef527ad47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3d78f7d2-0774-4c78-afa4-4e2ef527ad47" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fbcfdde6-6ada-4b2a-9a93-4b0e20fa7c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fbcfdde6-6ada-4b2a-9a93-4b0e20fa7c06" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8a0aa83f-508d-484c-8b8b-315b678c2fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8a0aa83f-508d-484c-8b8b-315b678c2fed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cac0b795-ac8c-496f-a2ff-5c497565f250" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8a0aa83f-508d-484c-8b8b-315b678c2fed" xlink:to="loc_srt_CounterpartyNameAxis_cac0b795-ac8c-496f-a2ff-5c497565f250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cac0b795-ac8c-496f-a2ff-5c497565f250_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cac0b795-ac8c-496f-a2ff-5c497565f250" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cac0b795-ac8c-496f-a2ff-5c497565f250_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd51939-7b2c-4892-9784-5835a8f7bf14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cac0b795-ac8c-496f-a2ff-5c497565f250" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd51939-7b2c-4892-9784-5835a8f7bf14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_09ac1bcb-cecb-4043-876e-eaaf1f0b5f96" xlink:href="sgmo-20230331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd51939-7b2c-4892-9784-5835a8f7bf14" xlink:to="loc_sgmo_BiogenMAIncMember_09ac1bcb-cecb-4043-876e-eaaf1f0b5f96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c0f67d53-82be-487b-bbad-8fd156cc8357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8a0aa83f-508d-484c-8b8b-315b678c2fed" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c0f67d53-82be-487b-bbad-8fd156cc8357" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0f67d53-82be-487b-bbad-8fd156cc8357_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c0f67d53-82be-487b-bbad-8fd156cc8357" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0f67d53-82be-487b-bbad-8fd156cc8357_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d71a989-a20d-4403-8764-5b8107067ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c0f67d53-82be-487b-bbad-8fd156cc8357" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d71a989-a20d-4403-8764-5b8107067ad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_e24785d2-f067-44b8-866c-dd0ff9a583d4" xlink:href="sgmo-20230331.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d71a989-a20d-4403-8764-5b8107067ad6" xlink:to="loc_sgmo_StockPurchaseAgreementMember_e24785d2-f067-44b8-866c-dd0ff9a583d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_256fa5b6-ecfb-48db-a545-32cc1164caed" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d71a989-a20d-4403-8764-5b8107067ad6" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_256fa5b6-ecfb-48db-a545-32cc1164caed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_987bb3c9-21c5-42ed-8e3f-6a0d8c1e045e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8a0aa83f-508d-484c-8b8b-315b678c2fed" xlink:to="loc_srt_ProductOrServiceAxis_987bb3c9-21c5-42ed-8e3f-6a0d8c1e045e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_987bb3c9-21c5-42ed-8e3f-6a0d8c1e045e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_987bb3c9-21c5-42ed-8e3f-6a0d8c1e045e" xlink:to="loc_srt_ProductsAndServicesDomain_987bb3c9-21c5-42ed-8e3f-6a0d8c1e045e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_40257cfe-ecbe-434c-8e75-f61da428ee7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_987bb3c9-21c5-42ed-8e3f-6a0d8c1e045e" xlink:to="loc_srt_ProductsAndServicesDomain_40257cfe-ecbe-434c-8e75-f61da428ee7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_45b64a24-27fc-400e-a5b2-38990f12bc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_40257cfe-ecbe-434c-8e75-f61da428ee7c" xlink:to="loc_us-gaap_LicenseAndServiceMember_45b64a24-27fc-400e-a5b2-38990f12bc3b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails" xlink:type="extended" id="i88299234259640d98bf73dabfa8f541d_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_727c0f25-8471-4b85-a80b-7fdf4d1706b2" xlink:href="sgmo-20230331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_MilestonePaymentsReceived_727c0f25-8471-4b85-a80b-7fdf4d1706b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_187d516b-1a5e-4214-9262-a0962fef6780" xlink:href="sgmo-20230331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_187d516b-1a5e-4214-9262-a0962fef6780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_9ea48076-bfac-4833-953e-3432d3d73a4c" xlink:href="sgmo-20230331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_9ea48076-bfac-4833-953e-3432d3d73a4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment_08f311c1-5e03-4a04-9511-acd60a3c4553" xlink:href="sgmo-20230331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment_08f311c1-5e03-4a04-9511-acd60a3c4553" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_98c6a20a-08d0-44d9-b32f-06c3ac6ed001" xlink:href="sgmo-20230331.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_98c6a20a-08d0-44d9-b32f-06c3ac6ed001" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_de5aac44-78e4-44d9-ab5e-12578ae209bd" xlink:href="sgmo-20230331.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_de5aac44-78e4-44d9-ab5e-12578ae209bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_23158113-8293-4f83-8da9-f575e1792adf" xlink:href="sgmo-20230331.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_23158113-8293-4f83-8da9-f575e1792adf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_faefef47-6c58-4cc4-b51c-4259b487db47" xlink:href="sgmo-20230331.xsd#sgmo_SeparateUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_SeparateUpfrontFee_faefef47-6c58-4cc4-b51c-4259b487db47" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_626da2cb-a1c6-44bc-934e-99a89423b523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_us-gaap_ContractWithCustomerLiability_626da2cb-a1c6-44bc-934e-99a89423b523" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueNumberOfRemainingPerformanceObligations_32c9279a-8d8c-4db6-b436-0256c84dc63b" xlink:href="sgmo-20230331.xsd#sgmo_RevenueNumberOfRemainingPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_RevenueNumberOfRemainingPerformanceObligations_32c9279a-8d8c-4db6-b436-0256c84dc63b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod_d68aeb65-43db-4de7-80e2-2a0a8b31d4ae" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod_d68aeb65-43db-4de7-80e2-2a0a8b31d4ae" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod_ae3d32be-8fb6-48b3-8cd3-26dd26215ecb" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationRenewalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod_ae3d32be-8fb6-48b3-8cd3-26dd26215ecb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount_8aff5fc3-aad3-4834-b9e4-93c50dc19df1" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount_8aff5fc3-aad3-4834-b9e4-93c50dc19df1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_617a9c7e-badc-4744-b384-51cae356ac55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_617a9c7e-badc-4744-b384-51cae356ac55" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_825d7cef-c985-4351-976b-06eb589a69f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_825d7cef-c985-4351-976b-06eb589a69f1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount_2c74ae36-c5d7-4471-b74d-738216d6e717" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount_2c74ae36-c5d7-4471-b74d-738216d6e717" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_3da49baf-3859-4f39-b0ce-94042cfbd3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_3da49baf-3859-4f39-b0ce-94042cfbd3d9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_eaedecb4-d4a6-4443-a922-08639fbc8861" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_eaedecb4-d4a6-4443-a922-08639fbc8861" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_9ec327e0-aa31-42f6-aefd-2efe0d762402" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_9ec327e0-aa31-42f6-aefd-2efe0d762402" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_a1b91224-40a2-4444-b2af-73ac2c0385d9" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_a1b91224-40a2-4444-b2af-73ac2c0385d9" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_68055219-362a-4f8e-9f79-0ff846584118" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:to="loc_srt_CounterpartyNameAxis_68055219-362a-4f8e-9f79-0ff846584118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68055219-362a-4f8e-9f79-0ff846584118_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_68055219-362a-4f8e-9f79-0ff846584118" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68055219-362a-4f8e-9f79-0ff846584118_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0c1c99f-a0d4-4ad7-b1a5-df420675a775" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_68055219-362a-4f8e-9f79-0ff846584118" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0c1c99f-a0d4-4ad7-b1a5-df420675a775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_cc9ad424-9d61-4258-b19a-23acb401f4f8" xlink:href="sgmo-20230331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0c1c99f-a0d4-4ad7-b1a5-df420675a775" xlink:to="loc_sgmo_KitePharmaIncMember_cc9ad424-9d61-4258-b19a-23acb401f4f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6ae57d48-7e03-4dcc-90d3-40be0aef1599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6ae57d48-7e03-4dcc-90d3-40be0aef1599" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae57d48-7e03-4dcc-90d3-40be0aef1599_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ae57d48-7e03-4dcc-90d3-40be0aef1599" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6ae57d48-7e03-4dcc-90d3-40be0aef1599_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8ca1763-91fa-4cfd-8df2-edd0980befaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ae57d48-7e03-4dcc-90d3-40be0aef1599" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8ca1763-91fa-4cfd-8df2-edd0980befaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_95d067d4-a167-4159-a602-c400e944bcc7" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8ca1763-91fa-4cfd-8df2-edd0980befaf" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_95d067d4-a167-4159-a602-c400e944bcc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1e7e0d74-4dc7-4621-a4d9-6f76baaea2fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:to="loc_srt_RangeAxis_1e7e0d74-4dc7-4621-a4d9-6f76baaea2fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1e7e0d74-4dc7-4621-a4d9-6f76baaea2fb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1e7e0d74-4dc7-4621-a4d9-6f76baaea2fb" xlink:to="loc_srt_RangeMember_1e7e0d74-4dc7-4621-a4d9-6f76baaea2fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_462309c4-33a8-4052-9c3a-b47b9236b053" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1e7e0d74-4dc7-4621-a4d9-6f76baaea2fb" xlink:to="loc_srt_RangeMember_462309c4-33a8-4052-9c3a-b47b9236b053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4943f9f-5045-46b7-bb97-58658cb7ac26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_462309c4-33a8-4052-9c3a-b47b9236b053" xlink:to="loc_srt_MaximumMember_f4943f9f-5045-46b7-bb97-58658cb7ac26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a117a1d-0491-4ce8-a2e8-fb75c8587053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a117a1d-0491-4ce8-a2e8-fb75c8587053" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3a117a1d-0491-4ce8-a2e8-fb75c8587053_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a117a1d-0491-4ce8-a2e8-fb75c8587053" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3a117a1d-0491-4ce8-a2e8-fb75c8587053_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_70b8402e-f842-4e4e-aea2-97ff7d2496a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a117a1d-0491-4ce8-a2e8-fb75c8587053" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_70b8402e-f842-4e4e-aea2-97ff7d2496a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_4d69d668-b7ce-4b80-9e75-c3f037988065" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_70b8402e-f842-4e4e-aea2-97ff7d2496a8" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_4d69d668-b7ce-4b80-9e75-c3f037988065" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_c88d3f07-f94c-4d45-89c3-f20e81f53234" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_70b8402e-f842-4e4e-aea2-97ff7d2496a8" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_c88d3f07-f94c-4d45-89c3-f20e81f53234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9a2aa17b-b4f1-49e8-868e-9dc04e150014" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:to="loc_srt_ProductOrServiceAxis_9a2aa17b-b4f1-49e8-868e-9dc04e150014" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9a2aa17b-b4f1-49e8-868e-9dc04e150014_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9a2aa17b-b4f1-49e8-868e-9dc04e150014" xlink:to="loc_srt_ProductsAndServicesDomain_9a2aa17b-b4f1-49e8-868e-9dc04e150014_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_01ff71d4-caf7-491c-88d0-a646a6c4b772" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9a2aa17b-b4f1-49e8-868e-9dc04e150014" xlink:to="loc_srt_ProductsAndServicesDomain_01ff71d4-caf7-491c-88d0-a646a6c4b772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_187aa7e2-874f-42e1-ba49-421dbb8d03c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_01ff71d4-caf7-491c-88d0-a646a6c4b772" xlink:to="loc_us-gaap_LicenseAndServiceMember_187aa7e2-874f-42e1-ba49-421dbb8d03c0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails" xlink:type="extended" id="idecf6f8d32434df9b5745535ae79c32e_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_ae334feb-7644-4bbe-9a5c-f2025b430963" xlink:href="sgmo-20230331.xsd#sgmo_NumberOfResearchProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_NumberOfResearchProgram_ae334feb-7644-4bbe-9a5c-f2025b430963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c94029cb-d365-44db-b878-5abffd1f6ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c94029cb-d365-44db-b878-5abffd1f6ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f9d5dbd6-a0d4-40ac-8486-fd6a9c2bce7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f9d5dbd6-a0d4-40ac-8486-fd6a9c2bce7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_ef3f248b-f5ec-4a78-b167-2b372964d70d" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_ef3f248b-f5ec-4a78-b167-2b372964d70d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_1474b1de-1b7d-4a79-9146-d3d8c91d85ca" xlink:href="sgmo-20230331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_1474b1de-1b7d-4a79-9146-d3d8c91d85ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate_fa590200-419c-4f8c-8d56-cb23b8a57292" xlink:href="sgmo-20230331.xsd#sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate_fa590200-419c-4f8c-8d56-cb23b8a57292" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate_d6be7c78-02f2-46be-a0fc-40fff80e1659" xlink:href="sgmo-20230331.xsd#sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate_d6be7c78-02f2-46be-a0fc-40fff80e1659" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_c078d00d-52b1-479f-9ed3-00d5e4ae0ea8" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_c078d00d-52b1-479f-9ed3-00d5e4ae0ea8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_c018c4c5-efef-4481-a444-4c1e4de541e0" xlink:href="sgmo-20230331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_MilestoneRevenueReceivable_c018c4c5-efef-4481-a444-4c1e4de541e0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_15fd2ff7-f6fc-4fcd-ad66-01f5d0f5510a" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_15fd2ff7-f6fc-4fcd-ad66-01f5d0f5510a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_75afbd26-5f1b-48b9-bb38-781cbdb9c397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_75afbd26-5f1b-48b9-bb38-781cbdb9c397" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9470c5e4-f7f2-481d-8adb-163eccf92618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9470c5e4-f7f2-481d-8adb-163eccf92618" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense_4fd33bb3-df20-4966-a090-891e79b2a101" xlink:href="sgmo-20230331.xsd#sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense_4fd33bb3-df20-4966-a090-891e79b2a101" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fab1607e-833f-43ec-aa7a-22d01fc41892" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:to="loc_srt_CounterpartyNameAxis_fab1607e-833f-43ec-aa7a-22d01fc41892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fab1607e-833f-43ec-aa7a-22d01fc41892_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fab1607e-833f-43ec-aa7a-22d01fc41892" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fab1607e-833f-43ec-aa7a-22d01fc41892_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af6ffa0a-0c95-47d5-a51e-080db23fd5a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fab1607e-833f-43ec-aa7a-22d01fc41892" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af6ffa0a-0c95-47d5-a51e-080db23fd5a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_cd4e7e2a-f4f9-4ea0-9f99-72afd7ea929a" xlink:href="sgmo-20230331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af6ffa0a-0c95-47d5-a51e-080db23fd5a5" xlink:to="loc_sgmo_SanofiMember_cd4e7e2a-f4f9-4ea0-9f99-72afd7ea929a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_91ecd138-16ee-4b7b-8c4f-ed50b0a81d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:to="loc_us-gaap_TypeOfArrangementAxis_91ecd138-16ee-4b7b-8c4f-ed50b0a81d34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91ecd138-16ee-4b7b-8c4f-ed50b0a81d34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_91ecd138-16ee-4b7b-8c4f-ed50b0a81d34" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_91ecd138-16ee-4b7b-8c4f-ed50b0a81d34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50732d4e-d62f-4dd7-94ae-1aa469213ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_91ecd138-16ee-4b7b-8c4f-ed50b0a81d34" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50732d4e-d62f-4dd7-94ae-1aa469213ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_0ad0775c-3976-4aa9-92d2-3ad0f701aaa9" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50732d4e-d62f-4dd7-94ae-1aa469213ee2" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_0ad0775c-3976-4aa9-92d2-3ad0f701aaa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_f20cfbb1-bfe9-4db5-8268-bf3375b6b227" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_f20cfbb1-bfe9-4db5-8268-bf3375b6b227" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_f20cfbb1-bfe9-4db5-8268-bf3375b6b227_default" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_f20cfbb1-bfe9-4db5-8268-bf3375b6b227" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_f20cfbb1-bfe9-4db5-8268-bf3375b6b227_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_e3cc202a-e646-4352-8ecd-41565cd056ab" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_f20cfbb1-bfe9-4db5-8268-bf3375b6b227" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_e3cc202a-e646-4352-8ecd-41565cd056ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_da0c1fb4-1b73-459b-b95c-0b14e612443c" xlink:href="sgmo-20230331.xsd#sgmo_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e3cc202a-e646-4352-8ecd-41565cd056ab" xlink:to="loc_sgmo_MilestoneThreeMember_da0c1fb4-1b73-459b-b95c-0b14e612443c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8a266bb8-3ab7-4539-87e3-18430c3ecd43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8a266bb8-3ab7-4539-87e3-18430c3ecd43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8a266bb8-3ab7-4539-87e3-18430c3ecd43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8a266bb8-3ab7-4539-87e3-18430c3ecd43" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8a266bb8-3ab7-4539-87e3-18430c3ecd43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e18b5830-4877-4f8d-8250-fe80eb7fbb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8a266bb8-3ab7-4539-87e3-18430c3ecd43" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e18b5830-4877-4f8d-8250-fe80eb7fbb5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8363bc62-29a2-4818-ad19-2fe97493b455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e18b5830-4877-4f8d-8250-fe80eb7fbb5a" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8363bc62-29a2-4818-ad19-2fe97493b455" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="extended" id="i05212b5b256d437dbe8fc5ba9132e174_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_386c04a3-9763-477b-ada0-af1898cb3192" xlink:href="sgmo-20230331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_AgreementTerminationTerm_386c04a3-9763-477b-ada0-af1898cb3192" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_26739daa-38f1-4d74-a58d-f410711294f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_26739daa-38f1-4d74-a58d-f410711294f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_3df87079-c62e-47d6-8b88-13653ed0c7dc" xlink:href="sgmo-20230331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_3df87079-c62e-47d6-8b88-13653ed0c7dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_2ead4910-6d70-42d1-b6b0-7162f395a600" xlink:href="sgmo-20230331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_2ead4910-6d70-42d1-b6b0-7162f395a600" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_fc37b36d-bd1b-41e3-9a14-05e53b494385" xlink:href="sgmo-20230331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_MilestoneRevenueReceivable_fc37b36d-bd1b-41e3-9a14-05e53b494385" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_5fd7653a-0679-4330-bf31-00ac282d379a" xlink:href="sgmo-20230331.xsd#sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_5fd7653a-0679-4330-bf31-00ac282d379a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_c599cae1-f7c4-4274-89c3-228c7a517a0b" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_c599cae1-f7c4-4274-89c3-228c7a517a0b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_3850520f-f951-4ab2-aed0-a31cc7f05eb0" xlink:href="sgmo-20230331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_MilestonePaymentsReceived_3850520f-f951-4ab2-aed0-a31cc7f05eb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_06efa595-00dd-49dd-b870-6e5113f9e239" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_06efa595-00dd-49dd-b870-6e5113f9e239" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_833ff1b1-751b-4e03-854a-ff8799505dea" xlink:href="sgmo-20230331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_833ff1b1-751b-4e03-854a-ff8799505dea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_2dba85ed-49ef-4cf1-90e1-212a8a1f75a8" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_2dba85ed-49ef-4cf1-90e1-212a8a1f75a8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_9fbc3068-fd6f-4202-9ac8-aa6e9cb9129f" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_9fbc3068-fd6f-4202-9ac8-aa6e9cb9129f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8964b5d7-1c15-4ba5-9064-5770d4572701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8964b5d7-1c15-4ba5-9064-5770d4572701" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_012ba237-5e02-4445-8a15-ff29882ce9bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:to="loc_srt_CounterpartyNameAxis_012ba237-5e02-4445-8a15-ff29882ce9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_012ba237-5e02-4445-8a15-ff29882ce9bf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_012ba237-5e02-4445-8a15-ff29882ce9bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_012ba237-5e02-4445-8a15-ff29882ce9bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82ee7f4c-8db4-4edd-8764-07b93cdac789" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_012ba237-5e02-4445-8a15-ff29882ce9bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82ee7f4c-8db4-4edd-8764-07b93cdac789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_57ceb315-cf7b-4713-997f-a2442fe7184d" xlink:href="sgmo-20230331.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82ee7f4c-8db4-4edd-8764-07b93cdac789" xlink:to="loc_sgmo_PfizerMember_57ceb315-cf7b-4713-997f-a2442fe7184d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_c4df3a25-2535-4dab-b7e7-d6cd119d0e24" xlink:href="sgmo-20230331.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82ee7f4c-8db4-4edd-8764-07b93cdac789" xlink:to="loc_sgmo_PfizerSB525Member_c4df3a25-2535-4dab-b7e7-d6cd119d0e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_bb1ddab3-d2bf-4627-aed7-697c3ee56806" xlink:href="sgmo-20230331.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82ee7f4c-8db4-4edd-8764-07b93cdac789" xlink:to="loc_sgmo_PfizerC9ORF72Member_bb1ddab3-d2bf-4627-aed7-697c3ee56806" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_61c31ea8-ebf7-412a-9450-397a7a5439d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:to="loc_srt_ProductOrServiceAxis_61c31ea8-ebf7-412a-9450-397a7a5439d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_61c31ea8-ebf7-412a-9450-397a7a5439d5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_61c31ea8-ebf7-412a-9450-397a7a5439d5" xlink:to="loc_srt_ProductsAndServicesDomain_61c31ea8-ebf7-412a-9450-397a7a5439d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_61c31ea8-ebf7-412a-9450-397a7a5439d5" xlink:to="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_7304894b-9a36-4805-81b5-4f518282b429" xlink:href="sgmo-20230331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_7304894b-9a36-4805-81b5-4f518282b429" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_6ab337a3-e9a0-4176-8368-810dc04f28ee" xlink:href="sgmo-20230331.xsd#sgmo_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:to="loc_sgmo_OtherProductsMember_6ab337a3-e9a0-4176-8368-810dc04f28ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_29b750be-e31a-411a-afe9-5b355c71d151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:to="loc_us-gaap_LicenseAndServiceMember_29b750be-e31a-411a-afe9-5b355c71d151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_b2a092dd-2e78-43bf-9d3a-02bc688e60c2" xlink:href="sgmo-20230331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:to="loc_sgmo_CNineORFSevenTwoMember_b2a092dd-2e78-43bf-9d3a-02bc688e60c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57811b4b-31e9-43fb-89fc-b2cdbb3f4494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57811b4b-31e9-43fb-89fc-b2cdbb3f4494" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_57811b4b-31e9-43fb-89fc-b2cdbb3f4494_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57811b4b-31e9-43fb-89fc-b2cdbb3f4494" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_57811b4b-31e9-43fb-89fc-b2cdbb3f4494_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57811b4b-31e9-43fb-89fc-b2cdbb3f4494" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_dfe2733e-8634-4bac-bd52-fbd14cb56a1d" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_dfe2733e-8634-4bac-bd52-fbd14cb56a1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_632e3a80-6517-4c04-aa3e-9e326e5ba63d" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_632e3a80-6517-4c04-aa3e-9e326e5ba63d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_45fb1499-6d6c-4932-8dac-1e7b34377e0e" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_45fb1499-6d6c-4932-8dac-1e7b34377e0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_b04d618e-27bd-4e8f-8f1d-c739aa1c898a" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_b04d618e-27bd-4e8f-8f1d-c739aa1c898a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_061d114a-7a46-4416-86e9-0895f52934c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:to="loc_srt_RangeAxis_061d114a-7a46-4416-86e9-0895f52934c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_061d114a-7a46-4416-86e9-0895f52934c8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_061d114a-7a46-4416-86e9-0895f52934c8" xlink:to="loc_srt_RangeMember_061d114a-7a46-4416-86e9-0895f52934c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_93519031-39df-4ca2-ac87-d9a352164c5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_061d114a-7a46-4416-86e9-0895f52934c8" xlink:to="loc_srt_RangeMember_93519031-39df-4ca2-ac87-d9a352164c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a77ce48-d550-4d7e-9227-a26a60612bfd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_93519031-39df-4ca2-ac87-d9a352164c5d" xlink:to="loc_srt_MinimumMember_4a77ce48-d550-4d7e-9227-a26a60612bfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dc84d6e7-2208-45d7-9d42-42254e95313b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_93519031-39df-4ca2-ac87-d9a352164c5d" xlink:to="loc_srt_MaximumMember_dc84d6e7-2208-45d7-9d42-42254e95313b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails" xlink:type="extended" id="ifd7a7c04ba8847e29ba0b0f01c2e50de_IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_542bafb8-d7bc-4c0b-a758-259281cef4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_542bafb8-d7bc-4c0b-a758-259281cef4eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LongLivedAssetsNumberOfAssetsGroups_ad0da4cb-757b-4269-8658-4cf2dadd826f" xlink:href="sgmo-20230331.xsd#sgmo_LongLivedAssetsNumberOfAssetsGroups"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:to="loc_sgmo_LongLivedAssetsNumberOfAssetsGroups_ad0da4cb-757b-4269-8658-4cf2dadd826f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_fc9a4e45-3a8c-4d4b-8661-8a58e90d0532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_fc9a4e45-3a8c-4d4b-8661-8a58e90d0532" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_904de25f-ef45-400d-b5fb-0d0fbc33ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_904de25f-ef45-400d-b5fb-0d0fbc33ca2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_5aee82cc-536f-437f-84c2-3d22e98e6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_5aee82cc-536f-437f-84c2-3d22e98e6e06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_41271fa4-4b65-4b12-96b2-7c424fe1272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_5aee82cc-536f-437f-84c2-3d22e98e6e06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_41271fa4-4b65-4b12-96b2-7c424fe1272b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_41271fa4-4b65-4b12-96b2-7c424fe1272b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_41271fa4-4b65-4b12-96b2-7c424fe1272b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_41271fa4-4b65-4b12-96b2-7c424fe1272b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9ce6c46-9549-4307-88df-65ae1cea97d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_41271fa4-4b65-4b12-96b2-7c424fe1272b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9ce6c46-9549-4307-88df-65ae1cea97d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_be9d2df8-e0fb-407c-b83c-1d8f67712d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9ce6c46-9549-4307-88df-65ae1cea97d4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_be9d2df8-e0fb-407c-b83c-1d8f67712d93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_cedb43e4-1097-4622-a98d-a06f19b5f331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9ce6c46-9549-4307-88df-65ae1cea97d4" xlink:to="loc_us-gaap_ConstructionInProgressMember_cedb43e4-1097-4622-a98d-a06f19b5f331" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="extended" id="i61bfc2f600f94deabaf6d8f557aa191a_STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa880639-008d-4cb3-8c3c-2b62cec9bf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9e3d741-94ce-4bfd-b1d7-1211da57b0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa880639-008d-4cb3-8c3c-2b62cec9bf6c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9e3d741-94ce-4bfd-b1d7-1211da57b0cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_938327fc-e7c4-4d9a-b2fd-3fb017826972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa880639-008d-4cb3-8c3c-2b62cec9bf6c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_938327fc-e7c4-4d9a-b2fd-3fb017826972" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_91d12888-2259-4f80-bd40-ede91fa584c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_938327fc-e7c4-4d9a-b2fd-3fb017826972" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_91d12888-2259-4f80-bd40-ede91fa584c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_91d12888-2259-4f80-bd40-ede91fa584c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_91d12888-2259-4f80-bd40-ede91fa584c9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_91d12888-2259-4f80-bd40-ede91fa584c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c4a5922c-f5ea-44b5-8e41-a7f5ee1c382c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_91d12888-2259-4f80-bd40-ede91fa584c9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c4a5922c-f5ea-44b5-8e41-a7f5ee1c382c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_73450ac1-6a44-4be2-8f71-e2dcbf7132d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c4a5922c-f5ea-44b5-8e41-a7f5ee1c382c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_73450ac1-6a44-4be2-8f71-e2dcbf7132d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8add0e53-2390-4171-85fd-9704c1f9dd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c4a5922c-f5ea-44b5-8e41-a7f5ee1c382c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8add0e53-2390-4171-85fd-9704c1f9dd14" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended" id="iaaaef77a02fd4858a617f2cce339408a_STOCKHOLDERSEQUITYDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_47ead966-4cda-4faf-b43d-dc1405c4ab88" xlink:href="sgmo-20230331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_47ead966-4cda-4faf-b43d-dc1405c4ab88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_0f08f877-92d5-4b93-925d-47d090d0bbe7" xlink:href="sgmo-20230331.xsd#sgmo_SaleOfStockIncreaseToAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:to="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_0f08f877-92d5-4b93-925d-47d090d0bbe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dd492e1b-b0ea-4a8a-8718-1c065bdb6277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dd492e1b-b0ea-4a8a-8718-1c065bdb6277" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9d41fa17-bf28-4b5c-ae40-ef68d1aadf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9d41fa17-bf28-4b5c-ae40-ef68d1aadf6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_446cf035-bfe0-4a8a-9e97-73e996e7e448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_446cf035-bfe0-4a8a-9e97-73e996e7e448" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9f17713a-71dc-4376-9b7f-9b5bf557ac85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_446cf035-bfe0-4a8a-9e97-73e996e7e448" xlink:to="loc_srt_CounterpartyNameAxis_9f17713a-71dc-4376-9b7f-9b5bf557ac85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f17713a-71dc-4376-9b7f-9b5bf557ac85_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9f17713a-71dc-4376-9b7f-9b5bf557ac85" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9f17713a-71dc-4376-9b7f-9b5bf557ac85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfc5a17e-d967-4c4f-90b9-56cf958b5f57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9f17713a-71dc-4376-9b7f-9b5bf557ac85" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfc5a17e-d967-4c4f-90b9-56cf958b5f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_3e60c5c0-72ee-4413-856e-dce1a159828a" xlink:href="sgmo-20230331.xsd#sgmo_JefferiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfc5a17e-d967-4c4f-90b9-56cf958b5f57" xlink:to="loc_sgmo_JefferiesLLCMember_3e60c5c0-72ee-4413-856e-dce1a159828a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8d4fa1bd-290c-4e93-a59f-fc4bd7498d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_446cf035-bfe0-4a8a-9e97-73e996e7e448" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8d4fa1bd-290c-4e93-a59f-fc4bd7498d75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8d4fa1bd-290c-4e93-a59f-fc4bd7498d75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8d4fa1bd-290c-4e93-a59f-fc4bd7498d75" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8d4fa1bd-290c-4e93-a59f-fc4bd7498d75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d622d476-add9-46d0-8395-e583e6e147b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8d4fa1bd-290c-4e93-a59f-fc4bd7498d75" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d622d476-add9-46d0-8395-e583e6e147b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_b98b52fd-4726-4a34-8a03-3566ca7fce3a" xlink:href="sgmo-20230331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d622d476-add9-46d0-8395-e583e6e147b4" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_b98b52fd-4726-4a34-8a03-3566ca7fce3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_07cc26bc-c327-4b7e-953d-25b5c6bc5b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_446cf035-bfe0-4a8a-9e97-73e996e7e448" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_07cc26bc-c327-4b7e-953d-25b5c6bc5b00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_07cc26bc-c327-4b7e-953d-25b5c6bc5b00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_07cc26bc-c327-4b7e-953d-25b5c6bc5b00" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_07cc26bc-c327-4b7e-953d-25b5c6bc5b00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0911a948-96ed-4088-8579-1a44b07913cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_07cc26bc-c327-4b7e-953d-25b5c6bc5b00" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0911a948-96ed-4088-8579-1a44b07913cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6c9171cf-cd58-497f-8541-d26cdfc2b12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0911a948-96ed-4088-8579-1a44b07913cd" xlink:to="loc_us-gaap_SubsequentEventMember_6c9171cf-cd58-497f-8541-d26cdfc2b12f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="iecf3e64bd7e840aa8345419051b5d0ad_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ba7d1b6f-4823-4b35-b2e9-1cec8919b077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_473f712f-e6ba-411a-af98-54b0b24de50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_ba7d1b6f-4823-4b35-b2e9-1cec8919b077" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_473f712f-e6ba-411a-af98-54b0b24de50a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_6b76d8f0-f973-43c5-b99f-b0a6621eaad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_ba7d1b6f-4823-4b35-b2e9-1cec8919b077" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_6b76d8f0-f973-43c5-b99f-b0a6621eaad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_14715093-42b8-4c80-adf5-ff2331f05a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_ba7d1b6f-4823-4b35-b2e9-1cec8919b077" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_14715093-42b8-4c80-adf5-ff2331f05a25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_38187333-3623-44ba-8192-4557ed1dcd97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_ba7d1b6f-4823-4b35-b2e9-1cec8919b077" xlink:to="loc_us-gaap_SubsequentEventTable_38187333-3623-44ba-8192-4557ed1dcd97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5af685fe-578f-400a-aaf7-57cd46a29199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_38187333-3623-44ba-8192-4557ed1dcd97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5af685fe-578f-400a-aaf7-57cd46a29199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5af685fe-578f-400a-aaf7-57cd46a29199_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5af685fe-578f-400a-aaf7-57cd46a29199" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5af685fe-578f-400a-aaf7-57cd46a29199_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9a1afe0d-1c69-42d4-a3bb-c3e89f8b980e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5af685fe-578f-400a-aaf7-57cd46a29199" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9a1afe0d-1c69-42d4-a3bb-c3e89f8b980e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b965f7d2-a34c-41a6-953c-fcdc09b913df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9a1afe0d-1c69-42d4-a3bb-c3e89f8b980e" xlink:to="loc_us-gaap_SubsequentEventMember_b965f7d2-a34c-41a6-953c-fcdc09b913df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ab13bb4b-2708-419e-b359-3914a848cfc7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_38187333-3623-44ba-8192-4557ed1dcd97" xlink:to="loc_srt_RangeAxis_ab13bb4b-2708-419e-b359-3914a848cfc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab13bb4b-2708-419e-b359-3914a848cfc7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ab13bb4b-2708-419e-b359-3914a848cfc7" xlink:to="loc_srt_RangeMember_ab13bb4b-2708-419e-b359-3914a848cfc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4d49bd2-68a3-43b3-a284-7a118a6d42fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ab13bb4b-2708-419e-b359-3914a848cfc7" xlink:to="loc_srt_RangeMember_c4d49bd2-68a3-43b3-a284-7a118a6d42fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a71fe44-d0f7-45af-a3f0-dcffb38278bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c4d49bd2-68a3-43b3-a284-7a118a6d42fd" xlink:to="loc_srt_MinimumMember_5a71fe44-d0f7-45af-a3f0-dcffb38278bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d0639b3d-3d05-4e9e-b739-ce7ee8244a52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c4d49bd2-68a3-43b3-a284-7a118a6d42fd" xlink:to="loc_srt_MaximumMember_d0639b3d-3d05-4e9e-b739-ce7ee8244a52" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sgmo-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1e97b392-2501-45be-8bcc-91b1f8c19bb8,g:c3a18027-401c-4098-a3df-6fe057e7c69a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec323059-81fc-466e-bca1-c5dc55ce4a3a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_fd24737b-1a1c-4e3d-bf58-753b00179aff_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_43cc8b88-fd4e-46dc-bdd7-2808c69c58cf_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16cb0c82-aeaa-452a-9353-72394d0941ca_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58c32d43-122b-4777-8f63-def1466b4f02_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b93aefee-eaf1-451c-86c9-3ad7dfda0887_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_a30e94f5-fa07-4d79-adbd-de23404fb339_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_53d51377-9f8c-4c9e-a88e-8bc515edfa09_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c5de5f6b-eb80-4b38-b713-26bc8150d5bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_5430a957-f4f6-4e8a-8d6a-62c365b1d0e6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_b3df4beb-1558-42e2-bfd4-b527935ad83a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues under agreement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_81a3afe8-bed3-45d2-a7f5-8323aae46893_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bd365355-c5f4-4cad-838f-6ca03fea360d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_14ab6019-3323-4714-9ff1-3298299e3e36_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_388108f7-9875-40a6-9ce1-9888e0cbcc3f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_b2a05118-2dd1-4ba2-b9df-ff1cb70b6cec_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_39da41b9-2c48-4503-ade0-5127e14f9554_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_ff8bb9f2-a6cb-4f6a-a06f-9efd5bbc4cf3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty_3a6552b5-c020-4ec5-a4fe-973f224e5f58_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of neurological disease gene targets selected by counterparty (in product targets)</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Selected Product Targets By Counterparty</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Selected Product Targets By Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty" xlink:to="lab_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22f72fc6-007c-4a3e-a977-913436e3cf9c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b978da28-62f7-4aa5-a121-8308f22fd5fe_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_e947d8b0-2450-49cb-8be3-962b516ff816_terseLabel_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_label_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember" xlink:href="sgmo-20230331.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockPurchaseAgreementMember" xlink:to="lab_sgmo_StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherProductsMember_9694a2e9-21e6-41cb-867d-b40dd000aa82_terseLabel_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_label_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember" xlink:href="sgmo-20230331.xsd#sgmo_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherProductsMember" xlink:to="lab_sgmo_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_JefferiesLLCMember_1830623b-3878-43e4-a484-9d12f67753cc_terseLabel_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_label_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC [Member]</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_documentation_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember" xlink:href="sgmo-20230331.xsd#sgmo_JefferiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_JefferiesLLCMember" xlink:to="lab_sgmo_JefferiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_d66d0847-754d-4caf-96ee-805dbe4fc05f_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6d807bdd-2dd2-44f1-a9ce-91e8e3ba39da_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_c443e3ff-3853-4b21-8bab-e1e8549c3d05_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2bee4b61-4a0e-4ac1-ba9d-db973db1c2a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_aa90559f-c204-4f60-b115-b33735b61d3b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_c135c1df-d525-476c-af5a-68ba74f11887_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss related to marketable securities, not previously recorded</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f1ef4b75-3d82-43fc-88df-573a1bc18cd8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_e728adff-11ca-4a41-9fbc-adb0ba1811c5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimate of transaction price, increase in revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b91f2b1b-7c4e-443a-a49d-b807e327b477_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SanofiMember_9418f19d-17d8-4c82-9f48-69d0c2e84e0e_terseLabel_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi S.A.</link:label>
    <link:label id="lab_sgmo_SanofiMember_label_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_sgmo_SanofiMember_documentation_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember" xlink:href="sgmo-20230331.xsd#sgmo_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SanofiMember" xlink:to="lab_sgmo_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount_6cabf1c9-d458-40fe-9c3a-0dc0c159871b_terseLabel_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation amount, related to material rights</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount_label_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Related To Material Rights, Amount</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount_documentation_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Related To Material Rights, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount" xlink:to="lab_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_09ab9590-ec98-47e5-91ef-e942540d63fc_terseLabel_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_label_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_documentation_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:href="sgmo-20230331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:to="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5a3b8b51-4029-462f-8f35-218db7ff8354_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired_2f6970c0-76f1-4f46-ab75-af38e327576d_terseLabel_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of material rights expired</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired_label_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Number Of Material Rights Expired</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired_documentation_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Number Of Material Rights Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired" xlink:to="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_4ccf020b-cd7b-4fe6-b6bb-1972745654c2_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized investment gains (losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1edd9ce7-34ec-4d7e-98e5-f932eb1e8f6b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueNumberOfRemainingPerformanceObligations_798dd5bc-b97f-4240-a937-6d1d106abfe1_terseLabel_en-US" xlink:label="lab_sgmo_RevenueNumberOfRemainingPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of remaining performance obligations</link:label>
    <link:label id="lab_sgmo_RevenueNumberOfRemainingPerformanceObligations_label_en-US" xlink:label="lab_sgmo_RevenueNumberOfRemainingPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Number Of Remaining Performance Obligations</link:label>
    <link:label id="lab_sgmo_RevenueNumberOfRemainingPerformanceObligations_documentation_en-US" xlink:label="lab_sgmo_RevenueNumberOfRemainingPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Number Of Remaining Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueNumberOfRemainingPerformanceObligations" xlink:href="sgmo-20230331.xsd#sgmo_RevenueNumberOfRemainingPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueNumberOfRemainingPerformanceObligations" xlink:to="lab_sgmo_RevenueNumberOfRemainingPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8b44211b-b119-4caf-9a27-26f52f2c5898_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_11230ed0-2778-4cc4-a1d8-03c921e83e78_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2cfe114a-bae6-4211-ac8e-9122606579c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f049d711-839e-46e8-960d-f67abaab7d03_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c11589a9-0fd4-4444-a958-d92652b47453_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_8c9c7178-96b7-4877-9cbf-f79cf4504ead_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:href="sgmo-20230331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:to="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a9bf0e31-01e4-45bf-99ec-21f4e73567c3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_02691409-a71b-42df-9a3d-a3089622d220_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_792d3f56-6349-4dba-8b7e-3cbb77d05c84_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_183f02a8-6f15-4457-80aa-9e64aecf3d25_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_56d30726-7735-4ac8-baff-cf5ce8e28ffa_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fb98cb33-377a-44c8-8924-3335b44655a5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_f6c9cf23-c684-4363-9e5a-a657584c4aba_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c8d92283-48bd-4f38-a0f8-39e07c08dbc9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2599d323-98c2-485b-a84c-bb528e8a0350_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_f4e747a0-9245-4829-9a97-7c941fe4288f_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6ee8af6c-a8d6-46bb-b354-43154e655abe_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment included in unpaid liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_317bb003-4e0c-43db-8f4c-868516d16f0d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_USGovernmentSponsoredAgencyBondMember_585b3056-9b0a-44cb-90d4-6e76231c43ac_terseLabel_en-US" xlink:label="lab_sgmo_USGovernmentSponsoredAgencyBondMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agency bonds</link:label>
    <link:label id="lab_sgmo_USGovernmentSponsoredAgencyBondMember_label_en-US" xlink:label="lab_sgmo_USGovernmentSponsoredAgencyBondMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-Sponsored Agency Bond [Member]</link:label>
    <link:label id="lab_sgmo_USGovernmentSponsoredAgencyBondMember_documentation_en-US" xlink:label="lab_sgmo_USGovernmentSponsoredAgencyBondMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-Sponsored Agency Bond</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_USGovernmentSponsoredAgencyBondMember" xlink:href="sgmo-20230331.xsd#sgmo_USGovernmentSponsoredAgencyBondMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_USGovernmentSponsoredAgencyBondMember" xlink:to="lab_sgmo_USGovernmentSponsoredAgencyBondMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a192d0e7-98f7-4a10-8279-9949945b880f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4341b9b8-a0c6-4d5b-862d-4fd5daf5d160_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_afd1e5a4-7cf3-42b0-a275-75dc8e2bc329_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Transaction Price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:to="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a01f77ff-26fe-4a5d-9e28-ee904922e283_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_173a10ba-5a1d-4662-a56a-2b450227796d_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d078bab8-1dcf-4025-a355-abbf3e8dd634_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_cd9da9e7-b0a7-4e75-8831-70bceeee76fb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_KitePharmaIncMember_d9bc8c09-0976-42ee-b332-c2ae5fdd1d08_terseLabel_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma, Inc.</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_label_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc [Member]</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_documentation_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember" xlink:href="sgmo-20230331.xsd#sgmo_KitePharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_KitePharmaIncMember" xlink:to="lab_sgmo_KitePharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_1e66b97a-eb62-4597-9cba-f58c3733d99c_terseLabel_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential amount to be funded for achievement of specified commercialized and sales milestones</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_label_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate additional revenue recognition milestone method revenue eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:href="sgmo-20230331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_70f3a69e-cee8-4ca0-afd3-0a062ce50633_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities and free shares asset</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a6264b46-0367-4442-b36c-10cc34a8211b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_656f6ff3-967f-47dc-ad58-da17b06e79b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impaired Long-Lived Assets Held and Used [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Impaired Long-Lived Assets Held and Used [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:to="lab_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_6e7c2e71-be57-43b3-b1ff-2595ba091d4c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_577638d9-0d59-41bd-8e77-746729c26881_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock offering program, increase to aggregate offering price</link:label>
    <link:label id="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_label_en-US" xlink:label="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Increase To Aggregate Offering Price</link:label>
    <link:label id="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Increase To Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:href="sgmo-20230331.xsd#sgmo_SaleOfStockIncreaseToAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:to="lab_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding_b8d628e8-077a-4f02-8c86-3a6a19b5c779_terseLabel_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of material rights outstanding</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding_label_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Number Of Material Rights Outstanding</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding_documentation_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Number Of Material Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding" xlink:to="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_40a6b4dd-7679-452a-95d1-6fcb58bd0c01_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_40cd7977-c10d-4426-bcc6-d0f489c878a4_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_267adc54-1f0b-4350-b8c0-f09fa018e578_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_54ffc4f9-23a9-4322-bb96-297bf8e9d7fb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_ad425926-8417-4ac0-b316-12517451a7ee_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, asset, after allowance for credit Loss</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e8187db9-59ca-4a3e-88ce-fc9c50a4137e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_a89aaf8a-0c5e-4f27-a73b-4b56a6f09406_negatedTerseLabel_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized loss before tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized loss before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20230331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_c21959e2-ab0a-40dc-b86f-1e0036b2b735_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_98eb683d-c8f1-45cc-a323-90e567f2f176_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f3d4f4fc-94b4-489e-837a-a93ebaa4c630_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5f76b3d0-263b-424b-b1f6-b39f92b72c3e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_16cb7ab0-3d2a-4d77-a4c1-7a3caa0b1e44_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneThreeMember_aa4c604b-1e19-4ed6-9732-2ad2846ba6a1_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_label_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember" xlink:href="sgmo-20230331.xsd#sgmo_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneThreeMember" xlink:to="lab_sgmo_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_02981a64-9543-4536-b2a0-d06765541faf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2669c772-d282-4fb5-8564-ce0abadec05c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_66147fab-340c-4c90-af12-344a15081513_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones included in transaction price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_label_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Or Regulatory Milestones Included In Transaction Price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical or regulatory milestones included in transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:href="sgmo-20230331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:to="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_dd49f924-08cb-4557-b8f6-7cf1cfeef08b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment on right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5e6895d4-65a0-4427-a113-28c7c0ff43b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_027d21da-94ce-4f6f-8dce-b1a0840f332e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c5024c01-5429-490f-85b3-bfc19f80ddae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_72437a41-dfe7-4104-b01b-784b0de0dcff_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c5a32558-3302-43f1-b5dc-f5583f1fb4bd_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_7dee9f98-572f-4e45-b5f2-ed24df72fb95_negatedLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, gross unrealized (losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_c3918287-ea2f-4f05-aba6-3e815972af9e_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, amortized cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for Sale Securities Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1d2ca7d7-03fa-4189-baab-e78cde397a46_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_fdf054f8-ed1d-4806-ae44-4443c2217d84_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f2017e03-2b98-4a95-90b8-30e07faf7c5c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bba1c267-b326-494f-9944-109344433326_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e90b8ca-5081-4cff-a32f-9d1231922779_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cb8c9b7d-3bec-46e8-89ea-0ba479166eb8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5ae5a393-e20a-469e-9a5d-cedbd0699ba6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfResearchProgram_bccb17e3-de19-42f9-b689-b432c54926d7_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_label_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Research Program</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_documentation_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram" xlink:href="sgmo-20230331.xsd#sgmo_NumberOfResearchProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfResearchProgram" xlink:to="lab_sgmo_NumberOfResearchProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5ccd161f-4d39-416e-a0fc-d7c24dff5c32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net pension (loss) gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_b92534b9-b9bb-4562-932f-89420bce3b17_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, estimated fair value</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_aa4972f7-e32a-4cdc-bb99-d659edf8f65d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_5f975475-b8f5-47e0-8db8-cb038b46d924_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_b35f52a7-a74c-404c-8525-cef90d082bcf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_18fdf737-d8b3-424c-890c-0661c5452e08_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5c57b902-68a5-4d28-bf80-225d540c6772_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_ecee16c9-e111-4a93-a9f2-d4c801bea4d3_terseLabel_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement" xlink:href="sgmo-20230331.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_InitialResearchTermOfAgreement" xlink:to="lab_sgmo_InitialResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8a6eacb3-416d-4b64-a752-36133cc98661_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87b4c017-2719-40eb-9eef-a1194942932c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_bfc230ea-7c32-4892-901e-65faf3382094_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_946cf214-8d27-4440-9b63-5290d2fbc790_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_57b8bcbd-a81e-42b0-aeaa-ee40333e05ce_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bfc51842-4c0f-493f-a1d7-ccceca3571be_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_925cda98-ca7d-4022-b6f4-3374ba797d2d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with at-the-market offering, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f94be134-4c5c-4cd0-a5b9-80de17331361_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5daa4a89-33a1-4d18-a86b-dc9e941f1f75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_61006cb4-3075-4e58-9b93-79a58fc3580a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized under Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_094c2a93-2064-4af9-8b5b-1f6b49a88fdf_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_60b99b18-0d7c-401e-a34a-3cba78a5e58f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8cebd8f5-ac99-4bb0-8064-5027e0dbfc5b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_cef0d7b7-0fb6-4787-afc5-5a5cebb4ba2f_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at carrying value, total</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_77d26f4a-62f9-4a2d-905a-0c3b5986b3fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b3c8267b-4e1c-4630-93e6-c438d110427d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b0c8fa47-6cf5-43a6-9309-3537c2a1ef70_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f3dc7d15-fdf3-41f5-a686-55811efebdd9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_8dc71a05-7491-4a4b-aae7-5dfa6e62985f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated in restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_49e34b0a-41bb-45e8-9e1c-f80683269e53_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, number of milestones achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerSB525Member_11ca2d2e-4439-4d37-97ee-bb4e22e95429_terseLabel_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_label_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_documentation_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member" xlink:href="sgmo-20230331.xsd#sgmo_PfizerSB525Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerSB525Member" xlink:to="lab_sgmo_PfizerSB525Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b5d8a122-df36-4c7c-a8ae-4d4237670aa1_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_89439f0e-30e8-4e73-a060-ea2d8e522517_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5d1512e0-ec81-4491-9578-751e068962a1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_bb8e6c12-3a1c-48f3-abc8-ff7923974b12_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_d39841d0-6290-46b8-a989-b25c761d4c33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Accounting Estimate [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:to="lab_us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_20f49bc5-784e-430c-96bb-db7aa445ae2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_083c6f26-b69a-4098-a441-4639ff77d0ef_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_753237db-9bf6-4e40-a622-84a07c6b2487_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_cb4ce78f-3aa3-45bc-a857-adc5936216a3_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to Sanofi agreement:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_5e1fdd89-c1a4-41ae-87a5-dbcebd94dd71_terseLabel_en-US" xlink:label="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share</link:label>
    <link:label id="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_ee5cbdb5-30d8-4377-ada3-095c17ded465_verboseLabel_en-US" xlink:label="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:label id="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic And Diluted EPS [Abstract]</link:label>
    <link:label id="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic And Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="sgmo-20230331.xsd#sgmo_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c12d5097-309b-4eb2-8178-3fa5a1ff9e55_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b867a87a-cc4b-416c-a45e-4028ef81de70_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_b030d741-8816-4a39-8dcc-03d80fedf4b0_terseLabel_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72</link:label>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_label_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_documentation_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member" xlink:href="sgmo-20230331.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerC9ORF72Member" xlink:to="lab_sgmo_PfizerC9ORF72Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_297ed159-72ce-4ede-9c90-8cfa32b6b0b5_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Commercial Milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Commercial Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Commercial Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:to="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_6f735d42-aa0d-4de6-aa6e-1bd2b2c1e8ae_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod_1b58c670-0ac3-4d99-b3e5-c4981a37d9d6_terseLabel_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of material rights for renewal of research period</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod_label_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Number Of Material Rights For Renewal Of Research Period</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod_documentation_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Number Of Material Rights For Renewal Of Research Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod" xlink:to="lab_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_70934caf-4c8f-45a1-bbdc-64273d168e06_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_03649e7a-c545-4465-b13a-f64a874a0da9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1b2d7c83-d7ef-4972-89c2-3e01fd6604f8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cee0278f-4973-4bf0-8a94-3b34801af960_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_09740e99-66ac-478d-8b91-0e2b11357484_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8e37bcf9-5686-484c-9b8e-6c89ba0c2dd4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerMember_4890025b-b315-4701-88d4-b13b107cc895_terseLabel_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:label id="lab_sgmo_PfizerMember_label_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_sgmo_PfizerMember_documentation_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember" xlink:href="sgmo-20230331.xsd#sgmo_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerMember" xlink:to="lab_sgmo_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_5dd78776-9160-4005-a225-da038292822c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_f6d73603-35c7-42c9-be2c-fd9b546aceb3_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_78d492bc-416a-468d-bba1-f6976aeadab5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net pension losses</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_b04fa7e6-7167-4a7b-aa1a-0f2b61496061_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate_b7ff0c2d-ef12-4a3e-b710-80e1f1873c02_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses reimbursable after December 31, 2023 (up to)</link:label>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate_label_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Expenses Reimbursable, After Specified Date</link:label>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate_documentation_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Expenses Reimbursable, After Specified Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate" xlink:href="sgmo-20230331.xsd#sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate" xlink:to="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_03c2a2dd-40c8-404a-8cb0-4e8f780ee081_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in net income</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_a874d014-c8e7-4142-aa9d-867221e76d48_verboseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increased net income</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Net Income (Loss) Attributable To Parent</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Net Income (Loss) Attributable To Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:to="lab_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_f47c9d1a-a7bd-4efc-a9a6-2217cb62563c_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9dc6ceb5-aadd-4fd5-a58c-7a55af1db42b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AtTheMarketOfferingMember_1a8ad652-a6d0-4454-bb2d-ad820466235a_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the Market Offering</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingMember" xlink:href="sgmo-20230331.xsd#sgmo_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketOfferingMember" xlink:to="lab_sgmo_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_02d4187f-0a83-4b4c-a6c4-ac029387b121_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_87ed51b6-3183-4233-8b5e-9e0ef46aaa10_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Accretion of discounts) amortization of premium on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d39a5076-90d8-4aaa-9aff-72a99e5acccc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_eb5a0381-6874-4744-b7d7-c7327aa1dd60_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ce486e6e-b8d9-423f-a791-2e29347bada2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2308aca2-5f7b-4149-bbaf-293649937f1a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_ada994f7-e443-4f29-8bac-fd53438ced8f_terseLabel_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C9ORF72</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_label_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C Nine O R F Seven Two [Member]</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_documentation_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C nine ORF seven two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember" xlink:href="sgmo-20230331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CNineORFSevenTwoMember" xlink:to="lab_sgmo_CNineORFSevenTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_615415c4-8f1a-43f2-bddc-2281548b207a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_77fd755b-7714-42d5-80f4-fcfaa604b8d0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_f0959167-aa5f-4c9d-b75c-8553c98a7d05_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_1d8ff205-4b12-402c-90c0-da5cb819f6fa_terseLabel_en-US" xlink:label="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net income (loss) per share</link:label>
    <link:label id="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_label_en-US" xlink:label="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic And Diluted [Abstract]</link:label>
    <link:label id="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_documentation_en-US" xlink:label="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic And Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:href="sgmo-20230331.xsd#sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:to="lab_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_964e7519-d4c3-478c-add9-e2065c12cc20_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_15a26960-5e6d-4e69-92b4-bfc9ed9710a9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8063316a-0fcc-49b2-aa80-e6e9489820c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fe0b7f0-c234-4794-8745-6dae73f859e3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_bc5f282b-ba3a-4466-bae6-81809f4088a3_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateLineItems_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="lab_us-gaap_ChangeInAccountingEstimateLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LongLivedAssetsNumberOfAssetsGroups_1c4cd46f-8826-424c-9c5b-d314cc193709_terseLabel_en-US" xlink:label="lab_sgmo_LongLivedAssetsNumberOfAssetsGroups" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets, number of assets groups</link:label>
    <link:label id="lab_sgmo_LongLivedAssetsNumberOfAssetsGroups_label_en-US" xlink:label="lab_sgmo_LongLivedAssetsNumberOfAssetsGroups" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets, Number Of Assets Groups</link:label>
    <link:label id="lab_sgmo_LongLivedAssetsNumberOfAssetsGroups_documentation_en-US" xlink:label="lab_sgmo_LongLivedAssetsNumberOfAssetsGroups" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets, Number Of Assets Groups</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LongLivedAssetsNumberOfAssetsGroups" xlink:href="sgmo-20230331.xsd#sgmo_LongLivedAssetsNumberOfAssetsGroups"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LongLivedAssetsNumberOfAssetsGroups" xlink:to="lab_sgmo_LongLivedAssetsNumberOfAssetsGroups" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_87e7077d-f629-49a6-99ee-027a1349f778_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_10f959d9-1963-44d2-8a76-ea488515a2c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_309192e1-1c7c-4391-a0c7-b5cf18b178ee_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_3331d2cb-6aba-4745-b9ce-febfbd9fcf2f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4637d4af-9a15-47b2-97bf-b1d7e19cc23d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4270bc70-d166-4f5f-8566-87265280f2cb_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b620d7c3-6aa3-4321-8f18-eb15729f43c9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_2629c135-0c2b-4457-a969-2809f4c11faa_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products approved</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements Number Of Products Approved Under Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements number of products approved under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentChargesTextBlock_0db67c49-2026-497d-8666-71c52b04e4e0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentChargesTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentChargesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentChargesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentChargesTextBlock" xlink:to="lab_us-gaap_AssetImpairmentChargesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2422aeda-b7f1-4ee0-8655-593476e4bf63_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_dfb35bfa-7d4d-4fad-9faa-cc56acf64d1a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7ea2d830-5a72-4b47-9f18-d632b9d90a96_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_5e975133-a30d-4168-ac99-32d815ba9632_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c357b54f-48d9-445d-96b0-771073f733d6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_bf017ca1-2e1c-4ff2-a1e7-7fea9b767543_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from at-the market offering/ issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_268c229c-6ed9-4800-9f2b-316c7480f9b9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b52c862e-cda9-4bc0-9b01-5b85b39c1250_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_508fc3bf-27dc-4df0-a3c5-80bee5bc93ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d785a45-5ef9-488b-b3f2-954735ed2139_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_dc731371-c7c3-4409-8c57-e6d0a8d8e6bd_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_5ef6eab8-095f-47d4-98aa-16d4561a6328_terseLabel_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments To Be Received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development and sales based milestone payments to be received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:href="sgmo-20230331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:to="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_3517d9d4-9d91-458c-b556-5e9b6fc0c00f_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:label id="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_label_en-US" xlink:label="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impaired Long-Lived Assets Held and Used [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:to="lab_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_69ba1548-2943-4b86-ad01-e390e5bcc431_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_896cb9b4-1559-4cc6-a2d6-5eea31eff8e2_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f4043e95-1964-4d6e-b848-5fccba8f14d2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5d753104-2390-4d89-b64b-2f5d0069471d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1b9bec44-431f-4e6e-bda9-bbd0d4e4cfab_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_46f039dc-8e18-4c97-8dcc-359a373695c4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_b03f507e-206a-4134-b89e-91f49719ea4a_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_5c2dea6a-48e1-49f6-a7a6-825ac8c2a6e8_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_4db0311a-45b6-4aa9-bce8-8766d9b96c73_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0229b333-1d7c-4718-97c3-76e153d45ca5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_f7566d0c-3abb-48c9-899a-33df86505993_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9bffa813-91bf-40ab-a32a-af2d290e32ac_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_8d0112dc-524a-4e91-bd6c-289bfcb2126f_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit established as a deposit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_cb04865f-903f-4b0b-9ce7-8dd562b4eb4f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a3dafad2-a727-4ce9-9691-c0f0ee61f6af_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_885b8774-c872-4553-83e1-e8f08f94c815_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ba7a584b-cd39-4bd7-8c56-a1239c148f03_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_c8ab4adb-14ce-4a99-b593-a8b1b39cbb38_terseLabel_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes for BioMedical Research, Inc.</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_label_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc. [Member]</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_documentation_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:href="sgmo-20230331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:to="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_92e89456-e6bb-4182-bae5-be1335e377b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7532261a-10ea-41cb-a9e9-9ecb57a66a46_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_451a5ae3-467d-4784-ab45-3f22d4ff3b2b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9337083b-e1ec-40d9-9595-61984f0a709e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_56c40ba3-bb22-4921-9ce1-a72ec3dc0131_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_77e1d026-6f6d-42a3-9bf3-24e6b2f06f69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_a9fb7855-e899-42eb-a003-10190de886b5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_1ddaa86a-6a2d-4105-b60f-42e7fb305193_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a90657e9-244e-4dc1-b4c2-a410e2d69e4f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c929db3f-86c3-468e-9158-19e049181ff8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_1521919c-11f7-4954-9e85-86cca6417bef_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional neurological disease gene targets (in product targets)</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:to="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_692fbadc-b081-4c3e-8a9f-34465b3eaa1d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b835c5cf-fac6-4f9e-8d42-64267ce8c304_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_4ae2fc1a-9856-4f62-9ae0-02c6d51ab619_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3e2ee997-fdef-45f1-9b57-8c9244b0d661_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4c9743fe-ee43-4468-8ce2-f17560171de5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f3744a59-d2ec-4d88-b4b2-4c4be9d11c9d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_9254f987-5028-4218-b996-a505c6f478d3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_d75071c6-76e7-4f1f-bbd8-c81b1efe3b45_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_77c1cc02-7474-4c5c-8be2-e6879a67ace4_negatedLabel_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other changes in operating lease right-of-use assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_label_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_documentation_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:href="sgmo-20230331.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:to="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1baf428e-9fdc-418d-bfa7-715014773af0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ea865966-10fc-48d8-91de-cbdeae2346f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of share-based payment arrangements (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b43a1c9b-b72c-4566-81c0-d187bc3020d8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4664de88-c866-4ebe-bf8b-c42650a15e9e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_17e01f6f-bcfc-45e3-8537-53315626423b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c854ddfb-d3ea-40d6-9cfd-5c46bd90f32d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_966e6fc4-2d75-4fac-b71d-e58bd341f94f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_1554ea8d-d47a-4c27-a5f8-3eed98147752_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1215451d-1468-4886-bb40-6f09086ba2f4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_d125e417-e7f3-4afb-aa86-12e1919fb935_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_label_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Revenue Receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_documentation_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone&#8203; revenue receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable" xlink:href="sgmo-20230331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneRevenueReceivable" xlink:to="lab_sgmo_MilestoneRevenueReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_898a460f-439c-4314-bc4b-fe64775061c4_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial advisory fees</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_label_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_documentation_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:to="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AgreementTerminationTerm_8134e63d-8265-4358-b93a-4aed3b77989d_terseLabel_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination, term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_label_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_documentation_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm" xlink:href="sgmo-20230331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AgreementTerminationTerm" xlink:to="lab_sgmo_AgreementTerminationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_ca1f9fe4-7bb4-4301-a152-a26644e8e345_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_aff69152-b33a-479d-8a80-f802c8516a59_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_265a5aa5-d743-4e62-be7b-7d28eb60e17e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_caa36b0e-7eeb-44fc-96f5-dfc5e7577b90_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_63998027-3ff0-4353-bbc9-6439d3cf7ee8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_8fa04e93-9d94-4388-aa46-8e3d3fae865b_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_0fbf0dd6-9d70-498f-93ac-dc59e0500905_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f90b0479-1e69-43dd-900a-80d0111b3508_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3079dc44-9993-4523-9781-8cd494985b6f_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_646aef86-252e-4a36-b97e-8db5a0a6c7bd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3ce074df-8908-40a9-9c74-70370031a740_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_3143d21c-2658-419c-ab33-0692b3f2d407_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_bdf044de-72fc-40a1-8112-4abfc1868d07_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_bab171c4-34ad-4ab9-8838-4a9b3ff7f436_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d48bc9fd-c964-4fd6-afe7-1a11a6821f0f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_777f897c-846d-408d-aad1-2287dcceb627_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_33348866-653d-4a36-b769-7a2472fa308a_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, license fee</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Fee</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementLicenseFee" xlink:to="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7a046fed-5bfc-405d-acdc-27aab134a118_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_47ce450b-f0af-4a69-993d-dda91ce026cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchServicesMember_4536da70-2556-4496-885d-dadd82bbeb59_terseLabel_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_label_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services [Member]</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_documentation_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember" xlink:href="sgmo-20230331.xsd#sgmo_ResearchServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchServicesMember" xlink:to="lab_sgmo_ResearchServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_81453792-ce27-48e3-8e44-7abbec8df833_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1befcf4a-daa9-4b70-acb1-7dde1e31079f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_3230f3d4-695d-4b48-ba71-66bcc41532e6_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering Agreement</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market offering agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:href="sgmo-20230331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:to="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_b0c802ac-0a93-4a5e-898e-3f02125beffa_terseLabel_en-US" xlink:label="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_label_en-US" xlink:label="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available To Common Stockholders, Basic And Diluted [Abstract]</link:label>
    <link:label id="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_documentation_en-US" xlink:label="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available To Common Stockholders, Basic And Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:href="sgmo-20230331.xsd#sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="lab_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_ec0fafe8-2150-4654-b455-bc26a7b9fa1c_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0d512417-24c6-48c4-ba78-91624a8abe9a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic_df228b36-19fd-4bf4-99d8-3b789b8aea6c_verboseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increased earnings per share, basic (in dollars per share)</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Basic</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:to="lab_sgmo_IncreaseDecreaseInEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_a6b4557b-2e0a-43f1-b8dd-911c380f84c6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_59bb3fd4-d480-4678-b0a2-d1e71baf7520_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_2c6db5d9-128b-4edf-83ab-31228645f5bb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0a9df396-d282-47d2-82cc-44f94f1574db_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f590efc8-8af7-404f-881a-45f84d75a79f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_8672d921-df6f-455d-a047-2fd968f8d3a0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_f0d65538-c394-4259-b5ae-f2193aa9a3da_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_13d86751-618c-46e4-8cd9-986ebb838250_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_e285dd21-fb48-4338-b37f-e2674aef698b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_59397203-7ef3-4d9a-ae29-59a2993fd759_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_ccac0b9a-bd6d-4f8d-9820-b3f6dfca92f6_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d571adee-aa6a-4d25-9fa3-18b7fefac816_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss related to marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_c00f48b0-4a09-456d-a307-54923246c5f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_eed19d03-98f7-4fd7-b052-08dd342106e5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_d7ea3d2e-653a-43d2-8c1d-47e5a587c4ad_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, amortization expense</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_33af03f2-962c-45fc-9f96-79491f67789a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_44138f82-16b6-4f76-a130-db3d78ba6662_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_b48299ce-08d1-4474-8fdc-f2eb6b623fdd_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research service fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:to="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4de390bc-3ab5-41cf-a010-7b14ed976ed4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_21d8d094-f050-449c-9d9d-ae4d549833a0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_79db2062-ce5a-464e-b0de-e699392aa6e3_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_9a30883b-08d5-4a02-b69f-226b6cc6e71d_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored entity debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9f402e04-a0e6-41e5-92d4-f8aef308f6eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_eaf13144-ab74-4fd2-9b6a-3b63a440f075_terseLabel_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock offering program, maximum value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_label_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_documentation_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue" xlink:href="sgmo-20230331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockOfferingProgramMaximumValue" xlink:to="lab_sgmo_StockOfferingProgramMaximumValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_6c48e31a-3dfc-4c6d-affd-21d9ac58eb26_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_739e7536-7255-4e85-b095-a65b6650bc24_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_d69b0727-33b3-4517-93c1-5339a6739696_terseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_label_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived" xlink:href="sgmo-20230331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentsReceived" xlink:to="lab_sgmo_MilestonePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_affc18f3-9e40-4596-b3f7-24b281029019_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_4ade80c6-4d8e-4014-80ee-9f7342e057d4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f540a132-1aec-49bf-ac60-a81dda619929_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_8d882068-2307-462f-a715-ed9750f6696a_terseLabel_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_label_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Contract Liability Milestone Payment Eligible To Receive</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer contract liability milestone payment eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:href="sgmo-20230331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:to="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_ccbbbbd9-cb9e-4e39-abe7-7d144de49816_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d3be6d4c-ed1e-4b7a-b372-d275bf9abe1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1d25dbe6-0525-44f6-84a9-1998041dafe8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ce26f566-5d7b-46c9-a512-34f941c61d55_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_f6c1f4b1-a61b-47dd-a26f-be350885fd73_terseLabel_en-US" xlink:label="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</link:label>
    <link:label id="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_label_en-US" xlink:label="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty</link:label>
    <link:label id="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_documentation_en-US" xlink:label="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:href="sgmo-20230331.xsd#sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:to="lab_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_c7b72a1e-05e8-46f1-8037-4af44004dd8f_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, equity issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementEquityIssued" xlink:to="lab_sgmo_CollaborationAgreementEquityIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6e0ffb69-d23c-489f-88c1-ccd4c0df547b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_8980ea95-8faf-442c-9edd-1eb995355747_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital resources</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount_e749811f-e71c-482b-a615-f36f1e63243e_terseLabel_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed consideration</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount_label_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Fixed Consideration Amount</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount_documentation_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Fixed Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount" xlink:to="lab_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2ca14ff7-9af5-4d7e-9d86-1a893e17b262_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_19a38c61-0ce3-4c95-b2af-80df85a73523_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_70412d34-e3af-4b1d-a1e4-7526dc67ddf2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c9b57de1-8526-440a-bb35-884b2b75a199_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_150abeaf-86de-43fd-913e-49f229005034_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a73760de-24ed-407f-810d-2f7118cb7409_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_6ee2eae9-1cd1-4bf4-9633-a1150c2b0897_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_65f10e0e-62b6-4471-9b27-5c086ab80bfe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other impairment charges related to marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale, Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_74af8964-bd26-4aa3-acdf-fca77f2eaf79_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b9389087-5966-47ee-8e62-320fec0d361e_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_ea4e63e5-bf58-4069-b332-bb73612abdd5_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, gross unrealized gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized gain, before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_668d2bcd-5c62-46f4-8d01-3bcb486e8cb4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Goodwill, Intangible Assets and Long-lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_350af583-f23d-4692-a4f8-5260a769509a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1a0ad9c7-6cc3-4432-bf9e-b29551b6a5d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_91ede2d5-b955-4b31-bfc1-0d10ba4e07ca_verboseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increased earnings per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Diluted</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:to="lab_sgmo_IncreaseDecreaseInEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_e9c653c8-c964-459a-b942-725ab93d8a89_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1b26c212-b024-4a3c-8c42-8d9c9b89c16a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_cdd2a1f1-35b6-4a7c-9f8c-d79e0022bbd0_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, excess consideration received on transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:href="sgmo-20230331.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:to="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_b6f34e77-0684-464b-ab60-b86dffb05c7d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_780ff53d-d4b5-4ff1-9db6-242e9578b35b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_bed27e5f-f9b8-4469-9da0-c264e4f5ca72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_616f0c11-9fa1-4ebe-9cbe-eb900e3de946_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b7c4c568-efe3-4d1c-8b5a-f2f9ab0ecd13_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a26c1486-4d78-4c2b-ba29-c99a2edf56bd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BiogenMAIncMember_b3ed86e2-b45c-44d8-a1c0-d4da18bc8ebc_terseLabel_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_label_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc. [Member]</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_documentation_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember" xlink:href="sgmo-20230331.xsd#sgmo_BiogenMAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BiogenMAIncMember" xlink:to="lab_sgmo_BiogenMAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cc54efca-06b5-49a8-8db2-694e9a88f944_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b47e200b-329c-48f1-b86d-50dd1784cc97_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_38f3a6b9-67e8-4fa2-9396-3e121974b7dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0e363402-daf2-4fed-a07a-d248eb54e657_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_fa56097a-e926-4dcd-86c7-076960c00346_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_91998ed0-9547-44ad-b178-88568f1be41a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate_9000284b-a4db-4c51-9954-485a2cdaf6b1_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses reimbursable through December 31, 2023 (up to)</link:label>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate_label_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Expenses Reimbursable, Through Specified Date</link:label>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate_documentation_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Expenses Reimbursable, Through Specified Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate" xlink:href="sgmo-20230331.xsd#sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate" xlink:to="lab_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SeparateUpfrontFee_05fb8863-0b1b-4f1a-b88f-40425ecbda50_terseLabel_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate fee for additional term</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_label_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Upfront Fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_documentation_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate upfront fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee" xlink:href="sgmo-20230331.xsd#sgmo_SeparateUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SeparateUpfrontFee" xlink:to="lab_sgmo_SeparateUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d0b2d422-3815-4880-a813-0a76328acf09_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod_82bdae2c-fae3-45c7-ad30-6f0af5b901f4_terseLabel_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal period</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod_label_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Renewal Period</link:label>
    <link:label id="lab_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod_documentation_en-US" xlink:label="lab_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Renewal Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationRenewalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod" xlink:to="lab_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fe9430e1-5598-41c2-9ac9-a9dc7f81483b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_c0983f4f-9f75-4cd3-83ef-bb8fa504bdcc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_bc47d47b-16d6-4665-874e-91db78973648_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="sgmo-20230331.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2587b717-1187-4de4-b790-06a5482b4d99_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d283a67d-1e6e-4ff7-9a81-95ba7e43b12f_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, gross unrealized (Losses)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_91c7ccdf-fa5d-459c-96f8-0c3c8c6f5a02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense_1aa4ab0b-6e33-423c-b1f0-5d876bfe09a9_negatedTerseLabel_en-US" xlink:label="lab_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in research and development expense</link:label>
    <link:label id="lab_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination And Transition Agreement, Increase (Decrease) In Research And Development Expense</link:label>
    <link:label id="lab_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination And Transition Agreement, Increase (Decrease) In Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense" xlink:href="sgmo-20230331.xsd#sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="lab_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b1e658a0-478d-42fe-a8de-b7bf14b9583e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_86a3dc33-0c80-453f-84ff-29217e0ee001_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneAchievementMember_1447a99b-a7df-4ffc-9402-3374c9e9228c_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_label_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember" xlink:href="sgmo-20230331.xsd#sgmo_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneAchievementMember" xlink:to="lab_sgmo_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ce667c71-8eb5-44e0-88f6-a6b4d414d679_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability_fc258276-369e-4e9a-9814-c0ebc0e8a1eb_terseLabel_en-US" xlink:label="lab_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance included in contra-lease liability</link:label>
    <link:label id="lab_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability_label_en-US" xlink:label="lab_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement, Allowance Within Contra Lease Liability</link:label>
    <link:label id="lab_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability_documentation_en-US" xlink:label="lab_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement, Allowance Within Contra Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability" xlink:href="sgmo-20230331.xsd#sgmo_TenantImprovementAllowanceWithinContraLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability" xlink:to="lab_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_04aaa4f1-9995-4a34-a2cd-dd15ae2a6787_terseLabel_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, gross unrealized gains</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized gain before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20230331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_81d87ab5-cdec-4c52-9dd9-5d51c564b82a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment_2b12f183-ea23-4ab7-a6bc-fe99d4258b0f_terseLabel_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of achieved milestones to receive payment</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment_label_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment_documentation_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment" xlink:href="sgmo-20230331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment" xlink:to="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_93199c51-bd47-4afa-8a04-83fad3b4734f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0a2a8c5b-9746-4791-b615-0cd6f85636c6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8d4ee6e3-d4e4-4801-8665-43216489ae4d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1dde5463-adeb-4ff1-8d24-b96d83e8f257_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_66851b28-824b-4d6d-8073-f5804ec9a3b7_terseLabel_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended research term of agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:href="sgmo-20230331.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:to="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_48e92685-69d0-4c3d-95b8-39551023d0c0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8dd335e4-dc19-4fae-9b64-f128db2d3e1a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f35b4fc0-44b3-4a2d-9839-1206b748c981_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Basic and Diluted Net Income (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_70de8c14-5491-4f56-9c60-9dbe3cc9d4a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_88dfbbd5-b677-49c1-8804-a670b6cf65d1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_3a0efcd6-77fb-4698-9f55-2878d888130c_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend initial research term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_label_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_documentation_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:href="sgmo-20230331.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:to="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b7b2375d-34f3-4c34-b366-3c76aa8abb79_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_d6449fbf-928d-4baf-b407-9ae7bfb8ae2e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of positions eliminated in restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_f4c16d1b-664d-4575-8137-3279dd280b3b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_68274a0b-5395-4db8-a6c1-a5e6568ba230_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of initial recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:to="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sgmo-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1e97b392-2501-45be-8bcc-91b1f8c19bb8,g:c3a18027-401c-4098-a3df-6fe057e7c69a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_787cbd7f-0326-4f0f-898c-d6d073bb9a41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_DocumentType_787cbd7f-0326-4f0f-898c-d6d073bb9a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_6c3c4c18-4459-4e29-ac98-d9581c536bfd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_DocumentQuarterlyReport_6c3c4c18-4459-4e29-ac98-d9581c536bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e1330145-7976-4833-bde7-c2c48a45f5d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_DocumentPeriodEndDate_e1330145-7976-4833-bde7-c2c48a45f5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e91efe23-05f2-44e6-94c7-ba8a94f68c63" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_DocumentTransitionReport_e91efe23-05f2-44e6-94c7-ba8a94f68c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_586266ab-9b43-4ba7-be64-f16c60c0f82f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityFileNumber_586266ab-9b43-4ba7-be64-f16c60c0f82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_df34bff9-1358-404c-9a48-0c61abff9ec4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityRegistrantName_df34bff9-1358-404c-9a48-0c61abff9ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e2c6c5f2-f45e-4d59-a62a-3ac2c7ac571c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e2c6c5f2-f45e-4d59-a62a-3ac2c7ac571c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b8b60e66-d42c-4e32-a8bc-dcfc9c4b44a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityTaxIdentificationNumber_b8b60e66-d42c-4e32-a8bc-dcfc9c4b44a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_658d39d4-1ab6-46df-8939-46fac1f69c9e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityAddressAddressLine1_658d39d4-1ab6-46df-8939-46fac1f69c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cff2faa4-79ee-4f18-a6a1-503368ebb977" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityAddressCityOrTown_cff2faa4-79ee-4f18-a6a1-503368ebb977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_2ca98f12-d085-42a2-9183-3b60d60e705c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityAddressStateOrProvince_2ca98f12-d085-42a2-9183-3b60d60e705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_756a34cc-6ea9-4e1f-a3f2-6df99a79c8ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityAddressPostalZipCode_756a34cc-6ea9-4e1f-a3f2-6df99a79c8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0bdc0ab2-0aa8-4b2b-8b06-07d293a18c35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_CityAreaCode_0bdc0ab2-0aa8-4b2b-8b06-07d293a18c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_34332119-32eb-4bdb-a4a6-59fd11237e8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_LocalPhoneNumber_34332119-32eb-4bdb-a4a6-59fd11237e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_37d931d5-74d8-4953-9a5d-c6c2fa2ab6db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_Security12bTitle_37d931d5-74d8-4953-9a5d-c6c2fa2ab6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e9c5377b-a136-4584-a54e-f66a42f08021" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_TradingSymbol_e9c5377b-a136-4584-a54e-f66a42f08021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a273a57c-f02d-43c5-b2ab-29c0ee7e78eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_SecurityExchangeName_a273a57c-f02d-43c5-b2ab-29c0ee7e78eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b611f7cf-9f2f-4de5-8c55-323d0e428be3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityCurrentReportingStatus_b611f7cf-9f2f-4de5-8c55-323d0e428be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_287f6139-4134-4c1f-a119-219d51f0f78d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityInteractiveDataCurrent_287f6139-4134-4c1f-a119-219d51f0f78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a7bc0183-8e78-4f5a-afe8-8ba20e0ddea6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityFilerCategory_a7bc0183-8e78-4f5a-afe8-8ba20e0ddea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_82b9a247-039a-42ff-bb88-d9ac2419a306" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntitySmallBusiness_82b9a247-039a-42ff-bb88-d9ac2419a306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6f6abb7d-bbc2-4fe4-a918-77857970ec5a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityEmergingGrowthCompany_6f6abb7d-bbc2-4fe4-a918-77857970ec5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c1c28cc0-856d-44be-9c9f-d4ee0b9d6a50" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityShellCompany_c1c28cc0-856d-44be-9c9f-d4ee0b9d6a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_943e14eb-e81e-4f91-af26-86f3aa49d55d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_943e14eb-e81e-4f91-af26-86f3aa49d55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3b6a1109-025d-476e-9bef-e27ecdac3520" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_AmendmentFlag_3b6a1109-025d-476e-9bef-e27ecdac3520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_658bdddf-50a6-4bab-ba12-b04ef07156c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_DocumentFiscalYearFocus_658bdddf-50a6-4bab-ba12-b04ef07156c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_245ada9d-45c6-44e3-96f3-6d778652cff6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_245ada9d-45c6-44e3-96f3-6d778652cff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9ee3b133-0408-4607-9108-87dbdee69408" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_EntityCentralIndexKey_9ee3b133-0408-4607-9108-87dbdee69408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_034773c0-472b-4542-bfd1-cc39a77e25a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cf971cac-5343-4f3e-8496-adc5d42e88f2" xlink:to="loc_dei_CurrentFiscalYearEndDate_034773c0-472b-4542-bfd1-cc39a77e25a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8834390c-360d-4d8d-92eb-dde1f276d924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4ca34d65-3abf-4cde-a410-10cbe223853e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8834390c-360d-4d8d-92eb-dde1f276d924" xlink:to="loc_us-gaap_AssetsAbstract_4ca34d65-3abf-4cde-a410-10cbe223853e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_79e8b33c-d689-46a1-bc48-5fb6637ee729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4ca34d65-3abf-4cde-a410-10cbe223853e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_79e8b33c-d689-46a1-bc48-5fb6637ee729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_403012db-4f68-4c5c-a869-025c823252a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79e8b33c-d689-46a1-bc48-5fb6637ee729" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_403012db-4f68-4c5c-a869-025c823252a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d57ea60f-da86-4332-92a1-792db768c80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79e8b33c-d689-46a1-bc48-5fb6637ee729" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d57ea60f-da86-4332-92a1-792db768c80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_4156d164-5420-44f7-a58a-1b5cb54a69a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79e8b33c-d689-46a1-bc48-5fb6637ee729" xlink:to="loc_us-gaap_InterestReceivableCurrent_4156d164-5420-44f7-a58a-1b5cb54a69a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_089787fb-b427-4076-8b9d-96677d101340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79e8b33c-d689-46a1-bc48-5fb6637ee729" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_089787fb-b427-4076-8b9d-96677d101340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4ff49d1c-16eb-476d-aaeb-f4169b82c408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79e8b33c-d689-46a1-bc48-5fb6637ee729" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4ff49d1c-16eb-476d-aaeb-f4169b82c408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b925a1f8-6426-4a90-83ed-ae1d88937c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79e8b33c-d689-46a1-bc48-5fb6637ee729" xlink:to="loc_us-gaap_AssetsCurrent_b925a1f8-6426-4a90-83ed-ae1d88937c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ab8252c7-a317-4aeb-8185-612b7cbed34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4ca34d65-3abf-4cde-a410-10cbe223853e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ab8252c7-a317-4aeb-8185-612b7cbed34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4e1ac99c-a4fd-41ee-97f5-35d95318a835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4ca34d65-3abf-4cde-a410-10cbe223853e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4e1ac99c-a4fd-41ee-97f5-35d95318a835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_26d3c8be-d394-4c92-96fa-233044da407e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4ca34d65-3abf-4cde-a410-10cbe223853e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_26d3c8be-d394-4c92-96fa-233044da407e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b5615d3a-8d21-4958-820a-14d7e64c9ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4ca34d65-3abf-4cde-a410-10cbe223853e" xlink:to="loc_us-gaap_Goodwill_b5615d3a-8d21-4958-820a-14d7e64c9ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2cd840d7-323b-40c8-aef5-43bf6943333e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4ca34d65-3abf-4cde-a410-10cbe223853e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2cd840d7-323b-40c8-aef5-43bf6943333e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9385af6d-c07c-437f-9026-bf4de48063bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4ca34d65-3abf-4cde-a410-10cbe223853e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9385af6d-c07c-437f-9026-bf4de48063bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c13a1ff5-c111-4a75-bf21-45117d490950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4ca34d65-3abf-4cde-a410-10cbe223853e" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c13a1ff5-c111-4a75-bf21-45117d490950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c1989375-3b70-4bf4-8335-89dc3a04d013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4ca34d65-3abf-4cde-a410-10cbe223853e" xlink:to="loc_us-gaap_Assets_c1989375-3b70-4bf4-8335-89dc3a04d013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ff5d23-6406-490a-8875-2edbfb7df7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8834390c-360d-4d8d-92eb-dde1f276d924" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ff5d23-6406-490a-8875-2edbfb7df7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5de28b18-0c7b-4866-ac52-3613202d22a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ff5d23-6406-490a-8875-2edbfb7df7d5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5de28b18-0c7b-4866-ac52-3613202d22a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0265cb8c-c7fd-49e6-9aff-a23ea6f65e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5de28b18-0c7b-4866-ac52-3613202d22a6" xlink:to="loc_us-gaap_AccountsPayableCurrent_0265cb8c-c7fd-49e6-9aff-a23ea6f65e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_a7c95b31-fba8-4de1-9ee0-df30e6cbc87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5de28b18-0c7b-4866-ac52-3613202d22a6" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_a7c95b31-fba8-4de1-9ee0-df30e6cbc87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c48f60b9-a0fa-41f6-a05f-7b8c3d9226af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5de28b18-0c7b-4866-ac52-3613202d22a6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c48f60b9-a0fa-41f6-a05f-7b8c3d9226af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cf370f62-5190-47c2-b1c4-4245f27d48fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5de28b18-0c7b-4866-ac52-3613202d22a6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cf370f62-5190-47c2-b1c4-4245f27d48fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_06c82c57-53ae-4ad7-a6cb-11b188f524b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5de28b18-0c7b-4866-ac52-3613202d22a6" xlink:to="loc_us-gaap_LiabilitiesCurrent_06c82c57-53ae-4ad7-a6cb-11b188f524b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a547579d-180d-4a35-8e19-2326f68d4047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ff5d23-6406-490a-8875-2edbfb7df7d5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a547579d-180d-4a35-8e19-2326f68d4047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c520fa0d-d7b9-452a-ab2e-c065d34e22e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ff5d23-6406-490a-8875-2edbfb7df7d5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c520fa0d-d7b9-452a-ab2e-c065d34e22e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_48569cc0-0c79-4d56-9960-df58591df4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ff5d23-6406-490a-8875-2edbfb7df7d5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_48569cc0-0c79-4d56-9960-df58591df4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bf03e089-0f87-47e6-b757-1d38df8b6c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ff5d23-6406-490a-8875-2edbfb7df7d5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bf03e089-0f87-47e6-b757-1d38df8b6c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ba59bc7-2f93-4ca0-b9d5-977cc29f8e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ff5d23-6406-490a-8875-2edbfb7df7d5" xlink:to="loc_us-gaap_Liabilities_5ba59bc7-2f93-4ca0-b9d5-977cc29f8e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_706d6857-cd7e-4ee2-b027-03af3eeb6ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ff5d23-6406-490a-8875-2edbfb7df7d5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_706d6857-cd7e-4ee2-b027-03af3eeb6ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61a9a99d-9f66-440f-a84f-b30371eb8d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ff5d23-6406-490a-8875-2edbfb7df7d5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61a9a99d-9f66-440f-a84f-b30371eb8d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_e0ea6fb4-f2f8-4065-aa96-aec03fe7c4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61a9a99d-9f66-440f-a84f-b30371eb8d4c" xlink:to="loc_us-gaap_PreferredStockValue_e0ea6fb4-f2f8-4065-aa96-aec03fe7c4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5c428281-1ad0-46dc-a987-b61745d951cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61a9a99d-9f66-440f-a84f-b30371eb8d4c" xlink:to="loc_us-gaap_CommonStockValue_5c428281-1ad0-46dc-a987-b61745d951cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_97ff9eb4-effd-4faf-a876-1a3131ed2a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61a9a99d-9f66-440f-a84f-b30371eb8d4c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_97ff9eb4-effd-4faf-a876-1a3131ed2a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ce406fb4-2deb-4d73-a89f-53a5dd652ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61a9a99d-9f66-440f-a84f-b30371eb8d4c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ce406fb4-2deb-4d73-a89f-53a5dd652ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d526f411-3bc9-452a-9d89-3614161a5758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61a9a99d-9f66-440f-a84f-b30371eb8d4c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d526f411-3bc9-452a-9d89-3614161a5758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e32a4d9e-144e-4040-9833-b08cb2a5c9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_61a9a99d-9f66-440f-a84f-b30371eb8d4c" xlink:to="loc_us-gaap_StockholdersEquity_e32a4d9e-144e-4040-9833-b08cb2a5c9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2ab869a4-ce5a-44f6-9f45-cf8f5f9dd103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6ff5d23-6406-490a-8875-2edbfb7df7d5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2ab869a4-ce5a-44f6-9f45-cf8f5f9dd103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2b8c09d9-995c-43b4-be68-e3538c5b00cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_2a06d774-6527-4f30-88de-871ef156f269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b8c09d9-995c-43b4-be68-e3538c5b00cb" xlink:to="loc_us-gaap_RevenuesAbstract_2a06d774-6527-4f30-88de-871ef156f269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e5036ee6-1218-434a-bb5e-04f8134de650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_2a06d774-6527-4f30-88de-871ef156f269" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e5036ee6-1218-434a-bb5e-04f8134de650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_78772884-0ce0-49ab-a083-3f4432937101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b8c09d9-995c-43b4-be68-e3538c5b00cb" xlink:to="loc_us-gaap_OperatingExpensesAbstract_78772884-0ce0-49ab-a083-3f4432937101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_57ed2d89-52a9-4a1a-8258-5b81f7d2131e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_78772884-0ce0-49ab-a083-3f4432937101" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_57ed2d89-52a9-4a1a-8258-5b81f7d2131e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a9509da0-4719-4ae2-b7cf-ce312038c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_78772884-0ce0-49ab-a083-3f4432937101" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a9509da0-4719-4ae2-b7cf-ce312038c16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2f7a5d47-2bcb-4c93-995f-5fb08ef30f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_78772884-0ce0-49ab-a083-3f4432937101" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2f7a5d47-2bcb-4c93-995f-5fb08ef30f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dafbc8bc-3c0e-40ba-b0b3-d57b258f3539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_78772884-0ce0-49ab-a083-3f4432937101" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dafbc8bc-3c0e-40ba-b0b3-d57b258f3539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_67c4c556-04f1-4444-9461-beea8167130d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_78772884-0ce0-49ab-a083-3f4432937101" xlink:to="loc_us-gaap_OperatingExpenses_67c4c556-04f1-4444-9461-beea8167130d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ee452ba3-1d3c-4b38-8c92-bf50d0d092ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b8c09d9-995c-43b4-be68-e3538c5b00cb" xlink:to="loc_us-gaap_OperatingIncomeLoss_ee452ba3-1d3c-4b38-8c92-bf50d0d092ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_f583f01b-158f-4ecf-aa87-dc6195bc96af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b8c09d9-995c-43b4-be68-e3538c5b00cb" xlink:to="loc_us-gaap_InterestAndOtherIncome_f583f01b-158f-4ecf-aa87-dc6195bc96af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4f40b1ff-e295-4533-873e-39032714fa35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b8c09d9-995c-43b4-be68-e3538c5b00cb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4f40b1ff-e295-4533-873e-39032714fa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7da9d014-fa7a-474b-a470-ffdfee61cbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b8c09d9-995c-43b4-be68-e3538c5b00cb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7da9d014-fa7a-474b-a470-ffdfee61cbaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47a90a98-c33a-4bb8-a183-4e5db3a20e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b8c09d9-995c-43b4-be68-e3538c5b00cb" xlink:to="loc_us-gaap_NetIncomeLoss_47a90a98-c33a-4bb8-a183-4e5db3a20e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_d759faec-5ce7-44e5-9b8c-a95884cacc9f" xlink:href="sgmo-20230331.xsd#sgmo_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b8c09d9-995c-43b4-be68-e3538c5b00cb" xlink:to="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_d759faec-5ce7-44e5-9b8c-a95884cacc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ae1c3699-e4d5-4758-9402-d72334fd34b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_d759faec-5ce7-44e5-9b8c-a95884cacc9f" xlink:to="loc_us-gaap_EarningsPerShareBasic_ae1c3699-e4d5-4758-9402-d72334fd34b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dca3cc4b-79e7-45bb-9674-c4439539ce20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_d759faec-5ce7-44e5-9b8c-a95884cacc9f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dca3cc4b-79e7-45bb-9674-c4439539ce20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_fd98ab08-6b38-4b36-bc5d-07ee9d40f670" xlink:href="sgmo-20230331.xsd#sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b8c09d9-995c-43b4-be68-e3538c5b00cb" xlink:to="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_fd98ab08-6b38-4b36-bc5d-07ee9d40f670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31fd9d97-36c9-4eeb-b816-cd1572b7d817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_fd98ab08-6b38-4b36-bc5d-07ee9d40f670" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31fd9d97-36c9-4eeb-b816-cd1572b7d817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aff4e9eb-4333-4a8f-8e81-5921c1faafa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract_fd98ab08-6b38-4b36-bc5d-07ee9d40f670" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_aff4e9eb-4333-4a8f-8e81-5921c1faafa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cf837884-0561-43cb-974c-5f047ddb88ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2ec7ddf6-6a10-4d8f-9ab3-4fd6ffd92258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cf837884-0561-43cb-974c-5f047ddb88ea" xlink:to="loc_us-gaap_ProfitLoss_2ec7ddf6-6a10-4d8f-9ab3-4fd6ffd92258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_51540d1b-cefb-4aa1-8de8-17f8adbea739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cf837884-0561-43cb-974c-5f047ddb88ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_51540d1b-cefb-4aa1-8de8-17f8adbea739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5a8b141d-93fc-41fd-8fb7-a4db59e81aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cf837884-0561-43cb-974c-5f047ddb88ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5a8b141d-93fc-41fd-8fb7-a4db59e81aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_195c5ca5-23b2-429c-8635-d843b3e181af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cf837884-0561-43cb-974c-5f047ddb88ea" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_195c5ca5-23b2-429c-8635-d843b3e181af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_335abf9a-ec36-4357-b2a4-b65af5a50715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cf837884-0561-43cb-974c-5f047ddb88ea" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_335abf9a-ec36-4357-b2a4-b65af5a50715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_61f0f84c-47a7-4917-87a0-5860fc5cda2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bd7e69ee-6f79-4df3-ada2-d587f2f9cf54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_61f0f84c-47a7-4917-87a0-5860fc5cda2d" xlink:to="loc_us-gaap_StatementTable_bd7e69ee-6f79-4df3-ada2-d587f2f9cf54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4843cd16-a50b-48ec-a727-8fb8a3414cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bd7e69ee-6f79-4df3-ada2-d587f2f9cf54" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4843cd16-a50b-48ec-a727-8fb8a3414cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4843cd16-a50b-48ec-a727-8fb8a3414cec" xlink:to="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d6624049-63af-43c9-923f-105a30d7cbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:to="loc_us-gaap_CommonStockMember_d6624049-63af-43c9-923f-105a30d7cbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_301f1dec-ff02-46ec-a5c3-b7f849d1095e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_301f1dec-ff02-46ec-a5c3-b7f849d1095e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d522bd22-50fe-40bc-8b1b-5bb5b48bef9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:to="loc_us-gaap_RetainedEarningsMember_d522bd22-50fe-40bc-8b1b-5bb5b48bef9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e1aa66e-4689-4893-9044-aa3f88c6e27c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c8d64a4b-724c-4fa6-9f2f-fa2ca9c46065" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e1aa66e-4689-4893-9044-aa3f88c6e27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f98f68ae-cfb8-42e2-8eb0-79eb069086eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bd7e69ee-6f79-4df3-ada2-d587f2f9cf54" xlink:to="loc_us-gaap_StatementLineItems_f98f68ae-cfb8-42e2-8eb0-79eb069086eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f98f68ae-cfb8-42e2-8eb0-79eb069086eb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_534f3925-d0a9-461c-bee6-4d262a165d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_CommonStockSharesIssued_534f3925-d0a9-461c-bee6-4d262a165d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64fc6d31-bb0a-4c88-8ed9-a45afbeaa96c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64fc6d31-bb0a-4c88-8ed9-a45afbeaa96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5e3e12c4-f56d-4ff1-94ae-590cb1955064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5e3e12c4-f56d-4ff1-94ae-590cb1955064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bb61d55b-56ac-42a2-8a5e-9a8548454ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_bb61d55b-56ac-42a2-8a5e-9a8548454ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f3aa71ca-f4e1-4531-a490-ce1152c4a7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f3aa71ca-f4e1-4531-a490-ce1152c4a7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ee650ea8-87ac-4f05-9b46-75716dd3714a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ee650ea8-87ac-4f05-9b46-75716dd3714a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47377f49-581a-46db-a75a-aea5559510f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47377f49-581a-46db-a75a-aea5559510f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_3e1e2f8c-47a4-47a5-865e-9b3b1fd4e2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_3e1e2f8c-47a4-47a5-865e-9b3b1fd4e2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_84c6b45e-b4bc-499a-a354-4fd0fa85c61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_84c6b45e-b4bc-499a-a354-4fd0fa85c61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e538f058-de0c-45d7-975b-f1454aea70b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e538f058-de0c-45d7-975b-f1454aea70b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c52923cd-638f-4586-87b8-e8a559cc1038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_ProfitLoss_c52923cd-638f-4586-87b8-e8a559cc1038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4c5d3817-0cec-471d-a960-dd06f343ba22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_CommonStockSharesIssued_4c5d3817-0cec-471d-a960-dd06f343ba22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4fdf6521-ceeb-4484-80bd-c5eb8cea3a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b814cdc7-085d-4636-8ec8-74a938beef13" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4fdf6521-ceeb-4484-80bd-c5eb8cea3a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2e33f199-da16-4ff5-bb90-3e5ce9e2f4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_741375bc-7662-47ef-bdc8-b9a93b202140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2e33f199-da16-4ff5-bb90-3e5ce9e2f4b6" xlink:to="loc_us-gaap_StatementTable_741375bc-7662-47ef-bdc8-b9a93b202140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_65c1c006-fcc3-4478-9966-c60946231d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_741375bc-7662-47ef-bdc8-b9a93b202140" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_65c1c006-fcc3-4478-9966-c60946231d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f47e07fb-bbf6-492e-9402-11de38c8f5be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_65c1c006-fcc3-4478-9966-c60946231d69" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f47e07fb-bbf6-492e-9402-11de38c8f5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingMember_11a44319-96ba-420d-9bcb-6d1f39b3ee97" xlink:href="sgmo-20230331.xsd#sgmo_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f47e07fb-bbf6-492e-9402-11de38c8f5be" xlink:to="loc_sgmo_AtTheMarketOfferingMember_11a44319-96ba-420d-9bcb-6d1f39b3ee97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_741375bc-7662-47ef-bdc8-b9a93b202140" xlink:to="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_40535f06-f287-4177-8a40-5f47d76ffb92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:to="loc_us-gaap_ProfitLoss_40535f06-f287-4177-8a40-5f47d76ffb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_26b93588-6f91-4f6e-be51-fc3ee64031c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_26b93588-6f91-4f6e-be51-fc3ee64031c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_204e1fef-f77a-483f-af56-84734e57e91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_204e1fef-f77a-483f-af56-84734e57e91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dfc4ba97-cdb5-4456-b5dc-282d152ec71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dfc4ba97-cdb5-4456-b5dc-282d152ec71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3336f28f-8306-4284-839a-3f1a212e8380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_3336f28f-8306-4284-839a-3f1a212e8380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_b67d89d9-e765-4b83-8a6b-b10acf5bee0d" xlink:href="sgmo-20230331.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_b67d89d9-e765-4b83-8a6b-b10acf5bee0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_10243d74-0a72-4f2e-93c4-3f62cbe3b74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_84c070e0-af67-4039-915a-7f913d3a4142" xlink:to="loc_us-gaap_ShareBasedCompensation_10243d74-0a72-4f2e-93c4-3f62cbe3b74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_7f47e40e-dca2-4015-9abb-f51c6ac0dfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_7f47e40e-dca2-4015-9abb-f51c6ac0dfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ff168dd1-1522-4971-9c4a-e01bfa36f35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ff168dd1-1522-4971-9c4a-e01bfa36f35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d65434f-6697-4752-935a-6603c7912c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4d65434f-6697-4752-935a-6603c7912c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_eb09eb68-e553-4f8f-8e4d-74de56c43cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_eb09eb68-e553-4f8f-8e4d-74de56c43cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ce9ad8be-32d8-4e9c-9450-7ed376c698ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ce9ad8be-32d8-4e9c-9450-7ed376c698ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cd4b0327-c6e4-40b9-9034-ab350cabc991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cd4b0327-c6e4-40b9-9034-ab350cabc991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b02392f1-4cc9-44a0-a2ad-cfcc6cf93e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b02392f1-4cc9-44a0-a2ad-cfcc6cf93e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_85b5eb96-795a-410c-9ba3-efd95d4723b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d17446f1-7717-420e-a463-ca66a4fe4c20" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_85b5eb96-795a-410c-9ba3-efd95d4723b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb742177-cd68-4a34-aa93-d8a7cd269d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8e4d66a6-8312-4942-b6b3-8feffe00474f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cb742177-cd68-4a34-aa93-d8a7cd269d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_97bafa0c-cb9d-4b3e-b6db-3b11034b455a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_97bafa0c-cb9d-4b3e-b6db-3b11034b455a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_1cbd3023-e4c8-4de8-a387-15c67ab53840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_1cbd3023-e4c8-4de8-a387-15c67ab53840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a1f46f2-b920-4cb6-9b08-d5ff2f5ddc13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a1f46f2-b920-4cb6-9b08-d5ff2f5ddc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d13b59a4-d86f-4682-a0af-485ec9e5d181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d22870dd-4ad9-45a1-abd4-861a3e77dfa2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d13b59a4-d86f-4682-a0af-485ec9e5d181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_120992f6-b271-4e5d-89a6-0a20a89e7021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_120992f6-b271-4e5d-89a6-0a20a89e7021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_62d25ab3-f97a-4d73-aefd-54f7ba3aaf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_62d25ab3-f97a-4d73-aefd-54f7ba3aaf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_84db641a-3505-4d0c-bbf0-1c4147b20901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_84db641a-3505-4d0c-bbf0-1c4147b20901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4d0eaad7-3f39-4ec8-afe6-a82d0e27033a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2aa8a075-e9e8-4b96-94a6-cce5e50f4b06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4d0eaad7-3f39-4ec8-afe6-a82d0e27033a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68a47b56-8b30-4eec-bfce-03ce7ba14768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68a47b56-8b30-4eec-bfce-03ce7ba14768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff835cd3-1301-466c-b9bd-831057ca1108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ff835cd3-1301-466c-b9bd-831057ca1108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30bd6ad0-f9ca-469f-8bcf-ee9d30df785d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30bd6ad0-f9ca-469f-8bcf-ee9d30df785d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d980c61e-6e43-43fd-bf55-2215b53a86e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d980c61e-6e43-43fd-bf55-2215b53a86e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b80f006c-5797-4edf-bdd8-934cd184246c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ae59b374-a01f-4f64-b926-b8a59ff134f7" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b80f006c-5797-4edf-bdd8-934cd184246c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_65fef2da-3f50-4b21-88e0-a9f59f742944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b80f006c-5797-4edf-bdd8-934cd184246c" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_65fef2da-3f50-4b21-88e0-a9f59f742944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability_9fead884-d152-4f18-8c6b-977e08d2913b" xlink:href="sgmo-20230331.xsd#sgmo_TenantImprovementAllowanceWithinContraLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b80f006c-5797-4edf-bdd8-934cd184246c" xlink:to="loc_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability_9fead884-d152-4f18-8c6b-977e08d2913b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sgmo-20230331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15807bbc-4cd4-4623-9189-5edce952529a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1c694d99-1c6c-4aa4-8d94-7de49591cfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15807bbc-4cd4-4623-9189-5edce952529a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1c694d99-1c6c-4aa4-8d94-7de49591cfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_642674ca-e8cd-46d2-ad1b-e3903a7bb871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_522d0d44-6564-49ab-8840-3865744d669a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_642674ca-e8cd-46d2-ad1b-e3903a7bb871" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_522d0d44-6564-49ab-8840-3865744d669a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_05927433-5728-4def-a553-f283d5dad3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_adf8cd7a-bffa-4a63-8a39-b1e87e79836d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_05927433-5728-4def-a553-f283d5dad3c4" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_adf8cd7a-bffa-4a63-8a39-b1e87e79836d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE" xlink:type="simple" xlink:href="sgmo-20230331.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d0056735-82a5-45c1-b0f6-e2bd3ae9b9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e0a913b1-000a-451f-bcd0-b6f70cce51ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d0056735-82a5-45c1-b0f6-e2bd3ae9b9c4" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e0a913b1-000a-451f-bcd0-b6f70cce51ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53804250-2a0c-433c-a49f-11cdf075a2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_af2fc0a8-4848-4533-ab58-b82894219362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_53804250-2a0c-433c-a49f-11cdf075a2a3" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_af2fc0a8-4848-4533-ab58-b82894219362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c76500e1-2272-467c-8b9d-179c6bafc391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentChargesTextBlock_51efca65-266d-4d12-b244-b0a2df19f13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentChargesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c76500e1-2272-467c-8b9d-179c6bafc391" xlink:to="loc_us-gaap_AssetImpairmentChargesTextBlock_51efca65-266d-4d12-b244-b0a2df19f13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="sgmo-20230331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41eaedfc-e3ea-4180-82fe-293c09103270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a5626cef-90ff-4942-910b-92f5219148a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41eaedfc-e3ea-4180-82fe-293c09103270" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a5626cef-90ff-4942-910b-92f5219148a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20230331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ac268286-3618-46cd-a273-dc7e4a81956f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7f4d0597-ce17-4315-9374-8115d7a72436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ac268286-3618-46cd-a273-dc7e4a81956f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7f4d0597-ce17-4315-9374-8115d7a72436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sgmo-20230331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_993939c6-ff50-473d-ad4f-2ecbd1992800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3cc241e1-7337-4a54-9471-d81663af0489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_993939c6-ff50-473d-ad4f-2ecbd1992800" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3cc241e1-7337-4a54-9471-d81663af0489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sgmo-20230331.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_fa45a72e-f1c0-4f64-9c08-a6229f332208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4e14c449-f241-4d29-8d08-6f3a170bbd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_fa45a72e-f1c0-4f64-9c08-a6229f332208" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_4e14c449-f241-4d29-8d08-6f3a170bbd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sgmo-20230331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24684801-ee19-4463-b711-2af11bc58da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f1cc1e07-0f59-4cf7-9ec7-6d0f054ce4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24684801-ee19-4463-b711-2af11bc58da0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f1cc1e07-0f59-4cf7-9ec7-6d0f054ce4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_23c14ac6-e1fa-431f-ace2-67da8c1f429a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24684801-ee19-4463-b711-2af11bc58da0" xlink:to="loc_us-gaap_UseOfEstimates_23c14ac6-e1fa-431f-ace2-67da8c1f429a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d0372e29-d0e0-4a4c-896d-b2c63d9b78cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24684801-ee19-4463-b711-2af11bc58da0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d0372e29-d0e0-4a4c-896d-b2c63d9b78cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_77082a78-87a1-4530-bf06-7ffedeafbc05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24684801-ee19-4463-b711-2af11bc58da0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_77082a78-87a1-4530-bf06-7ffedeafbc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8ecb9ac8-e9fe-41b2-8b2a-a35b57ace662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24684801-ee19-4463-b711-2af11bc58da0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8ecb9ac8-e9fe-41b2-8b2a-a35b57ace662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_881c6375-7da5-4da0-a6f8-0c1f5016f155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24684801-ee19-4463-b711-2af11bc58da0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_881c6375-7da5-4da0-a6f8-0c1f5016f155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6d5390e2-989d-4ca6-bd4f-ed4199b9057d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24684801-ee19-4463-b711-2af11bc58da0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6d5390e2-989d-4ca6-bd4f-ed4199b9057d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8e5a2541-3f3e-434c-b5e0-5c0ac139b51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24684801-ee19-4463-b711-2af11bc58da0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8e5a2541-3f3e-434c-b5e0-5c0ac139b51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sgmo-20230331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be2e5dc6-572b-4f73-baf3-8688799371e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_a1dd6867-0eb5-4738-9b54-98b08072ba14" xlink:href="sgmo-20230331.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be2e5dc6-572b-4f73-baf3-8688799371e2" xlink:to="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_a1dd6867-0eb5-4738-9b54-98b08072ba14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_c3148290-3b27-47d1-b7ba-053caf0a9261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be2e5dc6-572b-4f73-baf3-8688799371e2" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_c3148290-3b27-47d1-b7ba-053caf0a9261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_7a49f8af-cbfe-4a92-88f1-3360d61d4748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be2e5dc6-572b-4f73-baf3-8688799371e2" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_7a49f8af-cbfe-4a92-88f1-3360d61d4748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="sgmo-20230331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f8dcc73d-d4e4-475e-ba31-b25657cf5d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_d9f9ad61-5cfb-443a-ad16-4bfff15d551c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f8dcc73d-d4e4-475e-ba31-b25657cf5d15" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_d9f9ad61-5cfb-443a-ad16-4bfff15d551c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2a46349c-9af6-424e-9bbd-5329aab4076e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_7225af16-a3d3-4082-a0e9-703f52f9ee80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2a46349c-9af6-424e-9bbd-5329aab4076e" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_7225af16-a3d3-4082-a0e9-703f52f9ee80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f9e9082c-0ead-489e-a0b6-7642f26b2071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2a46349c-9af6-424e-9bbd-5329aab4076e" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_f9e9082c-0ead-489e-a0b6-7642f26b2071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables" xlink:type="simple" xlink:href="sgmo-20230331.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2ec13ca7-cb7b-4218-9bb3-98025c077260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_072c29f9-01d9-466d-89b3-b17d74e07b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2ec13ca7-cb7b-4218-9bb3-98025c077260" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_072c29f9-01d9-466d-89b3-b17d74e07b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de3af9e8-5dd1-4f6e-b1c8-0bb3b45a3818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0aeffc62-36f9-4c6a-93e5-b630c774293e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de3af9e8-5dd1-4f6e-b1c8-0bb3b45a3818" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0aeffc62-36f9-4c6a-93e5-b630c774293e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_08ee6f66-6522-4ef5-b449-622fddda592d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0aeffc62-36f9-4c6a-93e5-b630c774293e" xlink:to="loc_srt_CounterpartyNameAxis_08ee6f66-6522-4ef5-b449-622fddda592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_08ee6f66-6522-4ef5-b449-622fddda592d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6e51acff-b707-4bc5-bcbb-b6de39665ac8" xlink:href="sgmo-20230331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6e51acff-b707-4bc5-bcbb-b6de39665ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_a349058e-e63f-4db0-a0ee-29503f037e15" xlink:href="sgmo-20230331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:to="loc_sgmo_BiogenMAIncMember_a349058e-e63f-4db0-a0ee-29503f037e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_d3c25679-e1a7-441a-b384-d94c378a270c" xlink:href="sgmo-20230331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:to="loc_sgmo_KitePharmaIncMember_d3c25679-e1a7-441a-b384-d94c378a270c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_8e67e50d-ce51-4402-a82c-ad9e70c9db76" xlink:href="sgmo-20230331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2729fe85-fafb-4b68-9147-64e249194cbb" xlink:to="loc_sgmo_SanofiMember_8e67e50d-ce51-4402-a82c-ad9e70c9db76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_89012b31-c1c5-40ae-8725-6645ccb44240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_0aeffc62-36f9-4c6a-93e5-b630c774293e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_89012b31-c1c5-40ae-8725-6645ccb44240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_2523126a-4cac-4903-ac0d-1f3e26d481dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_89012b31-c1c5-40ae-8725-6645ccb44240" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_2523126a-4cac-4903-ac0d-1f3e26d481dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sgmo-20230331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3760d7d8-a35d-4b86-9fb4-8a929f0ab85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_96cbbf27-b0b1-4df4-9890-dc782b3767e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3760d7d8-a35d-4b86-9fb4-8a929f0ab85a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_96cbbf27-b0b1-4df4-9890-dc782b3767e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_00ff568d-94cc-458d-9014-4bee1049b90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49fc7b6e-a099-46a7-bb9b-2794aa82d995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_00ff568d-94cc-458d-9014-4bee1049b90e" xlink:to="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49fc7b6e-a099-46a7-bb9b-2794aa82d995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_824ee172-94ff-43eb-9358-25db7156de62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49fc7b6e-a099-46a7-bb9b-2794aa82d995" xlink:to="loc_srt_CounterpartyNameAxis_824ee172-94ff-43eb-9358-25db7156de62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4aa9aebc-b9d9-4963-abe8-740e66137576" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_824ee172-94ff-43eb-9358-25db7156de62" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4aa9aebc-b9d9-4963-abe8-740e66137576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_b8d099cf-0d50-4d3b-8b74-5d5b34fcbbe4" xlink:href="sgmo-20230331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4aa9aebc-b9d9-4963-abe8-740e66137576" xlink:to="loc_sgmo_KitePharmaIncMember_b8d099cf-0d50-4d3b-8b74-5d5b34fcbbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingEstimateLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfChangeInAccountingEstimateTable_49fc7b6e-a099-46a7-bb9b-2794aa82d995" xlink:to="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_ba330a94-40f8-49c8-989d-44540e751919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_ba330a94-40f8-49c8-989d-44540e751919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_366e6d5d-3e6e-4a1d-a82f-ad40f1cd43b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_us-gaap_NetIncomeLoss_366e6d5d-3e6e-4a1d-a82f-ad40f1cd43b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92ca8528-4ba6-42c9-876d-7bbac0984e19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92ca8528-4ba6-42c9-876d-7bbac0984e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_346d5adf-5968-4dae-8ebe-36cf771af0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_346d5adf-5968-4dae-8ebe-36cf771af0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_985c0a75-b60b-4536-99a5-443fc412a5c3" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_985c0a75-b60b-4536-99a5-443fc412a5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_57ed2e10-df3b-4f61-b326-6020a7550e63" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_57ed2e10-df3b-4f61-b326-6020a7550e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_ae0ad56c-8437-401b-9a08-fd3f3a4f2281" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_ae0ad56c-8437-401b-9a08-fd3f3a4f2281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_431a397b-9a20-4c2b-a802-5946ee5e96de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateLineItems_52784700-25d1-4374-881e-16d98038cbac" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_431a397b-9a20-4c2b-a802-5946ee5e96de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f13bff4a-7924-4b76-aa02-8c3602142d33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_864b3c11-0490-4f8d-89fe-1c39a80384c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f13bff4a-7924-4b76-aa02-8c3602142d33" xlink:to="loc_us-gaap_ConcentrationRiskTable_864b3c11-0490-4f8d-89fe-1c39a80384c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f9d36efa-3927-4700-bf59-df88b4f23b8f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_864b3c11-0490-4f8d-89fe-1c39a80384c7" xlink:to="loc_srt_CounterpartyNameAxis_f9d36efa-3927-4700-bf59-df88b4f23b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f9d36efa-3927-4700-bf59-df88b4f23b8f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_3e214769-6f38-4b22-9156-f855daf5681f" xlink:href="sgmo-20230331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:to="loc_sgmo_BiogenMAIncMember_3e214769-6f38-4b22-9156-f855daf5681f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_46a063e8-c267-447e-b28e-215468f25eb1" xlink:href="sgmo-20230331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:to="loc_sgmo_KitePharmaIncMember_46a063e8-c267-447e-b28e-215468f25eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_893ccb7a-816d-4850-8e47-945f36abd85c" xlink:href="sgmo-20230331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_893ccb7a-816d-4850-8e47-945f36abd85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_3711534c-6cd6-453b-b6f4-18c14ad12070" xlink:href="sgmo-20230331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_25ef9e41-af74-4012-8c33-d5ccbb435a43" xlink:to="loc_sgmo_SanofiMember_3711534c-6cd6-453b-b6f4-18c14ad12070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bcb50340-b8c5-4c94-81e7-dbe2446cbafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_864b3c11-0490-4f8d-89fe-1c39a80384c7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bcb50340-b8c5-4c94-81e7-dbe2446cbafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_38e4fd0f-ead4-444c-8cf9-5d573b74e179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bcb50340-b8c5-4c94-81e7-dbe2446cbafb" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_38e4fd0f-ead4-444c-8cf9-5d573b74e179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_05b8e687-1909-439e-89f1-d904a4e78e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_38e4fd0f-ead4-444c-8cf9-5d573b74e179" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_05b8e687-1909-439e-89f1-d904a4e78e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_03013f17-d38a-4644-8b26-894495927dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_864b3c11-0490-4f8d-89fe-1c39a80384c7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_03013f17-d38a-4644-8b26-894495927dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2d3e35fa-d1e0-45ce-9e52-7ceb770beb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_03013f17-d38a-4644-8b26-894495927dc1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2d3e35fa-d1e0-45ce-9e52-7ceb770beb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_a745601b-a69e-421a-92ec-839a512db3c4" xlink:href="sgmo-20230331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2d3e35fa-d1e0-45ce-9e52-7ceb770beb49" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_a745601b-a69e-421a-92ec-839a512db3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7e451dd1-6295-4910-b52b-f0a78b125121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_864b3c11-0490-4f8d-89fe-1c39a80384c7" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_7e451dd1-6295-4910-b52b-f0a78b125121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6490b0b4-e0fe-4946-911e-41e509421cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7e451dd1-6295-4910-b52b-f0a78b125121" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6490b0b4-e0fe-4946-911e-41e509421cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_687e04ea-93e5-4130-a2db-4eb93c2251d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1cee8ea1-dae8-4263-aaab-32b7d1d21427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_687e04ea-93e5-4130-a2db-4eb93c2251d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1cee8ea1-dae8-4263-aaab-32b7d1d21427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c3271a43-e167-4d91-aa0f-c9fd78c13b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_687e04ea-93e5-4130-a2db-4eb93c2251d2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c3271a43-e167-4d91-aa0f-c9fd78c13b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22b236b8-f7a1-41ae-9337-5d27219e409b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_687e04ea-93e5-4130-a2db-4eb93c2251d2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22b236b8-f7a1-41ae-9337-5d27219e409b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_af77cb38-0145-4ccf-ba79-4ea0cd9b3182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_de8f89cd-b597-44d5-a786-cbaef23e46e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_af77cb38-0145-4ccf-ba79-4ea0cd9b3182" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_de8f89cd-b597-44d5-a786-cbaef23e46e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_432d23b6-58b7-497f-977c-4f7287660360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_de8f89cd-b597-44d5-a786-cbaef23e46e6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_432d23b6-58b7-497f-977c-4f7287660360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_77414b1a-6c05-4036-8906-ad74843b8ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_432d23b6-58b7-497f-977c-4f7287660360" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_77414b1a-6c05-4036-8906-ad74843b8ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2f141525-8cee-46ce-a4ce-cb13a2692240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_77414b1a-6c05-4036-8906-ad74843b8ea3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2f141525-8cee-46ce-a4ce-cb13a2692240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97988ab7-f87b-432c-aebf-91b788e44107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_de8f89cd-b597-44d5-a786-cbaef23e46e6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97988ab7-f87b-432c-aebf-91b788e44107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_538a010b-5057-487c-abfb-0e73a9a00736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97988ab7-f87b-432c-aebf-91b788e44107" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_538a010b-5057-487c-abfb-0e73a9a00736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_31e4ea4a-9c31-425f-9071-5085b5e68261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_538a010b-5057-487c-abfb-0e73a9a00736" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_31e4ea4a-9c31-425f-9071-5085b5e68261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_21167297-f1a2-4643-adf1-262b714b2383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_538a010b-5057-487c-abfb-0e73a9a00736" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_21167297-f1a2-4643-adf1-262b714b2383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7b41cf88-9a1e-4d9f-a986-842441d990a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_538a010b-5057-487c-abfb-0e73a9a00736" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7b41cf88-9a1e-4d9f-a986-842441d990a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_64ba947a-ebf9-4027-b958-c9a30a7f98ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_de8f89cd-b597-44d5-a786-cbaef23e46e6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_64ba947a-ebf9-4027-b958-c9a30a7f98ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_64ba947a-ebf9-4027-b958-c9a30a7f98ae" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0558650a-a213-4ec7-b593-c2a4243190bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0558650a-a213-4ec7-b593-c2a4243190bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_9a730bc0-4dfc-4015-9fce-fe0f40ddf553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_9a730bc0-4dfc-4015-9fce-fe0f40ddf553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4c8050cd-d5d4-41a2-a3d1-93b56fec0ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_CommercialPaperMember_4c8050cd-d5d4-41a2-a3d1-93b56fec0ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0ed3226f-3b58-46fe-9d0c-8108b2009fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0ed3226f-3b58-46fe-9d0c-8108b2009fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_34ed380b-7eac-4877-a14b-e2ef0fc17fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_34ed380b-7eac-4877-a14b-e2ef0fc17fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_8ea3ff31-2e7a-4f7e-94f9-9281512d765f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_8ea3ff31-2e7a-4f7e-94f9-9281512d765f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_91c4a64b-2751-48b5-ba18-3c650067695a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_91c4a64b-2751-48b5-ba18-3c650067695a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_USGovernmentSponsoredAgencyBondMember_e957c2be-45f2-4004-85e5-c4652f6ac44f" xlink:href="sgmo-20230331.xsd#sgmo_USGovernmentSponsoredAgencyBondMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47df74fc-db99-4c11-9874-cdbada4e40d9" xlink:to="loc_sgmo_USGovernmentSponsoredAgencyBondMember_e957c2be-45f2-4004-85e5-c4652f6ac44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2d0ba26-9612-449a-b834-11f9bf5adc21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_de8f89cd-b597-44d5-a786-cbaef23e46e6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2d0ba26-9612-449a-b834-11f9bf5adc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ccf4ed22-b2c0-4e08-b35e-40b6b9767c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2d0ba26-9612-449a-b834-11f9bf5adc21" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ccf4ed22-b2c0-4e08-b35e-40b6b9767c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_572e81ee-cc20-4ed3-8635-f086842e07a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2d0ba26-9612-449a-b834-11f9bf5adc21" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_572e81ee-cc20-4ed3-8635-f086842e07a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a31a1571-1734-4069-8648-c093a02904f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b2d0ba26-9612-449a-b834-11f9bf5adc21" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a31a1571-1734-4069-8648-c093a02904f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7c6855b-f3c3-415f-bdeb-f9050d9cac99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a1e1c9a-9e7c-490a-9a06-3b54103a7c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d7c6855b-f3c3-415f-bdeb-f9050d9cac99" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a1e1c9a-9e7c-490a-9a06-3b54103a7c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6bbd83cb-4a0c-4027-8a77-8f3a6bcb4729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a1e1c9a-9e7c-490a-9a06-3b54103a7c70" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6bbd83cb-4a0c-4027-8a77-8f3a6bcb4729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6bbd83cb-4a0c-4027-8a77-8f3a6bcb4729" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0d6679b1-4542-4ed0-a038-695d35d4ed06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0d6679b1-4542-4ed0-a038-695d35d4ed06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_2be8ed71-9863-4199-9a4c-b31f12519877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_CashEquivalentsMember_2be8ed71-9863-4199-9a4c-b31f12519877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32508de2-839f-4081-a0c8-61d6d5d24b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_32508de2-839f-4081-a0c8-61d6d5d24b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_567a4129-ffdf-458b-92e5-2b177c77a20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_CommercialPaperMember_567a4129-ffdf-458b-92e5-2b177c77a20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fcecdff0-5e8c-4f7e-9c23-aa214844c097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fcecdff0-5e8c-4f7e-9c23-aa214844c097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_4fceae92-d92f-4047-af81-6518d469ffc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_4fceae92-d92f-4047-af81-6518d469ffc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_392899b0-100d-453d-9344-0059dd48498f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_392899b0-100d-453d-9344-0059dd48498f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_27c3fbf8-764b-4ba4-be6f-d47a8a050497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_us-gaap_CertificatesOfDepositMember_27c3fbf8-764b-4ba4-be6f-d47a8a050497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_USGovernmentSponsoredAgencyBondMember_e98b7261-9d29-49c4-a219-dcc2e87a4366" xlink:href="sgmo-20230331.xsd#sgmo_USGovernmentSponsoredAgencyBondMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f73757d-d073-4ebf-972b-9a0558fa717d" xlink:to="loc_sgmo_USGovernmentSponsoredAgencyBondMember_e98b7261-9d29-49c4-a219-dcc2e87a4366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4a1e1c9a-9e7c-490a-9a06-3b54103a7c70" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:to="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a590d96-bae3-4cb5-be88-e17b315ef64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1a590d96-bae3-4cb5-be88-e17b315ef64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_7e963152-6761-4347-a1ea-0c3a42feb4db" xlink:href="sgmo-20230331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_7e963152-6761-4347-a1ea-0c3a42feb4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_30ffde48-ba5f-4af5-b228-814efcc4708a" xlink:href="sgmo-20230331.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_30ffde48-ba5f-4af5-b228-814efcc4708a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8a1bd6a-b7e2-467d-bbad-995713e3e15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a8a1bd6a-b7e2-467d-bbad-995713e3e15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b38537ab-171c-464e-8bd1-f857b2988146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b38537ab-171c-464e-8bd1-f857b2988146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e7f79c92-926b-4fc6-a764-bc024e006075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e7f79c92-926b-4fc6-a764-bc024e006075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2bf56a7d-1e00-4fd8-8140-bced57446425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2bf56a7d-1e00-4fd8-8140-bced57446425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87a95160-1fd3-4662-b29f-1e4e7301e4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6877e24f-7a54-4a6a-b758-3743c4512e17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_87a95160-1fd3-4662-b29f-1e4e7301e4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_ab433d7f-ad13-42d9-a3a7-f50917c80800" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_ab433d7f-ad13-42d9-a3a7-f50917c80800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_a084bd92-213a-40ec-b98b-01828798bc56" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_a084bd92-213a-40ec-b98b-01828798bc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_d0f7d9db-bb44-4b15-bc69-c7147cefceaa" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_d0f7d9db-bb44-4b15-bc69-c7147cefceaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_be960458-7865-4d3b-b5f9-c72f707ef8de" xlink:href="sgmo-20230331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_700de1db-a1d7-400a-9639-2773e86ef978" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_be960458-7865-4d3b-b5f9-c72f707ef8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8592973d-03da-4a54-b111-3e28b1713fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_12aa6b28-2a93-4095-a55b-ce2d43c9f1be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8592973d-03da-4a54-b111-3e28b1713fd8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_12aa6b28-2a93-4095-a55b-ce2d43c9f1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c401f975-a73e-481e-9bae-adb61e88b560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8592973d-03da-4a54-b111-3e28b1713fd8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c401f975-a73e-481e-9bae-adb61e88b560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1a2b80e6-8bd0-4b87-b86f-5b6cb9e74491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8592973d-03da-4a54-b111-3e28b1713fd8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1a2b80e6-8bd0-4b87-b86f-5b6cb9e74491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_370f3a2b-242d-4039-9407-5fbd9f6b9011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_492f3deb-ce31-48e4-8e2b-b5254ae9df71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_370f3a2b-242d-4039-9407-5fbd9f6b9011" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_492f3deb-ce31-48e4-8e2b-b5254ae9df71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_1efa07ba-475f-4a9e-9ef5-c3c571ee6867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_370f3a2b-242d-4039-9407-5fbd9f6b9011" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_1efa07ba-475f-4a9e-9ef5-c3c571ee6867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_7bdef16b-66d7-4857-9fac-806f64a96661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_370f3a2b-242d-4039-9407-5fbd9f6b9011" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_7bdef16b-66d7-4857-9fac-806f64a96661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d1669a9d-d966-441e-b552-5112168167d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_370f3a2b-242d-4039-9407-5fbd9f6b9011" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_d1669a9d-d966-441e-b552-5112168167d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f4ba7c49-8f91-4e24-9535-758f96d34eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_32aa6221-e4b6-42cc-b41e-209b6b4fda8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4ba7c49-8f91-4e24-9535-758f96d34eb2" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_32aa6221-e4b6-42cc-b41e-209b6b4fda8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3a2571b6-3cf7-41c0-afbc-5f355ac7cc6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_32aa6221-e4b6-42cc-b41e-209b6b4fda8c" xlink:to="loc_us-gaap_AwardTypeAxis_3a2571b6-3cf7-41c0-afbc-5f355ac7cc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_936a6e94-1cbe-4141-93f4-45f26e45447d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3a2571b6-3cf7-41c0-afbc-5f355ac7cc6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_936a6e94-1cbe-4141-93f4-45f26e45447d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5dd7482b-c92c-4d56-998e-f71f53682bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_936a6e94-1cbe-4141-93f4-45f26e45447d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5dd7482b-c92c-4d56-998e-f71f53682bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_f667f79f-0c06-44dc-b978-da6cebc5d265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_936a6e94-1cbe-4141-93f4-45f26e45447d" xlink:to="loc_us-gaap_StockCompensationPlanMember_f667f79f-0c06-44dc-b978-da6cebc5d265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_8a52f66e-e269-417a-a10b-e2e393b473d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_32aa6221-e4b6-42cc-b41e-209b6b4fda8c" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_8a52f66e-e269-417a-a10b-e2e393b473d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_ce8d70d6-04ab-4eed-a6ea-51d872a1692f" xlink:href="sgmo-20230331.xsd#sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8a52f66e-e269-417a-a10b-e2e393b473d6" xlink:to="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_ce8d70d6-04ab-4eed-a6ea-51d872a1692f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4f523e7b-2fc9-4179-8c68-d698dde4191a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_ce8d70d6-04ab-4eed-a6ea-51d872a1692f" xlink:to="loc_us-gaap_NetIncomeLoss_4f523e7b-2fc9-4179-8c68-d698dde4191a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_07317c2b-8185-42cd-b84d-d8df2d38e2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_8a52f66e-e269-417a-a10b-e2e393b473d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_07317c2b-8185-42cd-b84d-d8df2d38e2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_09cd8558-f1bf-4f22-8020-89e05facaad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_07317c2b-8185-42cd-b84d-d8df2d38e2b4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_09cd8558-f1bf-4f22-8020-89e05facaad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_747383ec-3a56-4367-9226-2e2c24b949c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_09cd8558-f1bf-4f22-8020-89e05facaad5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_747383ec-3a56-4367-9226-2e2c24b949c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9352fdd-1bcd-4ebe-86e4-e5893f6b3b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_07317c2b-8185-42cd-b84d-d8df2d38e2b4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9352fdd-1bcd-4ebe-86e4-e5893f6b3b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_edc680a5-7f49-4656-a3da-8736fe965792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9352fdd-1bcd-4ebe-86e4-e5893f6b3b27" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_edc680a5-7f49-4656-a3da-8736fe965792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6dc9ebe1-1df8-4c62-a23d-db66b64646e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9352fdd-1bcd-4ebe-86e4-e5893f6b3b27" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6dc9ebe1-1df8-4c62-a23d-db66b64646e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8f298782-fb27-4322-b1fd-a586200463b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d9352fdd-1bcd-4ebe-86e4-e5893f6b3b27" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8f298782-fb27-4322-b1fd-a586200463b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_4017026e-2a51-45d1-9f18-89426928978c" xlink:href="sgmo-20230331.xsd#sgmo_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_07317c2b-8185-42cd-b84d-d8df2d38e2b4" xlink:to="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_4017026e-2a51-45d1-9f18-89426928978c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_86d4972e-ecda-4f87-8d2a-7f61aaf023a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_4017026e-2a51-45d1-9f18-89426928978c" xlink:to="loc_us-gaap_EarningsPerShareBasic_86d4972e-ecda-4f87-8d2a-7f61aaf023a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_53d184fd-5191-4cdc-86ff-39573ad665da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract_4017026e-2a51-45d1-9f18-89426928978c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_53d184fd-5191-4cdc-86ff-39573ad665da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#BASICANDDILUTEDNETINCOMELOSSPERSHARENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c3c71b23-9739-43c6-a7f5-9d9767f3d14a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35c29d5b-5df5-4ff1-a8bb-707a96a1fee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c3c71b23-9739-43c6-a7f5-9d9767f3d14a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35c29d5b-5df5-4ff1-a8bb-707a96a1fee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ea6bd158-94cf-481d-8e80-2d277152154c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_09430a3c-5cd5-4380-9dfb-d4f4a0180449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ea6bd158-94cf-481d-8e80-2d277152154c" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_09430a3c-5cd5-4380-9dfb-d4f4a0180449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f49d8480-869e-42de-bb17-37bb892e9cc2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_09430a3c-5cd5-4380-9dfb-d4f4a0180449" xlink:to="loc_srt_CounterpartyNameAxis_f49d8480-869e-42de-bb17-37bb892e9cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f92978a2-620a-4dd8-90a5-746a90679344" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f49d8480-869e-42de-bb17-37bb892e9cc2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f92978a2-620a-4dd8-90a5-746a90679344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_b53352f1-1075-4aa2-a567-1c8b7888f25a" xlink:href="sgmo-20230331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f92978a2-620a-4dd8-90a5-746a90679344" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_b53352f1-1075-4aa2-a567-1c8b7888f25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6cc44bd8-b4d9-49c3-9105-babefa4a8190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_09430a3c-5cd5-4380-9dfb-d4f4a0180449" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6cc44bd8-b4d9-49c3-9105-babefa4a8190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0292438-605c-4a65-a938-d6c1077d840b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6cc44bd8-b4d9-49c3-9105-babefa4a8190" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0292438-605c-4a65-a938-d6c1077d840b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_5ceca189-d5b4-48f2-a166-5458a6633223" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0292438-605c-4a65-a938-d6c1077d840b" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_5ceca189-d5b4-48f2-a166-5458a6633223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_09430a3c-5cd5-4380-9dfb-d4f4a0180449" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_f5fea9b1-438d-4d27-b217-fab7912e0f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_us-gaap_ProceedsFromCollaborators_f5fea9b1-438d-4d27-b217-fab7912e0f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_81464e36-2f57-4ad3-8493-c15b7bf99ca1" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_81464e36-2f57-4ad3-8493-c15b7bf99ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee_65c49ba4-ab68-4d46-aa96-82c51027fd93" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_sgmo_CollaborativeArrangementLicenseFee_65c49ba4-ab68-4d46-aa96-82c51027fd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_ab2e98a8-8760-4f35-a172-b95b6cf59d5a" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_ab2e98a8-8760-4f35-a172-b95b6cf59d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8cc8af38-07ac-4ed7-a541-83ca45b10b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8cc8af38-07ac-4ed7-a541-83ca45b10b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_cb2a5310-16c3-49c2-bd54-efd1a2b51e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_us-gaap_ContractWithCustomerLiability_cb2a5310-16c3-49c2-bd54-efd1a2b51e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_194f81f9-e893-4bd2-b617-b1d1af2a1720" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_194f81f9-e893-4bd2-b617-b1d1af2a1720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_0034139b-05e0-484e-bb6c-abab98125d75" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_0034139b-05e0-484e-bb6c-abab98125d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_2984ee0d-71a5-4ad2-83d8-dc112c89a4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_a1a4647b-09e8-48d3-ad17-be5a370a0004" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_2984ee0d-71a5-4ad2-83d8-dc112c89a4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f35ad367-2427-4f38-bcfb-6bb950609f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f9501cae-59d8-46cd-9647-1a78c7d71aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f35ad367-2427-4f38-bcfb-6bb950609f45" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f9501cae-59d8-46cd-9647-1a78c7d71aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8f4ba978-c103-4635-ad7b-1bcf62472a89" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f9501cae-59d8-46cd-9647-1a78c7d71aa4" xlink:to="loc_srt_CounterpartyNameAxis_8f4ba978-c103-4635-ad7b-1bcf62472a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8f4ba978-c103-4635-ad7b-1bcf62472a89" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_0d306079-c5c4-4546-8e89-783d7905d269" xlink:href="sgmo-20230331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_0d306079-c5c4-4546-8e89-783d7905d269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_603d633c-2cf6-4e9b-89ea-71f38d13dbf4" xlink:href="sgmo-20230331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:to="loc_sgmo_BiogenMAIncMember_603d633c-2cf6-4e9b-89ea-71f38d13dbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_1f1495c7-3d98-4c3d-a314-5b6b433857cb" xlink:href="sgmo-20230331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:to="loc_sgmo_KitePharmaIncMember_1f1495c7-3d98-4c3d-a314-5b6b433857cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_c20e4806-549f-42ed-b080-098f7a0e1225" xlink:href="sgmo-20230331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49f2e905-18db-4937-9394-4a6ec2bb76ad" xlink:to="loc_sgmo_SanofiMember_c20e4806-549f-42ed-b080-098f7a0e1225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_49e496ec-523b-4958-8053-679804045e53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f9501cae-59d8-46cd-9647-1a78c7d71aa4" xlink:to="loc_srt_ProductOrServiceAxis_49e496ec-523b-4958-8053-679804045e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c819c86b-d82c-4923-a1d8-347428922af5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_49e496ec-523b-4958-8053-679804045e53" xlink:to="loc_srt_ProductsAndServicesDomain_c819c86b-d82c-4923-a1d8-347428922af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_15c86162-fdf2-4570-a376-be9b42e239a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c819c86b-d82c-4923-a1d8-347428922af5" xlink:to="loc_us-gaap_LicenseAndServiceMember_15c86162-fdf2-4570-a376-be9b42e239a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_3bffb737-d422-475a-8d95-484a72560dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LicenseAndServiceMember_15c86162-fdf2-4570-a376-be9b42e239a3" xlink:to="loc_us-gaap_LicenseMember_3bffb737-d422-475a-8d95-484a72560dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_076492ba-cc06-4a33-86bc-c9927caf3e2f" xlink:href="sgmo-20230331.xsd#sgmo_ResearchServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LicenseAndServiceMember_15c86162-fdf2-4570-a376-be9b42e239a3" xlink:to="loc_sgmo_ResearchServicesMember_076492ba-cc06-4a33-86bc-c9927caf3e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_785e149a-2095-411e-aaa9-d80bad353bf4" xlink:href="sgmo-20230331.xsd#sgmo_MilestoneAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c819c86b-d82c-4923-a1d8-347428922af5" xlink:to="loc_sgmo_MilestoneAchievementMember_785e149a-2095-411e-aaa9-d80bad353bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25c5ecff-1b72-45a4-8907-6af7a387a81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f9501cae-59d8-46cd-9647-1a78c7d71aa4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25c5ecff-1b72-45a4-8907-6af7a387a81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_4187bb0c-b0be-4f8f-8b43-e715987d7f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_25c5ecff-1b72-45a4-8907-6af7a387a81f" xlink:to="loc_us-gaap_RevenuesAbstract_4187bb0c-b0be-4f8f-8b43-e715987d7f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e237179-df68-4dd7-9985-9503f053e10f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_4187bb0c-b0be-4f8f-8b43-e715987d7f6c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e237179-df68-4dd7-9985-9503f053e10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_abcb52b1-6e4b-43c4-bc74-cc2d5cf75ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8a0aa83f-508d-484c-8b8b-315b678c2fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_abcb52b1-6e4b-43c4-bc74-cc2d5cf75ef1" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8a0aa83f-508d-484c-8b8b-315b678c2fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cac0b795-ac8c-496f-a2ff-5c497565f250" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8a0aa83f-508d-484c-8b8b-315b678c2fed" xlink:to="loc_srt_CounterpartyNameAxis_cac0b795-ac8c-496f-a2ff-5c497565f250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd51939-7b2c-4892-9784-5835a8f7bf14" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cac0b795-ac8c-496f-a2ff-5c497565f250" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd51939-7b2c-4892-9784-5835a8f7bf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_09ac1bcb-cecb-4043-876e-eaaf1f0b5f96" xlink:href="sgmo-20230331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7cd51939-7b2c-4892-9784-5835a8f7bf14" xlink:to="loc_sgmo_BiogenMAIncMember_09ac1bcb-cecb-4043-876e-eaaf1f0b5f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c0f67d53-82be-487b-bbad-8fd156cc8357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8a0aa83f-508d-484c-8b8b-315b678c2fed" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c0f67d53-82be-487b-bbad-8fd156cc8357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d71a989-a20d-4403-8764-5b8107067ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c0f67d53-82be-487b-bbad-8fd156cc8357" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d71a989-a20d-4403-8764-5b8107067ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_e24785d2-f067-44b8-866c-dd0ff9a583d4" xlink:href="sgmo-20230331.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d71a989-a20d-4403-8764-5b8107067ad6" xlink:to="loc_sgmo_StockPurchaseAgreementMember_e24785d2-f067-44b8-866c-dd0ff9a583d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_256fa5b6-ecfb-48db-a545-32cc1164caed" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d71a989-a20d-4403-8764-5b8107067ad6" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_256fa5b6-ecfb-48db-a545-32cc1164caed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_987bb3c9-21c5-42ed-8e3f-6a0d8c1e045e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8a0aa83f-508d-484c-8b8b-315b678c2fed" xlink:to="loc_srt_ProductOrServiceAxis_987bb3c9-21c5-42ed-8e3f-6a0d8c1e045e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_40257cfe-ecbe-434c-8e75-f61da428ee7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_987bb3c9-21c5-42ed-8e3f-6a0d8c1e045e" xlink:to="loc_srt_ProductsAndServicesDomain_40257cfe-ecbe-434c-8e75-f61da428ee7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_45b64a24-27fc-400e-a5b2-38990f12bc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_40257cfe-ecbe-434c-8e75-f61da428ee7c" xlink:to="loc_us-gaap_LicenseAndServiceMember_45b64a24-27fc-400e-a5b2-38990f12bc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8a0aa83f-508d-484c-8b8b-315b678c2fed" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_740de082-44d7-491d-9d0a-0cd7b2d2fe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_740de082-44d7-491d-9d0a-0cd7b2d2fe5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c96095fa-fa6c-4099-a921-01270e921e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c96095fa-fa6c-4099-a921-01270e921e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0f7bb6bf-a184-458f-a5a6-1bb5561666b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0f7bb6bf-a184-458f-a5a6-1bb5561666b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_ea3d133f-a4b8-4bc8-bfd7-dadf26c26964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_ProceedsFromCollaborators_ea3d133f-a4b8-4bc8-bfd7-dadf26c26964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty_e49fa0b2-b39e-4474-bc61-cc62d9fcfec3" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty_e49fa0b2-b39e-4474-bc61-cc62d9fcfec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_d8a46f70-b1a9-4178-9279-a7704b2e126a" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_d8a46f70-b1a9-4178-9279-a7704b2e126a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_5cb6a778-2cb9-4bfa-9ed1-8b8267e8bac5" xlink:href="sgmo-20230331.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_5cb6a778-2cb9-4bfa-9ed1-8b8267e8bac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_3fbd07d0-9397-4a42-9451-752d131f3bac" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_3fbd07d0-9397-4a42-9451-752d131f3bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount_1afc1cc1-ae21-4faa-b5d2-ce5b965084fd" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount_1afc1cc1-ae21-4faa-b5d2-ce5b965084fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired_94e13afe-3943-4ce2-ac4b-59d401a7679c" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired_94e13afe-3943-4ce2-ac4b-59d401a7679c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding_ecd26ee6-5e71-453b-981f-a4b127611cd4" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding_ecd26ee6-5e71-453b-981f-a4b127611cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_eb85ee5c-3c58-4655-b83e-d787691b9a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_eb85ee5c-3c58-4655-b83e-d787691b9a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e5b3eb6a-a4d7-4ff6-af76-ef74720a8051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e5b3eb6a-a4d7-4ff6-af76-ef74720a8051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_841ff4f2-c3c8-4ff7-b9eb-4abb7cc9107c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_841ff4f2-c3c8-4ff7-b9eb-4abb7cc9107c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_067a4044-5cb3-4ed3-8dd9-9beb877d060e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_067a4044-5cb3-4ed3-8dd9-9beb877d060e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_3588a1b1-d328-4db9-8bd7-dffabf688301" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_3588a1b1-d328-4db9-8bd7-dffabf688301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_0928a758-8bff-4493-a0bf-c5cbeac362fc" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_0928a758-8bff-4493-a0bf-c5cbeac362fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_5db1e25d-e1c0-410e-b400-0273e1fc2b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_5db1e25d-e1c0-410e-b400-0273e1fc2b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3d78f7d2-0774-4c78-afa4-4e2ef527ad47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3d78f7d2-0774-4c78-afa4-4e2ef527ad47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fbcfdde6-6ada-4b2a-9a93-4b0e20fa7c06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_26a95bd4-1245-4156-b2f1-7b97222a4f3e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fbcfdde6-6ada-4b2a-9a93-4b0e20fa7c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7790750-aed3-4c3d-8db2-31218bd99f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e7790750-aed3-4c3d-8db2-31218bd99f78" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_68055219-362a-4f8e-9f79-0ff846584118" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:to="loc_srt_CounterpartyNameAxis_68055219-362a-4f8e-9f79-0ff846584118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0c1c99f-a0d4-4ad7-b1a5-df420675a775" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_68055219-362a-4f8e-9f79-0ff846584118" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0c1c99f-a0d4-4ad7-b1a5-df420675a775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_cc9ad424-9d61-4258-b19a-23acb401f4f8" xlink:href="sgmo-20230331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d0c1c99f-a0d4-4ad7-b1a5-df420675a775" xlink:to="loc_sgmo_KitePharmaIncMember_cc9ad424-9d61-4258-b19a-23acb401f4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6ae57d48-7e03-4dcc-90d3-40be0aef1599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6ae57d48-7e03-4dcc-90d3-40be0aef1599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8ca1763-91fa-4cfd-8df2-edd0980befaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6ae57d48-7e03-4dcc-90d3-40be0aef1599" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8ca1763-91fa-4cfd-8df2-edd0980befaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_95d067d4-a167-4159-a602-c400e944bcc7" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b8ca1763-91fa-4cfd-8df2-edd0980befaf" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_95d067d4-a167-4159-a602-c400e944bcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1e7e0d74-4dc7-4621-a4d9-6f76baaea2fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:to="loc_srt_RangeAxis_1e7e0d74-4dc7-4621-a4d9-6f76baaea2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_462309c4-33a8-4052-9c3a-b47b9236b053" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1e7e0d74-4dc7-4621-a4d9-6f76baaea2fb" xlink:to="loc_srt_RangeMember_462309c4-33a8-4052-9c3a-b47b9236b053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f4943f9f-5045-46b7-bb97-58658cb7ac26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_462309c4-33a8-4052-9c3a-b47b9236b053" xlink:to="loc_srt_MaximumMember_f4943f9f-5045-46b7-bb97-58658cb7ac26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a117a1d-0491-4ce8-a2e8-fb75c8587053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a117a1d-0491-4ce8-a2e8-fb75c8587053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_70b8402e-f842-4e4e-aea2-97ff7d2496a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_3a117a1d-0491-4ce8-a2e8-fb75c8587053" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_70b8402e-f842-4e4e-aea2-97ff7d2496a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_4d69d668-b7ce-4b80-9e75-c3f037988065" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_70b8402e-f842-4e4e-aea2-97ff7d2496a8" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_4d69d668-b7ce-4b80-9e75-c3f037988065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_c88d3f07-f94c-4d45-89c3-f20e81f53234" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_70b8402e-f842-4e4e-aea2-97ff7d2496a8" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_c88d3f07-f94c-4d45-89c3-f20e81f53234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9a2aa17b-b4f1-49e8-868e-9dc04e150014" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:to="loc_srt_ProductOrServiceAxis_9a2aa17b-b4f1-49e8-868e-9dc04e150014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_01ff71d4-caf7-491c-88d0-a646a6c4b772" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9a2aa17b-b4f1-49e8-868e-9dc04e150014" xlink:to="loc_srt_ProductsAndServicesDomain_01ff71d4-caf7-491c-88d0-a646a6c4b772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_187aa7e2-874f-42e1-ba49-421dbb8d03c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_01ff71d4-caf7-491c-88d0-a646a6c4b772" xlink:to="loc_us-gaap_LicenseAndServiceMember_187aa7e2-874f-42e1-ba49-421dbb8d03c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_8bad8a26-a224-40e5-b668-8722c71fd9a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_727c0f25-8471-4b85-a80b-7fdf4d1706b2" xlink:href="sgmo-20230331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_MilestonePaymentsReceived_727c0f25-8471-4b85-a80b-7fdf4d1706b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_187d516b-1a5e-4214-9262-a0962fef6780" xlink:href="sgmo-20230331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_187d516b-1a5e-4214-9262-a0962fef6780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_9ea48076-bfac-4833-953e-3432d3d73a4c" xlink:href="sgmo-20230331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_9ea48076-bfac-4833-953e-3432d3d73a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment_08f311c1-5e03-4a04-9511-acd60a3c4553" xlink:href="sgmo-20230331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment_08f311c1-5e03-4a04-9511-acd60a3c4553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_98c6a20a-08d0-44d9-b32f-06c3ac6ed001" xlink:href="sgmo-20230331.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_98c6a20a-08d0-44d9-b32f-06c3ac6ed001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_de5aac44-78e4-44d9-ab5e-12578ae209bd" xlink:href="sgmo-20230331.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_de5aac44-78e4-44d9-ab5e-12578ae209bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_23158113-8293-4f83-8da9-f575e1792adf" xlink:href="sgmo-20230331.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_23158113-8293-4f83-8da9-f575e1792adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_faefef47-6c58-4cc4-b51c-4259b487db47" xlink:href="sgmo-20230331.xsd#sgmo_SeparateUpfrontFee"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_SeparateUpfrontFee_faefef47-6c58-4cc4-b51c-4259b487db47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_626da2cb-a1c6-44bc-934e-99a89423b523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_us-gaap_ContractWithCustomerLiability_626da2cb-a1c6-44bc-934e-99a89423b523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueNumberOfRemainingPerformanceObligations_32c9279a-8d8c-4db6-b436-0256c84dc63b" xlink:href="sgmo-20230331.xsd#sgmo_RevenueNumberOfRemainingPerformanceObligations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_RevenueNumberOfRemainingPerformanceObligations_32c9279a-8d8c-4db6-b436-0256c84dc63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod_d68aeb65-43db-4de7-80e2-2a0a8b31d4ae" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod_d68aeb65-43db-4de7-80e2-2a0a8b31d4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod_ae3d32be-8fb6-48b3-8cd3-26dd26215ecb" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationRenewalPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod_ae3d32be-8fb6-48b3-8cd3-26dd26215ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount_8aff5fc3-aad3-4834-b9e4-93c50dc19df1" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount_8aff5fc3-aad3-4834-b9e4-93c50dc19df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_617a9c7e-badc-4744-b384-51cae356ac55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_617a9c7e-badc-4744-b384-51cae356ac55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_825d7cef-c985-4351-976b-06eb589a69f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_825d7cef-c985-4351-976b-06eb589a69f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount_2c74ae36-c5d7-4471-b74d-738216d6e717" xlink:href="sgmo-20230331.xsd#sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount_2c74ae36-c5d7-4471-b74d-738216d6e717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_3da49baf-3859-4f39-b0ce-94042cfbd3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_3da49baf-3859-4f39-b0ce-94042cfbd3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_eaedecb4-d4a6-4443-a922-08639fbc8861" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent_eaedecb4-d4a6-4443-a922-08639fbc8861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_9ec327e0-aa31-42f6-aefd-2efe0d762402" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareBasic"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareBasic_9ec327e0-aa31-42f6-aefd-2efe0d762402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_a1b91224-40a2-4444-b2af-73ac2c0385d9" xlink:href="sgmo-20230331.xsd#sgmo_IncreaseDecreaseInEarningsPerShareDiluted"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_62a7a6d4-010f-4deb-9e23-6df7c8df06de" xlink:to="loc_sgmo_IncreaseDecreaseInEarningsPerShareDiluted_a1b91224-40a2-4444-b2af-73ac2c0385d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fc3b68cf-f3f4-4e60-b7d8-1d8ad40cb2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fc3b68cf-f3f4-4e60-b7d8-1d8ad40cb2cb" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fab1607e-833f-43ec-aa7a-22d01fc41892" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:to="loc_srt_CounterpartyNameAxis_fab1607e-833f-43ec-aa7a-22d01fc41892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af6ffa0a-0c95-47d5-a51e-080db23fd5a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fab1607e-833f-43ec-aa7a-22d01fc41892" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af6ffa0a-0c95-47d5-a51e-080db23fd5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_cd4e7e2a-f4f9-4ea0-9f99-72afd7ea929a" xlink:href="sgmo-20230331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_af6ffa0a-0c95-47d5-a51e-080db23fd5a5" xlink:to="loc_sgmo_SanofiMember_cd4e7e2a-f4f9-4ea0-9f99-72afd7ea929a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_91ecd138-16ee-4b7b-8c4f-ed50b0a81d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:to="loc_us-gaap_TypeOfArrangementAxis_91ecd138-16ee-4b7b-8c4f-ed50b0a81d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50732d4e-d62f-4dd7-94ae-1aa469213ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_91ecd138-16ee-4b7b-8c4f-ed50b0a81d34" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50732d4e-d62f-4dd7-94ae-1aa469213ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_0ad0775c-3976-4aa9-92d2-3ad0f701aaa9" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50732d4e-d62f-4dd7-94ae-1aa469213ee2" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_0ad0775c-3976-4aa9-92d2-3ad0f701aaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_f20cfbb1-bfe9-4db5-8268-bf3375b6b227" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_f20cfbb1-bfe9-4db5-8268-bf3375b6b227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_e3cc202a-e646-4352-8ecd-41565cd056ab" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_f20cfbb1-bfe9-4db5-8268-bf3375b6b227" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_e3cc202a-e646-4352-8ecd-41565cd056ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_da0c1fb4-1b73-459b-b95c-0b14e612443c" xlink:href="sgmo-20230331.xsd#sgmo_MilestoneThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e3cc202a-e646-4352-8ecd-41565cd056ab" xlink:to="loc_sgmo_MilestoneThreeMember_da0c1fb4-1b73-459b-b95c-0b14e612443c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8a266bb8-3ab7-4539-87e3-18430c3ecd43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8a266bb8-3ab7-4539-87e3-18430c3ecd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e18b5830-4877-4f8d-8250-fe80eb7fbb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8a266bb8-3ab7-4539-87e3-18430c3ecd43" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e18b5830-4877-4f8d-8250-fe80eb7fbb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8363bc62-29a2-4818-ad19-2fe97493b455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e18b5830-4877-4f8d-8250-fe80eb7fbb5a" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_8363bc62-29a2-4818-ad19-2fe97493b455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_df8608a2-e233-4aaa-aff6-93ed70165f31" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_ae334feb-7644-4bbe-9a5c-f2025b430963" xlink:href="sgmo-20230331.xsd#sgmo_NumberOfResearchProgram"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_NumberOfResearchProgram_ae334feb-7644-4bbe-9a5c-f2025b430963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c94029cb-d365-44db-b878-5abffd1f6ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c94029cb-d365-44db-b878-5abffd1f6ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f9d5dbd6-a0d4-40ac-8486-fd6a9c2bce7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f9d5dbd6-a0d4-40ac-8486-fd6a9c2bce7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_ef3f248b-f5ec-4a78-b167-2b372964d70d" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_ef3f248b-f5ec-4a78-b167-2b372964d70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_1474b1de-1b7d-4a79-9146-d3d8c91d85ca" xlink:href="sgmo-20230331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_1474b1de-1b7d-4a79-9146-d3d8c91d85ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate_fa590200-419c-4f8c-8d56-cb23b8a57292" xlink:href="sgmo-20230331.xsd#sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate_fa590200-419c-4f8c-8d56-cb23b8a57292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate_d6be7c78-02f2-46be-a0fc-40fff80e1659" xlink:href="sgmo-20230331.xsd#sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate_d6be7c78-02f2-46be-a0fc-40fff80e1659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_c078d00d-52b1-479f-9ed3-00d5e4ae0ea8" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_c078d00d-52b1-479f-9ed3-00d5e4ae0ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_c018c4c5-efef-4481-a444-4c1e4de541e0" xlink:href="sgmo-20230331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_MilestoneRevenueReceivable_c018c4c5-efef-4481-a444-4c1e4de541e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_15fd2ff7-f6fc-4fcd-ad66-01f5d0f5510a" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_15fd2ff7-f6fc-4fcd-ad66-01f5d0f5510a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_75afbd26-5f1b-48b9-bb38-781cbdb9c397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_75afbd26-5f1b-48b9-bb38-781cbdb9c397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_9470c5e4-f7f2-481d-8adb-163eccf92618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_9470c5e4-f7f2-481d-8adb-163eccf92618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense_4fd33bb3-df20-4966-a090-891e79b2a101" xlink:href="sgmo-20230331.xsd#sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6c6be1b2-025d-4847-bc85-e2271ff02dc6" xlink:to="loc_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense_4fd33bb3-df20-4966-a090-891e79b2a101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c37c187b-223b-42ac-b659-8806b9a162eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c37c187b-223b-42ac-b659-8806b9a162eb" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_012ba237-5e02-4445-8a15-ff29882ce9bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:to="loc_srt_CounterpartyNameAxis_012ba237-5e02-4445-8a15-ff29882ce9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82ee7f4c-8db4-4edd-8764-07b93cdac789" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_012ba237-5e02-4445-8a15-ff29882ce9bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82ee7f4c-8db4-4edd-8764-07b93cdac789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_57ceb315-cf7b-4713-997f-a2442fe7184d" xlink:href="sgmo-20230331.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82ee7f4c-8db4-4edd-8764-07b93cdac789" xlink:to="loc_sgmo_PfizerMember_57ceb315-cf7b-4713-997f-a2442fe7184d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_c4df3a25-2535-4dab-b7e7-d6cd119d0e24" xlink:href="sgmo-20230331.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82ee7f4c-8db4-4edd-8764-07b93cdac789" xlink:to="loc_sgmo_PfizerSB525Member_c4df3a25-2535-4dab-b7e7-d6cd119d0e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_bb1ddab3-d2bf-4627-aed7-697c3ee56806" xlink:href="sgmo-20230331.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82ee7f4c-8db4-4edd-8764-07b93cdac789" xlink:to="loc_sgmo_PfizerC9ORF72Member_bb1ddab3-d2bf-4627-aed7-697c3ee56806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_61c31ea8-ebf7-412a-9450-397a7a5439d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:to="loc_srt_ProductOrServiceAxis_61c31ea8-ebf7-412a-9450-397a7a5439d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_61c31ea8-ebf7-412a-9450-397a7a5439d5" xlink:to="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_7304894b-9a36-4805-81b5-4f518282b429" xlink:href="sgmo-20230331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_7304894b-9a36-4805-81b5-4f518282b429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_6ab337a3-e9a0-4176-8368-810dc04f28ee" xlink:href="sgmo-20230331.xsd#sgmo_OtherProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:to="loc_sgmo_OtherProductsMember_6ab337a3-e9a0-4176-8368-810dc04f28ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_29b750be-e31a-411a-afe9-5b355c71d151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:to="loc_us-gaap_LicenseAndServiceMember_29b750be-e31a-411a-afe9-5b355c71d151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_b2a092dd-2e78-43bf-9d3a-02bc688e60c2" xlink:href="sgmo-20230331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78cadef7-ae5c-4bca-a355-d6a1598dcb94" xlink:to="loc_sgmo_CNineORFSevenTwoMember_b2a092dd-2e78-43bf-9d3a-02bc688e60c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57811b4b-31e9-43fb-89fc-b2cdbb3f4494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57811b4b-31e9-43fb-89fc-b2cdbb3f4494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_57811b4b-31e9-43fb-89fc-b2cdbb3f4494" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_dfe2733e-8634-4bac-bd52-fbd14cb56a1d" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_dfe2733e-8634-4bac-bd52-fbd14cb56a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_632e3a80-6517-4c04-aa3e-9e326e5ba63d" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_632e3a80-6517-4c04-aa3e-9e326e5ba63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_45fb1499-6d6c-4932-8dac-1e7b34377e0e" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_45fb1499-6d6c-4932-8dac-1e7b34377e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_b04d618e-27bd-4e8f-8f1d-c739aa1c898a" xlink:href="sgmo-20230331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7f2a25ef-24b4-47a0-8767-bc047b2d524c" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_b04d618e-27bd-4e8f-8f1d-c739aa1c898a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_061d114a-7a46-4416-86e9-0895f52934c8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:to="loc_srt_RangeAxis_061d114a-7a46-4416-86e9-0895f52934c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_93519031-39df-4ca2-ac87-d9a352164c5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_061d114a-7a46-4416-86e9-0895f52934c8" xlink:to="loc_srt_RangeMember_93519031-39df-4ca2-ac87-d9a352164c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4a77ce48-d550-4d7e-9227-a26a60612bfd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_93519031-39df-4ca2-ac87-d9a352164c5d" xlink:to="loc_srt_MinimumMember_4a77ce48-d550-4d7e-9227-a26a60612bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dc84d6e7-2208-45d7-9d42-42254e95313b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_93519031-39df-4ca2-ac87-d9a352164c5d" xlink:to="loc_srt_MaximumMember_dc84d6e7-2208-45d7-9d42-42254e95313b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_295166bc-3123-4115-a785-f8d2bc26de27" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_386c04a3-9763-477b-ada0-af1898cb3192" xlink:href="sgmo-20230331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_AgreementTerminationTerm_386c04a3-9763-477b-ada0-af1898cb3192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_26739daa-38f1-4d74-a58d-f410711294f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_26739daa-38f1-4d74-a58d-f410711294f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_3df87079-c62e-47d6-8b88-13653ed0c7dc" xlink:href="sgmo-20230331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_3df87079-c62e-47d6-8b88-13653ed0c7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_2ead4910-6d70-42d1-b6b0-7162f395a600" xlink:href="sgmo-20230331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_2ead4910-6d70-42d1-b6b0-7162f395a600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_fc37b36d-bd1b-41e3-9a14-05e53b494385" xlink:href="sgmo-20230331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_MilestoneRevenueReceivable_fc37b36d-bd1b-41e3-9a14-05e53b494385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_5fd7653a-0679-4330-bf31-00ac282d379a" xlink:href="sgmo-20230331.xsd#sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty_5fd7653a-0679-4330-bf31-00ac282d379a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_c599cae1-f7c4-4274-89c3-228c7a517a0b" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_c599cae1-f7c4-4274-89c3-228c7a517a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_3850520f-f951-4ab2-aed0-a31cc7f05eb0" xlink:href="sgmo-20230331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_MilestonePaymentsReceived_3850520f-f951-4ab2-aed0-a31cc7f05eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_06efa595-00dd-49dd-b870-6e5113f9e239" xlink:href="sgmo-20230331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_06efa595-00dd-49dd-b870-6e5113f9e239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_833ff1b1-751b-4e03-854a-ff8799505dea" xlink:href="sgmo-20230331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_833ff1b1-751b-4e03-854a-ff8799505dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_2dba85ed-49ef-4cf1-90e1-212a8a1f75a8" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_2dba85ed-49ef-4cf1-90e1-212a8a1f75a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_9fbc3068-fd6f-4202-9ac8-aa6e9cb9129f" xlink:href="sgmo-20230331.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_9fbc3068-fd6f-4202-9ac8-aa6e9cb9129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8964b5d7-1c15-4ba5-9064-5770d4572701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_65b4ff18-e91a-4476-a324-ba02e51eff51" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8964b5d7-1c15-4ba5-9064-5770d4572701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b7c375d-a313-4bce-a884-ccc1a4e65179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_5aee82cc-536f-437f-84c2-3d22e98e6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3b7c375d-a313-4bce-a884-ccc1a4e65179" xlink:to="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_5aee82cc-536f-437f-84c2-3d22e98e6e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_41271fa4-4b65-4b12-96b2-7c424fe1272b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_5aee82cc-536f-437f-84c2-3d22e98e6e06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_41271fa4-4b65-4b12-96b2-7c424fe1272b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9ce6c46-9549-4307-88df-65ae1cea97d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_41271fa4-4b65-4b12-96b2-7c424fe1272b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9ce6c46-9549-4307-88df-65ae1cea97d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_be9d2df8-e0fb-407c-b83c-1d8f67712d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9ce6c46-9549-4307-88df-65ae1cea97d4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_be9d2df8-e0fb-407c-b83c-1d8f67712d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_cedb43e4-1097-4622-a98d-a06f19b5f331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9ce6c46-9549-4307-88df-65ae1cea97d4" xlink:to="loc_us-gaap_ConstructionInProgressMember_cedb43e4-1097-4622-a98d-a06f19b5f331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable_5aee82cc-536f-437f-84c2-3d22e98e6e06" xlink:to="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_542bafb8-d7bc-4c0b-a758-259281cef4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_542bafb8-d7bc-4c0b-a758-259281cef4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LongLivedAssetsNumberOfAssetsGroups_ad0da4cb-757b-4269-8658-4cf2dadd826f" xlink:href="sgmo-20230331.xsd#sgmo_LongLivedAssetsNumberOfAssetsGroups"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:to="loc_sgmo_LongLivedAssetsNumberOfAssetsGroups_ad0da4cb-757b-4269-8658-4cf2dadd826f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_fc9a4e45-3a8c-4d4b-8661-8a58e90d0532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_fc9a4e45-3a8c-4d4b-8661-8a58e90d0532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_904de25f-ef45-400d-b5fb-0d0fbc33ca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems_001920d2-636f-40d8-bdc9-6489531159af" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_904de25f-ef45-400d-b5fb-0d0fbc33ca2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1baeb1b4-d4fe-4e6b-991f-26bfd0ecd7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_938327fc-e7c4-4d9a-b2fd-3fb017826972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1baeb1b4-d4fe-4e6b-991f-26bfd0ecd7ed" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_938327fc-e7c4-4d9a-b2fd-3fb017826972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_91d12888-2259-4f80-bd40-ede91fa584c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_938327fc-e7c4-4d9a-b2fd-3fb017826972" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_91d12888-2259-4f80-bd40-ede91fa584c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c4a5922c-f5ea-44b5-8e41-a7f5ee1c382c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_91d12888-2259-4f80-bd40-ede91fa584c9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c4a5922c-f5ea-44b5-8e41-a7f5ee1c382c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_73450ac1-6a44-4be2-8f71-e2dcbf7132d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c4a5922c-f5ea-44b5-8e41-a7f5ee1c382c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_73450ac1-6a44-4be2-8f71-e2dcbf7132d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8add0e53-2390-4171-85fd-9704c1f9dd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c4a5922c-f5ea-44b5-8e41-a7f5ee1c382c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8add0e53-2390-4171-85fd-9704c1f9dd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa880639-008d-4cb3-8c3c-2b62cec9bf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_938327fc-e7c4-4d9a-b2fd-3fb017826972" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa880639-008d-4cb3-8c3c-2b62cec9bf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9e3d741-94ce-4bfd-b1d7-1211da57b0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa880639-008d-4cb3-8c3c-2b62cec9bf6c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9e3d741-94ce-4bfd-b1d7-1211da57b0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a8ac62b4-fa89-4c67-be1f-6a4f577d15c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_446cf035-bfe0-4a8a-9e97-73e996e7e448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a8ac62b4-fa89-4c67-be1f-6a4f577d15c9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_446cf035-bfe0-4a8a-9e97-73e996e7e448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9f17713a-71dc-4376-9b7f-9b5bf557ac85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_446cf035-bfe0-4a8a-9e97-73e996e7e448" xlink:to="loc_srt_CounterpartyNameAxis_9f17713a-71dc-4376-9b7f-9b5bf557ac85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfc5a17e-d967-4c4f-90b9-56cf958b5f57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9f17713a-71dc-4376-9b7f-9b5bf557ac85" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfc5a17e-d967-4c4f-90b9-56cf958b5f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_3e60c5c0-72ee-4413-856e-dce1a159828a" xlink:href="sgmo-20230331.xsd#sgmo_JefferiesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cfc5a17e-d967-4c4f-90b9-56cf958b5f57" xlink:to="loc_sgmo_JefferiesLLCMember_3e60c5c0-72ee-4413-856e-dce1a159828a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8d4fa1bd-290c-4e93-a59f-fc4bd7498d75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_446cf035-bfe0-4a8a-9e97-73e996e7e448" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8d4fa1bd-290c-4e93-a59f-fc4bd7498d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d622d476-add9-46d0-8395-e583e6e147b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8d4fa1bd-290c-4e93-a59f-fc4bd7498d75" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d622d476-add9-46d0-8395-e583e6e147b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_b98b52fd-4726-4a34-8a03-3566ca7fce3a" xlink:href="sgmo-20230331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d622d476-add9-46d0-8395-e583e6e147b4" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_b98b52fd-4726-4a34-8a03-3566ca7fce3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_07cc26bc-c327-4b7e-953d-25b5c6bc5b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_446cf035-bfe0-4a8a-9e97-73e996e7e448" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_07cc26bc-c327-4b7e-953d-25b5c6bc5b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0911a948-96ed-4088-8579-1a44b07913cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_07cc26bc-c327-4b7e-953d-25b5c6bc5b00" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0911a948-96ed-4088-8579-1a44b07913cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6c9171cf-cd58-497f-8541-d26cdfc2b12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0911a948-96ed-4088-8579-1a44b07913cd" xlink:to="loc_us-gaap_SubsequentEventMember_6c9171cf-cd58-497f-8541-d26cdfc2b12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_446cf035-bfe0-4a8a-9e97-73e996e7e448" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_47ead966-4cda-4faf-b43d-dc1405c4ab88" xlink:href="sgmo-20230331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_47ead966-4cda-4faf-b43d-dc1405c4ab88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_0f08f877-92d5-4b93-925d-47d090d0bbe7" xlink:href="sgmo-20230331.xsd#sgmo_SaleOfStockIncreaseToAggregateOfferingPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:to="loc_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice_0f08f877-92d5-4b93-925d-47d090d0bbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dd492e1b-b0ea-4a8a-8718-1c065bdb6277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dd492e1b-b0ea-4a8a-8718-1c065bdb6277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9d41fa17-bf28-4b5c-ae40-ef68d1aadf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd10e8d-9164-481d-aaff-80495fd4e05c" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9d41fa17-bf28-4b5c-ae40-ef68d1aadf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_60771553-754a-4b86-b41f-a647e628c746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c753cb00-8538-4209-8f49-f29444d97a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_60771553-754a-4b86-b41f-a647e628c746" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c753cb00-8538-4209-8f49-f29444d97a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sgmo-20230331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_effe21bd-6d9b-4a3d-9b80-fbf3ebcd0c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_38187333-3623-44ba-8192-4557ed1dcd97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_effe21bd-6d9b-4a3d-9b80-fbf3ebcd0c5c" xlink:to="loc_us-gaap_SubsequentEventTable_38187333-3623-44ba-8192-4557ed1dcd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5af685fe-578f-400a-aaf7-57cd46a29199" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_38187333-3623-44ba-8192-4557ed1dcd97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5af685fe-578f-400a-aaf7-57cd46a29199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9a1afe0d-1c69-42d4-a3bb-c3e89f8b980e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5af685fe-578f-400a-aaf7-57cd46a29199" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9a1afe0d-1c69-42d4-a3bb-c3e89f8b980e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b965f7d2-a34c-41a6-953c-fcdc09b913df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9a1afe0d-1c69-42d4-a3bb-c3e89f8b980e" xlink:to="loc_us-gaap_SubsequentEventMember_b965f7d2-a34c-41a6-953c-fcdc09b913df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ab13bb4b-2708-419e-b359-3914a848cfc7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_38187333-3623-44ba-8192-4557ed1dcd97" xlink:to="loc_srt_RangeAxis_ab13bb4b-2708-419e-b359-3914a848cfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4d49bd2-68a3-43b3-a284-7a118a6d42fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ab13bb4b-2708-419e-b359-3914a848cfc7" xlink:to="loc_srt_RangeMember_c4d49bd2-68a3-43b3-a284-7a118a6d42fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a71fe44-d0f7-45af-a3f0-dcffb38278bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c4d49bd2-68a3-43b3-a284-7a118a6d42fd" xlink:to="loc_srt_MinimumMember_5a71fe44-d0f7-45af-a3f0-dcffb38278bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d0639b3d-3d05-4e9e-b739-ce7ee8244a52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c4d49bd2-68a3-43b3-a284-7a118a6d42fd" xlink:to="loc_srt_MaximumMember_d0639b3d-3d05-4e9e-b739-ce7ee8244a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ba7d1b6f-4823-4b35-b2e9-1cec8919b077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_38187333-3623-44ba-8192-4557ed1dcd97" xlink:to="loc_us-gaap_SubsequentEventLineItems_ba7d1b6f-4823-4b35-b2e9-1cec8919b077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_473f712f-e6ba-411a-af98-54b0b24de50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_ba7d1b6f-4823-4b35-b2e9-1cec8919b077" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_473f712f-e6ba-411a-af98-54b0b24de50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_6b76d8f0-f973-43c5-b99f-b0a6621eaad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_ba7d1b6f-4823-4b35-b2e9-1cec8919b077" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_6b76d8f0-f973-43c5-b99f-b0a6621eaad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_14715093-42b8-4c80-adf5-ff2331f05a25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_ba7d1b6f-4823-4b35-b2e9-1cec8919b077" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_14715093-42b8-4c80-adf5-ff2331f05a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898075581776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Marina Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,825,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898073682512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 78,241<span></span>
</td>
<td class="nump">$ 100,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">127,146<span></span>
</td>
<td class="nump">177,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">7,026<span></span>
</td>
<td class="nump">3,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">13,651<span></span>
</td>
<td class="nump">18,223<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">227,087<span></span>
</td>
<td class="nump">300,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">35,610<span></span>
</td>
<td class="nump">29,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">59,877<span></span>
</td>
<td class="nump">63,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">51,555<span></span>
</td>
<td class="nump">50,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">48,696<span></span>
</td>
<td class="nump">62,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">16,242<span></span>
</td>
<td class="nump">17,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">440,567<span></span>
</td>
<td class="nump">562,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">19,920<span></span>
</td>
<td class="nump">22,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">12,949<span></span>
</td>
<td class="nump">21,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">15,395<span></span>
</td>
<td class="nump">16,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">9,575<span></span>
</td>
<td class="nump">51,780<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">57,839<span></span>
</td>
<td class="nump">111,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">109,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">37,701<span></span>
</td>
<td class="nump">38,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="nump">6,372<span></span>
</td>
<td class="nump">6,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,229<span></span>
</td>
<td class="nump">1,207<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">104,957<span></span>
</td>
<td class="nump">267,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">1,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,467,062<span></span>
</td>
<td class="nump">1,450,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,127,412)<span></span>
</td>
<td class="num">(1,148,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5,758)<span></span>
</td>
<td class="num">(8,404)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">335,610<span></span>
</td>
<td class="nump">294,958<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 440,567<span></span>
</td>
<td class="nump">$ 562,509<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898071018496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 157,957<span></span>
</td>
<td class="nump">$ 28,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">63,216<span></span>
</td>
<td class="nump">58,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,136<span></span>
</td>
<td class="nump">14,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">38,138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">20,433<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">139,923<span></span>
</td>
<td class="nump">73,492<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">18,034<span></span>
</td>
<td class="num">(45,261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">3,293<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">21,327<span></span>
</td>
<td class="num">(43,919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 21,133<span></span>
</td>
<td class="num">$ (43,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract', window );"><strong>Shares used in computing net income (loss) per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">168,533<span></span>
</td>
<td class="nump">146,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">169,181<span></span>
</td>
<td class="nump">146,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic And Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number Of Shares Outstanding, Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898073675120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 21,133<span></span>
</td>
<td class="num">$ (43,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="num">(1,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension (loss) gain</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities, net of tax</a></td>
<td class="nump">604<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 23,779<span></span>
</td>
<td class="num">$ (46,945)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898074048560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,921,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 375,343<span></span>
</td>
<td class="nump">$ 1,459<span></span>
</td>
<td class="nump">$ 1,334,138<span></span>
</td>
<td class="num">$ (956,267)<span></span>
</td>
<td class="num">$ (3,987)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="num">(1,567)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">(1,575)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension (loss) gain</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities, net of tax</a></td>
<td class="num">(1,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(43,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,664,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">334,522<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">1,340,254<span></span>
</td>
<td class="num">(1,000,244)<span></span>
</td>
<td class="num">(6,955)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,793,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">294,958<span></span>
</td>
<td class="nump">$ 1,668<span></span>
</td>
<td class="nump">1,450,239<span></span>
</td>
<td class="num">(1,148,545)<span></span>
</td>
<td class="num">(8,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,962,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with at-the-market offering, net of offering expenses</a></td>
<td class="nump">9,705<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">9,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,015,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="num">(1,109)<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(1,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension (loss) gain</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities, net of tax</a></td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">21,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,771,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 335,610<span></span>
</td>
<td class="nump">$ 1,718<span></span>
</td>
<td class="nump">$ 1,467,062<span></span>
</td>
<td class="num">$ (1,127,412)<span></span>
</td>
<td class="num">$ (5,758)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898071460720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 21,133<span></span>
</td>
<td class="num">$ (43,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">38,138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">20,433<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,489<span></span>
</td>
<td class="nump">2,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">(Accretion of discounts) amortization of premium on marketable securities</a></td>
<td class="num">(1,048)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets', window );">Amortization and other changes in operating lease right-of-use assets</a></td>
<td class="nump">2,092<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8,277<span></span>
</td>
<td class="nump">7,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(3,348)<span></span>
</td>
<td class="num">(925)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">6,223<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="num">(1,905)<span></span>
</td>
<td class="nump">3,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(8,599)<span></span>
</td>
<td class="num">(8,270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="num">(149,766)<span></span>
</td>
<td class="num">(21,004)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(1,212)<span></span>
</td>
<td class="num">(972)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(66,300)<span></span>
</td>
<td class="num">(58,975)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(36,225)<span></span>
</td>
<td class="num">(65,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">82,153<span></span>
</td>
<td class="nump">70,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(10,200)<span></span>
</td>
<td class="num">(2,839)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">35,728<span></span>
</td>
<td class="nump">1,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(1,109)<span></span>
</td>
<td class="num">(1,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">8,002<span></span>
</td>
<td class="num">(1,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(22,203)<span></span>
</td>
<td class="num">(58,615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">101,944<span></span>
</td>
<td class="nump">180,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">79,741<span></span>
</td>
<td class="nump">121,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in unpaid liabilities</a></td>
<td class="nump">5,184<span></span>
</td>
<td class="nump">2,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability', window );">Tenant improvement allowance included in contra-lease liability</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingMember', window );">At the Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at-the market offering/ issuance of common stock</a></td>
<td class="nump">$ 9,111<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization And Other Changes In Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AmortizationAndOtherChangesInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_TenantImprovementAllowanceWithinContraLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant Improvement, Allowance Within Contra Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_TenantImprovementAllowanceWithinContraLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898078930768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The Condensed Consolidated Balance Sheet data at December&#160;31, 2022 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;2022 Annual Report&#8221;) as filed with the SEC on February&#160;23,&#160;2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2022, included in the 2022 Annual Report.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity, Capital Resources and Management&#8217;s Plans</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. In recent years, the Company&#8217;s operations have been funded primarily through collaborations and strategic partnerships, research grants and from the issuance of equity securities. As of March&#160;31, 2023, the Company had capital resources of $241.0&#160;million consisting of cash, cash equivalents, and marketable securities. Management believes that the Company&#8217;s existing cash, cash equivalents, and marketable securities in combination with other planned cost reduction initiatives will be sufficient to fund its operations for at least the next 12 months from the date these Condensed Consolidated Financial Statements are issued.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standard Codification (&#8220;ASC&#8221;) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements&#8212;Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 205-40&#8221;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the Condensed Consolidated Financial Statements are issued. As required under ASC Topic 205-40, management&#8217;s evaluation should initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the Condensed Consolidated Financial Statements are issued. </span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Substantial Doubt Raised</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the first step of the evaluation, the Company concluded that the following conditions raised substantial doubt about its ability to continue as a going concern:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although the Company reported net income of $21.1&#160;million for the three months ended March 31, 2023 primarily due to the termination of a collaboration agreement, the Company has a history of recurring net losses, including $192.3&#160;million and $178.3&#160;million for the years ended December 31, 2022 and 2021, respectively; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company had an accumulated deficit of $1,127.4&#160;million and $1,148.5&#160;million as of March&#160;31, 2023 and December 31, 2022, respectively.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consideration of Management&#8217;s Plans</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing the second step of this assessment, the Company is required to evaluate whether it is probable that its plans will be effectively implemented within one year after the Condensed Consolidated Financial Statements are issued and whether it is probable those plans will alleviate the substantial doubt about its ability to continue as a going concern.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified several actions, including cost reduction measures that already have been initiated or that would be initiated in a timely manner, to address the Company&#8217;s liquidity needs over the twelve-month period from the date the Condensed Consolidated Financial Statements are issued, as follows:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Deferral and reprioritization of certain research and development programs that would involve reduced program and headcount spend;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduction in force that would be intended to extend the cash runway necessary to fund operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pause on any new hiring and reduction in ancillary expenses such as travel and recruitment expenses; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduction in non-critical capital and operating expenditures including additional equipment, lab improvements, efficiency projects, and business support spend.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Assessment of Ability to Continue as a Going Concern</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes management&#8217;s plans, as described more fully above, will provide sufficient liquidity to meet its financial obligations and maintain levels of liquidity over the twelve-month period from the date the Condensed Consolidated Financial Statements are issued. Therefore, management has concluded these plans alleviate the substantial doubt that was raised about the Company&#8217;s ability to continue as a going concern for at least twelve months from the date that the Condensed Consolidated Financial Statements are issued. Determining the extent to which conditions or events raise substantial doubt about the Company&#8217;s ability to continue as a going concern and the extent to which mitigating plans sufficiently alleviate any such substantial doubt requires significant judgment and estimation by the Company. The Company makes assumptions that management&#8217;s plans will be effectively implemented and alleviate substantial doubt and its ability to continue as a going concern. The Company believes that the estimated values used in its going concern analysis are based on reasonable assumptions. However, such assumptions are inherently uncertain and actual results could differ materially from those estimates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Plans and Considerations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be required to raise substantial additional capital to fund its operations and support its research and development endeavors. In this regard, the Company is actively seeking substantial additional capital, including through public or private equity or debt financings, royalty financings or other sources, such as strategic collaborations. However, additional capital may not be available to the Company, on terms that are acceptable or at all. If adequate funds are not available to the Company on a timely basis, or at all, the Company will be required to take additional actions to address its liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering its research and development activities, which could have a material adverse effect on the Company&#8217;s business. If the Company raises additional capital through public or private equity offerings, including sales pursuant to the Company&#8217;s at-the-market offering program with Jefferies LLC, the ownership interest of its existing stockholders will be diluted, and such dilution may be substantial, and the terms of any new equity securities may have a preference over, and include rights superior to, the Company&#8217;s common stock. If the Company raises additional capital through royalty financings or other collaborations, strategic alliances or licensing arrangements with third parties, it may need to relinquish certain valuable rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable. If the Company raises additional capital through debt financing, the Company may be subject to specified financial covenants or covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or pursuing certain transactions, any of which could restrict the Company&#8217;s ability to commercialize its product candidates or operate as a business. In addition, management&#8217;s cost reduction plans are intended to reduce the Company&#8217;s operating expenses and optimize its cash resources. Based on the timing of these cost reduction plans, the Company expects to start realizing the benefit of its efforts beginning in the second quarter of 2023; however, there can be no assurance that the Company will realize the benefits of the cost reduction plans on the anticipated timeline, or at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Kite Pharma, Inc. This adjustment was driven by a reduction in the estimated future level of the Company&#8217;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of $8.9&#160;million, an increase in net income of $8.9&#160;million, and an increase in the Company&#8217;s basic and diluted earnings per share of $0.06 and $0.05, respectively, for the three months ended March 31, 2023.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and licensing agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#8217; product sales. All funds received from the Company&#8217;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. One of the Company&#8217;s contracts also contains a provision where the Company reimburses its customer for certain costs they incur which is accounted for as a reduction to the contract transaction price as the Company does not acquire any distinct goods or services in exchange for such payments. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the Company&#8217;s performance obligations in its collaboration agreements represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct. Options to license the Company&#8217;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g., a right to a discount the customer would not have received if they did not purchase the Company&#8217;s services under the existing contract. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from bundles of licenses of intellectual property and research and development services are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#8217;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#8217;s performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period of performance and level of effort, including the value of Company researchers&#8217; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current expectations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"/><td style="width:74.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi S.A.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill, Intangible Assets and Long-lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased in-process research and development (&#8220;IPR&amp;D&#8221;) projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events and circumstances indicate that these assets may be impaired. The Company evaluates the fair value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In testing for goodwill impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the Company elects to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, the Company performs a quantitative goodwill impairment test to compare the fair value of its reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit&#8217;s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value (but not in excess of the carrying value of goodwill). </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to testing goodwill for impairment, the Company also tests impairment for its other indefinite-lived and long-lived assets. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates that the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,241&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,444&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,257&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,872&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,741&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,944&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,757&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,372&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company will evaluate the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is recognized, the Company will recognize lease impairment and subsequently amortize the remaining lease asset on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#8217;s useful life or the end of the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898159208704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,756&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,853&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,033&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898077085248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">CASH EQUIVALENTS AND MARKETABLE SECURITIES</a></td>
<td class="text">CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,516&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,230&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,853&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:74.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,756&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no realized gains and losses on the sales of investments during the three months ended March&#160;31, 2023. Realized gains and losses on the sales of investments were not material during the three months ended March&#160;31, 2022. Total unrealized gains for securities with net gains in accumulated other comprehensive income were not material for the three months ended March&#160;31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">did not record an allowance for credit losses or other impairment charges related to its marketable securities for the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2023 and 2022. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that are in a continuous unrealized loss position for greater than 12 months as of March&#160;31, 2023 and December&#160;31, 2022. Based on the scheduled maturities of its investments, the Company determined that it was more likely than not that it will hold these investments for a period of time sufficient for a recovery of its amortized cost basis. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#8217;s ability and intent to hold the investments until maturity, the Company determined that no allowance for credit losses related to its marketable securities was required at either March&#160;31, 2023 or December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898077176224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</a></td>
<td class="text">BASIC AND DILUTED NET INCOME (LOSS) PER SHARE<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share has been computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,218&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The computation of diluted net income per share for the three months ended March&#160;31, 2023 excluded 14.7&#160;million shares subject to stock options because their inclusion would have had an anti-dilutive effect on diluted net income per share. The computation of diluted net loss per share for the three months ended March 31, 2022 excluded 19.1&#160;million shares subject to stock options, restricted stock units outstanding, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898077055792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</a></td>
<td class="text">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Institutes for BioMedical Research, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize certain of its zinc finger (&#8220;ZF&#8221;) transcriptional regulators (&#8220;ZF-TRs&#8221;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company was performing early research activities over the collaboration period for each gene target and manufacture the ZF-TRs required for such research, costs of which are funded by Novartis. Novartis was responsible for additional research activities, studies enabling INDs, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company was prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also had the option to license certain of the Company&#8217;s proprietary adeno-associated viruses (&#8220;AAVs&#8221;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Novartis notified the Company of its termination for convenience, effective June 11, 2023 (the &#8220;Novartis Termination Date&#8221;), of the collaboration agreement. Novartis has indicated to the Company that the termination relates to a recent strategic review. As of the Novartis Termination Date, the collaboration agreement will be terminated in its entirety and following the Novartis Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Novartis. As of the Novartis Termination Date, the parties will have no further obligations to develop or to fund the development of any collaboration research programs under the collaboration agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon entering the agreement, Novartis paid the Company a $75.0&#160;million upfront license fee. Novartis was also obligated to pay the Company for the use of its resources and reimburse third-party costs incurred in the Company&#8217;s conduct of early research activities. The Company was also eligible to earn from Novartis development and commercial milestones and royalties on potential commercial sales of licensed products arising from the collaboration, none of which have been triggered or earned. The agreement was going to continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments received under the agreement are non-refundable and non-creditable. The transaction price of $95.1&#160;million includes the upfront license fee of $75.0&#160;million and research costs of $20.1&#160;million. All clinical or regulatory milestone amounts were considered fully constrained throughout the term of the agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Novartis in accordance with ASC Topic 606 and concluded that Novartis was a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license was not discrete as it did not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notice of termination was accounted for as a modification of the contract, as it changed both the scope of the Company&#8217;s remaining services and the consideration to which the Company was entitled. The effect of the modification was not material, as the Company was nearing the completion of its assigned early research activities, and consequently, of its sole performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had a receivable of $2.1&#160;million and $2.2&#160;million, respectively, and deferred revenue of $1.9&#160;million and $9.6&#160;million, respectively, related to this agreement. The deferred revenue is expected to be recognized during the quarter ended June 30, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,755&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $1.5&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $75.0&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $1.5&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance is released into general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic&#160;340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC Topic&#160;340&#8221;). The Company recognized as expense $0.2&#160;million and $0.1&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies planned to leverage the Company&#8217;s proprietary ZF technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million. The collaboration agreement became effective in April 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Biogen notified the Company of its termination for convenience, effective June 15, 2023 (the &#8220;Biogen Termination Date&#8221;), of the collaboration agreement. Biogen has indicated to the Company that the termination relates to a recent strategic review. As of the Biogen Termination Date, the collaboration agreement will be terminated in its entirety and following the Biogen Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Biogen. As of the Biogen Termination Date, the parties will have no further obligations to develop or to fund the development of any collaboration research programs under the collaboration agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company was also eligible to receive target selection, research, development, regulatory and commercial milestone payments and royalties on potential net commercial sales of licensed products arising from the collaboration, none of which have been triggered or earned. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize ZF and/or AAV-based products directed to certain neurological disease gene targets selected by Biogen. Biogen had selected four targets over the course of the collaboration and had exclusive rights to nominate up to seven additional targets. These rights will expire upon the Biogen Termination Date. For each gene target selected by Biogen, the Company performed early research activities, costs of which were shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZF-TRs (or potential other ZF products) targeting therapeutically relevant genes. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price included the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represented the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the clinical or regulatory milestones were included in the transaction price, as all such amounts were fully constrained throughout the term of the collaboration agreement. The transaction price also included actual and estimated cost-sharing payments by Biogen for the work by Company researchers and reimbursement of the Company&#8217;s costs incurred with third parties. The amounts paid and expected to be paid to Biogen for the use of Biogen&#8217;s resources and its expenses were consideration paid to a customer. Since the Company did not acquire distinct goods or services in exchange for these payments, they reduced the transaction price and were recorded as reduction in revenue. The Company used the expected value method to estimate cost sharing payments, taking into account the impact of the constraint. Variable consideration was included in the transaction price only to the extent it was probable a significant reversal of cumulative revenues recognized would not occur. The Company re-evaluated the transaction price as uncertain events were resolved or other changes in circumstances occurred.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the licenses to its intellectual property for each target were not distinct from the related research and development activities, as the licensed technology was not shared with and could not be utilized by Biogen without the research services to be performed by the Company pursuant to the agreement. On the other hand, each combination of a license to the Company's intellectual property as applied to a specific target and the related research and development activities are a discrete research project that is distinct from any other target&#8217;s project. The targets Biogen could select were options that provided Biogen with material rights, as the exercise of the options did not require payment of a fee commensurate with the value of the incremental license rights. As a result, such options also represented performance obligations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company allocated fixed consideration of $204.6&#160;million included in the initial transaction price to the existing targets&#8217; license and research services performance obligations and those performance obligations for options that include material rights, based on their relative standalone selling prices. Through March 31, 2023, one material right had expired, and seven material rights remained outstanding and are expected to expire during the quarter ending June 30, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notice of termination was accounted for as a modification of the contract, as it changed both the scope of the Company&#8217;s remaining services and the consideration to which the Company was entitled. The remaining research and development activities to be undertaken by the Company after the notice of termination were not distinct from the related </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities performed prior to the modification on the same targets but were distinct from the activities on other targets. The remaining material rights were also distinct from the prior research and development activities. To account for the effects of the modification, the Company updated its estimate of the transaction price and allocated the remaining transaction consideration based on the relative standalone selling prices of the remaining distinct goods and services. Progress for each ongoing performance obligation was then remeasured using an updated estimate of the total level of effort required for each performance obligation and the total revised transaction price and a cumulative catch-up in revenue was recorded. The modification resulted in an increase in revenue of $127.1&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had a receivable of $0.7&#160;million and $0.5&#160;million, respectively, and deferred revenue of $1.5&#160;million and $132.2&#160;million, respectively, related to this agreement. Changes in deferred revenue balances during the three months ended March 31, 2023 relate primarily to the impact of the contract modification. The amounts of transaction price remaining to be recognized were $1.7&#160;million and $151.3&#160;million as of March&#160;31, 2023 and December&#160;31, 2022, respectively. The amounts remaining at March 31, 2023 are expected to be recognized during the quarter ending June 30, 2023. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and other fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost-sharing payments for research services, net variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,193&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $7.0&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the initial transaction price of $204.6&#160;million, as a contract cost asset. This balance is released into general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340. The Company recognized as expense $2.6&#160;million and $0.1&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively. The Company recognized $2.9&#160;million, which represented 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in net proceeds during the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kite Pharma, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), a Gilead Sciences, Inc. subsidiary, which became effective on April 5, 2018 (&#8220;Effective Date&#8221;), and was amended and restated in September 2019, for the research, development, and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered ex&#160;vivo using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research program term and subject to certain exceptions, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of ex vivo genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of ex vivo genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Effective Date, the Company received a $150.0&#160;million upfront payment from Kite. In addition, Kite reimburses the Company&#8217;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.0&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $1.3&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.8&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first 10 times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial research term in the agreement is six years from the Effective Date. Kite has an option to extend the research term for up to two additional one-year periods for a separate upfront fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. Through the amendment and restatement of the agreement in September 2019, the Company and Kite agreed to expand the scope of the collaboration program to incorporate the use of lentiviral or retroviral vectors provided by Kite. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. The transaction price includes the upfront license fee of $150.0&#160;million and estimated reimbursable service costs for the research projects over the estimated performance period. None of the clinical or regulatory milestones have been included in the transaction price, as none of the milestones have yet been achieved, and all amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price also includes actual and estimated payments by Kite for the work by Company researchers and reimbursement of the Company&#8217;s costs incurred with third-parties. The Company uses the expected value method to estimate payments related to the Company&#8217;s researchers&#8217; work, taking into account the impact of constraint. Variable consideration is included in the transaction price only to the extent it is probable a significant reversal of cumulative revenues recognized would not occur. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified four performance obligations within the Kite agreement as follows: (1) a license to the technology combined with the obligation to perform research and development services to apply the Company&#8217;s technology to Kite-selected targets; (2) production of research materials; and (3-4) two material rights, each for an extension of the research period for an additional one-year term. Such extensions contain material rights because their exercise does not require payment of a fee that is commensurate with the value of the incremental research term. The license to the Company&#8217;s intellectual property is not distinct from the related research and development activities as the licensed technology is not shared with and cannot be utilized by Kite without the research services performed by the Company. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated variable consideration (payments by Kite for the work performed by the Company&#8217;s researchers and third-party costs, as well as any future milestones and royalties) to the specific performance obligations to which they relate, as such allocation would meet the allocation objective in ASC Topic 606. The Company allocated the fixed consideration of $150.0&#160;million to the performance obligations based on their relative standalone selling prices. Standalone selling prices of optional research years are similar to those of the initial year, but additionally take into account the intrinsic value of the discount upon exercise and the likelihood of exercise. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fees allocated to options with material rights are deferred until the options are exercised or expire. The exercise of options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#8217;s performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the combined license and research services performance obligations is recognized over time, as Kite consumes the benefit of such services as they are being performed by the Company. For the license combined with research and development services performance obligation, the Company recognizes revenue based on proportional performance of the ongoing research services over the period during which the Company performs the services. The estimation of progress towards the satisfaction of this performance obligation and project costs are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s assumptions regarding the estimated volume of required activities. The production of research materials performance </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligation is accounted for under the right to invoice practical expedient, as the Company has the right to invoice Kite for these services in an amount that corresponds directly with the value of the services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had a receivable of $1.0&#160;million and $0.7&#160;million, respectively, and deferred revenue of $8.0&#160;million and $19.4&#160;million, respectively, related to this agreement. Changes in deferred revenue balances during the three months ended March 31, 2023 relate to a reduction in the estimated future level of the Company's research and development services, as well as ongoing normal progress in the delivery of the performance obligations. The amounts of transaction price (excluding the amounts recognized as invoiced for the production of research materials performance obligation) remaining to be recognized were $8.6&#160;million and $21.2&#160;million, of which $1.5&#160;million relates to fees allocated to options with material rights, as of March&#160;31, 2023 and December&#160;31, 2022, respectively. These amounts are expected to be recognized over the period through 2024. The timing of recognition will be affected by the volume of annual activity under the agreement and by whether and when Kite exercises options for additional years of services and could be subject to significant changes.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license fee fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Kite. This adjustment was driven by a reduction in the estimated future level of the Company&#8217;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of $8.9&#160;million, an increase in net income of $8.9&#160;million, and an increase in the Company&#8217;s basic and diluted earnings per share of $0.06 and $0.05, respectively, for the three months ended March 31, 2023.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi S.A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement (&#8220;2014 Collaboration Agreement&#8221;) to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The 2014 Collaboration Agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi S.A (&#8220;Sanofi&#8221;). Under the 2014 Collaboration Agreement, the Company was originally jointly conducting two research programs: a beta thalassemia program, which was discontinued in the third quarter of 2021, and the SCD program, which resulted in the development of SAR445136 (now known as BIVV003), a ZFN, gene-edited cell therapy product candidate for the treatment of SCD. In December 2021, Sanofi notified the Company of its termination for convenience, effective June 28, 2022 (the &#8220;Termination Date&#8221;), of the 2014 Collaboration Agreement. A termination and transition agreement (the &#8220;Termination and Transition Agreement&#8221;) was executed by the parties on September 6, 2022. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the SCD program, the Company and Sanofi were jointly responsible for research and development activities prior to filing of an IND, but Sanofi was responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. Subject to the terms of the agreement, the Company had granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZF and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company had also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company was not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2014 Collaboration Agreement, the Company received an upfront license fee of $20.0&#160;million and was eligible to receive additional payments upon the achievement of specified clinical development, regulatory milestones, and sales milestones, as well as royalty payments for each licensed product based on net sales of such product. Sanofi was also to reimburse Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. Through the Termination Date, a total of $13.5&#160;million was received based on achievement of clinical development milestones. No products have been approved and therefore no royalty fees have been or will be earned under the 2014 Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In its termination notice to the Company, Sanofi indicated that its termination relates to Sanofi&#8217;s change in strategic direction to focus on allogeneic universal genomic medicine approaches rather than autologous personalized cell therapies. As of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Termination Date, the 2014 Collaboration Agreement was terminated in its entirety and following the Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Sanofi. As of the Termination Date, Sanofi has no further obligations under the 2014 Collaboration Agreement to develop or to fund the development of any collaboration research programs under the 2014 Collaboration Agreement. The licenses granted to Sanofi under the 2014 Collaboration Agreement have been terminated, and the license rights have reverted to the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Termination and Transition Agreement, Sanofi granted to the Company exclusive, worldwide, fully paid, royalty-free, perpetual, irrevocable licenses, with the right to grant sublicenses through multiple tiers, to certain of its intellectual property, to develop, manufacture, have manufactured, use, sell, offer to sell, import and otherwise commercialize BIVV003, the product candidate in development under the SCD program. The Company agreed to take on responsibilities for all clinical trials related to BIVV003, including completion of the ongoing clinical trial and the related long-term follow-up study. The Company also assumed all regulatory responsibilities related to BIVV003. Sanofi transferred and assigned to the Company all documentation, materials and contracts with third parties related to BIVV003, and the right to use certain Sanofi-owned or leased equipment related to BIVV003.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi has also agreed to reimburse the Company for the costs of conducting the ongoing clinical trial of BIVV003 and the costs of the long-term follow-up study through December 31, 2023, up to $7.0&#160;million. In addition, should the Company elect not to continue the development of BIVV003 past December 31, 2023, Sanofi will become obligated to reimburse the Company for the costs of the long-term follow-up study incurred after 2023, up to $5.3&#160;million. Sanofi&#8217;s reimbursement obligations will terminate upon certain triggering events, including the Company&#8217;s entering into a contract with a third party for collaboration, partnership, sale, licensing, or divestiture of BIVV003, or if the FDA permits early closure of the clinical trial and/or the long-term follow-up study.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the 2014 Collaboration Agreement in accordance with ASC&#160;Topic&#160;606 and concluded that Sanofi was a customer under that arrangement. The Company identified the performance obligation within this arrangement as a license to the technology combined with ongoing research services activities. The Company concluded that the license was not distinct as it did not have stand-alone value to Sanofi without the research services. As a result, the Company recognized revenue from the upfront payment and the milestones based on progress of performance of the ongoing research services. The estimation of progress towards the satisfaction of the performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s then current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. Sanofi&#8217;s December 2021 notice of termination of the 2014 Collaboration Agreement represented a modification that reduced the expected scope of the Company&#8217;s services and the estimated transaction price and shortened the remaining performance timeline. Consistent with this change, all services provided by the Company under the 2014 Collaboration Agreement were completed by June 28, 2022, and all amounts ultimately included in the transaction price were recognized by such date. The final transaction price of $96.3&#160;million included the upfront license fee of $20.0&#160;million, two milestone payments in the aggregate amount of $13.5&#160;million and reimbursement of research costs of $62.8&#160;million. As of March&#160;31, 2023 and December&#160;31, 2022, the Company had no receivable or deferred revenue related to the 2014 Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that Sanofi is not a customer under the Termination and Transition Agreement as Sanofi is not entitled to receive and cannot use the results of the ongoing clinical trial or the long-term follow-up study. This relationship is also not a collaboration in the scope of ASC Topic&#160;808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company concluded that the assets acquired from Sanofi do not represent a business, as substantially all of their value is concentrated in the acquired or re-acquired licenses to intellectual property. The Company has no obligation to repay Sanofi for its ongoing funding of the clinical trial or long-term follow-up study costs. Therefore, the Company will recognize Sanofi reimbursements as reductions to its research and development expense. During the three months ended March&#160;31, 2023, the Company decreased its research and development expense by $0.5&#160;million for these reimbursements, which is included within prepaid expenses and other current assets on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2023. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the 2014 Collaboration Agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Giroctocogene Fitelparvovec Global Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer Inc. (&#8220;Pfizer&#8221;), pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) fifteen years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are 14% - 20% of the annual worldwide net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The total transaction price under this agreement was $134.0&#160;million, which represented the upfront fee and research services fees of $79.0&#160;million and fees related to two achieved milestones in an aggregate amount of $55.0&#160;million. Sangamo was responsible for internal and external research costs as part of the upfront fee and had the ability to request additional reimbursement from Pfizer if certain conditions were met. None of the constrained clinical or regulatory milestones were included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at the time was uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license was not discrete as it did not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period during which the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and no revenues have been recognized during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C9ORF72 Research Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZF-TRs to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZF-TRs that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZF-TRs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory exclusivity for a licensed product in a country, and (iii) 15 years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million in commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties of 14% - 20% of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pfizer agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The Company concluded the total transaction price under this agreement was $17.0&#160;million, which represented the upfront fees of $12.0&#160;million and fees related to achievement of one milestone in the amount of $5.0&#160;million. None of the constrained clinical or regulatory milestones were included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at the time was uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $5.0&#160;million milestone, which the Company recognized on a cumulative basis during the year ended </span></div>December 31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and no revenues have been recognized during the three months ended March&#160;31, 2023 and 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898078848896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesTextBlock', window );">IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</a></td>
<td class="text">IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, as a result of the sustained decline in the Company&#8217;s stock price and related market capitalization, termination of the collaboration agreements with Biogen and Novartis, and a general decline in equity values in the biotechnology industry, the Company performed an impairment assessment of goodwill, indefinite-lived intangible assets, and long-lived assets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#8217;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#8217;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represents a level&#160;2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a non-cash, pre-tax goodwill impairment charge of $38.1&#160;million during the three months ended March 31, 2023. As a result, the goodwill was fully impaired as of March 31, 2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before completing the goodwill impairment assessment, the Company first tested its indefinite-lived intangible assets and then its long-lived assets for impairment. The Company determined its indefinite-lived intangible assets were not impaired, as their carrying values were not in excess of their individual fair values. The Company determined all of its long-lived assets represent one asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the single asset group is not recoverable as it exceeded the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. To allocate and recognize the impairment loss, the Company determined individual fair value of long-lived assets. The Company, with the assistance of a third-party valuation firm, applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction. This represents a level&#160;3 nonrecurring fair value measurement. Based on this analysis, the Company recognized non-cash, pre-tax long-lived asset impairment charges of $11.2&#160;million on the right-of-use assets, $5.0&#160;million on the related leasehold improvements, and $4.2&#160;million on construction-in-progress, during the three months ended March&#160;31, 2023. No impairment was recognized on the remaining long-lived assets as their carrying values were not in excess of their fair values.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898076999392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"/><td style="width:74.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898078876496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#8217;s sales agent or principal. In December 2022, the Company entered into Amendment No. 2 to the Open Market Sale Agreement&#8480; which increased the aggregate offering price under the at-the-market offering program by an additional $175.0 million. The Company is not obligated to sell any shares under the sales agreement. During the three months ended March&#160;31, 2023, the Company sold 3,962,430 shares of its common stock for net proceeds of approximately $9.7&#160;million, of which approximately $0.6&#160;million was received in April 2023 and recorded within prepaid expenses and other current assets on the Company&#8217;s Condensed Consolidated Balance Sheet as of March&#160;31, 2023. No shares were sold under the sales agreement during the three months ended March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898077091104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s provision for income taxes for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. During the three months ended March&#160;31, 2023 and 2022, the Company recorded income tax expense of $0.2&#160;million and $0.1&#160;million, respectively. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company continues to maintain a full valuation allowance on its U.S. federal and state net deferred tax assets and on the Sangamo France net deferred tax assets, as the Company believes it is not more likely than not that these benefits will be realized. The tax expense for the three months ended March&#160;31, 2023 was primarily due to foreign income tax expense.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act of 2022 was signed into law, and became effective in 2023, with tax provisions primarily focused on implementing a 15% minimum tax on global adjusted financial statement income and a 1% excise tax on share repurchases. The Company has evaluated the provisions of the tax law and noted that the law change would not have a material impact on the Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898077087680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTSIn April 2023, the Company announced a restructuring of operations and corresponding reduction in workforce (the &#8220;Restructuring&#8221;), designed to reduce costs and increase focus on its key strategic priorities. Sangamo expects the Restructuring to result in the elimination of approximately 120 roles in the United States, or approximately 27% of its total United States workforce. The Company currently estimates that it will incur approximately $5&#160;million to $7&#160;million in cash-based expenses related to employee severance and notice period payments, benefits and related costs in connection with the Restructuring. The Company expects that the majority of the Restructuring charges will be incurred in the second quarter of 2023 and that the execution of the Restructuring will be substantially complete by the end of the third quarter of 2024. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the Restructuring.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898074052016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The Condensed Consolidated Balance Sheet data at December&#160;31, 2022 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#8220;2022 Annual Report&#8221;) as filed with the SEC on February&#160;23,&#160;2023.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2022, included in the 2022 Annual Report.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and licensing agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#8217; product sales. All funds received from the Company&#8217;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. One of the Company&#8217;s contracts also contains a provision where the Company reimburses its customer for certain costs they incur which is accounted for as a reduction to the contract transaction price as the Company does not acquire any distinct goods or services in exchange for such payments. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of the Company&#8217;s performance obligations in its collaboration agreements represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct. Options to license the Company&#8217;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g., a right to a discount the customer would not have received if they did not purchase the Company&#8217;s services under the existing contract. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from bundles of licenses of intellectual property and research and development services are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#8217;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#8217;s performance obligation. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period of performance and level of effort, including the value of Company researchers&#8217; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current expectations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"/><td style="width:74.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi S.A.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Goodwill, Intangible Assets and Long-lived Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill, Intangible Assets and Long-lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased in-process research and development (&#8220;IPR&amp;D&#8221;) projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events and circumstances indicate that these assets may be impaired. The Company evaluates the fair value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In testing for goodwill impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the Company elects to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, the Company performs a quantitative goodwill impairment test to compare the fair value of its reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit&#8217;s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value (but not in excess of the carrying value of goodwill). </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to testing goodwill for impairment, the Company also tests impairment for its other indefinite-lived and long-lived assets. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates that the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company will evaluate the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is recognized, the Company will recognize lease impairment and subsequently amortize the remaining lease asset on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#8217;s useful life or the end of the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898074133712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"/><td style="width:74.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi S.A.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,241&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,444&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,257&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,872&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,741&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,944&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,757&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,372&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,241&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,444&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,257&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,872&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,741&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,944&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,757&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,372&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898077093536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,756&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,853&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,033&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898077090272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,516&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,230&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,820&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(918)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,853&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair value of investments available-for-sale</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:74.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,756&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898077174560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Components of Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.193%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,977)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of common stock pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,218&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898073465920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,755&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,895&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and other fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost-sharing payments for research services, net variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,193&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license fee fixed consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services variable consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the 2014 Collaboration Agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898071025600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"><tr><td style="width:1.0%"/><td style="width:74.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,873&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,277&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898074903680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Capital resources</a></td>
<td class="nump">$ 241,000<span></span>
</td>
<td class="nump">$ 241,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,133<span></span>
</td>
<td class="num">$ (43,977)<span></span>
</td>
<td class="num">$ (192,300)<span></span>
</td>
<td class="num">$ (178,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">1,127,412<span></span>
</td>
<td class="nump">1,127,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,148,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit established as a deposit</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Change in Accounting Estimate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Change in estimate of transaction price, increase in revenue</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent', window );">Increase in net income</a></td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInEarningsPerShareBasic', window );">Increased earnings per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInEarningsPerShareDiluted', window );">Increased earnings per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Earnings Per Share, Basic</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Earnings Per Share, Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Net Income (Loss) Attributable To Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898074140016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Details) - Revenue from contract with customer - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898074056944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 78,241<span></span>
</td>
<td class="nump">$ 100,444<span></span>
</td>
<td class="nump">$ 120,257<span></span>
</td>
<td class="nump">$ 178,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 79,741<span></span>
</td>
<td class="nump">$ 101,944<span></span>
</td>
<td class="nump">$ 121,757<span></span>
</td>
<td class="nump">$ 180,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898069578192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 162,756<span></span>
</td>
<td class="nump">$ 207,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">34,474<span></span>
</td>
<td class="nump">50,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">33,720<span></span>
</td>
<td class="nump">18,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">70,836<span></span>
</td>
<td class="nump">101,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">8,311<span></span>
</td>
<td class="nump">11,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">14,613<span></span>
</td>
<td class="nump">24,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">5,596<span></span>
</td>
<td class="nump">7,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">29,680<span></span>
</td>
<td class="nump">37,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sgmo_USGovernmentSponsoredAgencyBondMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">34,474<span></span>
</td>
<td class="nump">50,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">162,756<span></span>
</td>
<td class="nump">207,033<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">197,230<span></span>
</td>
<td class="nump">257,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">34,474<span></span>
</td>
<td class="nump">50,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">33,720<span></span>
</td>
<td class="nump">18,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">70,836<span></span>
</td>
<td class="nump">101,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">8,311<span></span>
</td>
<td class="nump">11,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">14,613<span></span>
</td>
<td class="nump">24,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">5,596<span></span>
</td>
<td class="nump">7,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">29,680<span></span>
</td>
<td class="nump">37,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">34,474<span></span>
</td>
<td class="nump">50,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">34,474<span></span>
</td>
<td class="nump">50,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">34,474<span></span>
</td>
<td class="nump">50,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">162,756<span></span>
</td>
<td class="nump">207,033<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">162,756<span></span>
</td>
<td class="nump">207,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">33,720<span></span>
</td>
<td class="nump">18,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">70,836<span></span>
</td>
<td class="nump">101,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">8,311<span></span>
</td>
<td class="nump">11,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">14,613<span></span>
</td>
<td class="nump">24,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">5,596<span></span>
</td>
<td class="nump">7,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">29,680<span></span>
</td>
<td class="nump">37,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sgmo_USGovernmentSponsoredAgencyBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sgmo_USGovernmentSponsoredAgencyBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898073936752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at carrying value, total</a></td>
<td class="nump">$ 78,241<span></span>
</td>
<td class="nump">$ 100,444<span></span>
</td>
<td class="nump">$ 120,257<span></span>
</td>
<td class="nump">$ 178,872<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">163,042<span></span>
</td>
<td class="nump">207,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(391)<span></span>
</td>
<td class="num">(918)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">162,756<span></span>
</td>
<td class="nump">207,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost', window );">Total cash equivalents and available-for-sale securities, amortized cost</a></td>
<td class="nump">197,516<span></span>
</td>
<td class="nump">258,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax', window );">Total cash equivalents and available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and available-for-sale securities, gross unrealized (losses)</a></td>
<td class="num">(391)<span></span>
</td>
<td class="num">(918)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and available-for-sale securities, estimated fair value</a></td>
<td class="nump">197,230<span></span>
</td>
<td class="nump">257,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at carrying value, total</a></td>
<td class="nump">34,474<span></span>
</td>
<td class="nump">50,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents accumulated gross unrealized loss before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">34,474<span></span>
</td>
<td class="nump">50,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at carrying value, total</a></td>
<td class="nump">34,474<span></span>
</td>
<td class="nump">50,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents accumulated gross unrealized loss before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">34,474<span></span>
</td>
<td class="nump">50,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">33,753<span></span>
</td>
<td class="nump">18,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">33,720<span></span>
</td>
<td class="nump">18,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">70,906<span></span>
</td>
<td class="nump">101,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">70,836<span></span>
</td>
<td class="nump">101,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">8,335<span></span>
</td>
<td class="nump">11,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">8,311<span></span>
</td>
<td class="nump">11,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">14,689<span></span>
</td>
<td class="nump">24,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">14,613<span></span>
</td>
<td class="nump">24,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury bills</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">5,598<span></span>
</td>
<td class="nump">7,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">5,596<span></span>
</td>
<td class="nump">7,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">29,761<span></span>
</td>
<td class="nump">37,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">$ 29,680<span></span>
</td>
<td class="nump">37,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=sgmo_USGovernmentSponsoredAgencyBondMember', window );">Agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for Sale Securities Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized gain, before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sgmo_USGovernmentSponsoredAgencyBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sgmo_USGovernmentSponsoredAgencyBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898079198656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 127,147<span></span>
</td>
<td class="nump">$ 177,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">35,609<span></span>
</td>
<td class="nump">29,845<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 162,756<span></span>
</td>
<td class="nump">$ 207,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898073624064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized investment gains (losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded', window );">Allowance for credit loss related to marketable securities, not previously recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings', window );">Other impairment charges related to marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss related to marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898075536272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 21,133<span></span>
</td>
<td class="num">$ (43,977)<span></span>
</td>
<td class="num">$ (192,300)<span></span>
</td>
<td class="num">$ (178,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding - basic (in shares)</a></td>
<td class="nump">168,533<span></span>
</td>
<td class="nump">146,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding - basic (in shares)</a></td>
<td class="nump">168,533<span></span>
</td>
<td class="nump">146,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding - diluted (in shares)</a></td>
<td class="nump">169,181<span></span>
</td>
<td class="nump">146,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of share-based payment arrangements (in shares)</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-Based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of share-based payment arrangements (in shares)</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic And Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss) Available To Common Stockholders, Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898074202496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">14.7<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898071459312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 27, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized contract cost, amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="nump">$ 95,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementLicenseFee', window );">Collaborative arrangement, license fee</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="nump">$ 20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue', window );">Financial advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition', window );">Percent of initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Percent Of Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementPercentOfInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement estimated reimbursable service costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, License Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898071256352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">102 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 157,957<span></span>
</td>
<td class="nump">$ 28,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">9,755<span></span>
</td>
<td class="nump">8,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | License and Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,696<span></span>
</td>
<td class="nump">7,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,059<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">132,302<span></span>
</td>
<td class="nump">11,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">130,630<span></span>
</td>
<td class="nump">7,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">3,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">12,308<span></span>
</td>
<td class="nump">6,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">11,440<span></span>
</td>
<td class="nump">6,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A. | License and Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A. | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898069383776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>product_target </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>material_right</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,136<span></span>
</td>
<td class="nump">$ 14,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Change in estimate of transaction price, increase in revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | License and Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount', window );">Fixed consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired', window );">Number of material rights expired | material_right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding', window );">Number of material rights outstanding | material_right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction', window );">Sale of stock, excess consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborationAgreementEquityIssued', window );">Collaboration agreement, equity issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Net pension losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty', window );">Number of neurological disease gene targets selected by counterparty (in product targets) | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets', window );">Number of additional neurological disease gene targets (in product targets) | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue', window );">Financial advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition', window );">Percent of initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract with customer, asset, after allowance for credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementEquityIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Equity Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementEquityIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Additional Product Targets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementNumberOfAdditionalProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Selected Product Targets By Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Percent Of Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementPercentOfInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Fixed Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Number Of Material Rights Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Number Of Material Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Excess Consideration Received on Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898074015472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>performance_obligation </div>
<div>material_right</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>option</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 7,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Change in estimate of transaction price, increase in revenue</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent', window );">Increased net income</a></td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInEarningsPerShareBasic', window );">Increased earnings per share, basic (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInEarningsPerShareDiluted', window );">Increased earnings per share, diluted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | License and Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RevenueNumberOfRemainingPerformanceObligations', window );">Number of remaining performance obligations | performance_obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod', window );">Number of material rights for renewal of research period | material_right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod', window );">Renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount', window );">Fixed consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation amount</a></td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount', window );">Remaining performance obligation amount, related to material rights</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Initial research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm', window );">Number of options to extend initial research term | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ExtendedResearchTermOfAgreement', window );">Extended research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SeparateUpfrontFee', window );">Separate fee for additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer liability</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment', window );">Maximum amount of achieved milestones to receive payment | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration And License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent development and sales based milestone payments to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ExtendedResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended Research Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ExtendedResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Earnings Per Share, Basic</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Earnings Per Share, Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Net Income (Loss) Attributable To Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Extend Initial Research Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfOptionsToExtendInitialResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RevenueNumberOfRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Number Of Remaining Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RevenueNumberOfRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Fixed Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Number Of Material Rights For Renewal Of Research Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Related To Material Rights, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_RevenueRemainingPerformanceObligationRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Renewal Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_RevenueRemainingPerformanceObligationRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SeparateUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Separate upfront fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SeparateUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898069339920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">102 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 06, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>product </div>
<div>milestone</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,957,000<span></span>
</td>
<td class="nump">$ 28,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,026,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,678,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense', window );">Decrease in research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_NumberOfResearchProgram', window );">Number of research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,499,000<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate', window );">Expenses reimbursable through December 31, 2023 (up to)</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate', window );">Expenses reimbursable after December 31, 2023 (up to)</a></td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A. | Collaboration And License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi S.A. | Collaboration And License Agreement | Milestone Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement estimated reimbursable service costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of research program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Expenses Reimbursable, After Specified Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Expenses Reimbursable, Through Specified Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination And Transition Agreement, Increase (Decrease) In Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898069899808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">64 Months Ended</th>
<th class="th" colspan="1">71 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>product</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,957,000<span></span>
</td>
<td class="nump">$ 28,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five And Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five And Other Products | Achievement of specified clinical development intellectual property and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | S B Five Two Five And Other Products | Achievement of first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | License and Service | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty', window );">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | License and Service | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty', window );">Percentage of net sales per developed licensed product which will trigger royalties by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementResearchServiceFees', window );">Research service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | S B Five Two Five And Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved', window );">Collaborative arrangement, number of milestones achieved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | C9ORF72 | Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | C9ORF72 | Achievement Of Commercial Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AgreementTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Milestones Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementResearchServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Research Service Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementResearchServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898073472048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>asset_group</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 38,138<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_LongLivedAssetsNumberOfAssetsGroups', window );">Long-lived assets, number of assets groups | asset_group</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment on right-of-use assets</a></td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">20,433<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems', window );"><strong>Impaired Long-Lived Assets Held and Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LongLivedAssetsNumberOfAssetsGroups">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Lived Assets, Number Of Assets Groups</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LongLivedAssetsNumberOfAssetsGroups</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898069306304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,277<span></span>
</td>
<td class="nump">$ 7,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,873<span></span>
</td>
<td class="nump">4,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,404<span></span>
</td>
<td class="nump">$ 3,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898073632096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Jefferies LLC - At-The-Market Offering Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_StockOfferingProgramMaximumValue', window );">Stock offering program, maximum value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice', window );">Stock offering program, increase to aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,962,430<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockIncreaseToAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Increase To Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockIncreaseToAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockOfferingProgramMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Offering Program, Maximum Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_StockOfferingProgramMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898075579408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139898074000352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($) </div>
<div>employee</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of positions eliminated in restructuring | employee</a></td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of positions eliminated in restructuring</a></td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Restructuring expected cost</a></td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>sgmo-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgmo="http://www.sangamo.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sgmo-20230331.xsd" xlink:type="simple"/>
    <context id="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7a52ec1aaba84b2281ad30d4bd939c0c_I20230504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2023-05-04</instant>
        </period>
    </context>
    <context id="i9a68418627e64a97967175e21376a7f3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic4324bd7b11f411d9e7d667c237daef0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia30a9e39409b461c99159daa010f6c5c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iedb9034932fc40c08ea5573339590e7f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac4ded14953b49d1addd06f731f72c7b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5f7c9d06ff1b4ead8670defb0e972860_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0c77020818e4b5580a54602bc3733dc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icc69df1bb8ee4558ae36144749414ed9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id60c69134c4f4a03998a810770abe5f2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6a6b4846ff7445a7bd06205ce088da41_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iccea421e2a0c4b47b469cdf5d493c0e0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iba3dfb89f8ba47408fd34040b407e005_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5abbb2c7d7944601bf890210157c2b4d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i91ca40960ab74c8fbafd0d9349205312_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9c7722be40df413c8e437a49f401590f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff108f8c09274a6cbb44e10d8867b38a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac6d1271621d4cac8be74b9a037e4707_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53a89059a55449d3bc69e3f6de7098b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i579b5f75540647cd977142ae38f4b321_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7ccefc4a682e42bda1dd7730db19dcc0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e912a9a7bc746bd96bb5d87a08b8206_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie1a85436c7c142278657c85e7ea9997b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibeae407467224307ae4941c1984b4b7f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic68b3111e2494397846164214ce99690_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia3bdcc1051374821b3877c109bd673ae_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i34bf2d104a444cc9834054ced8faa7f7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie262d508238d48dc8b762871a33221db_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id596b784d404435db73b47602bb3f897_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i02b85f2e8972441db23e17a30d5bff74_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i76070b5a1a6143119c52bcf7c53c9b73_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0c3ceda2ae9f4af0871fc85dd870550f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaca29c7b3b79472aaf0ee13bc56470ac_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib5248b3610244c38b223f129709425f6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i90890f44b0704bb8ac590e628ae519de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie1342bd78484460185b8895a3f6308ea_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i228888ff63774a0da4d18154fc729ad5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie462eedb4107492bbce0acc5ff5754d8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icc8ea2db07274d118686e8a982ad7e70_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1352fdf2ec644672809d7dd3d3bed33d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i76977228f122459ba5f628b5569cae61_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7f7da342c5ac4a7ea636981a736322b9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6d6fe81f256c4cc8b6f7fc522fdd2281_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2f61e5cec7984b35ac4292098852fc91_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie9898b19bcd74221a4ff8f06d9cb7cf7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i92619e333cc24f9e975a7de1bb2abeea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6a1749f9f00c4883957a94b42aedc00f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3eacf9813ba44226a063dc9009a4a15f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4dceda8408ab4f4fbd7740cca575d5b0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iea9e2a9aacec47b5a0dad2b07a352357_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i869c2ae932a24254b8289f3374d6a37b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie603a77a75c24e5bb6587690295c6f3d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iee59432e21b44a0e8975d6f3b16c5c4a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i26ea0b74cc8544e1a3c671264db84d1e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5d56b50a62c74d6185fdc6510e7cc1eb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6032041d43be43a9bb2dc9299dffabad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i483c837a581a4a55b5c3d56642557778_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i43cfc63e1c6c4f118396790ecc913456_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic2b09c75601c44e5b6a50a7decb6edde_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i13fb183572b948d48d0e0dde8e690e47_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if1429086824143138e26fa0505ab0fed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iead8dc5bda5146e0849851aa8f041938_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id37baec065284201ae771b20cce5ff25_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iae8f85ae07f54b72871595f4e0b87538_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i862b92b01544466ba544053538532461_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i749604d15996441483daf9b51492bbbb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i07e496ca5ed849de88c1758f1bfec843_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i030f27a6938f4ae3b1d61555d37da11b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia99bbd5a24a34bdb914d71eed48233f3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i78fdaa779102440c8193f79514249c1b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id2ef8c6fa4624c93842e0f3638e26f25_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i75fa9da1a76b437cb308a2069d2b6eab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iceb0eb1a3d40494d975a79e8bcfe27f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5c39a22139a4538b0384f237621d593_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f4b7dc92a60450187eb7cba78d4c993_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iab229808f3044fba8b9d5250cb15ae30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b36ed08a50e40e19b52b258e576bdcb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i202c7c1338114a3bb3508dd0e372fd84_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7057bf4fdd9c4e7eaa545683b37732c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if73e2cb32fab46ffbe55e9f5a5da0de2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i02fe7f2d5f244d2b94f1aaaaefcea866_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9260c94253f4086af0b69700e462ff9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd16acd018e74a0eb2ef2d18b3ee3a05_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i023a682c38c1450e86a5514fd42920ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if75b8fa59ce34fb895f1352a74043e96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7724b0150a1d4054a320c6e4ef27fccd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3ed6d25a758441dbb31e2700f31431a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6febdf9b3c3b4c168661eb22fdc0ed1e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0ce4a249017b49d09aabf529ed967fae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb946291e031440cbc217d13ca32b3be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d5cfc64a3af4b758962c25f72175778_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4dfcb895014c45b9afa399178f988a8f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb05bb816d48471695d20ca909641996_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e171ab888a84b13bd2208636c991ac8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i710edc7861594a64934aa92ebca6d053_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic22c629aefe14ad9a522a27354756d3e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c5f113b72b84c4b83630824ece95871_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e703c64cdfb44f3ba9f51bd3b3515d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2beb4271e37a4f91875382a0f384b26b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9bac443782f4620ba81a5a825bcf681_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if22b2e9750244dc98e0c8b4d07365f2c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b64c2dbe567488896866da512af7840_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72394fea9c574b08a7bf8ac3b21f6a13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i46d82c5052ab497b84f515cc2d04ad09_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:USGovernmentSponsoredAgencyBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i33ecf1a446814705933fbfd6cb111914_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:USGovernmentSponsoredAgencyBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0be6f0fd28e547138aedec8a3f9ad6c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:USGovernmentSponsoredAgencyBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b32d58beb5e49b0addbd7559d9a7775_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:USGovernmentSponsoredAgencyBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i93fcf6ad011a47d8bd403279bf5444bd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i19697738bf094279973b7cad292bc53f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i054c316aa399405fb28e17d9ac5f6b7b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3e3248fa7b3248df8737d1c52d665c5b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8f9b4275c69b4a3da6c127b76ab498d0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id4f486712abb466bb4fed83def8c8c69_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1e554d5745be4b61b64b3b228f9ea2b6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1113f5d2f3014aeab32e8e98f8161f84_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i739dc723663c47d7b30394d8567919dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i382c5b6d179045cab6406d5372cc5441_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib74d65ada2ff4867ab5f3259d7d950ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if54118fa133440819c9192da179240e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if9f8bb01a8d149d993b5ba9c67d52a69_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0441be5e852742ed898a9eb78b769265_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i775d20c1dc4c46e68398640e2b73e1dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if04730ad90e0401eb7693f8828b8bc5d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if03492c5aa4e4c55a0716a7facf39b4e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:USGovernmentSponsoredAgencyBondMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iddef1edbf4fe4f019d6237e6e633beb1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie99095be5cac40ca995b3b8a0de25abf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia4f07d68b8514889b8593d1beef8cb7e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1be2098986b14f5aba5262c6164a6fbf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0cdb317881c34a669c3a4df636cafb89_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i9e26658540754e0ba357cda42d689a27_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i2e5f30daa4cb48669190ba5dc2800f62_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i588781fc38e24f71a49cbdd5825112e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3b05399697d7401c8737c92e33455724_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i172244f350cb475a8efec0046cc9297b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0092f362bc744248b2ee6e610a3b5e63_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id24f43f5449b47339b9d23c5322eea68_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5044101e1ffb43ab96fa6fd4cd659e29_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic8aae65c355c4bd7aef72344aa0fafbf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f7ce4041a0342d09c2e6c57209b7339_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i977ddd133dc44b5c99432be67e32bb97_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i1ad08cddce894baca70373a9ee5375ff_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="if9678c76539b432b81f74d4fb3103970_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="if8df8676b78c46d5b518f1f954613aa3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf5d83fd29e747b2a85c289b3b68ab01_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibe0c5537708d428dbd32614f200d7d29_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie59f379330a44413acc5ad3572d12de6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if3bd4a20f8df4d748a7351f9176c8c95_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ife0d48cc54154af988cfabb60294c669_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i97d4c70ae0c0480394a8206308620896_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6b3bd979dbaf42b2bf7fdb23a295bcbd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iff80b48ae31a4224bcf6ebf172a029de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9a46a4d74d0f40ca9fe4e5cc2553ae18_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icb85aa7ee95148ddb651de001786d085_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i82bf0e01b49943c59780d56860d0ef71_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idb9738ab009e47ebac491659d9db20da_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie1079febd1d943e5ace3d337ff8b9934_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifdb866cb8cc240e6abb838057088d3c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ia36d19d9949d425a80f1c8e75d714302_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i3d2d40bca9274579a944d3bfb4f13ab1_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ieaf64bd796644ec09771a94c61a501b4_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="if7e6bd6cba7449d5b279f7359132b372_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i1cab29510fb3439faf882035775ddfa8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if963029c76a14422a76e678b607647db_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idee75a68ffae4d08aad2ebe053849936_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifc29cb92c1914e68bb97632d9995dd99_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba08bfacba1f4aae9ffd92a1c8ee0b02_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iecd84ec8a1904360957c6aa234b8c110_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i012246fb152f4311b9ef64728a20ab16_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibf91751f6b9c4cd9aa62ef768250ea52_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i06bd9d0df2534688ae2923ab3b06ae9a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i044b8bca774a41859553cfa2ca705546_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i16fce833379e4e6f95302de92112cbfe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0996de9b8bdd4847801e39a50b5843fe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifb3c135c2da14ac9b065d23532ddd743_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="ie1283de320cb4464a5b41896a5803c3e_D20140101-20220628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2022-06-28</endDate>
        </period>
    </context>
    <context id="i040ae2a932da4ee5aba8f53c0572ebbc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8f019967b98f4beba43811efc7cd5926_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6db635d14915401bb7ab7d501b675ba5_D20220906-20220906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-06</startDate>
            <endDate>2022-09-06</endDate>
        </period>
    </context>
    <context id="i7fc0f7863a60402b9f2453ef3b887ecb_D20140101-20220628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2022-06-28</endDate>
        </period>
    </context>
    <context id="i65542dbae8514435bdf257a1ff5bcbdf_I20220628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-28</instant>
        </period>
    </context>
    <context id="i46c2c921be69493ab19f0a486451504a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iddc8eb02f5594eb4bb70b4f4e16dfa8a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i739fc14c91ed4a9398145c3822bdc624_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i64cb91ba588b40d3823c99c78f047007_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3d62212323d64616b08b97898e6dca41_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1b80b373e4f543d3b9c64cd42f6123e0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i29862757a85b4766a731ee17cf896271_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie1f62cc7bdbf4e2ca26b9868e600b6d1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3ae7e8c20abb44979f894b0080a9de5b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i667f4bba088b4392976bb60dcc384764_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i804a404f96394a898c058d278efa5149_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="iebe23428fae3453f85cfddd95fced287_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ib47491017133498e9f1034163ad56858_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ibe6c9c6208944000ac68a96e46025955_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="id44c480d79c746f99af60191b7721577_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i7bbeee49f7d24edbb0671d6d2fd4fe37_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i82259a8cc3b54b86845b0a1e5c8c8688_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i37f8e9f8ba844603a13fb45940884450_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id8b7dbf6a794472a89a395389c47d284_D20170501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8723ec4942574f6abacf98a666e76565_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaf3bbfd75e0a43a385745a5d6b39cac5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i36ed8ae1e943412696f1b850bcd91902_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ifc4df0af832c47e19018df300e7262e2_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i8f057163ceda4cb2866e24c3fb357cfe_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i8a4ef27fa9844922a3e39563222cc964_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic2c186114dc94e028f5fe60291fb4cc4_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i560f370cf92a49b99828eb1352749470_D20171201-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1e962757cf94476a83ff1404fcbf850b_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i9a15336c720b4849b73c702ec05c48ae_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i9b6cafe71ed842fe933713b923d60a51_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iec01e4d31367438cb373cd06b7a6321f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fc67d44a220419d862851946595abe3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3e652ef597fe49c8b7cf086423e5272b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4de9bbe9fefc453f850b2fe7edb090a7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if8b032998eb547589205c3c16fdb0326_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i25d41c01311744a48c5daac7d4e3944b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idca29878377148449e09cef54c91263d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i28c3caeac8e54328899e8c3cb465e877_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5f991f47f9a74b6b9b29e3bac240a7eb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i817e2132beca4a9a89cee830995c6d63_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i4b85c71c37b542f2882458b5be990823_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7ced4258fc4d4d42a76a05c7d77967a2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9d74086bfd334bcea39a99837791ca5d_D20230401-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="i7c3f507349cf479bbcbd3ad2bdc85b31_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0d843ac73dfb466ab2ba144b1a49bdb5_D20230401-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="i4127fb82d88648f383b7c0ae50821b64_I20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="ifae7a07494d54449804932a865f643bc_I20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="product_target">
        <measure>sgmo:product_target</measure>
    </unit>
    <unit id="material_right">
        <measure>sgmo:material_right</measure>
    </unit>
    <unit id="milestone">
        <measure>sgmo:milestone</measure>
    </unit>
    <unit id="option">
        <measure>sgmo:option</measure>
    </unit>
    <unit id="performance_obligation">
        <measure>sgmo:performance_obligation</measure>
    </unit>
    <unit id="program">
        <measure>sgmo:program</measure>
    </unit>
    <unit id="product">
        <measure>sgmo:product</measure>
    </unit>
    <unit id="asset_group">
        <measure>sgmo:asset_group</measure>
    </unit>
    <unit id="employee">
        <measure>sgmo:employee</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180L2ZyYWc6NTY1YTZmYTQ1NTZhNDhlN2FmMWUwNGU5MjFkMmQ4OTkvdGFibGU6MWUxZTdlMWExNDQxNDUyMDk2YmFlY2E4YWJlYmQ3MWYvdGFibGVyYW5nZToxZTFlN2UxYTE0NDE0NTIwOTZiYWVjYThhYmViZDcxZl8yLTEtMS0xLTcwMjc1_be3a74f1-22a5-402e-98dd-aa0fc2555b35">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180L2ZyYWc6NTY1YTZmYTQ1NTZhNDhlN2FmMWUwNGU5MjFkMmQ4OTkvdGFibGU6MWUxZTdlMWExNDQxNDUyMDk2YmFlY2E4YWJlYmQ3MWYvdGFibGVyYW5nZToxZTFlN2UxYTE0NDE0NTIwOTZiYWVjYThhYmViZDcxZl8zLTEtMS0xLTcwMjc1_709db881-dbb0-4732-90e8-c397d1a38cdf">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180L2ZyYWc6NTY1YTZmYTQ1NTZhNDhlN2FmMWUwNGU5MjFkMmQ4OTkvdGFibGU6MWUxZTdlMWExNDQxNDUyMDk2YmFlY2E4YWJlYmQ3MWYvdGFibGVyYW5nZToxZTFlN2UxYTE0NDE0NTIwOTZiYWVjYThhYmViZDcxZl80LTEtMS0xLTcwMjc1_df97d1ac-b084-440c-bc57-e96bc2d61ea6">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180L2ZyYWc6NTY1YTZmYTQ1NTZhNDhlN2FmMWUwNGU5MjFkMmQ4OTkvdGFibGU6MWUxZTdlMWExNDQxNDUyMDk2YmFlY2E4YWJlYmQ3MWYvdGFibGVyYW5nZToxZTFlN2UxYTE0NDE0NTIwOTZiYWVjYThhYmViZDcxZl81LTEtMS0xLTcwMjc1_d626476c-c837-4b3d-ac19-5ab53fc2e7de">0001001233</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180L2ZyYWc6NTY1YTZmYTQ1NTZhNDhlN2FmMWUwNGU5MjFkMmQ4OTkvdGFibGU6MWUxZTdlMWExNDQxNDUyMDk2YmFlY2E4YWJlYmQ3MWYvdGFibGVyYW5nZToxZTFlN2UxYTE0NDE0NTIwOTZiYWVjYThhYmViZDcxZl82LTEtMS0xLTcwMjc1_61f8ed31-13a1-40eb-a7a9-85c928481dba">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjcx_1719e036-8c5b-4599-b184-7728ab8c5fe4">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6YmE3MjVlOWMzYjIzNDA1Yzk5MjM0NjhlYjk1ODFlMWYvdGFibGVyYW5nZTpiYTcyNWU5YzNiMjM0MDVjOTkyMzQ2OGViOTU4MWUxZl8wLTAtMS0xLTcwMjc1_eb09a0df-c2e0-4574-9427-2ee6f7e1be34">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMzE_049edcab-1712-4296-b8ba-15e2acd7b3bb">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6Y2E3YTlhNjQxMTYyNGU5OTlmMmRkZGJiYWUwODJjOTkvdGFibGVyYW5nZTpjYTdhOWE2NDExNjI0ZTk5OWYyZGRkYmJhZTA4MmM5OV8wLTAtMS0xLTcwMjc1_465cb1f5-55e6-45bb-a4b3-3bdf4e2b8c3c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY2_219f0ebb-f362-48ad-b0c5-65496e5bac53">000-30171</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY3_0f730648-661b-4d9b-a762-f75fd8d0a3cf">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18wLTAtMS0xLTcwMjc1_dbfd2f38-7dad-4165-acd9-91b310fb58c8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18wLTQtMS0xLTcwMjc1_fc85f3a5-4030-4dd8-8b87-80c6862915e7">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18zLTAtMS0xLTcwMjc1L3RleHRyZWdpb246ZTE2ODY4MTM2OTY4NDdkMWFiMTMzODk2NTI2YzYzZTZfNA_d4ff39db-f0e5-422b-9868-2f4e79b6e26f">7000 Marina Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18zLTAtMS0xLTcwMjc1L3RleHRyZWdpb246ZTE2ODY4MTM2OTY4NDdkMWFiMTMzODk2NTI2YzYzZTZfOA_1e382c23-8a49-4dee-8859-259bdb2d24e1">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18zLTAtMS0xLTcwMjc1L3RleHRyZWdpb246ZTE2ODY4MTM2OTY4NDdkMWFiMTMzODk2NTI2YzYzZTZfMTI_04756797-1abb-4ef2-8396-d22707e58806">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NjExZTdiYmU0M2U5NDcwOWI0OTU2MzA2ZGI0NGI1NDMvdGFibGVyYW5nZTo2MTFlN2JiZTQzZTk0NzA5YjQ5NTYzMDZkYjQ0YjU0M18zLTAtMS0xLTcwMjc1L3RleHRyZWdpb246ZTE2ODY4MTM2OTY4NDdkMWFiMTMzODk2NTI2YzYzZTZfMTY_a9141a2c-e85e-4ed0-b4c3-0adb4ee2362a">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY4_17f07b45-2c41-4ad9-b3de-60128a324a6b">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY5_1b03777d-eea9-446b-b62d-98c7c06351f9">970-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NzViOWUwMmRmMGQyNDMwMTk3Zjg1OWYzYjg5ZGJjMzIvdGFibGVyYW5nZTo3NWI5ZTAyZGYwZDI0MzAxOTdmODU5ZjNiODlkYmMzMl8xLTAtMS0xLTcwMjc1_1c76ea86-b09f-40ee-919d-1a6ce448ebf0">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NzViOWUwMmRmMGQyNDMwMTk3Zjg1OWYzYjg5ZGJjMzIvdGFibGVyYW5nZTo3NWI5ZTAyZGYwZDI0MzAxOTdmODU5ZjNiODlkYmMzMl8xLTItMS0xLTcwMjc1_aed16af0-0380-48f6-a5a1-180088fb6185">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6NzViOWUwMmRmMGQyNDMwMTk3Zjg1OWYzYjg5ZGJjMzIvdGFibGVyYW5nZTo3NWI5ZTAyZGYwZDI0MzAxOTdmODU5ZjNiODlkYmMzMl8xLTQtMS0xLTcwMjc1_7afc3384-6eb2-4dcd-97b4-cda83e775659">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY0_0f7b6239-425c-4ad3-970a-d8aa5980eec3">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjY1_c592fa81-5e3c-490b-a152-2b282a08dee0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6YWJlYzQ2NWU5MWQ5NDA2NjhlZWIwZmUxZTBmZDM2MTIvdGFibGVyYW5nZTphYmVjNDY1ZTkxZDk0MDY2OGVlYjBmZTFlMGZkMzYxMl8wLTAtMS0xLTcwMjc1_d47da5d3-29a1-495e-ad31-e9689873a249">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6YWJlYzQ2NWU5MWQ5NDA2NjhlZWIwZmUxZTBmZDM2MTIvdGFibGVyYW5nZTphYmVjNDY1ZTkxZDk0MDY2OGVlYjBmZTFlMGZkMzYxMl8xLTQtMS0xLTcwMjc1_99bc2e5c-0fc6-479f-a9f3-7ba87554dd43">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGFibGU6YWJlYzQ2NWU5MWQ5NDA2NjhlZWIwZmUxZTBmZDM2MTIvdGFibGVyYW5nZTphYmVjNDY1ZTkxZDk0MDY2OGVlYjBmZTFlMGZkMzYxMl8yLTQtMS0xLTcwMjc1_c39b5df5-ea1d-4c16-bac0-f55a807b1772">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMjcw_4ab77afb-c0a7-4d50-9d58-10b7a71f866b">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7a52ec1aaba84b2281ad30d4bd939c0c_I20230504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xL2ZyYWc6MjViYzEwZDc2NmU0NGQyMzkwNjIzYjA1NDViZmM1N2MvdGV4dHJlZ2lvbjoyNWJjMTBkNzY2ZTQ0ZDIzOTA2MjNiMDU0NWJmYzU3Y18yMTc4_99186126-c4b8-4f06-8ab2-1409115b798a"
      unitRef="shares">171825530</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMy0xLTEtMS03MDI3NQ_7469e025-55b9-4354-a724-a6991daadccd"
      unitRef="usd">78241000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMy0zLTEtMS03MDI3NQ_85678995-2326-4564-b666-e171cd179b7a"
      unitRef="usd">100444000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNC0xLTEtMS03MDI3NQ_84f46bbc-796f-4d74-af49-ae020903dbe2"
      unitRef="usd">127146000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNC0zLTEtMS03MDI3NQ_e279733b-d059-49b6-97da-cd15ad18bb9a"
      unitRef="usd">177188000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNS0xLTEtMS03MDI3NQ_22fd7406-1dda-460b-8204-1dfbf807a182"
      unitRef="usd">1023000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNS0zLTEtMS03MDI3NQ_fa8d26cf-1e2a-45ab-b82a-6546cb7fea9b"
      unitRef="usd">794000</us-gaap:InterestReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNi0xLTEtMS03MDI3NQ_20d1a411-350f-4027-9d1d-4ca2ad58b09d"
      unitRef="usd">7026000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNi0zLTEtMS03MDI3NQ_eb0ca283-6a31-479c-a0cc-38a2f12b342d"
      unitRef="usd">3678000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNy0xLTEtMS03MDI3NQ_5af0e3ac-1675-4be3-9f9f-83282bf5f9b1"
      unitRef="usd">13651000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfNy0zLTEtMS03MDI3NQ_e7e1790f-7d4a-4f04-87dd-5e8f17da8eb3"
      unitRef="usd">18223000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfOC0xLTEtMS03MDI3NQ_c70efcfe-9244-441d-aa6c-3cfb92ec60e6"
      unitRef="usd">227087000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfOC0zLTEtMS03MDI3NQ_c3c75aa9-3528-47fc-8c33-f00339f9dfd0"
      unitRef="usd">300327000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfOS0xLTEtMS03MDI3NQ_0498924c-071a-4a00-8592-a8e3551c92d5"
      unitRef="usd">35610000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfOS0zLTEtMS03MDI3NQ_25c407ac-3f6f-4c00-b886-3bdfd12fbc59"
      unitRef="usd">29845000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTAtMS0xLTEtNzAyNzU_c5b5623a-b259-46b9-8163-7bf6de3e8b29"
      unitRef="usd">59877000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTAtMy0xLTEtNzAyNzU_35a3180e-80dd-43d4-b07e-38f3287c4100"
      unitRef="usd">63531000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTEtMS0xLTEtNzAyNzU_d79b3a90-4eaa-4f24-8bb3-894968e96519"
      unitRef="usd">51555000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTEtMy0xLTEtNzAyNzU_fa1cc973-00ae-4ca9-a33a-c0452e041273"
      unitRef="usd">50729000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTItMS0xLTEtNzAyNzU_697d5986-3d2e-4f5b-96e3-51dadd17ba96"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTItMy0xLTEtNzAyNzU_2c7255b1-f7a1-4e47-8787-373d5112af68"
      unitRef="usd">37552000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTMtMS0xLTEtNzAyNzU_3b48ae51-9d7f-447a-b45f-a16c73439c05"
      unitRef="usd">48696000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTMtMy0xLTEtNzAyNzU_0b82494c-34fc-4a4d-ba4d-5a9c1229ae7b"
      unitRef="usd">62002000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTQtMS0xLTEtNzAyNzU_e2fe6d2c-0e34-440d-ac07-fdc42208ab18"
      unitRef="usd">16242000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTQtMy0xLTEtNzAyNzU_69a7a4f0-7ea9-4651-8f91-b5be16ea4ef2"
      unitRef="usd">17023000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTUtMS0xLTEtNzAyNzU_fd548bd9-1baa-4d77-b2c2-f15acb6fd435"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTUtMy0xLTEtNzAyNzU_e81ba7ad-ad2d-47a1-930d-5caeadea6905"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTYtMS0xLTEtNzAyNzU_9b55bb03-151d-496b-a29d-d70cdeae823b"
      unitRef="usd">440567000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTYtMy0xLTEtNzAyNzU_88afce86-da8e-4529-9a3e-d30c00d422b8"
      unitRef="usd">562509000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTktMS0xLTEtNzAyNzU_1a5238a6-d349-4266-be7f-d68f88a9de26"
      unitRef="usd">19920000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMTktMy0xLTEtNzAyNzU_8d555722-b196-4aae-b053-78bdbe906f90"
      unitRef="usd">22418000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjAtMS0xLTEtNzAyNzU_c83136cb-fdab-4939-9b2c-4dfd81a81007"
      unitRef="usd">12949000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjAtMy0xLTEtNzAyNzU_09768e40-3b86-4f1e-a037-76c7dade8918"
      unitRef="usd">21506000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjEtMS0xLTEtNzAyNzU_c157a5c5-2296-4076-9ce2-06ebb407a594"
      unitRef="usd">15395000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjEtMy0xLTEtNzAyNzU_95c6a648-544b-4110-b32b-31a8d8186e8f"
      unitRef="usd">16007000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjItMS0xLTEtNzAyNzU_5753d39f-6707-4a18-93b3-ba3c9cb66a41"
      unitRef="usd">9575000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjItMy0xLTEtNzAyNzU_2da710bd-3d70-4e48-b90c-c98a3e6f1552"
      unitRef="usd">51780000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjMtMS0xLTEtNzAyNzU_c3587880-a858-468e-bc64-730114979c37"
      unitRef="usd">57839000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjMtMy0xLTEtNzAyNzU_e7e71433-b409-4c87-94c2-52388aa1d1cf"
      unitRef="usd">111711000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjQtMS0xLTEtNzAyNzU_490a71b1-cadc-410d-a3c9-18bbed6806e6"
      unitRef="usd">1816000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjQtMy0xLTEtNzAyNzU_b36c9052-b436-4c8d-8e31-5481a5e42b1a"
      unitRef="usd">109377000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjUtMS0xLTEtNzAyNzU_70e10f62-3db8-43eb-8e24-f05ee1f1696c"
      unitRef="usd">37701000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjUtMy0xLTEtNzAyNzU_bdf6d896-6d85-4e09-abcb-369924560918"
      unitRef="usd">38986000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjYtMS0xLTEtNzAyNzU_62a57228-3936-473f-a9c9-06a3ade5f17d"
      unitRef="usd">6372000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjYtMy0xLTEtNzAyNzU_c73f041b-c9a8-4fbf-80d0-1379f67fef60"
      unitRef="usd">6270000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjctMS0xLTEtNzAyNzU_9203b65d-9d8f-4d42-b047-631d77f14516"
      unitRef="usd">1229000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjctMy0xLTEtNzAyNzU_6798e880-4666-4525-a480-235d61643fc1"
      unitRef="usd">1207000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjgtMS0xLTEtNzAyNzU_573f90d0-a69d-4007-b1d3-9fe284b8201a"
      unitRef="usd">104957000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjgtMy0xLTEtNzAyNzU_ea8b3927-1858-4da6-b31b-cba7dee97273"
      unitRef="usd">267551000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjktMS0xLTEtNzAyNzU_12ddff0e-4d29-44fb-af3b-27030ff40433"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMjktMy0xLTEtNzAyNzU_3ae8f8e4-0299-4b5a-8b3f-dbd2935effbc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzEtMS0xLTEtNzAyNzU_285b8caa-7449-4e0d-a6be-576493c295e5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzEtMy0xLTEtNzAyNzU_40523772-b3e3-4af5-80a9-165168d5ac4c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzItMS0xLTEtNzAyNzU_f02ebc54-69f5-49e4-9ca0-ebfdf0a715e4"
      unitRef="usd">1718000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzItMy0xLTEtNzAyNzU_284a2be0-9c17-4575-8501-6ded7821054f"
      unitRef="usd">1668000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzMtMS0xLTEtNzAyNzU_87ed1c12-f1f5-4e7e-b0bd-40ebe421ae1d"
      unitRef="usd">1467062000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzMtMy0xLTEtNzAyNzU_b856a4a9-f8af-4628-b971-2abeed60ce8e"
      unitRef="usd">1450239000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzQtMS0xLTEtNzAyNzU_21fc2271-c7b3-465e-9fd3-3ae3bbcd178e"
      unitRef="usd">-1127412000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzQtMy0xLTEtNzAyNzU_e4c668d4-73ed-4754-9687-feabae1657b2"
      unitRef="usd">-1148545000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzUtMS0xLTEtNzAyNzU_98a02b18-fc3a-4777-a356-991e27340508"
      unitRef="usd">-5758000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzUtMy0xLTEtNzAyNzU_a4f236f8-5afc-4bab-a41c-dc2a1513e8f2"
      unitRef="usd">-8404000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzYtMS0xLTEtNzAyNzU_27a617c6-f61f-47db-b27e-cc272c338142"
      unitRef="usd">335610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzYtMy0xLTEtNzAyNzU_82bb8f4b-2bdd-498e-ae8a-24b37c387a7c"
      unitRef="usd">294958000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzktMS0xLTEtNzAyNzU_b89e2d4f-ea20-4b03-9a0a-40f9cb345c73"
      unitRef="usd">440567000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yMi9mcmFnOmFhZGQ4MGMwYjA0YTQ2YjJhMTVjZDc1ODIyODQ2NzE1L3RhYmxlOjdhYzg1ZmQ2ZGUzOTRmNzA5YmU2MzkyYzY3ZWM2MTU4L3RhYmxlcmFuZ2U6N2FjODVmZDZkZTM5NGY3MDliZTYzOTJjNjdlYzYxNThfMzktMy0xLTEtNzAyNzU_3d4b1d27-1b56-42a1-be38-29f413e2b152"
      unitRef="usd">562509000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMi0xLTEtMS03MDI3NQ_2a8dedc7-bfd6-4903-8f64-33ad694f3a48"
      unitRef="usd">157957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMi0zLTEtMS03MDI3NQ_3aa9ddfc-ebb3-46a3-9939-69c7f9b2516b"
      unitRef="usd">28231000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNC0xLTEtMS03MDI3NQ_62ba8749-8439-4418-a447-9a6955a9ba1c"
      unitRef="usd">63216000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNC0zLTEtMS03MDI3NQ_c343b606-bba8-4105-9cb9-7564c936b852"
      unitRef="usd">58584000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNS0xLTEtMS03MDI3NQ_90a2b23b-482a-4252-b16b-8d3f10b1acb6"
      unitRef="usd">18136000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNS0zLTEtMS03MDI3NQ_e7e3b816-7c00-4725-8567-c111760234d3"
      unitRef="usd">14908000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNi0xLTEtMS03NTc4NQ_a990f9c8-4679-48c5-abbd-034f891b5365"
      unitRef="usd">38138000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNi0zLTEtMS03NTc5Mw_a38e4d57-6036-44ba-aefb-5105073a8d65"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNy0xLTEtMS03NzkxMQ_cdc86a7d-c53b-4902-bc0b-0f469a08cc2e"
      unitRef="usd">20433000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNy0zLTEtMS03NzkxMQ_8523e0be-3a5d-4959-b552-9e64709951c4"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OperatingExpenses
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNi0xLTEtMS03MDI3NQ_aad7af59-f91a-4df9-b002-266ce3fb057b"
      unitRef="usd">139923000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNi0zLTEtMS03MDI3NQ_1a89a6cd-c2b9-4461-95fc-14a3d08a2c0b"
      unitRef="usd">73492000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNy0xLTEtMS03MDI3NQ_3e9043e5-a9b0-4a14-af09-8a1d1d618921"
      unitRef="usd">18034000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfNy0zLTEtMS03MDI3NQ_86a13e89-29c3-4fcd-af35-217f79a85aab"
      unitRef="usd">-45261000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfOC0xLTEtMS03MDI3NQ_8c214bf1-edea-411a-b11d-e0aa3ba16e4c"
      unitRef="usd">3293000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfOC0zLTEtMS03MDI3NQ_c960be12-ff62-4af9-a00d-674c9c761e85"
      unitRef="usd">1342000</us-gaap:InterestAndOtherIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfOS0xLTEtMS03MDI3NQ_a663b45b-c02b-4ae5-bfa1-225f89b4d150"
      unitRef="usd">21327000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfOS0zLTEtMS03MDI3NQ_bc7f278c-df61-4675-942b-a83bbe0e8ec0"
      unitRef="usd">-43919000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTAtMS0xLTEtNzAyNzU_5a85f55b-7541-4d20-831c-3443791d4df2"
      unitRef="usd">194000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTAtMy0xLTEtNzAyNzU_dfc17d6d-6dff-4d48-bfd4-f4acf30e509b"
      unitRef="usd">58000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTMtMS0xLTEtNzAyNzU_ddc94f8e-06dd-413f-951d-aa8c94b003bd"
      unitRef="usd">21133000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTMtMy0xLTEtNzAyNzU_efeef886-3aa3-409c-b695-adcb6d75d08a"
      unitRef="usd">-43977000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTQtMS0xLTEtNzAyNzU_74a64542-4dfe-4890-9207-505cad9900d9"
      unitRef="usdPerShare">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTQtMy0xLTEtNzAyNzU_051261bc-55cb-4842-85e7-e7d874ab62c6"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTYtMS0xLTEtNzM5ODA_64404d27-45b3-440d-bed6-f0bae357999a"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTYtMy0xLTEtNzM5ODg_0e6391ba-4b96-4a84-8111-5ada282f768f"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTUtMS0xLTEtNzAyNzU_c5b07f5c-9b61-4908-a8af-fe25cb150565"
      unitRef="shares">168533000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTUtMy0xLTEtNzAyNzU_421b2e0d-de08-49c1-9a08-cf356c81d75e"
      unitRef="shares">146218000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTktMS0xLTEtNzM5OTY_0fd6f2d7-cc52-45d0-812a-7c1d7690c152"
      unitRef="shares">169181000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yNS9mcmFnOmNhYzdmOTVlNjVmNzQwNmNhMWQxMTFhYjhkNTk0NWE3L3RhYmxlOjdlMzY3N2RiNDQzMzQ2NjA5NjM5NDFmOWFmODhiNTE1L3RhYmxlcmFuZ2U6N2UzNjc3ZGI0NDMzNDY2MDk2Mzk0MWY5YWY4OGI1MTVfMTktMy0xLTEtNzQwMDQ_203d4f4b-1ac4-4416-a222-c8abb4ddbfe1"
      unitRef="shares">146218000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfMi0xLTEtMS03MDI3NQ_22ec58bd-6a8f-487d-a93d-fae6d2c41498"
      unitRef="usd">21133000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfMi0zLTEtMS03MDI3NQ_fa4a806a-448e-47f1-9099-baafbd870147"
      unitRef="usd">-43977000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfMy0xLTEtMS03MDI3NQ_24a99a0b-881f-43f3-83d7-24f415e9e9bf"
      unitRef="usd">2045000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfMy0zLTEtMS03MDI3NQ_210fe362-3910-418f-9714-8c1cb26cce07"
      unitRef="usd">-1904000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfNC0xLTEtMS03MDI3NQ_7bde5a56-3cba-4066-a0e0-d1076dd8e34b"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfNC0zLTEtMS03MDI3NQ_28be355b-bdb4-48e6-8bf8-fa65d0bbd649"
      unitRef="usd">-19000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfNS0xLTEtMS03MDI3NQ_a335e0b9-826f-4681-9543-81153d937202"
      unitRef="usd">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfNS0zLTEtMS03MDI3NQ_a9462161-b03f-4287-a8a6-b1c5a85ad55b"
      unitRef="usd">-1083000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfOS0xLTEtMS03MDI3NQ_2de31bcf-39b3-4648-afff-a401f6c55311"
      unitRef="usd">23779000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18yOC9mcmFnOmJkYzg1NmYxNTJjNzRjODM5MGZmMjljNmUxOGU4MWEyL3RhYmxlOjcyZjgwMjM5ZWE3ZDQ4OTlhYzNmMzM2NGZiNGQwNWZlL3RhYmxlcmFuZ2U6NzJmODAyMzllYTdkNDg5OWFjM2YzMzY0ZmI0ZDA1ZmVfOS0zLTEtMS03MDI3NQ_0b50049a-d899-480d-963e-6800c5021fba"
      unitRef="usd">-46945000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia30a9e39409b461c99159daa010f6c5c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy0xLTEtMS03MDI3NQ_b6cd1439-2f78-4c15-a392-adf029f3963e"
      unitRef="shares">166793320</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia30a9e39409b461c99159daa010f6c5c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy0zLTEtMS03MDI3NQ_c4345085-703e-49d0-9c72-026773fb6b4f"
      unitRef="usd">1668000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iedb9034932fc40c08ea5573339590e7f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy01LTEtMS03MDI3NQ_10fdc0e1-713e-4f2e-a8cd-51a42732d78b"
      unitRef="usd">1450239000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac4ded14953b49d1addd06f731f72c7b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy03LTEtMS03MDI3NQ_0b8a6e22-5e55-4d8e-8679-e9538aed0096"
      unitRef="usd">-1148545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f7c9d06ff1b4ead8670defb0e972860_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy05LTEtMS03MDI3NQ_295150da-22e4-423d-b141-83ac1752d9cb"
      unitRef="usd">-8404000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMy0xMS0xLTEtNzAyNzU_01222d17-a7b8-4f9c-992b-b95f0ec8f5fb"
      unitRef="usd">294958000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic0c77020818e4b5580a54602bc3733dc_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNC0xLTEtMS03MDI3NQ_3e28b91c-d572-4cc6-97b0-5c146eb8ee68"
      unitRef="shares">3962430</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic0c77020818e4b5580a54602bc3733dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNC0zLTEtMS03MDI3NQ_663da430-530f-4b09-bd2e-199807f1111c"
      unitRef="usd">40000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icc69df1bb8ee4558ae36144749414ed9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNC01LTEtMS03MDI3NQ_99e47949-07b0-48c2-a068-ff202c8f6d6e"
      unitRef="usd">9665000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNC0xMS0xLTEtNzAyNzU_f9fb9b14-fbb4-439a-a4f4-5ae63686b6ea"
      unitRef="usd">9705000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic0c77020818e4b5580a54602bc3733dc_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNS0xLTEtMS03MDI3NQ_7e74049f-3448-45b9-a402-dde63034798a"
      unitRef="shares">1015818</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic0c77020818e4b5580a54602bc3733dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNS0zLTEtMS03MDI3NQ_f91a37da-8378-4c8b-940d-d96920574b6b"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icc69df1bb8ee4558ae36144749414ed9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNS01LTEtMS03MDI3NQ_2be61be1-9f4e-4c47-90c3-0379e01dbfb6"
      unitRef="usd">-1119000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNS0xMS0xLTEtNzAyNzU_eba774ca-4b09-4c78-a8da-4b317afbeead"
      unitRef="usd">-1109000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icc69df1bb8ee4558ae36144749414ed9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNy01LTEtMS03MDI3NQ_13459ab8-e6fe-4aa3-a611-688781360f9c"
      unitRef="usd">8277000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfNy0xMS0xLTEtNzAyNzU_68a6cc46-4bbf-4aa0-8931-a1ca2c41fba1"
      unitRef="usd">8277000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="id60c69134c4f4a03998a810770abe5f2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfOS05LTEtMS03MDI3NQ_3735bee6-2a87-4f28-8def-a5b5148dcf69"
      unitRef="usd">-2045000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfOS0xMS0xLTEtNzAyNzU_3729da10-a694-414a-a340-31c2c7b8fce9"
      unitRef="usd">-2045000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="id60c69134c4f4a03998a810770abe5f2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTAtOS0xLTEtNzAyNzU_c2bb0d0e-0ddc-4d3b-aed4-58e841912c0e"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTAtMTEtMS0xLTcwMjc1_5de03ee3-fe94-450e-9807-625fe40692df"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id60c69134c4f4a03998a810770abe5f2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTEtOS0xLTEtNzAyNzU_361f89e4-78b0-4a63-9528-bce0263bf8af"
      unitRef="usd">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTEtMTEtMS0xLTcwMjc1_7306061a-38b0-43c7-9592-dfbc7ea44210"
      unitRef="usd">604000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i6a6b4846ff7445a7bd06205ce088da41_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTMtNy0xLTEtNzAyNzU_e2a271d9-1140-4c6b-9b59-80cc6d0b20dd"
      unitRef="usd">21133000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTMtMTEtMS0xLTcwMjc1_4c89f76e-518e-46dc-a6f1-0cabbc70f215"
      unitRef="usd">21133000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="iccea421e2a0c4b47b469cdf5d493c0e0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtMS0xLTEtNzAyNzU_441aabf9-cf6e-4ba9-8f6e-999112dfb436"
      unitRef="shares">171771568</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iccea421e2a0c4b47b469cdf5d493c0e0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtMy0xLTEtNzAyNzU_8e5354d3-eab4-4dda-9af4-43e2abf03802"
      unitRef="usd">1718000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba3dfb89f8ba47408fd34040b407e005_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtNS0xLTEtNzAyNzU_22f1af98-bbba-4d60-99ca-5695dfc70d2d"
      unitRef="usd">1467062000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5abbb2c7d7944601bf890210157c2b4d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtNy0xLTEtNzAyNzU_50148880-32d5-47cf-a988-4172830a1e3d"
      unitRef="usd">-1127412000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91ca40960ab74c8fbafd0d9349205312_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtOS0xLTEtNzAyNzU_d377bf77-a0ea-42fc-a5fc-12f85457f314"
      unitRef="usd">-5758000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOjhiNGZmM2U0MTM1NjQyZDJhZGEzY2VkNjUwNDM1Nzc3L3RhYmxlcmFuZ2U6OGI0ZmYzZTQxMzU2NDJkMmFkYTNjZWQ2NTA0MzU3NzdfMTQtMTEtMS0xLTcwMjc1_10445f2d-f813-4beb-916d-8a6ad8a32a46"
      unitRef="usd">335610000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9c7722be40df413c8e437a49f401590f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy0xLTEtMS03MDI3NQ_87ee4383-befe-4742-a98f-34db444e1dad"
      unitRef="shares">145921530</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c7722be40df413c8e437a49f401590f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy0zLTEtMS03MDI3NQ_66c7a998-dea0-4471-92d8-6401fcc57c6f"
      unitRef="usd">1459000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff108f8c09274a6cbb44e10d8867b38a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy01LTEtMS03MDI3NQ_dc812f1d-a1e2-445f-b192-b5841eeeed99"
      unitRef="usd">1334138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac6d1271621d4cac8be74b9a037e4707_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy03LTEtMS03MDI3NQ_8f0b5e06-77f5-42ff-b4ca-d382ea852c41"
      unitRef="usd">-956267000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i53a89059a55449d3bc69e3f6de7098b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy05LTEtMS03MDI3NQ_9e2d829b-2306-49da-b254-e69056123270"
      unitRef="usd">-3987000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMy0xMy0xLTEtNzAyNzU_2e3b0874-d0c7-4000-8d11-b606fae3695d"
      unitRef="usd">375343000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i579b5f75540647cd977142ae38f4b321_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNS0xLTEtMS03MDI3NQ_7b4748b7-dfdd-4c6d-b267-90e6ba1f3b7b"
      unitRef="shares">743230</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i579b5f75540647cd977142ae38f4b321_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNS0zLTEtMS03MDI3NQ_e268999f-917e-41da-898b-70215d846818"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7ccefc4a682e42bda1dd7730db19dcc0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNS01LTEtMS03MDI3NQ_3e5ac3cb-e381-4a06-876e-8d07752f6820"
      unitRef="usd">-1575000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNS0xMy0xLTEtNzAyNzU_bbbccc95-fd06-4ca6-b2a0-de6e20015ecd"
      unitRef="usd">-1567000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7ccefc4a682e42bda1dd7730db19dcc0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNy01LTEtMS03MDI3NQ_91d511bb-05e4-4ee4-9c99-4d7b68f3d1b9"
      unitRef="usd">7691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfNy0xMy0xLTEtNzAyNzU_774b5439-dd18-4d1a-92b6-da6cae868916"
      unitRef="usd">7691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i9e912a9a7bc746bd96bb5d87a08b8206_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfOS05LTEtMS03MDI3NQ_018e968b-8f37-4232-a37d-ff9f8d0337fb"
      unitRef="usd">1904000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfOS0xMy0xLTEtNzAyNzU_9497cfc5-b4e4-4299-8065-4e2e52503bd8"
      unitRef="usd">1904000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i9e912a9a7bc746bd96bb5d87a08b8206_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTAtOS0xLTEtNzA3Njg_e49ec20f-afd7-47a0-9335-aaa9f776d4e4"
      unitRef="usd">-19000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTAtMTMtMS0xLTcwOTAy_503f8d70-15ee-4339-824d-c3d9491ac596"
      unitRef="usd">-19000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i9e912a9a7bc746bd96bb5d87a08b8206_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTAtOS0xLTEtNzAyNzU_ea6211ca-e578-4791-b89e-95fbc3d3f9a2"
      unitRef="usd">-1083000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTAtMTMtMS0xLTcwMjc1_7de7ce4c-c1a3-42d5-9d6a-78558c27b7fd"
      unitRef="usd">-1083000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ie1a85436c7c142278657c85e7ea9997b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTItNy0xLTEtNzAyNzU_5d1cd66f-a62d-4801-b32c-5ed8fe7065b3"
      unitRef="usd">-43977000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTItMTMtMS0xLTcwMjc1_47af44dd-4b50-4a2d-adfd-aa47d9e67c1c"
      unitRef="usd">-43977000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibeae407467224307ae4941c1984b4b7f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtMS0xLTEtNzAyNzU_352d0d0a-81f3-4aef-ab3b-b9f8711e8ad0"
      unitRef="shares">146664760</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibeae407467224307ae4941c1984b4b7f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtMy0xLTEtNzAyNzU_36fc3d72-a1c5-4565-937f-b07f9ee8d93c"
      unitRef="usd">1467000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic68b3111e2494397846164214ce99690_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtNS0xLTEtNzAyNzU_24044a60-c812-4475-87b2-c9da0868cc47"
      unitRef="usd">1340254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3bdcc1051374821b3877c109bd673ae_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtNy0xLTEtNzAyNzU_9af5cfe5-4892-49ca-825c-7e07400ab517"
      unitRef="usd">-1000244000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34bf2d104a444cc9834054ced8faa7f7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtOS0xLTEtNzAyNzU_c716f458-8111-4e21-a7f0-ff682c60ba32"
      unitRef="usd">-6955000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zMS9mcmFnOjA2Y2M2OTllMzYxNDRlNTg5MDk5MmNkYTc4M2M5NGE3L3RhYmxlOmJmN2RmYWJiZmQzMjQ3OWI4N2VhMzMyYmJlMGE1NTkxL3RhYmxlcmFuZ2U6YmY3ZGZhYmJmZDMyNDc5Yjg3ZWEzMzJiYmUwYTU1OTFfMTMtMTMtMS0xLTcwMjc1_cb6cef30-9fb2-46f7-8bcc-14f6465ce860"
      unitRef="usd">334522000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMy0xLTEtMS03MDI3NQ_407f39cf-5176-4d19-8178-48f8da7846c5"
      unitRef="usd">21133000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMy0zLTEtMS03MDI3NQ_1ca14b67-71c4-43d2-959d-296d34a54dd1"
      unitRef="usd">-43977000</us-gaap:ProfitLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNS0xLTEtMS03NTk1Nw_b5775063-59d3-4e61-8a26-97c53df7e0ba"
      unitRef="usd">38138000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNS0zLTEtMS03NTk2Ng_873705f6-5d60-4b9b-b1f4-dc871af6d458"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNy0xLTEtMS03NzkzNg_d2879dd8-4bfb-47c4-8c8f-5329047ff152"
      unitRef="usd">20433000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNy0zLTEtMS03NzkzNg_19902290-4368-4bbc-b2a3-368f25965c3d"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNS0xLTEtMS03MDI3NQ_6b1f5790-730f-429b-b761-6560cf56eadc"
      unitRef="usd">3489000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNS0zLTEtMS03MDI3NQ_0b7b0a97-71ce-434c-bbe8-6ae13ab20a9b"
      unitRef="usd">2832000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNi0xLTEtMS03MDI3NQ_adecc40e-97d1-4ddd-8324-58e5287e328b"
      unitRef="usd">1048000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNi0zLTEtMS03MDI3NQ_b0a77e31-1b97-4428-ae5c-3a79304a93ab"
      unitRef="usd">-164000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNy0xLTEtMS03MDI3NQ_6e91642d-18b2-4586-8c86-11e5b8b2bbe2"
      unitRef="usd">-2092000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNy0zLTEtMS03MDI3NQ_e72c3bea-0d3c-4031-a617-e1a115435520"
      unitRef="usd">-2106000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfOS0xLTEtMS03MDI3NQ_89ff0663-37e5-406b-8960-837cb5ff165a"
      unitRef="usd">8277000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfOS0zLTEtMS03MDI3NQ_b6775239-7f50-4586-81c3-dac1b7906083"
      unitRef="usd">7691000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTItMS0xLTEtNzAyNzU_fc4709fd-4726-4ed0-9b91-0a131aa2c14d"
      unitRef="usd">229000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTItMy0xLTEtNzAyNzU_c0c4ad74-8c27-402c-a267-fc8fa9814584"
      unitRef="usd">7000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTMtMS0xLTEtNzAyNzU_255e60ab-58b0-401d-b24a-a66ad2d65634"
      unitRef="usd">3348000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTMtMy0xLTEtNzAyNzU_c20554c3-4229-421a-a81a-3e98f4c19ba0"
      unitRef="usd">925000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTQtMS0xLTEtNzAyNzU_b98937f3-8b02-4632-b577-67d40be57d97"
      unitRef="usd">-6223000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTQtMy0xLTEtNzAyNzU_a3aefada-9c36-4830-b06b-8e7cbce49f8f"
      unitRef="usd">241000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTUtMS0xLTEtNzAyNzU_28727f34-cf5f-4522-9b0c-4eb3d4374da6"
      unitRef="usd">-1905000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTUtMy0xLTEtNzAyNzU_d730b596-b538-42b1-afc3-31c4e00ce5dd"
      unitRef="usd">3609000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTctMS0xLTEtNzAyNzU_f55b5c97-4e83-47f7-b28b-606c167e4d03"
      unitRef="usd">-8599000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTctMy0xLTEtNzAyNzU_e1ccdfd2-6da9-4c49-a0b7-57fe0bab122f"
      unitRef="usd">-8270000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTktMS0xLTEtNzAyNzU_c59285a9-f1d0-401d-ab15-7d4a34137bc2"
      unitRef="usd">-149766000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMTktMy0xLTEtNzAyNzU_cacc3cbf-8f35-4d28-989f-7ad57d6f0acd"
      unitRef="usd">-21004000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjAtMS0xLTEtNzAyNzU_10301ea6-9237-43ef-aef4-1a83c32f395b"
      unitRef="usd">-1212000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjAtMy0xLTEtNzAyNzU_ba115c5f-c386-40c1-be49-0493fd5f59d5"
      unitRef="usd">-972000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjEtMS0xLTEtNzAyNzU_28ac59eb-db6d-4a6a-a781-f563f3a2c515"
      unitRef="usd">22000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjEtMy0xLTEtNzAyNzU_4ebe2f2b-1ca2-41ad-9138-2136e8ecdcf3"
      unitRef="usd">19000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjItMS0xLTEtNzAyNzU_3110aa94-be3c-4a88-80c0-f3326c7b55fe"
      unitRef="usd">-66300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjItMy0xLTEtNzAyNzU_38d2fef8-8540-46a9-8f51-8cb45c2ceba9"
      unitRef="usd">-58975000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjQtMS0xLTEtNzAyNzU_3e7e57e9-633f-485e-ae05-57ecb3138030"
      unitRef="usd">36225000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjQtMy0xLTEtNzAyNzU_d43177e6-192c-4239-93b5-405182745624"
      unitRef="usd">65756000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjUtMS0xLTEtNzAyNzU_ad1ba6f9-b636-4fe3-b470-da83a51d8662"
      unitRef="usd">82153000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjUtMy0xLTEtNzAyNzU_ce059791-6e7c-435e-99f8-d379e25ee78c"
      unitRef="usd">70300000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjctMS0xLTEtNzAyNzU_9682e9af-3de3-422b-a599-6d2c35e0b340"
      unitRef="usd">10200000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMjctMy0xLTEtNzAyNzU_90b429b9-22ef-4c78-95c4-7cf7b15e1347"
      unitRef="usd">2839000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzAtMS0xLTEtNzAyNzU_3148e555-87bf-4eb4-95d1-96f1f9b8e1f0"
      unitRef="usd">35728000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzAtMy0xLTEtNzAyNzU_83cc2793-c9dd-48b4-bac5-c8617d843257"
      unitRef="usd">1705000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie262d508238d48dc8b762871a33221db_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzItMS0xLTEtNzAyNzU_15c2eae3-c68e-4a7d-9c90-f8e80b4b3dbd"
      unitRef="usd">9111000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id596b784d404435db73b47602bb3f897_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzItMy0xLTEtNzAyNzU_5a3280fa-821c-4c23-aa92-8ea054b25518"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzQtMS0xLTEtNzAyNzU_18c4b5d0-cd50-43a5-aef4-9425386f1214"
      unitRef="usd">1109000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzQtMy0xLTEtNzAyNzU_1b1bb0e9-9527-467f-8ec3-b016accc39d7"
      unitRef="usd">1641000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzUtMS0xLTEtNzAyNzU_d9f1a151-4ead-4d6c-af5e-a898fefb457e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzUtMy0xLTEtNzAyNzU_7213884b-eb53-4e93-9bc3-ef6570d64d80"
      unitRef="usd">74000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzctMS0xLTEtNzAyNzU_2ce0226f-205c-4d73-bb81-2aa6eaa86472"
      unitRef="usd">8002000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzctMy0xLTEtNzAyNzU_2a69a884-a5d4-4f01-858a-db7148fe6d54"
      unitRef="usd">-1567000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzgtMS0xLTEtNzAyNzU_c377f424-0743-40f0-be6d-e06f264632be"
      unitRef="usd">367000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzgtMy0xLTEtNzAyNzU_07f31527-f793-423b-9747-a6df44e9552c"
      unitRef="usd">222000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzktMS0xLTEtNzAyNzU_b2a8fec2-b834-4150-893c-faa9e7b9b6d0"
      unitRef="usd">-22203000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfMzktMy0xLTEtNzAyNzU_31eedfab-5546-47de-a41b-b4e1760386cc"
      unitRef="usd">-58615000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDAtMS0xLTEtNzAyNzU_f15f8945-55fd-4ac8-8d01-a21322ebab3a"
      unitRef="usd">101944000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDAtMy0xLTEtNzAyNzU_4d65d93a-07d6-4322-8ab7-15a91f3bdd3f"
      unitRef="usd">180372000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDEtMS0xLTEtNzAyNzU_d72292c5-ddc5-4beb-bccc-53dc398841f3"
      unitRef="usd">79741000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDEtMy0xLTEtNzAyNzU_2b149776-8528-4929-b033-f19221232cfb"
      unitRef="usd">121757000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDMtMS0xLTEtNzAyNzU_50b26076-46d4-4606-a77d-002b44183f09"
      unitRef="usd">5184000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDMtMy0xLTEtNzAyNzU_95c0ae72-5753-4635-b736-fb21dc2d9dd9"
      unitRef="usd">2257000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <sgmo:TenantImprovementAllowanceWithinContraLeaseLiability
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDUtMS0xLTEtNzAyNzU_f253792e-c745-40eb-82e2-11cead6d6374"
      unitRef="usd">243000</sgmo:TenantImprovementAllowanceWithinContraLeaseLiability>
    <sgmo:TenantImprovementAllowanceWithinContraLeaseLiability
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18zNC9mcmFnOmNhMWRlMDNjMmE1NzRhNjBhYjE2Yzc0MjI2MzE1ZjYwL3RhYmxlOmFmYTcyOTNlMmUxZDQxZmU4NGYyMjdkM2FkYTVlMjhkL3RhYmxlcmFuZ2U6YWZhNzI5M2UyZTFkNDFmZTg0ZjIyN2QzYWRhNWUyOGRfNDUtMy0xLTEtNzAyNzU_6e7ad268-8118-403d-9dd3-3495ab6330ec"
      unitRef="usd">0</sgmo:TenantImprovementAllowanceWithinContraLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwNDA_3c8f2f50-3147-4331-9559-f847db4fd65b">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization and Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo Therapeutics, Inc. (&#x201c;Sangamo&#x201d; or &#x201c;the Company&#x201d;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The Condensed Consolidated Balance Sheet data at December&#160;31, 2022 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#x201c;2022 Annual Report&#x201d;) as filed with the SEC on February&#160;23,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2022, included in the 2022 Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity, Capital Resources and Management&#x2019;s Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. In recent years, the Company&#x2019;s operations have been funded primarily through collaborations and strategic partnerships, research grants and from the issuance of equity securities. As of March&#160;31, 2023, the Company had capital resources of $241.0&#160;million consisting of cash, cash equivalents, and marketable securities. Management believes that the Company&#x2019;s existing cash, cash equivalents, and marketable securities in combination with other planned cost reduction initiatives will be sufficient to fund its operations for at least the next 12 months from the date these Condensed Consolidated Financial Statements are issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements&#x2014;Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 205-40&#x201d;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the Condensed Consolidated Financial Statements are issued. As required under ASC Topic 205-40, management&#x2019;s evaluation should initially not take into consideration the potential mitigating effects of management&#x2019;s plans that have not been fully implemented as of the date the Condensed Consolidated Financial Statements are issued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Substantial Doubt Raised&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing the first step of the evaluation, the Company concluded that the following conditions raised substantial doubt about its ability to continue as a going concern:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Although the Company reported net income of $21.1&#160;million for the three months ended March 31, 2023 primarily due to the termination of a collaboration agreement, the Company has a history of recurring net losses, including $192.3&#160;million and $178.3&#160;million for the years ended December 31, 2022 and 2021, respectively; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company had an accumulated deficit of $1,127.4&#160;million and $1,148.5&#160;million as of March&#160;31, 2023 and December 31, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consideration of Management&#x2019;s Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing the second step of this assessment, the Company is required to evaluate whether it is probable that its plans will be effectively implemented within one year after the Condensed Consolidated Financial Statements are issued and whether it is probable those plans will alleviate the substantial doubt about its ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified several actions, including cost reduction measures that already have been initiated or that would be initiated in a timely manner, to address the Company&#x2019;s liquidity needs over the twelve-month period from the date the Condensed Consolidated Financial Statements are issued, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Deferral and reprioritization of certain research and development programs that would involve reduced program and headcount spend;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Reduction in force that would be intended to extend the cash runway necessary to fund operations;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Pause on any new hiring and reduction in ancillary expenses such as travel and recruitment expenses; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Reduction in non-critical capital and operating expenditures including additional equipment, lab improvements, efficiency projects, and business support spend.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Assessment of Ability to Continue as a Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes management&#x2019;s plans, as described more fully above, will provide sufficient liquidity to meet its financial obligations and maintain levels of liquidity over the twelve-month period from the date the Condensed Consolidated Financial Statements are issued. Therefore, management has concluded these plans alleviate the substantial doubt that was raised about the Company&#x2019;s ability to continue as a going concern for at least twelve months from the date that the Condensed Consolidated Financial Statements are issued. Determining the extent to which conditions or events raise substantial doubt about the Company&#x2019;s ability to continue as a going concern and the extent to which mitigating plans sufficiently alleviate any such substantial doubt requires significant judgment and estimation by the Company. The Company makes assumptions that management&#x2019;s plans will be effectively implemented and alleviate substantial doubt and its ability to continue as a going concern. The Company believes that the estimated values used in its going concern analysis are based on reasonable assumptions. However, such assumptions are inherently uncertain and actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Future Plans and Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will be required to raise substantial additional capital to fund its operations and support its research and development endeavors. In this regard, the Company is actively seeking substantial additional capital, including through public or private equity or debt financings, royalty financings or other sources, such as strategic collaborations. However, additional capital may not be available to the Company, on terms that are acceptable or at all. If adequate funds are not available to the Company on a timely basis, or at all, the Company will be required to take additional actions to address its liquidity needs, including additional cost reduction measures such as further reducing operating expenses and delaying, reducing the scope of, discontinuing or altering its research and development activities, which could have a material adverse effect on the Company&#x2019;s business. If the Company raises additional capital through public or private equity offerings, including sales pursuant to the Company&#x2019;s at-the-market offering program with Jefferies LLC, the ownership interest of its existing stockholders will be diluted, and such dilution may be substantial, and the terms of any new equity securities may have a preference over, and include rights superior to, the Company&#x2019;s common stock. If the Company raises additional capital through royalty financings or other collaborations, strategic alliances or licensing arrangements with third parties, it may need to relinquish certain valuable rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable. If the Company raises additional capital through debt financing, the Company may be subject to specified financial covenants or covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or pursuing certain transactions, any of which could restrict the Company&#x2019;s ability to commercialize its product candidates or operate as a business. In addition, management&#x2019;s cost reduction plans are intended to reduce the Company&#x2019;s operating expenses and optimize its cash resources. Based on the timing of these cost reduction plans, the Company expects to start realizing the benefit of its efforts beginning in the second quarter of 2023; however, there can be no assurance that the Company will realize the benefits of the cost reduction plans on the anticipated timeline, or at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Kite Pharma, Inc. This adjustment was driven by a reduction in the estimated future level of the Company&#x2019;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of $8.9&#160;million, an increase in net income of $8.9&#160;million, and an increase in the Company&#x2019;s basic and diluted earnings per share of $0.06 and $0.05, respectively, for the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and licensing agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#x2019; product sales. All funds received from the Company&#x2019;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. One of the Company&#x2019;s contracts also contains a provision where the Company reimburses its customer for certain costs they incur which is accounted for as a reduction to the contract transaction price as the Company does not acquire any distinct goods or services in exchange for such payments. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most of the Company&#x2019;s performance obligations in its collaboration agreements represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct. Options to license the Company&#x2019;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g., a right to a discount the customer would not have received if they did not purchase the Company&#x2019;s services under the existing contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from bundles of licenses of intellectual property and research and development services are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#x2019;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#x2019;s performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period of performance and level of effort, including the value of Company researchers&#x2019; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi S.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Goodwill, Intangible Assets and Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events and circumstances indicate that these assets may be impaired. The Company evaluates the fair value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In testing for goodwill impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the Company elects to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, the Company performs a quantitative goodwill impairment test to compare the fair value of its reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit&#x2019;s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value (but not in excess of the carrying value of goodwill). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to testing goodwill for impairment, the Company also tests impairment for its other indefinite-lived and long-lived assets. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates that the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. The Company will evaluate the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is recognized, the Company will recognize lease impairment and subsequently amortize the remaining lease asset on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#x2019;s useful life or the end of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzU_a41d88cf-634c-4f1c-adbf-ae66c23a2693">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The Condensed Consolidated Balance Sheet data at December&#160;31, 2022 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 (the &#x201c;2022 Annual Report&#x201d;) as filed with the SEC on February&#160;23,&#160;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2022, included in the 2022 Annual Report.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNDM5ODA0NjU1ODYzMA_16ab28cf-57ed-4dc7-846a-739f0949f639"
      unitRef="usd">241000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MTk0_fee0dd20-16b2-4d98-bd1e-7b7663c0ce4e"
      unitRef="usd">21100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i02b85f2e8972441db23e17a30d5bff74_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODI3ODM3_af7c7b9d-0506-4f65-ab84-78df4f75b8b6"
      unitRef="usd">-192300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i76070b5a1a6143119c52bcf7c53c9b73_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODI3ODQ1_7ed6b3c3-eeab-4c19-affb-aef0251b0c0e"
      unitRef="usd">-178300000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MTU5_62bfd9cd-8c28-4a5b-a529-7ba36aca933b"
      unitRef="usd">-1127400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MTY4_a294ece8-3b1c-4bcf-b32b-5a15c6d79582"
      unitRef="usd">-1148500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:UseOfEstimates
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwNDU_2339d9ac-bd55-43ff-86b3-56c125c2652f">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, income taxes, fair value of assets and liabilities, including from acquisitions, useful lives and impairment of long-lived assets, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MDAx_cbe4eba4-de0f-4f3e-b123-2b383829a2d9"
      unitRef="usd">8900000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent
      contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MDIw_519392f1-389b-451a-926a-5f35d889e1d6"
      unitRef="usd">8900000</sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent>
    <sgmo:IncreaseDecreaseInEarningsPerShareBasic
      contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MDg1_2922173e-dc6b-416a-b0b2-6e2e5e72928f"
      unitRef="usdPerShare">0.06</sgmo:IncreaseDecreaseInEarningsPerShareBasic>
    <sgmo:IncreaseDecreaseInEarningsPerShareDiluted
      contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfNTQ5NzU1ODU4MDkz_00973f9f-3438-4096-acf8-d4a2a07c323b"
      unitRef="usdPerShare">0.05</sgmo:IncreaseDecreaseInEarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzY_0eb33e11-1c2c-4552-b220-f87384b54422">&lt;div style="margin-top:9pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research services. Research and licensing agreements typically include nonrefundable upfront signing or license fees, payments at negotiated rates for time incurred by Company researchers, third-party cost reimbursements, additional target selection fees, sublicense fees, milestone payments tied to ongoing development and product commercialization, and royalties on future licensees&#x2019; product sales. All funds received from the Company&#x2019;s collaboration partners are generally not refundable. Non-refundable upfront fees are fixed at the commencement of the contract. All other fees represent variable consideration in contracts. One of the Company&#x2019;s contracts also contains a provision where the Company reimburses its customer for certain costs they incur which is accounted for as a reduction to the contract transaction price as the Company does not acquire any distinct goods or services in exchange for such payments. Deferred revenue primarily represents the portion of nonrefundable upfront fees or milestone payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Most of the Company&#x2019;s performance obligations in its collaboration agreements represent distinct bundles of licenses of intellectual property and research and development services, with these components being individually non-distinct. Options to license the Company&#x2019;s intellectual property and/or acquire research and development services also represent performance obligations when they grant customers a material right, e.g., a right to a discount the customer would not have received if they did not purchase the Company&#x2019;s services under the existing contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from bundles of licenses of intellectual property and research and development services are recognized over time using a proportional performance method. Under this method, revenue is recognized by measuring progress towards satisfaction of the relevant performance obligation using a measure that best depicts the progress towards satisfaction of the relevant performance obligation. For most of the Company&#x2019;s agreements the measure of progress is an input measure based on a level of effort incurred, which includes the value of actual time by Company researchers plus third-party cost reimbursements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration allocated to options that include material rights is deferred until the options are exercised or expire. The exercise of such options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#x2019;s performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. For variable consideration, the amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. A cumulative catch-up is then recorded in the current period to reflect the updated transaction price and the updated measure of progress. The estimated period of performance and level of effort, including the value of Company researchers&#x2019; time and third-party costs, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, discount rates and probabilities of exercise of technical and regulatory success, and the expected level of effort for research and development services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract modifications occur when the price and/or scope of an arrangement changes. If the modification consists of adding new distinct goods or services in exchange for consideration that reflects standalone selling prices of these goods and services, the modification is accounted for as a separate contract with the customer. Otherwise, if the remaining goods and services are distinct from those previously provided, the existing contract is considered terminated, and the remaining consideration is allocated to the remaining goods and services as if this was a newly signed contract. If the remaining goods and services are not distinct from those previously provided, the effects of the modification are accounted for in a manner similar to the effect of a change in the estimated measure of progress, with cumulative catch-up in revenue recorded at the time of the modification. If some of the remaining goods and services are distinct from those previously provided and others are not, to account for the effects of the modification the Company applies principles consistent with the objectives of the modification accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi S.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMjk_2166e608-1351-4242-95fe-88e47178e733">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi S.A.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0c3ceda2ae9f4af0871fc85dd870550f_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMi0xLTEtMS03NDIyNg_a135f0b7-c35a-4472-ad3f-bfa91f2718a4"
      unitRef="number">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaca29c7b3b79472aaf0ee13bc56470ac_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMi0zLTEtMS03NDIyNg_ca794735-ff69-4d20-b7a4-6725742d54df"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib5248b3610244c38b223f129709425f6_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMy0xLTEtMS03NDIzNg_cc1f0fa3-df31-4c08-993a-ba930d4ac020"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i90890f44b0704bb8ac590e628ae519de_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMy0zLTEtMS03NDIzNg_4ab68dbe-872c-4d61-a746-f578ed60d6e3"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie1342bd78484460185b8895a3f6308ea_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMi0xLTEtMS03MDI3NQ_70901e2a-44d3-4094-91b7-8d2228aad6cb"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i228888ff63774a0da4d18154fc729ad5_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfMi0zLTEtMS03MDI3NQ_16afddc7-1b24-4892-977f-3fdc2539950a"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie462eedb4107492bbce0acc5ff5754d8_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfNS0xLTEtMS03MDI3NQ_0f549ad0-42ad-4fa4-a73e-0f5579dd1b17"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icc8ea2db07274d118686e8a982ad7e70_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOjNmNzI4NWM5NmRmOTQ5ZmE5YTRlMDQyMDA1OTk3MTlkL3RhYmxlcmFuZ2U6M2Y3Mjg1Yzk2ZGY5NDlmYTlhNGUwNDIwMDU5OTcxOWRfNS0zLTEtMS03MDI3NQ_b870efa9-ca0b-42c0-b767-1fd7bdd64ca5"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMjE5OTAyMzMxMzU0NQ_46c95f99-98ff-4f5f-9259-b93ac22a5722">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Goodwill, Intangible Assets and Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and indefinite-lived intangible assets are assessed for impairment on an annual basis and whenever events and circumstances indicate that these assets may be impaired. The Company evaluates the fair value of long-lived assets, which include property and equipment, leasehold improvements and right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the asset may not be fully recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In testing for goodwill impairment, the Company has the option of first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If the Company elects to bypass the qualitative assessment, or if a qualitative assessment indicates it is more likely than not that the carrying value exceeds its fair value, the Company performs a quantitative goodwill impairment test to compare the fair value of its reporting unit to its carrying value, including goodwill. If the carrying value, including goodwill, exceeds the reporting unit&#x2019;s fair value, the Company will recognize an impairment loss for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value (but not in excess of the carrying value of goodwill). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to testing goodwill for impairment, the Company also tests impairment for its other indefinite-lived and long-lived assets. The long-lived asset evaluation is performed at the asset group level, i.e., the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;comparison of the carrying amounts of an asset group to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such a review indicates that the carrying amount of the asset group is not recoverable, an impairment loss shall be measured as the amount by which the carrying amount of an asset group exceeds its fair value. Any impairment loss is allocated to the long-lived assets of the group on a pro rata basis using the relative carrying amounts of those assets, except that the carrying amount of an individual asset shall not be reduced below its fair value.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Factors that may indicate potential impairment and trigger an impairment test include, but are not limited to, general macroeconomic conditions, conditions specific to the industry and market, an adverse change in legal factors, business climate or operational performance of the business, and sustained decline in the stock price and market capitalization compared to the net book value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Calculating the fair value of a reporting unit, an asset group and an individual asset involves significant estimates and assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables. Changes in these factors and assumptions used can materially affect the amount of impairment loss recognized in the period the asset was considered impaired.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzE_79f48ed6-54bd-47ef-98ee-cfd562639a32">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash, deposits in demand money market accounts and U.S. government-sponsored entity debt securities. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTE2Mzc_7ff4562b-a923-457a-a7bf-1168b2c3088e"
      unitRef="usd">1500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzg_201c9b5e-5186-46fa-9253-f8c3c8b1b5d0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzg_7d3c596e-2fbb-4110-ba44-ce1d9b33e4b9">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMS0xLTEtMS03MDI3NQ_9f6b9c46-b5d9-48cd-a363-54a1f148243b"
      unitRef="usd">78241000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMS0zLTEtMS03MDI3NQ_8a39f882-69b4-4a67-8ac7-0db5ed763a60"
      unitRef="usd">100444000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMS01LTEtMS03MDI3NQ_d8f648e1-dfcd-41e6-9f6d-d93836aa7f52"
      unitRef="usd">120257000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMS03LTEtMS03MDI3NQ_29065a33-3548-45cd-83e1-85bd8727a201"
      unitRef="usd">178872000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMi0xLTEtMS03MDI3NQ_249edf83-a8b1-4a32-aecb-6baeaa4cd1ec"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMi0zLTEtMS03MDI3NQ_2287ce51-8420-49b4-a370-a811d1ca1984"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMi01LTEtMS03MDI3NQ_d9fddf5e-8249-4c14-93c9-6a19f5ad75ac"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMi03LTEtMS03MDI3NQ_a6631e20-caa3-45fd-a629-919cac49abf4"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMy0xLTEtMS03MDI3NQ_14a136eb-89c3-49d9-ac27-b65ed26680e8"
      unitRef="usd">79741000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMy0zLTEtMS03MDI3NQ_db77c51e-1e6d-4b94-b12e-58cd0b5bd39b"
      unitRef="usd">101944000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icbe0a9ef2e5b4cd19f30bd0c029f573d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMy01LTEtMS03MDI3NQ_c9685869-5720-4e5d-b735-42cdc728dad1"
      unitRef="usd">121757000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i50c3ccf2f215471eb76c4dfe87a19d86_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RhYmxlOmEwZDhkYzlhMzNkOTRmYjlhZWNhMjk5YTZmYjQ1ZDFiL3RhYmxlcmFuZ2U6YTBkOGRjOWEzM2Q5NGZiOWFlY2EyOTlhNmZiNDVkMWJfMy03LTEtMS03MDI3NQ_f5a019e4-2e15-477e-93e3-272246dce7ba"
      unitRef="usd">180372000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMjE5OTAyMzMyNTc5NQ_ee94b5f5-00b9-4667-bc33-387180a4bf3c">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Right-of-use assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. The Company will evaluate the lease arrangement for impairment whenever events or changes in circumstances indicate that the carrying amounts of the right-of-use asset may not be fully recoverable. To the extent an impairment of the right-of-use asset is recognized, the Company will recognize lease impairment and subsequently amortize the remaining lease asset on a straight-line basis (unless another systematic basis is more representative of the pattern in which the Company expects to consume the future economic benefits from the asset) from the date of impairment to the earlier of the end of the right-of-use asset&#x2019;s useful life or the end of the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180MC9mcmFnOjdjMzM0NTRlZTQ1ZTQ0OWQ4MTVlM2RiOTAyYTg5NDdlL3RleHRyZWdpb246N2MzMzQ1NGVlNDVlNDQ5ZDgxNWUzZGI5MDJhODk0N2VfMTIwMzk_dbdc3624-364e-4682-9eb6-aafbe55058ae">&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RleHRyZWdpb246YWI2Zjk3ZjMwNTcyNDlmMjkyYWNkNTY4ODFjMGM1NGFfMjI1Ng_9141f492-e279-4395-9930-15517dbf3a8f">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RleHRyZWdpb246YWI2Zjk3ZjMwNTcyNDlmMjkyYWNkNTY4ODFjMGM1NGFfMjI2MA_5ae03b7f-38e3-4cbb-9a7e-41e08cc9b03c">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and marketable securities. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RleHRyZWdpb246YWI2Zjk3ZjMwNTcyNDlmMjkyYWNkNTY4ODFjMGM1NGFfMjI1OA_2ca330c5-ce5d-43c0-b1cc-942f6044bab5">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents and marketable securities are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1352fdf2ec644672809d7dd3d3bed33d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfNS0xLTEtMS03MDI3NQ_a158e9de-ea42-4b12-8efc-852c9f0c0a64"
      unitRef="usd">34474000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i76977228f122459ba5f628b5569cae61_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfNS0zLTEtMS03MDI3NQ_940f2ef3-0e70-4538-a537-dadc1db67edc"
      unitRef="usd">34474000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7f7da342c5ac4a7ea636981a736322b9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfNS01LTEtMS03MDI3NQ_6eadc4af-89cc-4d6f-a403-e164855b188f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6d6fe81f256c4cc8b6f7fc522fdd2281_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfNS03LTEtMS03MDI3NQ_d41c60c2-69a2-4c66-bea9-b386c45b888f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f61e5cec7984b35ac4292098852fc91_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfOC0xLTEtMS03MDI3NQ_a20d709a-7081-46fb-805d-cbb8b130d056"
      unitRef="usd">34474000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie9898b19bcd74221a4ff8f06d9cb7cf7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfOC0zLTEtMS03MDI3NQ_aec56d1d-fdb1-421f-b7e3-22f83350c325"
      unitRef="usd">34474000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i92619e333cc24f9e975a7de1bb2abeea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfOC01LTEtMS03MDI3NQ_809ad2fc-c046-4fad-a80b-790f0d025431"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6a1749f9f00c4883957a94b42aedc00f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfOC03LTEtMS03MDI3NQ_d0c64087-e9e1-44cd-aad0-4547b0b37f04"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3eacf9813ba44226a063dc9009a4a15f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTAtMS0xLTEtNzAyNzU_8814c1e1-0041-419a-a1a2-b2fba58842b3"
      unitRef="usd">33720000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4dceda8408ab4f4fbd7740cca575d5b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTAtMy0xLTEtNzAyNzU_29a6fd11-fd7c-41bb-af72-d7eba3fc7f30"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iea9e2a9aacec47b5a0dad2b07a352357_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTAtNS0xLTEtNzAyNzU_09353fd8-1fb8-400f-ab3c-a93c911d0948"
      unitRef="usd">33720000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i869c2ae932a24254b8289f3374d6a37b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTAtNy0xLTEtNzAyNzU_efc55d78-ed74-4440-bd36-afa2d2a3500f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie603a77a75c24e5bb6587690295c6f3d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTEtMS0xLTEtNzAyNzU_b8ef62f1-83b9-4a37-8f70-8d4fef640259"
      unitRef="usd">70836000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee59432e21b44a0e8975d6f3b16c5c4a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTEtMy0xLTEtNzAyNzU_75f0d900-42c7-4f25-b0a7-d7454ce79e7a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26ea0b74cc8544e1a3c671264db84d1e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTEtNS0xLTEtNzAyNzU_e7372fcc-ca61-47c4-a203-41d7f179e7c2"
      unitRef="usd">70836000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5d56b50a62c74d6185fdc6510e7cc1eb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTEtNy0xLTEtNzAyNzU_0d73f841-5586-4847-9216-29bf4de675d3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6032041d43be43a9bb2dc9299dffabad_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTItMS0xLTEtNzAyNzU_00ff1fb9-e9d9-46df-8842-e2437351f68b"
      unitRef="usd">8311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i483c837a581a4a55b5c3d56642557778_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTItMy0xLTEtNzAyNzU_13e1c0c9-69dc-476d-9d8a-2d3bb4ff2a2d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i43cfc63e1c6c4f118396790ecc913456_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTItNS0xLTEtNzAyNzU_3d714758-624f-473a-bab1-b63894a505ab"
      unitRef="usd">8311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2b09c75601c44e5b6a50a7decb6edde_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTItNy0xLTEtNzAyNzU_9ce9a52b-889e-4d89-9e32-6eb981115d96"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13fb183572b948d48d0e0dde8e690e47_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTMtMS0xLTEtNzAyNzU_e6be0d93-730d-4710-8e80-f80e608211a1"
      unitRef="usd">14613000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1429086824143138e26fa0505ab0fed_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTMtMy0xLTEtNzAyNzU_40f28f55-3558-4d1f-bbfa-b13120d35b9f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iead8dc5bda5146e0849851aa8f041938_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTMtNS0xLTEtNzAyNzU_f5477062-6fdf-4c50-b11c-01a3ebba80c8"
      unitRef="usd">14613000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id37baec065284201ae771b20cce5ff25_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTMtNy0xLTEtNzAyNzU_2198f79d-d620-4e78-aadc-94fc69b82d1f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae8f85ae07f54b72871595f4e0b87538_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTQtMS0xLTEtNzAyNzU_3788455d-0620-418e-a275-0c27d0125130"
      unitRef="usd">5596000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i862b92b01544466ba544053538532461_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTQtMy0xLTEtNzAyNzU_56379ba2-49cb-4c63-9328-f64a82088fb8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i749604d15996441483daf9b51492bbbb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTQtNS0xLTEtNzAyNzU_0912dde1-bec5-42e5-8ffb-22b4e75ec21c"
      unitRef="usd">5596000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07e496ca5ed849de88c1758f1bfec843_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTQtNy0xLTEtNzAyNzU_948fcd5c-2e8a-48bf-93da-1649c36b88b2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i030f27a6938f4ae3b1d61555d37da11b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTUtMS0xLTEtNzAyNzU_79822569-8307-40f1-95d2-f34dccc8614c"
      unitRef="usd">29680000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia99bbd5a24a34bdb914d71eed48233f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTUtMy0xLTEtNzAyNzU_3f940f65-faba-46d5-9da6-0f9bbf1a1db7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78fdaa779102440c8193f79514249c1b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTUtNS0xLTEtNzAyNzU_4adc011c-e609-4c98-af2e-dbc8300b5f80"
      unitRef="usd">29680000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id2ef8c6fa4624c93842e0f3638e26f25_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTUtNy0xLTEtNzAyNzU_e5aa9c5a-d15f-4f10-a7d0-a506b2f9d08a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f61e5cec7984b35ac4292098852fc91_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTYtMS0xLTEtNzAyNzU_6e3a5aa5-3109-4d94-9232-c16ce7af6b71"
      unitRef="usd">162756000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9898b19bcd74221a4ff8f06d9cb7cf7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTYtMy0xLTEtNzAyNzU_69197231-bd50-4436-8f90-dcd48a9335f7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i92619e333cc24f9e975a7de1bb2abeea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTYtNS0xLTEtNzAyNzU_781a4435-395c-40e9-ab26-4b71984a7f7f"
      unitRef="usd">162756000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6a1749f9f00c4883957a94b42aedc00f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTYtNy0xLTEtNzAyNzU_e739a03f-bc74-49b1-af57-9c5b36e89097"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2f61e5cec7984b35ac4292098852fc91_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTctMS0xLTEtNzAyNzU_bafa6ddf-1d03-4702-b368-36db4e7f0ed2"
      unitRef="usd">197230000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie9898b19bcd74221a4ff8f06d9cb7cf7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTctMy0xLTEtNzAyNzU_44f365a2-abb4-4240-8114-199c833595d7"
      unitRef="usd">34474000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i92619e333cc24f9e975a7de1bb2abeea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTctNS0xLTEtNzAyNzU_d93c05a1-f8e6-4ac8-aaf5-1d9cea7db1f0"
      unitRef="usd">162756000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6a1749f9f00c4883957a94b42aedc00f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmZlNWYwYjk1YzlkOTRkOWI5NTFmYmQxZDk0MjgyN2RlL3RhYmxlcmFuZ2U6ZmU1ZjBiOTVjOWQ5NGQ5Yjk1MWZiZDFkOTQyODI3ZGVfMTctNy0xLTEtNzAyNzU_8ecd562e-c1d4-451a-9bb6-6771f36a3449"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i75fa9da1a76b437cb308a2069d2b6eab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNS0xLTEtMS03MDI3NQ_6a3040bd-ddea-421e-bc42-dc27af142c65"
      unitRef="usd">50820000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iceb0eb1a3d40494d975a79e8bcfe27f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNS0zLTEtMS03MDI3NQ_d368c85a-d382-435b-b4c3-17c18096139b"
      unitRef="usd">50820000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic5c39a22139a4538b0384f237621d593_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNS01LTEtMS03MDI3NQ_867892ba-2beb-418b-bb22-68506295017d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9f4b7dc92a60450187eb7cba78d4c993_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNS03LTEtMS03MDI3NQ_028a9e6a-b1a6-4dd5-a985-edf473da6c2b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iab229808f3044fba8b9d5250cb15ae30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNi0xLTEtMS03MDI3NQ_b426d2cf-84b8-4918-b348-fecdd6471bff"
      unitRef="usd">50820000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8b36ed08a50e40e19b52b258e576bdcb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNi0zLTEtMS03MDI3NQ_2203a7ec-ff5c-44d7-9a10-a413a913c886"
      unitRef="usd">50820000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i202c7c1338114a3bb3508dd0e372fd84_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNi01LTEtMS03MDI3NQ_e0bdee6e-ccf6-47d1-9b0b-94372340e57f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7057bf4fdd9c4e7eaa545683b37732c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfNi03LTEtMS03MDI3NQ_fc971556-1f51-49c4-916a-218975171515"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if73e2cb32fab46ffbe55e9f5a5da0de2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOC0xLTEtMS03MDI3NQ_4cfda76d-8b29-4685-aa5d-29fc8874e94d"
      unitRef="usd">18417000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02fe7f2d5f244d2b94f1aaaaefcea866_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOC0zLTEtMS03MDI3NQ_deba7efe-e95a-4540-b7ef-0f001400f539"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic9260c94253f4086af0b69700e462ff9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOC01LTEtMS03MDI3NQ_754951ca-e691-43f0-a221-30218076e8d9"
      unitRef="usd">18417000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifd16acd018e74a0eb2ef2d18b3ee3a05_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOC03LTEtMS03MDI3NQ_cc72587c-bb6f-470d-b303-efbcbd1c0f28"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i023a682c38c1450e86a5514fd42920ab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOS0xLTEtMS03MDI3NQ_3232cae3-95a5-4f78-94e1-f5341f4bc2ae"
      unitRef="usd">101165000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if75b8fa59ce34fb895f1352a74043e96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOS0zLTEtMS03MDI3NQ_79642652-20fc-4e0c-9c9e-9ceac53b809a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7724b0150a1d4054a320c6e4ef27fccd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOS01LTEtMS03MDI3NQ_67a6638c-c0b6-4578-810a-09168716f1f8"
      unitRef="usd">101165000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ed6d25a758441dbb31e2700f31431a6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfOS03LTEtMS03MDI3NQ_1b72631d-7eee-4dc1-bb8b-703b9994aa5b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6febdf9b3c3b4c168661eb22fdc0ed1e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTAtMS0xLTEtNzAyNzU_df5dc39d-9a01-4d08-9a56-9ab3844d5960"
      unitRef="usd">11670000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ce4a249017b49d09aabf529ed967fae_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTAtMy0xLTEtNzAyNzU_25c3094c-421f-4583-b78c-7f44af6cd960"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb946291e031440cbc217d13ca32b3be_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTAtNS0xLTEtNzAyNzU_bd7ae44c-907e-4b3e-a397-96789adb5998"
      unitRef="usd">11670000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d5cfc64a3af4b758962c25f72175778_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTAtNy0xLTEtNzAyNzU_d020f7ad-35fd-4f71-9432-2d664d7ca7a6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4dfcb895014c45b9afa399178f988a8f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtMS0xLTEtNzEyMjM_5f8195f1-5bb5-442f-8816-8d3971e0936f"
      unitRef="usd">24792000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb05bb816d48471695d20ca909641996_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtMy0xLTEtNzEyMjM_3041a834-37e9-4b30-b92d-9d70c53f90b2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6e171ab888a84b13bd2208636c991ac8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtNS0xLTEtNzEyMjM_5a47ae08-567c-4dc0-920a-ac3d6e070d02"
      unitRef="usd">24792000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i710edc7861594a64934aa92ebca6d053_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtNy0xLTEtNzEyMjM_939f547f-1355-4251-a5a9-2c8c9c4f8e25"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic22c629aefe14ad9a522a27354756d3e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtMS0xLTEtNzExNzQ_b4db5bc9-d770-44a2-b2ce-1df04384309e"
      unitRef="usd">7938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c5f113b72b84c4b83630824ece95871_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtMy0xLTEtNzExOTA_7df65f8c-cc20-448c-bf61-346b0f764bbb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e703c64cdfb44f3ba9f51bd3b3515d0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtNS0xLTEtNzExNzQ_1ce668dc-24c9-4fd7-b191-9ff136af5573"
      unitRef="usd">7938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2beb4271e37a4f91875382a0f384b26b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTEtNy0xLTEtNzExOTA_4f331d59-875d-48e3-9acb-daf5bc4e242e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic9bac443782f4620ba81a5a825bcf681_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTItMS0xLTEtNzAyNzU_6eb11fb4-7371-4f19-8b11-7488200d3513"
      unitRef="usd">37461000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if22b2e9750244dc98e0c8b4d07365f2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTItMy0xLTEtNzAyNzU_01b52cdb-7d3f-4a25-92e8-ffb675638e10"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b64c2dbe567488896866da512af7840_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTItNS0xLTEtNzAyNzU_3873146a-2a56-4374-a206-f020537b9635"
      unitRef="usd">37461000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i72394fea9c574b08a7bf8ac3b21f6a13_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTItNy0xLTEtNzAyNzU_6dbb1fc4-f790-4bdb-a159-b6133d70e414"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46d82c5052ab497b84f515cc2d04ad09_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtMS0xLTEtNzEyMTU_96235082-efd4-4126-87f3-320529aaaecf"
      unitRef="usd">5590000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33ecf1a446814705933fbfd6cb111914_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtMy0xLTEtNzEyMTU_4ce84d59-9272-4683-ba6d-abfe6aa37c87"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0be6f0fd28e547138aedec8a3f9ad6c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtNS0xLTEtNzEyMTU_ef905001-fe4b-4303-b27f-ad92dfb7e649"
      unitRef="usd">5590000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b32d58beb5e49b0addbd7559d9a7775_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtNy0xLTEtNzEyMTU_e88c12e2-a8b5-438d-942e-5679c58266f6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iab229808f3044fba8b9d5250cb15ae30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTMtMS0xLTEtNzAyNzU_399bead3-4b2d-4302-b146-3e3f589dad1c"
      unitRef="usd">207033000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b36ed08a50e40e19b52b258e576bdcb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTMtMy0xLTEtNzAyNzU_2bc071c5-671a-4f86-b6f2-68d3d26032b7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i202c7c1338114a3bb3508dd0e372fd84_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTMtNS0xLTEtNzAyNzU_9c09cf33-3e48-4501-ad33-b36eec575987"
      unitRef="usd">207033000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7057bf4fdd9c4e7eaa545683b37732c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTMtNy0xLTEtNzAyNzU_98623a7c-e30e-48ea-b200-236416c51eee"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iab229808f3044fba8b9d5250cb15ae30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtMS0xLTEtNzAyNzU_365e44c5-9251-412d-85ad-3b692b84cd52"
      unitRef="usd">257853000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b36ed08a50e40e19b52b258e576bdcb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtMy0xLTEtNzAyNzU_9f200a26-1054-48db-aedf-b3eedc19b1df"
      unitRef="usd">50820000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i202c7c1338114a3bb3508dd0e372fd84_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtNS0xLTEtNzAyNzU_a5fda2ca-9574-4016-a57a-6f5fc66882fa"
      unitRef="usd">207033000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7057bf4fdd9c4e7eaa545683b37732c2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180My9mcmFnOmFiNmY5N2YzMDU3MjQ5ZjI5MmFjZDU2ODgxYzBjNTRhL3RhYmxlOmYxY2E2ODkxYTUwNzQzMjRhMzhlMWMzNzZjMzhkYzhlL3RhYmxlcmFuZ2U6ZjFjYTY4OTFhNTA3NDMyNGEzOGUxYzM3NmMzOGRjOGVfMTQtNy0xLTEtNzAyNzU_67b98157-1b57-4242-b9eb-f765d6c7b11d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjczOQ_32976dbb-ca70-4c59-8952-c97e7e125951">CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no realized gains and losses on the sales of investments during the three months ended March&#160;31, 2023. Realized gains and losses on the sales of investments were not material during the three months ended March&#160;31, 2022. Total unrealized gains for securities with net gains in accumulated other comprehensive income were not material for the three months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;did not record an allowance for credit losses or other impairment charges related to its marketable securities for the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2023 and 2022. The Company had no material unrealized losses, individually and in the aggregate, for marketable securities that are in a continuous unrealized loss position for greater than 12 months as of March&#160;31, 2023 and December&#160;31, 2022. Based on the scheduled maturities of its investments, the Company determined that it was more likely than not that it will hold these investments for a period of time sufficient for a recovery of its amortized cost basis. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews its marketable securities for indications of credit losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#x2019;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#x2019;s ability and intent to hold the investments until maturity, the Company determined that no allowance for credit losses related to its marketable securities was required at either March&#160;31, 2023 or December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjc0NA_e3806a2e-45e1-4586-9ce8-8b23192afe04">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(918)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i93fcf6ad011a47d8bd403279bf5444bd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNC0xLTEtMS03MDI3NQ_b768ec37-abeb-43e9-929c-eef4be5af6e2"
      unitRef="usd">34474000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i93fcf6ad011a47d8bd403279bf5444bd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNC0zLTEtMS03MDI3NQ_ec382301-fb73-42a1-9dbb-61f40f2957d5"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i93fcf6ad011a47d8bd403279bf5444bd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNC01LTEtMS03MDI3NQ_02804faf-f64e-465c-8404-bf49527b2c40"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i93fcf6ad011a47d8bd403279bf5444bd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNC03LTEtMS03MDI3NQ_5fdf7514-a395-4167-a1af-ef78a8a9a5e8"
      unitRef="usd">34474000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i19697738bf094279973b7cad292bc53f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNy0xLTEtMS03MDI3NQ_88df9861-cf5c-495b-849b-9ef88f229c48"
      unitRef="usd">34474000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i19697738bf094279973b7cad292bc53f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNy0zLTEtMS03MDI3NQ_20ea6ed6-1d8a-4b23-87ab-6793293c4210"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i19697738bf094279973b7cad292bc53f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNy01LTEtMS03MDI3NQ_04a919d8-6dfa-4597-988c-d8ccddf7a0d9"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i19697738bf094279973b7cad292bc53f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfNy03LTEtMS03MDI3NQ_1e519318-84ea-45cf-8380-33e4ca800fa2"
      unitRef="usd">34474000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i054c316aa399405fb28e17d9ac5f6b7b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfOS0xLTEtMS03MDI3NQ_e7b3adf2-5b99-41a3-9e74-34f41dfb3e12"
      unitRef="usd">33753000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i054c316aa399405fb28e17d9ac5f6b7b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfOS0zLTEtMS03MDI3NQ_c0f573d5-39d4-47bb-8e06-f6cd0d011373"
      unitRef="usd">94000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i054c316aa399405fb28e17d9ac5f6b7b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfOS01LTEtMS03MDI3NQ_f081cb1f-e684-4ed2-8acf-9655e3e6e4a8"
      unitRef="usd">127000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i054c316aa399405fb28e17d9ac5f6b7b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfOS03LTEtMS03MDI3NQ_a85fdfcb-cbab-40b9-9a4f-f6add8bc80a4"
      unitRef="usd">33720000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3e3248fa7b3248df8737d1c52d665c5b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTAtMS0xLTEtNzAyNzU_8d15f56e-267b-4067-b732-65c28be1ef23"
      unitRef="usd">70906000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3e3248fa7b3248df8737d1c52d665c5b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTAtMy0xLTEtNzAyNzU_8dfb4e9c-4915-457c-970e-c94c7e564424"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3e3248fa7b3248df8737d1c52d665c5b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTAtNS0xLTEtNzAyNzU_b9fc7c5f-63c2-4568-b7bb-e929dac86320"
      unitRef="usd">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e3248fa7b3248df8737d1c52d665c5b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTAtNy0xLTEtNzAyNzU_b52ce681-79c3-4495-8e77-5c99673fde24"
      unitRef="usd">70836000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8f9b4275c69b4a3da6c127b76ab498d0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTEtMS0xLTEtNzAyNzU_5cf5f8e5-78d2-4232-93bb-21640fe93d96"
      unitRef="usd">8335000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8f9b4275c69b4a3da6c127b76ab498d0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTEtMy0xLTEtNzAyNzU_402f1fb1-a193-4fd6-98ff-b27b0283f445"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8f9b4275c69b4a3da6c127b76ab498d0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTEtNS0xLTEtNzAyNzU_5a9984f1-0702-4f31-8e1f-8e4aec8dae75"
      unitRef="usd">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f9b4275c69b4a3da6c127b76ab498d0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTEtNy0xLTEtNzAyNzU_e68f7fc5-f148-464e-9e14-0c545e70db2a"
      unitRef="usd">8311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id4f486712abb466bb4fed83def8c8c69_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTItMS0xLTEtNzAyNzU_611fb858-8a97-4e07-a1fe-e47fef0afa87"
      unitRef="usd">14689000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id4f486712abb466bb4fed83def8c8c69_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTItMy0xLTEtNzAyNzU_12e14bf3-3ffc-4645-80a0-153c7e50ba7e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id4f486712abb466bb4fed83def8c8c69_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTItNS0xLTEtNzAyNzU_7e810fe5-afe2-41af-8e19-046da88bffd3"
      unitRef="usd">76000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id4f486712abb466bb4fed83def8c8c69_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTItNy0xLTEtNzAyNzU_adaaaa84-e6b9-455c-9907-a12b9073df5c"
      unitRef="usd">14613000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1e554d5745be4b61b64b3b228f9ea2b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTMtMS0xLTEtNzAyNzU_2c302156-30d6-4cd5-af65-618c0680910f"
      unitRef="usd">5598000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1e554d5745be4b61b64b3b228f9ea2b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTMtMy0xLTEtNzAyNzU_7389d964-9f19-4e0e-8193-5a861f6adb3c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1e554d5745be4b61b64b3b228f9ea2b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTMtNS0xLTEtNzAyNzU_9416aba0-c0ce-4132-9c8d-99dc12a80fab"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e554d5745be4b61b64b3b228f9ea2b6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTMtNy0xLTEtNzAyNzU_099ede52-ad62-4ab6-aeb5-ca16a9cd9937"
      unitRef="usd">5596000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1113f5d2f3014aeab32e8e98f8161f84_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTQtMS0xLTEtNzAyNzU_edfef7c7-36a1-42fe-911f-388e6807f8e4"
      unitRef="usd">29761000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1113f5d2f3014aeab32e8e98f8161f84_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTQtMy0xLTEtNzAyNzU_c99f5d97-53a1-44ae-b506-077d3790f172"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1113f5d2f3014aeab32e8e98f8161f84_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTQtNS0xLTEtNzAyNzU_042d902c-2fb2-4457-ad05-b25fe1dcbb72"
      unitRef="usd">83000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1113f5d2f3014aeab32e8e98f8161f84_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTQtNy0xLTEtNzAyNzU_3ae807dc-c3f5-4f78-b1a0-995e8d473a85"
      unitRef="usd">29680000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTUtMS0xLTEtNzAyNzU_d4d80305-62e8-4c5e-8f41-34e39d6e65c1"
      unitRef="usd">163042000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTUtMy0xLTEtNzAyNzU_55eb4caf-886c-4e6f-9a5f-1b9e183f26e1"
      unitRef="usd">105000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTUtNS0xLTEtNzAyNzU_2f80aa73-942a-4b32-8f3d-aae0eb1c9d6f"
      unitRef="usd">391000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTUtNy0xLTEtNzAyNzU_2e60f305-829f-4840-b531-3ca4cfb4cfc8"
      unitRef="usd">162756000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTYtMS0xLTEtNzAyNzU_5a854553-3da1-4393-8eb3-31a1f5123678"
      unitRef="usd">197516000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTYtMy0xLTEtNzAyNzU_abefd35f-d579-4acd-aa36-9ea58030791b"
      unitRef="usd">105000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTYtNS0xLTEtNzAyNzU_3f357f11-f21c-42e7-9e68-ceede16b39c9"
      unitRef="usd">391000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMTYtNy0xLTEtNzAyNzU_819e0174-0681-4d6a-a182-fac3e8d7954f"
      unitRef="usd">197230000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i739dc723663c47d7b30394d8567919dc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjEtMS0xLTEtNzAyNzU_81b157db-2913-4cb1-bba0-50bb35685f3a"
      unitRef="usd">50820000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i739dc723663c47d7b30394d8567919dc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjEtMy0xLTEtNzAyNzU_7474553a-1966-44da-82c1-70f957caa1f6"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i739dc723663c47d7b30394d8567919dc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjEtNS0xLTEtNzAyNzU_f638dc5d-9986-4617-9e86-d054dda7eff1"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i739dc723663c47d7b30394d8567919dc_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjEtNy0xLTEtNzAyNzU_490cdb3d-e33f-43b9-a3a1-ea75fc8c7661"
      unitRef="usd">50820000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i382c5b6d179045cab6406d5372cc5441_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjItMS0xLTEtNzAyNzU_6b0f0c4c-a408-44f8-830e-cb783982eb22"
      unitRef="usd">50820000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i382c5b6d179045cab6406d5372cc5441_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjItMy0xLTEtNzAyNzU_3c2757ae-d039-47c9-9ded-0b53fd598e9a"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i382c5b6d179045cab6406d5372cc5441_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjItNS0xLTEtNzAyNzU_0311a696-ae23-471b-bcca-7fce4cb9b0ec"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i382c5b6d179045cab6406d5372cc5441_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjItNy0xLTEtNzAyNzU_a26e3e97-78ce-4a4e-b89a-7f3b1cf0b0ae"
      unitRef="usd">50820000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib74d65ada2ff4867ab5f3259d7d950ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjQtMS0xLTEtNzAyNzU_d2bf7477-f483-4121-ad13-f98ba8534b84"
      unitRef="usd">18710000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib74d65ada2ff4867ab5f3259d7d950ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjQtMy0xLTEtNzAyNzU_c217abcf-c178-4909-aeab-9a7e0105f807"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib74d65ada2ff4867ab5f3259d7d950ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjQtNS0xLTEtNzAyNzU_a2cae439-a7a5-47cf-8364-7acda6a4a304"
      unitRef="usd">293000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib74d65ada2ff4867ab5f3259d7d950ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjQtNy0xLTEtNzAyNzU_8d1bbe57-39cf-439c-bef8-53e7180a1a36"
      unitRef="usd">18417000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if54118fa133440819c9192da179240e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjUtMS0xLTEtNzAyNzU_99c191d7-1825-408e-a2d0-eec14073e6d1"
      unitRef="usd">101336000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if54118fa133440819c9192da179240e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjUtMy0xLTEtNzAyNzU_8bc3f25b-c6c2-45d1-8545-5296626870de"
      unitRef="usd">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if54118fa133440819c9192da179240e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjUtNS0xLTEtNzAyNzU_83d61b5b-c58a-4d13-afe0-1ee2015b1d2b"
      unitRef="usd">193000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if54118fa133440819c9192da179240e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjUtNy0xLTEtNzAyNzU_f7faf1e6-bc59-4fb0-ad17-ce3814f309fe"
      unitRef="usd">101165000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if9f8bb01a8d149d993b5ba9c67d52a69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjYtMS0xLTEtNzAyNzU_48799567-6e1b-4ca4-9aea-98684c83002b"
      unitRef="usd">11760000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if9f8bb01a8d149d993b5ba9c67d52a69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjYtMy0xLTEtNzAyNzU_3110bfc7-e68c-4de0-9d00-66ed2c58ba56"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if9f8bb01a8d149d993b5ba9c67d52a69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjYtNS0xLTEtNzAyNzU_a850dfcc-287c-4044-839b-47b6a647003b"
      unitRef="usd">90000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if9f8bb01a8d149d993b5ba9c67d52a69_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjYtNy0xLTEtNzAyNzU_9f6c9f3e-7968-4adf-b042-1b955dbe2e74"
      unitRef="usd">11670000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0441be5e852742ed898a9eb78b769265_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjctMS0xLTEtNzAyNzU_abf977ae-eee1-4a53-b806-8aed67ea5211"
      unitRef="usd">24970000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0441be5e852742ed898a9eb78b769265_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjctMy0xLTEtNzAyNzU_d7d092e4-b95d-4bef-bd50-d3c1278500c9"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0441be5e852742ed898a9eb78b769265_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjctNS0xLTEtNzAyNzU_5641d96a-950a-4f0d-9e29-9a6d459948db"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0441be5e852742ed898a9eb78b769265_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjctNy0xLTEtNzAyNzU_33ab22d6-2274-4b28-9c0a-9ccf5e9ce258"
      unitRef="usd">24792000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i775d20c1dc4c46e68398640e2b73e1dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtMS0xLTEtNzEzNDM_ab93939f-e478-4cca-ba72-18703b4fa210"
      unitRef="usd">7950000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i775d20c1dc4c46e68398640e2b73e1dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtMy0xLTEtNzEzNDM_37669743-6282-4b6f-b3a6-8e46b42f6bf0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i775d20c1dc4c46e68398640e2b73e1dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtNS0xLTEtNzEzNDM_3ba476e0-b9cc-4f7c-abfa-6dd89806307b"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i775d20c1dc4c46e68398640e2b73e1dd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtNy0xLTEtNzEzNDM_3b1ad094-3351-47f6-b671-19a4856d86de"
      unitRef="usd">7938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if04730ad90e0401eb7693f8828b8bc5d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtMS0xLTEtNzAyNzU_0c4e66fe-9e85-4ac5-8ace-1084db5c2c9f"
      unitRef="usd">37599000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if04730ad90e0401eb7693f8828b8bc5d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtMy0xLTEtNzAyNzU_d0c51a77-f9d9-462a-ac70-4eb8dab92b38"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if04730ad90e0401eb7693f8828b8bc5d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtNS0xLTEtNzAyNzU_c4f9da5a-2839-44f3-8a79-6ee300294ceb"
      unitRef="usd">142000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if04730ad90e0401eb7693f8828b8bc5d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjgtNy0xLTEtNzAyNzU_873b30f6-59ae-4048-a8ee-0113c49feddc"
      unitRef="usd">37461000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if03492c5aa4e4c55a0716a7facf39b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtMS0xLTEtNzEzNTE_8a0df2fd-a390-4cfd-b4cf-e14df05fdca7"
      unitRef="usd">5598000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if03492c5aa4e4c55a0716a7facf39b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtMy0xLTEtNzEzNTE_121b0bc3-94bd-4b68-a733-1799a4ae5c6f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if03492c5aa4e4c55a0716a7facf39b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtNS0xLTEtNzEzNTE_93776e05-c842-4aa7-a852-746a39725729"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if03492c5aa4e4c55a0716a7facf39b4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtNy0xLTEtNzEzNTE_f8953ba3-9c12-40ca-b551-5d29a535533d"
      unitRef="usd">5590000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjktMS0xLTEtNzAyNzU_e685ecc4-1323-497f-b257-99f9d891225e"
      unitRef="usd">207923000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjktMy0xLTEtNzAyNzU_55ea4ad1-42bc-427f-9430-caba84ed3e2e"
      unitRef="usd">28000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjktNS0xLTEtNzAyNzU_101a5bc8-94fd-4d08-ba2c-5bb047addd1f"
      unitRef="usd">918000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMjktNy0xLTEtNzAyNzU_cd7014f4-a652-406f-9713-acb3d8470d3d"
      unitRef="usd">207033000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtMS0xLTEtNzAyNzU_a72ce3c8-0dea-4cbd-b426-fdff9277f866"
      unitRef="usd">258743000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtMy0xLTEtNzAyNzU_11f4cb4f-1e0a-49e6-9b61-36f67ea88069"
      unitRef="usd">28000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtNS0xLTEtNzAyNzU_5928018a-6a15-4904-9112-74224fc235de"
      unitRef="usd">918000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjlhMDI4MDcxYjVjODQ4YWQ5YzllYzhhMjc3MWJmNTEzL3RhYmxlcmFuZ2U6OWEwMjgwNzFiNWM4NDhhZDljOWVjOGEyNzcxYmY1MTNfMzAtNy0xLTEtNzAyNzU_fde3f23b-da08-48b2-88ec-d111b40d142d"
      unitRef="usd">257853000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjc0Ng_1348f896-cfcd-4743-8d2d-3126bc668bb7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMS0xLTEtMS03MDI3NQ_9abf6fdc-9485-457c-87d1-862fffe05728"
      unitRef="usd">127147000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMS0zLTEtMS03MDI3NQ_b64b4b68-a9ee-45ef-a90a-9f43733239f8"
      unitRef="usd">177188000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMi0xLTEtMS03MDI3NQ_f22999fc-4b64-4132-8896-d3652213cb15"
      unitRef="usd">35609000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMi0zLTEtMS03MDI3NQ_2a0a251b-72fe-42f3-b682-b7d490770b83"
      unitRef="usd">29845000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMy0xLTEtMS03MDI3NQ_f96a4c75-bc70-45c2-9879-fbf841c0a671"
      unitRef="usd">162756000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RhYmxlOjQ3NTc4ZTNiMWQyZjQ0N2Y4NmJhNjY3ZTdhZTQzNmJhL3RhYmxlcmFuZ2U6NDc1NzhlM2IxZDJmNDQ3Zjg2YmE2NjdlN2FlNDM2YmFfMy0zLTEtMS03MDI3NQ_84acfcf3-c58a-4208-94a0-4597d0cc3968"
      unitRef="usd">207033000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjY0_897bad46-7d6d-4894-927e-7c8eae9e2845"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjc0ODc3OTA3MjY5NQ_3ccdd538-c24a-4396-b467-813edcfcd811"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfNzA4_8a1ca219-1e07-4b1d-8ba0-82ae9578ee0b"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfNzA4_9c37a077-fa3f-42ca-a64f-e3ee3680343e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfNzA4_cd659d12-069d-4433-ac9e-ebcd5c9b26c7"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfNzA4_d9bc8f1a-ff1f-4ff3-9e8c-010968b39d1f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i9a68418627e64a97967175e21376a7f3_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjY0MA_507ef156-1d7c-4573-9b1e-768e5d19755d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ic4324bd7b11f411d9e7d667c237daef0_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N180Ni9mcmFnOmZmNjg4M2E5OWQ1MzQxODc5YjgzYTRmYTg4M2U4N2MzL3RleHRyZWdpb246ZmY2ODgzYTk5ZDUzNDE4NzliODNhNGZhODgzZTg3YzNfMjY0MA_62701416-a86a-48b8-9b19-b1a036eef59c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RleHRyZWdpb246MGRkYmZhYzcwYjMwNDJlNTlkZmFmMzhhNGFjYzU3MWZfMTE0MA_0e52cb28-99bd-4f34-a993-4b3c1f888a16">BASIC AND DILUTED NET INCOME (LOSS) PER SHARE&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share has been computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of common stock pursuant to employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The computation of diluted net income per share for the three months ended March&#160;31, 2023 excluded 14.7&#160;million shares subject to stock options because their inclusion would have had an anti-dilutive effect on diluted net income per share. The computation of diluted net loss per share for the three months ended March 31, 2022 excluded 19.1&#160;million shares subject to stock options, restricted stock units outstanding, and the employee stock purchase plan shares reserved for issuance because their inclusion would have had an anti-dilutive effect on diluted net loss per share.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RleHRyZWdpb246MGRkYmZhYzcwYjMwNDJlNTlkZmFmMzhhNGFjYzU3MWZfMjE5OTAyMzI1ODE5MA_c640e208-07bc-4e56-9932-8bc8c2373d9a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.193%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of common stock pursuant to employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMy0xLTEtMS03NTY2MA_26e8561d-435d-40b0-a8af-1dec90aeee32"
      unitRef="usd">21133000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMy0zLTEtMS03NTY2MA_de43b60a-ec66-4bcd-9a50-e57a966ec8f3"
      unitRef="usd">-43977000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNi0xLTEtMS03NTY2MA_a57a5882-6143-44e9-bd3e-f245896ecc4e"
      unitRef="shares">168533000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNi0zLTEtMS03NTY2MA_4f301c8d-206f-4a9a-96d5-20c8215a63b7"
      unitRef="shares">146218000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfOS0xLTEtMS03NTY2MA_7ac8102b-a940-464c-aaf7-ab587f3310c0"
      unitRef="shares">168533000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfOS0zLTEtMS03NTY2MA_10ae6677-b7e6-43d5-9ebb-ecf0d65de719"
      unitRef="shares">146218000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iddef1edbf4fe4f019d6237e6e633beb1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTEtMS0xLTEtNzU2NjA_11957cb3-231f-430c-8976-1c2d727fd2b3"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie99095be5cac40ca995b3b8a0de25abf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTEtMy0xLTEtNzU2NjA_9f71aece-e2a2-40a0-b503-f963042d31e5"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia4f07d68b8514889b8593d1beef8cb7e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTItMS0xLTEtNzU2NjA_e03ce4ca-bd50-4d32-afea-087ec4cb1656"
      unitRef="shares">348000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i1be2098986b14f5aba5262c6164a6fbf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTItMy0xLTEtNzU2NjA_5d610f06-a4a1-407f-8383-354b9a814037"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTMtMS0xLTEtNzU2NjA_f8b6839e-4191-47bc-b56d-181fda0fa8c6"
      unitRef="shares">169181000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfMTMtMy0xLTEtNzU2NjA_fa105b89-b7f7-46b5-ad5c-bf21a5ac00be"
      unitRef="shares">146218000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNC0xLTEtMS03NTYyMw_cad198ca-e679-4559-9fe4-762c54778b50"
      unitRef="usdPerShare">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNC0zLTEtMS03NTYyMw_d0de4e11-94aa-405a-9809-061b11a2bec0"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNS0xLTEtMS03NTYyMw_83fa9603-b614-447f-bfe5-d49c85737a2c"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RhYmxlOjYxNjhjZmU0MmE4NjRhNWQ5ZjZmOGEyYjVjNjU3ZWNhL3RhYmxlcmFuZ2U6NjE2OGNmZTQyYTg2NGE1ZDlmNmY4YTJiNWM2NTdlY2FfNS0zLTEtMS03NTYyMw_0eaffae4-9a12-4a31-9071-9ca118add8bb"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RleHRyZWdpb246MGRkYmZhYzcwYjMwNDJlNTlkZmFmMzhhNGFjYzU3MWZfNTQ5NzU1ODE4Mjg3_5a463656-0b34-41b7-a751-a3fbd57ed69d"
      unitRef="shares">14700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181Mi9mcmFnOjBkZGJmYWM3MGIzMDQyZTU5ZGZhZjM4YTRhY2M1NzFmL3RleHRyZWdpb246MGRkYmZhYzcwYjMwNDJlNTlkZmFmMzhhNGFjYzU3MWZfNTQ5NzU1ODE4NTE2_861f851e-7d08-4e3c-bcb9-cc1a303f487d"
      unitRef="shares">19100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5NzY_2f4e8cab-b27f-4b21-a20c-330932c6aa76">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#x201c;Novartis&#x201d;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercialize certain of its zinc finger (&#x201c;ZF&#x201d;) transcriptional regulators (&#x201c;ZF-TRs&#x201d;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company was performing early research activities over the collaboration period for each gene target and manufacture the ZF-TRs required for such research, costs of which are funded by Novartis. Novartis was responsible for additional research activities, studies enabling INDs, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company was prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also had the option to license certain of the Company&#x2019;s proprietary adeno-associated viruses (&#x201c;AAVs&#x201d;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, Novartis notified the Company of its termination for convenience, effective June 11, 2023 (the &#x201c;Novartis Termination Date&#x201d;), of the collaboration agreement. Novartis has indicated to the Company that the termination relates to a recent strategic review. As of the Novartis Termination Date, the collaboration agreement will be terminated in its entirety and following the Novartis Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Novartis. As of the Novartis Termination Date, the parties will have no further obligations to develop or to fund the development of any collaboration research programs under the collaboration agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon entering the agreement, Novartis paid the Company a $75.0&#160;million upfront license fee. Novartis was also obligated to pay the Company for the use of its resources and reimburse third-party costs incurred in the Company&#x2019;s conduct of early research activities. The Company was also eligible to earn from Novartis development and commercial milestones and royalties on potential commercial sales of licensed products arising from the collaboration, none of which have been triggered or earned. The agreement was going to continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All payments received under the agreement are non-refundable and non-creditable. The transaction price of $95.1&#160;million includes the upfront license fee of $75.0&#160;million and research costs of $20.1&#160;million. All clinical or regulatory milestone amounts were considered fully constrained throughout the term of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Novartis in accordance with ASC Topic 606 and concluded that Novartis was a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license was not discrete as it did not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notice of termination was accounted for as a modification of the contract, as it changed both the scope of the Company&#x2019;s remaining services and the consideration to which the Company was entitled. The effect of the modification was not material, as the Company was nearing the completion of its assigned early research activities, and consequently, of its sole performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, the Company had a receivable of $2.1&#160;million and $2.2&#160;million, respectively, and deferred revenue of $1.9&#160;million and $9.6&#160;million, respectively, related to this agreement. The deferred revenue is expected to be recognized during the quarter ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Novartis agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront license fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $1.5&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $75.0&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $1.5&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance is released into general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic&#160;340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC Topic&#160;340&#x201d;). The Company recognized as expense $0.2&#160;million and $0.1&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#x201c;BIMA&#x201d;) and Biogen International GmbH (together with BIMA, &#x201c;Biogen&#x201d;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies planned to leverage the Company&#x2019;s proprietary ZF technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company&#x2019;s common stock (the &#x201c;Biogen Shares&#x201d;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million. The collaboration agreement became effective in April 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, Biogen notified the Company of its termination for convenience, effective June 15, 2023 (the &#x201c;Biogen Termination Date&#x201d;), of the collaboration agreement. Biogen has indicated to the Company that the termination relates to a recent strategic review. As of the Biogen Termination Date, the collaboration agreement will be terminated in its entirety and following the Biogen Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Biogen. As of the Biogen Termination Date, the parties will have no further obligations to develop or to fund the development of any collaboration research programs under the collaboration agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company was also eligible to receive target selection, research, development, regulatory and commercial milestone payments and royalties on potential net commercial sales of licensed products arising from the collaboration, none of which have been triggered or earned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize ZF and/or AAV-based products directed to certain neurological disease gene targets selected by Biogen. Biogen had selected four targets over the course of the collaboration and had exclusive rights to nominate up to seven additional targets. These rights will expire upon the Biogen Termination Date. For each gene target selected by Biogen, the Company performed early research activities, costs of which were shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZF-TRs (or potential other ZF products) targeting therapeutically relevant genes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price included the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represented the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the clinical or regulatory milestones were included in the transaction price, as all such amounts were fully constrained throughout the term of the collaboration agreement. The transaction price also included actual and estimated cost-sharing payments by Biogen for the work by Company researchers and reimbursement of the Company&#x2019;s costs incurred with third parties. The amounts paid and expected to be paid to Biogen for the use of Biogen&#x2019;s resources and its expenses were consideration paid to a customer. Since the Company did not acquire distinct goods or services in exchange for these payments, they reduced the transaction price and were recorded as reduction in revenue. The Company used the expected value method to estimate cost sharing payments, taking into account the impact of the constraint. Variable consideration was included in the transaction price only to the extent it was probable a significant reversal of cumulative revenues recognized would not occur. The Company re-evaluated the transaction price as uncertain events were resolved or other changes in circumstances occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the licenses to its intellectual property for each target were not distinct from the related research and development activities, as the licensed technology was not shared with and could not be utilized by Biogen without the research services to be performed by the Company pursuant to the agreement. On the other hand, each combination of a license to the Company's intellectual property as applied to a specific target and the related research and development activities are a discrete research project that is distinct from any other target&#x2019;s project. The targets Biogen could select were options that provided Biogen with material rights, as the exercise of the options did not require payment of a fee commensurate with the value of the incremental license rights. As a result, such options also represented performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company allocated fixed consideration of $204.6&#160;million included in the initial transaction price to the existing targets&#x2019; license and research services performance obligations and those performance obligations for options that include material rights, based on their relative standalone selling prices. Through March 31, 2023, one material right had expired, and seven material rights remained outstanding and are expected to expire during the quarter ending June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notice of termination was accounted for as a modification of the contract, as it changed both the scope of the Company&#x2019;s remaining services and the consideration to which the Company was entitled. The remaining research and development activities to be undertaken by the Company after the notice of termination were not distinct from the related &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;activities performed prior to the modification on the same targets but were distinct from the activities on other targets. The remaining material rights were also distinct from the prior research and development activities. To account for the effects of the modification, the Company updated its estimate of the transaction price and allocated the remaining transaction consideration based on the relative standalone selling prices of the remaining distinct goods and services. Progress for each ongoing performance obligation was then remeasured using an updated estimate of the total level of effort required for each performance obligation and the total revised transaction price and a cumulative catch-up in revenue was recorded. The modification resulted in an increase in revenue of $127.1&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, the Company had a receivable of $0.7&#160;million and $0.5&#160;million, respectively, and deferred revenue of $1.5&#160;million and $132.2&#160;million, respectively, related to this agreement. Changes in deferred revenue balances during the three months ended March 31, 2023 relate primarily to the impact of the contract modification. The amounts of transaction price remaining to be recognized were $1.7&#160;million and $151.3&#160;million as of March&#160;31, 2023 and December&#160;31, 2022, respectively. The amounts remaining at March 31, 2023 are expected to be recognized during the quarter ending June 30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and other fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost-sharing payments for research services, net variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $7.0&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the initial transaction price of $204.6&#160;million, as a contract cost asset. This balance is released into general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340. The Company recognized as expense $2.6&#160;million and $0.1&#160;million during the three months ended March&#160;31, 2023 and 2022, respectively. The Company recognized $2.9&#160;million, which represented 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in net proceeds during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#x201c;Kite&#x201d;), a Gilead Sciences, Inc. subsidiary, which became effective on April 5, 2018 (&#x201c;Effective Date&#x201d;), and was amended and restated in September 2019, for the research, development, and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#x201c;ZFNs&#x201d;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#x201c;NK-cells&#x201d;) including the insertion of genes that encode chimeric antigen receptors (&#x201c;CARs&#x201d;), T-cell receptors (&#x201c;TCRs&#x201d;), and NK-cell receptors (&#x201c;NKRs&#x201d;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered ex&#160;vivo using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the research program term and subject to certain exceptions, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of ex vivo genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of ex vivo genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the Effective Date, the Company received a $150.0&#160;million upfront payment from Kite. In addition, Kite reimburses the Company&#x2019;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.0&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $1.3&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.8&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first 10 times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial research term in the agreement is six years from the Effective Date. Kite has an option to extend the research term for up to two additional one-year periods for a separate upfront fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. Through the amendment and restatement of the agreement in September 2019, the Company and Kite agreed to expand the scope of the collaboration program to incorporate the use of lentiviral or retroviral vectors provided by Kite. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. The transaction price includes the upfront license fee of $150.0&#160;million and estimated reimbursable service costs for the research projects over the estimated performance period. None of the clinical or regulatory milestones have been included in the transaction price, as none of the milestones have yet been achieved, and all amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price also includes actual and estimated payments by Kite for the work by Company researchers and reimbursement of the Company&#x2019;s costs incurred with third-parties. The Company uses the expected value method to estimate payments related to the Company&#x2019;s researchers&#x2019; work, taking into account the impact of constraint. Variable consideration is included in the transaction price only to the extent it is probable a significant reversal of cumulative revenues recognized would not occur. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified four performance obligations within the Kite agreement as follows: (1) a license to the technology combined with the obligation to perform research and development services to apply the Company&#x2019;s technology to Kite-selected targets; (2) production of research materials; and (3-4) two material rights, each for an extension of the research period for an additional one-year term. Such extensions contain material rights because their exercise does not require payment of a fee that is commensurate with the value of the incremental research term. The license to the Company&#x2019;s intellectual property is not distinct from the related research and development activities as the licensed technology is not shared with and cannot be utilized by Kite without the research services performed by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated variable consideration (payments by Kite for the work performed by the Company&#x2019;s researchers and third-party costs, as well as any future milestones and royalties) to the specific performance obligations to which they relate, as such allocation would meet the allocation objective in ASC Topic 606. The Company allocated the fixed consideration of $150.0&#160;million to the performance obligations based on their relative standalone selling prices. Standalone selling prices of optional research years are similar to those of the initial year, but additionally take into account the intrinsic value of the discount upon exercise and the likelihood of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fees allocated to options with material rights are deferred until the options are exercised or expire. The exercise of options is accounted for as contract continuation, with target selection fees and estimated variable consideration included in the transaction price at that time and allocated specifically to the respective target&#x2019;s performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue for the combined license and research services performance obligations is recognized over time, as Kite consumes the benefit of such services as they are being performed by the Company. For the license combined with research and development services performance obligation, the Company recognizes revenue based on proportional performance of the ongoing research services over the period during which the Company performs the services. The estimation of progress towards the satisfaction of this performance obligation and project costs are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s assumptions regarding the estimated volume of required activities. The production of research materials performance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;obligation is accounted for under the right to invoice practical expedient, as the Company has the right to invoice Kite for these services in an amount that corresponds directly with the value of the services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, the Company had a receivable of $1.0&#160;million and $0.7&#160;million, respectively, and deferred revenue of $8.0&#160;million and $19.4&#160;million, respectively, related to this agreement. Changes in deferred revenue balances during the three months ended March 31, 2023 relate to a reduction in the estimated future level of the Company's research and development services, as well as ongoing normal progress in the delivery of the performance obligations. The amounts of transaction price (excluding the amounts recognized as invoiced for the production of research materials performance obligation) remaining to be recognized were $8.6&#160;million and $21.2&#160;million, of which $1.5&#160;million relates to fees allocated to options with material rights, as of March&#160;31, 2023 and December&#160;31, 2022, respectively. These amounts are expected to be recognized over the period through 2024. The timing of recognition will be affected by the volume of annual activity under the agreement and by whether and when Kite exercises options for additional years of services and could be subject to significant changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license fee fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Kite. This adjustment was driven by a reduction in the estimated future level of the Company&#x2019;s research and development services and as a result, future project costs. This resulted in an increase in proportional cumulative performance on this collaboration and an increase in revenue of $8.9&#160;million, an increase in net income of $8.9&#160;million, and an increase in the Company&#x2019;s basic and diluted earnings per share of $0.06 and $0.05, respectively, for the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanofi S.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement (&#x201c;2014 Collaboration Agreement&#x201d;) to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#x201c;SCD&#x201d;). The 2014 Collaboration Agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi S.A (&#x201c;Sanofi&#x201d;). Under the 2014 Collaboration Agreement, the Company was originally jointly conducting two research programs: a beta thalassemia program, which was discontinued in the third quarter of 2021, and the SCD program, which resulted in the development of SAR445136 (now known as BIVV003), a ZFN, gene-edited cell therapy product candidate for the treatment of SCD. In December 2021, Sanofi notified the Company of its termination for convenience, effective June 28, 2022 (the &#x201c;Termination Date&#x201d;), of the 2014 Collaboration Agreement. A termination and transition agreement (the &#x201c;Termination and Transition Agreement&#x201d;) was executed by the parties on September 6, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the SCD program, the Company and Sanofi were jointly responsible for research and development activities prior to filing of an IND, but Sanofi was responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. Subject to the terms of the agreement, the Company had granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZF and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company had also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#x2019;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company was not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2014 Collaboration Agreement, the Company received an upfront license fee of $20.0&#160;million and was eligible to receive additional payments upon the achievement of specified clinical development, regulatory milestones, and sales milestones, as well as royalty payments for each licensed product based on net sales of such product. Sanofi was also to reimburse Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. Through the Termination Date, a total of $13.5&#160;million was received based on achievement of clinical development milestones. No products have been approved and therefore no royalty fees have been or will be earned under the 2014 Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In its termination notice to the Company, Sanofi indicated that its termination relates to Sanofi&#x2019;s change in strategic direction to focus on allogeneic universal genomic medicine approaches rather than autologous personalized cell therapies. As of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Termination Date, the 2014 Collaboration Agreement was terminated in its entirety and following the Termination Date, the Company will not be entitled to receive any further milestone payments or royalties from Sanofi. As of the Termination Date, Sanofi has no further obligations under the 2014 Collaboration Agreement to develop or to fund the development of any collaboration research programs under the 2014 Collaboration Agreement. The licenses granted to Sanofi under the 2014 Collaboration Agreement have been terminated, and the license rights have reverted to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Termination and Transition Agreement, Sanofi granted to the Company exclusive, worldwide, fully paid, royalty-free, perpetual, irrevocable licenses, with the right to grant sublicenses through multiple tiers, to certain of its intellectual property, to develop, manufacture, have manufactured, use, sell, offer to sell, import and otherwise commercialize BIVV003, the product candidate in development under the SCD program. The Company agreed to take on responsibilities for all clinical trials related to BIVV003, including completion of the ongoing clinical trial and the related long-term follow-up study. The Company also assumed all regulatory responsibilities related to BIVV003. Sanofi transferred and assigned to the Company all documentation, materials and contracts with third parties related to BIVV003, and the right to use certain Sanofi-owned or leased equipment related to BIVV003.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sanofi has also agreed to reimburse the Company for the costs of conducting the ongoing clinical trial of BIVV003 and the costs of the long-term follow-up study through December 31, 2023, up to $7.0&#160;million. In addition, should the Company elect not to continue the development of BIVV003 past December 31, 2023, Sanofi will become obligated to reimburse the Company for the costs of the long-term follow-up study incurred after 2023, up to $5.3&#160;million. Sanofi&#x2019;s reimbursement obligations will terminate upon certain triggering events, including the Company&#x2019;s entering into a contract with a third party for collaboration, partnership, sale, licensing, or divestiture of BIVV003, or if the FDA permits early closure of the clinical trial and/or the long-term follow-up study.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the 2014 Collaboration Agreement in accordance with ASC&#160;Topic&#160;606 and concluded that Sanofi was a customer under that arrangement. The Company identified the performance obligation within this arrangement as a license to the technology combined with ongoing research services activities. The Company concluded that the license was not distinct as it did not have stand-alone value to Sanofi without the research services. As a result, the Company recognized revenue from the upfront payment and the milestones based on progress of performance of the ongoing research services. The estimation of progress towards the satisfaction of the performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s then current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. Sanofi&#x2019;s December 2021 notice of termination of the 2014 Collaboration Agreement represented a modification that reduced the expected scope of the Company&#x2019;s services and the estimated transaction price and shortened the remaining performance timeline. Consistent with this change, all services provided by the Company under the 2014 Collaboration Agreement were completed by June 28, 2022, and all amounts ultimately included in the transaction price were recognized by such date. The final transaction price of $96.3&#160;million included the upfront license fee of $20.0&#160;million, two milestone payments in the aggregate amount of $13.5&#160;million and reimbursement of research costs of $62.8&#160;million. As of March&#160;31, 2023 and December&#160;31, 2022, the Company had no receivable or deferred revenue related to the 2014 Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that Sanofi is not a customer under the Termination and Transition Agreement as Sanofi is not entitled to receive and cannot use the results of the ongoing clinical trial or the long-term follow-up study. This relationship is also not a collaboration in the scope of ASC Topic&#160;808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company concluded that the assets acquired from Sanofi do not represent a business, as substantially all of their value is concentrated in the acquired or re-acquired licenses to intellectual property. The Company has no obligation to repay Sanofi for its ongoing funding of the clinical trial or long-term follow-up study costs. Therefore, the Company will recognize Sanofi reimbursements as reductions to its research and development expense. During the three months ended March&#160;31, 2023, the Company decreased its research and development expense by $0.5&#160;million for these reimbursements, which is included within prepaid expenses and other current assets on the Company&#x2019;s Condensed Consolidated Balance Sheet as of March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the 2014 Collaboration Agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Giroctocogene Fitelparvovec Global Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;), pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#x2019;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) fifteen years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are 14% - 20% of the annual worldwide net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The total transaction price under this agreement was $134.0&#160;million, which represented the upfront fee and research services fees of $79.0&#160;million and fees related to two achieved milestones in an aggregate amount of $55.0&#160;million. Sangamo was responsible for internal and external research costs as part of the upfront fee and had the ability to request additional reimbursement from Pfizer if certain conditions were met. None of the constrained clinical or regulatory milestones were included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at the time was uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license was not discrete as it did not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period during which the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and no revenues have been recognized during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C9ORF72 Research Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZF-TRs to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZF-TRs that bind to and specifically reduce expression of the mutant form of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZF-TRs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory exclusivity for a licensed product in a country, and (iii) 15 years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following termination by the Company for Pfizer&#x2019;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time. Following termination by Pfizer for the Company&#x2019;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million in commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties of 14% - 20% of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pfizer agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer was a customer. The Company concluded the total transaction price under this agreement was $17.0&#160;million, which represented the upfront fees of $12.0&#160;million and fees related to achievement of one milestone in the amount of $5.0&#160;million. None of the constrained clinical or regulatory milestones were included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at the time was uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $5.0&#160;million milestone, which the Company recognized on a cumulative basis during the year ended &lt;/span&gt;&lt;/div&gt;December 31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and no revenues have been recognized during the three months ended March&#160;31, 2023 and 2022.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i0cdb317881c34a669c3a4df636cafb89_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTgyNw_a5919ad5-db43-4322-a1ea-6ef484c5a1d2"
      unitRef="usd">75000000</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i9e26658540754e0ba357cda42d689a27_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjk4NA_62b888c9-2e33-481b-8b6a-f32d0e91f9a7"
      unitRef="usd">95100000</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementLicenseFee
      contextRef="i9e26658540754e0ba357cda42d689a27_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzAyMw_fb906c62-364b-4344-972a-9890a5b12491"
      unitRef="usd">75000000</sgmo:CollaborativeArrangementLicenseFee>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i9e26658540754e0ba357cda42d689a27_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzA1OA_7e789a82-b90b-4cca-bc31-eb2d4e8282a5"
      unitRef="usd">20100000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2e5f30daa4cb48669190ba5dc2800f62_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDY3NA_894f65b6-7f19-4344-ace1-c4fad94fbcb8"
      unitRef="usd">2100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i588781fc38e24f71a49cbdd5825112e5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDY4MQ_3557c041-cbf4-43ed-a99e-d9412176aa56"
      unitRef="usd">2200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2e5f30daa4cb48669190ba5dc2800f62_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDcyMw_61c41730-a330-4057-b876-9625706e0fa3"
      unitRef="usd">1900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i588781fc38e24f71a49cbdd5825112e5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDczMA_3a6e6046-20c0-4aba-8c01-a5b6720215e4"
      unitRef="usd">9600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5Nzc_9a15ef74-a7a3-4046-87dc-c9adeb3e94d8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Novartis agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront license fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b05399697d7401c8737c92e33455724_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfMy0xLTEtMS03MDI3NQ_72dca1ea-4892-4ce9-bf6a-af75363fc91c"
      unitRef="usd">7696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i172244f350cb475a8efec0046cc9297b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfMy0zLTEtMS03MDI3NQ_3c1e5e95-7404-40fb-b21d-a38ccb0d0ff8"
      unitRef="usd">7018000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0092f362bc744248b2ee6e610a3b5e63_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfNC0xLTEtMS03MDI3NQ_5d99a933-6a8c-4dc5-805d-239342a3b084"
      unitRef="usd">2059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id24f43f5449b47339b9d23c5322eea68_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfNC0zLTEtMS03MDI3NQ_aeb68c63-cf26-4297-98cb-a86c2c9d4d2d"
      unitRef="usd">1877000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfNS0xLTEtMS03MDI3NQ_6721cc6b-e26c-48e5-945d-ef57129d0d06"
      unitRef="usd">9755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5044101e1ffb43ab96fa6fd4cd659e29_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjI0MDI1Njk3ZGIwMjQzYTViMTY1NmVlYWRiZTk2YjgwL3RhYmxlcmFuZ2U6MjQwMjU2OTdkYjAyNDNhNWIxNjU2ZWVhZGJlOTZiODBfNS0zLTEtMS03MDI3NQ_7f96b4a2-4d26-451a-af76-37c4c0861279"
      unitRef="usd">8895000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="ic8aae65c355c4bd7aef72344aa0fafbf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDg2NQ_1c92e1b0-abb9-4283-a81b-0a59e7a7f436"
      unitRef="usd">1500000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i6f7ce4041a0342d09c2e6c57209b7339_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0Ng_e09f2f43-104e-46d2-a25a-5c8c7db39f72"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i0cdb317881c34a669c3a4df636cafb89_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk1Mg_52581ebf-0c56-49c7-9569-2ce11848aed4"
      unitRef="usd">75000000</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="ic8aae65c355c4bd7aef72344aa0fafbf_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTA4MQ_d13f61df-599f-4a85-8a3a-262e81d59d72"
      unitRef="usd">1500000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQyOQ_cedbbb7f-ab15-47ab-98c4-eba2404b5825"
      unitRef="usd">200000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i5044101e1ffb43ab96fa6fd4cd659e29_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY0OTI2NzUwMzM1NA_4debb9a6-584b-4306-b7bf-8743b5ddbc41"
      unitRef="usd">100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjE4Ng_029eb40a-4bb9-4c18-ae82-b3af4a59a3b5"
      unitRef="shares">24420157</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i977ddd133dc44b5c99432be67e32bb97_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjI3Mw_13e82db2-533c-4456-8154-0f5405133716"
      unitRef="usdPerShare">9.2137</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjMyNg_dbb8e626-0595-4018-b6f8-9cb10ddac64d"
      unitRef="usd">225000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i1ad08cddce894baca70373a9ee5375ff_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjcyMQ_7b33baaf-d736-422b-a9db-d7930b4088c4"
      unitRef="usd">125000000</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty
      contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ4NQ_112d1d33-5dad-4df7-8c61-dd3c68eba49a"
      unitRef="product_target">4</sgmo:CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty>
    <sgmo:CollaborationAgreementNumberOfAdditionalProductTargets
      contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ3NQ_2488557e-0b06-4b29-99d9-1444ce7cd4fd"
      unitRef="product_target">7</sgmo:CollaborationAgreementNumberOfAdditionalProductTargets>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODY0MTc2_ee662491-83cf-4c92-a5f5-ebaac19d9126"
      unitRef="usd">125000000</us-gaap:ProceedsFromCollaborators>
    <sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction
      contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODY0MjQ1_0fc7c39e-0082-400e-8f9d-585681568b95"
      unitRef="usd">79600000</sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODY0Mjkz_9e804dc9-be25-4398-9a93-9da76e5cf330"
      unitRef="usd">225000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODY0MzUy_57d0e55c-3c2a-4f90-887d-dd1f711b65cf"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <sgmo:RevenueRemainingPerformanceObligationFixedConsiderationAmount
      contextRef="if9678c76539b432b81f74d4fb3103970_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTEwMDY_c6c9f986-6801-4084-9db3-2d5cfe645ff6"
      unitRef="usd">204600000</sgmo:RevenueRemainingPerformanceObligationFixedConsiderationAmount>
    <sgmo:RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired
      contextRef="if8df8676b78c46d5b518f1f954613aa3_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODc3NA_e6adfc05-f849-4374-9ed4-3f6d0dd30cd4"
      unitRef="material_right">1</sgmo:RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired>
    <sgmo:RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding
      contextRef="if8df8676b78c46d5b518f1f954613aa3_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODc2NA_369ea9d4-0588-458a-95c8-d4e4457c0acc"
      unitRef="material_right">7</sgmo:RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="idf5d83fd29e747b2a85c289b3b68ab01_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1OTQ3MTg2_a606bbc7-7518-4676-a182-a3b0fa5160b7"
      unitRef="usd">127100000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibe0c5537708d428dbd32614f200d7d29_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTMyMjY_1537f25d-b652-4a0a-88a7-0360a1f944cc"
      unitRef="usd">700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie59f379330a44413acc5ad3572d12de6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTMyMzM_ed30bd22-9e8b-4dd8-a173-253eb7157c8e"
      unitRef="usd">500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibe0c5537708d428dbd32614f200d7d29_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTMyNzU_33d079b7-7d37-44a0-bbd9-9249777cdb36"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie59f379330a44413acc5ad3572d12de6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTMyODI_dabd5a67-52ea-4486-88e8-48aec6d2b532"
      unitRef="usd">132200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="if3bd4a20f8df4d748a7351f9176c8c95_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY0OTI2NzUwMzEyNg_e797e756-4557-48f0-b940-954802b16447"
      unitRef="usd">1700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="if8df8676b78c46d5b518f1f954613aa3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY0OTI2NzUwMzEwNA_ce0a0111-c1aa-4cb5-86f3-804bfe494198"
      unitRef="usd">151300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="idf5d83fd29e747b2a85c289b3b68ab01_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5ODY_e3d8dee5-c85f-4c05-af88-be008b6c031f">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and other fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost-sharing payments for research services, net variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife0d48cc54154af988cfabb60294c669_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfMy0xLTEtMS03MDI3NQ_1a119f81-304b-4298-aafe-fa6a6d4ece8b"
      unitRef="usd">130630000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97d4c70ae0c0480394a8206308620896_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfMy0zLTEtMS03MDI3NQ_acf96721-813a-474e-8e0d-2851371008af"
      unitRef="usd">7306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b3bd979dbaf42b2bf7fdb23a295bcbd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfNC0xLTEtMS03MDI3NQ_a51be67b-003e-442b-88fa-e97e76c7f567"
      unitRef="usd">1672000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff80b48ae31a4224bcf6ebf172a029de_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfNC0zLTEtMS03MDI3NQ_7c6a248a-1f2d-4d71-9f08-865e590981f3"
      unitRef="usd">3887000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf5d83fd29e747b2a85c289b3b68ab01_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfNS0xLTEtMS03MDI3NQ_3f32597d-2a55-44e1-a142-e80431face85"
      unitRef="usd">132302000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a46a4d74d0f40ca9fe4e5cc2553ae18_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjdkYWYwZTE3NWM2ODRjNWViNjRhZDNiYWRiMWRlNGI0L3RhYmxlcmFuZ2U6N2RhZjBlMTc1YzY4NGM1ZWI2NGFkM2JhZGIxZGU0YjRfNS0zLTEtMS03MDI3NQ_4a10a5be-c643-4b23-a09f-c9019e6c71b2"
      unitRef="usd">11193000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="icb85aa7ee95148ddb651de001786d085_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM0MTk_b75f91eb-6b2f-4128-9aa9-47f67eb112cc"
      unitRef="usd">7000000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM1MDA_6d27c6c1-50e2-4871-8d4a-0a1a81497d12"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM1MDY_9e804dc9-be25-4398-9a93-9da76e5cf330"
      unitRef="usd">225000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM1NDU_c4fc6563-b884-420e-902e-3da20a6053a8"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM1NTE_ee662491-83cf-4c92-a5f5-ebaac19d9126"
      unitRef="usd">125000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i82bf0e01b49943c59780d56860d0ef71_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM4NjA_69cbd9d2-eaa9-4f4e-a2b1-103336bc35a5"
      unitRef="usd">4100000</us-gaap:ContractWithCustomerAssetNet>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM4ODE_65689fd5-e17d-41d2-9a14-b61fdd93fe96"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <sgmo:RevenueRemainingPerformanceObligationFixedConsiderationAmount
      contextRef="if9678c76539b432b81f74d4fb3103970_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTM5MTI_0e0f3d56-7c42-4d3b-8d87-8b1fbcabaaa0"
      unitRef="usd">204600000</sgmo:RevenueRemainingPerformanceObligationFixedConsiderationAmount>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idb9738ab009e47ebac491659d9db20da_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTQxNDg_679f8cac-0b05-4b36-8615-d7c6f48df37f"
      unitRef="usd">2600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie1079febd1d943e5ace3d337ff8b9934_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY0OTI2NzUwMzI4Mw_452f3274-bb86-45ea-b6a4-0c209dad02eb"
      unitRef="usd">100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ifdb866cb8cc240e6abb838057088d3c1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTQyODU_b5972332-583c-403a-bbf5-07f4692afcad"
      unitRef="usd">2900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i1774dd0c65624d4b836d7ff8dde76e45_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTQzMDc_eb1cb4f5-d40e-471a-bb70-42e6977ab151"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="iba2f136f30f9441b981f5b537f75d100_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTQzMTc_57d0e55c-3c2a-4f90-887d-dd1f711b65cf"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <sgmo:MilestonePaymentsReceived
      contextRef="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY2NzY_b4d1ce4c-6356-4692-a2f7-f8fd90cb5293"
      unitRef="usd">150000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ia36d19d9949d425a80f1c8e75d714302_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTY5MTk_bd889af2-8bb9-49d5-94eb-d5dfdb8868c6"
      unitRef="usd">3000000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="i3d2d40bca9274579a944d3bfb4f13ab1_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTcwMjk_12c1763c-1688-41a0-a105-f020e61d0c72"
      unitRef="usd">1300000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="ieaf64bd796644ec09771a94c61a501b4_D20180401-20180430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTcxNzE_19966b2a-0942-4355-b1ee-3e311282e8e6"
      unitRef="usd">1800000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment
      contextRef="ieaf64bd796644ec09771a94c61a501b4_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTc1NTI_c6e61cc8-5ca4-4817-b882-82be5680e1f6"
      unitRef="milestone">10</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment>
    <sgmo:InitialResearchTermOfAgreement
      contextRef="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTgxMjU_4c885c58-7ecc-482c-b207-5934a8d7664b">P6Y</sgmo:InitialResearchTermOfAgreement>
    <sgmo:NumberOfOptionsToExtendInitialResearchTerm
      contextRef="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTgyMTA_4c250785-cb09-4d95-a4b1-51ebecf60f53"
      unitRef="option">2</sgmo:NumberOfOptionsToExtendInitialResearchTerm>
    <sgmo:ExtendedResearchTermOfAgreement
      contextRef="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5ODE_af29be26-2256-422a-92a3-2191b5a12943">P1Y</sgmo:ExtendedResearchTermOfAgreement>
    <sgmo:SeparateUpfrontFee
      contextRef="i8dd426863cd64d5b9c24a9f6f092b9e6_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTgyNzA_34e5b598-8226-4212-b0a3-d02e8454a0fa"
      unitRef="usd">10000000</sgmo:SeparateUpfrontFee>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if7e6bd6cba7449d5b279f7359132b372_I20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODg0OTUz_4be4b78a-5d61-439c-bb73-e84b676a8b8c"
      unitRef="usd">150000000</us-gaap:ContractWithCustomerLiability>
    <sgmo:RevenueNumberOfRemainingPerformanceObligations
      contextRef="i1cab29510fb3439faf882035775ddfa8_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODc4Mw_387e8bbe-c021-4a7c-8250-598862af6845"
      unitRef="performance_obligation">4</sgmo:RevenueNumberOfRemainingPerformanceObligations>
    <sgmo:RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod
      contextRef="i1cab29510fb3439faf882035775ddfa8_I20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODc5Mw_6edd6d68-4711-4491-b8a2-58ec45d4ac53"
      unitRef="material_right">2</sgmo:RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod>
    <sgmo:RevenueRemainingPerformanceObligationRenewalPeriod
      contextRef="if963029c76a14422a76e678b607647db_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODgxMQ_7840aee8-21e0-4adf-bd56-e8434e1da985">P1Y</sgmo:RevenueRemainingPerformanceObligationRenewalPeriod>
    <sgmo:RevenueRemainingPerformanceObligationFixedConsiderationAmount
      contextRef="i1cab29510fb3439faf882035775ddfa8_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMTA5OTUxMTcxMjk0NQ_1ca31fab-b356-48e0-a4b2-4d52bffb3ffc"
      unitRef="usd">150000000</sgmo:RevenueRemainingPerformanceObligationFixedConsiderationAmount>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idee75a68ffae4d08aad2ebe053849936_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjEyNTQ_e609a943-60fd-4398-9fed-25f258dc7be7"
      unitRef="usd">1000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifc29cb92c1914e68bb97632d9995dd99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjEyNjE_b40e81fb-78fd-4875-91f1-ca380e3f04b5"
      unitRef="usd">700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="idee75a68ffae4d08aad2ebe053849936_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjEzMDM_59461cdc-c14a-4239-b7f3-befa03603921"
      unitRef="usd">8000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ifc29cb92c1914e68bb97632d9995dd99_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjEzMTA_e01b6248-f31e-4336-bdea-ba60bf1b489f"
      unitRef="usd">19400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="iba08bfacba1f4aae9ffd92a1c8ee0b02_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODkxNTQ5_96effd01-29a6-42c1-b731-55c0846de208"
      unitRef="usd">8600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="iecd84ec8a1904360957c6aa234b8c110_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1ODkxNTI4_eb2d06e8-6f40-41b7-8ee2-3a736c16e1f1"
      unitRef="usd">21200000</us-gaap:RevenueRemainingPerformanceObligation>
    <sgmo:RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount
      contextRef="iecd84ec8a1904360957c6aa234b8c110_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1OTE3ODQ1_3cee4096-cf79-4c14-91d0-f42b62936f81"
      unitRef="usd">1500000</sgmo:RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount>
    <sgmo:RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount
      contextRef="iba08bfacba1f4aae9ffd92a1c8ee0b02_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNTQ5NzU1OTE3ODQ1_80c72b18-732f-4b60-a57a-10aa6d89bf67"
      unitRef="usd">1500000</sgmo:RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i012246fb152f4311b9ef64728a20ab16_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5ODI_f6218f29-75c9-4c2c-b5fc-8e6ca85db3da">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license fee fixed consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf91751f6b9c4cd9aa62ef768250ea52_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfMy0xLTEtMS03MDI3NQ_8f507814-d605-4169-9f28-402ce25a0544"
      unitRef="usd">11440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06bd9d0df2534688ae2923ab3b06ae9a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfMy0zLTEtMS03MDI3NQ_0456cd09-c2a7-4b92-977d-8d38b2e2d199"
      unitRef="usd">6159000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i044b8bca774a41859553cfa2ca705546_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfNC0xLTEtMS03MDI3NQ_c66fb3f0-fe6b-4fef-98e5-b0ab10b8ee92"
      unitRef="usd">868000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16fce833379e4e6f95302de92112cbfe_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfNC0zLTEtMS03MDI3NQ_14ff7411-28a0-4a7d-905f-bd1fb99c7450"
      unitRef="usd">149000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i012246fb152f4311b9ef64728a20ab16_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfNS0xLTEtMS03MDI3NQ_0a0e90eb-87e6-4d9c-bd79-bb601eaf951e"
      unitRef="usd">12308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0996de9b8bdd4847801e39a50b5843fe_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOjUwZGQ4NDE1OGE0MzRkYzA5MDQwYTU5YWFhMTBjYjdlL3RhYmxlcmFuZ2U6NTBkZDg0MTU4YTQzNGRjMDkwNDBhNTlhYWExMGNiN2VfNS0zLTEtMS03MDI3NQ_ecd2af80-c9d3-4ccc-99ba-493717ee2093"
      unitRef="usd">6308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjU5NzA2OTkwMjI5Mg_cbe4eba4-de0f-4f3e-b123-2b383829a2d9"
      unitRef="usd">8900000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent
      contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjU5NzA2OTkwMjMyNg_519392f1-389b-451a-926a-5f35d889e1d6"
      unitRef="usd">8900000</sgmo:IncreaseDecreaseInNetIncomeLossAttributableToParent>
    <sgmo:IncreaseDecreaseInEarningsPerShareBasic
      contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjU5NzA2OTkwMjQwNA_2922173e-dc6b-416a-b0b2-6e2e5e72928f"
      unitRef="usdPerShare">0.06</sgmo:IncreaseDecreaseInEarningsPerShareBasic>
    <sgmo:IncreaseDecreaseInEarningsPerShareDiluted
      contextRef="i70943e701a414ed49bfbf12a19ca9b83_D20230301-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNjU5NzA2OTkwMjQxMg_00973f9f-3438-4096-acf8-d4a2a07c323b"
      unitRef="usdPerShare">0.05</sgmo:IncreaseDecreaseInEarningsPerShareDiluted>
    <sgmo:NumberOfResearchProgram
      contextRef="ifb3c135c2da14ac9b065d23532ddd743_D20140101-20140131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5MjA_934279dc-6d62-4761-ac67-926d64928da7"
      unitRef="program">2</sgmo:NumberOfResearchProgram>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ifb3c135c2da14ac9b065d23532ddd743_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjM2ODI_5d1d18d5-d87f-4073-95b3-981248187f1d"
      unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1283de320cb4464a5b41896a5803c3e_D20140101-20220628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjQwOTg_c1ad8ac1-3375-437b-92ec-73f44dd3e168"
      unitRef="usd">13500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="i040ae2a932da4ee5aba8f53c0572ebbc_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjQxNzg_c51300b1-36f3-47fe-bb0a-4a3c2dae510b"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i8f019967b98f4beba43811efc7cd5926_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjQyMjM_f904e282-362a-4cdf-8813-95333b462a7a"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate
      contextRef="i6db635d14915401bb7ab7d501b675ba5_D20220906-20220906"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjYyOTE_632baf89-946c-47d3-807b-c409b87070ec"
      unitRef="usd">7000000</sgmo:ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate>
    <sgmo:ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate
      contextRef="i6db635d14915401bb7ab7d501b675ba5_D20220906-20220906"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjY1Mjg_fa01f00b-1603-48af-8dd6-fe5515009a38"
      unitRef="usd">5300000</sgmo:ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i7fc0f7863a60402b9f2453ef3b887ecb_D20140101-20220628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjgyODg_37e1be0d-ee16-472a-a607-bd77cd887aad"
      unitRef="usd">96300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i7fc0f7863a60402b9f2453ef3b887ecb_D20140101-20220628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjgzMjc_96eb39ae-c44d-48ae-b516-f871e2f40869"
      unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i65542dbae8514435bdf257a1ff5bcbdf_I20220628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjgzODE_42c02e49-593a-44f3-b15e-aa030d9ecdbd"
      unitRef="usd">13500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i7fc0f7863a60402b9f2453ef3b887ecb_D20140101-20220628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjg0MjM_755dcfc9-62b3-45e9-88e8-78c3f0776c76"
      unitRef="usd">62800000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i46c2c921be69493ab19f0a486451504a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ2Nw_281046b7-151f-43b3-8b51-38ddb9436b90"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i46c2c921be69493ab19f0a486451504a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ2Nw_28da7bdc-b276-4af7-8d05-21efc625b332"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iddc8eb02f5594eb4bb70b4f4e16dfa8a_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ2Nw_53e0c41a-8526-4bc2-b7fb-efee84fae18b"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iddc8eb02f5594eb4bb70b4f4e16dfa8a_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjE5OTAyMzM5MDQ2Nw_9bdd8bb0-0c5e-49f4-b896-a2206a85c823"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <sgmo:TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="i739fc14c91ed4a9398145c3822bdc624_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMjk1MjY_8b54f67f-5988-4e75-bfd2-47538dd1030c"
      unitRef="usd">-500000</sgmo:TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i040ae2a932da4ee5aba8f53c0572ebbc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5Nzk_4b0ca81e-04e1-4ebc-bcaf-12698771246c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the 2014 Collaboration Agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64cb91ba588b40d3823c99c78f047007_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfMy0xLTEtMS03MDI3NQ_db157aed-9bb8-4520-9aa5-6786c4d44761"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d62212323d64616b08b97898e6dca41_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfMy0zLTEtMS03MDI3NQ_563c3361-0479-40f1-ac5c-30989cee4ed3"
      unitRef="usd">311000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b80b373e4f543d3b9c64cd42f6123e0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNC0xLTEtMS03MDI3NQ_80438e43-d247-4962-81c0-74b095f4ca16"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29862757a85b4766a731ee17cf896271_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNC0zLTEtMS03MDI3NQ_b252a1ae-cf90-48a3-899e-777018f75dbb"
      unitRef="usd">978000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1f62cc7bdbf4e2ca26b9868e600b6d1_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNS0xLTEtMS03MDI3NQ_9542c210-453e-4982-bd44-973c124c6be5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ae7e8c20abb44979f894b0080a9de5b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNS0zLTEtMS03MDI3NQ_d1aafb57-7f5d-41ed-a31f-50e7a3122ac4"
      unitRef="usd">210000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i040ae2a932da4ee5aba8f53c0572ebbc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNi0xLTEtMS03MDI3NQ_68103bd0-1788-423c-bad7-4b895863ab6c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i667f4bba088b4392976bb60dcc384764_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RhYmxlOmZiNzdkODIzYzQwNjRkYWFiYzhlNjI4M2NlYWU5NWNmL3RhYmxlcmFuZ2U6ZmI3N2Q4MjNjNDA2NGRhYWJjOGU2MjgzY2VhZTk1Y2ZfNi0zLTEtMS03MDI3NQ_d5de29bf-7d69-4b89-a55b-962a6e3487f8"
      unitRef="usd">1499000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:AgreementTerminationTerm
      contextRef="i804a404f96394a898c058d278efa5149_D20170501-20170531"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzIzMzI_5583bcd8-a7bc-44f9-b9b5-9903097d40f9">P15Y</sgmo:AgreementTerminationTerm>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="iebe23428fae3453f85cfddd95fced287_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzMyNTM_9044c275-45df-49f6-9c8f-053fad34ddf0"
      unitRef="usd">70000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ib47491017133498e9f1034163ad56858_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzMyODk_29fc763f-c32a-4756-9a74-aa34767e368d"
      unitRef="usd">208500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
      contextRef="iebe23428fae3453f85cfddd95fced287_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzM0MTg_a51c8b6c-f275-4075-a0dd-027c8d957b9b"
      unitRef="usd">266500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ibe6c9c6208944000ac68a96e46025955_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzM3NDc_0dc745c6-3092-4d98-9e72-58680d50786d"
      unitRef="usd">475000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestoneRevenueReceivable
      contextRef="id44c480d79c746f99af60191b7721577_I20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzM3NzI_1ee4bce4-c3e6-410e-b234-e3952154b9ea"
      unitRef="usd">300000000</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i7bbeee49f7d24edbb0671d6d2fd4fe37_I20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzM4MTc_f1c913bc-ade8-413b-b027-060e73d91531"
      unitRef="usd">175000000</sgmo:MilestoneRevenueReceivable>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty
      contextRef="i82259a8cc3b54b86845b0a1e5c8c8688_I20170531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODgxMw_24f6ad0f-c5d1-427b-b478-4f4058d1b5aa"
      unitRef="number">0.14</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty
      contextRef="i37f8e9f8ba844603a13fb45940884450_I20170531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODgxOA_5cc908d3-95f3-49e9-89d2-b95271187d34"
      unitRef="number">0.20</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:CollaborativeArrangementNumberOfMilestonesAchieved
      contextRef="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQzOTY_38108c71-a753-4d8e-94e0-ef3b640926c0"
      unitRef="milestone">2</sgmo:CollaborativeArrangementNumberOfMilestonesAchieved>
    <sgmo:MilestonePaymentsReceived
      contextRef="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ0MTM_b9d7da84-d5b0-4aa9-ab44-00a284f1d2aa"
      unitRef="usd">55000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ0NjY_bb10032f-6cee-49e4-ba8c-822498a4fb8b"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ1MTE_a3b8547f-ef1c-414f-8b40-987bb8cb7d14"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="id8b7dbf6a794472a89a395389c47d284_D20170501-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ3Mzk_f97d29fe-a0a2-46c2-b48a-7f75de45e17b"
      unitRef="usd">134000000</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementResearchServiceFees
      contextRef="id8b7dbf6a794472a89a395389c47d284_D20170501-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ4MDc_fca4910b-b840-49e6-87b3-b44c68a0a83c"
      unitRef="usd">79000000</sgmo:CollaborativeArrangementResearchServiceFees>
    <sgmo:CollaborativeArrangementNumberOfMilestonesAchieved
      contextRef="i608c4b32c1604cc7abcd2e055c12a732_D20170501-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ4MzA_159876b3-88cc-4ce5-bb37-bd5ea1bed55a"
      unitRef="milestone">2</sgmo:CollaborativeArrangementNumberOfMilestonesAchieved>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="id8b7dbf6a794472a89a395389c47d284_D20170501-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzQ4Nzk_4488465d-7912-41e4-9d52-e783dc2e575f"
      unitRef="usd">55000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8723ec4942574f6abacf98a666e76565_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzY3MTc_56435719-3ef9-4519-8167-8b9c2023efba"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf3bbfd75e0a43a385745a5d6b39cac5_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzY3MTc_624a5b2f-10d4-4004-abd4-89b8649fc761"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:AgreementTerminationTerm
      contextRef="i36ed8ae1e943412696f1b850bcd91902_D20171201-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzgyMTk_9c51fa05-e948-499e-accf-954190d1926b">P15Y</sgmo:AgreementTerminationTerm>
    <sgmo:MilestonePaymentsReceived
      contextRef="i36ed8ae1e943412696f1b850bcd91902_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzk5MTM_db695c23-d0fe-4a04-85c6-92763b6cf925"
      unitRef="usd">12000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ifc4df0af832c47e19018df300e7262e2_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfMzk5Nzc_fe487e85-be42-497a-8f53-7b7e3f74adfc"
      unitRef="usd">60000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i8f057163ceda4cb2866e24c3fb357cfe_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDAxNjM_b4b333c7-a684-40b2-976a-db6445ff8071"
      unitRef="usd">90000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty
      contextRef="i8a4ef27fa9844922a3e39563222cc964_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODgyMw_120a37a9-a1c8-4ff5-b1e1-bc9af44df3b9"
      unitRef="number">0.14</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty
      contextRef="ic2c186114dc94e028f5fe60291fb4cc4_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDk0NzgwMjQyODgyOA_ac16b5ea-4760-4b06-ac07-b6a9b277eeec"
      unitRef="number">0.20</sgmo:ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty>
    <sgmo:MilestonePaymentsReceived
      contextRef="i560f370cf92a49b99828eb1352749470_D20171201-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDA5MTM_d3e41fea-0f7a-46c5-a961-a208fd866e15"
      unitRef="usd">5000000</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="i560f370cf92a49b99828eb1352749470_D20171201-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDA5NTI_1fed12c5-4d85-4a79-bce6-fb1100a5f0fe"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i560f370cf92a49b99828eb1352749470_D20171201-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDA5OTc_b103f84d-7587-4344-867a-26c17bbb71dc"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i1e962757cf94476a83ff1404fcbf850b_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDEyNjM_eed0f5aa-231a-43a6-9136-caf9ed266aa1"
      unitRef="usd">17000000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i9a15336c720b4849b73c702ec05c48ae_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDEzMDU_954fc08e-11e2-49db-875c-c94bc77f9d6f"
      unitRef="usd">12000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i1e962757cf94476a83ff1404fcbf850b_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDEzNzQ_9300b90d-dfc7-4d7a-9696-812b354ae2e2"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i9b6cafe71ed842fe933713b923d60a51_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI2ODM_289f2da9-b785-4e43-8a33-92a0ee9e2d75"
      unitRef="usd">5000000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="iec01e4d31367438cb373cd06b7a6321f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI2ODM_744ca230-f257-43b2-a4ed-6f51b542b73d"
      unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fc67d44a220419d862851946595abe3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5MDM_2faec358-d68f-48ae-9ca0-cbcdad993598"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e652ef597fe49c8b7cf086423e5272b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181NS9mcmFnOjk2OWFjZjlkY2YyMTQ0MWVhMzJiMWRjMGVjNmFmN2FlL3RleHRyZWdpb246OTY5YWNmOWRjZjIxNDQxZWEzMmIxZGMwZWM2YWY3YWVfNDI5MDM_4de2f0e9-d813-43df-a787-14604b1fcdbc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AssetImpairmentChargesTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF8yMTk5MDIzMjYyNjgz_8124a6cc-0b3e-450a-9491-7a097cc708f1">IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, as a result of the sustained decline in the Company&#x2019;s stock price and related market capitalization, termination of the collaboration agreements with Biogen and Novartis, and a general decline in equity values in the biotechnology industry, the Company performed an impairment assessment of goodwill, indefinite-lived intangible assets, and long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as a single reporting unit based on its business and reporting structure. For goodwill, a quantitative impairment assessment was performed using a market approach, whereby the Company&#x2019;s fair value of equity was compared to its carrying value. The fair value of equity was derived using both the market capitalization of the Company and an estimate of a reasonable range of values of a control premium applied to the Company&#x2019;s implied business enterprise value. The control premium was estimated based upon control premiums observed in comparable market transactions. This represents a level&#160;2 nonrecurring fair value measurement. Based on this analysis, the Company recognized a non-cash, pre-tax goodwill impairment charge of $38.1&#160;million during the three months ended March 31, 2023. As a result, the goodwill was fully impaired as of March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Before completing the goodwill impairment assessment, the Company first tested its indefinite-lived intangible assets and then its long-lived assets for impairment. The Company determined its indefinite-lived intangible assets were not impaired, as their carrying values were not in excess of their individual fair values. The Company determined all of its long-lived assets represent one asset group for purposes of long-lived asset impairment assessment. The Company concluded that the carrying value of the single asset group is not recoverable as it exceeded the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. To allocate and recognize the impairment loss, the Company determined individual fair value of long-lived assets. The Company, with the assistance of a third-party valuation firm, applied a discounted cash flow method to estimate fair values of its leasehold improvements and right-of-use assets, including leasehold improvements in the process of construction. This represents a level&#160;3 nonrecurring fair value measurement. Based on this analysis, the Company recognized non-cash, pre-tax long-lived asset impairment charges of $11.2&#160;million on the right-of-use assets, $5.0&#160;million on the related leasehold improvements, and $4.2&#160;million on construction-in-progress, during the three months ended March&#160;31, 2023. No impairment was recognized on the remaining long-lived assets as their carrying values were not in excess of their fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetImpairmentChargesTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF81NDk3NTU4MjEwMjM_aadd65d1-785e-42e9-b2c7-3be270aa6c98"
      unitRef="usd">38100000</us-gaap:GoodwillImpairmentLoss>
    <sgmo:LongLivedAssetsNumberOfAssetsGroups
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF8yMTk5MDIzMjY4ODA1_d1c52ff2-3631-419f-9aba-034782c0bfb0"
      unitRef="asset_group">1</sgmo:LongLivedAssetsNumberOfAssetsGroups>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF81NDk3NTU4MjY3Mzc_d091654b-9c2f-4f6c-83a4-51d94b58e27c"
      unitRef="usd">11200000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i4de9bbe9fefc453f850b2fe7edb090a7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF81NDk3NTU4MjY3NTc_46a41fbd-2ca9-4166-8558-8223e0a69a18"
      unitRef="usd">5000000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="if8b032998eb547589205c3c16fdb0326_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N18xMzM3L2ZyYWc6YTNkN2VmNDBjNmU5NGI0Njg3ZjdlNmJhMmUwNDA1MzAvdGV4dHJlZ2lvbjphM2Q3ZWY0MGM2ZTk0YjQ2ODdmN2U2YmEyZTA0MDUzMF81NDk3NTU4MjY3Nzc_f38234f0-5f59-4516-ba0e-df863fd734e5"
      unitRef="usd">4200000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RleHRyZWdpb246NDZjODExNTBmOGU3NGIxYWFlMTc4NDc5MTIyYzFlNGJfMTgy_3835f8e7-77c5-417d-a68b-cc38bbfd4f14">STOCK-BASED COMPENSATION&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RleHRyZWdpb246NDZjODExNTBmOGU3NGIxYWFlMTc4NDc5MTIyYzFlNGJfMTgx_bf4aa1dc-8914-4a68-a3c1-774639fa7e1f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense recognized in the accompanying Condensed Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i25d41c01311744a48c5daac7d4e3944b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfMi0xLTEtMS03MDI3NQ_a59496e9-a56b-4216-ad18-b9e3b576984d"
      unitRef="usd">4873000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idca29878377148449e09cef54c91263d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfMi0zLTEtMS03MDI3NQ_dcaa9992-a118-44b4-b8f5-654193463068"
      unitRef="usd">4670000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i28c3caeac8e54328899e8c3cb465e877_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfMy0xLTEtMS03MDI3NQ_ed19accc-b938-4d14-b785-7971e824a775"
      unitRef="usd">3404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5f991f47f9a74b6b9b29e3bac240a7eb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfMy0zLTEtMS03MDI3NQ_7d6ce181-a4d9-4876-acbb-1c38e4902fa1"
      unitRef="usd">3021000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfNC0xLTEtMS03MDI3NQ_79ff789a-7213-4d8d-9b87-54aa978f8183"
      unitRef="usd">8277000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N181OC9mcmFnOjQ2YzgxMTUwZjhlNzRiMWFhZTE3ODQ3OTEyMmMxZTRiL3RhYmxlOjUwZWQzMTZhNTZiZDQzZmRiNjBmZGU5M2JjMjNhNGU2L3RhYmxlcmFuZ2U6NTBlZDMxNmE1NmJkNDNmZGI2MGZkZTkzYmMyM2E0ZTZfNC0zLTEtMS03MDI3NQ_c1f8d74a-30b2-4c9b-bec7-f0e9914bc883"
      unitRef="usd">7691000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfOTk1_48bbfaf8-e886-4ece-aee3-c6fafe318d9f">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into an Open Market Sale Agreement&#x2120; with Jefferies LLC (&#x201c;Jefferies&#x201d;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#x2019;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#x2019;s sales agent or principal. In December 2022, the Company entered into Amendment No. 2 to the Open Market Sale Agreement&#x2120; which increased the aggregate offering price under the at-the-market offering program by an additional $175.0 million. The Company is not obligated to sell any shares under the sales agreement. During the three months ended March&#160;31, 2023, the Company sold 3,962,430 shares of its common stock for net proceeds of approximately $9.7&#160;million, of which approximately $0.6&#160;million was received in April 2023 and recorded within prepaid expenses and other current assets on the Company&#x2019;s Condensed Consolidated Balance Sheet as of March&#160;31, 2023. No shares were sold under the sales agreement during the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <sgmo:StockOfferingProgramMaximumValue
      contextRef="i817e2132beca4a9a89cee830995c6d63_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfMzg4_470b09e3-e25d-4b6b-b891-5202188ff4f0"
      unitRef="usd">150000000</sgmo:StockOfferingProgramMaximumValue>
    <sgmo:SaleOfStockIncreaseToAggregateOfferingPrice
      contextRef="i4b85c71c37b542f2882458b5be990823_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfNTQ5NzU1ODE1MDg5_ee79f0c4-8de3-4f1a-b1c6-d76e70cd0398"
      unitRef="usd">175000000</sgmo:SaleOfStockIncreaseToAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7ced4258fc4d4d42a76a05c7d77967a2_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfNTc1_deba2263-5c65-43a7-b0a5-2a472f60f06a"
      unitRef="shares">3962430</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i7ced4258fc4d4d42a76a05c7d77967a2_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfNjQ2_21a2b804-3471-4b66-9fff-9952cad1ad76"
      unitRef="usd">9700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i9d74086bfd334bcea39a99837791ca5d_D20230401-20230430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfNjk0_5c77d941-632d-428f-8ed2-1d99d2ec1154"
      unitRef="usd">600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7c3f507349cf479bbcbd3ad2bdc85b31_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182MS9mcmFnOjhlMGY3NmRhZmQ5ZjRhMGM4MjNhODI3NjJkMGI5MGE3L3RleHRyZWdpb246OGUwZjc2ZGFmZDlmNGEwYzgyM2E4Mjc2MmQwYjkwYTdfNDk0NzgwMjMyNjQxNQ_d794c4e2-3752-44c3-93a8-2dd342d6733a"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182Ny9mcmFnOjZkMmVkMjYzNTk0YTQ1MDg4ZWU3NzFkMDQ2NzE3NTM0L3RleHRyZWdpb246NmQyZWQyNjM1OTRhNDUwODhlZTc3MWQwNDY3MTc1MzRfMjY3Ng_bf640429-e68c-40f6-8589-cc6ae43477ee">INCOME TAXES&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s provision for income taxes for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. During the three months ended March&#160;31, 2023 and 2022, the Company recorded income tax expense of $0.2&#160;million and $0.1&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company continues to maintain a full valuation allowance on its U.S. federal and state net deferred tax assets and on the Sangamo France net deferred tax assets, as the Company believes it is not more likely than not that these benefits will be realized. The tax expense for the three months ended March&#160;31, 2023 was primarily due to foreign income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2022, the Inflation Reduction Act of 2022 was signed into law, and became effective in 2023, with tax provisions primarily focused on implementing a 15% minimum tax on global adjusted financial statement income and a 1% excise tax on share repurchases. The Company has evaluated the provisions of the tax law and noted that the law change would not have a material impact on the Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182Ny9mcmFnOjZkMmVkMjYzNTk0YTQ1MDg4ZWU3NzFkMDQ2NzE3NTM0L3RleHRyZWdpb246NmQyZWQyNjM1OTRhNDUwODhlZTc3MWQwNDY3MTc1MzRfNDM5ODA0NjUyNTM4MA_993cc031-f847-4158-96f3-aa0bbb579d87"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1b96e0b26e504a079e73b598b0a1d637_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N182Ny9mcmFnOjZkMmVkMjYzNTk0YTQ1MDg4ZWU3NzFkMDQ2NzE3NTM0L3RleHRyZWdpb246NmQyZWQyNjM1OTRhNDUwODhlZTc3MWQwNDY3MTc1MzRfNjU5NzA2OTc4NzAyNQ_a5796325-2699-417a-931d-a18a6d53da9f"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N183Ni9mcmFnOmIzNzY0Mzg1YTgyNTRiMzliYmFhYjU4YmM2ZmE1OTJkL3RleHRyZWdpb246YjM3NjQzODVhODI1NGIzOWJiYWFiNThiYzZmYTU5MmRfNDg3_a2847ec4-fe1f-49b1-ba0f-dd44b22359ef">SUBSEQUENT EVENTSIn April 2023, the Company announced a restructuring of operations and corresponding reduction in workforce (the &#x201c;Restructuring&#x201d;), designed to reduce costs and increase focus on its key strategic priorities. Sangamo expects the Restructuring to result in the elimination of approximately 120 roles in the United States, or approximately 27% of its total United States workforce. The Company currently estimates that it will incur approximately $5&#160;million to $7&#160;million in cash-based expenses related to employee severance and notice period payments, benefits and related costs in connection with the Restructuring. The Company expects that the majority of the Restructuring charges will be incurred in the second quarter of 2023 and that the execution of the Restructuring will be substantially complete by the end of the third quarter of 2024. The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the Restructuring.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="i0d843ac73dfb466ab2ba144b1a49bdb5_D20230401-20230430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N183Ni9mcmFnOmIzNzY0Mzg1YTgyNTRiMzliYmFhYjU4YmM2ZmE1OTJkL3RleHRyZWdpb246YjM3NjQzODVhODI1NGIzOWJiYWFiNThiYzZmYTU5MmRfOTkzOQ_81bc5060-6c26-4182-a26a-619911c1d087"
      unitRef="employee">120</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i0d843ac73dfb466ab2ba144b1a49bdb5_D20230401-20230430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N183Ni9mcmFnOmIzNzY0Mzg1YTgyNTRiMzliYmFhYjU4YmM2ZmE1OTJkL3RleHRyZWdpb246YjM3NjQzODVhODI1NGIzOWJiYWFiNThiYzZmYTU5MmRfMjE5OTAyMzI2NDkwNA_506f160b-c709-48b2-a53a-619233ae7605"
      unitRef="number">0.27</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i4127fb82d88648f383b7c0ae50821b64_I20230430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N183Ni9mcmFnOmIzNzY0Mzg1YTgyNTRiMzliYmFhYjU4YmM2ZmE1OTJkL3RleHRyZWdpb246YjM3NjQzODVhODI1NGIzOWJiYWFiNThiYzZmYTU5MmRfMjE5OTAyMzI2NDkxNA_989267a6-72a6-499e-833e-bf9603b8c811"
      unitRef="usd">5000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ifae7a07494d54449804932a865f643bc_I20230430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjA1NmNlN2RhNDQ3ZjQ4YTg5NGYyMGUwMjAyYmZiMzY3L3NlYzowNTZjZTdkYTQ0N2Y0OGE4OTRmMjBlMDIwMmJmYjM2N183Ni9mcmFnOmIzNzY0Mzg1YTgyNTRiMzliYmFhYjU4YmM2ZmE1OTJkL3RleHRyZWdpb246YjM3NjQzODVhODI1NGIzOWJiYWFiNThiYzZmYTU5MmRfMjE5OTAyMzI2NDkyNg_bb35cf1d-0b22-4cb9-99c7-b52c9230960f"
      unitRef="usd">7000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M [-@[/4<\@[,!VA-*OG4S -5G#;0+$C0S(U:=]Z&,H(DCL;I-9B%-*#8HG9
M37QH\;/R-E,)MD^!G8\]C3@(@K%&@YD7D<2BL4<;=M)D_K<0RX<LSXW2B';/
M\7,VF- H"(A%5D\A[,;0)3QF)K/R%N4<^B]4J49K*E;3;>U,)M7D^'&8C$N5
MP2R$EM:FND<2=C/ILJE,@P7DDFH 3DA\,I9JXI)GJT^XYQ)V@^D'0*G*4LE;
MTAL5&J@4>-H,.&"UKZ\'$W:3J:V@CO3IN/%]+PBUM:W;!2$)/-O"Z<F$HQ<U
MA7G&;K*\J9W&SA ["??:UO!W>=L/NL<:=G.MZQ<V[,G6+&"=5CA)B#9O3.SS
ML:5AP#W4L)MJ(+':JEDM"M4SL'8?J'!1;'+QQ#FZX25?999II8,+D\1/QN(-
M?(-9'YK%DYYOQ,VWMH"P70B#J67<<^C8P@%-QN0PF86>9VD>2$\WXJ;;.5]Q
M6 )+Z!WO>;FU:-2QE021)M'$P"BV%!$RV+>YX;;?AAU*IXZR((KI^-$;S##&
M$;9T"Z1''G$C3\OGP5:,Z!C#,1[#SF3E)32R38">=L1-NZ^BO)W"]J9 &U$U
MRTRL=K@^E&H=:J#'&[?F)K,XB6VKK&<?<;.ORW160I7@2+)'HTJ=;"&-QH V
M64$/;]'8\X^X^:>W$H=RJH,.$Z+-7I.5M1;T,"3N?5J[T XI-&RU/!_*P5BC
M;D=":"IM*ZRG%W'3ZTP412;5CJ'=2*:B5"TF+U.;8J<_,VV1\43G_SO:C[G'
M(4F<;<I"BO1N+?(EK^IW;V*"HX_-QDD^F<^QG'!]]4'6;_*V?Y+5TY0>VBT^
M+_1:9<%X@J7#<=RH.$WVE?7LI&YVJID(]=(N2P<B("8>*S-8A:&E@Z(]-:F;
MFJ?+9:;*.:QH=?@RS4K8(FPR6.%&J08>^F'DA>-":30,8"MC:<7IX,C234YH
M^;;%-F=J,[.$UB[-C+BD.@BG&)/(QYI4HZ4?![83#-I#D[JA.=2Z.\B"1K7B
M:_72XQ[(*6KS4:O.PBDT4MJ4,)C%OF<Y)J0],JD;F6V!KZW%Q"A9)R,UG149
M[%3+'=@F<L]0^I(]Y(!*3=5_91"A=GIMW&<:[(S[S-G@+8QZ!?:-5;=964/?
MM(*!WH<(TE"U;Y7:"RDVS8N9&R&E*)J/:\Y O#* WU="R.<+]:ZG>[<W_P]0
M2P,$%     @ 8HFH5@O52&:?!   ^1$  !@   !X;"]W;W)K<VAE971S+W-H
M965T,RYX;6RMF&UOHS@0Q[^*Q:U.7:DMV#P$>DFD-NG>5;H^J,G>O7:#DZ %
MG+.=I/?M;X $$FS8J]0WX2$SPV]F;/\QPST7/^2:,87>LS27(VNMU.;&MN5B
MS3(JK_F&Y?#/DHN,*K@4*UMN!*-QZ92E-G&<P,YHDEOC87GO18R'?*O2)&<O
M LEMEE'Q[QU+^7YD8>MXXS59K55QPQX/-W3%9DQ]W[P(N++K*'&2L5PF/$>"
M+4?6+;Z9D-*AM/@K87MY<HZ*5-XX_U%</,0CRRF(6,H6J@A!X;!C$Y:F123@
M^.<0U*J?63B>GA^C?RN3AV3>J&03GOZ=Q&H]LD(+Q6Q)MZEZY?L_V"$AOXBW
MX*DL?]'^8.M8:+&5BF<'9R#(DKPZTO=#(4X<(([9@1P<2-O!ZW!P#PYNF6A%
M5J8UI8J.AX+OD2BL(5IQ4M:F](9LDKQHXTP)^#<!/S6>/#]-[Y]F]U,$9[/G
M/Q^FMW.XF,WA\'C_-)^AYV_H^>7^]7;^  ;H"GV?3='%EZ](KJE@$B4YFJ_Y
M5M(\EI?HR]GUT%: 6#S(7AQP[BH<TH'CHD>>J[5$]WG,XG-_&U*K\R/'_.Y(
M;\!'*JZ1BR\1<8AKX)G\?W?2@^/6Y7;+>&Y'O%>V8_F6R1M3:2I7S^Q:S.<;
MN:$+-K)@PDHF=LP:__H+#IS?3'E]4K"S++TZ2Z\O>IVE*<G*,R@]BS5F-\;^
M(/('0WMWBJ^;D9"XN+8ZX_)K+K^W^L\;)JA*\A5B[[ .RHX^^)_9AT\*=I9O
M4.<;_*0/DE&Q6".8C+"V[6#1WL 2K$Q)5Y'\DX('+L%!JRVZE1_ZH6=NRZ#&
M'/1B_LYRZ$M:4M(8%KE$JJ)/.V8"'6@(.,1N&]1@Y45.: 8-:]"P%_0AV]!$
M%!5$?(E6G,?[)$U-D*'V>!<@PQ:D;N68 :,:,/H 8,KSU54*982R2LF4<3Y&
M&@-Q/-=MD>I6':38:83'Z66=<P4]Y]J4-(J&H[?3C2+2QC38#5PO(AVL)R*)
M^^N:+WC&T$7*I?R*EH)G1W">FX&Q890ZKM?FU<VN/)\$'>L<)@TP^0FP8K">
MJ').<;5F H2YR.$2Y<PX_P\!SX8LB;0"ZU;8];KJVZ@B[I6C5GW?&+R>L@,P
M4O2]8U"X^M#%+FDKB<'LRG,C''5 -R*'^U7NH>8[CETCI:=7+-+&@6[D=ZQ5
MN!$[W*LMXR?8!"2GA37B^;K08JS-?X-94<3!H .R42@<]$JR!HE@7E7OED;<
M7L'[J#9_5K3SW!O9P_VZ=T=ELD 7\,8<\S2E0C:YFWM5A1N<KL+76&N5;G7E
M7+L=C6JD#_=KWS1)MPJ4Y .XH0F7M'%UJQ[<1@AQU#NN9M7N9"L!&8AA@&VV
MI<SD'QQPO8+[X0'W2='.MT*-Y))^R6T&7+5Y,[:-&+0V"'UM23#9>0'!'>L6
M:<26](OMZ4CKXS1(;!#!NV";TV!GXK1/-M$9$ZORVX*$D;/-5;7?K._6WR]N
MRUU[Z_X=OIE47R&:,-5'$=A-KI)<HI0M(:1S/0 H47UGJ"X4WY1;]3>N8.-?
MGJX9C9DH#.#_)>?J>%$\H/[:,_X/4$L#!!0    ( &*)J%8S#I:'-0,  )P(
M   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULK5;;<MHP$/T5C9OI)#,E
MOG%-P3,)D"DS#<G$2?K0Z8.P%^S&EJ@D(.W7=R4;EX!#^] 7K,ONT3DK[2[]
M#1?/,@%0Y"7/F!Q8B5++"]N640(YE>=\"0QWYESD5.%4+&RY%$!CXY1GMN<X
M;3NG*;."OEF[$T&?KU26,K@31*[RG(J?5Y#QS<!RK>W"?;I(E%ZP@_Z2+B $
M];B\$SBS*Y0XS8')E#,B8#ZP+MV+85?;&X.G%#9R9TRTDAGGSWHRB0>6HPE!
M!I'2"!0_:QA"EFD@I/&CQ+2J([7C[GB+?FVTHY89E3#DV9<T5LG ZEHDACE=
M9>J>;SY!J:>E\2*>2?-+-J6M8Y%H)17/2V=DD*>L^-*7,@X[#HA3[^"5#MZ^
M0_,-![]T\(W0@IF1-:**!GW!-T1H:T33 Q,;XXUJ4J9O,50"=U/T4\'P=CH:
M3\/QB. HO/T\&5T^X"1\P,_->/H0DMMKW+JYNQ]_0KO)TYA,IC@?D]//MV%X
M1AKD,1R1TY,S<D)21AX2OI*4Q;)O*Z2G#[&CDLI50<5[@XI/;CA3B21C%D/\
MVM]&694V;ZOMRCL*>$/%.?'=#\1S/+^&S_#?W;TC=/PJU+[!\]_ "Q55@ F@
M")^3(<\QZQ*=#FL@$Q;Q',C7RYE4 E_VM[KH%>C->G2=[1=R22,86 @L0:S!
M"MZ_<]O.QSKI_PGL52":52":Q]"#*1:GM%!\FG$IS^K4%A!M Z%+T3KP7-?'
M:USORCBT:C3]7J=3F;TBV*H(MHX2Q *!Z<\P_X0 %OTD>"E,9K0H//%W3$M]
MCW6T"^#6+FVGV=IC?6C4<'M.LYYTNR+=_FM4EV5Y+<)*%EC%ZTBV#\_?#^RA
MB=NKY]>I^'6.\GMDV&6R]!?$AM>6([+%]O$,BLXR(!(PYJE*07X@#$RF*/I2
MIZ%S0+"]$\%"Q*%-PW6Z?KV.;J6C>U3'Z\S]ZSON'KYCO]/I[3$]M&HTV[V=
MAU-0M7<*?0YB8?J?)!%?,574Q6JU:K&7IK/LK5]AZRTZY1^8HF]CU5ND3)(,
MY@CIG'<P?*+HA<5$\:5I)S.NL#F988)_'T!H ]R?<ZZV$WU ]8<D^ U02P,$
M%     @ 8HFH5O_ZT@!9!P  3S   !@   !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6S-6VMOVS84_2N$5VP-4-<B];*[Q$!C2VBP-LGB=,,P[ ,CT[%6/5R1
MCM/]^I&R8EDB35L8,?1++-F\YY+WD%>\1\SY)B^^T"4A##RG248O>DO&5N\&
M QHM28KIVWQ%,O[+(B]2S/AM\3B@JX+@>6F4)@-D6=X@Q7'6&Y^7W]T6X_-\
MS9(X([<%H.LTQ<6W2Y+DFXL>[+U\<1<_+IGX8C ^7^%',B/L\^JVX'>#'<H\
M3DE&XSP#!5E<]-[#=R'RA4'9XK>8;.C>-1!#><CS+^+F:G[1LT2/2$(B)B P
M_W@B$Y(D HGWXVL%VMOY%(;[UR_H83EX/I@'3,DD3WZ/YVQYT1OVP)PL\#IA
M=_GF ZD&Y J\*$]H^1=LJK96#T1KRO*T,N8]2.-L^XF?JT#L&4#[@ &J#-"I
M!G9E8+<,>"C5!DYEX+0-#HW!K0S<EH'C'3#P*@.OC/TV6&6DIYCA\7F1;T A
M6G,T<5'255KS ,>9F%DS5O!?8V['QI.;ZVEP/0NF@%_-;CY>3=_?\YO9/?_X
M%%S?S\!-R.]N)K]\N/DX#>YF/X'@U\]7]W^ /O@\FX+7K\[ *Q!GX'Z9KRG.
MYO1\P'B_!/H@JOIPN>T#.M"'^YSA1&$VT9M-\C3E<W/&\NB+PGJJMWX_G\=B
M;N,$W.)XWN=#F.!5K.Y)< 0KBM;I.L&,S,&4+.(H9@J0\'20&[8D!> #Y-EB
M*9;Q$P%7692G!+S^F%-ZUH0?<-)WS*,=\ZCTYQSP=TD>XRR+LT>^,A.<11R:
MQX N<4'H&<",CR1Z"VSX!B +016K6GR1$M_1%8[(18^/@I+BB?3&/_X />MG
M%==;,+<$$^GP:0P==X2@:UOG@Z=]7DVZ#4R"A8; &G3:.SKMCG2>0N$6T]N+
MNNV[MF,W0SZ1FPER6KPH&MFV ^UALUT@M^N/7 ]Y?K-=J&AGCX9UJT:8G%V8
MG-+,/A FOHKX YCRR<YC4UZ=B>Q5)I%EGLQ)07F&^[J.V3?PYUV>)( _P#:X
MF/^E"I]C<@68!)N:! M,@H6&P!KLNSOV7>TBN:)T7:Z-? &B[>.#"N;!>L4O
MR3,IHIB6OVZ_SE?B$4$!?ZZ)61+E65;MB#8Q6_*=%65%'(F,7<%D,:-O0,9W
MA!R#X>?]G*J:0-KN=IU KI1"?<=&4OXTZ3,P"18: FM,#6\W-;SO:VJHIH,G
M,=B';CLQ3CPI,;92[%2)X[NM1*P-2%?N#($UN/-WW/E:[LKLW1<%QEQPQZLN
MB@45JA#[\B+Q1K 58:V[KJGX%(^!28^A(; &%\,=%T,M%_QQR:LYOB#614&R
MZ!M@!<YH@K=UY/QO7M+PPE2U/[X<*F;MR'):W&C==^7&)%A@$BP\%HP&.:,=
M.2,M.=<\^ZPJ6>!U(@H)\(ACY3H9R?OQUH9OHO75E0F38(%)L% ;B08-T*JK
M;NLH$>N,[S^3^!^>M 0)@'.2XN(+8?@A(8 2OH)XA4J./C0J5\VI8@W;>WA]
MC[K2910M,(H6'@U(D[0]J00>)2VNJO!$KL(K-J#LW+%'?OLAKO?5F0Z3:,&)
M8PA->6WR40L84*]@!-E<(U]\PL6N]D5*IHSJ%U E8'B>Y_A>>P-NU'%@%"TT
MA=:DM!8QH%[%:%%Z$HVV%'C;=ES1N+G@5")&>V\]5:!!V[&0V]J&!(J&/,E8
M%G*<]BI1M/1&KGL@'=5*!M26RMT$/'7HC.H7%5HC=)[GCVP;22O J#QA%"TT
MA=9DM58HH%ZB.*KCJ9F4:W\T<D;NL+T(7'D1>%Z[?%2@0<>UD#UJ+P*Y81]"
M9^@Z;GL1*%H.G4/[65A7[=#['_4\:+(DGAA%FQI%"XRBA:;0FI.@+O^AOOX_
MK-UD? * U?HAB2/^XX(4?&'M]M/QBUF44T:/277Z/G2>&[(J8(\\Y$AJG5&W
M@5&TT!1:D_9::8!ZJ>$@[0H]#K,^6Y+^ML"2I\++%X \B_J8J-]BRC7YR+?<
M=HH=2BG6D4A5('E>6Y_3#[\S68;0FF35R@/42P_?G?2N[V_G]:Q0"2SH#J'T
M;#4J=!A%"TVA-=]'UZ((THLBWX4$CU3B ;3:VE?5K+&1DEY4*Z':,EJ@CTKG
M=]"&T)H<UAH)TFLD7:1X),L,0R0))7J'77=1)_D,C/H,3:$U*=D[YZ&72?Z#
M(H]D40-9[;W]1.^_,T-FSW>8/>!Q)!Y-AFK5 ^E5CPZR/%*("6VE5^^M,Q\F
MT0*C:*$^&DTV:ET%Z745D]H\DC413WJCI>]/9[Z,:BM&T<(CX6@25DLF2"^9
MG*3+(X5" J$MK1V3!QJF1M&"TX80FG+:9*-69)#^(,7IJKRMY,FH!(/DDQ#0
MA[X/74GT,NHX,(H6FD)K4EKK*TBOK^A5>36-OK0_MFW7:^^1)XIVG"")&T4K
MQ_,M#[4W;G)#ON5&O@-1>Y4H6KK^GF"ZC=5@[VBU.&K/!_X8\YHC(0MN9[WU
M^=0JMJ?7MS<L7Y6GK1]RQO*TO%P2/">%:,!_7^0Y>[D1![AW_T,P_A=02P,$
M%     @ 8HFH5C1%(-+,!P  #2(  !@   !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6RM6EUSH[@2_2LJ[]:MF:KQ&$D&3&[B*D^2J4W5Y*/6V=UG!>28'4!>
M23C)_?6W!0[8()2DUB^)@59S6NKN<P2</@GY4ZTYU^@YSPIU-EIKO3F93%2\
MYCE37\6&%W!E)63.-!S*QXG:2,Z2:E">38CG!9.<I<5H?EJ=NY/S4U'J+"WX
MG42JS',F7[[Q3#R=C?#H]<3OZ>-:FQ.3^>F&/?(EUW]L[B0<31HO29KS0J6B
M0)*OSD8+?'(^]<R RN+/E#^IO=_(A/(@Q$]S<)6<C3R#B&<\UL8%@W];?LZS
MS'@"'/_LG(Z:>YJ!^[]?O7^O@H=@'ICBYR+[*TWT^FPT&Z&$KUB9Z=_%TV]\
M%Y!O_,4B4]5?]+2S]48H+I46^6XP(,C3HO[/GG<3L3< _-@'D-T TATP'1A
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ME\HH5=,#\PAG-V:H2Q1:C!X X]8:2.S")MQ=AE(LNHMHY(G<X=-3^5ADOU2
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MF\?%R5"4'*44?R>/,"W!P "2?N+DV"ZD=PC\;R)75^0'H6RZY9%LRK$'S$L
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M O[X3$*+3P6'5<\S-SG7U8>FK3BAF+)*JM<8V<77=8P(V"I*)TG0B-Y5,[=
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M]/$]%D[W2V]:^B-D2]/W9DL_8BRI.WP OL>_YN!^P0G\7Z5[\7]02P,$%
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M7<#Y0J&<^ 4):+^^7OX)4$L#!!0    ( &*)J%:9\9O$DP,   P)   9
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M,2YX;6S=76ESV\B9_BLHQ9NUJZ"#NNVQ7:6QQXDG\5&69[8J6_L!))IDQR#
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MFZCB !?10>-2L<10YUQ@H%<:"9ZD*A@;O=8:/$<]5K45Y. 5;=)* 9=VND(
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MSPBA8.1ITT[!Y&I8FV5*#RA16: $81@FEVZ&G]PC,6R!:J!(SQ532=+FQD(
MKB&Y9[+!<$_3[0 B"S$=0!#YYI,J%Y"8$AUG$$9+O\EBB68H"#4Q@GC?Z>]>
M0V $XH :CH5S#CE"\!/16(Q;W)071^T30@]%0B',%55 8<#P[&O9SLB.A.=:
MWYL(EW6CT;+8GEM#J5'=KALY; K&P?='+ (I^;R/>V>/ WEABT-\ 27",B=]
MX0Y!_X6?=%/Z4ZYL/7'\ *4E5A_$ILIABTL-K "3DP'M%XH=V3HZI_OJZE.
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M?\NB;3 :'I@K//[0M<$6 <>U4#["X##PLK$!U-=#?)^'QH[?GWC<16"0I1M
MJ@:)DD<SV<OG1H&4=\(ZN^!-1KY%G_IB00_T-@I\]$7'"$Y'M5-YY""TBZ0B
MM%O[<S 6O4M)(B.A:+O]GX;I)B*[6&R)/USH@U/%@*[^[9Z9X'RI$'425 7D
MN#GSVFV\PY,A3@1T1E",%U$/>7&_62;A2ZV ('2GJ&4&%2+\"U7MDGF&M 6F
M8+L/?UOV0@F!6,6]2!>0!/?*4ONS\W)0+/&1)&,T7$+I+Y;E@J+TGBC()B)"
MCHXZ"@^TI1:0 @'>X9,5_IZC+A43">B-JIRQFUAB:MLVZ"D0< .6!D^0<H\R
M/@86WNPZ?*7KG5'ZO6ZQ_1=?7\NDW[Y)X>>2S/+@9;6[R=#WNM-VN]P&77,3
M7IHJN]IQZ<'=K8Z;/FF(;S7BAPDTT\<!15"Q+KW' EW'@V#]46KL8ZL@4O#!
M01PUI"CO:X5^/$TTV,F;:A8>!S,[!6*N>+C"XVQK=$>:?O@R.#0CZ<=@Y#!Z
MHVS*] L^@?6W&!YB9Q@S#CSL3/>QXI]ZA846'P/>:J,Z%])*)I:&->,@V:(*
MO9<_+Q%!=M#IF3OL+?6163XY<L=?[[2G1Z/S@@U7I,-K%.RR/. I_B65L.L6
MC^,DSPY7P'/[@IU&<X)7GN#/9_8P$^!(J76E&!(5^/K>%OI+=4[9GCFOE05*
M26FA(Y@X10[6F@ MW([TQ7F+1L3VE!FX)7*05F[C5C##7(!7MP\).+?(Y= ]
M-M^8MUNVM+1QAF=N^.MS_?3!W:\;5BO&.8975O*4;@]N!+(A8QQTBM9M!0 U
MY%#117B5?71ZPBSY"%)H+*BGB4ZD\;_]-F2%[7+7&:0# Y/; (WC"2X[AK_V
MMR/YMF_>A7*,\(ZV?>8O;3GH!A$=-&@$J4/_[B#?'#:* ,G%W/0CNP3WZV)P
MN^F2LK^CZ'YH0P 6<M[$"_1&*B_1 7+\H@2KN=1@ S$.3L4(4_()S^=@U.F'
MJKGLZM0 CSHRZ=Z\OI),R<AMT/@KQO(\$;IG.0XMTF!'HQ%BU;=ZR8> UL,P
MW^'6G1&F,[SN!^+B=048RO'FXT-_:RY&7XQC'\9^2W*W'Z!C/-ZN/T#G%&X+
M>.X;_:*<-5$!E"T$BG 7N)K?"R?R&X >H]SMXCR^]2_(-=B@O._/R$E;'&,J
MZCP6[@IFP5/92UY<J($-"B^;$D&"Q()C%F!4<&S2>OY>0[-G!*-*\<@%@#L4
M<)/PMI7.%8HDW>'%QJ[[O/72Q-Y5B;Z/-XS?!D<&K"S=YFW_/I0+1&B!L5/T
MDSF=>W*TS2M3OJ#;H::",TVALNR8%\C=TA2U\2!1$;U_?@2#93G[>C=JSET'
M+6IK#W?F66,O>M+EZ&U%3\^#2\W\5?3/#YN7SP^U@?^;P?_JZA;^WRR5:B#=
MRUX^!_.[4*_HV@\"&+W8F^P%GZ*ZO-B[FCR[.MX[A#?]XR^?K[.%>I?5"PT*
M4J@YO'IT<'&VQ\&:_:.IUC@D7D4%MI[^N5094!L?@._G5=78/W "!.O2\E[^
M+U!+ P04    " !BB:A6976-  @&   '$   &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6RU5UM3VS@4_BN:+-.G7""A+=,",U!HEQEN4[KMP\X^*/9)
MK$&67$DFI+]^OR,YQH' M'MY:(EEG=MWOO-)WE]8=^L+HB#N2VW\0:\(H7HW
M&OFLH%+ZH:W(X,W,NE(&/+KYR%>.9!Z-2CT:;V^_&952F=[A?ER[=H?[M@Y:
M&;IVPM=E*=WRF+1='/1V>JN%SVI>!%X8'>Y7<DXW%/ZHKAV>1JV77)5DO+)&
M.)H=](YVWAWO\OZXX:NBA>_\%ES)U-I;?CC+#WK;G!!IR@)[D/AS1Q](:W:$
M-+XW/GMM2#;L_EYY_QAK1RU3Z>F#U=]4'HJ#WEY/Y#23M0Z?[>)W:NIYS?XR
MJWW\7RS2WM>3GLAJ'VS9&".#4IGT5]XW.'0,]K:?,1@W!N.8=PH4LSR101[N
M.[L0CG?#&_^(I49K)*<,-^4F.+Q5L N'9Q?71V>?+TXOOXBKC^+3U=7)M[/S
M<W%T>2+.KRX_#<[/OIZ>B*.;F],O-_NC@(AL-\H:[\?)^_@9[Q-Q84THO#@U
M.>7K]B-DVJ8[7J5[/'[1X85T0S'9Z8OQ]GCR@K])6_XD^IL\X^^3M?E":2VD
MR<69"=+,U523./*>@A<GRF?:^MJ1^/-HZH,#B?[:!$.*LKLY"@_6.U_)C YZ
MF!Q/[HYZAZ]^VWFS_?Z%&G;;&G9?\OZO6_C?>1<GM5-F+D)!^.>(1)G:3]Q^
M@>9E1=N]OI!>2 RVQP ).XM6'HR'DF!S3AFG(I2)+S[8LI)F^>JWO?'.V_=>
M8#"R6U$YE5'LG2,M \R@++>0LDQ6*DBM?DB>_;X(Y# \\6$5"I.CY=2ZM"CG
M2!=B@Z8O5"C$L;)S,M'UI;V3+BC?CT]28)V<U-T,Z7NMPE+<25V37Z4\5390
M5ABK[7R)Q1RUN66_6XZHR+&P(G%IA,*:<IP$H/'D??R)=.<-2_OLA6;*J$ #
M#37+L=!R5D;.IBRU-?-F1UH>BB^=L-!TU(U48PL\>@9[1Y5%G>A?C0!1ZW(!
M:!0PF=;8A(P:K%<;45"=!8S'4$ C.WE*\;V6)J '++K/5+9 ] < .,(<ADT'
M954Y*[.B+Q8%.9HN-])@!K<)=L:I:0/[S7BC@]M@8P&9=&[) >+FA,:SQCFY
M"%U*:6K!!PZ^D5LK.JV@C1P!(WQ0.#.B9R:Y]-9([I)#N^)J0Y;X/L.8.&@_
MU*%4=<G%:Y62WU0UX(ROVZX 37(8!D_=^AY[Y=)6>>5-?^L*)3S:B*2F4:28
M7@V2,?<& ,B@\3*>JI%7RC,E6-AX?*30=$=:C(6QQE%6NZ@)';!+H '., >&
MXGA%L\!^I)%ZZ7G6NIC"BYT;]8/9S%X'F?0@!D(.@KQO:=>E659(EW#>FNP-
M=W!T:LW=RG]!H88X!EJ%2AFUH1C+6:WUL@D:!XW#/79Q3. W110UA57L32D_
M3,9Z]3/E/$!'Y[@AP?^$"$06PD<:WB=B()!2)_*Z-N24Q/+G@RTPGVA+:*&(
MTH[PZ/CZW'7W8D;N,R9O&B#L12AUI_(:VOK %O]L=A+PP79SA2TA0:TF43%W
MMJYB[57M*NO3]#VVW=R2]2PP,)FNF3&AD"$=)VN%MN=9DM9N?+"<ZV=.WU&:
M*Z %P64X*/F$-M4LJU#B'%<06QON/;->S'"-CN"VK<8VNJ]PRTV"D8XG*,_,
MV3)NK'TZ(S&6)C"Z\(GR%0\PZK*,I,W8)*E[,VS1M@,&+D*/YK)+E4V]VP3O
M>C_[Z;1MRE$X_$W6:";TP.4#2$]SL":UQ3"4_58?I=@$#P0F%#:"T<IPAU M
M:2!#5%B=<Y$.S4C'?\2 [_(#.QM$Z)IS5<6><XN?L6S.?:RL> V>I",R(?V,
M4D[^%Z5\JI,O,3WI94QZ:V=G.&X%TZ:B-B*R]7JX_61C<Q';C%&ZG6SMK@?H
MPC109H#]N(XQVWY-KB]MMR26Z X>;7[\J1J[^$0T_I%J=:5JTVU^U/DX*PD@
M\R<H7U# VO2=UJZV7[E'Z>/N87OZ1$:]<V68N3.8;@_?ONZEQJP>@JWBIQZN
M+/APC#\+?*F3XPUX/[.XDC8/'*#]]C_\&U!+ P04    " !BB:A6W=\-O<@"
M   :!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R556UOVC 0_BNG
MK)HVB38A28$Q0 +6;=74@@K;/DS[8)(CL9K8F6U*NU^_LP,9E0K:OMAW]MWC
MYW(O&6RENM<YHH''LA!ZZ.7&5'W?UTF.)=,7LD)!-VNI2F9(59FO*X4L=4YE
MX8=!T/%+QH4W&KBSN1H-Y,847.!<@=Z4)5-/$RSD=NBUO?W!'<]R8P_\T:!B
M&2[0?*WFBC2_04EYB4)S*4#A>NB-V_U);.V=P3>.6WT@@XUD)>6]5:[3H1=8
M0EA@8BP"H^T!IU@4%HAH_-IA>LV3UO%0WJ-_=+%3+"NF<2J+[SPU^=#K>9#B
MFFT*<R>WGW$7SZ7%2V2AW0K;VC:./$@VVLARYTP,2B[JG3WNOL.!0R\XXA#N
M'$+'NW[(L?S #!L-E-R"LM:$9@47JO,F<ES8I"R,HEM.?F:T6,ZF7\XGX\75
M!YC.;N97MXOQ\GIV._ -H5L;/]DA36JD\ A2!#=2F%S#E4@Q?>[O$ZN&6KBG
M-@E/ MXP=0%1NP5A$$8G\*(FU,CA1<="S9G"\PFE,(4Y>Z+*,C!6BHD,G?QC
MO-)&49G\?"GX&CM^&=NV3E]7+,&A1[VA43V@-WK]JMT)WI]@'C?,XU/H_Y6D
MDT@O\SP&#\L<82T+:EPN,C!L52#H7&XU&&E8 52=R?WYRGW11)8T*#1SO8:/
M5D;JVD1F@O^F>R[ $!Q+K"$33Q9Q*JE4A/4F2<N"I\R0LC"TV91HD&N85:@<
MJH8W#D1N-!.I?MLG?@KQ6=FY6K%+"'<4'E-)#F1,??I \Z=R>3Z#N-7K1F[O
M= /XA()>*)P=2ZG'N"T#.RP@:L5!3&L0MF'Y;R&?0:\5=KNT=UN==VUX*?W^
M0;^6J#(WE33A;82I6[<Y;0;?N.[WO^;UU*0FR3A]F@+7Y!I<="\]4/4DJA4C
M*]?]*VEHEC@QI^&-RAK0_5I*LU?L \WO8/0'4$L#!!0    ( &*)J%;5JHJF
M#00  %,)   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;(U6;6_;1@S^
M*X1:=!O@2K+LO#2Q#3A.AF9+FRQ.-PS#/IPE6CI$NE/O3G'\[TN>9,?9$B-?
M;)U(/B0?\DB-5MK<VP+1P6-5*CL."N?JDRBR:8&5L*&N49%DJ4TE'!U-'MG:
MH,B\455&21P?1I60*IB,_+L;,QGIQI52X8T!VU25,.LS+/5J'/2#S8M;F1>.
M7T2342URG*/[5M\8.D5;E$Q6J*S4"@PNQ\&T?W(V9'VO\*?$E=UY!LYDH?4]
M'RZS<1!S0%ABZAA!T-\#SK L&8C"^-YA!EN7;+C[O$'_U>=.N2R$Q9DN_Y*9
M*\;!<0 9+D53NEN]^HQ=/@>,E^K2^E]8M;H)>4P;ZW35&=.YDJK]%X\=#SL&
MQ_$K!DEGD/BX6T<^RG/AQ&1D] H,:Q,:/_A4O34%)Q479>X,2279N<G\[GKV
M^^?KJ_.+V_E/</''M\N[OT>1(V261VF'<M:B)*^@#."+5JZP<*$RS)[;1Q31
M-JQD$]99LA?PBS A#/H]2.)DL =OL$USX/$&K^!=?&^D6\,_TX5UACKAWY=R
M;"&&+T/P[3BQM4AQ'%#[6S0/&$P^O.L?QJ=[ AQN QSN0W]S'=Z.\N'=<=(_
M.NVP8.H^N@(_$K'W=-6OETLT4N4PS0TB73('EPJF34X=QYS'/2!MF.FJ%FH-
M)$>#&4CE- @%US03H(.:BQ*?8,CK\#@^I2YV!?R&W@U:N+J:P<\<41*?;M_Z
M<__TEU:9.*WIJD+K0;3A5JT/O0FW-CHWHH*&^LS JI!I\2S02JQ;9<+(@"Y_
MV8.ET14XFB0,[?^% ^DL6$V19]*F!GE"], 6@J(@@%W,CD<+J:XJFB-T)=-[
M*,0#Q\.1YI1[+ASN1BE3/D)3L\_W_8,XC.GVEB4/(E<8W>2[[ C[HD-+S)(P
MY^IHPZ@JE;4H0Z[5.:98+2A1JE:RIUI3JDKF"_Q5AY!X#DCW#17TY))+FO66
MT-CJU5S;>GB5_85;K#UG62:9<E$2.4<'3^2$<+>3B+2@-($L2LE.,PZ>:PHL
M[(KUY'E#5Y='".>-=\TRXAP1JG9((0\I3I[RV\R8YPQ29V0PZ'TZ3'K#0;S3
M%]PVS_J UB(H2I3R2Q$SKR1J.CU*6AE8KN']I_!HDUZ/Q2VQ_U&*P\-M@ZRH
M'PR5E]85%Q&FQ''IH_1=32)M. .^-B2F:50+F0$^4DTM4T!*FM(QM$",X=(+
M:Y$B]\WW_SZ;:2)$<8WIB5*7F2?[3)1"46WG_N- ^-2>DQ923VW(65'+M;R]
M6A'(WEZ0)'QIJ$8[BZY"D_MUSA5IE&MWWO;M]HMAVB[*)_7V<X.\Y5)9*'%)
MIG%X=!" :5=X>W"Z]FMSH1TM8?]8T%</&E8@^5)KMSFP@^UWU.0'4$L#!!0
M   ( &*)J%:E,CT(8 0  - )   9    >&PO=V]R:W-H965T<R]S:&5E=#$U
M+GAM;(U6VTXD-Q#]E5)O=I]&<P46L3 25V4?R"*&32)%>?!T5T\[N.U>V\U
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M%2L,NS#V#M[7NZB&GU"LC$M#E+[,MKS/:JD#YG\?(.)1:(AS6NF#B@G6P=.
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M7.+@S:6Y@.=S(?1V8PRTH_SP7U!+ P04    " !BB:A6QID#+DX#  !^!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RU5=N.XC@0_9529C5J));<
M:)IA (G;:I"F&=0P.P^K?3!)A42=V%G;:7K^?LM.R-):FH>5]H'@2]4YIUSE
M\O@DY+-*$36\%CE7$R?5NARYKHI2+)CJB1(Y[21"%DS35!Y=54IDL74J<C?P
MO(%;L(P[T[%=V\KI6%0ZSSAN):BJ*)C\.<=<G":.[YP7GK)CJLV".QV7[(@[
MU-_+K:29VZ+$68%<98*#Q&3BS/S1O&_LK<'O&9[4Q1A,) <AGLUD'4\<SPC"
M'"-M$!C]O> "\]P D8R_&DRGI32.E^,S^F\V=HKEP!0N1/XCBW4Z<88.Q)BP
M*M=/XO0%FWCN#5XD<F6_<*IM!YX#4:6T*!IG4E!DO/YGK\TY7#@,WW,(&H?
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M.TSI@41I#&@_$4*?)X:@?7*G?P-02P,$%     @ 8HFH5HW=JX1C!   S!
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M0M LOUPAF""F N3S!:7B[49U4/U&,OH74$L#!!0    ( &*)J%8Z0X<5QP,
M "D/   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;*U7:X_J-A#]*U8J
M7;72ECQ@6>X6D$+VT:B7A\ANJ[;J!V\8B+5)3&T#]_[[.TY"(#1$72E?%C]F
MCN>,SSHSPP,7[S("4.1K$J=R9$1*;>]-4X81)%1V^!92W%ESD5"%4[$QY58
M765.26PZEM4W$\I28SS,UA9B/.0[%;,4%H+(79)0\6T",3^,#-LX+BS9)E)Z
MP1P/MW0# :C7[4+@S"Q15BR!5#*>$@'KD>':]Y[=TPZ9Q>\,#O)L3#25-\[?
M]<1?C0Q+1P0QA$I#4/S9@P=QK)$PCG\+4*,\4SN>CX_H3QEY)/-&)7@\_H.M
M5#0R!@99P9KN8K7DAU^A('2K\4(>R^PO.12VED'"G50\*9PQ@H2E^2_]6B3B
MS %QZAV<PL&Y=.A=<>@6#MV,:!Y91NN!*CH>"GX@0ELCFAYDN<F\D0U+]34&
M2N N0S\UGB^?W9G_E_OBSV<W9.(&?D#F3V2Q? P>9R_9,G%G#R1XG4[=Y9]Z
M+_"?9_Z3[[FS%^)ZWOQU]N+/GLEB_L7W_,> _$R6L(=T!Y*L!4\('D<5;%A(
M%E2H% 1+-P33'M,WCCOZ,MV- $!Q*$EHND)_"52$$7'U)3/UC3P+JC=_? !%
M62Q_.AV2GQ'R%$\)%69/147>0*"5=QRB10C:*#M0,/D^-!4F4*?!#(MD3?)D
M.5>2U253/">2Y#%=P:KJ;V+BR^P[Q^Q/G$; *14=TK5OB&,YW9IXO/_O[C2$
MTRW%T,WP>E?P)HQO("53]X;X:=BI2U C@'YS[N66AC R\%&1(/9@C#_]8/>M
M7^K8M016X=HKN?8R].X5KEY%#TO4 _G["]H07T$B_ZGCWFN3>TM@%>ZW)??;
MQGM>@-#<\9DF?(V/<?[?6D<YQQED./J+L!];G4%O:.[/J=09G6PJ$?;+"/N-
M$?[&%)!%1/&AOJ[%1HB/WD=+8!6V=R7;N[:U>-<F]Y; *MP')?=!2UH<U,C,
M&EQHL<Y(OXUU8OQ<AOBY,<09W^.'BTD4HE1,[93^LG%!\+F<PHJ%-"Z_6-?%
MVGC$1R^L);!*-FSK5#)8;<NU0&R)?EMH5?YG)9/=DF0+H O-]B\T6VO5O2):
MVSF%Z32&&="4KQD).FZM()N]/WPE+:%5N9X*%[O;NB1;+67:0JOR/Q4S=F.]
M\!%)]OXKMDL]UIATK-L+/9IG30<6V)NL%Y-89^]2E5? Y6K9[[E9EW.Q/M%]
M8-;,G&#R)A+KVPU+)8EAC9!6YPXK#9'W9?E$\6W6VKQQA55^-HRPEP6A#7!_
MS;DZ3O0!97<\_@Y02P,$%     @ 8HFH5N;]08I7 P  O D  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&ULK59KC]HX%/TK5K9:M1*=/ @#G85(&1[3
M2#L!$::KW=5^\ 1#K"9V:AMH]]?WVLFD4#)3/LP7L)USKN_QN7X,#UQ\EADA
M"GTM<B9'5J94>6/;,LU(@>45+PF#+QLN"JR@*[:V+ 7!:T,J<MMSG&N[P)19
MP=",+40PY#N54T86 LE=46#Q[9;D_#"R7.MI8$FWF=(#=C L\98D1#V4"P$]
MNXFRI@5ADG*&!-F,K-"]F?8TW@ ^47*01VVDE3QR_EEWHO7(<G1")">ITA$P
M_.W)F.2Y#@1I?*EC6LV4FGC<?HH^,]I!RR.69,SSO^A:92-K8*$UV>!=KI;\
M\)'4>DR"*<^E^46'&NM8*-U)Q8N:#!D4E%7_^&N]#D<$UW^&X-4$[U)"MR9T
M+R7X-<&_E-"K"4:Z76DW"S?!"@=#P0](:#1$TPVS^H8-ZT69KI-$"?A*@:>"
M^?(NC*-_PE4TCSOH-DRB!,UG:+&<)M-X9891&$]0\G!_'R[_UM^2Z"Z.9M$X
MC%<H'(_G#_$JBN_08OYG-(ZF"7J/EB3E+*4YQ:88^ :-L<P09NNJ,?VRHWN<
M$Z8D>CLA"M-<O@/>0S)!;]^\0V\096B5\9T$BAS:"H3J=.VT%G5;B?*>$76/
MQ17JNAWD.5ZWA3Y^F3XA:4/W6NB3RV=OHT\OG]T]I=M@;N.PUSCLF7C=YQP6
M6\SH_\:*#AIS)GE.UY4SVI&%(!*<:*R:48;!/)RC! 9)85SZ-WR42L"N_J_-
MC2H!OST!?=+=R!*G9&25>BZQ)U;P^V_NM?-'FS>O&6SRFL&FKQ3LQ,5NXV+W
MI>A!LX%2W2 _-E";'U6H:Q-*7Q3[H#_P?"BF_?%"GZ-<Q_%]_Q0V:8%!9?;Z
MI[!I"ZP_&/2]!G8BVV]D^R_*CCE[G^Z$ *5P*T$)TE21:A':A%?!>L=)]!SG
M)]V7@":7@*:_ )TH[C6*>[\TNG/F<L=X_],*("QAJ.1"#QRHRN#45!F!RS?E
M18G9-\JV>L.OX5H'Q(^M#YVCO?UT/,_@S=!:3KWS<OK0/RNG<Y3KN!_.RJD%
MYKG]LW)J@0V<[EDYV4<WGW[7P-F[I4RBG&R Z%SU(8ZHW@I51_'27(:/7,'5
M:IH9/*^(T #XON%</77T_=H\V(+O4$L#!!0    ( &*)J%9EE1R-R@P  %B0
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;,U=;6_;.!+^*X)O<=@%
MMK&H=_62 &G:Q15H%D73]CXL[H/B,+$0V_)*2K(%[L>?I-@>4J1'XF8$\$L;
MVZ/A<#B4'S\CSIP^%^5#M>2\=OY:KS;5V6Q9U]NW\WFU6/)U5IT46[YI/KDK
MRG56-R_+^WFU+7EVVUVT7LT]UXWFZRS?S,Y/N_<^E^>GQ6.]RC?\<^E4C^MU
M5OYXQU?%\]F,S?9O?,GOEW7[QOS\=)O=\VM>?]M^+IM7\X.6VWS--U5>;)R2
MWYW-+MC;2Q;X[16=R/></U?"WTX[EYNB>&A??+P]F[FM27S%%W6K(VO^>^*7
M?+5J536&_+G3.CL,VEXH_KW7_ELW^V8V-UG%+XO5?_+;>GDV2V;.+;_+'E?U
ME^+YWWPWH[#5MRA65?>O\[R3=6?.XK&JB_7NXL:"=;YY^3_[:^<)X0(6'+G
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MJ#D.<31A&0*6"W$L-[0[/O$GOG*8=GZD%!^5-MD/@!)#NXY"A*1PDDJ;[#R
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M*]!\?E<4]?[%O-'_7)0/W1CG_P=02P,$%     @ 8HFH5NUNY\H2"@  0V
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M0L\Y5#: OB^E-'<=.T'U0/1_ %!+ P04    " !BB:A6P<6ZIO4$  #)'
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M=5]H2(MSLZ+!R48=#+T0SDFF+M<8Q9A* W%_20A_:\@!JM/+R7]02P,$%
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M7Q#&0=]O.5?'@WF@&^?1'U!+ P04    " !BB:A6<CQ<CID%  !O)@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6S%FFUOVD@0Q[_*BJM.K92+'PB0
MY B2@Q^:*DD1I'<O3O=B8P^PJNWE=A>25O?A;VV,P6#<<!JI;Q+;>'X[Z_E[
MQCO:_@L77^4<0)'7)$[E36NNU.+:,&0XAX3*<[Z 5/\RY2*A2I^*F2$7 FB4
M&R6Q89MFUT@H2UN#?GYM) 9]OE0Q2V$DB%PF"17?;B'F+S<MJ[6Y,&:SN<HN
M&(/^@LY@ NK+8B3TF5%2(I9 *AE/B8#I3<NQK@.KEQGD=_S!X$7N')-L*L^<
M?\U.[J*;EIEY!#&$*D-0_6\%0XCCC*3]^*> MLHQ,\/=XPW=SR>O)_-,)0QY
M_">+U/RF==DB$4SI,E9C_O(1B@EU,E[(8YG_)2_%O6:+A$NI>%(8:P\2EJ[_
MT]?B0>P86!='#.S"P-XWZ!PQ:!<&[;<:7!0&%V]UJ5,8=/8-ND<,NH5!]ZTC
M] J#//K&^NGFH7&IHH.^X"]$9'=K6G:0QS>WUA%A:2;%B1+Z5Z;MU.#!^?1Y
M3(9?)D^?'[SQY(R,G/'3HS[Z>#>:$.?1)9.GL?/D!7=#XMS?WSF/0V]"?B./
M?$6%8I+<I5(QM50@B7XQR"WC#Q"QD,9D#!*H".=G^I[PG+QW05$6RP_:^LO$
M)>_??2#O"$O)TYPO)4TCV3>4GE'FEQ$6W@_7WMM'O+?( T_57!(OC2"JL7>;
M[=L_LO=_,+[= #!T*,IXV)MXW-J-Q$_+^)S8O3-BF[99]T":S9WE[)RTK:/F
M;K/Y Q6E>;O&W'N[N5WW-)O-70@;G0_>;FXWA*)=OAKMG-<^PMOHEVAM$A=6
M.FTO=!)6Q!&"IC/(CL_(4,=?Z(1*%"<C$%EQR%^$SVH.0I*_[C65W"E(Y-\U
M4[I=NW!1[T)6AZ[E@H9PT]*%1H)806OPZR]6U_R]3AN8,!<3YF'"?$Q8@ 2K
M*.RB5-A%$WW@A"%?IDKJFAX"6]'G&.HTT@@Y52.8,'<-Z^:P[*-G->B9=K=O
MK'9CCSFBCPD+#MUO=WN7I?N5F';*F'8:8WIR8:R+>.,0IT8<$^9BPCQ,F(\)
M"Y!@%05U2P5U?W[=Z6(J#!/F8L(\3)B/"0N08!6%]4J%]1ISU) NF*(Q^PX1
M"3<Z"KG4LJ()U]GK.\W7B?"J5[RRMB8U#G"J?C!A[AK6V4GJ>EF^5Y)Z!XG?
MVK_'QW0J0()5HGU91OL2MR*1?W5VB6/ZS,5:!XY.1/<LS+1 G)F / 75J:+1
MD5-5@0ES,6$>)LS'A 5(L(K.KDJ=7?W\NG6%J3!,F(L)\S!A/B8L0()5%&:9
MVVZ5V9C+1H*' )%.8((GNF1MLA07==VCVV;:J7(I:)7E3L?<+QPNZJ >*LU'
MI058M*H8=EJ75O-GS+9(K8#0;98A.L.DDJZ;W0NA*U>M.*R#<%YU#KX#ALU.
MG)HE4&D>*LU'I058M*HX[*TX[/\GCC,2%Y\R4ZC7A7WP!5GSF@^;QS]9%Y@T
M#Y7FH]("+%I5%]NFKM78T6M(&J"_CA.J])I( $N>ET)F#3F2N: %DZ^/ZHM,
M^R"/V&9-'D'MSJ+2/%2:CTH+L&A5O6Q;M!9*C[:9<O*7!FJ7MJ!5EL0'^O10
MQ_11:4'=#'97]=78;ENU5G.OUH4I")&_\"M(E_6!1>W%HM+<@E;I8UP=!A:U
MS8I*"VIF<-4]&MAM!]5J;)\-?);2-&0T)C1:,<G%MZS8UV=OU$XH*LU%I7FH
M-+^@5;37V==>@#5F50?;/J?5W.@<@0BSTLZGA*5,98+0:9S/LF.>ULH!M;&)
M2G-1:1XJS2]HESMR,,]->U\.J'U08V?;2P)BEN]HDB2OU^L=%^75<M>4D^\5
MVKON6M?>>N_3%K/>BO5 Q8REDL0PU4CSO*?SE5CO;EJ?*+[(-]<\<Z5XDA_.
M@48@LAOT[U/.U>8D&Z#<8S;X#U!+ P04    " !BB:A6L+3QO'P&   '-0
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M9?"I>7S?),<B5?N*Z%2?B U!V*YJT=R(MD4JRTW-EKOH)(O+2:,+-6>?W3U
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M>)MO;KB_XDD6(']_BF-QW,E.4*Y]&O\/4$L#!!0    ( &*)J%;J,S_^[@@
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MV,D939QJ?NT7>5[<\%4V;T<7?%R9@W>66-->Q8,!MNSA^' N#!G7 Z7YH+0
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M^JJHV[SXVWT'7_&"*K-1T8(*[:B2P[+:]G@CH#V[@+[+>*'3Q>8Y@O21*HU
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MQ2;3XD0D^WR/XSH1<AJ4'^XH\2G+;I"?;Y)$'$^R JJMOK-_ 5!+ P04
M" !BB:A6ZTPDGLT,  !;K   &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6S-W5UOXLH=!O"O,J)5=2KM+F!L2+9)I 3/6[79C<*>]J+JA0,#6,=@:IMD
M4_7#=PP.PR1F@O<\1\G-+A#/;PS\;<9^_'+VD&:_Y7.E"O)CD2SS\]:\*%:?
MV^U\/%>+*/^4KM12_V6:9HNHT$^S63M?92J:;!HMDK;7Z?3;BRA>MB[.-J_=
M9!=GZ;I(XJ6ZR4B^7BRB[/%*)>G#>:O;>GKA-I[-B_*%]L79*IJID2I^7=UD
M^EE[ITSBA5KF<;HDF9J>MRZ[GV6_4S;83/&/6#WD>X])^5;NTO2W\HF<G+<Z
MY1RI1(V+DHCT?_=JJ)*DE/1\_*="6[L^RX;[CY]TMGGS^LW<1;D:ILD_XTDQ
M/V^=M,A$3:-U4MRF#T)5;R@HO7&:Y)M_R4,U;:=%QNN\2!=58ST'BWBY_3_Z
M47T0>PT\[T #KVK@'=N@5S7H/6_0/=# KQKXQ_805 V"8QOTJP;]8QL,J@:#
M9PW\0Q_K2=7@Y-@&IU6#TTTY;+^_S9<?1D5T<9:E#R0KI]9:^6!309O6^CN/
MEV6QCXI,_S76[8J+Z\N_?[LEPU]'W[]=T]O1!W)S>?O]JWXDY,V(7'X-R>C[
M[>5WRN607'[Y(B^_#NF(?"0WT_B_*B-R.?Y$?@E5$<5)_M>S=J%GJ83;XZK[
MJVWWWH'NN^0Z71;SG-#E1$UJVE-W^]YK[?DK_7NO <(-]/W7 .D&!JZ/H*V_
MS=U7ZCU]I5>>4QRIU2?2ZWP@7L?KD%]'(?GESW5?S=#-A$I_M;UNR70'#B9T
M,]?1XS$*?4W)GF;&ZSD8=CSC.1A^]$?C_(3%3[PIO9 G2B_V2T5663I9CXNZ
MFOH#8*O6>KO51V_34^] 3[<J5U$VGI-H.2&ANM<_GBO]4UB0RRR+EC-5/OY
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MI(AUV[M',BX/+U/9*LJ*Q]KE IJ?5MK)WF"D\ZGKV^.0\*BI*'3.&%3C4$U
M-8G2[#HV>:=W]#F<AT<KT8^#HQ5HN@G50JA&H1J#:ARJ":@F49I=WR8 ]=[!
MV9X>-.V$:B%4HU"-034.U014DRC-7@I,VNFY3XA\J]$*-/^L-'L<XCT?K!PQ
M$87.%X-J'*H)J"91FEW%)JWTFIP*.CS]=LL&7FW=05-(J!9"-0K5&%3C4$U
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M)T6Z.F]U6^0N+8ITL7DX5]%$9>4$^N_3-"V>GI0=/*39;YNW<_%_4$L#!!0
M   ( &*)J%;# $I9DP,  !4.   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y
M+GAM;+U7VV[;.!#]E8$V6+1 $]U\2VH;\"5M#3B)$2?I0[%8,-98$BJ)*DG9
M76 _OB0E*[XH:A(8?;%)BG/FG.&0'';7E'WG :* GW&4\)X1")%>F"9?!!@3
M?D933.27)64Q$;++?).G#(FGC>+(="RK9<8D3(Q^5X_-6+]+,Q&%"<X8\"R.
M"?MOB!%=]PS;V S<AGX@U(#9[Z;$QSF*^W3&9,\L4;PPQH2'- &&RYXQL"]&
MMJL,](R'$-=\JPU*RB.EWU5GXO4,2S'""!="01#YM\(11I%"DCQ^%*!&Z5,9
M;K<WZ)^T>"GFD7 <T>AKZ(F@9W0,\'!)LDC<TO47+ 0U%=Z"1ES_PCJ?V[8,
M6&1<T+@PE@SB,,G_R<\B$%L&;N,9 Z<P</8,'.<9 [<PT)$S<V9:UI@(TN\R
MN@:F9DLTU="QT=9239BH99P+)K^&TD[T)U>SP>3VZO+Z#FX^P>>;F_'7R70*
M@^LQ3&^N/Y].)P^78QC,YY=W<W@W1D'"B+^'$P@3N MHQDGB\:XI)!4%:"X*
MM\/<K?.,6Q>N:"("#I>)A]ZNO2DEE#J<C8ZA4PMX1=@9N/8'<"S'A?OY&-Z=
MO ?".8I_?4:SM(+CZ.60S@:RAJI;AMS5N.YS(8]3$C+T8$H3_W0JL]B#@2+*
MX0M&'LB(PCV7@]^FTA(F F/^3U6(<S>-:C=J_U_PE"RP9\@-SI&MT.C__9?=
MLCY6Q>)(8#L1:901:=2A%Q&1AX, N@2?4F\=1E&5Y!RGI7'4";7JNQW;[73-
MU;:6PUE6.6.'8+,DV*PEJ%<JTBNE4XI_@"2+'Y$IOOD(Z"SC\/]ODFZ8>VIN
MD;/WZ-=R>>-2M$JEK1<OA3RGU2%X2I>G&<="9Y6DUD&\;5O>(WNR:AV_45:[
ME-5^189%^\M9):I]L$Z.U7#=/5'MEZ9:IV3:J4\UE)=20.4Y(#DSND)%NI)@
M+<YKM_^1P'8DGY>2S__,@7A^S(@<"6PG(K;U="U;QT[8 G$[8YO6P2ZL]_M6
M75OEAEVK:T03+EB6UW"RAI@QZDL_U8)JH5Z[GL="VQ7N/ EW_DR2%WZ.%94C
MH>U&Y:D4LFOKBC>EN7MPY#8.+YMZOZ_596X5V#$R7[\[."QHEHB\1BU'R[?-
M0%?T>^-#]>;1A?L33/Y@DM6F'R8<(EQ*2.NL+?<QR]\@>4?05)?QCU3(1X%N
M!O+=ADQ-D-^7E(I-1SDH7X+]7U!+ P04    " !BB:A60\=UI34#  #S"P
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MX:W*T3J?)S2J[#Q!&>P*8"C=R2(FI$!'L!,0JI2+XR:O6Z=PJ-<F8;Y)6%#
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MG)W#)H$7AV=%0[*U/NR9,RE9JB]7!$,.J0%P?\F8W#54@.H(<_PW4$L#!!0
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MNF..NQ.4#<#[I91F9]@$[39.?@-02P,$%     @ 8HFH5I,R/,/: @  #@D
M !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULM59;;]HP%/XK5E9-G;21
M"^72#B*5EFF51L7*Z!ZF/9CD %;M.+4=H-)^_&PGI&D5HJEB+XGM^+OX'-LG
M@RT7#W(-H-".T40.G;52Z87KRF@-#,L63R'17Y9<,*QT5ZQ<F0K L04QZ@:>
MUW49)HD3#NS85(0#GBE*$I@*)#/&L'@: >7;H>,[^X$[LEHK,^"&@Q2O8 9J
MGDZ%[KDE2TP8))+P! E8#IU+_V+D6X"=<4]@*RMM9):RX/S!=&[BH>,91T A
M4H8"Z]<&KH!2PZ1]/!:D3JEI@-7VGOV+7;Q>S )+N.+T)XG5>NCT'13#$F=4
MW?'M5R@6U#%\$:?2/M$VG]O5BE$F%6<%6/<92?(WWA6!J #:AP!! 0BL[US(
MNKS&"H<#P;=(F-F:S33L4BU:FR.)R<I,"?V5:)P*9_/1;/Q]/K[]@<;W^CE#
MI]>@,*'R _J$9ME"PF,&B4+CC7F>()*@":%41U0.7*4=&!XW*M1&N5IP0,U'
M$YZHM43C)(;X)=[5SDO[P=[^*&@DO$Q%"[6]CRCP@C::SZ[1Z<D'!"RE_ F@
M0:!=QJ=M!=J'XO,Z K^^Z1GH1@&3O^L"D-.=U=.9,W8A4QS!T-&'2(+8@!.^
M?^=WO<\-9L]*LV=-[.%MQA8@$%^BE$MB=KU$0(G>-EA!;%*G-97((I4)DJS0
MGP.1RE>2:W6LECG<F] /O(&[J3'8*0UV&@U.040ZB/JX_[/).F>Y2+_BS&L%
MO7IKW=):M]':A"2$9:Q.KA'XQI3V2EN]X^Z_WG\PVR_-]AMC>/=B=\$NU5>O
M3FG$I:JSFI-U*VGLU.?PO-0_;\XAWAW*82/PC6'QO>=+UCMN%@N^(_NM% 7_
MF(DLV*J9?'T:W4J)8B!6MA!+S9@E*J]6Y6A9["_S$O<\/?]3F&"Q(OK2H+#4
M4*_5T]>!R(MOWE$\M05OP94NG[:YUC\L(,P$_7W)N=IWC$#Y"Q3^!5!+ P04
M    " !BB:A6K>R%O#4#  !&$P  #0   'AL+W-T>6QE<RYX;6S=6&UOVC 0
M_BN1NTZM-!$@:TI60-J0*DW:IDKMAWVK#'&")<?.'-/!?OU\<0@O]2'6#UM9
M4(E]C^^YYWR7QNVP,BO![N>,F6!9"%F-R-R8\D,85K,Y*VC54263%LF4+JBQ
M4YV'5:D932MP*D38[W;CL*!<DO%0+HK;PE3!3"VD&9&X-07N]CD=D5[\G@2.
M;J)2-B*/%V]_+)2Y>1.X^]F[L[/NX^7-OOVB!BY)Z"6].H*TT\5Y+891Q[O4
M]?)S2^0<SS&W:X];I]OZ==!X@^-2.9P,GDYR%/T![IHX;&H]'F9*;DH>$6>P
MD6G!@B<J1F1"!9]J#EX9+;A8.7,?##,EE Z,[34KI0>6ZI>#>VX&;=CP%%PJ
M7<=V$=SWM%F^!ZQG() +T0KL$V<8#TMJ#-/RUD[JQ;7Q&10TXX=5:17FFJYZ
M_2NR<:AO-LA4Z93I-DR/K$WCH6 9R-$\G\/=J#($T!A5V$'*::XDK36L/9J!
MI9TQ(>[A&?V>[7 OLZV:=J&BLAU:0<W0T;@)\&^S.>YMVOZ+>(.2/RGS:6'3
MD?4<>H7=:9;Q93U?9JT C+V'L].R%*N/@N>R8"[YHP..AW3M%\R5YK]L-&B5
MF34P38(GI@V?;5M^:EH^L*59M],RPS7W3U#SW]WGG$FFJ=@6;7O_->_RBQ5'
MU_]*<OU;95^P5V/SXGWM(J].061\"B)/HB<'IR R>94BP^8%OG5*V#DCM-8
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M_YX!   (&@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=F[;L)
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M;%!+ 0(4 Q0    ( &*)J%99O5 I[P   "L"   1              "  :\
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M2P$"% ,4    " !BB:A6"]5(9I\$  #Y$0  &               @(&]%
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 8HFH5C,.EH<U
M P  G @  !@              ("!DAD  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( &*)J%;_^M( 60<  $\P   8              "
M@?T<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !BB:A6
M-$4@TLP'   -(@  &               @(&,)   >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ 8HFH5D&5M,+U(0  H6X  !@
M     ("!CBP  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M &*)J%9?4F3>% <  -02   8              " @;E.  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " !BB:A6;D,Y[ X(  ")%0  &
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M970Q,RYX;6Q02P$"% ,4    " !BB:A6U:J*I@T$  !3"0  &0
M    @(&JC@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M &*)J%:E,CT(8 0  - )   9              " @>Z2  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ 8HFH5G$=ST_< P  K @  !D
M             ("!A9<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " !BB:A6ZEV_=T89  ".3P  &0              @(&8FP  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &*)J%8*W)[B.00
M (8,   9              " @16U  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ 8HFH5I<V"+$+!   ,0L  !D              ("!
MA;D  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !BB:A6
M5:W7R-D$  #6"P  &0              @(''O0  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( &*)J%;&F0,N3@,  'X'   9
M      " @=?"  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ 8HFH5HW=JX1C!   S!   !D              ("!7,8  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !BB:A6:",@.M0"   2!@
M&0              @('VR@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( &*)J%8(F%/,T 0  "\9   9              " @0'.  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 8HFH5CI#AQ7'
M P  *0\  !D              ("!"-,  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " !BB:A6YOU!BE<#  "\"0  &0
M@($&UP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( &*)
MJ%9EE1R-R@P  %B0   9              " @93:  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ 8HFH5NUNY\H2"@  0V   !D
M         ("!E><  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " !BB:A6K/']J<T"  #(!@  &0              @('>\0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &*)J%8.[GA(+@,  "P*
M   9              " @>+T  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ 8HFH5L'%NJ;U!   R1P  !D              ("!1_@
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !BB:A6(*MJ
MV8,"  #:!0  &0              @(%S_0  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( &*)J%9R/%R.F04  &\F   9
M  " @2T  0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M8HFH5K"T\;Q\!@  !S4  !D              ("!_04! 'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " !BB:A6ZC,__NX(  !420  &0
M            @(&P# $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( &*)J%8H['I=A@@  #H_   9              " @=45 0!X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ 8HFH5I-1,-$7!P
M]CL  !D              ("!DAX! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " !BB:A6ZTPDGLT,  !;K   &0              @('@
M)0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( &*)J%;#
M $I9DP,  !4.   9              " @>0R 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ 8HFH5D/'=:4U P  \PL  !D
M     ("!KC8! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M  !&$P  #0              @ $?1 $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( &*)J%:7BKL<P    !,"   +              "  7]' 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( &*)J%8R] 4#P0,  "\=   /              "
M 6A( 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !BB:A6[DG=_YX!   (
M&@  &@              @ %63 $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " !BB:A6J,J'V:L!  !!&@  $P              @ $L
L3@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ,P S -P-   (4 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>237</ContextCount>
  <ElementCount>224</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE</Role>
      <ShortName>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS</Role>
      <ShortName>IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables</Role>
      <ShortName>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails</Role>
      <ShortName>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARENarrativeDetails</Role>
      <ShortName>BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails</Role>
      <ShortName>IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/INCOMETAXES</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sgmo-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sgmo-20230331.htm">sgmo-20230331.htm</File>
    <File>sgmo-20230331.xsd</File>
    <File>sgmo-20230331_cal.xml</File>
    <File>sgmo-20230331_def.xml</File>
    <File>sgmo-20230331_lab.xml</File>
    <File>sgmo-20230331_pre.xml</File>
    <File>sgmo-20230331xex311.htm</File>
    <File>sgmo-20230331xex312.htm</File>
    <File>sgmo-20230331xex321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="554">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgmo-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 17,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 554,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 237,
   "dts": {
    "calculationLink": {
     "local": [
      "sgmo-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgmo-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sgmo-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 373,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 51,
   "keyStandard": 173,
   "memberCustom": 26,
   "memberStandard": 29,
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.sangamo.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE",
     "shortName": "BASIC AND DILUTED NET INCOME (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS",
     "shortName": "IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentChargesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - STOCK-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - STOCKHOLDERS' EQUITY",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.sangamo.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.sangamo.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "17",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables",
     "shortName": "BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i0c3ceda2ae9f4af0871fc85dd870550f_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i0c3ceda2ae9f4af0871fc85dd870550f_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i2f61e5cec7984b35ac4292098852fc91_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Available-for-Sale Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetails",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
     "shortName": "BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Components of Basic and Diluted Net Income (Loss) per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "iddef1edbf4fe4f019d6237e6e633beb1_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Narrative (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARENarrativeDetails",
     "shortName": "BASIC AND DILUTED NET INCOME (LOSS) PER SHARE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "ibb5064fc34184ca2b857ad894b0d3db6_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "idf5d83fd29e747b2a85c289b3b68ab01_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9a68418627e64a97967175e21376a7f3_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "if7e6bd6cba7449d5b279f7359132b372_I20180430",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i739fc14c91ed4a9398145c3822bdc624_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "sgmo:TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i804a404f96394a898c058d278efa5149_D20170501-20170531",
      "decimals": null,
      "lang": "en-US",
      "name": "sgmo:AgreementTerminationTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails",
     "shortName": "IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "0",
      "lang": "en-US",
      "name": "sgmo:LongLivedAssetsNumberOfAssetsGroups",
      "reportCount": 1,
      "unique": true,
      "unitRef": "asset_group",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails",
     "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i817e2132beca4a9a89cee830995c6d63_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sgmo:StockOfferingProgramMaximumValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i817e2132beca4a9a89cee830995c6d63_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sgmo:StockOfferingProgramMaximumValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - INCOME TAXES (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.sangamo.com/role/INCOMETAXESDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i0d843ac73dfb466ab2ba144b1a49bdb5_D20230401-20230430",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i0d843ac73dfb466ab2ba144b1a49bdb5_D20230401-20230430",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9c7722be40df413c8e437a49f401590f_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i9c7722be40df413c8e437a49f401590f_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20230331.htm",
      "contextRef": "i8a7527d581d9483ab63f9ea6a6fa5286_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 55,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sgmo_AchievementOfCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Commercial Milestones.",
        "label": "Achievement Of Commercial Milestones [Member]",
        "terseLabel": "Achievement Of Commercial Milestones"
       }
      }
     },
     "localname": "AchievementOfCommercialMilestonesMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of first commercial sale milestones.",
        "label": "Achievement Of First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified clinical development intellectual property and regulatory milestones.",
        "label": "Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of specified clinical development intellectual property and regulatory milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified preclinical development clinical development and first commercial sale milestones.",
        "label": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones.",
        "label": "Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.",
        "label": "Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]",
        "terseLabel": "Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate additional revenue recognition milestone method revenue eligible to receive.",
        "label": "Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive",
        "terseLabel": "Potential amount to be funded for achievement of specified commercialized and sales milestones"
       }
      }
     },
     "localname": "AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AgreementTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Termination, Term",
        "label": "Agreement Termination, Term",
        "terseLabel": "Agreement termination, term"
       }
      }
     },
     "localname": "AgreementTerminationTerm",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_AmortizationAndOtherChangesInRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization And Other Changes In Right-of-Use Assets",
        "label": "Amortization And Other Changes In Right-of-Use Assets",
        "negatedLabel": "Amortization and other changes in operating lease right-of-use assets"
       }
      }
     },
     "localname": "AmortizationAndOtherChangesInRightOfUseAssets",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AtTheMarketOfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering agreement.",
        "label": "At The Market Offering Agreement [Member]",
        "terseLabel": "At-The-Market Offering Agreement"
       }
      }
     },
     "localname": "AtTheMarketOfferingAgreementMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At the Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BiogenMAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen MA, Inc.",
        "label": "Biogen MA, Inc. [Member]",
        "terseLabel": "Biogen MA, Inc."
       }
      }
     },
     "localname": "BiogenMAIncMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CNineORFSevenTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C nine ORF seven two.",
        "label": "C Nine O R F Seven Two [Member]",
        "terseLabel": "C9ORF72"
       }
      }
     },
     "localname": "CNineORFSevenTwoMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents accumulated gross unrealized gain before tax.",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Cash equivalents, gross unrealized gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents accumulated gross unrealized loss before tax.",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax",
        "negatedTerseLabel": "Cash and cash equivalents accumulated gross unrealized loss before tax"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities.",
        "label": "Cash Equivalents And Available For Sale Securities",
        "terseLabel": "Total cash equivalents and available-for-sale securities, estimated fair value"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for Sale Securities Amortized Cost",
        "label": "Cash Equivalents And Available For Sale Securities Amortized Cost",
        "totalLabel": "Total cash equivalents and available-for-sale securities, amortized cost"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized gain, before tax.",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax",
        "terseLabel": "Total cash equivalents and available-for-sale securities, gross unrealized gains"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized loss, before Tax",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax",
        "negatedLabel": "Total cash equivalents and available-for-sale securities, gross unrealized (losses)"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationAgreementEquityIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Equity Issued",
        "label": "Collaboration Agreement, Equity Issued",
        "terseLabel": "Collaboration agreement, equity issued"
       }
      }
     },
     "localname": "CollaborationAgreementEquityIssued",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationAgreementNumberOfAdditionalProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Additional Product Targets",
        "label": "Collaboration Agreement, Number Of Additional Product Targets",
        "terseLabel": "Number of additional neurological disease gene targets (in product targets)"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfAdditionalProductTargets",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Selected Product Targets By Counterparty",
        "label": "Collaboration Agreement, Number Of Selected Product Targets By Counterparty",
        "terseLabel": "Number of neurological disease gene targets selected by counterparty (in product targets)"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration And License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements number of products approved under agreement.",
        "label": "Collaboration And License Agreements Number Of Products Approved Under Agreement",
        "terseLabel": "Number of products approved"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "label": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "terseLabel": "Financial advisory fees"
       }
      }
     },
     "localname": "CollaborationArrangementCommissionFeePortionOfGrossProceedsValue",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Axis]",
        "terseLabel": "Collaborative Agreement Milestone [Axis]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneAxis",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Domain]",
        "terseLabel": "Collaborative Agreement Milestone [Domain]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneDomain",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborativeAgreementPercentOfInitialRecognition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Percent Of Initial Recognition",
        "label": "Collaborative Agreement, Percent Of Initial Recognition",
        "terseLabel": "Percent of initial recognition"
       }
      }
     },
     "localname": "CollaborativeAgreementPercentOfInitialRecognition",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement estimated reimbursable service costs.",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCosts",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, License Fee",
        "label": "Collaborative Arrangement, License Fee",
        "terseLabel": "Collaborative arrangement, license fee"
       }
      }
     },
     "localname": "CollaborativeArrangementLicenseFee",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Milestones Achieved",
        "label": "Collaborative Arrangement, Number Of Milestones Achieved",
        "terseLabel": "Collaborative arrangement, number of milestones achieved"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfMilestonesAchieved",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementResearchServiceFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Research Service Fees",
        "label": "Collaborative Arrangement, Research Service Fees",
        "terseLabel": "Research service fees"
       }
      }
     },
     "localname": "CollaborativeArrangementResearchServiceFees",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction price.",
        "label": "Collaborative Arrangement Transaction Price",
        "terseLabel": "Collaborative arrangement transaction price"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPrice",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment",
        "label": "Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment",
        "terseLabel": "Maximum amount of achieved milestones to receive payment"
       }
      }
     },
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent development and sales based milestone payments to be received.",
        "label": "Contingent Development And Sales Based Milestone Payments To Be Received",
        "terseLabel": "Contingent development and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty",
        "label": "Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty",
        "terseLabel": "Percentage of net sales per developed licensed product which will trigger royalties by counterparty"
       }
      }
     },
     "localname": "ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer contract liability milestone payment eligible to receive.",
        "label": "Customer Contract Liability Milestone Payment Eligible To Receive",
        "terseLabel": "Development and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "CustomerContractLiabilityMilestonePaymentEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Basic And Diluted EPS",
        "label": "Earnings Per Share, Basic And Diluted EPS [Abstract]",
        "terseLabel": "Net income (loss) per share",
        "verboseLabel": "Net income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_ExtendedResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended Research Term Of Agreement",
        "label": "Extended Research Term Of Agreement",
        "terseLabel": "Extended research term of agreement"
       }
      }
     },
     "localname": "ExtendedResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_IncreaseDecreaseInEarningsPerShareBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Earnings Per Share, Basic",
        "label": "Increase (Decrease) In Earnings Per Share, Basic",
        "verboseLabel": "Increased earnings per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "IncreaseDecreaseInEarningsPerShareBasic",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sgmo_IncreaseDecreaseInEarningsPerShareDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Earnings Per Share, Diluted",
        "label": "Increase (Decrease) In Earnings Per Share, Diluted",
        "verboseLabel": "Increased earnings per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncreaseDecreaseInEarningsPerShareDiluted",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Net Income (Loss) Attributable To Parent",
        "label": "Increase (Decrease) In Net Income (Loss) Attributable To Parent",
        "terseLabel": "Increase in net income",
        "verboseLabel": "Increased net income"
       }
      }
     },
     "localname": "IncreaseDecreaseInNetIncomeLossAttributableToParent",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_InitialResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial research term of agreement.",
        "label": "Initial Research Term Of Agreement",
        "terseLabel": "Initial research term of agreement"
       }
      }
     },
     "localname": "InitialResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC",
        "label": "Jefferies LLC [Member]",
        "terseLabel": "Jefferies LLC"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_KitePharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kite Pharma Inc.",
        "label": "Kite Pharma Inc [Member]",
        "terseLabel": "Kite Pharma, Inc."
       }
      }
     },
     "localname": "KitePharmaIncMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_LongLivedAssetsNumberOfAssetsGroups": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Lived Assets, Number Of Assets Groups",
        "label": "Long-Lived Assets, Number Of Assets Groups",
        "terseLabel": "Long-lived assets, number of assets groups"
       }
      }
     },
     "localname": "LongLivedAssetsNumberOfAssetsGroups",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_MilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "terseLabel": "Milestone achievement"
       }
      }
     },
     "localname": "MilestoneAchievementMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments received.",
        "label": "Milestone Payments Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentsReceived",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneRevenueReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone\u200b revenue receivable.",
        "label": "Milestone Revenue Receivable",
        "terseLabel": "Milestone revenue receivable"
       }
      }
     },
     "localname": "MilestoneRevenueReceivable",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss) Available To Common Stockholders, Basic And Diluted",
        "label": "Net Income (Loss) Available To Common Stockholders, Basic And Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_NovartisInstitutesForBioMedicalResearchIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Institutes For BioMedical Research Inc.",
        "label": "Novartis Institutes For BioMedical Research Inc. [Member]",
        "terseLabel": "Novartis Institutes for BioMedical Research, Inc."
       }
      }
     },
     "localname": "NovartisInstitutesForBioMedicalResearchIncMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of clinical or regulatory milestones included in transaction price.",
        "label": "Number Of Clinical Or Regulatory Milestones Included In Transaction Price",
        "terseLabel": "Number of milestones included in transaction price"
       }
      }
     },
     "localname": "NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfOptionsToExtendInitialResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Options To Extend Initial Research Term",
        "label": "Number Of Options To Extend Initial Research Term",
        "terseLabel": "Number of options to extend initial research term"
       }
      }
     },
     "localname": "NumberOfOptionsToExtendInitialResearchTerm",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfResearchProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of research program.",
        "label": "Number Of Research Program",
        "terseLabel": "Number of research programs"
       }
      }
     },
     "localname": "NumberOfResearchProgram",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other products.",
        "label": "Other Products [Member]",
        "terseLabel": "Other products"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerC9ORF72Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer C9ORF72",
        "label": "Pfizer C9ORF72 [Member]",
        "terseLabel": "Pfizer C9ORF72"
       }
      }
     },
     "localname": "PfizerC9ORF72Member",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer.",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer Inc."
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerSB525Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer SB-525 [Member]",
        "label": "Pfizer SB-525 [Member]",
        "terseLabel": "Pfizer SB-525"
       }
      }
     },
     "localname": "PfizerSB525Member",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement, Expenses Reimbursable, After Specified Date",
        "label": "Research and Development Arrangement, Expenses Reimbursable, After Specified Date",
        "terseLabel": "Expenses reimbursable after December 31, 2023 (up to)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement, Expenses Reimbursable, Through Specified Date",
        "label": "Research and Development Arrangement, Expenses Reimbursable, Through Specified Date",
        "terseLabel": "Expenses reimbursable through December 31, 2023 (up to)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services.",
        "label": "Research Services [Member]",
        "terseLabel": "Research services"
       }
      }
     },
     "localname": "ResearchServicesMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk",
        "label": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RevenueNumberOfRemainingPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Number Of Remaining Performance Obligations",
        "label": "Revenue, Number Of Remaining Performance Obligations",
        "terseLabel": "Number of remaining performance obligations"
       }
      }
     },
     "localname": "RevenueNumberOfRemainingPerformanceObligations",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Fixed Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Fixed Consideration Amount",
        "terseLabel": "Fixed consideration"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationFixedConsiderationAmount",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Number Of Material Rights Expired",
        "label": "Revenue, Remaining Performance Obligation, Number Of Material Rights Expired",
        "terseLabel": "Number of material rights expired"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationNumberOfMaterialRightsExpired",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Number Of Material Rights For Renewal Of Research Period",
        "label": "Revenue, Remaining Performance Obligation, Number Of Material Rights For Renewal Of Research Period",
        "terseLabel": "Number of material rights for renewal of research period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Number Of Material Rights Outstanding",
        "label": "Revenue, Remaining Performance Obligation, Number Of Material Rights Outstanding",
        "terseLabel": "Number of material rights outstanding"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationNumberOfMaterialRightsOutstanding",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Related To Material Rights, Amount",
        "label": "Revenue, Remaining Performance Obligation, Related To Material Rights, Amount",
        "terseLabel": "Remaining performance obligation amount, related to material rights"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_RevenueRemainingPerformanceObligationRenewalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Renewal Period",
        "label": "Revenue, Remaining Performance Obligation, Renewal Period",
        "terseLabel": "Renewal period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationRenewalPeriod",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_SBFiveTwoFiveAndOtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "S B Five Two Five And Other Products",
        "label": "S B Five Two Five And Other Products [Member]",
        "terseLabel": "S B Five Two Five And Other Products"
       }
      }
     },
     "localname": "SBFiveTwoFiveAndOtherProductsMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Excess Consideration Received on Transaction",
        "label": "Sale of Stock, Excess Consideration Received on Transaction",
        "terseLabel": "Sale of stock, excess consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockExcessConsiderationReceivedOnTransaction",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SaleOfStockIncreaseToAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Increase To Aggregate Offering Price",
        "label": "Sale Of Stock, Increase To Aggregate Offering Price",
        "terseLabel": "Stock offering program, increase to aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockIncreaseToAggregateOfferingPrice",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi.",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi S.A."
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues",
        "label": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_SeparateUpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separate upfront fee.",
        "label": "Separate Upfront Fee",
        "terseLabel": "Separate fee for additional term"
       }
      }
     },
     "localname": "SeparateUpfrontFee",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_StockOfferingProgramMaximumValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Offering Program, Maximum Value",
        "label": "Stock Offering Program, Maximum Value",
        "terseLabel": "Stock offering program, maximum value"
       }
      }
     },
     "localname": "StockOfferingProgramMaximumValue",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_TenantImprovementAllowanceWithinContraLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Improvement, Allowance Within Contra Lease Liability",
        "label": "Tenant Improvement, Allowance Within Contra Lease Liability",
        "terseLabel": "Tenant improvement allowance included in contra-lease liability"
       }
      }
     },
     "localname": "TenantImprovementAllowanceWithinContraLeaseLiability",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination And Transition Agreement, Increase (Decrease) In Research And Development Expense",
        "label": "Termination And Transition Agreement, Increase (Decrease) In Research And Development Expense",
        "negatedTerseLabel": "Decrease in research and development expense"
       }
      }
     },
     "localname": "TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_USGovernmentSponsoredAgencyBondMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Government-Sponsored Agency Bond",
        "label": "US Government-Sponsored Agency Bond [Member]",
        "terseLabel": "Agency bonds"
       }
      }
     },
     "localname": "USGovernmentSponsoredAgencyBondMember",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Number Of Shares Outstanding, Basic And Diluted",
        "label": "Weighted Average Number Of Shares Outstanding, Basic And Diluted [Abstract]",
        "terseLabel": "Shares used in computing net income (loss) per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDilutedAbstract",
     "nsuri": "http://www.sangamo.com/20230331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r258",
      "r262",
      "r453",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r299",
      "r424",
      "r439",
      "r449",
      "r450",
      "r465",
      "r471",
      "r477",
      "r511",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r299",
      "r424",
      "r439",
      "r449",
      "r450",
      "r465",
      "r471",
      "r477",
      "r511",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r207",
      "r426",
      "r467",
      "r476",
      "r507",
      "r508",
      "r512",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r207",
      "r426",
      "r467",
      "r476",
      "r507",
      "r508",
      "r512",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r292",
      "r299",
      "r327",
      "r328",
      "r329",
      "r400",
      "r424",
      "r439",
      "r449",
      "r450",
      "r465",
      "r471",
      "r477",
      "r506",
      "r511",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r248",
      "r292",
      "r299",
      "r327",
      "r328",
      "r329",
      "r400",
      "r424",
      "r439",
      "r449",
      "r450",
      "r465",
      "r471",
      "r477",
      "r506",
      "r511",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r158",
      "r159",
      "r258",
      "r262",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r475"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "(Accretion of discounts) amortization of premium on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r20",
      "r21",
      "r138",
      "r435",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r17",
      "r21",
      "r91",
      "r390",
      "r440",
      "r441",
      "r487",
      "r488",
      "r489",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r493",
      "r494",
      "r495",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r83",
      "r84",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r76",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Net pension losses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r468",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentChargesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the details of the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value. Disclosure may also include a description of the impaired asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired asset is reported.",
        "label": "Asset Impairment Charges [Text Block]",
        "terseLabel": "IMPAIRMENT OF GOODWILL AND LONG-LIVED ASSETS"
       }
      }
     },
     "localname": "AssetImpairmentChargesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r108",
      "r117",
      "r137",
      "r155",
      "r198",
      "r201",
      "r205",
      "r220",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r358",
      "r362",
      "r376",
      "r475",
      "r509",
      "r510",
      "r520"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r131",
      "r139",
      "r155",
      "r220",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r358",
      "r362",
      "r376",
      "r475",
      "r509",
      "r510",
      "r520"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total cash equivalents and marketable securities and free shares asset"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale securities, gross unrealized (Losses)"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r214",
      "r227"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Available-for-sale securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r60",
      "r217",
      "r433"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r60",
      "r216",
      "r432"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r57",
      "r212",
      "r227",
      "r428"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Total marketable securities",
        "totalLabel": "Total",
        "verboseLabel": "Available-for-sale securities, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r56",
      "r227"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r56",
      "r134",
      "r227"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment included in unpaid liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Capitalized contract cost, amortization expense"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r133",
      "r452"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents, at carrying value, total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents",
        "verboseLabel": "Cash equivalents, estimated fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Capital resources"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r30",
      "r36",
      "r41"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r30",
      "r104"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Change in Accounting Estimate [Line Items]",
        "terseLabel": "Change in Accounting Estimate [Line Items]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper securities"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r13",
      "r110",
      "r122"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r493",
      "r494",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r475"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r22",
      "r143",
      "r145",
      "r149",
      "r429",
      "r436"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r47",
      "r48",
      "r101",
      "r102",
      "r209",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r47",
      "r48",
      "r101",
      "r102",
      "r209",
      "r446",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r47",
      "r48",
      "r101",
      "r102",
      "r209",
      "r448",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r47",
      "r48",
      "r101",
      "r102",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r49",
      "r101",
      "r103",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r47",
      "r48",
      "r101",
      "r102",
      "r209",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Change in estimate of transaction price, increase in revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r276",
      "r278",
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract with customer, asset, after allowance for credit Loss"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r276",
      "r277",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract with customer liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r276",
      "r277",
      "r290"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r276",
      "r277",
      "r290"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r468",
      "r470",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r215",
      "r227",
      "r230",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss related to marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded",
        "terseLabel": "Allowance for credit loss related to marketable securities, not previously recorded"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r34",
      "r196"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r304",
      "r332",
      "r333",
      "r334",
      "r338",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r150",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r173",
      "r175",
      "r181",
      "r182",
      "r183",
      "r187",
      "r367",
      "r368",
      "r430",
      "r437",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r150",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r175",
      "r181",
      "r182",
      "r183",
      "r187",
      "r367",
      "r368",
      "r430",
      "r437",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "BASIC AND DILUTED NET INCOME (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r76",
      "r128",
      "r146",
      "r147",
      "r148",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r172",
      "r189",
      "r221",
      "r275",
      "r335",
      "r336",
      "r337",
      "r345",
      "r346",
      "r366",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r390",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r369",
      "r370",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurements of Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r259",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r370",
      "r397",
      "r398",
      "r399",
      "r463",
      "r464",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r372",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r259",
      "r293",
      "r298",
      "r370",
      "r397",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r259",
      "r293",
      "r298",
      "r370",
      "r398",
      "r463",
      "r464",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r259",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r370",
      "r399",
      "r463",
      "r464",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r259",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r397",
      "r398",
      "r399",
      "r463",
      "r464",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r373",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r218",
      "r219",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r228",
      "r229",
      "r233",
      "r260",
      "r273",
      "r364",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r461",
      "r500",
      "r501",
      "r502",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r135",
      "r235",
      "r427",
      "r462",
      "r475",
      "r504",
      "r505"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r34",
      "r236",
      "r237",
      "r238",
      "r462"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Impaired Long-Lived Assets Held and Used [Line Items]",
        "terseLabel": "Impaired Long-Lived Assets Held and Used [Line Items]"
       }
      }
     },
     "localname": "ImpairedLongLivedAssetsHeldAndUsedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r34",
      "r70",
      "r73"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Goodwill, Intangible Assets and Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r23",
      "r105",
      "r111",
      "r124",
      "r198",
      "r200",
      "r204",
      "r206",
      "r431",
      "r460"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r239",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r156",
      "r342",
      "r343",
      "r344",
      "r347",
      "r349",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r171",
      "r172",
      "r197",
      "r341",
      "r348",
      "r350",
      "r438"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedTerseLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r425",
      "r490"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r490",
      "r519"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r183",
      "r303"
     ],
     "calculation": {
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive effect of share-based payment arrangements (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r68",
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r485"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Fair value of investments available-for-sale"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r106",
      "r115",
      "r126",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "CASH EQUIVALENTS AND MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit established as a deposit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r155",
      "r220",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r359",
      "r362",
      "r363",
      "r376",
      "r459",
      "r509",
      "r520",
      "r521"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r109",
      "r120",
      "r475",
      "r492",
      "r503",
      "r517"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r132",
      "r155",
      "r220",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r359",
      "r362",
      "r363",
      "r376",
      "r475",
      "r509",
      "r520",
      "r521"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "License and Service",
        "verboseLabel": "License and Service"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r30",
      "r32",
      "r35"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r24",
      "r35",
      "r112",
      "r123",
      "r130",
      "r142",
      "r144",
      "r148",
      "r155",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r180",
      "r198",
      "r200",
      "r204",
      "r206",
      "r220",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r368",
      "r376",
      "r460",
      "r509"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r198",
      "r200",
      "r204",
      "r206",
      "r460"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment on right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r42",
      "r53",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r136"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r15",
      "r19",
      "r377",
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedTerseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r16",
      "r18"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTerseLabel": "Net pension (loss) gain"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities, net of tax",
        "verboseLabel": "Net unrealized gain on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale, Recognized in Earnings",
        "terseLabel": "Other impairment charges related to marketable securities"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r475"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r486"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from at-the market offering/ issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r29",
      "r81"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r27",
      "r55"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Held-to-Maturity Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r130",
      "r142",
      "r144",
      "r152",
      "r155",
      "r163",
      "r171",
      "r172",
      "r198",
      "r200",
      "r204",
      "r206",
      "r220",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r357",
      "r360",
      "r361",
      "r368",
      "r376",
      "r431",
      "r460",
      "r473",
      "r474",
      "r489",
      "r509"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r72",
      "r121",
      "r434",
      "r475"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized investment gains (losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r86",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Revenues under agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r85",
      "r127",
      "r528"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r36",
      "r41",
      "r447"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r447",
      "r484",
      "r491"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r240",
      "r242",
      "r243",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Restructuring expected cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of positions eliminated in restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Percentage of positions eliminated in restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r77",
      "r119",
      "r443",
      "r445",
      "r475"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r128",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r172",
      "r221",
      "r335",
      "r336",
      "r337",
      "r345",
      "r346",
      "r366",
      "r440",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r194",
      "r195",
      "r199",
      "r202",
      "r203",
      "r207",
      "r208",
      "r209",
      "r288",
      "r289",
      "r426"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r209",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from contract with customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r291",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:",
        "verboseLabel": "Revenue related to Sanofi agreement:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "auth_ref": [
      "r45",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summarization of the nature of changes in accounting estimates, including changes that occur in interim periods. Changes in accounting estimate have the effect of adjusting the carrying amounts of existing assets or liabilities or altering the subsequent accounting for existing or future assets or liabilities. Changes in accounting estimates are a necessary consequence of assessments, in conjunction with the periodic presentation of financial statements, of the present status and expected future benefits and obligations associated with assets and liabilities. Changes in accounting estimates result from new or better information. Examples of items for which estimates are necessary are uncollectible receivables, inventory obsolescence, service lives and salvage values of depreciable assets, warranty obligations, and regulatory reviews.",
        "label": "Schedule of Change in Accounting Estimate [Table]",
        "terseLabel": "Schedule of Change in Accounting Estimate [Table]"
       }
      }
     },
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Revenues Recognized under Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Components of Basic and Diluted Net Income (Loss) per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r43",
      "r44",
      "r175",
      "r179",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r80",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a long-lived asset to be held and used by an entity, the table may include a description of the impaired long-lived asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported.",
        "label": "Schedule of Impaired Long-Lived Assets Held and Used [Table]",
        "terseLabel": "Schedule of Impaired Long-Lived Assets Held and Used [Table]"
       }
      }
     },
     "localname": "ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLANDLONGLIVEDASSETSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r41",
      "r107",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r300",
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r76",
      "r128",
      "r146",
      "r147",
      "r148",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r172",
      "r189",
      "r221",
      "r275",
      "r335",
      "r336",
      "r337",
      "r345",
      "r346",
      "r366",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r390",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r189",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Share-Based Payment Arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r1",
      "r2",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r76",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in connection with at-the-market offering, net of offering expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r1",
      "r2",
      "r77",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r54",
      "r475",
      "r492",
      "r503",
      "r517"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r89",
      "r90",
      "r92",
      "r128",
      "r129",
      "r147",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r221",
      "r275",
      "r335",
      "r336",
      "r337",
      "r345",
      "r346",
      "r366",
      "r379",
      "r380",
      "r385",
      "r390",
      "r441",
      "r442",
      "r492",
      "r503",
      "r517"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r154",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r386",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r386",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r386",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r386",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.sangamo.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r391",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r218",
      "r219",
      "r260",
      "r273",
      "r364",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r500",
      "r501",
      "r502",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncDetails",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSADetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r514",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored entity debt securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r457",
      "r468",
      "r470",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury bills"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r190",
      "r191",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r174",
      "r183"
     ],
     "calculation": {
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted average number of common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Diluted:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r173",
      "r183"
     ],
     "calculation": {
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Basic:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETINCOMELOSSPERSHAREComponentsofBasicandDilutedNetIncomeLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e777-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r479": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r481": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r482": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r483": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001628280-23-016486-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-016486-xbrl.zip
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M*'ZY^--H7I!K+"%:(14I8BQ:HZSVG'#D+.8F4+10R'TB,DN;  8/+@!'@:&
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MIKW6U')KM!/2<V+$<@AFD2O?$9@;&WA0G$A&P/?1RNA@I0(G51.Q"+'^^7.
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MI&VR-77$M]8&#6P6#S;7([[WU4C7,/8+&LD:$C$5D:*H4]JA5CARRZF,DGL
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M!,%)B%S+&)AVR@+=14HP0@.X*L0NRY+J4B+FT3N FM3*Y=-1WA^>WMX%=.R
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M\B.2X[-91V^D-RWI?>A=[5O?VC.=JN=@G2(]M@MIBN=]*,K.5C7-;K3O\J"
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MQY7:2)&5TW],ER7]"D3?#T'5NK2Q=>JS5RF)TWYB I4VNJ[<X*PTK:OY7.K
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M2)P!)LH06(L%MH1(1"->$<+J')55LR>GKJZ5ZI=UC)-5?\&J/T-5)#9&!FH
M-LX!JJ0'VDL-HC")L$0*+>S&)E8I:[VL")&GSF!U[<%I1Y^GD?B?H\6RWKEN
M#WR_["%5<6?67$F3(F7X[NSQCAF9HS&^)'%:7._,='RA$[=KRZ]WE,K-Y/\^
MR=2LS2:[@)HP6UV7M]Q%;KGS">-&*H\=#<!K# $UD "EH084!F4-H<RFHA&4
MPCKC956R*D./GMA[F%$THVBE3)6,HDM%T=FB!HX:Y%+I'<,XH%@C8#R1 *LH
M5.*Q046O:8[K#);<O?5)4+1@W+\/=?RZ^*]K?]O\(_Z8//*)[G]I=XOOGF'3
MUL>EWU^^5N*BL(+W-6W3T:_NGL<9J#5[PWCW8:^VW4N9? /OTJMBJHJSXM?M
MKN[:=J3;!\/XAZ(*R(M+,<V.>OQ=-+F;3WN#(O[S9=]W]+#]S;_ZWG;#HPD\
M3'UJ+#YX]1%MXA.<#6__2%7FDU^?BNF?Z6D+((&,VXAHFE(1J-12T8"AAQ'3
M3#"$B\^8;4P^=-2?C.!4?_' ]+W^"G2( WRI.]_U^6#C]^O++*ZQZ4F_;;[&
M"QZDK3,MR-NG*X2%3==("R+>]E*;F2CFJ-"^G]X5'T=7YEEJ1_VT+?W/KP4G
MHBF:]#^U'_OC=[VR@T@U?9)B%V.X84$_J>*)FX%LJ_EFJ[%?:_VU^V'KW>['
MUM[V0;VVU]R^'9RF()D_"23?/)+M_>;.;O-@=Z<67QWLO]W;V6K%7PY:\9_&
M;K-U4-M_7=M_%X?9VHMO^-7PQF!:I1'^]K&KSUP[;B>O:NUN;7C4.XNW<X-Z
MS?^P/FZ_IS["WI'NQ[WI).[RP\%_2ACEYA^F__OF(V]4;.]7^U3!)^*T=?3I
MP+^<O'@U<<BUN\7@BP^]NOX%;#X_OOB^T>4Q;BOY0K("NL>>O/$7CU']17%I
MAAN-K@GZ0B%QZV7X MUZ[6>W1? %PP^[[<^O,<P7\K#D]LLSMUT'K^XOC\C4
MW%MO,*='BWTYQJ/\%6",_+MQ\_*U1GS?T:"V&_<T5^AR0_?M48V@^AUJ@#WM
MO$]Y5>YQM%)MH21/YEV*K]VGFN%SF3B\\!5;X3.E2KON/OAOOGLV7V+VCIZ'
M!T86W#0-\58KYKZ\P^!_Z5-YNE'?PT$IM8@TR#&)G**2:,-)4%YSS8-F6/+/
M.\4Q#X((W.V\9[SJ7O=[)S<U>]_]83MG:1*W!@,?_^]6)D"T>3!Q7C:/#B_<
MR7[KGT[S^)^3YL7[[_%[CQK_OO_1:+T^.CP^^MIL?87-?W?)E/.RD[XW/EL[
M/MM%X^(];AYOL>9Q@S5W7I_L_QO_VSEJ-UM7#L\KY^7'B^:Q)9_>[,'F3N.B
MN7.(&SM?D],3-OX]9(?_'M+]-WNHT?HG--HCQV7C )+X_*3Y_C/6,I(,*X )
MC@.J( $R< H(T8Y'BYEH*C<V$1-EM JXKQ+=W4$Y4J8G../),/@<8! 9Q3TT
MF'L&J89">4$,4]) C1PGHH!!/(%!G&&PZC!X,0.#1&OE7+# FR(K5Q.@%%&
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M?$LP&F'280@D01802HE0R%$7<+2$5<4KQF1G5F6<65E/2]'3F29Z+E@D''>
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MVT1@>7QGF35L[U4%;V'Q\T\]\"ZEZ/KNH"A4E5V'I4'O?%5>X06%5 5 *)6
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M.V-E "81&J/4-3"84>!Y7 D\RAH+N+%)ZDH^%TQ<8%19QMFUQ=G[P"RTQ-J
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M95.\9.0%G#XTR[Z02K"4B=#>C626DFI'LGI[):K,4LI#M8_S;A(I<"0I%-C
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M=N^+B_/S"OC!CBKS-XTF'P9A./.CR>QBNKTNI0QV(4PN<D.I'6Y3>M-1_F@
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MX.PX9IDS&L+-XZ'=H :[4;W/DC2WJS&[8+D-[VS6HC^V_GSSFF+BC1,1"9
MB,,2YXP>AI+VS&M'G CK&3K?:O.NV+(?'I48]DT%YH61$='D'.*$8.0LY\A'
M6'C'6.3.K.W;]U#O!\7N'OOA:-CZ I767-6K>PW.\)*RJQRJ6ML/&S3O+$NR
M"9"[]F5HRA+*^=F.BA?[XC3&ZNASX1#,-CXH*^9R[I-EY15/?3&'?RK3(_<3
MR6/ZI83>AK,.J/'@'^61DPM8JS#[9XMQ_(T1C,T^:.TO03 6>)]Q<QN@P-SP
M6T$P_K*G]H/];H.]&9#U]K!_[Q1*[0)<.4,MWQ#L][XNQI/H8RZAZ:['33!\
M[^MZK!''C[P8FXB#+*W'YV.UI(23WUB'4ZR<:ZIYP<WY3F4X5\8H;EY@7DW]
MQG#?&VOS=FM1_NOV)G]M4=;WF_7M!WS8S>+2!_/']9GFO_.QR,VB/NQNNG%5
MG>+9TP]_/3E]]^KCZ/3PX]&[_(Y7;T>G?_UY='KX]IUX=?(7_ W/>O++<+5.
M\=7)S^^.?WW^]OC/IQ\/Z1\PG[^&QW_^,GI%GUX>YWI%F!.XA.\.__S?=+A>
MW6R2=,9SB<!--XAK'Y!EDB'!+4F$:\J9>_!(Z3W*R5=#47PFL]R\DK%BFL\#
MEEF6V*LZKA=WO;A;5%YS1KD+RA&2."'!1!6D5)XR%6Q,N(@[2F@O[G9-W*V6
M96O+3-*:(FD<1]Q*A;3U"N'@1 Q*,BOQ@T= ('N<?SVR?B_O>GFW,[/^''GG
M(K8F)AJ%XSX0DQAV 7M,31**A4K>]>;=[LD[LB+O@DZ2ZTA02&#9<1(E HLO
MH&"89M*"K2XHR#N*]ZA0O;SKY=T/*>]$;HSD$TV4"*Y(=$IZ'E+4RA(3M"SR
MCO3VW>[).[8B[ZC!4EC&$!-<(RY Z&D&XD\+%[2BRE),0-Z!/PM_W0EYMR4\
MP3L0BCR:C)&_F$YSNN7*&>ZW1QF\$W)K6V&XZU)<8&?JC>F%U]:$USJ$-.4F
MAJ09LMH1<$X9139ZAZ2ST=ILB$</PFM/X*_NX?15N&%?8(U]=YR_.\'/VXHS
M]?S\7?AY-=A$J58^"K ^.,6(YXB390H#>\/>$@^VI>8]/]]G?MY2'*7GY^_"
MSVO!%)-"2"(B#9H:<4\X,LP;)(&3D[!!"=OKY_O,S]N*$_3\_%WX>3588*5D
M)()J]M;F@HD4D)74($.,MYX;Z]*NZ>>M)B:9#=& ;J$%,ALRAK]KIM)-4[[M
M]I.UOS J5.=>,UCS,+G(F=S-2FT_POQ=\9R_-,B\C07:;:3K[Y17M:)3UG3.
M\@>=*WN=LS6=<[D6XR'<$B:C0]IXT#DF&&0]5<A)$0.54N.H'SQ29D]M.]]J
M"XSV!=#RW^',KA>YO<C]/KE=O<C=!9&[&H8+3BDO2$0DRH"X,QPY0B,2V@?L
MA O,N)SS1?;,MG.^>IG;R]Q>YMYJ?EDO<W=!YJZ&2KV16FAID%#YZ".*@)QB
M(C=""EY1'6S(>1B4[*EMYYWU,K>7N;W,O=4<MU[F[H+,70UG)V$Q,9$C&@E(
M6J4B,BPR1!6E7 8?E;,@<S7>8]O.??N.,G>Y<=@&F/"EOQOPX5L$G_DM=QR)
MOV60I!\=86_1_NORZ,0+H-$8#7<B"82Q,XB#HXV<S^F:6L$ +7>)^?L ME=M
M_QW#T>LVK&F;D-3]CP9V.LWPFDW7I-PL!AYHA^-909#+D&"V(-C&JNM)!O$O
M_3_R64O3R*0<PG0>M'C$N.U!T/8YJ#OR-!U0FJXJ1294[3O&\^FDZA:U>O/^
MX/EZ!YP%L%FW84/;WZ)]< 5R/:B@SRMHY3*@90"TO#Y5FX/R9[?3V*??,W$@
MQNJV9KEUU+OFB>?VLN[@,QV696MAM\OW^X/?UMY4=2!K44EK>,+J<7YR!H_S
MU4H7H,)NYZA!,\06>K;&9UT92]MM;3'KS8N;A[+T@AJ6N]NS:WFI*B3BTB^C
M:76426]E &>VM$"J6W%DZ.'QI@D65/*_JZ=47P]+>]NJ U9I&34L<,QA.,U(
MKWY2.G14!^UA+Q\9VO-SX.[2HNB.<>Y!Q1K#LSR!886X.VBAKI;)KRQ.P9Y:
M=#J[&+\;3SZ,EQN97)3+JD6JMC$WRYI,IY,/F3BG:Q0U'%?67:9L^]X.1P6Y
MZAJ:+("7E:QI$)'7*!/>;JNOEVFC:I#RB>%UN@O"IC1@QPTU#C,P2<;=GE:=
MK3J]=4KKM4(<>?P;QIXQ/\N[BFRL>^CDYD<M'/P*&V7X]X+6-<]KWC1R&W88
MK B4&I"SHE_X=38$<K'3!6IR'+\?3JM.>,LMQA;HIZ5/487DF1&9]]HGM^.J
M498G><E694]FR0+AO&@@E%&,_;QNR]A,H;#,..;F/W9ZN5?UQ_,=<.M/DT[3
MW::5*K,:/[UBX4F-U0RK"2P685!Y+#4@=.RL<'EMU51J"A],QD!TL!A@,MIE
M!J@:)L6_X]0/9Y6D*<T*)@TB]O/2,?#O\YP4T$Y]37A7N.<-*<ZJ][8"N&PS
M.#^V",@"=;ZRRUTQ>K(VNKI-7.?*KKK\)@W<UEO'7=/-[612M^Z<5W)XJ='>
ME<]<6K=/=K:JN6$917]VX6; ;_!G!N^N>R/6K126A47UNBLWYA\7XPK9=USU
M+YI=SN8Q"S%?7]!T*VME2=6HH9[9N<V0M1F/O=-LHNV@5GIIS&IC)7<?[3;D
M:%G:P3:FTH2AT?=ES/]<_!UJJ=5M&%"ONIV.AA5X;_DS,\I5:]X2<=L=,A4L
M_Y4;.Q1ZQ]1@EY^RN5@ZV %7EN9RD\$L9K#X><M9X_S-&+72_7PR+GS4].H"
M>3+*2B/?4B"2)N=YJ6O&AT\JJR%G'UV,,E)_ ]*<'["P9*Y\3[DY&WJCCGJL
MOER6#7DNQ4Q:F5 V6"YKHB_<4E3O-)8&N V5M .I>[S:5AT0N@9OG?NG3N*L
M[NW6V&1-)\-.C]NJ&\RJA=P*EV;D5TCE22N'KT$$[OM\+?7Y$GV?K[[/URY-
MXHOZ?-VL;]<MANA@"0\J60V4_3M8T_!K9=?7$;L?/&Y7$*+?O0XN>"8I1TSR
MB+C4%)GH)+(VN2@$%MK&^Q"L>QY]94<>!%!TH%X7Q#%8IHX[9@\=@2WQ10JV
M8M/K^)]G3OW44N2F7[<^]<U[>G1\\G1 B\5+?[IE<?(+V.0%VN%P$?':23ER
M6<N1LU^&1V>O!%S_\?#)2W;X%F3!6Y !9[^\_>O)2WH,<N'5QY_?@IPY794C
MK_Y\1O]Z^P[&=@CO]I='3T;PKG>7K_X\>G=T\HH?/_GE[>&OAR!G?DF';Y^1
MHS>O#>$D<4-1I,H@SHQ QC",B!!$!9>8U6FUM6,BVA,LF),:<[A.\\"XM QN
MP(YI^8T;"K0[_&0X\Z-)WN3=Z?OP[7>5'AZ\%C9BYE1"3$>&N'<.&:MBQA@"
MM>Z-P_DD9WE7K<>&)JP%B8;C9)VR- 78!0D6@65V=5=_.7CV?/#O@]]>/AT<
M/CUX\?+YT\.G1R<OKC_FZTJ\C2;(]2-9'CF8)UHYY9,W!N8*-)P2<XEP'(47
MEE[5:O1:.KX#6J3KB=8Q_5GKRJ7AV([]L&E#M];X.8=/NQWNQL5?SD'WK%U+
MA*7;&7VM4]*B25S5!J'3U.B7Q6/!S6P/K,(B*&VK)DYHGMWV4_B14; O*[>U
MBK-<S$\GT[97_,4PE/8/V7_O#+ISD%&[R LI4+F\Y7ABF$-0=2!^?'XQKQO-
MP2)5#R@G.HNG+CH_/+RI6;'DBWU'BO@MMP^O$@;(P\'+<=OR[S\7D_Q/:>A8
M@I YN>!]TZZO7JQ\4&1]CAL/.^<#W=.B$NXJ49ARK.=SL/EBW"GR:AJL3KND
M]M,=7D;Z</#'ZMJM+5H.RM0+FM>FHK$JZIB_GC@8Q_NJ76X<EF!F==8%EFVY
MOOEKKZQMCJ#.;6E16@>1<FQWZ:R@#ITN5OGRITS_=WB=V4.PZ,L"3RH^K,]A
MHS\=#_]ST?!S'4)KUKC= 3>9GRXUV&Q:+']"6%R,%QLS^,=P/^[OP=J?U]6)
M+G>HF\]'94O'DT6_-]AF6.]_?N?&D:WA<U X[F <?ELP7&WNAN/Q\T:BPP7@
M=+0"_N<LWW>KV])WL(&/#UY3;QG#7B"?4V$Y\Q@YXCTRG":).7?6B1NZTCMF
M&5Q%^K4(63T_N[F"+PS7S>NH]$2E,ZOC'6#K6;>^MS.6A;;OVRK=C^8__6#O
M=ELE2AZLL%O-0,MYH:M)H;O=2J;MJS-8:[BT_?5:3Z*]6XM5'+9B30PZD;+9
M5E>-7;]H=V[=3G*>S@WZ-=UHQC_4RA7+?T#ZM?OBM;M)G[!^[3:OW6?I@PTE
M%C[&=<R@W<7OK5S$AS<AF*OFNC5*NFXQO^89_2"_WR"WBH9-]ZG8989ZO.(K
M?QEKW13:KW_&[CQC2[JBD#D5^VJGR?QP,HZ73> SP:0^ VMM?=KWJQ_'AOG=
M#RA-PD0^<*712\ZEHAJ;H$)@@;D86 T!\<4=)#><U]^1TN,O"T_7I<=_C8[^
M?/7AU=MWY-7'42X]?G?\YS-Q=/++V:NS/_[^Z\D[?/CVS26,?;1:>OS7V4OR
MU]N?A\<G_WY[_&<N/?Y#Y.<<_OG7\*\GO\"S_K@\?O*,_?7KO]/1>A=)2X2.
M)D04+:>(.T*1CLDC+:@W"7ML)7_PB/$]KKX>8>=J47<[C80^;>_TLNG>R28E
MC5*4ZD0HY<(X*Y*DV@DAC;=1DEXV[;)L6H7_ROD]-":&<%08<<$TLH(I%&SP
M)#BI8O"];.IETQV134D%RSCUPGIN5;222:.)54PR2IVY9=F4AG_'@#[&Z:07
M2Y\GEE81LF0$^<-MRD"P'O$@$[(<,Q2)Y%H(1[1.#QXU"<R]7.KETD[+)0D$
M'#5)5$C/O==.)I6\H.#D!3"E;MMFZN72E\JE512IP(F7V.<.V19<.2\E<M$:
ME+.5/1=.[Z)<NB9>UF3QP$CCIT59?^7RE?W"?I^%O5\'&9].8+A!3Z&;)<#<
MLVY#-$D2A8]>&<T=RP8_-10;K05-WO1AB-W5J\>/UT.D% >%C44*:X*X3 YI
M+(#0G=..,!RPD-L*0WP6U]R5OF(_I R(1AL@#^-\4)Q28GE*.F$9C,_5:*J7
M ;LL U9#D39Z(0,)*(7<X)>2A)S*"*TT:<8R0B\5O0SH9<!*4R@JB8F,,>\I
M3R8:):P*D3A'K8O1]J[UCK+_:LA/@_H/8+HAC[E$/-F K,8.*8,3Z'\J.&SA
MMESKGO_O"_]+2Q0WR22,/=>:&:&LX8Y3&X/'./7\OZ/\OQ9:PUYRK!6*)H+Z
MYQ[XWX9\)LF5PXZIA/D=XO]M)JGM? CC<%.)XNWD.N]^>FX_PML:X3;#@CN?
M^/ER_\7^X$T&DBUPQFAVGAOQ3F,8Y*+?>0:A=_,.NWU-!/$>VP<L6I^,)LQ9
MSBF5%DL6O,%@;7)+Q(WM@X,&LON7R?0%Z/D7[<(_@7U8_-6'"+9E(QR>'&3[
MH(0*CSX>7!Y]?/E::\(] ?L 8PY& C$666(I<C0Y*[3FU+$'CQC;4W1GNI)_
M!T_@'O,S#SX&J\%2M(XGGEQ0BF/OK5 B"(=OEY][<__+6?ERF96IL3(%0E *
MR@,K.X=L4A0%%9UER:O$\+;M_9Z7=XJ7HS616F.MCQZ</&%QL($ZK"P3E(D;
MQ^][W?P]&/IH13=CPP1+02.2G$9 ' E9QSRRAGE#2,"&ZUXWWV=^UM)X:J-A
MU%).!7>::I,84SQ(RY3K=?.NLO**;H[)"Q&41C$HCCCG&+G )"AH2P,%Z0S,
MO7.Z^8<J"WV<VRU-"[3HN3W/G5F^+A!PT]SBNRN<HL3,*F65\)1'X9P46DF#
MJ1%>IIO75/;&QK>74$_7 @%.QR1I(DBSW"H3M O226&D T_P#<=4F >/%-[3
M3.Y*'NZV ZP_.#]'83BCD1+'N<51&R4",+(CT@O/;WSPWQL;WYJ55XP-)1(.
M!F/$J5>()RJ0PU8A,#T$]U&9J.S.Y=3WO+S59%X9+78JE\8(SB.QS$M%J.3!
M:1Y(['7S+C/T:B @*J9H\AYY*PGBRG-D*6:(DZ 2R?SL::^;[S,_BR"D$]A*
MD.C@^Q,M4O!2$ Q;[TGL P$[R\HKNAD'Q9+F! FA)>*:*V0HD8@:EWB($DPN
MMG.Z^8=*$W@\F9Y/2M_./A_@1OF"F%$,FH@S%SFSQCD:O*'&A)2LLWT88(?E
MT[.U,$!N TF2,RB:8!"7(:&<!( BY4PQ09+4[L$CO<<(V94P97_DL-5T ,V\
M9LH*32RW0CCA&1@?DE,AE%*ZMS1VE9-7+ W"(O'8&R1-\. TR(!,T!;1P)SC
M*5%+P\X=.?2\O%5>9CYYF>E >IX(T<Q(97#TWA#&A>Q5\RXS]&H4@ 5%N!(:
M2<H3,#2SR%E'D)-,&Q#56-A>-=]G=O;48>.5D)AXGD_<)&QZKLWS3L80;CFH
MUZOF+^?D%=5L?#164 >FM8F(!VV0B8PB&9W1A! 1C-PYU?Q#90.4Y@(HSRF&
M/A/@>G3EY,"X$(HZPW6 _^&(02#I*,':X'W:X0Y+I\.U$$"4#G;/,*08#F!G
M$(QTU!@EC:/$().()0\>$;XG"=N5"&5_VK!-?DZ$4X.UU)03S@C3D<ID<;$P
M<8JW'-+K#8TO9^450R-C$>LD!&("_ 8>,@*(2^ W$$8H#DPXLWOH>CTO;[<D
M(.C@A0M6$"XCUMQH0:S5"7-BV"W'\WK=_'4,O1H#2((KA26X"BDDQ+W(C7V)
M1YA8%IVS&GO=Z^;[S,^!*6>CQU)0S2GL>U2*.(IAYB(E*GK=O*NLO%JN1XQ.
MR@04),6(1Z4S/$?NT9V\-$Y3T-8[IYM_J$R  A@PGY;>L9<#-QR-^AR S4+)
M1IVTL!$K4%!.4:V(,"+QB)U6HC<R=EDR_;$6 &!*:RY$0+A()J(CLE0)A#U5
M 1,J2"XD%GO"?'6V87_0L(OLK"5UACI,!.=<2F?A7RP8,+)@E-^\(U%O8WQK
M3EZQ,81DRK@,K&^\R^CZ#!E&-4J26TVQULGIG3MHZ'EYJQU\N)&8!]#'1G).
MN&;!)N,$X<#A\%^OFG>9H=<A 0@-(1+DHA>(TRB03LDA2AUX$")Z2GROFN\Q
M.V,5@:&]%3%H;D+4VA,E="(N1:\YZU7SKG+R:@X U\D'X1&-VB*N70+5'"PB
M$G0UDTYK1W=.-?]0.0"/\T 2#&4.SYPD8*?SR6PX[W, -@LFAA-55AJF$[>1
M.1(D$>!%,A4L(;V=L</2Z>5:"$ 93:F0!FF&%>(X$61$H"@Q'KSW6A(.=@8U
M>U)_-?10?\ZPB_QLC7$N"$NY9=P%9P@/BL08N*:,I=[0V%E67C$T6,HMB:5
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M&?1\T3J)O3BPW>Y%RW?M<-A),)U6!R:[]JBZ98>M_\3/L5NIJ72W]:HW' T
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M2]P(JASU_.Z*LC9 U0#5=@/5Y9;>DTV_\$3 B2V!DT@A*4$XLLP(Q(D$NX\
M5L6DM-766!'UMEE[S:W*YKKJTWKSASKF:,JI?(M8)48:I9AV"1L.XM0HYI2W
M@1KJO&"I<:!NITB]6'&@:AV2T9(@GT#5!QW?@;YO'#(Q:9TH-9[?F4AMDJ@W
M_-\X*K<+#Y8=E11'*V.0B 1M<WTEAK2R#DEE&#7,<TKNSOYO *$!A,8AN%V
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MEB+4FG*B#B?LN4>68PV67M)(,QR1=THSHVETE-X50CV9 ,(& .X9 !K7S_8
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M#"&BY380Q*GS\ ^ @.$,(V^=U3P&%FD&@5L["QO^WVK^OXG?X;$!H/$[W 8
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MY[!F!_YR1Q;PM9,Q/ EOV(^*"P]U=MO@PH/@PI*ZEBS!PFF#G$H*<>D$LD$
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MO\S?[-YMRN5L!G&*FW(Y3;F<;9K$MY7+N:K\S5*Y'"4CSRX3Y0-($JF<3F#
M*QVQDC(R=^TR=_?KJ-RH+:XO<_=KIP^*=>MP[TD6L7O5:[V,;C#.I4+NKHC=
MTII,:XW\^NIP;UIK)']?O_@J]U.EI@/[Y+<S][^M?XS@25'$JQ9?Y<8FS92O
M[J_.W;26<"YV-RFT4,H0=?LG54F<SC ;5L-9E6+;RU_FRJV]RH'0A3$, ,*O
MK-#RX>5\;LL0NR#U!J50BVWM[?V5VSKKASS*8J?E'(OU##[%B[K&3*?WN=_]
M7*66WS!08/$Z#6+W8F;%3>ON75$\Y%*Z6"I?NTP,9>OF4U]6B?[RWZMWJU3[
MD\]O5I89E-Y$F$P,)P.HXHPF23C!5%(B@!BL_71\XJ<#U6B#1W::A<7F#"QO
M\YS:Q0<,OY2>7PV' &6O>G-95JZGG^(?3#]M?SS@[9-C3$UT'%O$B]??$XUL
MS#F!F4W<"I.#O$$9XCL<<(>(U?C 20WD#;DE,U?GDLR%^N9+Y=2H4NW:K#Q.
M+L-4IZV?U0V_RBT\*;>]G(1:J1 "82QX#B:7-X8SZJ)4$?[CC*J<=#>CMI*K
M?M;?#TL\K]CAEV/"@%2"HT@PYA'G0B)-!$<X"8X%++PB.:QGEQ*V2C@[54K3
MC%\G.<_K*,X5UY[4+2B%R/XN"6X!$6_D$KD=YJQ:PG-$\&(^*^J;VFG]^N:8
M\Z/9Q.V/AQ> .<$Y'265" LC$.R 1DXFC8QW!(=@O>0!,(=>>6 PD>SKZU3E
M^NMG<:YN%\C=/:"L;E&BGJ 2.%_/K(;/.ZMF)M94,ZO[^/9:9G4#]U_);,-(
M[Z&.V:4]W5L5LZK7:\^XJ6!V-Q7,KIK0E U7JYBM+65UT_-M8@/6/@0?LRO?
M>JLP4\R:&$&.B91J&28F,DPTY]MW+*_\Q>$?Q\HQYJQ-*"B6K\]0AZP)#GXU
M#(/RK+7GSYZ3J^55QI=#6QGQUR@2-H&+NCKM,.;<^9/\G*M6]&+=UPT5Q&8H
M<TDEL5X</48UL>\/'N8A 4"R5\N_&C5L*9+;'0]ADW>FE<Q<G?T^[\^7_J ;
MOH"J.5GZG1IEJZ)VW?C9ELH2H^F.?NKUOZ#3_I>=.6S?62AJO.QKR26.\Q]_
M@IW8V_L+5?4IICL<0!).,KDN5'M>\E[,%U(>UK1:54">"*^I-A!FCS>"8=W_
M<=7@2HX'Q4/ 7@I)>>!.,QE42CJ$F/V7X@K='E\2A3'9NZE7H1[I[]5XCJKY
M_7KQHI1E&)32@0O@"=3D,X#"UH5A[/VP)N+AQP/Q^FCOXO#KH3C<_X/G"$-"
M PF,(1%L0#PDA;27!(7 O-3166[LL^>I/QZL>ADFA#57U;M4<%RO@@*)9S*;
M<E>KQ!$7?:?7KY0]D,^7AA;>)P%>$F*XA@3WIJ7!%XFP(;NKR2X'Q5.NM1 J
M(NPPB&]'#3(F&$0XYS[F@XX$YN8P7V58I;NYNNPU"1;!/9R25-&Q2XG*3%*5
MBWJ3=K[;>KFN[/PJ6"Y*CEEMHDM*GBP5H2\YB(OWK#0[FO> [[1L)[=6&UY+
MJG[]JIL,O"H;-/6$9UML4'2$P>?^>%C'(4U<XA>MSS 54"@+#WYXB8[>#%O_
M@$G/E(M^L4) YDQ$S#_GRK//%6^WW3+56L85%_J34Q$V%OW:;)/.3F:NCLO:
M4 5L\OUJ";#5VJ"=V9=W4A#RELC8F"RWCS\2[:]_DM?[[_'AD:?',4J9"S\B
MS7Q"W!N*K$@B1R)93P '"977,UXF-:% JN828HNEH:8&P-(YTPW)Y\Z\MD6N
MSKEL#\J@&\?M'5#5QS_(,4Y>>69 IF)-$8!?1#J9@(064A/XGS/BV7-UC5(3
ME;B:AM#62!0Z*8$$R\#GXNA+,1E/;Q@3V1P ;#D=??IZ;*+&/'B#7*0"<68T
MRKF(D D6Q(7PB<&N7.<H8/7NP#P$S>EDU8'C%,P>#YS6*_T'_QUW1A?5*79#
M0U?2T-<_+XZ%"C@*X1'SU"*>#$9:JP!F)4F*$">!C$#"<;'+KZ"A62W-9#N#
MNIAH33ZQ; PH57EGZCJ'\W^:\^MD9U[Y-K3&P\J5T^J?3Y6N_)>S/BC,\Q4Q
M)ZZ5TWZWU+NL:GAF57\$GQ1O_6ZK77O3B@9Y1;W=NM#N5+_K]&8W N8UP%*!
M$73M^1L-];<WJLR[\1!HO=Y9G)W3P6775'WI8;8'V:)!V80IZS%Q6TYMI"FC
M@\G[*?]Y%DY?F4>QMD(&=7'H.&_AK,8I9/.I4X7?A$GL36<0)H<IU40FZU,<
M_F6XBX6.JH. _O(0QQ4,S6*BZKJ;PSZ 5(U&Y>!I<L5CH4ARM:23IN=U^K>=
M+"'G;<5)95SK@3@'69#">O: P$[Z_5".EJ9W0#K%_5@JA4X&.ISYAXL)FA<3
M;+1:**_9Q>RCS$/-5Q@&H;K 4#X9U>[NNB;4HK=[/#&#IJM7L=I9')WVRR0G
M5%!=IUDF AB;_93_4,4V554$2X,=Z,#/F;$UZ0(9_@5-E"C0Q57]4LXFK^"1
M5K\'C% ?7((XR'34J0K@@A'K2K.YC/))KU0Z+5>"P!@>9NY,L%UGXRI.>K(:
M"Q6$OO3'W6K/^AZH;_EJ"(IY;>QH\Q[DD[<)?.3V)^R;R:O$F\'>5D9WM=EE
MYWUG ./*I9,S*92>8=^>V@G=]:I(%[]?I[#W*'8SW&:PR4X-6+6+0OO%)U.[
M8\KBU46G*]Z9JQ[=72RU7%5,G MDG"]".YP?1)@/()R4P:T=- 5M*D-^0@N
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MG6#G8QP*-<!L6$4OHIJH#N;9>1.>J<PZ?QQ[15!]:WK91BO!CU;3E<0ZX]$
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MQL%,7HS&K^W07L@![J[P>G][I;C93#=OIAPV4V&-*4S!L1\<-A/BX2DN$2[
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M<T)9D5E*I2@9=1FGI10N+;32)A5"7-?F_IUV:DM++UE4+12>JJZG/_PX\C5
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MQU6Y[%X<@6J1M$1T@4PC[(X#M9W9+%%:2,?@N*5*W!, CR8ZXT66,:,1Q(+
MH>!LD1*1.<6TW@C*PQ64@YTCJ;-"Y1;A<XLT82HM$JG3,E&%%(J4I;56?PD
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M;&F-2D4JRSO+22,9!V[AJ/T?.S#@0;^=/([RF>\N,+U#?<0*R3*G3$*T%'#
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M?__A]4GW99>AACC 7?WAS]/NR_V\^W*/+B& O42MI,G[ER_.WN\.SGHO]RY
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M1@J'@G #R\!6E8$%W32XW%[!UO6@3Z]%X'!O"W@V<X2<1"HAT+Y(?M!"N49
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MWPJD)J=>:@BETI9%FC]Y2I;+#?ZK"J@%(.0YJ6ETX0*G4L@2@Q!5L:Q),.;
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MYI1H'?1J&+5MH*V%RP*U:1IIE"#5[DQ(P5!Y$,+*=.>[K1ECH/LPVIRUX;3
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MKF("[%QBFQB+]:[4NZV_2 >]*U)R6E=CS3:S3>^ODBMD5PJ[X1)*(Y9 $YT
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M%7 P3[#A\[7E/\AGP14M7(2B2P?@:'&W$_/^6]_!X%3B5<<D'=.S-\L$VNH
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M1L[$-QJO/-PZ'P_O?*Q#BENGN'A8'B!ZXOI]:CVL_;%#;W=2=S4V@^FHJW;
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MUK5E+87'8+V5[ >_93<8DS Y*6?<A$:[4CEOIBT-I2$@,"$1-:!#/5&,P><
MSWW.B /9#2S,UP4H1;/JGE"/^  RP''P)IZL+3?+&E)D64I1'3@5^$6.F5I&
M#DK_("J"IAGGDVJ.2S2AO!N&BTQ@5U@<QFJ9R:))M71/AC,ACZ J9!%A:>R
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M'?!VP-L!;P>\'?!VP)LTX WRCO; @/P_6_?H^XC5Z$#+WN[>WH#B+!(I/J_
M:QGLA0$Y#\,7P>#I3^'/3O!7LL+O<G!*XD68@/^AB_O/L+I9Y=^Y^[!91WZX
M/?+?[9$??NJ1?V58Y;9'?M.._/!NM_R=#N?7F-#_?AC]M55*7T<I#<4.\;1/
M$;S#1N(AER,.#H+W_8O^43^X$$K%P=[^[E8%;8H*&NP.^J=O+S;+[O@:"_6O
ME^>O@].4"Y,-#C/8H1A_K'\?Z=]'F9#MAHN%"DUI\BGN?L@4^\=A&<+MG1 '
M"35Y0I9:>D\9SK@#&*8WHTBJELTSJ-:>/JC?UV\#A&Z/V:.1'CQF%T>_;8_9
M;0OE"O=E^#%+L_D2O-I2I=2^]V)RI>;A2ACT5NH?S6:BU!^-7F^E_IY2?Q0F
M$VS:@3^_CM,/V)EM>P8VYPP<G[S:GH%[GH%CIE?9'H'-/ *O1R^W1^">1^!U
M.%;)5OHW4/K?G9]LI?^>TO\.6UJDY=8*VLQ#\'2S#L"J*/*#KM0E<;MBXS9D
M!?%ZR*Q;7BATOEW,@<Q<H.D#D8P/"1C#LF32._<8V@9S2+/'3+;P$8-RW1UT
M!7F?$!O!WRPAPM=A;?F_J_ZOD[3!(VG8?UHG:<#??/ES1//YWT$7$P7)C1^G
MARW%SJ+4Q$"V3/9^V!\$X43WGB ZS"Z9XF^08"U6Q?WE<WO[NUQ*&V4+:E;O
M?,?[Y.'N,U/I%N;C,%7%SMG'1"V#T81JX(:[NT.F\BRNL%,"!E.I$8M"LE \
M"T-8:41,T\^#%PC&YM9LLQA;N%$?UQQ'L,@*9LOWQWI@2^TF%;=Y@W427F@9
MQ>!P[ZE;&]S-B-00&A&1O_W_X_S)WQI?^_+:90_DYW]UB8\>GSLH;-,[R[,J
MC79D?%/ZOQ=?:K2G0OZ-3>12T(;,6 E?H^9'U+]WCNWAN)TI-G.BI@]YCCOH
MA\7]95]K3[[Z]/]/UV:]HCH![)B!:8$[3K)F%3T\@U<K#]"CH?5Z]EEHO?9V
M?_C; ]-Z;1"#UU<?RY8_?#W^\,&PS6UX\*/83KAU<?KKV]'ENK28@SIWUE>T
MREQ !#>3=+KGK&MC\!>-Z8)]LJ(*>[2&1$?M-+"2/DO2VQ;[85!3%+"2IMH&
M(BG2S6_QHJA2^!(]3[I^_[5FXY3!EV!@:U_68RRQ^P7)!OC:DV9=AG+ZR[*D
M@4;N[[)6OBM-VO[S_N[!>AQA=WGLT]W^\\%Z7&AK1A(VAU=K36_Z8O3VU]&;
MLP"Y6$?O3MY?GAY=](+3MT?K "8&^P\8,?I>=^1)\208O3[YU^CM\<EY<-P/
MWHR.SD<G;=OQ&=9&M (ILD49@*4:1P%.\L4C6;5;^>$&2,PX2M3'$%4Z+5@X
MR4/U0 NV*<M"LH0AX3C2[?6.KF(U;59 ;!?JA[_]M*)"Y.=U-.%PJPD?1!.^
M.Q]=_O;?[R]^&P7'[\]'IR]'+]]O5>'J,Q^65\NJN J#XRH/XW$XKK9'')D/
MTSC+@W]B1[DVO=@H$]DNFJ<7[?K@FHTFDZQ*J<5IMYILY#A6NT^WQ.-:VWH]
MEAC>HPG7/>\.UST99]$2_N>JG"=_^W]02P,$%     @ 8HFH5ML;+B)U$0
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MSA3Y7)'']M3!4C7X?] 9:NJH.QIW)HK6@[>[H);!L1"^JW+P1>S1J(LB 6]
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M*VO82TRM$G7M8&91:\['_DJB7-%3PM7&#LR?_$IF5;<*AP,9-[ '#4K4-L3
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M:50<C(A!EQ^QM"[=LW33!5/H6:4[SNZ,OY^WDE>;<GT!ON/S#_\%4$L#!!0
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M+3VZ@I>O1B?C$_BS7O5_OBA-^F8\>23*T,HL#43%2JB)'MDI!E@R,[2L(BB
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M6QI+OV%!R\NW@GDZTT>LHAR./EU* $8)C^+I\-,<]IOAG_/ZB3<LWSNKQ_!
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M#]!GY?Y7G<R( ;<.-->:F115[;2DF,\YL!!IZW3DLEO>/ARE [ =I%-[A3U
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M;HFIY(R66<C =)3  LP;#G*4O(!+O'7GM57P[B#]UJ;>![BY] -"#PGW'CB
M5X49[G--J$LU&B R)4RTSB=9L%/9J!^E%'L-G]V,PK>VE&*"Q*,+AD'R-87-
M%@:2[%23='#&FB)-IPCOW2REN! %GBNEN(@J-E8<KPO('2ZEN) .EZJ2MXP"
M-L86E[(1007:FFN"K ^2!><U,UX9(*,T%K&#S=KZ)\DB<F^=YG^_RAL/D$1,
MD26D/S37BGEGD2% $85'4\(=&_Y[+Y&WD/R?+I&WB/#6UD\M\6)=-@1%UH+K
MWD46(V3F2R9K+"6:9FN__Z7V4UO&A&BGG"WHI]8%[H]^:BLI><7^5\MH: OZ
MJ8E:Y"[X0(<KIY6E^7SGK+4HO>"NOBSFYE='VT"HI?JIK9-/BRBFM75RD9%]
M]QB_:AHFM?,U=KH0" (6/?/6)I8S+R4 G=X=0T&?&F7[>Z<MI)]Q'\)M7;:Y
M8U,W:6P!.G89ID*V5BVF"D8;IF1*0EB=X.X5W@OOHK<T$WH0>#^5);\MIQAJ
M'R&5 I,BF8L2N![)-K/ LT\":T'%!O[J"RTYN^QMV,JJZ*<:\0,%O[J VJ&2
MLPOIJ%/UT64$O+:2LYI+XU(AWSM5&TE5?J,SK%B104N/V"T(=;NTOFC)V?9*
M7T2N:RPYJVG7TB UDZ[42CT<Z7"*DBD? B]"QJ1:Q\9L><G9A135L>3L(E+>
MQD:ZWW1!6%_%PP>'77O-P^<G?Z?JH?<R!*FT-,%JGH./Q:D,L8 O1HN\:-7#
M!P%L0=U#*\&!S9IQP0O3&2,+*!6SN;CD,[E ^275/?RVJ.D'^#KW,*Y*)PR<
M=(D7:9C7-3DO>L/ \\A<R45G08Y$E)W\JD>'^$[C;A:AR<,%9%>2=7,W^S)^
M\6KJU^DA=^$>G X_#<EEJ,EM<]P#X5TVPD8FP-#1(H5F05K)@ =+?D,A_X%W
MHLCR&':-0VO25NL;O IW2/*IS<YO9$9F!1#J5S#%?&]QG(Q?X?4""0C:\UIW
MNT!]FU.*!:.0*:UD5MDIT%UCY5<"LG-T6Z/>6I<[7P+[._AS>'9^=E&DXZA<
M%OJ^^;WYY*Y6%LGY\M\-N"]*B"28P=IG$3@M+2,$@Y0M!Y6TN=OUJ!T]E\3\
M@\E;P8;6U1BO<UDN9'V"DS-"?G6#.P@^69"UT+'/O!8_#BPJ61BW24&RF'G'
MY+:GQ]DU<C64>NL*B5=5.(Z^S-\(3L8'<^?N <2#C 8@:<V<1WT!$R*9"D(:
MYP$E#[';2TKW,7>-*#UIHW7UPX/+"X#'""V5,%Z(^O!<X_Z+KQF^$%@QSJ!P
M04+NUO[EF8%VC1XMY=ZZ@N$Q?H$)S/"W+R2UT>P-XJ  DM^@';/STB4I:1:-
M(#M/FA!K9XQX-Y/LL:?W>Y^]:YI?4;H-*Q)V*QUAI<T@4V0@DJV! 8D%I9&%
M #YHJ:*1K5N[O<3:'LOPI;V">JHP>'78/5TN8CI0,M6ZOK6K60VMSI'<1:TL
MX]+8Y'5.]NZ;S=/%W#J.NT.4Z5LK6U0ED"3V$4?X!YS>!$?0/Q^.\R!;LINB
M-4RKVG$YHV.>HV02./BH1-;P[(M/?_!VE(X;U''+DH+=IW2)_!(OH,JJ1F_Z
M0@M,$T3F4U:,=N\LK10&.S:O7WSL'X1KJIV6M?D:5!CV4(HI23$  JR]TK6V
MER8C(!F>DPBY=+OIV<6JT/URK(G.^BCG]V2M02L<A.201<AD#SA-X%1-CZH-
MZY6QD$SK8J8OL!3D*@9_,_5LKI:?ER:[A(6EX.L9;00+SD;&+4;C ]AP=U?Z
M4<NO)S:U5UCS6GX=3^Q3,@[SR?A;&_%R2Y7)D<5';DLRM4)J#:^(3F?FE)?"
M9HM.=+NB6AW+#G%L$]IK6=%O7;6?508=(A2FO E,%Q58Y E9T%S+5&)6.:SA
M%NU'@?#6]W";(DG+6H27+YMI@C#%UWCQW\,1V1ST39KDV_%TNC>;38;Q? ;S
M2*,/<%&5&C"38Z09.=OUZE&KVBU5,NZM"B4F[VW71^:%!]\A_JU%/RT+%#X"
M^  F]7B87G7;?07381H$3$HZY.0+*<&TK*7-L60FL2#/SDK-NX6?=ASP!W%6
MUT/+0H0=0;X>GIZ3_3  $8.04C/-H7;UKNZ/I#W3*4@R<=HZ[YZD2]/E<L@?
MA&FABVVO#TC>M =)G+^8#QH6K?7,.TFVJ2@Y0&M_=4?K ZYB@6U(X5M;']!Z
M;HP4@2F2:@T3(6.QN,!X*5Y;X[6@?;D#:W>T/N B%'BN/N BJMA8Q;<N('>X
M/N!".ERJ]-LR"M@86S)/(H50&'#:KC5D5QLT&Y:+EMPZ \YU>@C8;I8L6A^P
M?Y(L(O?6^3O?I&Q>59A* ;*F+3)D6ST#XPE/ ";)S(N:BT)"Z&1R/_#AVUHC
M<"$=C!L*<&U5 BV@<5E[YN;)"SDE%GA]C>01.7E^PH365Y(OMDK@$H9$.^5L
M097 +G!_5 E<2<DK5G5;1D-;4"4P^@3"6<6"*'38II(9N8B28<X\>,)>H+Q$
M0BU5)7"=?%I$,>USC#N5+PLFTTE-IS>(6M*.9L_ <LE2+6,2:J!TZO8B_%+J
MQ2VDLR7JQ2TB\);%#:IA5Z<]7P0"7;VNUI7_!,)*47NF!F:+LQ$ 099.=8&>
M<UJN!MQ1\V5YH3<N!S<'<540L0.,EM<;-T.O_P)C2>'?5=\*DFM]+W$+#@%0
M/"3-E )/C#22A:2 1>UBD,I&?C?-?CL5^,3=0EO]+2*PQGJ[3)Z_!%)TT*J$
M6F6R=O^QD?SF&!PSWAJ?HH,D.Y5U?D9SWPRZYCN$9<4^;B&S'JX'5C@_7GVM
MENB<Q0J$<" RXSH(,B[0TW%"?Y3H3/+&NXY+=CTUM6Z [^CYO3GE-ZQ[T& 2
M=0J75WY=)M'3)4:3"6SF:F,#!&I'X16UW\,%29O).!Z]YA)9\5HRC1I9M2-8
M<*7V&M7!0J=WX9=!X6<N4UX*@Q=1>NLKF<N2217K43G^@FE8AC?5+?;IWPP3
MG-Z:W$?\5$-FQY.O-.DWP\ETWOV=CL\AG-9*33>UEZY,K6Q#KJ=:= EKY43.
M0JUNFU3AR@7ON;WS&/G(;4[O4+^K>+%E^3/>6N6W+IOY\.P>J"8V/2Q[H]$Y
MG/Y]/#G-?PQSS=J:_]Y1N;PQRU?5FS\BI,_7'_:VBN:ZGX_WF:;E6 FZIN.3
M2^#)J6!%<O2B&"55MS8G:P;^@_9;1(RUM., "2!J*R)=Z,0+6%O&U&B(G+A&
M83AOTC[RI;;C6/+2=655M"PA]G2WB Z@=JD=QR(ZZM:.8PD!KZT=!Q>T?8JL
M68+B")Q(S->BB&"U!9MT=$Y^?UI?N!U'<Z4O(M<UMN,0W@$XE+1_Z5+[C@@6
M08=:?3K'2 !5ZM2I_.6TXUA(41W;<2PBY6ULQW$,HW$9'N^MKQ/'W1'7WH3C
MR2G?Z;^1,15;R,J36NE<0C2NEA V@(X,/8F+]M^X._8VM-Y(-J*(LE87FW<A
M<RPF;QA*249/X3*GUFT_-]YZXZ80VV4%J\GXTP3.:M$AI0M&YJPF$S"2#1K
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M0!;Y$_A[7OR9?2,0_FM]TU7^_%)D#X\5"+P@?/UM\1=?X(2&.(!!Y/D0153
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M.(U)Z%R0AN<;C8\2$;0R@I];*0_;=WV(Y1@.[CAD;R]CT\4Q5?<PP]'+^Y'
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M5)\D1DEL5.S:D3Q3>_W7.7A?[0L!T0CL>M/A^&BYVA]R-@;3V1]:I_I_M<<
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M#NJ,^JU6]56;:H):SS-"%-P^!&:D^&9#.S")OLFH6M/O(.@[HFNWLHU*[X/
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MY$&:,@]*#TOB^:F($J-P.J=238V)MHO/Z8"0#9?6"_"@50'+E2[@02ES9M'
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M]8F7(D^&86 4 W^JHZE11YNMJ17VHD[2)/1:H!/8-KW5 7R/LX9+U 9FC/Z
M]4AP=1R-,Q)<'6AXY 17Q]7;37!UXOHSL[1?+YZ75?E)N^+[72!?Y 6(>3Z,
M4( APIYBA4@7593,QS+U."=6F3&.]#4U8JAE W[/S.M[L#2S&QPA-# )K+.K
MZUI)6M +T (V0(YC TQ<9U#?T]/;Y$P_K/+!+.E';K'<QB^JV56^7*C7[9D4
MU<MG]41<_LC*61*@,"'(AUR*!"+?0Y!Z/H5)BJC'A<>9-'*%.-3!U+A@4T:@
MA53VL1+3U+?I$(PG=LD=@#,P#5CC8KXG>D+Y8^^[NG?C75=_K=_S@\V.L[%Y
M0JG57N6IZWH&O7TG!;]7]]8/'XM(&$11"L/0"R *I0]IQ!F4ZC/UAZ2(<JO(
MMLW6I_8"U\(!+9W5F[L?.;.)O#<> [^SYE#8A]SL4]E57,U6V^,&S^Q3:R="
M9N]%/=-5;>8$6?##P3='$^DD7 @L<0JC)) 0"12I%UP&4/  <:D^HSCJ,E>=
MF*9=RF7T*FSGKQJ8')K8UMV<.]H5R++<P,\Z%X\H?[',EN1DO$]8$Z./X8C9
MK;:26FF/HTXKH-1J4ERL%7.=ZLK)X%EFO1I[$,=,@'7P':R3'9]^!_4KZ+:"
MQ""PG\R,Y:2S<9-DN<1G)U^6T\8'GIA;'SI=S+ZL9BS$?AJD"11$S\32BR"A
M)(:A2/T()P&1V"AH_CPQK&SRL4+H>TV[I%,+,*770'2]/82.)]?> S.]V72E
M"K@::S &FBQ[#\IT9L>>@S/<3+@74V=3WW;KTYSK]B+0>W+;WUJ__:"_"^UH
M)51OHB /HG..NWLDZJG=J +\CI096[D_^#Q@).$)]$))(/)3#"DA%(HD95R$
M."'(*B-2+RFFMK]4"_<7NTVE?O";;3X-#NK \U G/V@5 &M_W4:'S4KE%Z!6
M8Q"?E;. =+3UU4^&4;?(SH+I]5;:>8WUX\+/HM(T7!^I<\'?O7PMM0/PRIGO
MDE79MS8Q&5<&/)(I%-SG$*5>#(E ""*$0A8$?L)39),"R[SKJ5GP2O+&?E^6
MC7=\OG)')2NA[4C18AS,F' 8= >F/PUL;>UU8@/Z G[^VJ#\"UA[_5Z>AMF:
M\NP1<\1S%AV/2F[V@+QFM!XM]'7ONUZPO'C.BWHM4CL*U2>)Q<M5SL5,!IZ?
M""^$ <4I1 1'$'LTA:$GO$02F3"S>%_#_J9FIK6^:ULR;WBPM9(#+;JMV]]Q
MW(]SU0!H#DQ0+H#LX0YH!,\97H''VQ_9.=!(V5T?0;/;^EE)VN(J;^0E8[I)
M15RW^3QC+\W/>_&C>J=4^'-&*?%9$">0AD$,$4828JPL)-_#H;:20O6QS1+1
MK-NID4TMM5ZQW*I6N]TA.VO($&\S2\@]B@.3S K M<@7H!$7_-'^J^4&M> .
M%WUV2#FR?@P['=7RL0/BM=5C>7<_2OH@I6#5C?SP@SVJAT=\T:[1"VUMO=I6
M^R+40C%C:EW9%E_9_F#CREDJM%'$"-1)!B!B4NJDWXK$N!^$/@Z")+$*I1I
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M')UH8KRS(C-=MDZ'#&\YN]!CX]-PN>![/!U62>%2$@O"]&+)CSE$-$:0)%$
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MZ7,5U:#6SXM5!GL+FNTS"#H*CWL^@BP5:G'DUTF$,(=IG 2!+Y*8H]2B:L#
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M[H>GRXK)EA*,7SNY'T1[JRCW;*J/)W=U_RA^)\6?HKJ14N@.6Q]*GZ2$QU$
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M%(M!,>.88: >F'4<HMPC>8@M8,ZRB1AW/')Z$5M =O.-6+?0.Z-Y_B3N*K7
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M- &M*J#1I:X&T S3ACH7H%:H3OK?JF3MV.)DB"QVNT8<JI&VQ<X=,D<[:(Z
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M(<\81%F80ZQ+BK-4A$G,4<)(8N.KNA!J:MM-JU-U;[M37M+-<&L5TQ4*C6I
M_5+W4UZ=D2'M9)W-O.:Q5\_S]C7>PEE[X2Z1=N2L.Q%I5)_>)8AO77^G8P^\
MT7BA*_%?+VJNZY]5/<PF!I99HMS^@,&84 I1SC#,,28PCKG,TR1(,+9B2CXZ
MT]1,\?WW#_?7__9=MPR]_KOZU;(OZ'%$#:\:7.#D^W9A(R.HA?34N>\D%JXN
M$([.,^Z=P2EU]ZX)3CXPE$==2+%<"E[=0_Q==YJ;82HER<,8XI!*B )"(8DC
M HF,>(0#H?[,[)C3]^:8FB78B#B,_'P?0S,+<"8RGM_]+2B5>!>@$O"BN6MT
M26Q^% 5G5.;[,XQ,7GY4Q7VZ\N,?'7C[)];Z';J55VK48MUAG[U\*E\6ZUG.
M@S",.(-)A A$ H>0\I3!*%>F@-$HC%*K&M53$T[M[:_EK;(7*H&!"JP)G1>K
M'YH<>P4(X.*Y7!5KRUO$4[@;7BPZ1-/W76,M:M4#H49RA[^ZEM?A!:0A,J[N
M)$]--^XUI:'R>S>7IL\-,S:_BX58DKD*="[Y4[&H,K+6Q4_1U'XUQZZ,!DB%
M%A+B(%8N!@THQ$SHY"F>I!%%@B(KBV,TZ]3,3B-T=9Y =L2VLS-FD)L9&^=
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M5\08JK$SF/$0(2X0MN38'R##U':Q+L/,YKQ':5&S?%V 1I$+0%]!K0NHE+D
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M($B"V(@1<V?4J45+^FZW6*T+1N;@BT+S9=G<H6MA#?,)=F$[<;H^% S/K_Y
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M>/<X&RBEMLZ]IO6K"'4ZOC^H- -;U8#6#=3*Z5Y;[[%X-E00[["(8Q%&]+Z
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M>0I1FB8PSY" ..0TRW$6IR@WO[!X=WTF9]HZE#R-Q$!_&\$&%;"%!>S@ K;
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MX(77.4CH5D$-6*?3Z>0K3.?7IR./*W*<2G#[M1S@X6X^D,!\= Z#6)D3D0R
M.)-1DBHY)9CU]LTJT,WVO-?I:<$/KP*K:D)O $ 83/CQYR&ND:6 D(6#/^+H
MJB07_3J9I-^'H]& ZR2B#4"2<"6=W?%R>>P)%X)*F3QZB+4/#E:AJP6?O J@
MJBNA 6#=T1V49BH)3VSBK)146F(YQ:!4)@,:^0AOWM-N IZU -*Q>UT%(!L)
MLP$0G*"=]*5TZ@C\#,Y*;_.3_&FVA/F QV0E3:943F$D0*-%3P]-I10A:R<%
M_J^V67F3H!:<ZRIPJ2?V%C!T'T(^\-,<"L!GC!TC-1%)-YDXBD%#R#*!M%2+
M\%9'G(VP\Q(A_?3EZP(S6XNY :R< 4IB&.>PN.EYP$=D @-+!'ED#.VF-PI9
M*!94,6:2=-2]6:*P"5Q>HZ6?]GP=(*:*L!L S5(D2+4K1PPHBF HD8AP8H50
MQ+H4A:<R4?96Q?3F1SO]M.3K[-Y^+4$V<(IS-/1A.%J< V LMRBS^#(9H=!G
M):Z;7]^))FO$=.*":$DU^E[H=EF+;')((0>3LGFS?_PF %F5MGY/;#K/&NI$
M10U8G@=\/3U450FX#:ST3#;HI%FMB8^*H_280)@D7C\QY'5J^LT&Z4;[KT-L
M&U4T *K;F[U3?_WP;AB]-A6#C22:<B[E2F]^GS/Q7(#762O0;_46W>8^]3$E
MS8!I*SV_<IVZA=#;@,[T"M+!Y=?1Y!K@'8PA#^^O9[R)3@7!2 ZE-1X:;N(
M*$E94- Q1&MJQUQO4]3OMM<=E&HIH1U(/9?5($J;-0V.>)H]D2RCC*C*Q.!Z
M$>@-<.VK7X6]1DR_5Q/= FE+T3> H?W)>"&-OP_G7_:O9O/))4QON;J^XRD+
M0[/F1#%7"E@B)X%%2227"OW+A"S7/DQ<A:Y^[R@Z0E9UA30 LA>6"=71\J@,
M4<(#D3X9XM'"$L90;C8K+D/M$X$-35-G=Q@= 6A+83=P:O#F$GB83Z"D4<8E
MPFP)>WTY!X'2"4QP]/]LDE36=KM7)*T9YZF[H*X+)35@JAY?[[S$$*Y#W-F1
MEV1PEY>*>^(#!Q*I5DE(X!QJ'W=_EZAF?*SN\%97,;VV[;AEZ?W-B\ODIDNX
M\'\\$.0BW<4J[4K3(MP%7)G9A!&NTR4<458YEK+,M;WX[Y#4C,?5'<YJ*J4%
M>U:N'A^R<+]>0J8"J'6$9FO0B01- IIJPI*P*=N@,5[IXIKW16J:<<4ZM&!U
M5-$ J!XP,5#!*Q>B(3P[063TE 27%''&Q,A=MJ!KUZX_>'V_:26[/CU?2]A-
M./*7E\/YY:(<=)R*QXC[-XQC8<50G;1%C,=D,"8!*)V4>.GBZ;, 0,C#6TWU
M-W/>7R6GWU23'3GL=931@/UY+B'<K9<IG:>EG3AJ;3Z?#L/5O%P87$R*I2WA
MRF2$3_Q\6^-W)U7-O/.NU&!E7?HWT4R\E9D$085A$#!(J7WV7I>#?M->=H+>
M'E7> .!/;]^[$,.RH!YHN>8*DF2>RR!@K8CWI4,11"HRF"AS[=./%\CHNZ=*
M?ZAX7IZWE8H:0-F#9JA+^E64W'++"/.)EK&?D7B'#FK0S,A2<\%B[0CA*0U]
M9]\T@Z^ME-, N/926B0M^=&I'V)TO>^_#M'/?,#6P)DROAR7"^1RHY]]$8_1
MR*!@@D'B7M:&V_>IZO=HK2$ 5E9@ Y \@[D?CB$=^.D8I37;B_'J\FKDYY#>
M0Q[&X7P0 :UVL> \E8+J9 1RY'*Y2%$I:<6A>H'-]ZGJ]Q2N(4A65F #D'S
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M;+KA:J ,)%YB5PQB,93U#+U+KBQ1P3+T+'DY'*QNLMX@J%_C5$GISSL&5-)
M W#Z%<8HHQ'RLI<NA^-AD4^9 WW+CG<*EYPOI0^LL%/R%<K4\ B"<8K+CNG:
M?N)W2.K7-G4#J9I:: %4-XV>#B^_^N&TK(YRWC;@V7B5I"$\Q%!Z?XEBR7-I
ML4DMH*>0;>U[])<IZ?>FJ2,(;2_S!I!S3_U)/IJ,/Q_A(DC+CAR_P2A]F$P_
MX7)(/H=H0R0BTG*:%M#GHT&0I$Q 6YO1'Z@=X:U$6+_71=W@JKY&&H#9,U$-
MM(DR*J5+W,"(Q/\1)S5#!Q.\9=HP0:NG:#\EHM\+G&[@LYVD&S@*OV/@_N)H
M " 5#UZ4K'$,1(*PQ)9.EB$KFO _QZN7B[Q 1K^[6*=!VH:R;@ N=Q=)-UWC
MEYP,LK(B4Q8(0V-()*#OYKTU)$7-G K1U6\3\#(E_6Y178"F@L0;V)'N$7][
M^C4<7^%*N%D2D_'L'>3)%.Z*I6!V\ <*#S4V'/OI]2%*=/;RG>9 9MR062YC
MM9TB4@E!K!% A*."&R:SK]Y!NT-V^MTENT%P&[IOPGS>L'CC+MSTC1F8,O69
M,DFR-QZC8(DNB#24Y)PR@&8Q>-\)A)^1TF^60W?PVT[F#5C08Y@_<!ND\8YZ
M9TD4 HD/P1+/T&>5H%(0GE/0M6W>(P+Z+7/J B:;R[='NU(2  :W28NG,#W_
M@O)[YV?#6$YOAZ.K.:2#T_,[ 26C7/80B8I@RH!Y15SI?.:=P@ H^AC=$S_M
M>8K!FN_LMZ2H)E*Z%'8#!N9%S@8>6!3:.0(RX09KE,5PEG*2#!="YB1DJ)UZ
M]R(A_=RT=*KR26WY-PBB&QD-4O0B1MQBC2N"42$0IXTD44KAE' 1>.U<@U=(
MZ>=^I4\@;:*#'J&T$-7?H<Q#@+3W#6.$SW!\=1E@>I(7_,Q.KN:SN1^75(DG
M(KQ/0TS.^D MT>5$10:A28@J$6H 7)(T:T-7VNBV)*3?K,WJN]\NU=* -5N+
MW8%@R%YRA@A=\NP! @F6:1(34X8'DRRK??^W%H$];J$[Q<UD5TIL%Z$W\GO&
MX\#G+,&5 B8A,)KQ-A,+EA'E.(LL>Y^KEZ&M26*/^W.#**VBR&HXW7$J_/[)
MQ].S@]_P=P[_=G!XC-\>')V<=Y,7_]J[=I(DOQ*CE3+F'\R!6+H'BQXNSRK(
M[D =LQ5F<3NJ-$.T1?0:C43'-%-I4@K60NVCR35)K#">,P]OTDD@(D]9$^T9
M+?,O,G$^X/K*2>=<FBY7KX*\?WO?'3"ZP\4+LSDWD7@#^^U;!9<?)E,TXN-E
MK]QX?3'UXQE*JNAOG!;?C9;:3/_G:C:_&46Z+-%43$F:6" 1,IIT[QFQ"2QA
M)EN? GA3/>.G&T[Z[K*Q.PPW@(3&U\-I^6#!\N*W3B<H=9@/IPL-W=S"E.F\
MLY?$X&U@DB7B1(ZE^7TB-@=#O$Q!.71T/-3.R^V(E;[;?K2Q(G:%A?67A%LN
MB3%\+@7U%YVOC$_C*?C1\+\@_389+68'^^&XB.AD?#_K?&\ZG.&/WN.WX\^G
M,!U.TITXF%-11:\(%X$3R5TD5@M%DI4B"& HC^K961WQTG?_D?[7QD[1T,!^
M\8(([E@10OF0G2<0,7*60AD2N)<D:.6S\HH:5OMLX@UR^FXWLCMLUM+)CUIQ
M?WYQLO_7WTZ.WA^<G1_\VZ?#B__HY(3AA=?LY'#A>^S5/U=XHSV$9IEFB\"4
MQALB'3/$&D^)LIIF-&3)\]IYZ"L1MGW3FIN77)3V*X-0!KT[ *+SHK=[%L0C
M:R0I:S+/+F95OV'-0PJ:.4NHA(7G/6@VEG<#N^ =]4N)% ,\&2_Z*?\QG TD
M;MTQ,4W0O):9/1")-]P4I]=Z(9F,4+^+\!L$-8*E#33]&FBV%GL#&'K"P_O)
M)7J.@VB3EK[<\?.RL+(O'7)X)MGSZ%V4FE;/"WR1D$8PL[VBG^96;"WU!J#S
MH-/F1RCW3(.D-9=4.J*%S\5]=,1QD0FCR@N:3 RY=GK.,R+ZA4P%Q;[>9W<#
M*3< DU?ZM-XP(RC++.':R9EBX*G+*E)1D&!P3W>)4:=JMV)XDZ!^3Y[KPZ>>
M]!N TM/^JK<+0G$>$N=$T;PHJXW$!A:("D$%:0-@Y%D90R]3TN\A;7WP5)!W
M ZA9H='I#6,<F/=:(T_:HE=H2QL *B7Q7F1KHP;>Q=#KU8CK]Y"S \/4B58:
M@-N=UWB$2V=1=#;(SF9M/9"(OB&1'#BQ$&C)H U4.VIU]6NHYU0T<J=:,?[:
M3, -0 3A/2U3(]_#\N_#\?/SC;/):/1A,OW=3],@6(PF4C2$6I5P&0B-[$5+
MC/1.H+V%S&KWD5V3Q$8"M0T1\;S4KS/U-("^!Q'%,B'P<#:[@C100F;AN"*)
MEIY<FL72;4+CZN2:>Z95DKHRREXAI??&H-VI__7H;F-=; RIKXL[0%P\TWE'
M+=<W:2X^T#)'G00C(5!/9+06Y9D<\5+Y'*!,+&IS_%GO_2!W!ML>--T6RI?+
M].%5^G+Y'L/OBQ_-!@H$,!XER4J7V3.9$2=Q/U*.QL"<4K3Z'-+5*.N](<YN
M45I74PULWZ]PM1C"=<]4")HEI3 HUQY#,XZ^M?4*B/-622N5A%#[7&TEPGKO
MK-,W^K;04[O@6RZIVVI46.288"2_T.L@"^\-BYYD":PT5V%HX!TE$1A3N.Z\
MZ2#U?VTR>V^8TS<PJ^FP79@NUMXK'$)I@0[>EN2!<I9%2ZFTU,0HPW1*PC"Y
M(Y2^067O;77Z!FDM#3: T?L4Y=G%Y)5KF@6GX2FG9X"BG@WG< [3;\,(2]&<
M09Q\'B^>LAS(*8TP)DM'E&6^#.0,Q!OEB0>OE'**T5S; ^V:I][[!>T,_TVA
MHX'5LFZ=S-/*F$46*C#@V2XRQ63Y0Q&KBZ\51& Y2>!0NRRO MF]=S[:&>9W
MK>/VJSRVK7FQ,NH@D?T@ XK$.5S?0LE2%DDS1AA1LY^I_JG+#BA-K()=8:']
ME;%UQ0LH8=%%M"0!17&H9(@S&(=GAD$W;H*&AEUM!CNI?V+T9UX<.X7#QN[0
M-YB&2:6%\:#X/2KNN(B):%&:."N+ C7!$K#HRKD8&15]MQOX*2[K-A1Y ][S
M:]>,,JHD+#-E9D%QF5@BWFE*4J(Z"RF"Y[PR<K:Z\OTI+L]J*&/+V["#<6KI
MQA==D*P59R261EE26DDL#8E$!<%&\*(^#'=XX\M^GLNTW:JZ*LAWW71J[_RW
M#T<G?^^HS=3=TW?36.IE9NJ7?.[[V9</H\GO#P:E@A"9.4>29[I<SBH2@J-$
M@(K@,-27H792TEOT5"[P-)()]#(C,5IS-/F024BX((/#!1F0,B9K%\PT6N"Y
MG>:_4]>YCI@;\-;.K\)LF(9^>GWN1W!3_+JH.=,JLDBI)CE&@=;36.*<UB1J
MZJ3F@J7J0[M?):81Z&R@X:=@J2+N%G!S3_ZQO\0O'W2,NLG8SR@::G+ I91Q
M43D.RS[@C"40-MJLZJ>%?)>JGI%41_U/0557%WTWTMZ;7WR!CW[ZCW)>@J]'
ME^ZF.H,Q+Z5@CC@=/)&<)N+*$$V=6!8N" !GON?OO/V*GN%169&3ZE)MP?(\
M3\#WH)!.(XFG+./VK24:8ZY)L%ZYC(&&S+7;6#=>\[+5'K6=@!N R#',BX]W
M.IU\&V+,\.[ZTPS2X?ANF.$>KJAORV/:6P_0@DQ:>PQ2!4.!.<E)T$$0FP%7
M"Z72R-HMRM:GLA$W:$-</)]>U*62&H#A@S-<2950N6SOW!HBF3'$>DF)0GN>
MC,X9Q=;SL7E7L.E:SZ\?G*\C] ;@\B@-I^30C.-P!(^&?%U,UA:EC-10H,1G
MC3*@ K=YICPQV3&1A)=,U@9>%WSTN[GN&,*] Z&!Q?#K9))^'XY&]\/.E[VW
M=7!"64LTDETV'" !%,.H"=U4C5RQ6+LZ]65*^K6I_2-D4EU=#8#NGOJ3?#09
M?SX:?H.T-YO!?/8;C-*'R12E..!4 L-E3+(I4SBMR"@QA2M=&B%!&7"L^N3H
M50CKUT8V!\GZRFP H>\!WQR'"ZWBUR.XZ="^=UGNQ?YKF9R><I3!.T-B"HI(
MB>P$E2+AEB>FRO@"5KNH=16Z^BT&; Z?U579 #SW8IPN^7C 1!D)-(N3J]+,
M;IQ.IW YO+J<'8Z_P8T^!D((C3YZ1F<)O77)RT6M<)Z(S#QG'*RPM:^F-J.T
MWXK"YB"\ W5OFQU:X3CZ 6^WR;#[7_SX,R!39V4$UDE&,2]WED'0)MDRIQ",
MQ@4;++K\7@<2&/6Q',X"?=(M^+4CZG5>VV]!83.X[%A?O6+Q[A3NY8(T1KD4
MR4A"O<%X,Y=[ 1$EKBG-8P 1C*S>]JG!LL%FH%A170WLZ\^3O^[D=5,?=C\&
MF!DI=6;$&&;*;1(0+[4@T6OM9089JX]-7IVZ?EW0'1\C=:2T)N%8/)&K(LQE
MZA^N?!A^*S=A*/.!*9>F$GE*T:,0*5-E8%L@6;&H?:0II]JV<3T*6^M!50<G
MWX5C-:6U4T+T(I,+7_B>NT'.3-N4&,$(KBQJPXB+TA.@+&2/OK%0M2=*K$)7
M:RVE=H?";134A%/XG"N,N[[Z87I_0]'!'\7W@%M_^,;YQ;U%22$ST=JA((WB
MZ(6@8Z,U%=$XQN-],4UG0%R%TM;Z2.T(FM65V"A8;Y?@J;\NZZ\<@BVWAJ.A
M#\/1PB4:0* .@K8$E"K#5A?CHV4B1B90.DH1JS?\WXS2UMI.[=B.5E-BDX[F
MP>77T>0:X P6[:0?\A;!^60#$,&3)1)<)$XJ2@PD8734SOK:Q^[KT-=:TZD=
MP;*2PIH$XWXI>D*1_7TX_[)_-9M/+F%ZR^#U("89J."&1 VRM,YWQ%$AB0]"
MT>A#=*[[W?U-$EMK,;4C2-936Y.HO)/B4?G^GK% N7 <A2AC=$1*3XGG/I&8
M8]0Q.P&B=M>SE8EKK=G3CI!80U5M8K XR*4L=-'#9_[0ZEL5% 2GB7'H)4M&
MT>H'+PCDY%22AHM0NZYI'?I::\&T*R3645@#8%S]E'<0@Y&\I*7&A"ZQ],7*
M>R=(LM[$Q+5+O'8SC=6IZS>,V?%9>4=*JS9?N#H<E_?Q+PLR<6X-30F92VC]
ME6?H?"1)K&9>@#$I^]HYP^M3V4BYS5&7M1"UE-2 53SUU[<-)N-_7@VG-Z5H
MY:3@OFG2P)G@LT<#'X-#SH( 7,(I$!$80Q\X2*5JNX@K$=9D!44U=#RMH*BN
MJB:.'5%\$2#-/J!\/_KY#1^+(]8EOV5>O1^-9B>YY(=>3&Y^Z?H!TRR&)- W
M)NC=H.U/8(D7UA"FHC8^*&&K]U"H0':3Q1.=H7?':F[1MJ(,T'&97Y?VC'/D
MM_30^5I^9> \R^BT\[(U48SN@D9?FEJ25,X\JY1B]>E>JU/79';&SJQL':4U
M86I7%R5&D2(HYR6ZSSJ7J8L<_:<R:M@JB Y48K;V(>7JU#49 G4%R(Z4UFX(
M]&$X]N/XLB"Y]]93HP@X-/ZRG#XXB:%EC*! T2P#K=T*:GTJ^[67NPF!:BFI
MA6WZ@6=2VC B7W"2'W1H'#!.G>,9!<8-(Q(7$K$.&:*>4V\=&,IK&\/O$M5D
MZ%,-%6\XC]NKJ 7,W7@9-[>?%Y,+_T>Y=OJR[%S\83)])4%9\\25#X)D5^KB
MDA'$0TY$X1(.7GB?374H;DAKD^%-9PC=A4*;<")?7HO++K:?QJC40_Q@C,(M
MJ28O,[UH3W_7.G2Q@$^^EA_,!E:FH"7S1"BJ4!PTEHY*E+ HF30!5SG=C:FM
MQ%"3L=-NS70?T&C Q*\N^P'R MXG0T06&!Z4=KP^@R;><OP)-U14OX%?G;HF
M@ZVN$-R1TAH(M@YRAC@_R0=_Q$71W1EN""?CPFSY_W*H\<V/ECL8RG$8<;LH
M/\"%^OB#![\YT-;CPBM5^4%0% '@BLP1"!41<//"5:EKWY-VP$:_ *\<KO6M
MY@8,[U;,+D>"/,^#N-F0'HIU*>I!SE:HF 1A@F+DH35*QX54;KNI,M$S1FLO
M@MURV&^":N7UT3 X&M@DMK,3@H:D?:(8RL0R3M!EM!@Q$P"7!$W9V.KU4]T;
M_L[27%L"]EJJVW(D _(]G3> UN0LC9H!T2 %D0)C[I"5(IPS%93P5D/UN3>=
MH[6S5-BFT+J.ZAJ9DE-2*)&+^UN;<;H+*A;BO M?@J694MPHE"EU8Y!*B^!D
MB1,R)F8EE[IVN<K*Q/6;!%O[9J,3E33A "\R@A=EB6DXORKCI98)O.G=U?QX
M,O\/F)<AP@.M,F2>2H<?A8Y]X(Q86_IIN(S2,Y([67LZ]*JT]7R]T0TTGAG!
M#O34]Y2 "T YS0\OOTXGWQ:+=6\TFOQ>3@++<?CPILCF25V#R^"3M9*4YFFX
MC)DE-NI G#% ;>*.B2>=(%[ISK3)VWN^I^@4:KM1237,U1W0=7+VZ][QX?_>
MNS@\.7ZW=WYX?O+A].S@_.#X8O'1WO'[\T\?/^Z=_<?)A_/#7X\//QSN[^'/
M]O=//AU?'![_>GIR=+A_>+#1^*YJ[ZXQW*L;050:_74R_>S'-WW!$(FSR6B8
M;IN$G3[@^"3?K L_NG,$[A<'4Y::4(8:QR1)F<Q"'+..*$@1G.**N]I'Z%4(
MWWHV\C9$E(: H\D,-YYR'S/\/![F82Q9;LN2\<58O]$P#F%V@<I^-UI<M$?M
M9'*.X!<H;>\EL<E)8A)(IQR+.:J6!+T!C_WZ'KM?#\\&++>,J4;WF@][AV=_
MVSOZ=/#Q8._\T]ER:N(F&\?+#ZJQ"ZQ 8B63_L$/IW_SHRNX!\,],K7DVLCH
M"=A8!I F3GQB@8!P5'C$K*V>P?(6/=L:X)>>?8]LQ7FB24JB%8:FTOF GKND
M1%BMC"QU<=6WI3<)ZM>T5</%4XM53PF-FI<R??7@WSX=XOHMJQ8]-G37_GIP
ML??N"/VX??SW%QLZJBL^N<J,V0V8J&21'K0Y?@_A-HW_87')'0ZI<MQ((3#,
MXHLBDTQ\:8J3N15))9]$K'THLCIUVU?DW[WI<'SSKOLRLF=O':=]F,[]<'PQ
M]>6&:]G:ZGZ1W:\QGS(N6^-)R-GC%JY+OU[A2&!@#1AGA:[?.Z\;7OKN^M@)
M4I]7^C< A$:-;0F1,0!^__[PZ-/%P?OC XR!]T\^'AR=G)^?'IR=_[9W=K")
MJ5WIN34,[?H,5#*S!WXZ1G24B_)%>M]] 0RE2ANAB.5>$:DB(X%F38"')#RX
MX*H;U==HV3J1ZLES[Z$/U)=3,48HI0A]Q3(),5$2=#:T9)\Q7]L&ODI,OT:L
M"@Z>I395$7RC-N?CWO\Z.=O_='Z!R_3L_'3O[.*X+-3#T^(FG5^<[5T<_(IK
M^NCH<.]X?S-/;]U7U+!$6['5U &C$I9*KBCAI;@>=]U(O'29,!93ID9Y[FM7
MZ#9QP+@_&>&GD])NY1OL3:<EP:F\X,6]/_,<J4=?Q$K\0Z%KXH.R)%ANG>3,
M"5T]I6)U\GZ&8[UU4/CLNK$C339J40\_GNX=GI5#KI,/OYZ<O/_[X=$1&IVC
MD^-?CP[_=O!^[_S\8+,CNA6?7,-^;L)$);-Y.SH0\7F(I(\_#TOWV"=^_QTP
MH]&*4F"$\S(X0YM(;&E PHR+.O@<1?6FEFL1N/4$K?+<^]%U^^B ?'YTQL0@
M1Z\5X5HGC,48)X%+B=Z-YRDSEYFH[?M]AZ1^S5UWZ'DV[*JB9AHU9>@^[?\5
M@[J#]QC%G1X<GR^N;3<Q7:\\J8:I6H7(2J;I'D&+(N"[XK&;XLO]R6P^6X0(
MH927W99FWJ%-,O"0<B0@H#0NM!3#D0R$.Q&I8Z7):^UN0=M1O/5TRE7?_N[A
MVQ]X TIS'2$31W->=O!#,07B>%;H"S!IJS>>VY+D?HW?#O'Y;'KE#E7=LK7\
M[>3H/4::Y;KAXC\VMI2/GU+-2KY!7*V#N,4![AVB?.0:/7=-A&;HSNN8B.=&
MD!0-2&^94[KV:.3'%&P]7:\4 I=:>D3.\LG'DSF\%+F8+!-593(KE/:WHLPG
M*@G"EC&5C#=<BMH=8E8FKN=#N<TQ\6QZ7B?J:-2>+,_.+_;^?;-CMX?_O$I(
M^!HYU:Y*RT3&"__'"WZZ<P+_BYKD12*R$8B9)#/A$$-BSG%+.YCU\AHY%=J3
M/WWT/7!%C!PW8D:,$ A<KR1QTC"2+--:^$RE[: =^:OT]'TI60<3+_0;KZ.!
M1DW'^:=W99<_.+XX^-NF"6'/GE'%#7F3L$J6Y/PJS. _KY# @V^/'-SLI4+3
M#R2S2)=5.RY22[SFW&4A.*]>,OT:+5L[)D^>>P]?"4Q&*1W)B&(B$W?$)F12
M9^&9H0$7!W3,9"/6HPH.GKD@503?J-VHE;!_FVK;9P7#'0TM53*\+)BF+ARY
MU%9:R@@ *[->M"#!,$:XSXR%J&SRM7VM)BX<W_G9<':2G^2+7R__O%_E:#(B
M VH(S0K%$[,A#J(A.M%,E8P@8^TX;S7*?H9KQG6P]]0P=Z"_!FIJ/\W@)!_,
MYL-+%-9LP$5DTJ/3"ZQDN0F6B8_ B3;)V\BRK%]N])B"?HL6^T?9%OIH $UG
M@#[+%90^>2\-G7NZ5A(5Z"6A'Y,HH)_D9236Z40"CUHD%XR-M0>EKT=AOUT.
M^T=CA_IL *WWEZLG4PS4OTYF?G22CR;CST?#;Y"6M[IW79">7O>^;/Z-H99[
M8XDUGI4$$TI"IIJ8G"&!SR'2VF6$';#1;^NX_G'?-S(:6!PWS6J>=@I[PI2%
M&)R/EH#+0"0+G-C /?%"!65PJ]+U,^-6(:S?WF[] [B^]AJ Y!'@\H)%/X?G
MK%B&>XQ1!!VCTD2W3!#5V1**3I*B3&>F:MO=-\CIMP-;__"KI:D&0'<,OS\(
M^::3,7X9EZ)ZV<[KI(2CZ*,[6P:51:])*/<&D"1S+CBJ3.V,N75I[+?E6O_P
M[%2G#6#VKFSX(Z[ J^F"LY<9LZ \5Y*59L^X PCTV(-"WUU%ZB,3+BA6.X%B
M9>+Z;<K6/TJ[T>)/?C-P4<H\>[T7N*&@I5N!EX32U)U   XJ15TJ?@.1V> R
M\5D0JZTUS@G#JO<L[?5.8-&^[#Q^@70U@I/\X)CE')\[A\_#>.JG\S%,RR#T
M^_H6I.[S%.!VKN09DHDK^<M-]_[K7Z>^_&"V=PK3,I#"?\:'7Y0NRC=OF"V0
M\" KDJ6DK3:$0E EQ\$2-!82M[E +45=>":_MVX:X>5GN)Y89QD\ZH37O_C7
M@E(#+M*]Q%X.E9]P%P63ECM*1. &N4L,]_'@"54B^DR]X[IV&=!Z%/X,]R:;
MP'\'^FP*K<^Z23_E\_Z\L1106I])#.5P!UDBUF;T$86F2;,DC:R>C+0^F3_#
M#4L=W':CV4;=_1=[MFWNN[_UN,Y:S'7H5;_94"S;%&-)1TT2)-HN!0@W@0:,
M*ZU,S"JQVD>=.VDTM[P\0>#?-NL=PNPF]$TGX[/2M&>Z;"1\/!E/;[]=I&4\
ML>[)9>=Q)6  G'%!2N%+RS5-9,@Y,Y648K5;S=?GHN&6=NL@\-53C7[4W:@]
M7*V%W.8&<JWG[ZXG7H<F=(U^8]Q++:2+Q/F,J.$2,'0)B2C!G?=!4J-K9S3O
MKC/>??.S^V<_<"4X5S[C6O$B"2+I8K(Z.&*HR(IG!V!K)V.^25#?Y2"=8.:I
M":RGD@9"DP<RVQ_YV6R8AV6^Y&VZT)4???3SPN3U>W2<GUANY,8A@Y%0\(E(
MZP!Y#9H8+7GF.G!:O6?N-O3V&V3O")T[4VBC6_$J308WWXC7>/JN.B9VN F_
MVB^/0V0B>H,AK$&7C;-R6A@$<99R%:DQ7-?>=[KJFW@?P3]]0_%5(R[3]\/1
M59F=_GBI4,,C1\^54)9<&:&8B'4H@L!,,A*H"<I4%L&&I#;:<W$=#+U^[-*=
MTAJU;VNV+MS<U&WVHAZZ,S9_/9I ^%R&?JN46*DGQ'B;14LHPCU(Y85EM8]R
MFRB9>G0XNKR>PH4)WV T^;J8]W3?[._6/;F8X$+.D^GEA\GT9/X%5])"NP/J
M(>>H.1$ZE[(<[8D3H$C0@D931HV)ZE6KU:C_&>XVU\'PFX?DN\-!GR/GIO/!
M?DE0@RDJ:7Y]["]A[X_A;$ M@,Y:$ZTX)Q(RDEYJ@C7G.:7DE>,K91?B"QY@
M&+^[Q^]K[^ZYV+HG#$PJ*J1G0)W!URN4FY_!W=7_4Y;>3R[]<#S@!IT<L(ID
M7TY4@T;7BDE#M 0N'7,RAI4*L[Z#LI4)Z@=Z=70^Z5H!?4_&/)Y\0^J'L\/Q
M;#Z<H],\P_7V;CCY"&D82[[(<KD>CN-'N PP'>C2N#SF3(*A!IF+*#[D!]<?
M;A).:^6C_9YSN=&;^X-11YJ?[$H-?6,,^?@,XX][]]1[(1U5%@AHD8E,@99C
MTM),4%&1J3#P]!;T%1 ]>W0_IWP[0LEV@NP;!G\=SN$4H_1+?T]_$I$K;1P!
MYA'&DGD21)GOBD(0QGIN:%P)""\\O)_LE!U!85MA]@V&<S^>Y.$-X1:T 443
M*5,QD'#*B2_GT#XY0)I="D:OA(*'3^VG#'9'ZM]8? U<.FT1 AP-Q["8/SVP
MCC(>!".1X=8G,2H@UG!%M)8J1G3HN*Q]!EV#[GXOH7H.PWH#0 .@?Y#B^LK$
MB]DR62:^\N,+_&J&,D&H/$VAX8H+QE$#,OI(T"$0Q$<T!RP+X#I)RU+MC*D.
MV>GWI&+WV'P]%[I7H#1Z ?)R0__-[SG>?%YW$P@ZO+78LL^[,)HFDVSI(Y#0
M);&:N!PDL=ZAKT)]L*IV$ZE^YQ \N$U$P$RN <YA^FT8X;XC_4.B]D:+1RZ.
MS,\@3CZ/A_^%1,%T.%E2>K_<G$;W+7-# @VEYV,N!36.EF;6%LV#0:^MN[J3
MRLS\T+,+UL'T&Y?-/<*C46M<J\9U+Z5A(<6/#L=E3UW0]1[F?CCJM1SX3;I:
M*A)>78"5=IDGG10?30"F.2MM$\'P%;T,5;ZB3.*Z V!4EHX+M6]K7Z>FHM_^
MI7A8A^/[=]UV^EM&1-+E:((N.7.N9)=X7-C!!<*-DQ[C\>1<[<J.E8GKUWI7
MPLH;GG)%U;1X;VRY1'$8CE(J\V\$! RVE25<I6"8T@E6:]3U ]\;5U7Q]ZZ%
MUY'W#W,MC&)P'D(DP97L-Z?+]$RPQ$@*6C-AU--#UO]6U\)KZ7RC:^%U%-#W
M\?Q+UPO!)EQ;,1.:RDR-) *QP4BBD@I"9G1F8;5^$YO>U?1\N;N6_KYW5[..
M,!LXOGS=_-Z?>BENK#24EB6#\<QBH))E0)A.SE)A8_"UCR%7(*N5$_<N-K"N
MM-,"X/SLRY,:^KUQ.O\RF<XO8'KYH,YE$+P0U#MT&FFVN"ZCO>GT)A6N3*.8
M8[6'(JU.7;_^4W5@O-"IM ,M-8"_8Y@OYT =36:S@= :=%*)"-"E:0-+Y88U
MEYE2-+.8I BB,L0>$="O$>L:19O+N@&@G)5#EC&DVU(4%-+5Y=7B6/(]9(QV
MYP/'H[>*(^J#+P5]T1%K="(FH%"HLQ*J&ZCO4]5O[Y:N(559*^OCS"UQ-H;/
MY9UUML07FO@O^C#L+UD;?H-]/X]?/GW=2__G:FEW+R8W';]N!7XKYI/\X)[P
M=#J,,! 2EYU/F2BG;>GM"\1" ")TS,:PTEFI=DI%QRSUVPF_\\VW(3ST':_B
M_C$M#:O?P_+OP_&C365O/I\.P]6B;/]B<KI0W\#9TF+5E)P5&DI/?TV<*UVM
MI<A1,NY5?+*IOQ+/;O#R?EO<=X7,G:BB/:B]6(4Z4 82!T9)RJ(T%M.,!,$U
MT9075A4%O2F\7GQAOVWK=PRI[46^,8R^P31,=@.DFS+F@0?JD]*16%F&SE(6
MB//4DIQ$%EYFSBVK!*6;5_;;9+YG,&TB]E[A="NW(Y@7(W>2]_'MP_G)U7PV
M]^,RY6;OL@AR( 7SPIG"!Z=$1AXPMJ(<=WBI 10XG6I?S7Z/IGX;Q7?MHU75
MR$^>!'+;FSBOU?[8O];^N('TD8XX:BGQ9!=*:ZJ=0V8BY"P],8Z7/ 6CB?>X
M8&T4Z&8PR9.H?1381#L'?'%I);[4Y-EP]H_EM875,HC(&*'2E6G9MO14R6@<
MHW"^6$<9:S?">9F2GZ'-PCK8>N$T8%O]M)CZDET2&K(GPBUZ?=,R>$\Y]/"M
M#>B"B6!7FG'SPZ6^U-#G]_)<UA'N#Y/GPA5D!Y(1GTVY;6*+]2-(*J4700KE
MY4H&^B?-<UE+YYNU/UA# 7T?YCROJ!: AM9H1W06Y6Z <^*8TB1;I9(OR8I/
MAVI5+4WONX'!.KI[NS1]'4'V#8.7,G2D]E0+L"1R7:JI#9# +1#.E-0VHZ3"
M:H<NFZ8[]=VE8%,H;"O,OL&P=B\.ZP2*Q'ABF2Y]4Q4E%J0A3JHLM _)JM6:
M&'32$J7O#@>;PJA3-?2-L4?U^\(PILK</QV3+K<?I8U+EH39R*1/C%-#5\+/
M#]?^8%-L;"R^!A)&GCGV[Z[?P3A^N?33?RP\M!"#HD*B7V9+]7!T$A$-AJ0
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MF+V',#\O.]#-)K7@T7DCD(TR^0AE)RE3Q.4() /-*+*4E:H=AFQ"9[_Q23-
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M<\1&C09<.YL22.98[7XCCPCH!U9]:'Y22PT-8.CO,/S\I4CB&TS]9SB^*L[
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M8I Y,^)M",10XYWV+ -4GYU<@_"V,BPVPM>S%/&=*[11._EQ[W^=G.U_.K]
MTW%V?KIW=G%<C,?A:6E0<7YQMG=Q\"O:F:.CP[WC_8/SX\DW/YT/9V7.YG".
MF\4L3Z;OAI./D(;1C\Z0)F3QR^$X;F%3.Z>IAOW=K> JV>J3Z6<_'O[7@MO]
M,M)T-$S+A3Q.IP\D\6"BZCE^LCRWN5MXX'5(3%GB9,RE%5(B%BPE/'%CF.),
MR=K5+%4(KU=C=JNNXI+!-QA-OCXYY+IM3G@Q09-1^KA\F$P7!=(WF8C424&]
MB$3%A)9#H/1<RH$DF:6GS%(I:V\%]:CO=S_8/89?+U_;*0[Z3!J=S@?[9<N#
M*2II?ET2N!=5,%FZ9"52;;6#TI\=2 C,$&%"L(Z#BW&ELTY\P0,,XW?W^'WM
MW:W4M.T6 Y.*"ND94&?P]0KEYF>P]WD*-Z)ZS-)-D4 N[=6LYT1SZHE,"9?M
MXEI,:N^H-D[(E>Z$OH.RE0GJZ8BIBLXG72N@]]SV9Y[6AU<\K9M2D:!$N5]@
MA%&#Z\\CFUYI0UBTP5AK,W\ZV?"U5/8UW]P?C#K2_&17:FC@_+*4,YWD!V9^
ML11UC%(&%%*0"6-2%S$Z9521@ _(7GK+7.V&L"\2TDIM3B^;8ST5-8"SAS?G
M*,7CR=C??W*!7\U0>JC7V<TR LH=1SD1354L\Z$4\4Z4A/V("\O@1D%KCSU?
MD\1^';<*H'AZEM2AAOK>3/<G(_QH,KT-L(Z&$<8/=HW;BM\(T3/K2%)!8C25
MT78SK8F2RGJMA>!<K+2%KO:^GOL =*GO2;?";\"@;;$E'-T5DGCFI98F$.K
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M6'QXN1W^ZW)V\?/JXN!$EI"83:S2[=3F8$J 5YITIP4Y,+Q(FL\&F^'ML?:
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MTYX4>TV4-G)G P@AZ>07&"$8[<$Y9H)';D3^F[WFZ7PTX34W)D207$A0G&M
M2_M,<4F$*$S*=ZO!_F:O&0W#6V2OZ8.#*;+7,"X""FEKA]@EMYHF3XPF48KP
MSHF8?2A=</Q79J_IA8'GV&OZ&.3%L-<XD;,MJKYUA4HUE<C?MT8!L\'+F#!:
MUXE<>4_9:WK9?!![31\#C!UP73E2ZRIU&W.0I(M8:*]7EDOPWA9 H90HV7*G
MNB4AW?[4E\!>T\MB\Q;JFX;=CU]IH=?<.RH5B4*#T%*#2A@@V&PAF9@X]XEE
MH7H8_]9'CY/8NU,$#%7D-&#PVA]]^LV*E?PA\$1"4RPM0@%EA 7,R8+Q-LJ<
MM2&GKP<0?OGP<;)A=PJ%X<H<V<-893,>G:\>3):GI>%1\HP.<BB6W"V!X)5F
ME6<$+6HE?6I!A??0V'O#7S749=W8(-, 5"UO7,U@L5IBUD5,N=2UH".H$!%0
M:DU;)'EBWJ48?*=2E6ZHNB_ >#[)YC:]#Y -%3SV&73\ZK?9O_/G/^?U?^M2
MV/745MNHE4PYKP)XE+5?(R.GG0<Z78OF3C@1E.B6U=9AL-'!L:D]YUM4[MA@
M>4A^0^>KM"@A>ZRYGM: D\;1)%B*3!7A<K<^PD/!L!7?=0M@V%1Y$WB87M=B
M7"ME-0WA@]4L9,B28SUC:\ER]J #:29:GKAN37#^B"CCN;AM$=-2XV/O&J\_
MS,XRN>7'-5V--L.U<RZ0>9%J-Q7K0$GRT'V2"(S<,N-<-BQVR_M_^//'J:':
MTM[10(43V#XV\.5?_:RTH4M_35O'>: #D[PV3Y,N 9PO$8*(*019E.KFONZF
MTOI&\+UA.AP248T'@9>-^SKE]>91! J="PA5;T8L.0S.FIKTP90-(FFAXG1P
M?R/XBZ7*& JX=I ?:/VQ#_P#L@G-M,[MJ%P7TZS+(F\IX>W913X]S?'B$D_I
MU/R>SR]^DIH>*IM<LQ<6VERDS.",K!PC]2V<Y@XE)*YBT'20=GLDV9Z,+Q;O
M0]$VGY[I)[4"?IN=+TCMW[[E\V6&!Y[F>Y,S4F2)CH'1W((B-=>>@QE\EL)D
M'=#( ;CN,/*+Y7UICM;69IH4!J^7XL?S'.^OQ@<6*)FDBT:4+H$K[\$D0R&-
MEP)<HJ7)LPU226LSZW;]LQ-Q7RP?S/;VYC$!,:DE<C.O>W,*3"7#709A0P*5
M70%7>()HI4?DT7G7K>"LXX OEO^E.4P;&67L]+&JN:O\)\,3YPK!8N7R5MR0
M.T,A!7->%RV\5+%3\<YSZ6'K ?>&FGKH,^XPU4\!+RN8>ZFY9Y*#]*F0RX$"
M,#H+R:/4@AL5=2>BM2Z(&?L);J"Q[II[@.9&-OA[.FV_77Y;'Z%H;<S*0=*:
M@4J6'$Q1<U>$04.:$:&T,/DO@XYL]"$FF[?0W]B&QQ^W!$_1T9F6+0C!'"A=
M&Q4E)4 )H57V6G+9J5KE.</?'G3$_, 6AA^LOY=]+_SNI@Q0!U4*=Y!]?0E4
MU@!*H2 @$UGS7$KSM]>_Z;K'?PT9!H#1 ZYU]N>M&M3Z[8ETAN("E."M(2U:
M&P 3A0Q($_,N!LD[DL ]-L*+O94=:.AY:ZV_[/WR 9)F82A03(@@*6RL7H("
MU"Y!49Q9SH5794+OR/O)V#T T>.#8>Q-=$TRL9[@-=G$]17)1_RYK,\_G7V9
M57K&^14K2CZ1J3C+K(=H1*Z-HBFL"LX!ET;+G%BTJ5LCM>$RO-@KV 8;\8XL
M-S9 #[[0@5/9&@Y26C)+X.D-5=G\R]GR=]=3?I\OOL[3ZB_<G[C(F)3G#$RR
M%,R)Q"&8P,!R(XKTFB*Z;F1R+:5ZL1>T3;R)D:P[-JR?X-TK4=H@38*0*L$4
MS^12(5? =-8R**^DTYU NB'CX<29M8="KI'FQP;0@ST85DOBT_PGGE[,\N+S
M^>S+ETR2O?I)FHS5R%\H3OV0+^ISVX)^MS) 7E/CIU7"Z:N?MVOJ3G1)ELX&
M!&9LS5F2K/:3Y< 81N%$DM9W94G<H=C[P+T]V#V8+#[&7SD/4TZN*?=O'@=7
MKX?I)&KO(V8.Q49%)PMY],Y'"4*X:%%SBVQ(@^DN8^\#Z_9P#&_54F,#\:ZC
MON*;I%G0.<.T8 6*UQ1!8A"UUIB1VGB,MM!Y%'J2'M\=8A\HM#?V #;2^]CH
M:=7;AIE<NROH2@R>0'GZ$B@Z!$,ZY++X+&2W@LQ=]BN:.!MW@PUO9S8=&\<;
M=[IQ4I*R P>KJ]>>F02G%4(ISGI/"SKE"?4KFCJ1]U#H[M2,8V.V<Q,&D0(Z
MG>L:K!SZL7#PC+P3P04ZY,7J,5IC3)VZN[6_N)%9IHJUM:I79:&_Y;PX\25$
MR8RK#19I7@0C\!@=()KL8_!<^+(1W!X8="\HNULC;E/C3.*!M'^_3^>-"C53
MAD>N:UF-IG5E%&AK65+:"GN7HWNRC5RG3MB]T6OG=BW;#+QM^;C?OO]X\/;3
M^\,/GX]^^_WHZ,U_O7WW[N##FW=''WY_]_8?AV\.CH\//Q]OP+[=;X 67-L;
M3*D1L_;O\WGZ<W9Z2F!^2S,X6]XO5N!<+-[,%O%TOK@\S]?LPS+8**U.-:"6
ME;,@ SJG(,;(4>5:"-6)T+3'_M!+P'9,V6^_?<=9Q?W\[,N[>K=P->1_Y--$
MDORQ7%7UR4%CSD[$"%K60T': DY% 3()D;W+)M^EZ&M(B-U1R''3G;:'L,?Y
MK;=AO0D<Z>O:V(^GN"S!.OS7Y6QY^-RJ3E>\=GS 6A1;V\T'3EZ*"0)L5$*5
M3'\J6I/<=Q!K*J376P'&?+M6FC+P;M5XH8_91&7 :U6?D)@%YU(!0[KD,:.W
MJ74*70>QQ@5><RATA=I NTP :N]JDYFO\]-$2[5>C2ZO3==5?MDGD0HYS:P$
M4,Q&"$Y&X,D58RT7R<O&$'M"G(E":ZCI[Y*--;+#!"!5NVU<G%\N[X_>GI'B
MOI"MUG.).04ELP+.O*VTP +0._(_F"G<!UTH.FB,J:?D&3>1=]N@:F:)":#J
M>5?B)MIGC'O!D@"S="=8<A!2]&"4JX5(7'OLU&ZD!\AZB#<5>N==.&?;LMH$
M +D.M*ZF6%?MN_EB<:*5"%B"@V1#K#0E =!J!T)[X6C!%M6\Z]7#DHQ[7F[-
M\//F5AC[Q>*.BM8O@U<__7X^O_R^.,'$$JH8P.K:84,8#\[0?%0L(F%*3IAN
M+Q4=!AMW?]HV<+:B\@EL1T?D29"1:%[+MI&_+H<2/:JL-$ATM!R2"C07P\&A
M=MFSQ+04C3>EI^09MPYE5UM3,XM, %TWTA^5!_3VV_R<]';BF4I9Z *TOU)L
MS5@"\B,#T'3J8YZ,*%K39'82;-R2D5WAK;V-)OHR=?SYZ/5_OCHX/GSS^NC]
MQ\,/QP>?WQY].+Z8QW^^HI66?JDQO.J3N\$SU0:CM7BS:C791@]8-V\(2X*H
MZZ$_Y=/:(OCU?'&Q./Y*ZR)4X=89H]?O#3Q@#CPH2*ID4-D$\)X7$":4Q'),
M-G>B5^FQ0VPF<;LGKD,"V_QGSJL<A^60]RQX<+K\R&5?TE5)UW^34/E\-K^2
M]"HD\]))84N$O$S;3AXAB)) EL"X)<_$V];G^58F,FZ,LD,L/_YV-A8LIN!4
MG-$NEZ^[[KY;37%Y3>]YXL(YBM@H9 -5'*.#4#'(*9..R4E2L?73]Q/B3.4]
M;32PW'4U&EENNB!<W;Y&A=H+$:'H7/.&@@:7%0>T](O,HW3M/=JG!!KY4J>5
MV;O!:8 -)@"HA_/55J[9=>,II1E&#@95?8G, ERQ'+)(,= W4B36&%8=Q)HD
MN(: H!-=R7"+3 !DO^>S?(XUR><@?9N=S:I+4G-J?YV4PT2.B)8@I%^VN.+@
M-&WQWC(5>?$I\=8Y IT$&_F&<6M :V^5"4"MC<]Q<\6!Z!PST@-C+H&*08*+
M,H((1L0<?2BF]9':> I3><";BC<X)D(FL$!6,\OIX8FO%O])\5DF2SN)5Y'"
M18H1(?":(2XX3ZAM8+'UHW0WR<8]]D<%SWSKEISR%>I_'+U[<_CI^/!___'V
M\__=](;TP0]K=@'ZO*B-[C=K"L[%S^L['G08C0@*"CJ*:F(ET<^\5"^Q:&L3
MU\VO(7Z5H-W]XR,KZZ:.9O'JY\W?6=UV'?R)YZLT$*5,+$QJ""63VT*: 9^]
M!2NS]R;;K%0G^OQ!=XX;"C_R%C<<4X_?&^[2G",3==^FSOF WZ[R>'WAEL(R
M!,M3K%E)!GRPA;[H4+2V&._2?@WBZWYH[*G<!NX4 O.&]AB[Q4/^?GD>O^(M
MIHB[4UH'@R5JY#9#\J;VG%(T'Q8\:%*<URYH6K -0-99H/$Z!6QN\_FV#3!V
M'M?_RH4&G>7%NW>O5Z&^K&V =61@1<ZUE48E:3 TFYCYLNVPZ-B\Z/YGC]@T
M8CO6F[=3Y02"PN/+L)BE&9[_K-1PM%?7!_OEHG%)%>0A@?",%DWV$E#[ B6J
M0%&%=\EV.KCZ^%&/"3.5FXPQ3K*VEIH"Y&[$KVOPJ-SB\5@MR&2$2,OB]Y3(
M]32)@9->0]:.UE?FRH;6%\+/2S6R.]7&_'=!U=868Q]M!Q>?O^;W>/[/?'&T
MW)G/OESO_>LB)4_[>;TQ5%886H)2@4,F06IC(MH2L^S8I^_9L48&3&/3SK>G
MYREL2K2\\K\NZWO;OU>%35=-QFR,HK9NB5*0:Q!JGR@M::WIH"/]7H>[U.)-
M3L$'1!DW&7DZ9^"F5IHFV%8KDGG.T2L'I E:.LPY\AZM!XY*!68]E[%UWN&C
MPHQ_WFULZN?A,T#OTP/0NO-T]-SR6""F6O_A:P&<5AR2,#&5* (7K5]N'A1D
M<L 98N2GH3- XU. S7-;]V,[]\VS%8^)L^P2>&X4*,<3(!::-E->EZ0RTZU?
MQ3>7>BH=;D<].G=K^[$C@:7?N_9-EQ7E^&W5"/(?>'I)NK09DS?DFL:$0!%4
M@:#H'$F1*YJ'PN"Z47@^-]+(N^&.S3[?E@U&!]1-./7V+)[74KG/\^L^-S>S
MK#RDK#!7G+7@1:K<+121>Z%K*)18K9D+(=MNV.H^Z,A79&/";$N6F<*!O9S4
M8G&9TYO+Y2R6J21+52X^Y#^7?[0X24EYD7F P&HN8#T7G.4.>&1&AQ2,L)V>
M?_H<RITD&SEF'0>46S3>%"!YL]HJ;<LLY?-5,=)5LX6CVQ3@)SXI7I!;\E@$
M.<@4H@'FFFU?C$L<,173/)[M(^#(GN'( -V:*2>:3?;VP^NC]X>?#_[/X49\
ML/<_I0GIZS/"-4H<N\HJ_XP_'F#9-,Q:KK4$6QGZ57"&_#%>  UY:J:VVE&M
M64N?$*=-Q11]]"H?\E4^RV5V<1*MEC$P1J&Z=)6PVX,KRD,17BF5O$6YG5JI
M>Z),H9!E<R0\7"6UF=XGNH$<__&JYG8>?OA\^ _ZLLDN\MA'-4E%[2)FH_WD
MSL783=EQ38T0]5G2)!_J Q"=4<$Q**'('&*J61+;O8UL5QQ_YTIQ>1DC'7=6
M2@G2"%D+<,AOXUZ TMKFQ%,D1&_YJG[\E-$FUG_NFKZWNJ?@)C_R?*&1W"5=
M,FCK*G$*P^JO6?HQ)F50>.Y;)VIO\IZXLUOZ_C;N^#381^'3Q,WJ]<(CQY)9
MHL#0^-H&60'*$"#*['QQP3N6MX^<*3\-]C)UYZ?!/GJ?'H"NLS&,+C8)$EU%
M4!PK3ZN,4&**S ?/9?I+/PWV,G*GI\$^&A\[S[Q>-RQ7$ 9.LU8!A&7DHG.?
M(4CM07JNT"D72VR21[X><.1+ZU9GT' E3L'R:YYEE90/E=+-(4U<!@DHG *+
MG#LT28G2Z:JNB^U'3PT?9JR[YAZ@N9$-_GYV5I_?5H)KM+QDI2 Q.B85G9^T
M6Q4&*982I!/6A4XAVC,F_V70D8T^Q&3S%OH;V_!7[ZXKP5.M/ X4D\G$=$T9
M)M1;Z2%F6SFTE4+=B9?M.</?'G2<O;Z9X0?K;WH^X<WK04";>*@,GJX>=J&F
MEHCLR0O*T9&['%C[A\-'9!GYJ7#+X>@PE4\ .I_R56>&Y0/FP5FZQ3EXW;1Z
MOIA5.RT.3V??9F?UCT^4E<5R42 ;TIKBG$*QXAUH%5@0*F7-L#&PADDZJ8!D
M($KNTTAMVV0O%IA73_#T-9*Z3TRP)CDZL(NW]3"(I&7O"P2&Q@B>$9OWIFH@
M]J2"IC$A.]R8T\9O?3>+J^_Y"5>6:^9I2B)45G_' %/14(J0DA>F4;2NP^PJ
MVZ3.[*TC<;A9MO^:N?J#^J62 /_/__'_ 5!+ P04    " !BB:A6J*Z(#!4(
M   /)P  %P   '-G;6\M,C R,S S,S%X97@S,3$N:'1M[5IM;^,V$OY^OX)U
MT&T"^$U^R29.-D":N&B ?;N<#]M^.M#BR")"B2I)V7%__<V04NS$2=?=[7:]
M00LT:XE#S@SGX3-#4J??7;Z[F/SZ?LQ2ERGV_K\_OKZZ8(U6I_.A?]'I7$XN
MV<^3-Z_9H-V-V,3PW$HG=<Y5IS-^VV"-U+EBU.DL%HOVHM_69M:97'=HJ$%'
M:6VA+9QHG)W2&_P+7)S]Z_2[5HM=ZKC,('<L-L ="%9:F<_8!P'VAK5:E=2%
M+I9&SE+'>MU>GWW0YD;.>6AWTBDXJ\<Y[83GTXY7<CK58GEV*N2<2?&J(?N'
M,#SL#N (CGH#&!Q/HR$_3.(H20Y[R='+Y'\1&ME!\=#'NJ6"5XU,YJT42/]H
MT&N_'!;N9"&%2T=1M_M]PXN>G28Z=ZC/8/_P,PRS,9B#6]?B2L[RD7>I$;K6
MS;%6VHSVNOZ_$VII)3R3:CGZ82(SL.PM+-BUSGC^0]-B&%H6C$R"H)6_ ]J$
MYOG'13#Y)8ZC9 ZU"U&/C![?IG(J'>M'[>B^Q>N.<S-#WYTNL!<.NV9[C),-
MYJL8'\P0$&O#"82C,A=@2*IQ=C&^GES]='5Q/KEZ]W9;O[ZX%X-'0W#59.<*
M;CE9SR[;[ V/#8<FB\$XF2R92[E[L3<\.MG&CT-467 A</6T%"1N-!S4 9.H
M('>C%KWY2JY&[=J'OU_[_6D9'+:'- U7+.5S8 ;F$A;(.RZ5EOU6<H.H5DM\
M7VCCF,[93]ID+.JV_LUTPO[#\QG/-)ND8'@!I9.Q;;*K/&YCH(Z?0:!Z.Q>H
M'[G%\& @LB6[R?5"@9CA(O'QJJ(D-)J0:TPBJ('+G/%\R<K<F1+0 TPK/L-@
M^#C+\,E(KEC"8WQEF,Z0!)T.<AL".<1@+3=+$LGX#:#>M3$MOA-H#*I4/CVA
M#A*(I<%TA&(Y=F>>GM@BE7'*;$E_5OT78* :A!S(I%68MR@%+J1+T4%;0.P-
MI'$+-$T+='..W02;+M>GX9D@L/_M(!!8(G.,,<%E%=,FP@_%L=FLM<L\02+Q
M^0I_QZH4.";B9BV 3<2<)/(I,.R$6$*R4BM(5FBP#U0CZH6OQIHD42H40!QJ
M!(M79[T],;<I2Y1>V!JD!F;2.BSE'./T,MB-5C;7L&9K8S:L?29P&^P<W";W
M8O-B[Z@7O3RQ%:"JVH (0B>)Q,=]>^ #=\6X 0\1#+F<*J!0,D!<3I6T*?4@
ML0SYD3B2GH6TL=*VQ'[$G$:K@)7"Z!@$OK9L'Z$A +$6XC^^C5-,@<#.D92N
M2X4249^WHN$^!"NBH0A/X5%2D9@'C-+XC)AK#;H!2F3+UHJ2>XH25$1^/@0T
M2E!^__3R*>H>[1!*]_G!SL"TUSZ.:"(NP>)& ,/E<]K'L=2D=!OSTF[?A?+>
M%! 7E::0275I< #DI[FTGO50"G(_#I7,*[Y<YUP#BGN@5:ET!99FQ<?4*)$[
MT1:KE11^.VK+J95"<B/) 1D2OL\".8U46DK"?FE:G[$]1^)^%PW"C:CO5&!-
M*>-2<:)V=,L;L4KFV".4!NL5#?Z: @DB^V)_$)_.MCL&Y.DN ;D_V 3R]I3U
M ,[;=]P:U;@2YE(06+G5.2=2YQ:!3G4E(9@;4:,)\2WY5"KIEI3@'U-+:\L#
MSV,J+(M[HFMUJ<\=MY5#16D*Q+3U!4F,VV[A#? 5Z@QRK#,40AM;H* U0R)8
M?0?XXMJ2!=+WLP%PO$L #DP\GG-5>KJB\$*28)$HYQ@8^TBQ=U=0;$&_X?'Q
M^L\#%CLB==I094YUZ9ZV8)L$P>^D@4KHY..;'C:MBW._!B',!-KC\48*G@/F
MQ"YAKB+-$,Y-6-#>NZK=?,NCV/L37$D97<=Q:2CX:^GSD5$S;1V^IZ-)',O&
M.%!UHL/VG^B2((J1Q1Y(5X;CG@G\L0&=*.3EG5T'P:J4V[M:@_C/HQZ$KW/\
M?%2DO61*WH"JSA >R#<_>XH^#^D[M1D;/I_-F#]=%/4B::YXBFAS':@KRB*H
M;1WUYF8A>V<=QV+6:6/O,KY_@4-FF70.X ^2PE1C34'M0J)]?I!]A#-RL"6.
MQW^II*[7(/Q62C3?K[<RC_UIP\$_>ZXOE^G/%59I6#5*1!OM<VG''$M ;%39
M^F[OLP!^0^DW5&T^ ?MZTY]YUD=#?PIQU38EG#(\0FU<8$<+=\SV)#JK*A6[
M&+K#P<7A:P"+!8 M,P0(SI)WILHHCQZB/:O\OH.;HG-,XXE!XFABW,'3'2+'
MGU%7$&N&+"CSN59SH%28\UEUU&XJAH2L4'H)V+I(=>!$?@_ "+B_I$YH?QH,
M!AO9KW_H8>#\9JL:8HH@!=/">"A>6!C5/TZ0WPO%ER.9^UGUG4XJA5/MG,Y&
M=%D\ISR!]45U=>KUA>;J'GEPW#X:]NDJV1G\7]2*JUOFMK]E[CBQV79\U#[N
M/MW<;4?K;6BX+7C^JM%OU'*U"[FFZ],@V?%6F*>Z5%,XZA6W++I_*TRS^M#=
MX.GZ-?G?"' _-Y>(6)^5V!N^?+$7'79/CIK^4X('=_6?-$VU2*UR& #TAU/7
M99[.=R0P7R,F+_8&N,#]7W;^>OS+^=O+\;6_!3^_N#X?WP7F+YV@:B'[>_\"
M7:9C/E;[^HW,7C3\GNJ C>\&OLR,?2.3XB'UWF"%0RSNBX>+5$+"QK<0EW04
MP=Z%"OV?:=I_'P[E,'UNS,[!YTQ/Q^>_M13\Y$=1:^GYP7=5A0X?EHW">?T<
M-KZT6JUEGU^[JRY\B@NZ=)M=/O)Q5O4W?"KF/UH[^S]02P,$%     @ 8HFH
M5C&--@LA"   @B<  !<   !S9VUO+3(P,C,P,S,Q>&5X,S$R+FAT;>U:;6_;
MMA;^?G\%Y^!V"> W^:5IG#1 FJ1H@*W-3=U;[-,%)5(6$8K42,J.]^OO.:3D
ME\19W79=W6 #EEKB(7E>'C[GD-3)3Q?OSL>_75^2S.627']X]<O5.6FT.IV/
M_?-.YV)\0=Z,?_V%#-K=B(P-558XH165G<[EVP9I9,X5HTYG-INU9_VV-I/.
M^*:#0PTZ4FO+V\RQQND)OH&_G++3?YW\U&J1"YV4.5>.)(93QQDIK5 3\I%Q
M>TM:K4KJ7!=S(R:9([UNKT\^:G,KIC2T.^$D/ZW'.>F$YY..G^0DUFQ^>L+$
ME CVLB&.^BP:'+*T>W3(!KU^&D<]WC_L'S$V3-+N\^[_(E"R ^*ACW5SR5\V
M<J%:&<?Y1X->^W!8N..98"X;1=WNOQOKHM1,0-KI8O2\<-"6:N5 #0/#AI]A
M](=SK'4\=OS.M:@4$S7RAE<CU=*)EMJ,]KK^OV-L::4T%W(^^GDL<F[)6SXC
M-SJGZN>FA6"U+#<B#8)6_,%!<YC$/\Z"88<PCA2*UX9&/33M\BX3L7"D'[5[
MZP9L5CWJK>N>0$BX^2[*!S483[2A"-51J1@W*-4X/;^\&5^]OCH_&U^]>[NM
M7=_<BL'&$%PUR358D,U+FU%R41HJ8AJ739)PXT0Z)RZC[MG>\,7Q-H8@M@K*
M&"RREN2I&PT'=<0$^$>Y40O??"=;HW9MP]\_^[I;!L_;0W3#%<GHE!/#IX+/
M@)Y<)BSYO:0&8"WG\+[0QA&MR&MM<A)U6_\A.B7OJ9K07)-QQ@TM>.E$8IOD
M2B5M"-31$PA4;^<"]8I:" \$(I^36Z5GDK,);X9X55%B&E10&G(-S$"%(E3-
M2:F<*3E8 -G')R(('R4Y/!E!)4EI J\,T3FPH--![H& X@FWEIHYBN3TEL.\
M*V-:>,= &9A2^BP&<Z! (@QD+1!3T)UX?B*S3"09L27^6?:?<<.K0=" 7%@)
MZ0TSY4RX# RT!4^\@CAN :II!F9.H1LC\7S5#4\$@?T?!X&<I$)!C!$NRY@V
M 7X@#LUFI5VH%(C$)RSXG<B2P9B FY4 -@%S LFG@+ C8A')4BXA6:'!WIL:
M4,]\T=9$B5*" .!0 UC\=-;KDU";D53JF:U!:OA$6 <5GR,47P:]0<OF"M9L
MK<P#;9\(W 8[![?Q6FR>[;WH18?'M@)451L@0>@T%?"X;P]\X*X(-=Q#!$(N
M8LDQE(0#+F,I;(8]4"P'?D2.Q&<F;"*U+:$?,J?1,F"E,#KA#%Y;L@_08!RP
M%N)_>9=DD (Y.0-2NBDE2$1]VHJ&^SQH$0U9> J/ JM$%3"*XQ-DKA7H!BBA
M+EM/E*Y-E,)$:.=]0(,$YO<O+Y^B[HL=0ND^/=@9F/;:1Q$ZXH);V E N'Q.
M^S26FIAN$UK:[;M@WHLYX**:*61271H8 /AI*JQG/9#BRH^#)?.2+U<YUW!)
M/="J5+H$2[/B8VP4P)V@B]52,+]KM65L!1/4"#1 A(3OLX#"D4J+2=@O3>LS
MMN=(V!:#0K!?]9T*J"E%4DJ*U YF>266R1QZA-)@M:*!7S%'06!?Z,_9E[/M
MC@$YWB4@]P</@;P]9=V#\_8=MT8UK(2I8 A6:K6B2.K4 M"QKD0$4\-J- &^
M!8V%%&Z."7[3M+BV// \IL*R6!-=J4M][KBK#"I*4P"FK2]($MAW,Z^ KU G
M7$&=(0':T,(+7#,H M5W@"^L+5$ ?3\9 ">[!.# Q)=3*DM/5QA>GJ90)(HI
M!,9N*/86!<46]!L>-]=_'K#0$:C3ABHSUJ5[7(-M$@1=2',LH=-/;WI(7!?G
M?@WRX G0Q^,-)W@*F&.[A+F*-$,X'\("]]Y5[>9;-F+O,[@2,[I.DM)@\%?2
MYX91<VT=O,>S21C+)C!0=:)#]A_ID@**@<7N25>*PYZ)^V,#/%%0Y4*O@Z!5
M1NVBUD#^\ZCGS-<YWA\5:<^)%+=<5F<(]^2;7^VBKT/Z3FW&AD]G,^9/%UF]
M2)I+GD+:7 7JDK(0:EM'O?FPD%UH1Z&8==K81<;W+V#(/!?.<?XG22'64%-@
M.Q.@GQ]D'^ ,'&R1X^%?+*GK-<A_+P6H[]=;J1)_VG#PSY[KVV7Z,PE5&E2-
M M"&^US<,2>" S:J;+W8^\PXO<7T&ZHVGX!]O>G//.NCH<]"7+5-":<,&ZB-
M,NAH^8+9'D5G5:5"%X.7.+ X? U@H0"P90X  2]Y8ZJ,LO$0;<%ZY"E ;0=W
M16>0QU,#S-&$P'//=P =?TA=8:P9TJ!04RVG''.AHI/JK-U4%,GS0NHYA]99
MI@,ITC4$ ^+^DD*A_64P&#Q(?_UPO>O\;JL:(@:4<M.">$A:6#ZJ?QP#P1>2
MSD=">:_Z3L?5A+%V3N<CO%2>8J*  J.Z//7SA>;JOOEPV.Z&*V=GX']63US=
M1K=]4\>QAVU'+]I'W<>;N^UHM0T4MP55+QO]1BU7FZ T7J &R8[7PCS6I7+A
MJ%?<D6C]7AB]>M_<8&FX3O_; >Y]<P&(]6F)_$KGS_:BY]WC%TW_R<&]R_LO
M<E,M4D\Y# #Z4]=UB>?S'0G,]XC)L[T!+'#_EUS?G(W?_/;A_9LS<O'AYNSJ
MU=FK#XO(_*4>JE:RO_HOP&8\Z".UL3^2^S9].O!M7/8C>>4]5P)RSW^A%B?7
M!@H>Y'1?)9QG@J?D]2)QO L%^S\NV[\.9W3@DZ5WT&-GRV.\RED'7^.MCD^.
MG\S/CW]9M=+EWC=;A0X?K8W"(?^4/_H55Y63N\LN- 8.*-WC73[OPZ_J;_@Z
MS7\G=_I_4$L#!!0    ( &*)J%9.K-Z*6 8  * ;   7    <V=M;RTR,#(S
M,#,S,7AE>#,R,2YH=&WM66UOVS80_KY?<76PU@%L2[(=V['3 *Z=H@7ZDCK.
MNGX:*(FRB,JB1E)QO%^_.TIR[*1),VQ=TRWY(,3B\7CWW/&.?'3T9/I^,O]T
M>@*Q629P>O[BS>L)U)J.\[$S<9SI? JOYF_?0+?E>C!7+-7"")FRQ'%.WM6@
M%AN3#1UGM5JU5IV65 MG/G-(5==)I-2\%9JP=GQ$;_#)67C\T]&39A.F,LB7
M/#40*,X,#R'7(EW QY#KS]!LEE(3F:V56,0&VFZ[ Q^E^BPN6#%NA$GX<:7G
MR"E^'SEVD2-?ANOCHU!<@ B?UT0T\'MA/V"]0=COM@_=0]_M>9$[Z'?Z;NCW
MO=\\--)!\6*.-NN$/Z\M1=J,.:T_[+9;_8/,C%8B-/'0<]V?:[NB3"U0VLAL
MV,L,CD4R-6B&0K7%OX7VFVOL3!P9?FF:+!&+=&@=+S55TH%,I!KNN?9O1"/-
MB"U%LAX^FXLEU_".KV FERQ]UM 8K*;F2D2%H!9_<+0<%[$_5X5C?=23B)17
MCGIM<NWD,A:^,-!IM[Q=!^YE>H 1X>H[V3[ARHA(!(P25<-IKG3.T PCP1O
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M !$              ( !     '-G;6\M,C R,S S,S$N:'1M4$L! A0#%
M  @ 8HFH5ML;+B)U$0  S+(  !$              ( !P0@" '-G;6\M,C R
M,S S,S$N>'-D4$L! A0#%     @ 8HFH5N9$2!]B&0  =NP  !4
M     ( !91H" '-G;6\M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    ( &*)
MJ%90!CT>]U4  $*Y P 5              "  ?HS @!S9VUO+3(P,C,P,S,Q
M7V1E9BYX;6Q02P$"% ,4    " !BB:A6=8IVTE2W   ); < %0
M    @ $DB@( <V=M;RTR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ 8HFH
M5JIX?3*K=P  X4P% !4              ( !JT$# '-G;6\M,C R,S S,S%?
M<')E+GAM;%!+ 0(4 Q0    ( &*)J%:HKH@,%0@   \G   7
M  "  8FY P!S9VUO+3(P,C,P,S,Q>&5X,S$Q+FAT;5!+ 0(4 Q0    ( &*)
MJ%8QC38+(0@  ((G   7              "  =/! P!S9VUO+3(P,C,P,S,Q
M>&5X,S$R+FAT;5!+ 0(4 Q0    ( &*)J%9.K-Z*6 8  * ;   7
M      "  2G* P!S9VUO+3(P,C,P,S,Q>&5X,S(Q+FAT;5!+!08     "0 )
+ %D"  "VT ,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
